<SEC-DOCUMENT>0001390478-18-000035.txt : 20181114
<SEC-HEADER>0001390478-18-000035.hdr.sgml : 20181114
<ACCEPTANCE-DATETIME>20181114164127
ACCESSION NUMBER:		0001390478-18-000035
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20180930
FILED AS OF DATE:		20181114
DATE AS OF CHANGE:		20181114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SELLAS Life Sciences Group, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		181184621

	BUSINESS ADDRESS:	
		STREET 1:		15 WEST 38TH STREET
		STREET 2:		10TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10018
		BUSINESS PHONE:		(917) 438-4353

	MAIL ADDRESS:	
		STREET 1:		15 WEST 38TH STREET
		STREET 2:		10TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10018

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Galena Biopharma, Inc.
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sls-20180930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sA9BDBA187A275F768B5FC503323F897A"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:Helvetica,sans-serif;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:Helvetica,sans-serif;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Helvetica,sans-serif;font-size:12pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">________________________________</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:Helvetica,sans-serif;font-size:18pt;font-weight:bold;">FORM 10-Q</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">________________________________</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">For the quarterly period ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">OR</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Commission File Number: 001-33958</font></div><div style="line-height:120%;text-align:center;"><img src="sellas-logoa05.jpg" alt="sellas-logoa05.jpg" style="height:90px;width:277px;"></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:Helvetica,sans-serif;font-size:24pt;font-weight:bold;">SELLAS Life Sciences Group, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">________________________________</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.81481481481482%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:3%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">20-8099512</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(State of incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(I.R.S. Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">15 West 38</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">&#32;Street, 10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">&#32;Floor, New York, NY 10018</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">(917)&#160;438-4353</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(Address, including zip code, and telephone number, including </font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">area code, of registrant's principal executive offices)</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">________________________________</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Indicate by check mark whether the Registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;Yes&#160; </font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter time that the registrant was required to submit such files).&#160;&#160;&#160;Yes&#160; </font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-bottom:4px;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act (Check one):</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:40%;"></td><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Emerging growth company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="padding-bottom:16px;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;"><br></font></div><div style="padding-bottom:16px;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings 2;font-size:10pt;"><br></font></div><div style="padding-bottom:16px;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;&#160;Yes&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#32;&#160;No</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">November&#160;9, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">, SELLAS Life Sciences Group, Inc. had outstanding </font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">22,026,476</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#32;shares of common stock, $0.0001 par value per share, exclusive of treasury shares.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="s570205F8F2B95F749D61ED9F107880E2"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">FORM 10-Q - Quarterly Report</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">For the Quarter Ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:82%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Part</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Item</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Page</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">No.</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">I</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s416AA8AD8EEE55839A5E732B86E5A3ED"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">FINANCIAL INFORMATION</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s27EBFCD10619508CA232E3CB0F4C62AE"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s27EBFCD10619508CA232E3CB0F4C62AE">3</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Condensed Consolidated Balance Sheets as of September 30, 2018 (unaudited) and December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s416AA8AD8EEE55839A5E732B86E5A3ED">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2018 and 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sBCCF9D7A14AB5400832ACB280676428C">4</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Unaudited Condensed Consolidated Statement of Stockholders' Equity for the nine months ended September 30, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s088F85E726495F67A34F8A9F3A85DCA7">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2018 and 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sBB5547034B66595194C9042947177186">6</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Unaudited </font><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s74C7FFE7E76150A2B2B9B91E6E90ED04"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s74C7FFE7E76150A2B2B9B91E6E90ED04">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s9E2E614595D058C0ADB85846CDA2A002"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sE51101295F085505849E0302127D762E">25</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s205104546BCF5629AFDCC7748CA37F8B"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s205104546BCF5629AFDCC7748CA37F8B">34</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sBFC92921BC385B65A2DF0BEDD3742301"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sBFC92921BC385B65A2DF0BEDD3742301">35</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">II</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s3DCE24C577BD50D8A27516B2D73C69AF"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">OTHER INFORMATION</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Legal Proceedings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s0C16AA4AD3255C85B76F5FA8B3439F73">36</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Risk Factors</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s84DF9D095163509EAA592F85EFFEED97">36</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s43C5AFCA97D450B39B3226BC1840640D"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s43C5AFCA97D450B39B3226BC1840640D">36</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s2FC74473CE225A19BD2F636F641310ED"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Defaults Upon Senior Securities</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s43C5AFCA97D450B39B3226BC1840640D">36</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sE48DAD5877455F8A903989777F597741"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s2FC74473CE225A19BD2F636F641310ED">36</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sD650A82A4A4851EB8FD8260F7F8A60A2"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sE48DAD5877455F8A903989777F597741">36</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sCB7C3EA7162A5E5FBCE14B6EA8F151EB"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sD650A82A4A4851EB8FD8260F7F8A60A2">36</a></div></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s83C804AD917258A8A3C22C222906463C"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Signatures</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="sBA4357810A735A769732EA903CEACE9B"></a></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Some of the information contained in this quarterly report on Form 10-Q may include forward-looking statements that reflect our current views with respect to our development programs, business strategy, business plan, financial performance and other future events. These statements include forward-looking statements both with respect to us, specifically, and our industry, in general. Such forward-looking statements include the words &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;anticipate,&#8221; &#8220;will&#8221; and similar statements of a future or forward-looking nature identify forward-looking statements. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. There are or will be important factors that could cause actual results to differ materially from those indicated in these statements. These factors include, but are not limited to, those factors set forth in the sections captioned &#8220;Risk Factors,&#8221; &#8220;Legal Proceedings,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; in this quarterly report on Form 10-Q, in the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section of our annual report on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission, or SEC, on April 13, 2018, or the 2017 Annual Report, and under the caption "Risk Factors" in Exhibit 99.1 in our Current Report on Form 8-K dated July 18, 2018, all of which you should review carefully. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s416AA8AD8EEE55839A5E732B86E5A3ED"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">PART I FINANCIAL INFORMATION</font></div><div><a name="s27EBFCD10619508CA232E3CB0F4C62AE"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160; 1. FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s27332CC422EF5CAA8F0357A4938CD519"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands, except share and per share data)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Unaudited)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">9,968</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Restricted cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">114</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">10,431</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Other receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">6,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Litigation settlement insurance recovery</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">474</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">651</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">337</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">17,807</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">13,087</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">17,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">17,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,914</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,914</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Deposits and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,149</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">925</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">38,470</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">33,526</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current portion of long-term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">8,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">7,238</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">11,691</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">3,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Litigation settlement payable</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">11,997</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">24,569</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,722</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,673</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,319</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,294</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Long-term debt, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2,611</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">20,013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">31,456</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Commitments and contingencies (Note 8)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Stockholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Preferred stock, $0.0001&#160;par value; 5,000,000&#160;shares authorized; Series A convertible preferred stock, 17,500 shares designated; no shares issued and outstanding at September 30, 2018 and December 31, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Common stock, $0.0001&#160;par value; 350,000,000&#160;shares authorized, 20,501,476 shares issued and outstanding at September 30, 2018; 5,766,891&#160;shares issued and outstanding at December&#160;31, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">86,987</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">56,254</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(68,532</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(54,185</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">18,457</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2,070</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total liabilities and stockholders&#8217; equity </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">38,470</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">33,526</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="sBCCF9D7A14AB5400832ACB280676428C"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands, except share and per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,079</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,341</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,130</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total operating expenses and operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,061</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,290</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(15,246</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(14,429</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in fair value of warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in fair value of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(162</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,025</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss on settlement of liability-classified warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gain on extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">766</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">766</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interest expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(74</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(102</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(292</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(360</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total non-operating income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,771</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(102</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,062</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(360</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,392</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(14,184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(14,789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Income tax expense </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">180</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(14,347</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(14,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Deemed dividend arising from beneficial conversion feature of convertible preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,436</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impact of anti-dilution protection on liability-classified warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(491</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(491</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(9,435</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,455</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(27,928</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(14,969</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Per share information:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss per common share attributable to common stockholders, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.53</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2.75</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4.56</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Weighted-average common shares outstanding, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,635,671</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,962,822</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,161,153</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,284,351</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s088F85E726495F67A34F8A9F3A85DCA7"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands, except share amounts)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:31%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Preferred Stock</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Additional Paid-In Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Accumulated Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Total Stockholders' Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Amount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">5,766,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">56,254</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(54,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,070</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock and common stock warrants, net of issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">6,845,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">21,563</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">21,564</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of Series A convertible preferred stock, net of offering costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">10,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">9,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">9,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(5,039</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(5,039</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Beneficial conversion feature arising from Series A convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(4,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(4,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Deemed dividend arising from beneficial conversion feature of Series A convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">4,436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">4,436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Conversion of Series A convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(2,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">499,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock to Series A convertible preferred stockholders under most favored nation provision</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(7,802</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,748,184</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(8,654</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(8,654</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">8,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">8,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Impact of anti-dilution protection on liability-classified warrants<br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(491</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(491</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Convertible preferred stock dividends</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock as repayment of principal and interest on long-term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">715,277</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,896</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,896</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock in connection with litigation settlements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">228,672</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock upon conversion of promissory notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">118,644</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">825</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">825</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock in connection with warrant exchange agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">54,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">285</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">285</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock upon exercise of pre-funded warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,524,783</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(14,347</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(14,347</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Balance at September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">20,501,476</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">86,987</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(68,532</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">18,457</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="sBB5547034B66595194C9042947177186"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">For the nine months ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net loss </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(14,347</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(14,969</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Adjustment to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Gain on extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(766</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Non-cash interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Deferred taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">49</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">Loss on extinguishment of payables</sup>&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Non-cash stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">284</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,776</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Amortization of research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair value of common stock issued in exchange for services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">325</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair value of common stock issued in connection with litigation settlements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Change in fair value of common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(5,340</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Change in fair value of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">4,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Loss on settlement of liability-classified warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">727</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Other receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(6,600</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(538</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Litigation settlement insurance recovery</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(474</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(4,453</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">182</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">85</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(25,867</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(9,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">Net proceeds from issuance of Series A convertible preferred stock and common stock warrants</sup>&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">9,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Proceeds from issuance of common stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">21,564</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">6,007</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">Dividends paid</sup>&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Principal payments on long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(7,525</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(353</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">23,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">5,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(2,668</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(3,593</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">12,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">5,962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">10,082</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,369</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Supplemental disclosure of cash flow information:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash received during the periods for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash paid during the periods for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">321</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Supplemental disclosure of non-cash investing and financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock recorded as issuance cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">5,039</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Repayment of interest and principal on long-term debt through issuance of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,587</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Reclassification of warrant liabilities upon exchange for shares of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">285</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Impact of anti-dilution protection on liability-classified warrants</font></div><div style="font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Debt issued in connection with warrant exchange agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">966</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><a name="s74C7FFE7E76150A2B2B9B91E6E90ED04"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div><a name="s538175C83C155D63AB38702D660655E7"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">1.  Organization and Description of Business</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Overview</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">SELLAS Life Sciences Group, Inc. (the "Company," or &#8220;SELLAS&#8221;) is a late-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapeutics for a broad range of indications. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Merger of Galena Biopharma, Inc. and SELLAS Life Sciences Group Ltd.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As used in this quarterly report on Form 10-Q, the words the &#8220;Company,&#8221; and &#8220;SELLAS&#8221; refer to SELLAS Life Sciences Group, Inc. and its consolidated subsidiaries following completion of the business combination with Galena Biopharma, Inc., a Delaware corporation ("Galena"). This business combination is referred to as the Merger. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;29, 2017, Galena completed the Merger with SELLAS Life Sciences Group, Ltd., a privately held Bermuda exempted company ("Private SELLAS"), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of August&#160;7, 2017 and amended November&#160;5, 2017 (the "Merger Agreement"), among the Company, Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc., Galena Bermuda Merger Sub, Ltd., and Private SELLAS. As a result of the Merger, the Company&#8217;s business is now substantially comprised of the business of Private SELLAS, and although the Company is considered the legal acquiror of Private SELLAS, for accounting purposes, Private SELLAS is considered to have acquired the Company in the Merger. Consequently, the Merger was accounted for as a reverse acquisition and the Private SELLAS financial statements became the Company's financial statements. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Immediately prior to the Merger, Galena effected a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-for-</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">30</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;reverse stock split of its outstanding common stock, par value </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. Under the terms of the Merger Agreement, Galena issued shares of its common stock to Private SELLAS&#8217; securityholders at an exchange ratio of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">43.9972</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of its common stock in exchange for each common share of Private SELLAS outstanding immediately prior to the Merger. The Company also assumed all of the restricted stock units (&#8220;RSUs&#8221;) issued and outstanding under the Private SELLAS Stock Incentive Plan #1, and all of the issued and outstanding warrants of Private SELLAS. Accordingly, such RSUs will now be settled in, and such warrants now are exercisable for, shares of the Company&#8217;s common stock. Accordingly, immediately after the Merger, there were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,766,891</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the Company&#8217;s common stock outstanding, with the former Private SELLAS securityholders owning </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">67.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the Company&#8217;s fully diluted common stock, and the Company&#8217;s pre-Merger securityholders owning the remaining </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The number of shares and per share amounts of common stock in the accompanying condensed consolidated financial statements and notes to the condensed consolidated financial statements have been restated to give retroactive effect to the common stock conversion ratio and reverse stock split for all periods presented, including common stock options, RSUs, and common stock warrants. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Upon completion of the Merger, the Company&#8217;s name changed from &#8220;Galena Biopharma, Inc.&#8221; to &#8220;SELLAS Life Sciences Group, Inc.," the Company&#8217;s financial statements became those of Private SELLAS and the Company's common stock began trading on The Nasdaq Capital Market under a new ticker symbol &#8220;SLS&#8221; on January&#160;2, 2018. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><a name="s6678B8A3B4C95938B07E049D89BDF0FC"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">2.  Liquidity</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has not generated any revenues, including from product sales, and has funded operations primarily from the proceeds of sales of its equity interests and convertible notes, as well as through the Merger. Substantial additional financing will be required by the Company to continue to fund its research and development activities. No assurance can be given that any such financing will be available when needed or that the Company&#8217;s research and development efforts will be successful. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On July 16, 2018, the Company closed an underwritten public offering (the "July 2018 Offering"), issuing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,845,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,675,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;pre-funded warrants exercisable for shares of common stock and accompanying common stock warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,520,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share and accompanying common stock warrant. The pre-funded warrants and accompanying common stock warrants were sold at a combined price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.0999</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per pre-funded warrant and common stock warrant. Each common stock warrant sold with the shares of common stock and pre-funded warrants represents the right to purchase one share of the Company&#8217;s common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. The common stock warrants are exercisable immediately and will expire on July 16, 2023, five years from the date of issuance. The pre-funded warrants are exercisable immediately, have an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share, and will expire on July 16, 2023, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years from the date of issuance. The net proceeds to the Company from the July 2018 Offering, after deducting the underwriting discounts and commissions and other estimated July 2018 Offering expenses, and excluding the exercise of any warrants, were approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to the proceeds from the July 2018 Offering, on March&#160;7, 2018, the Company entered into a definitive securities purchase agreement to issue shares of its Series A convertible preferred stock (&#8220;Series A Convertible Preferred&#8221;) and warrants to purchase shares of its common stock in a private placement transaction to a select group of institutional investors. The sale of the aggregate </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,700</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of Series A Convertible Preferred and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.5</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;year warrants to acquire an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,383,631</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.59</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share closed in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">two</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;tranches and resulted in aggregate gross proceeds to the Company of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company closed the first tranche for approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;gross proceeds on March&#160;9, 2018. The Company closed the second tranche of the remaining </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;gross proceeds on May 1, 2018, following the receipt of necessary stockholder approval. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third parties and other strategic alliances and business transactions. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company currently does not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with third parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently, consider various other strategic alternatives, including a merger or sale of the Company, or cease operations. If the Company engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development process. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has evaluated the guidance of Accounting Standards Codification ("ASC") 205-40, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Presentation of Financial Statements - Going Concern</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year from the date its financial statements are available to be issued. The Company has prepared its condensed consolidated financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its potential product candidates, which raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Various internal and external factors will affect whether and when the Company&#8217;s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company&#8217;s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company&#8217;s financial condition and future operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the Company had cash and cash equivalents of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, restricted cash balance of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, other receivable of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(received in November 2018), and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in litigation insurance recovery (received in October 2018). In addition, the Company had outstanding accounts payable and accrued expenses of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$11.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and indebtedness of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company expects its existing cash as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, including amounts received in October and November 2018, will enable the Company to fund its operating expenses and capital expenditure requirements through March 2019. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="sF81F71F44DA357CF8A6FDE5F993DA984"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">3.  Basis of Presentation and Significant Accounting Policies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Basis of Presentation </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the ASC and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Principles of Consolidation </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The condensed consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Unaudited Interim Results </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company's annual consolidated financial statements and the notes thereto included in its Annual Report on Form 10-K for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which was filed with the Securities and Exchange Commission ("SEC") on April 13, 2018 (the "2017 Annual Report"). The accompanying condensed consolidated financial statements at&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;and for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2017, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;have been derived from the audited financial statements as of that date.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Preferred Stock</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&#8217; equity.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Convertible Instruments</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that feature conversion options. The accounting standards require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company also records, when necessary, deemed dividends for the intrinsic value of the conversion options embedded in preferred stock based upon the difference between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred stock.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements Pending Adoption</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Improvements to Nonemployee Share-Based Accounting</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The ASU supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees. As a</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (1) liability-classified nonemployee awards that have not been settled as of the adoption date and (2) equity-classified nonemployee awards for which a measurement date has not been established. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2019 and interim periods within those years. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">, Leases</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In July 2018, the FASB issued ASU 2018-10, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and No. 2018-11, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842) - Targeted Improvements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The new standard establishes a right-of-use</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;or ROU</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the potential impact of the adoption of the new standard on the consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In August 2018, FASB issued ASU 2018-13, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU 2018-13 modifies, adds and removes certain specific the disclosure requirements on fair value measurements in Topic 820</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;The amendments in ASU 2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date.  Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of the new standard on the consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements Adopted</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU No. 2016-18 requires that restricted cash be included&#160;with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the statement of cash flows.&#160;In accordance&#160;with ASU No. 2016-18, the Company adopted this standard in the first quarter of 2018. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's condensed consolidated balance sheets to the total of the amount presented in the condensed consolidated statements of cash flows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,968</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,431</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total cash, cash equivalents, restricted cash, and restricted cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,082</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In connection with the Company's Senior Secured Debenture described in Notes 7 and 8, the Company was required to maintain a minimum of the lesser of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$18.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;or the outstanding principal amount of unencumbered cash in a restricted account. Any funds in the restricted account in excess of the outstanding principal balance were to be transferred to the Company's unrestricted account to fund its ongoing operations. As of December&#160;31, 2017, the Company maintained </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of cash and cash equivalents in a restricted account. The Senior Secured Debenture was deemed to be no longer outstanding as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In addition, the Company maintained </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and December 31, 2017, respectively, on hand with the Company's financial institutions as collateral for its corporate credit cards.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Scope of Modification Accounting</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU&#160;No. 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting.&#160;This guidance is to be applied prospectively to awards modified on or after the adoption date and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted. In accordance with ASU No. 2017-09, the Company adopted this standard prospectively in the first quarter of 2018. The adoption of ASU No. 2017-09 did not have a material impact on the Company's condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Reclassifications&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><a name="s80B3DF9BD256511A8BD250B31E8BDC3C"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">4. Acquisition</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;29, 2017, the Company completed the Merger with Private SELLAS as discussed in Note 1. The Merger was accounted for as a reverse merger under the acquisition method of accounting whereby Private SELLAS was considered to have acquired the Company for financial reporting purposes because, immediately upon completion of the Merger, Private SELLAS stockholders held a majority of the voting interest of the combined company. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following summary pro forma condensed consolidated financial information reflects the Merger with Galena as if it had occurred on January 1, 2017 for purposes of the statements of operations. This summary pro forma information is not necessarily representative of what the Company&#8217;s results of operations would have been had the Merger in fact occurred on January 1, 2017, and is not intended to project the Company&#8217;s results of operations for any future period.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Three Months Ended September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Nine Months Ended September 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(9,066</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(21,690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.92</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pro forma combined net loss includes an adjustment to reduce historical interest expense of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;for the&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three and nine months ended September 30, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively,&#160;due to the conversion of the convertible notes of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company excluded a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;impairment charge incurred by the Company and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of transaction costs related to the Merger from the pro forma financial information for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three and nine months ended September 30, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s48CC12E40B455DCFA9E90170AF02A455"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">5.  Fair Value Measurements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,774</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,774</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,774</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,774</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,319</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,319</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,662</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,662</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,245</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,245</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,907</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,907</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,603</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,603</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company did not transfer any financial instruments into or out of Level 3 classification during the three and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.  See Note 10 for a reconciliation of the changes in the fair value of the warrant liability for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A reconciliation of the change in the fair value of the contingent consideration liability for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;is as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Measurements</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Using&#160;Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in the estimated fair value of the contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration, September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The fair value of the contingent consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The contingent consideration relates to Galena&#8217;s acquisition of Apthera, Inc. in 2011 and the future contingent payments of up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$32.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;based on the achievement of certain development and commercial milestones relating to the Company&#8217;s nelipepimut-S ("NeuVax</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM" </sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">or "NPS") product candidate. The contingent consideration is payable at the election of the Company in either cash or shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration unless it has first obtained approval of its stockholders in accordance with Rule 5635(a) of the Nasdaq Marketplace Rules. The significant unobservable assumptions include the probability of achieving each milestone, the date the Company expects to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. The change in the estimated fair value of the contingent consideration during the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;reflects an adjusted probability and timeline for the potential approval of NPS associated with the positive interim data in the triple-negative breast cancer cohort from the prospective, randomized, single-blinded, controlled Phase 2b investigator-sponsored clinical trial ("IST") of trastuzumab (Herceptin&#174;) +/- NPS in HER2 1+/2+ breast cancer patients in the adjuvant setting to prevent recurrences that was announced on April 2, 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><a name="sA3273618C9EC501B86E57AFD361BE862"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">6.  Accrued Expenses and Other Current Liabilities</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Professional fees*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">808</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">566</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Value-added tax</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">426</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Rebates and returns of former commercial products</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">276</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">191</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,683</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,201</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">*Includes approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of legal fees incurred related to the JGB litigation as described in Note 8 that was reimbursed to the Company in November 2018 by JGB.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s371DE49A8A655A4D89388516E735E40D"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">7.  Debt</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Debt</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Current portion of Senior Secured Debenture</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,377</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Short-term convertible promissory notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-current portion of Senior Secured Debenture</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,611</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,988</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Senior Secured Debenture</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On May 10, 2016, the Company's predecessor company, Galena, entered into a Securities Purchase Agreement (the &#8220;Securities Purchase Agreement&#8221;) with JGB (the "Purchaser") pursuant to which Galena sold to the JGB, at a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.375%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;original issue discount, a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$25.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;Senior Secured Debenture (the "Senior Secured Debenture") and warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,333</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the Company's common stock. Net proceeds to Galena from the sale of the Senior Secured Debenture and warrants, after payment of commissions and legal fees, were approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$23.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Senior Secured Debenture originally matured November&#160;10, 2018, with accrued interest at&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;per year, payable monthly. In addition, on the maturity date of the Senior Secured Debenture (or such earlier date that the principal amount of the Senior Secured Debenture is paid in full by acceleration or otherwise) a fixed amount, which would have been deemed interest under the Senior Secured Debenture, equal to&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was due and payable to JGB on such date in, at the option of the Company, cash and, subject to the same conditions for the payment of interest, in shares of the Company&#8217;s common stock, or a combination of cash and the Company&#8217;s common stock. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s obligations under the Senior Secured Debenture were secured under a security agreement by a senior lien on all of the Company&#8217;s assets, including all of the Company&#8217;s interests in its consolidated subsidiaries. Private SELLAS was not a party to the security agreement. Under the terms of a subsidiary guarantee agreement, each subsidiary guaranteed the performance of the Company of the Securities Purchase Agreement, Senior Secured Debenture and related agreements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:1pt;padding-left:66px;"><font style="font-family:Helvetica,sans-serif;font-size:1pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:Helvetica,sans-serif;font-size:1pt;">&#160;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company was required to maintain a minimum of the lesser of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$18.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;or the outstanding principal amount of unencumbered cash in a restricted account. Any funds in the restricted account in excess of the outstanding principal balance were transferred to the Company's unrestricted account to fund its ongoing operations. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the Company maintained </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of cash and cash equivalents in a restricted account. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the outstanding principal balance of the Senior Secured Debenture was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In addition to the outstanding principal balance, the Senior Secured Debenture had&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of additional interest that was included in the current portion of long-term debt as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. During the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, JGB redeemed </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of outstanding principal, which the Company satisfied with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">659,529</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of its common stock and redeemed </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of outstanding principal, which the Company satisfied with cash. As a result of the redemptions during 2018, the Company transferred </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of restricted cash into unrestricted cash and cash equivalents which was used to fund the Company&#8217;s ongoing operations. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">JGB commenced a lawsuit against the Company as described in Note 8 ("JGB Action"). On September 24, 2018, JGB unilaterally issued a directive to (i) the financial institution that maintained the restricted cash and cash equivalents and (ii) the manager of the account to liquidate all assets in the restricted account. As a result of such directive, approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in cash was removed from the restricted account, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in excess of the outstanding principal balance of the Senior Secured Debenture at the time of the removal. On October 16, 2018, JGB was required to deposit the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;excess that JGB removed from the restricted account into an escrow account, as ordered by the Court in the JGB Action, pending resolution of the dispute between the Company and JGB.  On October 23, 2018, the Court entered an order, granting, among other things, the Company's Motion for Judgment seeking dismissal of JGB's amended complaint and allowing four of the Company's counterclaims to proceed to trial. As a result of the October 23rd Court order, on November 5, 2018, the parties to the JGB Action entered into a settlement agreement. The settlement agreement provides, among other things, that JGB make a one-time payment to the Company of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, representing the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;excess cash removed from the amount in the restricted account from the outstanding principal balance of the Senior Secured Debenture and reimbursement of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of legal fees incurred by the Company. The Company recognized a gain on extinguishment of debt of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;that was previously accrued in long-term debt representing an additional interest payable at maturity as the amount is no longer required to be repaid by the Company. Accordingly, the Senior Secured Debenture is no longer outstanding and the related agreements have been terminated.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Short-term Convertible Promissory Notes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the Company entered into convertible promissory notes in the principal amount of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in exchange for the surrender and cancellation of warrants to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">412,667</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of its common stock pursuant to the February 2017 offering by Galena. The convertible promissory notes accrue interest at a rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per annum and the remaining outstanding principal balance and accrued interest is due and payable in November 2018. The outstanding principal balance and accrued interest is convertible into shares of the Company's common stock at a conversion price equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$7.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In April 2018, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of outstanding principal and accrued interest was converted into </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">118,644</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;principal balance and accrued interest remains outstanding.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><a name="sA00963D7B90C5AEB8F6E5958BEDCB179"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">8. Legal Proceedings, Commitments and Contingencies</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Legal Proceedings </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">From time to time, the Company is subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its condensed consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, when the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of the date hereof, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect the Company&#8217;s consolidated results of operations, financial position or cash flows. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s predecessor company, Galena, was involved in multiple legal proceedings and administrative actions, including stockholder class actions, both state and federal, some of which are ongoing and to which the Company are now subject as a result of the Merger. The Company is also involved in litigation matters as follows: </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On February&#160;13, 2017, putative shareholder securities class action complaints were filed in federal court alleging, among other things, that the Company and certain of the Company's former officers and directors failed to disclose that Galena&#8217;s promotional practices for Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(fentanyl sublingual tablets) were allegedly improper and that Galena may be subject to civil and criminal liability, and that these alleged failures rendered Galena&#8217;s statements about its business misleading. The actions were consolidated, lead plaintiffs were named by the Court and a consolidated complaint was filed. The Company filed a motion to dismiss the consolidated complaint. On August 21, 2018, the Company's motion to dismiss the consolidated complaint was granted without prejudice to file an amended complaint. On September 20, 2018, the plaintiffs filed an amended complaint. On October 22, 2018, the Company filed a motion to dismiss the amended complaint. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In March 2017, a derivative complaint was filed in U.S. District Court for the District of New Jersey against the Company&#8217;s former directors and Galena, as a nominal defendant. In July 2017, a derivative complaint was filed in California state court against the Company&#8217;s former directors and Galena, as a nominal defendant. In January 2018, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&#8217;s former directors, officers and employees, and the Company as a nominal defendant. In June 2018, a derivative complaint was filed in U.S. District Court for the Northern District of California against the Company&#8217;s current and former directors, and the Company as a nominal defendant. The plaintiff in the June 2018 case voluntarily withdrew his complaint from the U.S District Court of the Northern District of California and on August 27, 2018 refiled the complaint in the Court of Chancery of the State of Delaware. These complaints purport to assert derivative claims for breach of fiduciary duty on the Company&#8217;s behalf against the Company&#8217;s former directors and, in certain of the complaints, the Company&#8217;s current directors, and the Company&#8217;s former officers and former employees, based on substantially similar facts as alleged in the putative shareholder securities class action complaints mentioned above. The March 2017, July 2017, and January 2018 lawsuits are currently stayed pending resolution of motions to dismiss in the referenced securities class action. On October 29, 2018, the defendants in the August 2018 lawsuit notified the plaintiff of its intent to file a motion to dismiss the lawsuit.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:Helvetica,sans-serif;font-size:1pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In April 2017, a putative stockholder class action, captioned Patel vs. Galena Biopharma Inc. et. al, was filed in Delaware state court seeking relief under Section&#160;225 of the Delaware General Corporation Law ("DGCL") and alleging breaches of fiduciary duties by Galena&#8217;s former board of directors and former interim chief executive officer regarding the proposals to amend Galena&#8217;s certificate of incorporation to increase the amount of authorized shares of common stock and effectuate a reverse stock split at the July 2016 and October 2016 stockholder meetings, respectively. On June&#160;2, 2017, an amended verified complaint was filed along with a motion to expedite the proceedings. On June&#160;20, 2017, the Court consolidated the claims into In re Galena Biopharma, Inc., C. A. No. 2017-0423-JTL. On July&#160;24, 2017, Galena entered into a binding settlement term sheet, involving</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">payment of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$50,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in cash and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1,250,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in unrestricted shares of common stock. The Court enforced the settlement term sheet on November&#160;30, 2017. On February&#160;22, 2018, the plaintiff filed his brief in support of the settlement as well as his request for attorneys&#8217; fees and an incentive award. On June 14, 2018, the Court entered an Order and Final Judgment approving the settlement and awarding attorneys&#8217; fees to the plaintiff. All obligations related to the Order and Final Judgment were satisfied in full by the Company in June 2018. In October 2018, the Company received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;from its insurance carrier for previous amounts paid by the Company in excess of its deductible. The amount is recorded as a litigation insurance recovery as of September 30, 2018 in the Company's condensed consolidated balance sheet.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On or about April 9, 2018, JGB filed a lawsuit in the U.S. District Court for the Southern District of New York (the "Court") captioned JGB (Cayman) Newton, Ltd. v. Sellas Life Sciences Group, Inc., et al., Case 1:18-cv-3095 (DLC) (the "JGB Action"). The complaint in the JGB Action asserted claims under state law and federal securities law against the Company, the Company's Chief Executive Officer, Angelos M. Stergiou, M.D., ScD h.c., and the Company's former Interim Chief Financial Officer, Aleksey N. Krylov. On or about May 2, 2018, JGB filed an amended complaint, adding as defendants Jane Wasman, Stephen Ghiglieri, David Scheinberg, M.D., Robert Van Nostrand and John Varian, each of whom is a member of the Company's Board of Directors. On May 18, 2018, the Company filed an answer to the amended complaint and filed </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">seven</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;counterclaims. On June 18, 2018, the Company filed a motion for judgment on the pleadings and a motion to dismiss the amended complaint. On July 6, 2018, JGB filed a motion for partial judgment on the pleadings and motion to dismiss all of the Company's counterclaims. On September 24, 2018, without any prior written notice, JGB unilaterally directed that all of the funds, approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in cash, be removed from the restricted account, an amount in excess of the outstanding principal balance of the Senior Secured Debenture.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On October 23, 2018, the Court entered an Opinion and Order, granting, in full, the Company's motion to dismiss JGB's amended complaint and allowing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">four</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the Company's counterclaims to proceed to trial. Following the October 23 Opinion and Order of the Court, the parties to the JGB Action entered into a settlement agreement on November 5, 2018. The settlement agreement provides, among other things, that JGB will make a one-time payment to the Company of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, inclusive of the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;excess amount removed from the restricted account. The entire settlement amount was recorded as an other receivable as of September 30, 2018 in the condensed consolidated balance sheet as of September 30, 2018 and the amount was received in November 2018. The Company offset approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of legal fees incurred during the three months ended September 30, 2018 previously recorded in general and administrative expense in the condensed consolidated statement of operations with proceeds from the settlement and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;legal fees incurred subsequent to September 30, 2018 recorded as an accrued liability in the condensed consolidated balance sheet. The Company recognized a gain on extinguishment of debt of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;that was previously accrued in long-term debt for an additional interest payable at maturity as the amount is no longer payable by the Company. The settlement agreement also provides for the termination of the Senior Secured Debenture and all ancillary agreements, including the security agreement covering the Company's assets as well as a release of all security interests in the collateral. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><a name="sC54F84156F9F5354BFAE78AF6202690F"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">9.  Stockholders&#8217; Equity</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Preferred Stock</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has authorized up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;shares of preferred stock, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;par value per share, for issuance. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Series A Convertible Preferred </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On March&#160;7, 2018, the Company entered into a securities purchase agreement with investors, pursuant to which the Company agreed to sell to the investors, in a private placement pursuant to Rule 4(a)(2) and Regulation S under the Securities Act, an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,700</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the Company&#8217;s newly-created non-voting Series A Convertible Preferred, and warrants to acquire an aggregate </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,383,631</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the Company&#8217;s common stock, par value </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share at an aggregate purchase price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Series A Convertible Preferred was initially convertible into </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,844,835</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock based on an initial conversion price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.80</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">At the first closing of the Series A Convertible Preferred on March&#160;9, 2018, the Company issued an aggregate </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,987</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of Series A Convertible Preferred and warrants to acquire </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">774,186</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock for aggregate gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The second closing of the remaining </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,713</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the Series A Convertible Preferred and warrants to acquire </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">609,445</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of its common stock, for aggregate gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, occurred on May 1, 2018 following receipt of stockholder approval. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In the event of a "qualified offering," as defined in the securities purchase agreement, holders of the Series A Convertible Preferred (the "Series A Holders"), had the right to exchange their shares of Series A Convertible Preferred for the same securities sold in a qualified offering on a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;basis based on the stated value of their shares of Series A Convertible Preferred under the most favored nation provision. On July 16, 2018, following consummation of the July 2018 Offering, which was deemed a qualified offering as described below and also in Note 2 above, the Series A Holders exchanged an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$7,871,186</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of stated valued and accrued but unpaid dividends on their Series A Convertible Preferred for an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,748,184</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the Company&#8217;s common stock and warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,748,184</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the Company&#8217;s common stock. Following such exchange there are no shares of Series A Convertible Preferred issued and outstanding. The warrants have an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share and a term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years. The fair value of the common stock and warrants to purchase shares of common stock exceeded the carrying amount of the Series A Preferred by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and that amount is recorded as a deemed dividend in the condensed consolidated statements of operations during the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three and nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as it represents a transfer of value from the common stockholders to the preferred investors. Since the Company does not have accumulated earnings, the deemed dividend is taken from additional paid-in capital. This one-time, non-cash charge impacted net loss attributable to common stockholders and loss per share for the three and nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, pursuant to the terms of the warrants, the exercise price of the warrants issued to the investors in March 2018 and May 2018 was adjusted to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share from the original exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.59</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. The Company recognized the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;increase to the fair value of the warrant liability as a result of the adjusted stock price as a deemed dividend in the condensed consolidated statements of operations during the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three and nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. This one-time, non-cash charge impacted net loss attributable to common stockholders and loss per share for the three and nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Series A Convertible Preferred generally had no voting rights. However, for so long as any shares of Series A Convertible Preferred were outstanding, the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Convertible Preferred was required to: (a)&#160;alter or change adversely the powers, preferences or rights given to the Series A Convertible Preferred or alter or amend the Certificate of Designation, (b)&#160;authorize or create any class of stock ranking as to dividends, redemption or distribution of assets upon a Liquidation (as defined in the Certificate of Designation) senior to, or otherwise </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">pari passu</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;with, the Series A Convertible Preferred, (c)&#160;amend the Company's certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Convertible Preferred, (d)&#160;increase the number of authorized shares of Series A Convertible Preferred, or (e)&#160;enter into any agreement with respect to any of the foregoing. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary that is not a Fundamental Transaction (as defined in the Certificate of Designation), the holders of Series A Convertible Preferred were entitled to receive from the Company's assets the same amount they would have received on an as converted basis, disregarding any conversion limitations. Such amounts would have been paid on a</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">pari&#160;passu basis with all holders of common stock.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company evaluated the Series A Convertible Preferred in accordance with the provisions of ASC 815,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, including consideration of embedded derivatives requiring bifurcation. The issuance of the Series A Convertible Preferred could generate a beneficial conversion feature (&#8220;BCF&#8221;), which arises when a debt or equity security is issued with an embedded conversion option that is beneficial to the investor or in the money at inception because the conversion option has an effective conversion price that is less than the market price of the underlying stock at the commitment date. The Company recognized the BCF by allocating the intrinsic value of the conversion option, which is the number of shares of common stock available upon conversion multiplied by the difference between the effective conversion price per share and the fair value of common stock per share on the commitment date, to additional paid-in capital, resulting in a discount on the convertible preferred stock. As the Series A Convertible Preferred could have been converted immediately, the Company recognized a BCF of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as a deemed dividend in the condensed consolidated statements of operations related to the first closing on March 9, 2018 and an additional BCF of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as a deemed dividend related to the second closing on May 1, 2018.&#160;These one-time, non-cash charges impacted net loss attributable to common stockholders and loss per share for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Common Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has authorized up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">350,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;shares of common stock, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;par value per share, for issuance. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On July 16, 2018, the Company closed the July 2018 Offering, issuing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,845,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,675,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;pre-funded warrants exercisable for shares of common stock and accompanying common stock warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,520,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share and accompanying common stock warrant. The pre-funded warrants and accompanying common stock warrants were sold at a combined price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.0999</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per pre-funded warrant and common stock warrant.  Each accompanying common stock warrant sold with the shares of common stock and pre-funded warrants represents the right to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">one</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;share of the Company&#8217;s common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. The common stock warrants are exercisable immediately and will expire on July 16, 2023, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years from the date of issuance. The pre-funded warrants are exercisable immediately, have an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share, and will expire on July 16, 2023, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years from the date of issuance.  The net proceeds to the Company from the July 2018 Offering, after deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants, were approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During its evaluation of equity classification for the pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock issued in the July 2018 Offering, the Company considered the conditions as prescribed within ASC 815-40, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Contracts in an Entity&#8217;s own Equity</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(&#8220;ASC 815-40&#8221;). The conditions within ASC 815-40 are not subject to a probability assessment. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do not fall under the liability criteria within ASC 480, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Distinguishing Liabilities from Equity,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as they are not puttable and do not represent an instrument that has a redeemable underlying security. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do meet the definition of a derivative instrument under ASC 815, but are eligible for the scope exception as they are indexed to the Company&#8217;s own stock and would be classified in permanent equity if freestanding. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares of common stock for future issuance are reserved for as follows (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:84%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">September&#160;30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">434</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options reserved for future issuance under the Company&#8217;s 2017 Equity Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">381</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares reserved for future issuance under the Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted stock units</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total reserved for future issuance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,167</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s9363443CEF3D5F1E8E757A3373AC9A9F"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">10.  Warrants to Acquire Shares of Common Stock</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following is a summary of the Company's warrants to acquire shares of common stock activity for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:26%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Canceled/Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expiration</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">July 2018 Offering</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">July 2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Pre-funded July 2018 Offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,675</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,525</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,150</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">July 2023</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Series A Convertible Preferred</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2017 Equilibria</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">316</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">316</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 2022</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">February 2022</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">74</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2022</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,327</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,525</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(541</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,224</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants to acquire shares of common stock consist of warrants that may be settled in cash, which are liability-classified warrants, and equity-classified warrants. During the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, a total of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">534,333</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the Galena February 2017 liability-classified warrants to purchase shares of common stock were canceled under various warrant exchange agreements. The Company issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">54,613</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of its common stock in exchange for the surrender and cancellation of warrants to acquire </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">121,667</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of its common stock and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in convertible promissory notes in exchange for the surrender and cancellation of warrants to acquire </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">412,667</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of its common stock, as described in Note 7. The fair value of the common stock and promissory notes exchanged totaled </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which exceeded the fair value of the warrant liability of the warrants canceled by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and is recorded as loss on settlement of liability-classified warrants in the condensed consolidated statement of operations for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In April 2018, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of outstanding principal and accrued interest was converted into </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">118,644</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Warrants Classified as Liabilities </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liability-classified warrants consist of warrants to acquire common stock issued in connection with previous equity financings for the Series A Convertible Preferred, Galena's February 2017 financing, and various other Galena equity financings that were assumed by the Company at the consummation of the Merger. These warrants may be settled in cash and were determined to not be indexed to the Company&#8217;s common stock. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Prior to the consummation of the July 2018 Offering, the initial exercise price of the warrants to acquire shares of common stock in connection with the Series A Convertible Preferred was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.59</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share of common stock, subject to standard adjustments for certain transactions affecting the Company&#8217;s securities (such as stock dividends, and stock splits). From the original issue date until the one-year anniversary of a qualified offering, the initial exercise price and number of warrants to acquire shares of common stock are subject to anti-dilution protection in the event of non-exempt equity issuances at a price per share lower than the then exercise price (the "Base Share Price"). Simultaneously with the consummation of each non-exempt equity issuance the exercise price shall be reduced to equal the Base Share Price. Such adjustment shall be made whenever such common stock or common stock equivalents are issued.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the condensed consolidated statement of operations as change in fair value of warrant liability. The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:26%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding (in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Strike price (per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk-free rate %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Series A Convertible Preferred</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">83.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.38</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">85.39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">888.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">85.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding (in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Strike price (per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk-free rate %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">79.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28.40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.19</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">74.05</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.09</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The expected volatility assumptions are based on the Company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">zero</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">zero</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, because the Company has </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">no</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;present intention to pay cash dividends.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The changes in fair value of the warrant liability for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;were as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants canceled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Adjustment to exercise price of warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Series A Convertible Preferred</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,039</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,558</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,305</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(524</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(778</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,039</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(524</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">975</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Warrants Classified as Equity</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company issued warrants to acquire </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">316,163</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the its common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$7.42</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share, maturing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;from issuance, to EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund on December&#160;29, 2017. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent reporting periods. The fair value of the warrants granted was&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;per share using the Black-Scholes pricing model with the fair value assumptions for the grant including a volatility of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">90.10%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, expected term of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years, risk free rate of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.20%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and a dividend rate of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock issued during the July 2018 offering are recorded in equity upon issuance as described in Note 9.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s76EBD5C2CDFB56478E18674A328F2C4B"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">11.  Stock-Based Compensation</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Share and per share amounts below have been retroactively adjusted to reflect the exchange ratio and reverse stock split as described in Note 1. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">2017 Equity Incentive Plan </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;29, 2017, the 2017 Equity Incentive Plan was approved, and currently allows for the issuance of up to a maximum of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">575,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, not including shares subject to awards assumed in connection with certain transactions, including the Merger.  Upon the consummation of the Merger, the Company assumed approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,171</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares subject to outstanding common stock options granted under the Company&#8217;s 2016 Incentive Plan that will remain exercisable through December 29, 2018 for former Company employees and directors. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The number of shares reserved for issuance under the 2017 Equity Incentive Plan will automatically increase on January 1&#160;of each year, for a period of not more than </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years, commencing on January 1&#160;of the year following the year in which the effective date occurs and ending on (and including) January&#160;1, 2027, in an amount equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the total number of shares of common stock outstanding on December 31&#160;of the preceding calendar year. Notwithstanding the foregoing, the board of directors may act prior to January 1&#160;of a given year to provide that there will be no January 1&#160;increase in the share reserve for such year or that the increase in the share reserve for such year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. The number of shares reserved for issuance under the 2017 Equity Incentive Plan was automatically increased to approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">805,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;on January 1, 2018. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, an aggregate of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">381,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock were reserved for future grants under the Company&#8217;s 2017 Equity Incentive Plan. There were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">no</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;common stock options granted under the 2017 Equity Incentive Plan for the year ended December&#160;31, 2017. </font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:Helvetica,sans-serif;font-size:1pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of operations for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">724</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">229</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,047</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total stock-based compensation </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,267</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,776</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Options to Purchase Shares of Common Stock </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company uses the Black-Scholes option-pricing model and the following assumptions were used to determine the fair value of all its stock options granted during the nine months ended September 30, 2018:</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:85%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.73</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">80.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The weighted-average grant date fair value of options granted during the nine months ended September 30, 2018 was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.73</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. There were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">no</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;stock options granted during the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s expected common stock price volatility assumption is based upon the Company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method, which averages the contractual term of the Company&#8217;s options of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;with the average vesting term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">four years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for an average of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">six years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">zero</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, because the Company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company accounts for forfeitures as they occur.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, there was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of unrecognized compensation cost related to outstanding stock options that is expected to be recognized as a component of the Company&#8217;s operating expenses over a weighted-average period of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.46</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes stock option activity of the Company for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">:</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:41%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted Average Remaining Contractual Term (in years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at January&#160;1, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,240.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">483</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">434</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">34.17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9.26</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options exercisable at September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">265.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The aggregate intrinsic values of outstanding and exercisable stock options at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;were calculated based on the closing price of the Company&#8217;s common stock as reported on the Nasdaq Capital Market on </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.22</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the Company&#8217;s common stock and the exercise price of the underlying stock options.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s570205F8F2B95F749D61ED9F107880E2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">RSUs with Time-Based and Performance-Based Conditions </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company granted RSUs subject to both time-based and performance-based vesting conditions to certain of its employees and&#160;non-employees&#160;pursuant to the 2016 Incentive Plan. These RSUs vest based on both (i)&#160;continued service either over a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-year measurement period or at the end of the required service period and (ii)&#160;the achievement of a liquidity event. The initial vesting date for these RSUs was February&#160;27, 2018. The liquidity event, as defined in the relevant RSU grant agreements, will be satisfied upon the earlier of either: (a) change of control or (b) a qualified public offering. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and December 31, 2017, there were approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;RSUs outstanding with a weighted average grant date fair value of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$52.94</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company recognizes compensation expense related to these RSUs when the liquidity event is deemed probable. As such, no compensation expense was recorded to date as the liquidity event is outside the Company&#8217;s control and not deemed probable until it occurs. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="sDACAB05A571856AE97186988FFBA23E9"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">12.  Subsequent Events</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company evaluated all events or transactions that occurred after </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the condensed consolidated financial statements, the Company did not have any material subsequent events.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><a name="sE51101295F085505849E0302127D762E"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">This management&#8217;s discussion and analysis of financial condition as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">&#32;and results of operations for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">three and nine months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">, respectively, should be read in conjunction with Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in the 2017 Annual Report, and our other public reports filed with the SEC.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s176630BB66905B79ADAD60DE427BB556"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Merger of Galena Biopharma, Inc. and SELLAS Life Sciences Group Ltd. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;29, 2017, we completed the business combination with the privately held Bermuda exempted company, SELLAS Life Sciences Group Ltd., or Private SELLAS, in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of August&#160;7, 2017 and amended November&#160;5, 2017, or the Merger Agreement, among the Company, Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc., Galena Bermuda Merger Sub, Ltd., and Private SELLAS. We refer to this business combination throughout this quarterly report on Form 10-Q as the Merger. As a result of the Merger, our business is now substantially comprised of the business of Private SELLAS, and although we are considered the legal acquiror of Private SELLAS, for accounting purposes, Private SELLAS is considered to have acquired our Company in the Merger. Consequently, the Merger was accounted for as a reverse acquisition and the Private SELLAS financial statements became our financial statements. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Immediately prior to the Merger, we effected a 1-for-30 reverse stock split of our outstanding common stock, par value $0.0001 per share. Under the terms of the Merger Agreement, we issued shares of our common stock to Private SELLAS&#8217; securityholders at an exchange ratio of 43.9972 shares of our common stock in exchange for each common share of Private SELLAS outstanding immediately prior to the Merger. We also assumed all of the restricted stock units, or RSUs, issued and outstanding under the Private SELLAS Stock Incentive Plan #1, and all of the issued and outstanding warrants of Private SELLAS. Accordingly, such RSUs will now be settled in, and such warrants now are exercisable for, shares of our common stock. Accordingly, immediately after the Merger, there were 5,766,891 shares of our common stock outstanding, with the former Private SELLAS securityholders owning 67.5% of our fully diluted common stock, and our pre-Merger securityholders owning the remaining 32.5%.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Upon completion of the Merger, we changed our name from &#8220;Galena Biopharma, Inc.&#8221; to &#8220;SELLAS Life Sciences Group, Inc.,&#8221; our financial statements became those of Private SELLAS and our common stock began trading on The Nasdaq Capital Market under a new ticker symbol &#8220;SLS&#8221; on January&#160;2, 2018 and our financial statements became those of Private SELLAS. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As used in this quarterly report on Form 10-Q, the words &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company,&#8221; and &#8220;SELLAS&#8221; refer to SELLAS Life Sciences Group, Inc. and our consolidated subsidiaries following completion of the Merger. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Overview </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are a late-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapeutics for a broad range of indications. Our lead product candidate, galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. WT1 has been shown to be present in 20 or more cancer types and is one of the most commonly expressed cancer antigens. GPS has been engineered to incorporate novel technology to preserve WT1 antigenicity and overcome the tolerance the immune system commonly develops to tumor antigens, a major challenge in the development of effective immunotherapies for cancer. Based on its mechanism of action as a direct immunizing agent, GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematological malignancies and solid tumor indications. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Phase 2 clinical trials for GPS in two potential indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM, are completed. We have planned Phase 3 clinical trials (pending funding availability) evaluating GPS as monotherapy for these two indications with AML being our priority. GPS is also in early clinical development as a potential treatment for multiple myeloma, or MM, and epithelial ovarian cancer. We also plan to study GPS in up to four additional indications: as a combination therapy in small cell lung cancer, colorectal cancer, triple-negative breast cancer, or TNBC; and, as a monotherapy in chronic myelogenous leukemia, or CML. We received Orphan Drug Product designations from the U.S. Food and Drug Administration, or FDA, as well as Orphan Medicinal Product designations from the European Medicines Agency, or EMA, for GPS for AML, MPM and MM, and Fast Track designation for AML, MPM, and MM from the FDA.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:54px;font-size:1pt;"><font style="font-family:Helvetica,sans-serif;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our pipeline also includes the ongoing development programs of our predecessor company, including novel cancer immunotherapy programs for nelipepimut-S (NeuVax</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;or NPS; a vaccine against the E75 peptide derived from the human epidermal growth factor 2, or HER2, protein), GALE-301 (a vaccine against the E39 peptide derived from the folate binding protein, or FBP), GALE-302 (a vaccine against the J65 peptide derived from FBP) and GALE-401 (a controlled release version of the approved drug anagrelide).  NPS is currently in multiple investigator-sponsored Phase 2 clinical trials in breast cancer</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On April 2, 2018, we announced that a pre-specified interim analysis of safety and efficacy, conducted by an independent Data Safety Monitoring Board, or DSMB, for the investigator sponsored Phase 2b NPS + trastuzumab study demonstrated a clinically meaningful difference in median disease-free survival, or DFS, in favor of the active arm, a primary endpoint of the study. The interim analysis further demonstrated a statistically significant and clinically meaningful improvement in DFS among a cohort of patients with triple negative breast cancer, or TNBC, associated with the NPS + trastuzumab combination. Patients in the TNBC cohort were defined as harboring tumors that were hormone receptor-negative and had low expression (IHC 1+/2+) of HER2. Based on these results, and the DSMB&#8217;s recommendation, we plan to expeditiously seek regulatory guidance by the FDA for further development of NPS + trastuzumab combination therapy in TNBC, a population of breast cancer patients with large unmet need. In June 2018, we announced that the sponsor-principal investigator of this study, after taking into account that key clinical development objectives were met as well as other regulatory considerations, and with our agreement, determined to terminate the study early. In addition, in late May 2018, we conducted two advisory meetings with global experts in regulatory affairs and breast cancer clinical development in order to determine the optimal path for further development of the NPS + trastuzumab combination in TNBC in a pivotal setting and for engagement with the FDA and EMA. Moreover, on October 22, 2018, we announced that the final analysis of data from the Phase 2b NPS + trastuzumab study for the TNBC cohort confirmed the previously reported positive data (from the interim analysis), and further strengthened the evidence for a statistically significant and clinically positive outcome with the combination. This data was presented at the European Society for Medical Oncology (ESMO) 2018 Annual Meeting.  GALE-301 and GALE-302, our E39 folate binding peptide vaccine product candidates, have completed early stage trials in ovarian, endometrial and breast cancers. Both candidates have received Orphan Drug Product designation by the FDA.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Recent Developments</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On July 16, 2018, we consummated an underwritten public offering of 6,845,000 shares of common stock, 4,675,000 pre-funded warrants exercisable for shares of common stock and accompanying common stock warrants to purchase an aggregate of 11,520,000 shares of common stock. At closing, we received aggregate net proceeds from the offering of approximately $21.6 million, after deducting underwriting discounts and commissions and estimated offering expenses.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Following the consummation of the underwritten public offering, pursuant to Section 4.17 of the March 2018 securities purchase agreement, on July 16, 2018, the holders of our Series A Convertible Preferred exchanged an aggregate of $7,871,186 of stated valued and accrued but unpaid dividends on their Series A Convertible Preferred for an aggregate of 3,748,184 shares of our common stock and warrants to purchase an aggregate of 3,748,184 shares of our common stock, and there are no longer any shares of Series A Convertible Preferred issued and outstanding. The warrants have an exercise price of $2.10 per share and a term of five years. In addition, pursuant to their terms, the exercise price of the warrants was adjusted to $2.10 per share from the original exercise price of $6.59 per share.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;text-indent:42px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On November 5, 2018, we announced that we have agreed to a settlement with JGB (Cayman) Newton, Ltd., or JGB, regarding our counterclaims against JGB that were asserted in the litigation originally commenced by JGB.  As part of the settlement, JGB paid us approximately $6.6 million in exchange for a full discharge of all counterclaims asserted by us against JGB in the litigation. We and JGB have also agreed to terminate the senior secured debenture agreement and all related agreements, with JGB releasing all of its interests in the collateral for the senior secured debenture. See Note 8 to the condensed consolidated financial statements for a description of the litigation and settlement agreement.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Components of Results of Operations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Research and Development </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development expenses consist of expenses incurred in connection with the discovery and development of our product candidates. We expense research and development costs as incurred. These expenses primarily include expenses incurred under agreements with contract research organizations, as well as investigative sites and consultants that conduct our preclinical studies and clinical trials, manufacturing expenses, outsourced professional scientific development services, employee-related expenses, which include salaries, benefits and stock-based compensation, expenses relating to regulatory activities, including filing fees paid to regulatory agencies, laboratory materials and supplies used to support our research activities; and allocated expenses, utilities and other facility-related costs.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The successful development of our current and future product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of, or when, if ever, material net cash inflows may commence from any current or future product candidates. This uncertainty is due to the numerous risks and uncertainties associated with the duration and cost of clinical trials, which vary significantly over the life of a project as a result of many factors, including the number of clinical sites included in the trials, the length of time required to enroll suitable patients, the number of patients that ultimately participate in the trials, the number of doses patients receive, the duration of patient follow-up, the results of our clinical trials, the expenses associated with manufacturing, the receipt of marketing approvals, and the commercialization of current and future product candidates.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our expenditures are subject to additional uncertainties, including the terms and timing of regulatory approvals. We may never succeed in achieving regulatory approval for any of our current or future product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or target indications or focus on others. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA, or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. Cancer immunotherapy product commercialization may take several years and millions of dollars in development costs.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development activities are central to our business model. Cancer immunotherapy product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase significantly over the next several years as we add personnel which will increase costs, including stock-based compensation, conduct clinical trials and prepare regulatory filings for our product candidates.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">General and Administrative </font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative expenses consist principally of salaries and related costs for personnel in executive, administrative, finance and legal functions, including stock-based compensation, travel expenses and recruiting expenses. Other general and administrative expenses include facility related costs, patent filing and prosecution costs, professional fees for business development, legal, auditing and tax services and insurance costs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We anticipate that our general and administrative expenses will increase as a result of increased payroll, expanded infrastructure and an increase in accounting, consulting, legal and tax-related services associated with maintaining compliance with stock exchange listing and SEC requirements, investor relations costs, and director and officer insurance premiums associated with being a public company. We also anticipate that our general and administrative expenses will increase in support of our clinical trials as we expand and progress our development programs.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Non-Operating Income (Expense), Net</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense), net consists of change in fair value of our warrant liability, change in fair value of our contingent consideration, loss on settlement of liability-classified warrants, and interest expense, net.  Interest expense, net primarily reflects interest expense incurred on our convertible term notes and other loans held with current and former stockholders, offset by the interest earned from our cash and cash equivalents.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><a name="s6B30B8B51CC852048D8F39C6CAA07921"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Results of Operations for the Three and Nine Months Ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes our results of operations for the three and nine months ended September 30, 2018 and 2017:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(dollars in thousands)</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,720</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,068</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">652</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,881</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total operating expenses and operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,061</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,290</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,229</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,771</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(102</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,873</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(290</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,392</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,102</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(63</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(290</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,455</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, our net loss was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to a net loss of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The decrease of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in net loss was primarily attributable to a decrease in operating loss of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and an increase in non-operating income (expense) of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(dollars in thousands)</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,116</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,079</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,130</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total operating expenses and operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(15,246</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(14,429</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">817</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,062</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(360</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,422</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(14,184</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(14,789</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(605</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">180</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(14,347</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(14,969</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(588</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, our net loss was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$14.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared with a net loss of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The decrease of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in net loss was primarily attributable to an increase in non-operating income (expense) of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;partially offset by an increase in operating loss of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Further analysis of the changes and trends in our operating results are discussed below.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Research and Development </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development expenses were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;increase was primarily attributable to a $0.4 million increase in outsourced clinical and regulatory consulting and a $0.5 million increase in clinical expenses driven by startup costs incurred related to the Phase 1/2 basket trial of GPS in combination with pembrolizumab (Keytruda</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">in multiple tumor types during the third quarter of 2018 and ongoing costs incurred related to the Phase 2b trial of NPS in combination with trastuzumab. In addition, licensing fees increased $0.3 million due to our expanded clinical portfolio as a result of the Merger. These increases were partially offset by a reduction of $0.5 million in stock-based compensation.  We anticipate that our research and development expenses will increase in the remainder of 2018 as we continue to advance our product candidates into and through clinical trials.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development expenses were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the nine months ended September 30, 2017. As compared to the prior period, research and development expenses experienced a $0.7 million increase in clinical and regulatory consulting and a $0.3 million increase in clinical expenses driven by driven by startup costs incurred related to the Phase 1/2 basket trial of GPS in combination with pembrolizumab (Keytruda</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">  </sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">in multiple tumor types during the third quarter of 2018 and ongoing costs incurred related to the Phase 2b trial of NPS in combination with trastuzumab. In addition, personnel related expenses during the period increased $0.3 million due to a one-time severance charge. These increases were partially offset by a $0.7 million decrease in stock-based compensation expense, a $0.3 million decrease in licensing fees due to the timing of milestone payments, and a $0.3 million decrease in manufacturing expenses. We anticipate that our research and development expenses will increase in the remainder of 2018 as we continue to advance our product candidates into and through clinical trials.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">General and Administrative </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative expenses were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;decrease was primarily driven by a $2.0&#160;million decrease in legal fees, a $0.6 million decrease in stock-based compensation, and a $0.2 million decrease in accounting and audit fees. These decreases were partially offset by an increase of $0.4 million in personnel related expenses, a $0.3 million increase in insurance premiums, and a $0.2 million increase in other expenses. The reduction in legal fees during the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was primarily attributable to the settlement of the JGB litigation in November 2018 as described in Note 8 to the condensed consolidated financial statements. We recorded legal fee reimbursements totaling $2.5 million through </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;related to the settlement with JGB. In addition, we received reimbursement for legal fees of $0.5 million from our insurance carrier for previous amounts paid in excess of our deductible related to the Patel litigation described in Note 8 to the condensed consolidated financial statements. These amounts were recorded as a reduction of our general and administrative expenses for the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative expenses were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$9.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The $0.8 million increase was primarily driven by a $0.9&#160;million increase in outside services and public company costs, a $0.9 million increase in insurance premiums, a $0.7&#160;million increase in personnel related expenses, a $0.4&#160;million increase in accounting and audit fees and $0.7 million in other expenses. These increases were partially offset by a $2.8 million decrease in stock-based compensation expense. Overall, general and administrative expenses increased during the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, as a result of an increase in accounting, consulting, and tax-related services associated with maintaining compliance with listing and SEC requirements, investor relations costs, and director and officer insurance premiums associated with being a public company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Non-Operating Income (Expense), Net</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense), net for the three and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively, was as follows (dollars in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in fair value of warrant liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in fair value of the contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(162</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(162</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,025</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,025</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss on settlement of liability-classified warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gain on extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">766</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">766</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">766</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">766</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interest expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(360</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total non-operating income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,771</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(102</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,873</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,062</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(360</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,422</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The increase in our net non-operating income during the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was primarily due to a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;gain arising from the decrease in the fair value of liability-classified warrants to acquire shares of common stock and a $0.8 million gain on extinguishment of debt partially offset by a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;increase in the fair value of the contingent consideration liability. The increase in our net non-operating income during the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was primarily due to a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;gain arising from the decrease in the fair value of liability-classified warrants to acquire shares of common stock and a $0.8 million gain on extinguishment of debt partially offset by a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;increase in the fair value of the contingent consideration liability. The decrease in the estimated fair value of our warrant liability was primarily due to the decrease in our common stock price. The change in the estimated fair value of the contingent consideration during the three and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;reflects an adjusted probability and time line for the potential approval of NPS associated with the positive interim data from the prospective, randomized, single-blinded, controlled Phase 2b investigator-sponsored clinical trial of trastuzumab +/- NPS in HER2 1+/2+ breast cancer patients in the adjuvant setting to prevent recurrences that was announced on April 2, 2018.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The $0.8 million gain on extinguishment of debt relates to the settlement with JGB, the holder of our former senior secured debenture. As disclosed in the Overview and elsewhere in this quarterly report on Form 10-Q, we were involved in litigation with JGB regarding the senior secured debenture, and entered into a settlement agreement in November 2018. As a result of the settlement, the $0.8 million of additional interest that was due at maturity was forgiven. See Note 8 to the condensed consolidated financial statements for a description of the litigation and settlement agreement.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The $0.7 million loss on settlement of liability-classified warrants relates to warrants to acquire shares of common stock issued by Galena in February 2017 that were assumed in the Merger. During the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, a total of 534,333 of the Galena February 2017 liability-classified warrants to acquire shares of common stock were canceled under various warrant exchange agreements. We issued 54,343 shares of our common stock in exchange for the surrender and cancellation of warrants to acquire 121,667 shares of our common stock and $1.0 million in convertible promissory notes in exchange for the surrender and cancellation of warrants to acquire 412,667 shares of our common stock, as described in Note 7 to the condensed consolidated financial statements. The fair value of the consideration exchanged totaling $1.3 million exceeded the fair value of the warrant liability of the warrants canceled by $0.7 million and is recorded as loss on settlement of liability-classified warrants in the condensed consolidated statement of operations for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interest expense, net for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2017 primarily consists of interest expense incurred on our long-term debt, partially offset by nominal interest earned from our cash and cash equivalents.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The change in fair value of warrant liability, change in fair value of contingent consideration, loss on settlement of liability-classified warrants, and gain on extinguishment of debt are all non-cash in nature. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Income Tax Expense</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For the nine months ended September 30, 2018 and 2017, we recognized income tax expense of&#160;$0.2 million and for the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;we recognized $0.1 million of income tax expense. We continue to maintain a full valuation allowance against our net deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><a name="s55FBC3F14E8A545389BDEC95B609CD8A"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have not generated any revenue from product sales or collaboration and licensing agreements in the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2017. Since inception, we have incurred net losses, used net cash from our operations, and have funded substantially all of our operations through proceeds of private placements and convertible notes. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On July 16, 2018, we closed an underwritten public offering, or the July 2018 Offering, issuing 6,845,000 shares of common stock and 4,675,000 pre-funded warrants exercisable for shares of common stock and accompanying common stock warrants to purchase an aggregate of 11,520,000 shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined price of $2.10 per share and accompanying common stock warrant. The pre-funded warrants and accompanying common stock warrants were sold at a combined price of $2.0999 per pre-funded warrant and accompanying common stock warrant. Each common stock warrant sold with the shares of common stock represents the right to purchase one share of our common stock at an exercise price of $2.10 per share. The common stock warrants are exercisable immediately and will expire on July 16, 2023, five years from the date of issuance. The pre-funded warrants are exercisable immediately, have an exercise price of $0.0001 per share, and will expire on July 16, 2023, five years from the date of issuance. The net proceeds to us from the July 2018 Offering, after deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants, were approximately $21.6 million.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On March&#160;7, 2018, we entered into a definitive securities purchase agreement to issue an aggregate of 10,700 shares of Series A Convertible Preferred, and warrants to acquire 1,383,631 shares of our common stock in a private placement transaction to a select group of institutional investors. The sale of the Series A Convertible Preferred closed in two tranches and resulted in aggregate gross proceeds to us of approximately $10.7 million. We closed the first tranche for approximately $6.0 million gross proceeds on March&#160;9, 2018. We closed the second tranche of the remaining $4.7 million gross proceeds on May 1, 2018, following the receipt of necessary stockholder approval. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, in the first half of 2018, JGB redeemed $2.8 million of outstanding principal that was satisfied with 659,529 shares of our common stock and redeemed $0.6 million of outstanding principal, which we satisfied in cash. As a result of the redemptions, we transferred $1.8 million out of restricted cash and cash equivalents and into unrestricted cash and cash equivalents to be used to fund our ongoing operations. Pursuant to the terms of the settlement agreement in the JGB Action, as described in Note 8 to the condensed consolidated financial statements, JGB made a one-time payment to the Company of $6.6 million in November 2018.  We recorded the entire settlement amount as an other receivable as of September 30, 2018 in the condensed consolidated balance sheet as of September 30, 2018 and received the amount in November 2018.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$68.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, cash and cash equivalents of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and restricted cash and cash equivalents of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. We also received $6.6 million in November 2018 pursuant to the settlement agreement with JGB and $0.5 million in litigation insurance recovery in October 2018. In addition, we had accounts payable and accrued expenses and other current liabilities of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$11.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and indebtedness of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. Our outstanding indebtedness consists of $0.1 million in promissory notes.  These matters raise substantial doubt about our ability to continue as a going concern. Our condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. We anticipate incurring additional losses until such time, if ever, that we can generate significant sales of any current or future product candidates in development. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">This going concern assumption is based on management&#8217;s assessment of the sufficiency of our current and future sources of liquidity considering whether or not it is probable we will be able to meet our obligations as they become due for at least one year from the date our condensed consolidated financial statements are available to be issued, and if not, whether our liquidation is imminent. Our management believes that our cash of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, including amounts received in October and November 2018, will enable us to fund our operating expenses and capital expenditure requirements through March 2019. We will require substantial additional financing to fund our operations thereafter and to commercially develop any current or future product candidates. Alternatively, we will be required to scale back our plans and place certain activities on hold. We currently do not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. However, our management is currently evaluating different strategies to obtain the required funding for future operations. These strategies may include public and private placements of equity and/or debt securities, payments from potential strategic research and development collaborations, and licensing and/or marketing arrangements with pharmaceutical companies. Additionally, we continue to engage in active discussions with global and regional pharmaceutical companies for licensing and/or co-development rights to our late- and early-stage pipeline candidates. There can be no assurance that these future funding efforts will be successful. If we cannot obtain the necessary funding, we will need to delay, scale back or eliminate some or all of our research and development programs; consider other various strategic alternatives, including a merger or sale; or cease operations. However, at this stage our management does not believe liquidation is imminent. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our future operations are highly dependent on a combination of factors, including (i)&#160;the timely and successful completion of additional financing discussed above, (ii)&#160;our ability to complete revenue-generating partnerships with pharmaceutical companies, (iii)&#160;the success of our research and development activities, (iv)&#160;the development of competitive therapies by other biotechnology and pharmaceutical companies, and, ultimately, (v)&#160;regulatory approval and market acceptance of our proposed future products. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes our cash flows from operating, investing, and financing activities for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(amounts in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">For the Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Net cash (used in) provided by:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(25,867</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(9,247</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">23,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,668</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,593</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Net Cash Flow from Operating Activities</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net cash used in operating activities of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$25.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;during the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was primarily attributable to our net loss of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$14.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. This amount was offset by various net non-cash charges of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which was comprised of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;increase in the fair value of our contingent consideration liability, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;increase in the fair value of common stock issued in connection with litigation settlements, and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;loss on settlement of liability-classified warrants, partially offset by a gain of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;from the decrease in the fair value of liability-classified warrants and a $0.8 million gain on extinguishment of debt. The net change in our operating assets and liabilities of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$11.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;is primarily attributable to an increase in other receivables of $6.6 million related to the settlement with JGB that was received in November 2018 and a decrease in our accounts payable and accrued expenses. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net cash used in operating activities was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$9.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which was primarily attributable to our net loss of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. This amount was offset by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in non-cash stock-based compensation, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;on the loss on extinguishment of accounts payable satisfied with shares of common stock, and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of services paid with shares of common stock. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Net Cash Flow from Financing Activities</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We generated </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$23.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of net cash from financing activities for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which was primarily attributable to $21.6 million in net proceeds from the sale of common stock and common stock warrants, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$9.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in net proceeds from the sale of the Series A Convertible Preferred and warrants, partially offset by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$7.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in principal payments on our previously outstanding Senior Secured Debenture. We generated </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of net cash from financing activities for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which was primarily attributable to $6.0 million in net proceeds from the sale of shares of our common stock, partially offset by $0.3 million in principal payments on long-term debt.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s9E2E614595D058C0ADB85846CDA2A002"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have not entered into any off-balance sheet financing arrangements other than operating leases as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Critical Accounting Policies and Estimates</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In the 2017 Annual Report, we disclosed our critical accounting policies and estimates upon which our financial statements are derived. There have been no material changes to these policies since December&#160;31, 2017 that are not included in Note 3 of the accompanying condensed consolidated financial statements for the three and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. Readers are encouraged to read the 2017 Annual Report in conjunction with this quarterly report.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s205104546BCF5629AFDCC7748CA37F8B"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">&#160;ITEM&#160;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><a name="sBFC92921BC385B65A2DF0BEDD3742301"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;4. CONTROLS AND PROCEDURES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Based on the evaluation of our disclosure controls and procedures (as defined in the Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) required by Exchange Act Rules&#160;13a-15(b) or 15d-15(b), our principal executive officer and our principal financial officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were not effective as a result of the material weakness in our internal control over financial reporting discussed below.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Material Weakness and Remediation Plan </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In connection with the audit of our 2017 consolidated financial statements, we were informed by our independent registered public accounting firm that we had a material weakness in our internal control over financial reporting due to our lack of sufficient management and personnel with appropriate expertise in GAAP and SEC rules and regulations with respect to financial reporting during the year ended December 31, 2017. At that time, we had only one designated finance and accounting employee and relied primarily on consultants to provide many accounting, book-keeping, and administrative services. This reflects the fact that prior to the Merger, Private SELLAS was a small privately-held company, and that in connection with the Merger, Private SELLAS historical operations, and not that of the predecessor company, represent virtually the entirety of the combined business. In addition, following the Merger, which occurred on December 29, 2017, our accounting and financial systems, as well as personnel, were replaced by those of Private SELLAS</font><font style="font-family:inherit;font-size:10pt;">,</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In order to remedy these material weaknesses, during the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, we hired three additional finance and accounting personnel, including a Chief Financial Officer, to build out our financial reporting team and further develop and document accounting policies and procedures. Additionally, during the first quarter of 2018, we engaged a consulting firm to assist us in evaluating the design of our internal control over financial reporting, including disclosure controls and procedures. Our goal is to remediate this material weakness as soon as practical as part of our plan to implement and mature our system of internal control over financial reporting. We expect to complete our remediation of the material weakness by December 31, 2018.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Changes in Internal Control over Financial Reporting </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other than the remedial activities described above, there has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended September 30, 2018 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><a name="s3DCE24C577BD50D8A27516B2D73C69AF"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">PART II - OTHER INFORMATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s0C16AA4AD3255C85B76F5FA8B3439F73"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;1. LEGAL PROCEEDINGS</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Please refer to Note 8 (Legal Proceedings, Commitments and Contingencies) to our condensed consolidated financial statements contained in Part I, Item 1 (Financial Statements) of this quarterly report on Form 10-Q, which is incorporated into this item by reference.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s84DF9D095163509EAA592F85EFFEED97"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;1A. RISK FACTORS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Please refer to our note on forward-looking statements on page 2 of this quarterly report on Form 10-Q, which is incorporated into this item by reference.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in Exhibit 99.1 in our Current Report on Form 8-K dated July 18, 2018, which could materially affect our business, financial condition or future results. The risks described in such Current Report on Form 8-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition, operating results and stock price.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s43C5AFCA97D450B39B3226BC1840640D"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">None.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s2FC74473CE225A19BD2F636F641310ED"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">None.</font></div><div><a name="sE48DAD5877455F8A903989777F597741"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;4. Mine Safety Disclosures</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Not applicable.</font></div><div><a name="sD650A82A4A4851EB8FD8260F7F8A60A2"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;5. Other Information</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">None.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><a name="sCB7C3EA7162A5E5FBCE14B6EA8F151EB"></a></div><div><br></div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;6. EXHIBITS</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:9%;"></td><td style="width:58%;"></td><td style="width:7%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">#</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Filing Date</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex31.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Composite Amended and Restated Certificate of Incorporation of the Registrant (formerly, Galena Biopharma, Inc.) amended as of December 27, 2017</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">April 13, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex33.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amended and Restated By-Laws of the Registrant</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">January 5, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex11.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Underwriting Agreement dated July 12, 2018 between the Registrant and Cantor Fitzgerald &amp; Co. and Oppenheimer &amp; Co. Inc.</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">July 18, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex101.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Agreement including form of accompanying Common Warrant as Exhibit B thereto, dated as of July 16, 2018, among the Registrant, Computershare, Inc., and Computershare Trust Company N.A.</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">July 18, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex102.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Pre-funded Warrant</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">July 18, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.4</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/d610765dex103.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Form of Warrant issued in exchange of Series A Preferred Stock</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">July 18, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.5</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1390478/000139047818000032/sls-20181105x8xkxexhibit101.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Settlement Agreement between SELLAS Life Sciences Group, Inc. and individual named defendants, on the one hand, and JGB (Cayman) Newton, Ltd., JGB Collateral LLC, JGB Capital Offshore Ltd., JGB Partners L.P., and JGB Capital L.P., on the other hand, dated as of November 5, 2018.</font></a></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">November 9, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="sls20180930ex311.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Certification of Principal Executive Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.*</font></a></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31.2</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="sls20180930ex312.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Certification of Principal Financial Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.*</font></a></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32.1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="sls20180930ex321.htm"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;**</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Instance Document.*</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Schema.*</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase.*</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase.*</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase.*</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase.*</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Filed herewith</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The certification attached as Exhibit 32.1 accompany this quarterly report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><a name="s83C804AD917258A8A3C22C222906463C"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:47%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">SELLAS Life Sciences Group, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Angelos M. Stergiou</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Angelos M. Stergiou, MD, ScD h.c.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Date: November&#160;14, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Gene Mack</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gene Mack</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Date: November&#160;14, 2018</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>sls20180930ex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sDEED212080235E82A4DDA283BFF79AE3"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit&#160;31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">I, Angelos M. Stergiou, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1. I have reviewed this Quarterly Report on Form 10-Q of SELLAS Life Sciences Group, Inc.;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Dated: </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">November&#160;14, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Angelos M. Stergiou</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Angelos M. Stergious, MD, ScD h.c.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>sls20180930ex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sA37035C41773510DB7703FFADEA08485"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit&#160;31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">I, Gene Mack, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1. I have reviewed this Quarterly Report on Form 10-Q of SELLAS Life Sciences Group, Inc.;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Dated: </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">November&#160;14, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Gene Mack</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Gene Mack</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>sls20180930ex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5E68401CB4475D38A931A8AA1DA0AB08"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit&#160;32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In connection with the accompanying Quarterly Report of SELLAS Life Sciences Group, Inc., (the &#8220;Company&#8221;) on Form 10-Q for the period ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned officers of the Company certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1. The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2. The information contained in the Report fairly presents, in all material respects, the Company&#8217;s financial condition and result of operations.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:46%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Angelos M. Stergiou</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Angelos M. Stergious, MD, ScD h.c.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Date: November 14, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Gene Mack</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Gene Mack</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Date: November 14, 2018</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">A signed original of this written statement required by&#160;Rule&#160;13a-14(b)&#160;of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section&#160;1350 has been provided to the Registrant and will be retained by the Registrant and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">This certification accompanies the Form&#160;10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>gale-20180930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:9FB54F099F145FFCACCBDA91DC6E16DE,x:97a21d3dd8ec48a5befe4480a3d352bd-->
<xbrli:xbrl xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2018-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:gale="http://www.galenabiopharma.com/20180930" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="gale-20180930.xsd" xlink:type="simple" />
	<xbrli:context id="FD2018Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4Nov9">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_srt_LitigationCaseAxis_gale_PatelvsGalenabiopharmaIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gale:PatelvsGalenabiopharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_srt_LitigationCaseAxis_gale_PatelvsGalenabiopharmaIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gale:PatelvsGalenabiopharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_srt_LitigationCaseAxis_gale_PatelvsGalenabiopharmaIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gale:PatelvsGalenabiopharmaIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec28_dei_LegalEntityAxis_gale_GalenaBiopharmaIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:GalenaBiopharmaIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_srt_CounterpartyNameAxis_gale_PreMergerSecurityholdersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:PreMergerSecurityholdersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_srt_CounterpartyNameAxis_gale_PrivateSELLASSecurityHoldersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:PrivateSELLASSecurityHoldersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec29_dei_LegalEntityAxis_gale_GalenaBiopharmaIncMember_srt_CounterpartyNameAxis_gale_PrivateSELLASSecurityHoldersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:GalenaBiopharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gale:PrivateSELLASSecurityHoldersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-29</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec28_dei_LegalEntityAxis_gale_GalenaBiopharmaIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:GalenaBiopharmaIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-28</xbrli:startDate>
			<xbrli:endDate>2017-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1March7_us-gaap_StatementClassOfStockAxis_gale_SeriesANonvotingConvertibleMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesANonvotingConvertibleMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-16</xbrli:startDate>
			<xbrli:endDate>2018-07-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-16</xbrli:startDate>
			<xbrli:endDate>2018-07-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_FirstTrancheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:FirstTrancheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-09</xbrli:startDate>
			<xbrli:endDate>2018-03-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1March7_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q3July16">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-07-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2May01_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_SecondTrancheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:SecondTrancheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-07</xbrli:startDate>
			<xbrli:endDate>2018-03-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-16</xbrli:startDate>
			<xbrli:endDate>2018-07-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2_us-gaap_StatementClassOfStockAxis_gale_SeriesANonvotingConvertibleMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesANonvotingConvertibleMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-07</xbrli:startDate>
			<xbrli:endDate>2018-03-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q3July16_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-07-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:AmendmentAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_gale_CorporateCreditCardsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">gale:CorporateCreditCardsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_gale_CorporateCreditCardsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">gale:CorporateCreditCardsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:AmendmentAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_NonrecurringAdjustmentAxis_us-gaap_AcquisitionRelatedCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:AcquisitionRelatedCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_NonrecurringAdjustmentAxis_us-gaap_AcquisitionRelatedCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:AcquisitionRelatedCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BusinessAcquisitionAxis_gale_AptheraInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:AptheraInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_srt_LitigationCaseAxis_gale_JBGLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gale:JBGLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4November5th_srt_LitigationCaseAxis_gale_JGBActionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gale:JGBActionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-11-05</xbrli:startDate>
			<xbrli:endDate>2018-11-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May10_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Apr30_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2April30th_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q3September24th_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4October16th_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:AmendmentAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-10</xbrli:startDate>
			<xbrli:endDate>2016-05-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Aug_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:AmendmentAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4November5th2018_srt_LitigationCaseAxis_gale_JGBActionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gale:JGBActionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-05</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:AmendmentAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2May18th2018_srt_LitigationCaseAxis_gale_JGBActionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gale:JGBActionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-18</xbrli:startDate>
			<xbrli:endDate>2018-05-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3October2018_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4November14th_srt_LitigationCaseAxis_gale_JGBActionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gale:JGBActionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-11-14</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_srt_LitigationCaseAxis_gale_JGBActionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gale:JGBActionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3July24_srt_LitigationCaseAxis_gale_PatelvsGalenabiopharmaIncMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gale:PatelvsGalenabiopharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-24</xbrli:startDate>
			<xbrli:endDate>2017-07-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4October23rd_srt_LitigationCaseAxis_gale_JGBActionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gale:JGBActionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-23</xbrli:startDate>
			<xbrli:endDate>2018-10-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2May5th2018_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:AmendmentAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-18</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementFirstClosingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:PrivatePlacementFirstClosingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-09</xbrli:startDate>
			<xbrli:endDate>2018-03-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementClassOfStockAxis_gale_SeriesANonvotingConvertibleMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesANonvotingConvertibleMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2May2018">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementFirstClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:PrivatePlacementFirstClosingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Mar9_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementFirstClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:PrivatePlacementFirstClosingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-09</xbrli:startDate>
			<xbrli:endDate>2018-03-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementFirstClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:PrivatePlacementFirstClosingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-09</xbrli:startDate>
			<xbrli:endDate>2018-03-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementSecondClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:PrivatePlacementSecondClosingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-09</xbrli:startDate>
			<xbrli:endDate>2018-03-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2May01_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementFirstClosingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:PrivatePlacementFirstClosingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementSecondClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gale:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gale:PrivatePlacementSecondClosingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gale:PurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_Prefunded2018OfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:Prefunded2018OfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_July2018OfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2018OfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeriesAConvertiblePreferredWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_Prefunded2018OfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:Prefunded2018OfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_EqcWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:EqcWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_EqcWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:EqcWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:OtherWarrantIssuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_July2018OfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2018OfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:February2017WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeriesAConvertiblePreferredWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeriesAConvertiblePreferredWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_EqcWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:EqcWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:February2017WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:OtherWarrantIssuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:OtherWarrantIssuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:February2017WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_Prefunded2018OfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:Prefunded2018OfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_July2018OfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:July2018OfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-29</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:OtherWarrantIssuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:February2017WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4January1st">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec29_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-29</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1jan1_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec29_us-gaap_PlanNameAxis_gale_IncentivePlan2016Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:IncentivePlan2016Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-29</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gale:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="tranche">
		<xbrli:measure>gale:tranche</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="year">
		<xbrli:measure>gale:year</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="counterclaim">
		<xbrli:measure>gale:counterclaim</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2018Q3YTD" id="Fact-2485B334E6B7DA9CD5F317BC8F6C51FC">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2018Q3YTD" id="Fact-E5EE5EE06245890773EA17BC8FC067AC">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2018Q3YTD" id="Fact-0E2D6F4DABD2F97A421A17BC8FC4A891">Q3</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2018Q3YTD" id="Fact-00C56E5846EE0DB1EC3017BC8F91E2E8">2018</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2018Q3YTD" id="Fact-277D688A40EA833C4DBF17BC8FC8C59B">2018-09-30</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2018Q3YTD" id="Fact-3427E6B97FF37A4D270417BC8FC1E246">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2018Q3YTD" id="Fact-4DB30AC2ECAF183BB6D517BC8FC9396B">0001390478</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2018Q4Nov9" decimals="INF" id="Fact-39DB4B70521EF93445C917BC8FC83D4A" unitRef="shares">22026476</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityEmergingGrowthCompany contextRef="FD2018Q3YTD" id="Fact-1BE6B8E2EF5AC7FFC6B208B880538FDE">false</dei:EntityEmergingGrowthCompany>
	<dei:EntityFilerCategory contextRef="FD2018Q3YTD" id="Fact-4CB5C4F1AA39F759CDAF17BC8FBF5329">Non-accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2018Q3YTD" id="Fact-EDED72C7B1DFE192B6C317BC8F5FB082">SELLAS Life Sciences Group, Inc.</dei:EntityRegistrantName>
	<dei:EntitySmallBusiness contextRef="FD2018Q3YTD" id="Fact-CA7F3DA82E9281573E0708B9214E4F4E">true</dei:EntitySmallBusiness>
	<dei:TradingSymbol contextRef="FD2018Q3YTD" id="Fact-3438893CA2D0A0E2353917BC8FC2B852">SLS</dei:TradingSymbol>
	<gale:BalanceOfRestrictedCashOverSeniorSecuredDebenture contextRef="I2018Q3September24th_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-D30C44B902ADA39B2AB3F5D90090E531" unitRef="usd">1600000</gale:BalanceOfRestrictedCashOverSeniorSecuredDebenture>
	<gale:BalanceOfRestrictedCashOverSeniorSecuredDebenture contextRef="I2018Q4November5th2018_srt_LitigationCaseAxis_gale_JGBActionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-8EB4C03E9D9287873C45F5D90FBBCFCA" unitRef="usd">1600000</gale:BalanceOfRestrictedCashOverSeniorSecuredDebenture>
	<gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings contextRef="FD2017Q3YTD" decimals="-3" id="Fact-E267D71B8C183FAA1CF817BC8FBD38D8" unitRef="usd">0</gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
	<gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings contextRef="FD2018Q3YTD" decimals="-3" id="Fact-C390C39607FA74D43A3E17BC8FC61FBE" unitRef="usd">5340000</gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
	<gale:ChangeInFairValueOfContingentPurchaseConsideration contextRef="FD2017Q3YTD" decimals="-3" id="Fact-C00E7D1132BE79ED1FBD17BC8FBF070D" unitRef="usd">0</gale:ChangeInFairValueOfContingentPurchaseConsideration>
	<gale:ChangeInFairValueOfContingentPurchaseConsideration contextRef="FD2018Q3YTD" decimals="-3" id="Fact-4018417619544A0E981417BC8F92BD5C" unitRef="usd">-4025000</gale:ChangeInFairValueOfContingentPurchaseConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2017Q3QTD" decimals="-3" id="Fact-2F1DFAAF76E369F51CDD17BC8F6628C9" unitRef="usd">0</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2017Q3YTD" decimals="-3" id="Fact-FBE5A66FFAFCDDC846F417BC8F69B3B9" unitRef="usd">0</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2018Q3QTD" decimals="-3" id="Fact-0D5FFFA2448169403B8717BC8F6B791B" unitRef="usd">-162000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2018Q3YTD" decimals="-3" id="Fact-17B6DC9D6896B93C73FA17BC8F6132F8" unitRef="usd">-4025000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2018Q3YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-3E234541A95E76A9813717BC8FA7443F" unitRef="usd">4025000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-916D103FA74492C4B4D017BC8F99C404" unitRef="usd">5340000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-776AE1BE67C10E17779317BC8FA5E420" unitRef="usd">778000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-31EC0E2EF750E5E1001217BC8FAB3F4E" unitRef="usd">4000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="-3" id="Fact-9B887ACA21F9B7309A1117BC8FA7B17A" unitRef="usd">4558000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded contextRef="I2018Q3July16" decimals="INF" id="Fact-1744F706C488197B317A17BC8F8550C5" unitRef="usdPerShare">0.0001</gale:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2018Q3YTD" decimals="-3" id="Fact-727F40EBEBD99649693717BC8F9F90B5" unitRef="shares">2525000</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_EqcWarrantsMember" decimals="-3" id="Fact-85554C9DB08F38324EC417BC8F9D382A" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-302C8345EE7FF0F57B0B17BC8F9949A9" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_July2018OfferingMember" decimals="-3" id="Fact-CE91652A01F523BC5F8FF9F43A9B56C7" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-4B62054E0678F644596C17BC8F9A8DAF" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_Prefunded2018OfferingMember" decimals="-3" id="Fact-4AA72A7B787AE90E85E7F9F3271A9C84" unitRef="shares">2525000</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="-3" id="Fact-1EA8489CF2B82F632B8E17BC8FA09427" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassofWarrantorRightCanceledOrExpired contextRef="FD2018Q3YTD" decimals="-3" id="Fact-4E35397EF924490D845317BC8FC2F163" unitRef="shares">541000</gale:ClassofWarrantorRightCanceledOrExpired>
	<gale:ClassofWarrantorRightCanceledOrExpired contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-228BF036BBE14FB6E49717BC8FBF2F08" unitRef="shares">535000</gale:ClassofWarrantorRightCanceledOrExpired>
	<gale:ClassofWarrantorRightCanceledOrExpired contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_July2018OfferingMember" decimals="-3" id="Fact-FDBA8D504DA6B171BB0FF9F43EC3A3C1" unitRef="shares">0</gale:ClassofWarrantorRightCanceledOrExpired>
	<gale:ClassofWarrantorRightCanceledOrExpired contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-C460CA5710E4CF34D61717BC8FC11CA2" unitRef="shares">6000</gale:ClassofWarrantorRightCanceledOrExpired>
	<gale:ClassofWarrantorRightCanceledOrExpired contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_Prefunded2018OfferingMember" decimals="-3" id="Fact-922D2F2F3DD2E8971DE5F9F32A0B64F5" unitRef="shares">0</gale:ClassofWarrantorRightCanceledOrExpired>
	<gale:ClassofWarrantorRightGranted contextRef="FD2018Q3YTD" decimals="-3" id="Fact-F4E6553E20E740D48F8117BC8F9BD2F6" unitRef="shares">21327000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_EqcWarrantsMember" decimals="-3" id="Fact-3997C1E904C18E45356B17BC8F9CD02A" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-F8981051E07465C5E5B717BC8F9C93B6" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_July2018OfferingMember" decimals="-3" id="Fact-F388B3B66BA0D1D74ED4F9F435AC3D4C" unitRef="shares">15268000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-4AD88D37D2CDC6224F7C17BC8F9D2B52" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_Prefunded2018OfferingMember" decimals="-3" id="Fact-55E6B21CD044D72E1F04F9F32466F665" unitRef="shares">4675000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="-3" id="Fact-956FC10E7B0E42F5465B17BC8F9A0BF1" unitRef="shares">1384000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock contextRef="FD2018Q3YTD" decimals="INF" id="Fact-CF81593614771DE6E1F217BC8FB63E74" unitRef="shares">121667</gale:ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock>
	<gale:ClassofWarrantorRightTerm contextRef="D2017Q4Dec29" id="Fact-843572B1E05343A68B7517BC8FAA4018">P5Y</gale:ClassofWarrantorRightTerm>
	<gale:ClassofWarrantorRightTerm contextRef="D2018Q2_us-gaap_StatementClassOfStockAxis_gale_SeriesANonvotingConvertibleMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" id="Fact-1099CCC6A4F7E7372CAF17BC8F7FD58C">P5Y6M</gale:ClassofWarrantorRightTerm>
	<gale:ClassofWarrantorRightTerm contextRef="D2018Q3" id="Fact-D4BDC8C44A524E7D271517BC8F819166">P5Y</gale:ClassofWarrantorRightTerm>
	<gale:ClosingPriceOfCommonStock contextRef="FI2018Q3" decimals="INF" id="Fact-083FFBCE0DA267855F0117BC8F895258" unitRef="usdPerShare">1.22</gale:ClosingPriceOfCommonStock>
	<gale:CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan contextRef="FI2018Q3" decimals="-3" id="Fact-C34B03A2C02805149F2B17BC8F8C1A97" unitRef="shares">115000</gale:CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan>
	<gale:CommonStockConversionRatio contextRef="D2017Q4Dec29_dei_LegalEntityAxis_gale_GalenaBiopharmaIncMember_srt_CounterpartyNameAxis_gale_PrivateSELLASSecurityHoldersMember" decimals="INF" id="Fact-9B16215FD97DC3328D0917BC8F783B08" unitRef="number">43.9972</gale:CommonStockConversionRatio>
	<gale:CommonStockIssuedDuringThePeriodForCancellationOfWarrants contextRef="FD2018Q3YTD" decimals="INF" id="Fact-D25D4E5EC4B33B029C8C17BC8F8734AB" unitRef="shares">54613</gale:CommonStockIssuedDuringThePeriodForCancellationOfWarrants>
	<gale:CommonStockSharesAcquiredinExchangeforWarrants contextRef="FD2018Q3YTD" decimals="INF" id="Fact-1E141BB13FAC5342288617BC8FC0482C" unitRef="shares">412667</gale:CommonStockSharesAcquiredinExchangeforWarrants>
	<gale:CommonStockSharesAcquiredinExchangeforWarrants contextRef="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-CE0CC97D7CDA2258DD4417BC8F732FEE" unitRef="shares">412667</gale:CommonStockSharesAcquiredinExchangeforWarrants>
	<gale:ConsiderationExchangedFairValue contextRef="FI2018Q3" decimals="-5" id="Fact-554A9E1BC58808992F5217BC8FAE24EA" unitRef="usd">1200000</gale:ConsiderationExchangedFairValue>
	<gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion contextRef="FI2017Q4" decimals="-3" id="Fact-A5EBCBCC8F9B68262C5717BC8F63B3CE" unitRef="usd">1294000</gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
	<gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion contextRef="FI2018Q3" decimals="-3" id="Fact-422A7D3765D0900F458917BC8F77A2F1" unitRef="usd">5319000</gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
	<gale:ContractResearchPayable contextRef="FI2017Q4" decimals="-3" id="Fact-CC540A06D5D0D83192E717BC8F864CDF" unitRef="usd">51000</gale:ContractResearchPayable>
	<gale:ContractResearchPayable contextRef="FI2018Q3" decimals="-3" id="Fact-8BB40CF40CDB1876376517BC8F82EAD4" unitRef="usd">583000</gale:ContractResearchPayable>
	<gale:ConvertiblePreferredStockConversionPrice contextRef="FI2018Q3_us-gaap_StatementClassOfStockAxis_gale_SeriesANonvotingConvertibleMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="2" id="Fact-79DE0BF0D13E995A95BE17BC8F9145CA" unitRef="usdPerShare">1.00</gale:ConvertiblePreferredStockConversionPrice>
	<gale:ConvertiblePreferredStockConversionPrice contextRef="I2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-D11F7B909FC4E327420717BC8FA45300" unitRef="usdPerShare">5.80</gale:ConvertiblePreferredStockConversionPrice>
	<gale:ConvertiblePreferredStockConversionPrice contextRef="I2018Q1March7_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-20CC756F8D2100DD9D8217BC8F87A0AB" unitRef="usdPerShare">6.59</gale:ConvertiblePreferredStockConversionPrice>
	<gale:ConvertiblePreferredStockDividends contextRef="FD2018Q3YTD" decimals="-3" id="Fact-30552BE31ACB65BD9DCD17BC8F6E8A8D" unitRef="usd">487000</gale:ConvertiblePreferredStockDividends>
	<gale:ConvertiblePreferredStockDividends contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-9F2BD7F81D0010FD049617BC8F5FB915" unitRef="usd">487000</gale:ConvertiblePreferredStockDividends>
	<gale:ConvertiblePreferredStockIssuedShares contextRef="I2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementFirstClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-749D671963136A58A91917BC8F931513" unitRef="shares">5987</gale:ConvertiblePreferredStockIssuedShares>
	<gale:ConvertiblePreferredStockIssuedShares contextRef="I2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementSecondClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-C0AFB145109975BA774C17BC8FA66402" unitRef="shares">4713</gale:ConvertiblePreferredStockIssuedShares>
	<gale:ConvertiblePreferredStockNumberOfTranches contextRef="FI2018Q3_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-F6798FFDD6AECC442C460955D4079CE4" unitRef="tranche">2</gale:ConvertiblePreferredStockNumberOfTranches>
	<gale:DebtInstrumentCovenantLiquidityCovenant contextRef="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-211FCF015F534B2BBEC717BC8FA9EB48" unitRef="usd">18500000</gale:DebtInstrumentCovenantLiquidityCovenant>
	<gale:DebtInstrumentCovenantLiquidityCovenant contextRef="I2017Q3Aug_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-0E08CAB44A1863D89CA9FA19D02375A8" unitRef="usd">18500000</gale:DebtInstrumentCovenantLiquidityCovenant>
	<gale:DebtInstrumentRedemptionPrincipalAmountRedeemed contextRef="FD2018Q3YTD" decimals="-5" id="Fact-3CE3E4C66D3FF96175ABF5D5A6476F94" unitRef="usd">2800000</gale:DebtInstrumentRedemptionPrincipalAmountRedeemed>
	<gale:DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash contextRef="FD2018Q3YTD" decimals="-5" id="Fact-2F92C2060F0BD219A95417BC8F727688" unitRef="usd">600000</gale:DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash>
	<gale:DebtInstrumentRedemptionPrincipalAmountRedeemedShares contextRef="FI2018Q3" decimals="0" id="Fact-D3833C4561A149BDCB740A4626106D69" unitRef="shares">659529</gale:DebtInstrumentRedemptionPrincipalAmountRedeemedShares>
	<gale:DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock contextRef="D2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementFirstClosingMember" decimals="-5" id="Fact-B1F4E0324ABEE11D5FC917BC8F969E18" unitRef="usd">2000000</gale:DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock>
	<gale:DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock contextRef="D2018Q2May01_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementFirstClosingMember" decimals="-5" id="Fact-7448BE49F4A1BA5321CD17BC8F912401" unitRef="usd">2500000</gale:DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock>
	<gale:DepositOfRestrictedCashOverSeniorSecuredDebenture contextRef="I2018Q4October16th_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-00D94F81B378D5381A88F5D8469981B9" unitRef="usd">1600000</gale:DepositOfRestrictedCashOverSeniorSecuredDebenture>
	<gale:DividendModificationOfWarrants contextRef="FD2018Q3YTD" decimals="-3" id="Fact-8451CB4B58F3B301739A0874C71B49E7" unitRef="usd">-491000</gale:DividendModificationOfWarrants>
	<gale:DividendModificationOfWarrants contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-A52671330359013FA189087478EEF698" unitRef="usd">-491000</gale:DividendModificationOfWarrants>
	<gale:DividendOnConversionOfSeriesAConvertiblePreferredStock contextRef="FD2018Q3YTD" decimals="-3" id="Fact-E1BF224BA72063ED0AE617BC8F6716F8" unitRef="usd">4436000</gale:DividendOnConversionOfSeriesAConvertiblePreferredStock>
	<gale:DividendOnConversionOfSeriesAConvertiblePreferredStock contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-6F2746D614E811E1FD4217BC8F692D0C" unitRef="usd">4436000</gale:DividendOnConversionOfSeriesAConvertiblePreferredStock>
	<gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation contextRef="FD2017Q3QTD" decimals="-3" id="Fact-DDA239476AD4766FB16308B18A3EF9D0" unitRef="usd">0</gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation>
	<gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation contextRef="FD2017Q3YTD" decimals="-3" id="Fact-A7D0734C852395B8DE4308B18DC32264" unitRef="usd">0</gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation>
	<gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation contextRef="FD2018Q3QTD" decimals="-5" id="Fact-2A17C390961CD209FF1E08B2A3EE1434" unitRef="usd">8700000</gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation>
	<gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation contextRef="FD2018Q3QTD" decimals="-3" id="Fact-3605E5BC3EDE23A0965008B1882A3EC6" unitRef="usd">8654000</gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation>
	<gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation contextRef="FD2018Q3YTD" decimals="-3" id="Fact-D6453CEEA9560BE3C3F708B18C052D6D" unitRef="usd">8654000</gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation>
	<gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation contextRef="FD2018Q3YTD" decimals="-5" id="Fact-B3AD3EF171140DF78A6E08B4905AFF41" unitRef="usd">8700000</gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation>
	<gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-D51F037A3CB9C1F2155C08719EA18B01" unitRef="usd">8654000</gale:DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation>
	<gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts contextRef="FD2018Q3YTD" decimals="-5" id="Fact-248B4352E20D8C644C2017BC8F8DDF50" unitRef="usd">1200000</gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts>
	<gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition contextRef="FD2018Q3YTD" id="Fact-B050DD49E53288B99D5C17BC8F8AD7F7">P2Y5M16D</gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition>
	<gale:FairValueOfParentCompanyCommonStockIssuedInExchangeForServices contextRef="FD2017Q3YTD" decimals="-3" id="Fact-8FFA4D3D494F8CE6518417BC8FC1ACC9" unitRef="usd">325000</gale:FairValueOfParentCompanyCommonStockIssuedInExchangeForServices>
	<gale:FairValueOfParentCompanyCommonStockIssuedInExchangeForServices contextRef="FD2018Q3YTD" decimals="-3" id="Fact-BD53CC152198E460631A17BC8FBF752E" unitRef="usd">0</gale:FairValueOfParentCompanyCommonStockIssuedInExchangeForServices>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2017Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" id="Fact-DA888D463F5DC36A3D8E17BC8F75CBD3">P4Y1M13D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2017Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" id="Fact-A0D894D3D7754D10681317BC8F9514C7">P3Y2M9D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" id="Fact-FBBE0B21A0C1E6C06E7617BC8F719447">P3Y4M17D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" id="Fact-A5DC0FCB0C62C9966FBC17BC8F76BDE8">P2Y8M5D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" id="Fact-956A1B360186277AE1A017BC8F78DCF7">P5Y0M4D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantsCanceled contextRef="FD2018Q3YTD" decimals="-3" id="Fact-C6A63D85BDF2A9FF7EA717BC8FA40C2F" unitRef="usd">524000</gale:FairValueOfWarrantsCanceled>
	<gale:FairValueOfWarrantsCanceled contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-9DCE751D1E49BAF2BA9917BC8F8D1195" unitRef="usd">524000</gale:FairValueOfWarrantsCanceled>
	<gale:FairValueOfWarrantsCanceled contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-DF7856D9166B7F67B14B17BC8F87328D" unitRef="usd">0</gale:FairValueOfWarrantsCanceled>
	<gale:FairValueOfWarrantsCanceled contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="-3" id="Fact-BCEBD8FA8438EF45100E17BC8FA7E219" unitRef="usd">0</gale:FairValueOfWarrantsCanceled>
	<gale:FairValueOfWarrantsExercisePriceAdjustment contextRef="FD2018Q3YTD" decimals="-3" id="Fact-0730D3B7EBA06C6D9BB6FA6704A93C8B" unitRef="usd">491000</gale:FairValueOfWarrantsExercisePriceAdjustment>
	<gale:FairValueOfWarrantsExercisePriceAdjustment contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-EADBE635A59F8C788A5DFA670472D2E5" unitRef="usd">0</gale:FairValueOfWarrantsExercisePriceAdjustment>
	<gale:FairValueOfWarrantsExercisePriceAdjustment contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-916CCE70A536AAB7791EFA6705562615" unitRef="usd">0</gale:FairValueOfWarrantsExercisePriceAdjustment>
	<gale:FairValueOfWarrantsExercisePriceAdjustment contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="-3" id="Fact-4E80819699BC8CC949DCFA67050772D6" unitRef="usd">491000</gale:FairValueOfWarrantsExercisePriceAdjustment>
	<gale:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity contextRef="FD2018Q3YTD" decimals="-3" id="Fact-5058D2D71CE6699EC2B017BC8FC8D33D" unitRef="usd">5039000</gale:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2017Q4" decimals="-3" id="Fact-1957E9ECC3BC130A98EA17BC8F999F91" unitRef="usd">1309000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-58BB232D978B7F538EF217BC8FA7D16D" unitRef="usd">1305000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-940AD16AB994B95AF84617BC8FA75F00" unitRef="usd">4000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="-3" id="Fact-2D0C93400D2A952C1B5A17BC8FAA63D1" unitRef="usd">0</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2018Q3" decimals="-3" id="Fact-2624DDFE98A7F923EB1F17BC8FA2EA19" unitRef="usd">975000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-15465A9066E05CCE9C1517BC8F89D75A" unitRef="usd">3000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-E0D46530D714120E24A917BC8F88A800" unitRef="usd">0</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="-3" id="Fact-0321091A39BD1DBF250517BC8F970AA3" unitRef="usd">972000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2017Q4" decimals="-3" id="Fact-DCCE83F39A2895B51D3717BC8F5DD325" unitRef="usd">1309000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E6A5A70F7401A1E9DC6917BC8F80B50B" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-ECBBB5F34CBC315BC73417BC8F846905" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-2DBEBF6D17A463D8641617BC8FA1E3F5" unitRef="usd">1309000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-58986D1F0A2455E52F6917BC8F93A345" unitRef="usd">1309000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2018Q3" decimals="-3" id="Fact-5065B45F0C56BC64821417BC8F63C2BA" unitRef="usd">975000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-155A158AF8E2DF596C0917BC8F59E650" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-930BC745E52AB7E1BBF617BC8F7A97CA" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-31F65108BDEAD18CC64717BC8F7E29DE" unitRef="usd">975000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-0A1ADC30A34CE17206AE17BC8F7D00E8" unitRef="usd">975000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueofWarrantsGranted contextRef="FD2018Q3YTD" decimals="-3" id="Fact-8FC38DE1514D353E0A8517BC8FA95794" unitRef="usd">5039000</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-77BE3B52D2997AEA15AC17BC8FA91010" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-7C6F79BADE0A56ED44E617BC8FAA37E8" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2018Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="-3" id="Fact-A8C64E94D1C86A5BD9BA17BC8FAC5DAE" unitRef="usd">5039000</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGrantedperShare contextRef="I2017Q4Dec29" decimals="2" id="Fact-A6C654F41E7E48F75A0D17BC8FAEFECF" unitRef="usdPerShare">5.60</gale:FairValueofWarrantsGrantedperShare>
	<gale:GainLossOnExtinguishmentOfPayables contextRef="FD2017Q3YTD" decimals="-3" id="Fact-1D101E1B54A7B5E90E2417BC8FC2062D" unitRef="usd">-634000</gale:GainLossOnExtinguishmentOfPayables>
	<gale:GainLossOnExtinguishmentOfPayables contextRef="FD2018Q3YTD" decimals="-3" id="Fact-CF72480CDC1F1F9E544917BC8FBE7D23" unitRef="usd">0</gale:GainLossOnExtinguishmentOfPayables>
	<gale:InProcessResearchDevelopment contextRef="FI2017Q4" decimals="-3" id="Fact-11C7337FE189E637572E17BC8F6580FB" unitRef="usd">17600000</gale:InProcessResearchDevelopment>
	<gale:InProcessResearchDevelopment contextRef="FI2018Q3" decimals="-3" id="Fact-BB62BF30E1CC5483B52A17BC8F78AADC" unitRef="usd">17600000</gale:InProcessResearchDevelopment>
	<gale:IncreaseDecreaseInFairValueOfWarrantLiability contextRef="FD2017Q3YTD" decimals="-3" id="Fact-AA04B95BF74555A52015139E54288497" unitRef="usd">0</gale:IncreaseDecreaseInFairValueOfWarrantLiability>
	<gale:IncreaseDecreaseInFairValueOfWarrantLiability contextRef="FD2018Q3QTD" decimals="-5" id="Fact-77D5792F190F332637A60EFD12664C1E" unitRef="usd">500000</gale:IncreaseDecreaseInFairValueOfWarrantLiability>
	<gale:IncreaseDecreaseInFairValueOfWarrantLiability contextRef="FD2018Q3YTD" decimals="-5" id="Fact-9D78F0C6CD158E6C9E8708A24500F1EC" unitRef="usd">500000</gale:IncreaseDecreaseInFairValueOfWarrantLiability>
	<gale:IncreaseDecreaseInFairValueOfWarrantLiability contextRef="FD2018Q3YTD" decimals="-3" id="Fact-0152B00A7FD7E4DCFDB7139E542005AF" unitRef="usd">491000</gale:IncreaseDecreaseInFairValueOfWarrantLiability>
	<gale:LiabilityClassifiedWarrantsAntidilutionProtection contextRef="FD2017Q3QTD" decimals="-3" id="Fact-53731E8EA344B5336BFEF52D1F378BD3" unitRef="usd">0</gale:LiabilityClassifiedWarrantsAntidilutionProtection>
	<gale:LiabilityClassifiedWarrantsAntidilutionProtection contextRef="FD2017Q3YTD" decimals="-3" id="Fact-3E32F0E2B5302B8270B9F52D1F477306" unitRef="usd">0</gale:LiabilityClassifiedWarrantsAntidilutionProtection>
	<gale:LiabilityClassifiedWarrantsAntidilutionProtection contextRef="FD2018Q3QTD" decimals="-3" id="Fact-B3774F242369DD50569BF52D1F3F9CFA" unitRef="usd">491000</gale:LiabilityClassifiedWarrantsAntidilutionProtection>
	<gale:LiabilityClassifiedWarrantsAntidilutionProtection contextRef="FD2018Q3YTD" decimals="-3" id="Fact-AA272FBD23EE7C73EB46F52D1F4E6455" unitRef="usd">491000</gale:LiabilityClassifiedWarrantsAntidilutionProtection>
	<gale:LitigationSettlementIssuanceofCommonStockValue contextRef="D2017Q3July24_srt_LitigationCaseAxis_gale_PatelvsGalenabiopharmaIncMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" decimals="-3" id="Fact-A6C563ABC0D729476F3617BC8FBCC365" unitRef="usd">1250000</gale:LitigationSettlementIssuanceofCommonStockValue>
	<gale:LongtermDebtIssuedInConnectionWithWarrantExchanges contextRef="FD2017Q3YTD" decimals="-3" id="Fact-F97CA1D2DCAC397CF6F017BC8F96999F" unitRef="usd">0</gale:LongtermDebtIssuedInConnectionWithWarrantExchanges>
	<gale:LongtermDebtIssuedInConnectionWithWarrantExchanges contextRef="FD2018Q3YTD" decimals="-3" id="Fact-9E8261DD9BFD2CB2ED2217BC8FC086BB" unitRef="usd">966000</gale:LongtermDebtIssuedInConnectionWithWarrantExchanges>
	<gale:LossContingencyNumberOfCounterclaims contextRef="D2018Q2May18th2018_srt_LitigationCaseAxis_gale_JGBActionMember" decimals="INF" id="Fact-DDF1315C7E42AD82339413AB918A44EB" unitRef="counterclaim">7</gale:LossContingencyNumberOfCounterclaims>
	<gale:LossContingencyNumberOfCounterclaims contextRef="D2018Q4October23rd_srt_LitigationCaseAxis_gale_JGBActionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-8325246590A6AA6CCEEF134BC6104032" unitRef="counterclaim">4</gale:LossContingencyNumberOfCounterclaims>
	<gale:LossOnSettlementOfLiabilityClassifiedWarrants contextRef="FD2017Q3YTD" decimals="-3" id="Fact-077506B985D456C654F317BC8FC05386" unitRef="usd">0</gale:LossOnSettlementOfLiabilityClassifiedWarrants>
	<gale:LossOnSettlementOfLiabilityClassifiedWarrants contextRef="FD2018Q3YTD" decimals="-3" id="Fact-5799136C71A865E9568F17BC8F95DD19" unitRef="usd">727000</gale:LossOnSettlementOfLiabilityClassifiedWarrants>
	<gale:LossOnSettlementOfWarrantsLiability contextRef="FD2017Q3QTD" decimals="-3" id="Fact-6E6AD7E9E4CB19DC796117BC8F62F5D5" unitRef="usd">0</gale:LossOnSettlementOfWarrantsLiability>
	<gale:LossOnSettlementOfWarrantsLiability contextRef="FD2017Q3YTD" decimals="-3" id="Fact-4B41D36EFB7EDFED261917BC8F5F7904" unitRef="usd">0</gale:LossOnSettlementOfWarrantsLiability>
	<gale:LossOnSettlementOfWarrantsLiability contextRef="FD2018Q3QTD" decimals="-3" id="Fact-82E687DFB90CFD98122E17BC8F5CD3D1" unitRef="usd">0</gale:LossOnSettlementOfWarrantsLiability>
	<gale:LossOnSettlementOfWarrantsLiability contextRef="FD2018Q3YTD" decimals="-3" id="Fact-36ED44F928AB13E82C8817BC8F6E2B2D" unitRef="usd">727000</gale:LossOnSettlementOfWarrantsLiability>
	<gale:OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan contextRef="FI2018Q3" decimals="-3" id="Fact-86F1037F1097B52DB6F717BC8F8E173A" unitRef="shares">381000</gale:OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan>
	<gale:PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards contextRef="D2017Q4Dec29_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember" decimals="INF" id="Fact-36E6C4E71A07729DBDA417BC8F8992EF" unitRef="number">0.04</gale:PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards>
	<gale:PercentageOfFullyDilutedShareCapitalOwned contextRef="I2017Q4Dec29_srt_CounterpartyNameAxis_gale_PreMergerSecurityholdersMember" decimals="3" id="Fact-AF03409FC47DB7306F9B17BC8F762274" unitRef="number">0.325</gale:PercentageOfFullyDilutedShareCapitalOwned>
	<gale:PercentageOfFullyDilutedShareCapitalOwned contextRef="I2017Q4Dec29_srt_CounterpartyNameAxis_gale_PrivateSELLASSecurityHoldersMember" decimals="3" id="Fact-C729BE9220170672C74617BC8F792F85" unitRef="number">0.675</gale:PercentageOfFullyDilutedShareCapitalOwned>
	<gale:PreferredStockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q3YTD" decimals="-3" id="Fact-F9C5858EB0051A01484117BC8F607C6E" unitRef="usd">9647000</gale:PreferredStockIssuedDuringPeriodValueNewIssues>
	<gale:PreferredStockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-B7D01FB4DEE933DD209317BC8F61090E" unitRef="usd">9647000</gale:PreferredStockIssuedDuringPeriodValueNewIssues>
	<gale:ProceedsfromIssuanceofLongtermDebtandWarrantsNet contextRef="D2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-2B891E0608E72A6CD41D17BC8F7642C2" unitRef="usd">23400000</gale:ProceedsfromIssuanceofLongtermDebtandWarrantsNet>
	<gale:RebatesAndReturnsOfFormerCommercialProducts contextRef="FI2017Q4" decimals="-3" id="Fact-7B6BDAA9E76277EC864F17BC8FA407B6" unitRef="usd">223000</gale:RebatesAndReturnsOfFormerCommercialProducts>
	<gale:RebatesAndReturnsOfFormerCommercialProducts contextRef="FI2018Q3" decimals="-3" id="Fact-B71DF5FF74850B487A4317BC8F9024F7" unitRef="usd">22000</gale:RebatesAndReturnsOfFormerCommercialProducts>
	<gale:ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock contextRef="FD2017Q3YTD" decimals="-3" id="Fact-7B1BD512AC58CE1A794817BC8F9243E2" unitRef="usd">0</gale:ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock>
	<gale:ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock contextRef="FD2018Q3YTD" decimals="-3" id="Fact-52CB0C78E3644FF3C5F917BC8F93DCA1" unitRef="usd">285000</gale:ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock>
	<gale:ReimbursementOfLegalFees contextRef="D2018Q4November5th_srt_LitigationCaseAxis_gale_JGBActionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-BEF48A7A0E2EFB5A56DFFA7DC5D3D1BC" unitRef="usd">5000000</gale:ReimbursementOfLegalFees>
	<gale:RestrictedCashandCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-87D7C98E3D7ABD26BB8717BC8FA566C9" unitRef="usd">10245000</gale:RestrictedCashandCashEquivalentsFairValueDisclosure>
	<gale:RestrictedCashandCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-37881A24B2D182AA300917BC8F82A3D4" unitRef="usd">0</gale:RestrictedCashandCashEquivalentsFairValueDisclosure>
	<gale:RestrictedCashandCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-CE048BE55FE2B3D2FEF117BC8F823344" unitRef="usd">0</gale:RestrictedCashandCashEquivalentsFairValueDisclosure>
	<gale:RestrictedCashandCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B0EC5322265A7C4D080C17BC8F74395F" unitRef="usd">10245000</gale:RestrictedCashandCashEquivalentsFairValueDisclosure>
	<gale:RestrictedStockSharesReservedforFutureIssuance contextRef="FI2018Q3" decimals="-3" id="Fact-989B23A79D5853B6B3F917BC8F8E87CC" unitRef="shares">13000</gale:RestrictedStockSharesReservedforFutureIssuance>
	<gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger contextRef="D2017Q4Dec29_us-gaap_PlanNameAxis_gale_IncentivePlan2016Member" decimals="INF" id="Fact-55D396B8D6F11C4079E517BC8F8A8679" unitRef="shares">10171</gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger>
	<gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue contextRef="FD2018Q3YTD" decimals="-3" id="Fact-2F8A440B4958A19EA1FD17BC8FB07C8C" unitRef="usd">0</gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue>
	<gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue contextRef="FD2018Q3YTD" decimals="-3" id="Fact-BB61BC3987B55A9DDFF217BC8FAB946A" unitRef="usd">0</gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue>
	<gale:StockIssuedDuringPeriodSharesPrefundedWarrant contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-FD2D86FCFACEF068287117BC8FB9E339" unitRef="shares">2524783</gale:StockIssuedDuringPeriodSharesPrefundedWarrant>
	<gale:WarrantExchangeAgreementsAmount contextRef="FD2018Q3YTD" decimals="-3" id="Fact-1D16E173F736593CD35F17BC8F6476CD" unitRef="usd">285000</gale:WarrantExchangeAgreementsAmount>
	<gale:WarrantExchangeAgreementsAmount contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-16E7E4B803FF0B4929BA17BC8F5FD76F" unitRef="usd">285000</gale:WarrantExchangeAgreementsAmount>
	<gale:WarrantExchangeAgreementsIssuanceOfCommonStock contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-36AFBFF359A16E79AE1717BC8F5DD131" unitRef="shares">54343</gale:WarrantExchangeAgreementsIssuanceOfCommonStock>
	<gale:WarrantStrikePrice contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="INF" id="Fact-9784BB9E56710E95532B17BC8F671D32" unitRef="usdPerShare">13</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="INF" id="Fact-20C3319865FE646CF56F17BC8F6D0F6F" unitRef="usdPerShare">28.4</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="INF" id="Fact-EF568ED477FAF5723AC817BC8F963ADB" unitRef="usdPerShare">33</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="INF" id="Fact-D3AAFEEBA82DB496B3C717BC8F6FC298" unitRef="usdPerShare">888.22</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="INF" id="Fact-26280F3864C79AEF74F517BC8F701C3F" unitRef="usdPerShare">2.10</gale:WarrantStrikePrice>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="4" id="Fact-E5AEB45C5BF5C2937C2A17BC8F71D320" unitRef="number">0.7929</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="4" id="Fact-B233B6F7CD6A6A76B6B117BC8F74A577" unitRef="number">0.7405</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="4" id="Fact-9485E041A058EC92768217BC8F92E130" unitRef="number">0.8539</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="4" id="Fact-FA707B2290B23E0B915D17BC8F95C12C" unitRef="number">0.8596</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="4" id="Fact-0F7AD931F2A3E131AE2317BC8F748441" unitRef="number">0.8318</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="4" id="Fact-4275C5AE5836731FA98C17BC8FA0B0E6" unitRef="number">0.0209</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="4" id="Fact-2563814459B525EA56E117BC8F7A798F" unitRef="number">0.0209</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="4" id="Fact-0E2197D62BE43879E2CC17BC8F65B909" unitRef="number">0.0225</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="4" id="Fact-3987DBAECB444A0F505417BC8F94A426" unitRef="number">0.0232</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="4" id="Fact-F8C3034A4C74C98A797517BC8F6D355A" unitRef="number">0.0294</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsIssuedShares contextRef="D2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementSecondClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-2BB61698E5C1F0A8D21017BC8F98F39F" unitRef="shares">609445</gale:WarrantsIssuedShares>
	<gale:WarrantsIssuedShares contextRef="D2018Q1Mar9_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementFirstClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-779922913A2C39506E7A17BC8FB1C53E" unitRef="shares">774186</gale:WarrantsIssuedShares>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="FI2018Q3" decimals="-5" id="Fact-99F3AD80B5DDD817CE9917BC8F886703" unitRef="usd">11900000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-EB40E95EEA6B10F2FCF817BC8F737A06" unitRef="usd">11691000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-4A8764182460C6D0D1E017BC8F77F656" unitRef="usd">7238000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-25391A215D92E0946E0A17BC8F5B809C" unitRef="usd">3201000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-9149590284364FCB4BE917BC8F6AC379" unitRef="usd">4683000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-B1E9C57EF9466CAED29717BC8FA6DD07" unitRef="usd">1744000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-286DE6C11C514ACF24E717BC8FA65F6D" unitRef="usd">2836000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2017Q4" decimals="-3" id="Fact-BE888BB0B1276C4C199417BC8F7311D4" unitRef="usd">56254000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2018Q3" decimals="-3" id="Fact-4F0BB843D9D925BC00C717BC8FA757E0" unitRef="usd">86987000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdjustmentForAmortization contextRef="FD2017Q3YTD" decimals="-3" id="Fact-82941D711787BCEF516717BC8FC6FFA0" unitRef="usd">257000</us-gaap:AdjustmentForAmortization>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="FD2018Q3YTD" decimals="-3" id="Fact-42AE46C5BDB51B6856EC17BC8F718D54" unitRef="usd">-4436000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-8E2B5830A35DFA37479317BC8F698B0B" unitRef="usd">-4436000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2018Q3YTD" decimals="-3" id="Fact-694EB5CBAFE648F116A917BC8F5AB4D4" unitRef="usd">284000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-8167DC413AF88785194A17BC8F63B92B" unitRef="usd">284000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2018Q3YTD" decimals="-3" id="Fact-076DED54EF4654735BE317BC8F68268A" unitRef="usd">5039000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-10DD612C020F20ED4E0B17BC8F7485B5" unitRef="usd">5039000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-2333B9460525E7C45A0C17BC8FB7F313" unitRef="usd">1267000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-79BEC999C9928E974DAA17BC8FB903DD" unitRef="usd">543000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-DD8B3AA5B3D64B6CB8D917BC8FB8EA62" unitRef="usd">724000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-ED0C96C5C1D56C3377E817BC8FB9D8FE" unitRef="usd">3776000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-9CB3634A990695948B1D17BC8FB732B4" unitRef="usd">729000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-B02AC4F9E9BA4D85690917BC8FB8AE60" unitRef="usd">3047000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-245EABE3C1720CD542BF17BC8FB88C7F" unitRef="usd">136000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-2838F098E093CD983D8017BC8FB84E40" unitRef="usd">21000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-A32DCBF0694AD8AEEF4517BC8FB72A8D" unitRef="usd">115000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-9DAD72D48ED318D75F1817BC8FB946B0" unitRef="usd">284000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-EBDAC1761299BD70BB5E17BC8FB7E41A" unitRef="usd">55000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-456364C65881A7C6BC8717BC8FB81C94" unitRef="usd">229000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:Assets contextRef="FI2017Q4" decimals="-3" id="Fact-07248145946CDC1DD98A17BC8F5CA0AE" unitRef="usd">33526000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2018Q3" decimals="-3" id="Fact-2A9E41106C4B638D8F5B17BC8F72FBC3" unitRef="usd">38470000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-DAAF2CDAE3C9B3990DAB17BC8F68A2FD" unitRef="usd">13087000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-64AB64F36E50C8092D8F17BC8F6097B8" unitRef="usd">17807000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B9FEF026AFAB34BCA1C117BC8F830288" unitRef="usd">11907000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-52E5E7917A3926E697FC17BC8F87D901" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-D3C5BC56258D2AE8B89017BC8F840830" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-FB4FA80BE0218B07A87E17BC8F84823A" unitRef="usd">11907000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-180D05CBBE386035992C17BC8F827D6D" unitRef="usd">6774000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-23D93D8C50218417C84717BC8F7D0C5E" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-637D74D352F2CA2538BA17BC8F59D0C1" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A51E49E21261DDEE2C8917BC8F7C5968" unitRef="usd">6774000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic contextRef="FD2017Q3QTD" decimals="2" id="Fact-B11B714769D124AD632617BC8F8F83B5" unitRef="usdPerShare">-1.61</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
	<us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic contextRef="FD2017Q3YTD" decimals="2" id="Fact-A94CCEA4D74A9F17774717BC8F8D9572" unitRef="usdPerShare">4.92</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
	<us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted contextRef="FD2017Q3QTD" decimals="2" id="Fact-0C746DF0FEE0883078D017BC8FB9AA87" unitRef="usdPerShare">-1.61</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
	<us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted contextRef="FD2017Q3YTD" decimals="2" id="Fact-D321CB6A43FB8CCF8DD017BC8FB231C8" unitRef="usdPerShare">4.92</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
	<us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="FD2017Q3QTD" decimals="-3" id="Fact-2970F39E30DC5A62876617BC8F8CFAC1" unitRef="usd">-9066000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
	<us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="FD2017Q3YTD" decimals="-3" id="Fact-24537897B98A6019ADB417BC8F8FB5F5" unitRef="usd">-21690000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
	<us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="FD2017Q3QTD" decimals="-5" id="Fact-186884C4A0BDB6074D9FFA2274F7ED08" unitRef="usd">3300000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
	<us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="FD2017Q3YTD" decimals="-5" id="Fact-085680D783CD5FCDCAC00E66E03E2F25" unitRef="usd">3300000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_gale_AptheraInc.Member" decimals="-5" id="Fact-50381F8C5FA3D193F83617BC8FABACF5" unitRef="usd">32000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-3" id="Fact-9316D36FDEDEFBB20B4017BC8F5EDA0E" unitRef="usd">2319000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q3" decimals="-3" id="Fact-C91B1173E297831472CD17BC8FAF9FFD" unitRef="usd">9968000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q3" decimals="-5" id="Fact-A1DFB32706EC688B08EE17BC8F5BA63D" unitRef="usd">10000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-C96D893E960E4CD71B9417BC8FA1A439" unitRef="usd">1662000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5F0E53BC593908909DAE17BC8F815DE6" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-792C1D713866B838F46717BC8FA3BCB0" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-BCC5B2968E577878405517BC8F849DF9" unitRef="usd">1662000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B04118860B1E236A096F17BC8F7F6B4C" unitRef="usd">6774000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1FDC5F60F17826D0EF1317BC8F830980" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A88F770122C0616FEC8317BC8F7C289D" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A66347D2A70BC01BB7B917BC8F8547F5" unitRef="usd">6774000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2016Q4" decimals="-3" id="Fact-9CA191F387D25726145617BC8F9044B7" unitRef="usd">5962000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2017Q3" decimals="-3" id="Fact-2304A3DB5396CA436F0C17BC8FBD0AB1" unitRef="usd">2369000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2017Q4" decimals="-3" id="Fact-1C04A9B7E0E783058CD917BC8F94993B" unitRef="usd">12750000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q3" decimals="-3" id="Fact-AE8E73779A2F7FE15B1D17BC8FC152B1" unitRef="usd">10082000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2017Q3YTD" decimals="-3" id="Fact-500056CEB67C896C7C7E17BC8F904A3F" unitRef="usd">-3593000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2018Q3YTD" decimals="-3" id="Fact-8387378CC2BAF6CCA37E17BC8F92CCAE" unitRef="usd">-2668000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="INF" id="Fact-FAA242772E7E9CC8F7CA17BC8FAA0AF6" unitRef="usdPerShare">6.59</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2017Q4Dec29" decimals="INF" id="Fact-9537CE239E978C95C78917BC8FBFAA56" unitRef="usdPerShare">7.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2018Q2May2018" decimals="INF" id="Fact-AE88B26DE3C02A92501C17BC8F93B74D" unitRef="usdPerShare">6.59</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2018Q3July16" decimals="INF" id="Fact-4F978559A3CC9602853D17BC8F9186A9" unitRef="usdPerShare">2.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="I2018Q3July16" decimals="INF" id="Fact-7CADAA80B9473618F710138FFD1D1153" unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-F9BA76CBD70A48654AE717BC8F75C90A" unitRef="shares">3333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2017Q4Dec29" decimals="INF" id="Fact-020B1C048165DBF3654D17BC8FB75881" unitRef="shares">316163</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2018Q1March7_us-gaap_StatementClassOfStockAxis_gale_SeriesANonvotingConvertibleMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-B17327DEFC945531E0E317BC8F7FB445" unitRef="shares">1383631</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2018Q3July16" decimals="-3" id="Fact-5ED4AB192B310B784FBE17BC8FA79ACC" unitRef="shares">11520000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q4" decimals="-3" id="Fact-8FCB7FFA6FFE01EFFC0117BC8F9F58D6" unitRef="shares">963000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_EqcWarrantsMember" decimals="-3" id="Fact-20DEE11E6C29F56EF9CD17BC8F9F11C6" unitRef="shares">316000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-8428469A01F2EBB649B117BC8F9CD88C" unitRef="shares">567000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_July2018OfferingMember" decimals="-3" id="Fact-1DDB0BA97DA8900B9FA3F9F43223E15A" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-6D1D06CA758E9E9CEAE317BC8F9C5345" unitRef="shares">80000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_Prefunded2018OfferingMember" decimals="-3" id="Fact-7D79E8CBC3D7B23835A1F9F321D1EFEA" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="-3" id="Fact-2AE597BF49BC923314BD17BC8F9E991F" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2018Q3" decimals="-3" id="Fact-1953725AE3C565059E6317BC8F8D8ED2" unitRef="shares">19224000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_EqcWarrantsMember" decimals="-3" id="Fact-21C7DADCA6328C7ADA0217BC8F9E01C5" unitRef="shares">316000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_February2017WarrantsMember" decimals="-3" id="Fact-BF0C14ED8B7AB354730517BC8F9B14E6" unitRef="shares">32000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_July2018OfferingMember" decimals="-3" id="Fact-D67AB79AD143C6DC4B77F9F443993A9B" unitRef="shares">15268000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_OtherWarrantIssuesMember" decimals="-3" id="Fact-81A922D1C20814441FAA17BC8FA2B9C1" unitRef="shares">74000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_Prefunded2018OfferingMember" decimals="-3" id="Fact-405AF11779E077EE6E07F9F32F6FE842" unitRef="shares">2150000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2018Q3_us-gaap_ClassOfWarrantOrRightAxis_gale_SeriesAConvertiblePreferredWarrantsMember" decimals="-3" id="Fact-C213B1D7DEF0FBC1BF1817BC8FA0BC77" unitRef="shares">1384000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q4" id="Fact-370104C5F5D793785A1717BC8F65CCF1" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2018Q3" id="Fact-472A66E134B406F5E82217BC8F5CD010" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2018Q3" decimals="-3" id="Fact-D3A11989E40EE9A9ACDE17BC8F8E4086" unitRef="shares">20167000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-D67A21A6AD8D5FBEE4C617BC8F7F19EC" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q3" decimals="INF" id="Fact-263DC337B52DA64C9EC417BC8F80C5EC" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="I2017Q4Dec28_dei_LegalEntityAxis_gale_GalenaBiopharmaIncMember" decimals="INF" id="Fact-9B9B4974C419B981E2DD17BC8F9F4C6D" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-E0F2E16BCD0F5240DA3417BC8F59F4EC" unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2018Q3" decimals="INF" id="Fact-A0988ED9321291344CD317BC8FA31D93" unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-8C6E1F54140A34410A6217BC8F7DC8B8" unitRef="shares">5766891</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2018Q3" decimals="INF" id="Fact-25859770AE0316E6A3B717BC8F7E7F1E" unitRef="shares">20501476</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-601BC7DE1FF51855E9BA17BC8F81B56E" unitRef="shares">5766891</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q3" decimals="INF" id="Fact-1407C31B4C37ABA11ACA17BC8F7C1C57" unitRef="shares">20501476</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2017Q4Dec29" decimals="INF" id="Fact-3A33B9DCBE68FE6350AF17BC8F7CA2C0" unitRef="shares">5766891</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-176B27465D1C26C7F0D417BC8F734E27" unitRef="usd">1000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2018Q3" decimals="-3" id="Fact-E35BB18CDB5C63C4EF1217BC8FAE6E98" unitRef="usd">2000</us-gaap:CommonStockValue>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-C1C03360969F41757FA617BC8F91B1CD" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A9ED5890FE1718384B0617BC8F75999E" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-F2465350E9035017F4F417BC8FA564AC" unitRef="usd">1294000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-6F3FE912C058DF2EB13A17BC8F987EAF" unitRef="usd">1294000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-8201F948A13F0FD107C117BC8F832CD5" unitRef="usd">1294000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-0A08D6DB96790820A44217BC8F829A0B" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-58354A1FD592D536431D17BC8F8468A7" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-CD2F021258047B1299C317BC8F972F98" unitRef="usd">5319000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-3FB819660B7683DAA37217BC8F866874" unitRef="usd">5319000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-97864365E8F4CEB0D1CA17BC8F7C25BC" unitRef="usd">5319000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="FD2017Q3YTD" decimals="-3" id="Fact-F10E36B65952B5904A7617BC8FC9EF00" unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="FD2018Q3YTD" decimals="-3" id="Fact-83CA848FEFD5DD013C9F17BC8FC18874" unitRef="usd">3587000</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConvertiblePreferredStockConvertedToOtherSecurities contextRef="D2018Q3" decimals="INF" id="Fact-16AD242AA2B4D4978E7A17BC8FA308F4" unitRef="usd">7871186</us-gaap:ConvertiblePreferredStockConvertedToOtherSecurities>
	<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="I2018Q1March7_us-gaap_StatementClassOfStockAxis_gale_SeriesANonvotingConvertibleMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-F38D29382487C7098BB417BC8F96D2F0" unitRef="shares">1844835</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
	<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="I2018Q3July16" decimals="INF" id="Fact-09E0370A20F678CDE47517BC8F94BBBC" unitRef="shares">3748184</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
	<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="I2018Q3July16_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-87618A48821B09765EF117BC8FA8D5AE" unitRef="shares">3748184</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
	<us-gaap:CostsAndExpenses contextRef="FD2017Q3QTD" decimals="-3" id="Fact-6A1E25D1555CE7A33C1917BC8F5FB6C1" unitRef="usd">4290000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2017Q3YTD" decimals="-3" id="Fact-76BD36EC2E2A8E21F8FA17BC8F68E646" unitRef="usd">14429000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2018Q3QTD" decimals="-3" id="Fact-CA36AF1CD8E0F7313F4417BC8F6BAF58" unitRef="usd">3061000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2018Q3YTD" decimals="-3" id="Fact-753505C51773FB42EB7A17BC8F72141E" unitRef="usd">15246000</us-gaap:CostsAndExpenses>
	<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="FD2017Q3QTD" decimals="-5" id="Fact-E22F82CBF6EEFD73621B12E702906654" unitRef="usd">5800000</us-gaap:DebtConversionConvertedInstrumentAmount1>
	<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="FD2017Q3YTD" decimals="-5" id="Fact-8CB68BC6EC2F6F6B8B4B17BC8FC56D23" unitRef="usd">5800000</us-gaap:DebtConversionConvertedInstrumentAmount1>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-C1410DB2BA7E671F5D1917BC8F6F6B52" unitRef="usdPerShare">7.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-4D2F4B73857C1BCF139D17BC8F76B93D" unitRef="usd">1000000.0</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-3CBB774335A8D3FD8D4417BC8F76FC3E" unitRef="usd">25530000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2017Q4" decimals="-5" id="Fact-7A0DB32E914C46063A03F5D34F04C930" unitRef="usd">10200000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-B32D1023789494820DCB17BC8F7A55B9" unitRef="number">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-E388F5F00CBFD09893F217BC8F710FE9" unitRef="number">0.06375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2016Q2May10_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-62AA95D7C57101CD130617BC8F75FA02" unitRef="number">0.09</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-29535BF42E46AE8C038317BC8FB6E189" unitRef="usd">800000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
	<us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-DD934AED935848C137EB17BC8F705FDF" unitRef="usd">800000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
	<us-gaap:DebtLongtermAndShorttermCombinedAmount contextRef="FI2017Q4" decimals="-3" id="Fact-BE60EB1CC4A11309BBC217BC8F98F9D1" unitRef="usd">10988000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
	<us-gaap:DebtLongtermAndShorttermCombinedAmount contextRef="FI2018Q3" decimals="-3" id="Fact-82F8E83C6E177D3A1E1817BC8F999CA9" unitRef="usd">76000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
	<us-gaap:DecreaseInRestrictedCash contextRef="FD2018Q3YTD" decimals="-5" id="Fact-DFA70C85B3234C5A235717BC8F72AF54" unitRef="usd">1800000</us-gaap:DecreaseInRestrictedCash>
	<us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="FI2017Q4" decimals="-3" id="Fact-AB654CDB773E46A9206F17BC8FA94D58" unitRef="usd">1673000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
	<us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="FI2018Q3" decimals="-3" id="Fact-1CC15ECF1DBFFF4BF43A17BC8F6B488D" unitRef="usd">1722000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
	<us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="FD2017Q3YTD" decimals="-3" id="Fact-C808CB1000BB0DBAA16B17BC8FC4F889" unitRef="usd">7000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
	<us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="FD2018Q3YTD" decimals="-3" id="Fact-42E677FF8E85817FBEEB17BC8F902568" unitRef="usd">49000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
	<us-gaap:DepositsAssetsNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-1550D13E17D2B009157017BC8F72DE69" unitRef="usd">925000</us-gaap:DepositsAssetsNoncurrent>
	<us-gaap:DepositsAssetsNoncurrent contextRef="FI2018Q3" decimals="-3" id="Fact-5B45D9BFF6B880ADD99D17BC8F640575" unitRef="usd">1149000</us-gaap:DepositsAssetsNoncurrent>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q3QTD" decimals="2" id="Fact-30FBF74A4E3F42B0945917BC8F6C4E87" unitRef="usdPerShare">-2.27</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q3YTD" decimals="2" id="Fact-0DC8F19135C32B162E3517BC8F648FAF" unitRef="usdPerShare">-4.56</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q3QTD" decimals="2" id="Fact-F80D23C6AA9D3B645F3717BC8F6591AE" unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q3YTD" decimals="2" id="Fact-8310B77EA5D33A3DC5BB17BC8F5B2532" unitRef="usdPerShare">-2.75</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-8BC1ECEEBD1BACEB9E9D17BC8F83D4FC" unitRef="usd">566000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-A93358C6FFF009E4826417BC8F91E97F" unitRef="usd">808000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-C44E4155C7439893535017BC8F96AB4A" unitRef="usd">0</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-6F7ECE9F03549D74951217BC8F9D457F" unitRef="usd">0</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-16EAB2B0D422E010A3A817BC8F84D1DB" unitRef="usd">2603000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-0937E365263D099B2E6717BC8F84252D" unitRef="usd">2603000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-02A9E52598EDD716807A17BC8F815493" unitRef="usd">0</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-6FEE7CAEFBEB170B87C217BC8F85F4F1" unitRef="usd">0</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-64566BB184F826A2552D17BC8F58627F" unitRef="usd">6294000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-CB0BC52BCC2AE327720D17BC8F7DA272" unitRef="usd">6294000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2017Q3QTD" decimals="-3" id="Fact-30E0025AEE3D05C44D7217BC8F60C561" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2017Q3YTD" decimals="-3" id="Fact-B912DE473E620E566F3B17BC8F5E1A12" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2018Q3QTD" decimals="-3" id="Fact-10D0D95B95649BFC31AB17BC8F5AAAF5" unitRef="usd">-2241000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2018Q3YTD" decimals="-3" id="Fact-B4C733B9DB3D99C68FE317BC8F67B733" unitRef="usd">-5340000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="D2018Q4November14th_srt_LitigationCaseAxis_gale_JGBActionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-B0C74671E5223A585F3EF9FD8A993E6E" unitRef="usd">800000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="D2018Q4November5th_srt_LitigationCaseAxis_gale_JGBActionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-39F64EBA029A9920FBC9FA3D6BB393E2" unitRef="usd">800000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2017Q3QTD" decimals="-3" id="Fact-7487C38CCF5E5C77EE1FF5F1A3C3FC6F" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2017Q3YTD" decimals="-3" id="Fact-01133EF08952E7F24EA4F5F1A3CA1330" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2018Q3QTD" decimals="-3" id="Fact-9037D8CDB4ECED5739D8F5F1A3B9578F" unitRef="usd">766000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2018Q3YTD" decimals="-3" id="Fact-8DE1123006B62338986EF5F1A3BDA50C" unitRef="usd">766000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:Goodwill contextRef="FI2017Q4" decimals="-3" id="Fact-663DBF40BB95A7EAD09317BC8F62412C" unitRef="usd">1914000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2018Q3" decimals="-3" id="Fact-6145C901A0E84DB6719717BC8F70774A" unitRef="usd">1914000</us-gaap:Goodwill>
	<us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="FD2017Q3QTD" decimals="-5" id="Fact-AC704012A04AF96466DCFA23B5CC1B25" unitRef="usd">5200000</us-gaap:GoodwillAndIntangibleAssetImpairment>
	<us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="FD2017Q3YTD" decimals="-5" id="Fact-092A87737D271FE1864712EAA82CAFC6" unitRef="usd">5200000</us-gaap:GoodwillAndIntangibleAssetImpairment>
	<us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2017Q3YTD" decimals="-3" id="Fact-4CD0C5343BC51ED7F93C17BC8FC4D90D" unitRef="usd">-14969000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2018Q3YTD" decimals="-3" id="Fact-E92CEB9E1B66B83FED7E17BC8F957026" unitRef="usd">-14347000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q3QTD" decimals="-3" id="Fact-24C3958276B0ADF315CA17BC8F6DBC67" unitRef="usd">63000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q3YTD" decimals="-3" id="Fact-855133E731963AFF55FD17BC8F5CD978" unitRef="usd">180000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q3QTD" decimals="-3" id="Fact-48F824DC84154061D90617BC8F5F0284" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q3YTD" decimals="-3" id="Fact-8AB593F69A2584306A8117BC8F5945EC" unitRef="usd">163000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2017Q3YTD" decimals="-3" id="Fact-CD89DBC548BF5CF021AB17BC8F91C2F4" unitRef="usd">377000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2018Q3YTD" decimals="-3" id="Fact-308015274CDF141D231E17BC8FC2FA94" unitRef="usd">-4453000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-ED5C680A577A6674131617BC8F589EC4" unitRef="usd">85000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-8FE09A0BD6BE2969AE3E17BC8FBEAAE1" unitRef="usd">182000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable contextRef="FD2017Q3YTD" decimals="-3" id="Fact-5E4AE60D2F71AF88AE7D17BC8F80E14B" unitRef="usd">0</us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable>
	<us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable contextRef="FD2018Q3YTD" decimals="-3" id="Fact-7D381C0699A63E073E4917BC8F9676AC" unitRef="usd">474000</us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable>
	<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="FD2017Q3YTD" decimals="-3" id="Fact-899DBA2C568AAC12BD1217BC8F769A64" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherReceivables>
	<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="FD2018Q3YTD" decimals="-3" id="Fact-5037463455030F84382D17BC8F64C51C" unitRef="usd">6600000</us-gaap:IncreaseDecreaseInOtherReceivables>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2017Q3YTD" decimals="-3" id="Fact-AE1B54D4F29737E5F1BD17BC8F90FEA0" unitRef="usd">-3000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2018Q3YTD" decimals="-3" id="Fact-F2E02F1A6562939583DB17BC8FCA33E4" unitRef="usd">538000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:InsuranceSettlementsReceivableCurrent contextRef="FI2017Q3" decimals="-5" id="Fact-EDF4210812DADBE287AAF5A363D119C9" unitRef="usd">500000</us-gaap:InsuranceSettlementsReceivableCurrent>
	<us-gaap:InsuranceSettlementsReceivableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-F6093B0192CB8100836917BC8FBDDAC3" unitRef="usd">0</us-gaap:InsuranceSettlementsReceivableCurrent>
	<us-gaap:InsuranceSettlementsReceivableCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-82D422B02F3BF591878C17BC8F59F1BC" unitRef="usd">474000</us-gaap:InsuranceSettlementsReceivableCurrent>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2017Q3QTD" decimals="-3" id="Fact-21FC76AADAEC9F45010817BC8F70BAAF" unitRef="usd">-102000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2017Q3YTD" decimals="-3" id="Fact-EEF78B602C79E491AD7D17BC8F689794" unitRef="usd">-360000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2018Q3QTD" decimals="-3" id="Fact-DA85831FCBFB8D45776017BC8F6AEACD" unitRef="usd">-74000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2018Q3YTD" decimals="-3" id="Fact-3A8C5F822AA819A71A5A17BC8F6AE1DC" unitRef="usd">-292000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestPaidNet contextRef="FD2017Q3YTD" decimals="-3" id="Fact-84B4E7B5BCB52B4EE90317BC8FC82530" unitRef="usd">0</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2018Q3YTD" decimals="-3" id="Fact-E75185266A0772B5843717BC8FC3FD55" unitRef="usd">321000</us-gaap:InterestPaidNet>
	<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="FD2017Q3YTD" decimals="-3" id="Fact-2BDD21BCDD629283CD0117BC8F93004E" unitRef="usd">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
	<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="FD2018Q3YTD" decimals="-3" id="Fact-016EA86968F93AA4EBB317BC8FC6C639" unitRef="usd">1250000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
	<us-gaap:LegalFees contextRef="D2018Q4November14th_srt_LitigationCaseAxis_gale_JGBActionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-D2426703273AC79EB7EEF9FBD2A6F3FD" unitRef="usd">2500000</us-gaap:LegalFees>
	<us-gaap:LegalFees contextRef="FD2018Q3QTD_srt_LitigationCaseAxis_gale_JGBActionMember" decimals="-5" id="Fact-405C9141DE41A437BDEDF9FBB62B50BF" unitRef="usd">2500000</us-gaap:LegalFees>
	<us-gaap:Liabilities contextRef="FI2017Q4" decimals="-3" id="Fact-C9466E4D67BD1C0BCD1E17BC8FABEC74" unitRef="usd">31456000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2018Q3" decimals="-3" id="Fact-04E9B3EFED92F44E3FFD17BC8F64CF9F" unitRef="usd">20013000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-F181885FA88CEC9C34F617BC8F5C7F99" unitRef="usd">33526000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q3" decimals="-3" id="Fact-8B1917C3941E29303DBD17BC8F65B339" unitRef="usd">38470000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-BBA62B91283D3C049C2917BC8F6ECBC5" unitRef="usd">24569000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-A8893AF0AE6C521C548017BC8F5B9020" unitRef="usd">11997000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LitigationReserveCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-26DB4AC89E5896A3116217BC8F6A1728" unitRef="usd">1300000</us-gaap:LitigationReserveCurrent>
	<us-gaap:LitigationReserveCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-56BC977D73427E9C534517BC8F65E8C1" unitRef="usd">0</us-gaap:LitigationReserveCurrent>
	<us-gaap:LitigationReserveCurrent contextRef="FI2018Q3_srt_LitigationCaseAxis_gale_JBGLitigationMember" decimals="-5" id="Fact-24A4C0E8FBBCBD322C88F9FA928CC678" unitRef="usd">2500000</us-gaap:LitigationReserveCurrent>
	<us-gaap:LongTermDebt contextRef="FI2018Q3" decimals="-5" id="Fact-576E51913685F1D11E4117BC8F797F2C" unitRef="usd">100000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-8A85DE95934B12E20F4717BC8F5DA22B" unitRef="usd">8377000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-1A4A4D422A0A259D257917BC8F996A77" unitRef="usd">8377000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-14F92ABD3F7D7B14D8EF17BC8F5C7F38" unitRef="usd">76000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-CE0071EB997A480CC37D17BC8F9AC763" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-FDD193E834DAA6B7C77217BC8FA4A0B9" unitRef="usd">2611000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-C0292B79B1497CB3945D17BC8F9A314C" unitRef="usd">2611000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2018Q3" decimals="-3" id="Fact-79045E41AE6FB3AFBFF317BC8F5F719B" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_gale_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-0195D8636BD19CDE676C17BC8F989F20" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LossContingencyDamagesAwardedValue contextRef="D2018Q4November5th_srt_LitigationCaseAxis_gale_JGBActionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-0222ECA7BCD9D0903726FA0C470C13BA" unitRef="usd">6600000</us-gaap:LossContingencyDamagesAwardedValue>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-7F57D79F0DC1644ED8C917BC8FC5EEA5" unitRef="usd">5654000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-92FF62ADCB69D4F3C29217BC8F97C4EB" unitRef="usd">23199000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-33A3C579C11CBBE9F53317BC8FC9A013" unitRef="usd">-9247000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-BCDA7DD00CEA4D82B33B17BC8FC37615" unitRef="usd">-25867000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3QTD" decimals="-3" id="Fact-2ECD3E8E9549DE43C51B17BC8F6BEA4A" unitRef="usd">-4455000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3YTD" decimals="-3" id="Fact-46B022E68A4830419CA717BC8F5D1E53" unitRef="usd">-14969000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q3QTD" decimals="-3" id="Fact-913F2944317D3C25B2D917BC8F59E232" unitRef="usd">-290000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q3YTD" decimals="-3" id="Fact-BF509983F67AF3DEBDD517BC8F6E2066" unitRef="usd">-14347000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-1BED5FAAC300E1AED63C17BC8F66E37E" unitRef="usd">-14347000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2017Q3QTD" decimals="-3" id="Fact-4CAB221B724795C5234D17BC8F6C1D6A" unitRef="usd">-4455000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2017Q3YTD" decimals="-3" id="Fact-BCC31AAE3D58B54DB84217BC8F68EF96" unitRef="usd">-14969000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2018Q3QTD" decimals="-3" id="Fact-7E7826DCE8E3EFE577D817BC8F67CC2C" unitRef="usd">-9435000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2018Q3YTD" decimals="-3" id="Fact-5A596282692AC447E14617BC8F5A1FE9" unitRef="usd">-27928000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-8C7CD5FE69B860DAE3DC17BC8F5EAF2C" unitRef="usd">-4392000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-920AC99959A0C3FEDDC417BC8F5EAF66" unitRef="usd">-14789000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-E4D439B45D83ED3B81BF17BC8F6136E1" unitRef="usd">-290000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-91E1A32A950C46E3DBD017BC8F70B555" unitRef="usd">-14184000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-D9FF87C73B949BDEB47317BC8F927AA9" unitRef="usd">191000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-8E1508268170EA1B4DCB17BC8FA26F9C" unitRef="usd">276000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2017Q3QTD" decimals="-3" id="Fact-4AEEC874317A3D4998F617BC8F67545E" unitRef="usd">-102000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2017Q3YTD" decimals="-3" id="Fact-2B64CBE31DE13CCB605017BC8F5EC22B" unitRef="usd">-360000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2018Q3QTD" decimals="-3" id="Fact-77FE5B6B0CFE209E915117BC8F6CF9BD" unitRef="usd">2771000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2018Q3YTD" decimals="-3" id="Fact-D22088C61EA9DC60286A17BC8F6C303A" unitRef="usd">1062000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:OtherReceivablesNetCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-AFE2968F59AF736CB87F17BC8FC7199F" unitRef="usd">0</us-gaap:OtherReceivablesNetCurrent>
	<us-gaap:OtherReceivablesNetCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-3B27D4A97C151218BE1017BC8FADE9D9" unitRef="usd">6600000</us-gaap:OtherReceivablesNetCurrent>
	<us-gaap:OtherReceivablesNetCurrent contextRef="FI2018Q3" decimals="-5" id="Fact-BDD96ABDC0ACA075402CF5333B887BDC" unitRef="usd">6600000</us-gaap:OtherReceivablesNetCurrent>
	<us-gaap:PaidInKindInterest contextRef="FD2017Q3YTD" decimals="-3" id="Fact-563F5539A035F745B28C17BC8FC8C5DC" unitRef="usd">258000</us-gaap:PaidInKindInterest>
	<us-gaap:PaidInKindInterest contextRef="FD2018Q3YTD" decimals="-3" id="Fact-D5A5BD2970BD1C77D21B17BC8FBE1C99" unitRef="usd">134000</us-gaap:PaidInKindInterest>
	<us-gaap:PaymentsForLegalSettlements contextRef="D2017Q3July24_srt_LitigationCaseAxis_gale_PatelvsGalenabiopharmaIncMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" decimals="-3" id="Fact-26EFAE3101ED4FCF698317BC8FC28348" unitRef="usd">50000</us-gaap:PaymentsForLegalSettlements>
	<us-gaap:PaymentsOfDividends contextRef="FD2017Q3YTD" decimals="-3" id="Fact-3ECD4CF9706E4EBCA34617BC8F995005" unitRef="usd">0</us-gaap:PaymentsOfDividends>
	<us-gaap:PaymentsOfDividends contextRef="FD2018Q3YTD" decimals="-3" id="Fact-33ACFDD689183E41D9C517BC8F92899C" unitRef="usd">487000</us-gaap:PaymentsOfDividends>
	<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="FD2017Q3QTD" decimals="-3" id="Fact-5417D675891209EB26EB17BC8F643F9D" unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
	<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="FD2017Q3YTD" decimals="-3" id="Fact-BAA75BAE84036C7F95D217BC8F645547" unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
	<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="FD2018Q3QTD" decimals="-3" id="Fact-68163CE0F1E8EDCC8B2317BC8F6845E4" unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
	<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="FD2018Q3YTD" decimals="-3" id="Fact-29A0C9C8A02EA0438D9117BC8F69C8F2" unitRef="usd">4436000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-23DEA0114EA820FD3EDA17BC8F7DEBD4" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q3" decimals="INF" id="Fact-85845864C5C7DB5D3BB317BC8F5AE9DD" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="I2018Q1March7_us-gaap_StatementClassOfStockAxis_gale_SeriesANonvotingConvertibleMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-ACE0E4B6FA8A1833411317BC8F93D9F0" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-F530D77D06AED762B95E17BC8F7F8C71" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q3" decimals="INF" id="Fact-D92666B9A8078299D79E17BC8F9D9C0B" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q3_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-D28DCB0FA7DC9C32364B17BC8F86D58F" unitRef="shares">17500</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-2B42D31A2841E8EDCA0C17BC8F5E88A0" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2018Q3" decimals="INF" id="Fact-A3B5A384CD12D05C7D0A17BC8F5DE79B" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="I2018Q1March7_us-gaap_StatementClassOfStockAxis_gale_SeriesANonvotingConvertibleMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="INF" id="Fact-0E8B23FCD1ECFFF4EC6D17BC8F7D5BED" unitRef="shares">10700</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-99267ABFD9237AF9896017BC8F7588D9" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2018Q3" decimals="INF" id="Fact-B8789FBECFC04B060D2517BC8F62560D" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-963B06D925EEDA874C6C17BC8F60277D" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2018Q3" decimals="-3" id="Fact-D314DA43AAECF75CCEAD17BC8F6EEB2B" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-AE74F49AFAA04E181D5117BC8FA6410A" unitRef="usd">337000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-922727036E80A6FA8B5517BC8F64CD00" unitRef="usd">651000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromInsuranceSettlementOperatingActivities contextRef="D2018Q3October2018_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-E2B6224164F9EF16AE1DF5EF31DB9A0C" unitRef="usd">500000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
	<us-gaap:ProceedsFromInterestReceived contextRef="FD2017Q3YTD" decimals="-3" id="Fact-AF86D657066369EEE4F917BC8F94B5BE" unitRef="usd">0</us-gaap:ProceedsFromInterestReceived>
	<us-gaap:ProceedsFromInterestReceived contextRef="FD2018Q3YTD" decimals="-3" id="Fact-D49F3FFC195AB1DC463D17BC8FC9FA7E" unitRef="usd">166000</us-gaap:ProceedsFromInterestReceived>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2017Q3YTD" decimals="-3" id="Fact-758B455DA43CD0B37DA717BC8F95FDB7" unitRef="usd">6007000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2018Q3YTD" decimals="-3" id="Fact-AFDE28AA3BEBD0F9E5F717BC8FBEF3E7" unitRef="usd">21564000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="D2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementFirstClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="-5" id="Fact-0F93C56E166108FF958C17BC8FB00950" unitRef="usd">6000000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="D2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_PrivatePlacementSecondClosingMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="-5" id="Fact-C7832CAD89009D940BA117BC8FA09278" unitRef="usd">4700000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="D2018Q2_us-gaap_StatementClassOfStockAxis_gale_SeriesANonvotingConvertibleMember_us-gaap_TypeOfArrangementAxis_gale_PurchaseAgreementMember" decimals="-5" id="Fact-328716DC18172D54D53A17BC8F921A7E" unitRef="usd">10700000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="FD2017Q3YTD" decimals="-3" id="Fact-A2FED5183199A38D832F17BC8FC59B08" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="FD2018Q3YTD" decimals="-3" id="Fact-BC413ED5063E7FD7BC8317BC8F97D27A" unitRef="usd">9647000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
	<us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="D2018Q1Mar9_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_FirstTrancheMember" decimals="-5" id="Fact-20395C89D12282807B3E17BC8F58EA9C" unitRef="usd">6000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
	<us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="D2018Q2May01_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_gale_SecondTrancheMember" decimals="-5" id="Fact-4A8F39DF90D4A8DF79A717BC8F7D87C8" unitRef="usd">4700000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
	<us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="D2018Q2_us-gaap_StatementClassOfStockAxis_gale_SeriesAConvertiblePreferredStockMember" decimals="-5" id="Fact-EE73F19DDECACFA3FAD417BC8F74F8D4" unitRef="usd">10700000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
	<us-gaap:ProfitLoss contextRef="FD2017Q3QTD_us-gaap_NonrecurringAdjustmentAxis_us-gaap_AcquisitionRelatedCostsMember" decimals="-5" id="Fact-3A9BBC30592C82864D2B17BC8FBEF329" unitRef="usd">200000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2017Q3YTD_us-gaap_NonrecurringAdjustmentAxis_us-gaap_AcquisitionRelatedCostsMember" decimals="-5" id="Fact-92D33DF681D8B7709AF417BC8F9F0BC2" unitRef="usd">300000</us-gaap:ProfitLoss>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2017Q3YTD" decimals="-3" id="Fact-DC9260C5DF387FD14F5917BC8FC2D1B8" unitRef="usd">353000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2018Q3YTD" decimals="-3" id="Fact-DD31583CE575187EE4C417BC8FC1B56F" unitRef="usd">7525000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-BE796564992447A942D717BC8F618ADE" unitRef="usd">1068000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-76461DBFABF898FF97CD17BC8F599B43" unitRef="usd">5079000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-999A4ABC6D0C4D2A059017BC8F6BBC77" unitRef="usd">1720000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-5EE7751EA27A43CE0F0517BC8F66C828" unitRef="usd">5116000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestrictedCash contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-CD1471741A57750BBD8A17BC8F7DE977" unitRef="usd">10200000</us-gaap:RestrictedCash>
	<us-gaap:RestrictedCash contextRef="I2018Q2May5th2018_us-gaap_DebtInstrumentAxis_gale_AmendmentAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-5C1A90CA61B0238D42B7FA51BB3A68B4" unitRef="usd">8500000</us-gaap:RestrictedCash>
	<us-gaap:RestrictedCash contextRef="I2018Q3September24th_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-05A05CF9A09AF6C521AEFA1AC519241D" unitRef="usd">8500000</us-gaap:RestrictedCash>
	<us-gaap:RestrictedCash contextRef="I2018Q4November5th2018_srt_LitigationCaseAxis_gale_JGBActionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-7DDDDF8FD087F12B9E29FA795D95B922" unitRef="usd">1600000</us-gaap:RestrictedCash>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-3" id="Fact-009CA2174832D5582B0117BC8F618902" unitRef="usd">10431000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_gale_CorporateCreditCardsMember" decimals="-5" id="Fact-CB50B20C7496E1A8E32317BC8F85890C" unitRef="usd">200000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q3" decimals="-3" id="Fact-F894F633B191C01F201717BC8F67022D" unitRef="usd">114000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q3" decimals="-5" id="Fact-D13BB74E0FBE4AAF15D817BC8F5867CF" unitRef="usd">100000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q3_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_gale_CorporateCreditCardsMember" decimals="-5" id="Fact-A4A6121ED0F63921038AF59DE65994DD" unitRef="usd">100000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4" decimals="-3" id="Fact-B47306D19D71A6FDFCB317BC8FAC0202" unitRef="usd">-54185000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q3" decimals="-3" id="Fact-6E56450468E3281DC8F317BC8F708613" unitRef="usd">-68532000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2018Q3" decimals="-5" id="Fact-08B1A0AFC0002256D7B617BC8F7EC99C" unitRef="usd">21600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-01D678E5F14B33CD8D4317BC8F9057EC" unitRef="shares">6845000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-05D69B7A55C76E55057817BC8F7C2CD6" unitRef="shares">6845000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-100AB87427DC4804EBC517BC8FA5AEFA" unitRef="shares">4675000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2018Q3July16" decimals="INF" id="Fact-E33909BE5F896AAD58BA17BC8FA48422" unitRef="usdPerShare">2.10</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2018Q3July16" decimals="2" id="Fact-74612DE34D0E0DDF1E3917BC8F9BB5E2" unitRef="usdPerShare">2.10</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2018Q3July16_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="4" id="Fact-5E7F528E7144467DB91417BC8F97A738" unitRef="usdPerShare">2.0999</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2018Q3July16_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-B8D5BAC798E7F192B89B17BC8F812D57" unitRef="usdPerShare">2.0999</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-185D3553961A522A76C517BC8F67318C" unitRef="usd">3222000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-5230C7EA36C66524C62617BC8F6311EB" unitRef="usd">9350000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-C38D5F2578A80E9FAB9F17BC8F65C445" unitRef="usd">1341000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-033474846E6A28DA3BC817BC8F6BCD28" unitRef="usd">10130000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q3YTD" decimals="-3" id="Fact-F4561484C70F4A549CEA17BC8FC394E3" unitRef="usd">3776000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q3YTD" decimals="-3" id="Fact-CA41F1E24C4264AAF38E17BC8FC23E05" unitRef="usd">284000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-E69F241707EC05E8E38E17BC8FAEA58E" unitRef="shares">13000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-1E68E858D4ADC7942A7E17BC8F8EB545" unitRef="shares">13000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-C6FE0C44F86C92B7637B17BC8FAA548B" unitRef="usdPerShare">52.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-EF6DAB33A69CE760FBE317BC8F8AE6FD" unitRef="usdPerShare">52.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-63C0ABB0D2050C7F586917BC8F8BA069">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2018Q3YTD" decimals="INF" id="Fact-BFE9DEB390AFCD17556217BC8FB4E64D" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2018Q3YTD" decimals="4" id="Fact-069CCB07D7335C9AB58317BC8FB25210" unitRef="number">0.8083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2018Q3YTD" decimals="4" id="Fact-F9ED6DD08B155258799F17BC8FB5F697" unitRef="number">0.0273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="D2018Q1jan1_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember" decimals="-3" id="Fact-0F75FCFDCAB0B93E61AE17BC8F8E4149" unitRef="shares">805000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2018Q3_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember" decimals="-3" id="Fact-4CDE1A584053A6400FAE17BC8F8A2A1A" unitRef="shares">381000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2017Q4Dec29_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember" decimals="-3" id="Fact-B10446ED4642BB9191F517BC8F8C72AD" unitRef="shares">575000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2018Q3" decimals="-3" id="Fact-94822AAE048C4D79A38717BC8FB193C5" unitRef="shares">43000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2018Q3" decimals="2" id="Fact-B4BB410CBC1EE8A34AAA17BC8FB50CDD" unitRef="usdPerShare">265.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2018Q3YTD" decimals="-3" id="Fact-F1A9C57A24644268496317BC8FAC7C8C" unitRef="shares">59000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="FD2017Q3YTD" decimals="INF" id="Fact-B0CB50E7CD9C591056090E79629537E9" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember" decimals="INF" id="Fact-821F9C5B19A9122816EA17BC8F8C2000" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="FD2018Q3QTD" decimals="INF" id="Fact-7D5AA86810C16D043FF817BC8F890490" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2018Q3YTD" decimals="-3" id="Fact-68DC5793604205F6CF6217BC8FAF3950" unitRef="shares">483000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q3YTD" decimals="2" id="Fact-1D4B8FD9C3AB88D0E5E817BC8F8C924E" unitRef="usdPerShare">3.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2017Q4" decimals="-3" id="Fact-4B1FD93D3AE7B7755D7F17BC8FADBCA7" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2018Q3" decimals="-3" id="Fact-E5F141430E49A215A80F17BC8FB369B8" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q4" decimals="-3" id="Fact-A4991CEF4C4C914116C717BC8FB27CC1" unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2018Q3" decimals="-3" id="Fact-1829F0279CEB6CEE845317BC8F8C8DD1" unitRef="shares">434000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4" decimals="2" id="Fact-A2F0997208E10DFBC9E017BC8FACC7AF" unitRef="usdPerShare">1240.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2018Q3" decimals="2" id="Fact-B05A77C42F71F59F3A1317BC8FACA407" unitRef="usdPerShare">34.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="FI2018Q3" decimals="-3" id="Fact-893DB497504680AABA8A17BC8FB5D13A" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2018Q3YTD" decimals="2" id="Fact-C85D6452F461F677472517BC8FB47CE0" unitRef="usdPerShare">5.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2018Q3YTD" decimals="2" id="Fact-537B3B9E4D31E7CA272917BC8FB1F729" unitRef="usdPerShare">5.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="D2017Q4Dec29_us-gaap_PlanNameAxis_gale_TwoThousandAndSeventeenEquityIncentivePlanMember" id="Fact-4F67B36EB1519F4C7BB817BC8F8F926A">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2018Q3YTD" id="Fact-BDB69BE257F22295462017BC8FB1C7EF">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="D2017Q4January1st" id="Fact-E4D19A0242A493A9EDC2F9F087E909CD">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2018Q3YTD" id="Fact-258F7392A1FA4635373317BC8FB4680B">P7Y6M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2018Q3YTD" id="Fact-8C76CA9ACD79027DBDAF17BC8FB49F24">P9Y3M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2018Q3YTD_srt_RangeAxis_srt_MaximumMember" id="Fact-2D1B2E795B8EBB56EC6117BC8F8B0CC2">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2018Q3YTD_srt_RangeAxis_srt_MinimumMember" id="Fact-5B24DE5C86FE9DE473E217BC8F8CA303">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="FD2018Q3YTD" id="Fact-F1E30AF0C0EEB3937BD917BC8F8A57B0">P10Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharesOutstanding contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-F989CF6F26E265116A4317BC8F613240" unitRef="shares">5766891</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-7B16913EA0367DF26C1B17BC8F6AD749" unitRef="shares">0</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-50B182E4D67FB03DE8CC17BC8F6159B8" unitRef="shares">20501476</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-C568A43289D950D6229417BC8F79DED8" unitRef="shares">0</us-gaap:SharesOutstanding>
	<us-gaap:ShortTermBorrowings contextRef="FI2017Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="-3" id="Fact-B07FDB9EFD8D87F4E46717BC8F9939F2" unitRef="usd">0</us-gaap:ShortTermBorrowings>
	<us-gaap:ShortTermBorrowings contextRef="FI2018Q3_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="-3" id="Fact-577761340FBDD432C71417BC8F9B9F95" unitRef="usd">76000</us-gaap:ShortTermBorrowings>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-D76BAF3F8188DCADC76417BC8F627A8B" unitRef="shares">118644</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-2187EAE116477CCB6F49086B6F735FE8" unitRef="shares">3748184</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-1543973D3F6DD06B6177086C7E3CD50D" unitRef="shares">-7802</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-26E03738D08410ED687B17BC8F621515" unitRef="shares">499682</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-0BBB1679C86C7A63A75617BC8F630F1A" unitRef="shares">2898</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="D2018Q2April30th_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-81E425044DD485CFE3F317BC8F73EF19" unitRef="shares">118644</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q3YTD_srt_LitigationCaseAxis_gale_PatelvsGalenabiopharmaIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-91346E00BE6A0600D53F17BC8F6B0F21" unitRef="shares">228672</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-6C5A9839AAF773BE2E7317BC8F7AED49" unitRef="shares">715277</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-2541C83DACD5B5DF6B5004B5986DA2B3" unitRef="shares">6845000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-14606E817F06064DED8B17BC8F6048E5" unitRef="shares">10700</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertibleNotesPayableMember" decimals="-3" id="Fact-43976CAF4CF01F40ABA717BC8F5D942C" unitRef="usd">825000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertibleNotesPayableMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-58274D1E1CB036FCC0DC17BC8F6D5810" unitRef="usd">825000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="-3" id="Fact-0419D09639A2EBF0A0B4086AE565A509" unitRef="usd">-8654000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-9395F6EE674F469A4F270868D1727086" unitRef="usd">-8654000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q3YTD" decimals="-3" id="Fact-41007F8B24D54601CD6904B598834CEB" unitRef="usd">21564000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q3YTD_srt_LitigationCaseAxis_gale_PatelvsGalenabiopharmaIncMember" decimals="-3" id="Fact-C4466CFF935D5CFF72FC17BC8F5D0CA8" unitRef="usd">1250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q3YTD_srt_LitigationCaseAxis_gale_PatelvsGalenabiopharmaIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-24AF4CC44A4FB8E6432517BC8F5AC59A" unitRef="usd">1250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-BC7B52DB9A1F025F4D6017BC8F668F6F" unitRef="usd">2896000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q3YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-F0640617DD617E25B35517BC8F710A8F" unitRef="usd">2896000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-3FE5449E83AD96D3646604B5DC6D4A58" unitRef="usd">21563000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-BF45F558B35CBE45AFB304B5984A58B1" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-748BE676D2B161861BB217BC8F62B9AA" unitRef="usd">2070000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3" decimals="-3" id="Fact-236BE5E99E1DAC5D086E17BC8F6DC501" unitRef="usd">18457000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4" decimals="-3" id="Fact-766B0302A58F65E401FC17BC8F59122F" unitRef="usd">2070000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-48D22BD5B164C631B6CD17BC8F68CBF7" unitRef="usd">56254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-FAEE935DEDF9C82A70D217BC8F6D87ED" unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-A43DC92872C7D235940117BC8F6004F0" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-16A1A77D16045C9FD09D17BC8F6FA397" unitRef="usd">-54185000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q3" decimals="-3" id="Fact-008EBB9A2CED8C2E757417BC8F5B28EB" unitRef="usd">18457000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-904E94077EFDB32C8DEF17BC8F6083C5" unitRef="usd">86987000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-EDE19655066DFF1EC3B017BC8F6BFE85" unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-18CC84003AC6E3E4795217BC8F5F5B34" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-95B14040D65945FD478F17BC8F5C9696" unitRef="usd">-68532000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="D2017Q4Dec28_dei_LegalEntityAxis_gale_GalenaBiopharmaIncMember" decimals="4" id="Fact-2372122BAF55F456106017BC8F7BDCEB" unitRef="number">0.0333</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
	<us-gaap:TaxesPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-6BF05CE117315BAE5ACC17BC8FA21B12" unitRef="usd">426000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TaxesPayableCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-131B21ADDCBEF843C59617BC8F901B8A" unitRef="usd">158000</us-gaap:TaxesPayableCurrent>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="-5" id="Fact-91448F4E38AF33970D0F17BC8F72129C" unitRef="usd">100000</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="I2018Q2Apr30_us-gaap_DebtInstrumentAxis_gale_ConvertiblePromissoryNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="-5" id="Fact-0DE26020CDDCBD52356E17BC8F71D935" unitRef="usd">800000</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="FI2018Q3_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember" decimals="INF" id="Fact-4BDCAC8931D5CAD145DA17BC8FBC1F52" unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="FI2018Q3_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember" decimals="INF" id="Fact-C126A5FFA14AB0A739BC17BC8FC4DE45" unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="I2017Q4Dec29_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember" decimals="INF" id="Fact-C1532AA7826EFD5196A917BC8FA42F00" unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="I2017Q4Dec29_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember" decimals="INF" id="Fact-0A7AF01A9A95ADA72F560F4B7A306067" unitRef="year">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="I2017Q4Dec29_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember" decimals="4" id="Fact-5BA1D4FC66B33E0A63AD17BC8FA17479" unitRef="number">0.9010</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="I2017Q4Dec29_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember" decimals="4" id="Fact-7C7E45422AA56109BA1E17BC8FBBC171" unitRef="number">0.0220</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q3QTD" decimals="0" id="Fact-C734AE80B1D4540FC43017BC8F612813" unitRef="shares">1962822</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q3YTD" decimals="0" id="Fact-592519EC75D2E0CD01F217BC8F6D81E1" unitRef="shares">3284351</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q3QTD" decimals="0" id="Fact-E68FCD3573A07CB81B4C17BC8F5DC0E5" unitRef="shares">17635671</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q3YTD" decimals="0" id="Fact-64D3A757D52445A1CD4B17BC8F66A1B8" unitRef="shares">10161153</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<gale:ChangesInFairValueOfWarrantLiabilityTableTextBlock contextRef="FD2018Q3YTD" id="Fact-74975CDB873D6FB54E6C17BC8FBC42EA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The changes in fair value of the warrant liability for the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;nine months ended September 30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants canceled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Adjustment to exercise price of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Change in fair value of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Series A Convertible Preferred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4,558&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;972&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena February 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,305&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(524&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(524&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(5,340&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;975&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ChangesInFairValueOfWarrantLiabilityTableTextBlock>
	<gale:CommonStockAreReservedForFutureIssuanceTableTextBlock contextRef="FD2018Q3YTD" id="Fact-08C5657D12E6F4C1A49D17BC8F961BB8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shares of common stock for future issuance are reserved for as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;19,224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock options outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;434&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options reserved for future issuance under the Company&amp;#8217;s 2017 Equity Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;381&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shares reserved for future issuance under the Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total reserved for future issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20,167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:CommonStockAreReservedForFutureIssuanceTableTextBlock>
	<gale:ScheduleOfWarrantActivityTableTextBlock contextRef="FD2018Q3YTD" id="Fact-3B551BC14B3A5F061A3417BC8F83E3E6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following is a summary of the Company's warrants to acquire shares of common stock activity for the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Outstanding, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Canceled/Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Outstanding, September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;July 2018 Offering&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;15,268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;15,268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;July 2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Pre-funded July 2018 Offering&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2,525&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;July 2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Series A Convertible Preferred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,384&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,384&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September 2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2017 Equilibria&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena February 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;567&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(535&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;February 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;January 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;963&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;21,327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2,525&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(541&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;19,224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ScheduleOfWarrantActivityTableTextBlock>
	<gale:ScheduleOfWarrantValuationAssumptionsTableTextBlock contextRef="FD2018Q3YTD" id="Fact-647E724DD2EE0C30524517BC8FBAA9D1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Strike price (per share)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Series A Convertible Preferred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,384&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;83.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena February 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;85.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;888.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;85.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Strike price (per share)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena February 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;567&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;79.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;28.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3.19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;74.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ScheduleOfWarrantValuationAssumptionsTableTextBlock>
	<us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="FD2018Q3YTD" id="Fact-759AF999E163F0F5FD6217BC8F854EC1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Accrued Expenses and Other Current Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Professional fees*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,836&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Compensation and related benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;808&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;566&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Clinical trial costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Value-added tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;158&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;426&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Rebates and returns of former commercial products&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;276&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;191&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;*Includes approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of legal fees incurred related to the JGB litigation as described in Note 8 that was reimbursed to the Company in November 2018 by JGB.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2018Q3YTD" id="Fact-30A23EEEC61951EE1B1C17BC8F82AEE8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Basis of Presentation &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&amp;#8220;U.S. GAAP&amp;#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&amp;#160;GAAP as found in the ASC and Accounting Standards Updates (&amp;#8220;ASU&amp;#8221;) of the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;). &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="FD2018Q3YTD" id="Fact-96B94CE4744CE760E3C717BC8F979A48">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following summary pro forma condensed consolidated financial information reflects the Merger with Galena as if it had occurred on January 1, 2017 for purposes of the statements of operations. This summary pro forma information is not necessarily representative of what the Company&amp;#8217;s results of operations would have been had the Merger in fact occurred on January 1, 2017, and is not intended to project the Company&amp;#8217;s results of operations for any future period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Three Months Ended September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Nine Months Ended September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(9,066&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(21,690&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Basic and diluted net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1.61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2018Q3YTD" id="Fact-FDE3B0B56C10AB072F6517BC8FC43186">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Legal Proceedings, Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Legal Proceedings &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;From time to time, the Company is subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its condensed consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, when the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of the date hereof, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect the Company&amp;#8217;s consolidated results of operations, financial position or cash flows. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company&amp;#8217;s predecessor company, Galena, was involved in multiple legal proceedings and administrative actions, including stockholder class actions, both state and federal, some of which are ongoing and to which the Company are now subject as a result of the Merger. The Company is also involved in litigation matters as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On February&amp;#160;13, 2017, putative shareholder securities class action complaints were filed in federal court alleging, among other things, that the Company and certain of the Company's former officers and directors failed to disclose that Galena&amp;#8217;s promotional practices for Abstral&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (fentanyl sublingual tablets) were allegedly improper and that Galena may be subject to civil and criminal liability, and that these alleged failures rendered Galena&amp;#8217;s statements about its business misleading. The actions were consolidated, lead plaintiffs were named by the Court and a consolidated complaint was filed. The Company filed a motion to dismiss the consolidated complaint. On August 21, 2018, the Company's motion to dismiss the consolidated complaint was granted without prejudice to file an amended complaint. On September 20, 2018, the plaintiffs filed an amended complaint. On October 22, 2018, the Company filed a motion to dismiss the amended complaint. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In March 2017, a derivative complaint was filed in U.S. District Court for the District of New Jersey against the Company&amp;#8217;s former directors and Galena, as a nominal defendant. In July 2017, a derivative complaint was filed in California state court against the Company&amp;#8217;s former directors and Galena, as a nominal defendant. In January 2018, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&amp;#8217;s former directors, officers and employees, and the Company as a nominal defendant. In June 2018, a derivative complaint was filed in U.S. District Court for the Northern District of California against the Company&amp;#8217;s current and former directors, and the Company as a nominal defendant. The plaintiff in the June 2018 case voluntarily withdrew his complaint from the U.S District Court of the Northern District of California and on August 27, 2018 refiled the complaint in the Court of Chancery of the State of Delaware. These complaints purport to assert derivative claims for breach of fiduciary duty on the Company&amp;#8217;s behalf against the Company&amp;#8217;s former directors and, in certain of the complaints, the Company&amp;#8217;s current directors, and the Company&amp;#8217;s former officers and former employees, based on substantially similar facts as alleged in the putative shareholder securities class action complaints mentioned above. The March 2017, July 2017, and January 2018 lawsuits are currently stayed pending resolution of motions to dismiss in the referenced securities class action. On October 29, 2018, the defendants in the August 2018 lawsuit notified the plaintiff of its intent to file a motion to dismiss the lawsuit.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:1pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:1pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In April 2017, a putative stockholder class action, captioned Patel vs. Galena Biopharma Inc. et. al, was filed in Delaware state court seeking relief under Section&amp;#160;225 of the Delaware General Corporation Law ("DGCL") and alleging breaches of fiduciary duties by Galena&amp;#8217;s former board of directors and former interim chief executive officer regarding the proposals to amend Galena&amp;#8217;s certificate of incorporation to increase the amount of authorized shares of common stock and effectuate a reverse stock split at the July 2016 and October 2016 stockholder meetings, respectively. On June&amp;#160;2, 2017, an amended verified complaint was filed along with a motion to expedite the proceedings. On June&amp;#160;20, 2017, the Court consolidated the claims into In re Galena Biopharma, Inc., C. A. No. 2017-0423-JTL. On July&amp;#160;24, 2017, Galena entered into a binding settlement term sheet, involving&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;payment of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$50,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in cash and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1,250,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in unrestricted shares of common stock. The Court enforced the settlement term sheet on November&amp;#160;30, 2017. On February&amp;#160;22, 2018, the plaintiff filed his brief in support of the settlement as well as his request for attorneys&amp;#8217; fees and an incentive award. On June 14, 2018, the Court entered an Order and Final Judgment approving the settlement and awarding attorneys&amp;#8217; fees to the plaintiff. All obligations related to the Order and Final Judgment were satisfied in full by the Company in June 2018. In October 2018, the Company received &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; from its insurance carrier for previous amounts paid by the Company in excess of its deductible. The amount is recorded as a litigation insurance recovery as of September 30, 2018 in the Company's condensed consolidated balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On or about April 9, 2018, JGB filed a lawsuit in the U.S. District Court for the Southern District of New York (the "Court") captioned JGB (Cayman) Newton, Ltd. v. Sellas Life Sciences Group, Inc., et al., Case 1:18-cv-3095 (DLC) (the "JGB Action"). The complaint in the JGB Action asserted claims under state law and federal securities law against the Company, the Company's Chief Executive Officer, Angelos M. Stergiou, M.D., ScD h.c., and the Company's former Interim Chief Financial Officer, Aleksey N. Krylov. On or about May 2, 2018, JGB filed an amended complaint, adding as defendants Jane Wasman, Stephen Ghiglieri, David Scheinberg, M.D., Robert Van Nostrand and John Varian, each of whom is a member of the Company's Board of Directors. On May 18, 2018, the Company filed an answer to the amended complaint and filed &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;seven&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; counterclaims. On June 18, 2018, the Company filed a motion for judgment on the pleadings and a motion to dismiss the amended complaint. On July 6, 2018, JGB filed a motion for partial judgment on the pleadings and motion to dismiss all of the Company's counterclaims. On September 24, 2018, without any prior written notice, JGB unilaterally directed that all of the funds, approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$8.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in cash, be removed from the restricted account, an amount in excess of the outstanding principal balance of the Senior Secured Debenture.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On October 23, 2018, the Court entered an Opinion and Order, granting, in full, the Company's motion to dismiss JGB's amended complaint and allowing &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the Company's counterclaims to proceed to trial. Following the October 23 Opinion and Order of the Court, the parties to the JGB Action entered into a settlement agreement on November 5, 2018. The settlement agreement provides, among other things, that JGB will make a one-time payment to the Company of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$6.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, inclusive of the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; excess amount removed from the restricted account. The entire settlement amount was recorded as an other receivable as of September 30, 2018 in the condensed consolidated balance sheet as of September 30, 2018 and the amount was received in November 2018. The Company offset approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of legal fees incurred during the three months ended September 30, 2018 previously recorded in general and administrative expense in the condensed consolidated statement of operations with proceeds from the settlement and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; legal fees incurred subsequent to September 30, 2018 recorded as an accrued liability in the condensed consolidated balance sheet. The Company recognized a gain on extinguishment of debt of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; that was previously accrued in long-term debt for an additional interest payable at maturity as the amount is no longer payable by the Company. The settlement agreement also provides for the termination of the Senior Secured Debenture and all ancillary agreements, including the security agreement covering the Company's assets as well as a release of all security interests in the collateral.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2018Q3YTD" id="Fact-3C123D4FA56B0DB4F3E117BC8FA7FC89">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Principles of Consolidation &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The condensed consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2018Q3YTD" id="Fact-C17A44A4C087EBB9911117BC8F70075B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Debt&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Current portion of Senior Secured Debenture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Short-term convertible promissory notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Non-current portion of Senior Secured Debenture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,988&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Senior Secured Debenture&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On May 10, 2016, the Company's predecessor company, Galena, entered into a Securities Purchase Agreement (the &amp;#8220;Securities Purchase Agreement&amp;#8221;) with JGB (the "Purchaser") pursuant to which Galena sold to the JGB, at a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.375%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; original issue discount, a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$25.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; Senior Secured Debenture (the "Senior Secured Debenture") and warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,333&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the Company's common stock. Net proceeds to Galena from the sale of the Senior Secured Debenture and warrants, after payment of commissions and legal fees, were approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$23.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Senior Secured Debenture originally matured November&amp;#160;10, 2018, with accrued interest at&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;per year, payable monthly. In addition, on the maturity date of the Senior Secured Debenture (or such earlier date that the principal amount of the Senior Secured Debenture is paid in full by acceleration or otherwise) a fixed amount, which would have been deemed interest under the Senior Secured Debenture, equal to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; was due and payable to JGB on such date in, at the option of the Company, cash and, subject to the same conditions for the payment of interest, in shares of the Company&amp;#8217;s common stock, or a combination of cash and the Company&amp;#8217;s common stock. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company&amp;#8217;s obligations under the Senior Secured Debenture were secured under a security agreement by a senior lien on all of the Company&amp;#8217;s assets, including all of the Company&amp;#8217;s interests in its consolidated subsidiaries. Private SELLAS was not a party to the security agreement. Under the terms of a subsidiary guarantee agreement, each subsidiary guaranteed the performance of the Company of the Securities Purchase Agreement, Senior Secured Debenture and related agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:90px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:1pt;padding-left:66px;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:1pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:1pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:1pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company was required to maintain a minimum of the lesser of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$18.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; or the outstanding principal amount of unencumbered cash in a restricted account. Any funds in the restricted account in excess of the outstanding principal balance were transferred to the Company's unrestricted account to fund its ongoing operations. As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, the Company maintained &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$10.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of cash and cash equivalents in a restricted account. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, the outstanding principal balance of the Senior Secured Debenture was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$10.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. In addition to the outstanding principal balance, the Senior Secured Debenture had&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of additional interest that was included in the current portion of long-term debt as of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. During the nine months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, JGB redeemed &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of outstanding principal, which the Company satisfied with &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;659,529&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of its common stock and redeemed &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of outstanding principal, which the Company satisfied with cash. As a result of the redemptions during 2018, the Company transferred &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of restricted cash into unrestricted cash and cash equivalents which was used to fund the Company&amp;#8217;s ongoing operations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;JGB commenced a lawsuit against the Company as described in Note 8 ("JGB Action"). On September 24, 2018, JGB unilaterally issued a directive to (i) the financial institution that maintained the restricted cash and cash equivalents and (ii) the manager of the account to liquidate all assets in the restricted account. As a result of such directive, approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$8.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in cash was removed from the restricted account, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in excess of the outstanding principal balance of the Senior Secured Debenture at the time of the removal. On October 16, 2018, JGB was required to deposit the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; excess that JGB removed from the restricted account into an escrow account, as ordered by the Court in the JGB Action, pending resolution of the dispute between the Company and JGB.  On October 23, 2018, the Court entered an order, granting, among other things, the Company's Motion for Judgment seeking dismissal of JGB's amended complaint and allowing four of the Company's counterclaims to proceed to trial. As a result of the October 23rd Court order, on November 5, 2018, the parties to the JGB Action entered into a settlement agreement. The settlement agreement provides, among other things, that JGB make a one-time payment to the Company of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$6.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, representing the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; excess cash removed from the amount in the restricted account from the outstanding principal balance of the Senior Secured Debenture and reimbursement of approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of legal fees incurred by the Company. The Company recognized a gain on extinguishment of debt of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; that was previously accrued in long-term debt representing an additional interest payable at maturity as the amount is no longer required to be repaid by the Company. Accordingly, the Senior Secured Debenture is no longer outstanding and the related agreements have been terminated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Short-term Convertible Promissory Notes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, the Company entered into convertible promissory notes in the principal amount of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in exchange for the surrender and cancellation of warrants to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;412,667&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of its common stock pursuant to the February 2017 offering by Galena. The convertible promissory notes accrue interest at a rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per annum and the remaining outstanding principal balance and accrued interest is due and payable in November 2018. The outstanding principal balance and accrued interest is convertible into shares of the Company's common stock at a conversion price equal to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$7.00&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. In April 2018, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of outstanding principal and accrued interest was converted into &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;118,644&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; principal balance and accrued interest remains outstanding.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2018Q3YTD" id="Fact-A62373B02E1055DF02CF17BC8F8F7318">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Share and per share amounts below have been retroactively adjusted to reflect the exchange ratio and reverse stock split as described in Note 1. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;2017 Equity Incentive Plan &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On December&amp;#160;29, 2017, the 2017 Equity Incentive Plan was approved, and currently allows for the issuance of up to a maximum of approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;575,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, not including shares subject to awards assumed in connection with certain transactions, including the Merger.  Upon the consummation of the Merger, the Company assumed approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,171&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares subject to outstanding common stock options granted under the Company&amp;#8217;s 2016 Incentive Plan that will remain exercisable through December 29, 2018 for former Company employees and directors. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The number of shares reserved for issuance under the 2017 Equity Incentive Plan will automatically increase on January 1&amp;#160;of each year, for a period of not more than &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years, commencing on January 1&amp;#160;of the year following the year in which the effective date occurs and ending on (and including) January&amp;#160;1, 2027, in an amount equal to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the total number of shares of common stock outstanding on December 31&amp;#160;of the preceding calendar year. Notwithstanding the foregoing, the board of directors may act prior to January 1&amp;#160;of a given year to provide that there will be no January 1&amp;#160;increase in the share reserve for such year or that the increase in the share reserve for such year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. The number of shares reserved for issuance under the 2017 Equity Incentive Plan was automatically increased to approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;805,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; on January 1, 2018. As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, an aggregate of approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;381,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock were reserved for future grants under the Company&amp;#8217;s 2017 Equity Incentive Plan. There were &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; common stock options granted under the 2017 Equity Incentive Plan for the year ended December&amp;#160;31, 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:1pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:1pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of operations for the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;three and nine months ended September 30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, respectively (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;729&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;724&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;229&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total stock-based compensation &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,267&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,776&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Options to Purchase Shares of Common Stock &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company uses the Black-Scholes option-pricing model and the following assumptions were used to determine the fair value of all its stock options granted during the nine months ended September 30, 2018:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Nine Months Ended September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;80.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected lives (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The weighted-average grant date fair value of options granted during the nine months ended September 30, 2018 was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$3.73&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. There were &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; stock options granted during the three months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company&amp;#8217;s expected common stock price volatility assumption is based upon the Company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method, which averages the contractual term of the Company&amp;#8217;s options of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;ten years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; with the average vesting term of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;four years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; for an average of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;six years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, because the Company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company accounts for forfeitures as they occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, there was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of unrecognized compensation cost related to outstanding stock options that is expected to be recognized as a component of the Company&amp;#8217;s operating expenses over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.46&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes stock option activity of the Company for the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;nine months ended September 30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Shares &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Weighted Average Remaining Contractual Term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding at January&amp;#160;1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,240.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;483&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Canceled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding at September&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;434&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;34.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options exercisable at September&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;265.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The aggregate intrinsic values of outstanding and exercisable stock options at &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; were calculated based on the closing price of the Company&amp;#8217;s common stock as reported on the Nasdaq Capital Market on &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.22&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the Company&amp;#8217;s common stock and the exercise price of the underlying stock options.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;RSUs with Time-Based and Performance-Based Conditions &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company granted RSUs subject to both time-based and performance-based vesting conditions to certain of its employees and&amp;#160;non-employees&amp;#160;pursuant to the 2016 Incentive Plan. These RSUs vest based on both (i)&amp;#160;continued service either over a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;-year measurement period or at the end of the required service period and (ii)&amp;#160;the achievement of a liquidity event. The initial vesting date for these RSUs was February&amp;#160;27, 2018. The liquidity event, as defined in the relevant RSU grant agreements, will be satisfied upon the earlier of either: (a) change of control or (b) a qualified public offering. As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and December 31, 2017, there were approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; RSUs outstanding with a weighted average grant date fair value of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$52.94&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company recognizes compensation expense related to these RSUs when the liquidity event is deemed probable. As such, no compensation expense was recorded to date as the liquidity event is outside the Company&amp;#8217;s control and not deemed probable until it occurs.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2018Q3YTD" id="Fact-D48C490EF8FD50884D3A17BC8FAD109E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;A reconciliation of the change in the fair value of the contingent consideration liability for the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Using&amp;#160;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent consideration, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Change in the estimated fair value of the contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent consideration, September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2018Q3YTD" id="Fact-072470E596C088DDEE7117BC8FB1DE79">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Convertible Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that feature conversion options. The accounting standards require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company also records, when necessary, deemed dividends for the intrinsic value of the conversion options embedded in preferred stock based upon the difference between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="FD2018Q3YTD" id="Fact-A6B0E541F2F2E7F37FBB17BC8FC87B9D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Quoted&amp;#160;Prices&amp;#160;In&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Observable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs (Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,774&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,774&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,774&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,774&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;975&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;975&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Quoted&amp;#160;Prices&amp;#160;In&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Observable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs (Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Restricted cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,245&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,245&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,907&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,907&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company did not transfer any financial instruments into or out of Level 3 classification during the three and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.  See Note 10 for a reconciliation of the changes in the fair value of the warrant liability for the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;A reconciliation of the change in the fair value of the contingent consideration liability for the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Using&amp;#160;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent consideration, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Change in the estimated fair value of the contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent consideration, September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The fair value of the contingent consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The contingent consideration relates to Galena&amp;#8217;s acquisition of Apthera, Inc. in 2011 and the future contingent payments of up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$32.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; based on the achievement of certain development and commercial milestones relating to the Company&amp;#8217;s nelipepimut-S ("NeuVax&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;TM" &lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;or "NPS") product candidate. The contingent consideration is payable at the election of the Company in either cash or shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration unless it has first obtained approval of its stockholders in accordance with Rule 5635(a) of the Nasdaq Marketplace Rules. The significant unobservable assumptions include the probability of achieving each milestone, the date the Company expects to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. The change in the estimated fair value of the contingent consideration during the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;nine months ended&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; reflects an adjusted probability and timeline for the potential approval of NPS associated with the positive interim data in the triple-negative breast cancer cohort from the prospective, randomized, single-blinded, controlled Phase 2b investigator-sponsored clinical trial ("IST") of trastuzumab (Herceptin&amp;#174;) +/- NPS in HER2 1+/2+ breast cancer patients in the adjuvant setting to prevent recurrences that was announced on April 2, 2018.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
	<us-gaap:LiquidationBasisOfAccountingTextBlock contextRef="FD2018Q3YTD" id="Fact-79B80DA90F63E1F7CF7B17BC8F837A0F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Liquidity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company has not generated any revenues, including from product sales, and has funded operations primarily from the proceeds of sales of its equity interests and convertible notes, as well as through the Merger. Substantial additional financing will be required by the Company to continue to fund its research and development activities. No assurance can be given that any such financing will be available when needed or that the Company&amp;#8217;s research and development efforts will be successful. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On July 16, 2018, the Company closed an underwritten public offering (the "July 2018 Offering"), issuing &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,845,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,675,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; pre-funded warrants exercisable for shares of common stock and accompanying common stock warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,520,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share and accompanying common stock warrant. The pre-funded warrants and accompanying common stock warrants were sold at a combined price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.0999&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per pre-funded warrant and common stock warrant. Each common stock warrant sold with the shares of common stock and pre-funded warrants represents the right to purchase one share of the Company&amp;#8217;s common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. The common stock warrants are exercisable immediately and will expire on July 16, 2023, five years from the date of issuance. The pre-funded warrants are exercisable immediately, have an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share, and will expire on July 16, 2023, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years from the date of issuance. The net proceeds to the Company from the July 2018 Offering, after deducting the underwriting discounts and commissions and other estimated July 2018 Offering expenses, and excluding the exercise of any warrants, were approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$21.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In addition to the proceeds from the July 2018 Offering, on March&amp;#160;7, 2018, the Company entered into a definitive securities purchase agreement to issue shares of its Series A convertible preferred stock (&amp;#8220;Series A Convertible Preferred&amp;#8221;) and warrants to purchase shares of its common stock in a private placement transaction to a select group of institutional investors. The sale of the aggregate &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,700&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of Series A Convertible Preferred and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.5&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; year warrants to acquire an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,383,631&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock at &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$6.59&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share closed in &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; tranches and resulted in aggregate gross proceeds to the Company of approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$10.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The Company closed the first tranche for approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$6.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; gross proceeds on March&amp;#160;9, 2018. The Company closed the second tranche of the remaining &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; gross proceeds on May 1, 2018, following the receipt of necessary stockholder approval. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third parties and other strategic alliances and business transactions. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company currently does not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with third parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently, consider various other strategic alternatives, including a merger or sale of the Company, or cease operations. If the Company engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development process. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company has evaluated the guidance of Accounting Standards Codification ("ASC") 205-40, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Presentation of Financial Statements - Going Concern&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year from the date its financial statements are available to be issued. The Company has prepared its condensed consolidated financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its potential product candidates, which raises substantial doubt about the Company&amp;#8217;s ability to continue as a going concern. Various internal and external factors will affect whether and when the Company&amp;#8217;s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company&amp;#8217;s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company&amp;#8217;s financial condition and future operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, the Company had cash and cash equivalents of approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, restricted cash balance of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, other receivable of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$6.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (received in November 2018), and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in litigation insurance recovery (received in October 2018). In addition, the Company had outstanding accounts payable and accrued expenses of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$11.9 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and indebtedness of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The Company expects its existing cash as of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, including amounts received in October and November 2018, will enable the Company to fund its operating expenses and capital expenditure requirements through March 2019.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LiquidationBasisOfAccountingTextBlock>
	<us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="FD2018Q3YTD" id="Fact-39C85C3B5E38E5697DE717BC8FA05AF5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Acquisition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On December&amp;#160;29, 2017, the Company completed the Merger with Private SELLAS as discussed in Note 1. The Merger was accounted for as a reverse merger under the acquisition method of accounting whereby Private SELLAS was considered to have acquired the Company for financial reporting purposes because, immediately upon completion of the Merger, Private SELLAS stockholders held a majority of the voting interest of the combined company. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following summary pro forma condensed consolidated financial information reflects the Merger with Galena as if it had occurred on January 1, 2017 for purposes of the statements of operations. This summary pro forma information is not necessarily representative of what the Company&amp;#8217;s results of operations would have been had the Merger in fact occurred on January 1, 2017, and is not intended to project the Company&amp;#8217;s results of operations for any future period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Three Months Ended September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Nine Months Ended September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(9,066&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(21,690&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Basic and diluted net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1.61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Pro forma combined net loss includes an adjustment to reduce historical interest expense of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;for the&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;three and nine months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, respectively,&amp;#160;due to the conversion of the convertible notes of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$5.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The Company excluded a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$5.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; impairment charge incurred by the Company and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$3.3 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of transaction costs related to the Merger from the pro forma financial information for the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;three and nine months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2018Q3YTD" id="Fact-077511620526C8B2F06C17BC8F822596">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements Pending Adoption&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In June 2018, the FASB issued ASU 2018-07, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Improvements to Nonemployee Share-Based Accounting&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The ASU supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees. As a&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (1) liability-classified nonemployee awards that have not been settled as of the adoption date and (2) equity-classified nonemployee awards for which a measurement date has not been established. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2019 and interim periods within those years. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In February 2016, the FASB issued ASU 2016-02&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;, Leases&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. In July 2018, the FASB issued ASU 2018-10, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, and No. 2018-11, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842) - Targeted Improvements&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The new standard establishes a right-of-use&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; or ROU&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the potential impact of the adoption of the new standard on the consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In August 2018, FASB issued ASU 2018-13, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. ASU 2018-13 modifies, adds and removes certain specific the disclosure requirements on fair value measurements in Topic 820&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; The amendments in ASU 2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date.  Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of the new standard on the consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements Adopted&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In November 2016, the FASB issued ASU No. 2016-18,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Restricted Cash&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. ASU No. 2016-18 requires that restricted cash be included&amp;#160;with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the statement of cash flows.&amp;#160;In accordance&amp;#160;with ASU No. 2016-18, the Company adopted this standard in the first quarter of 2018. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's condensed consolidated balance sheets to the total of the amount presented in the condensed consolidated statements of cash flows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,968&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Restricted cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,431&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total cash, cash equivalents, restricted cash, and restricted cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In connection with the Company's Senior Secured Debenture described in Notes 7 and 8, the Company was required to maintain a minimum of the lesser of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$18.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; or the outstanding principal amount of unencumbered cash in a restricted account. Any funds in the restricted account in excess of the outstanding principal balance were to be transferred to the Company's unrestricted account to fund its ongoing operations. As of December&amp;#160;31, 2017, the Company maintained &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$10.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of cash and cash equivalents in a restricted account. The Senior Secured Debenture was deemed to be no longer outstanding as of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. In addition, the Company maintained &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and December 31, 2017, respectively, on hand with the Company's financial institutions as collateral for its corporate credit cards.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In May 2017, the FASB issued ASU No. 2017-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Scope of Modification Accounting&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. ASU&amp;#160;No. 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting.&amp;#160;This guidance is to be applied prospectively to awards modified on or after the adoption date and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted. In accordance with ASU No. 2017-09, the Company adopted this standard prospectively in the first quarter of 2018. The adoption of ASU No. 2017-09 did not have a material impact on the Company's condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Reclassifications&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock contextRef="FD2018Q3YTD" id="Fact-F9FF32F5905C226A206417BC8F87B0CD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Warrants to Acquire Shares of Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following is a summary of the Company's warrants to acquire shares of common stock activity for the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Outstanding, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Canceled/Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Outstanding, September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;July 2018 Offering&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;15,268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;15,268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;July 2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Pre-funded July 2018 Offering&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2,525&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;July 2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Series A Convertible Preferred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,384&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,384&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September 2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2017 Equilibria&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena February 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;567&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(535&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;February 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;January 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;963&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;21,327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2,525&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(541&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;19,224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants to acquire shares of common stock consist of warrants that may be settled in cash, which are liability-classified warrants, and equity-classified warrants. During the nine months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, a total of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;534,333&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the Galena February 2017 liability-classified warrants to purchase shares of common stock were canceled under various warrant exchange agreements. The Company issued &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;54,613&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of its common stock in exchange for the surrender and cancellation of warrants to acquire &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;121,667&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of its common stock and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in convertible promissory notes in exchange for the surrender and cancellation of warrants to acquire &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;412,667&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of its common stock, as described in Note 7. The fair value of the common stock and promissory notes exchanged totaled &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, which exceeded the fair value of the warrant liability of the warrants canceled by &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and is recorded as loss on settlement of liability-classified warrants in the condensed consolidated statement of operations for the nine months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. In April 2018, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of outstanding principal and accrued interest was converted into &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;118,644&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Warrants Classified as Liabilities &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liability-classified warrants consist of warrants to acquire common stock issued in connection with previous equity financings for the Series A Convertible Preferred, Galena's February 2017 financing, and various other Galena equity financings that were assumed by the Company at the consummation of the Merger. These warrants may be settled in cash and were determined to not be indexed to the Company&amp;#8217;s common stock. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Prior to the consummation of the July 2018 Offering, the initial exercise price of the warrants to acquire shares of common stock in connection with the Series A Convertible Preferred was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$6.59&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share of common stock, subject to standard adjustments for certain transactions affecting the Company&amp;#8217;s securities (such as stock dividends, and stock splits). From the original issue date until the one-year anniversary of a qualified offering, the initial exercise price and number of warrants to acquire shares of common stock are subject to anti-dilution protection in the event of non-exempt equity issuances at a price per share lower than the then exercise price (the "Base Share Price"). Simultaneously with the consummation of each non-exempt equity issuance the exercise price shall be reduced to equal the Base Share Price. Such adjustment shall be made whenever such common stock or common stock equivalents are issued.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the condensed consolidated statement of operations as change in fair value of warrant liability. The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Strike price (per share)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Series A Convertible Preferred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,384&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;83.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena February 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;85.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;888.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;85.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Strike price (per share)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena February 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;567&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;79.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;28.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3.19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;74.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The expected volatility assumptions are based on the Company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, because the Company has &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; present intention to pay cash dividends.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The changes in fair value of the warrant liability for the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;nine months ended September 30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants canceled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Adjustment to exercise price of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Change in fair value of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Series A Convertible Preferred&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4,558&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;972&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena February 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,305&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(524&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Galena Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(524&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(5,340&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;975&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Warrants Classified as Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company issued warrants to acquire &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;316,163&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the its common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$7.42&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share, maturing &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; from issuance, to EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund on December&amp;#160;29, 2017. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent reporting periods. The fair value of the warrants granted was&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$5.60&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;per share using the Black-Scholes pricing model with the fair value assumptions for the grant including a volatility of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;90.10%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, expected term of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years, risk free rate of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.20%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, and a dividend rate of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.00&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock issued during the July 2018 offering are recorded in equity upon issuance as described in Note 9.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="FD2018Q3YTD" id="Fact-976E9EC5E934423D7F5C17BC8F7F0EBC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt; Organization and Description of Business&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"&gt;Overview&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;SELLAS Life Sciences Group, Inc. (the "Company," or &amp;#8220;SELLAS&amp;#8221;) is a late-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapeutics for a broad range of indications. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"&gt;Merger of Galena Biopharma, Inc. and SELLAS Life Sciences Group Ltd.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As used in this quarterly report on Form 10-Q, the words the &amp;#8220;Company,&amp;#8221; and &amp;#8220;SELLAS&amp;#8221; refer to SELLAS Life Sciences Group, Inc. and its consolidated subsidiaries following completion of the business combination with Galena Biopharma, Inc., a Delaware corporation ("Galena"). This business combination is referred to as the Merger. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On December&amp;#160;29, 2017, Galena completed the Merger with SELLAS Life Sciences Group, Ltd., a privately held Bermuda exempted company ("Private SELLAS"), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of August&amp;#160;7, 2017 and amended November&amp;#160;5, 2017 (the "Merger Agreement"), among the Company, Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc., Galena Bermuda Merger Sub, Ltd., and Private SELLAS. As a result of the Merger, the Company&amp;#8217;s business is now substantially comprised of the business of Private SELLAS, and although the Company is considered the legal acquiror of Private SELLAS, for accounting purposes, Private SELLAS is considered to have acquired the Company in the Merger. Consequently, the Merger was accounted for as a reverse acquisition and the Private SELLAS financial statements became the Company's financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Immediately prior to the Merger, Galena effected a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;-for-&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; reverse stock split of its outstanding common stock, par value &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. Under the terms of the Merger Agreement, Galena issued shares of its common stock to Private SELLAS&amp;#8217; securityholders at an exchange ratio of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;43.9972&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of its common stock in exchange for each common share of Private SELLAS outstanding immediately prior to the Merger. The Company also assumed all of the restricted stock units (&amp;#8220;RSUs&amp;#8221;) issued and outstanding under the Private SELLAS Stock Incentive Plan #1, and all of the issued and outstanding warrants of Private SELLAS. Accordingly, such RSUs will now be settled in, and such warrants now are exercisable for, shares of the Company&amp;#8217;s common stock. Accordingly, immediately after the Merger, there were &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,766,891&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock outstanding, with the former Private SELLAS securityholders owning &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;67.5%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the Company&amp;#8217;s fully diluted common stock, and the Company&amp;#8217;s pre-Merger securityholders owning the remaining &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;32.5%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The number of shares and per share amounts of common stock in the accompanying condensed consolidated financial statements and notes to the condensed consolidated financial statements have been restated to give retroactive effect to the common stock conversion ratio and reverse stock split for all periods presented, including common stock options, RSUs, and common stock warrants. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Upon completion of the Merger, the Company&amp;#8217;s name changed from &amp;#8220;Galena Biopharma, Inc.&amp;#8221; to &amp;#8220;SELLAS Life Sciences Group, Inc.," the Company&amp;#8217;s financial statements became those of Private SELLAS and the Company's common stock began trading on The Nasdaq Capital Market under a new ticker symbol &amp;#8220;SLS&amp;#8221; on January&amp;#160;2, 2018.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2018Q3YTD" id="Fact-9E366F633504BC35021117BC8F83A8CF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Professional fees*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,836&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Compensation and related benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;808&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;566&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Clinical trial costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Value-added tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;158&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;426&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Rebates and returns of former commercial products&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;276&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;191&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;*Includes approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of legal fees incurred related to the JGB litigation as described in Note 8 that was reimbursed to the Company in November 2018 by JGB.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="FD2018Q3YTD" id="Fact-04F526BDAAEF51FECA3617BC8FB0A0D8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's condensed consolidated balance sheets to the total of the amount presented in the condensed consolidated statements of cash flows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,968&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Restricted cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,431&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total cash, cash equivalents, restricted cash, and restricted cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
	<us-gaap:ScheduleOfDebtTableTextBlock contextRef="FD2018Q3YTD" id="Fact-D606E866B83EA522A13C17BC8F70FA7F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Current portion of Senior Secured Debenture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Short-term convertible promissory notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Non-current portion of Senior Secured Debenture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,988&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2018Q3YTD" id="Fact-533C32BCFC0956A5DD3D17BC8F89A8EC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of operations for the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;three and nine months ended September 30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, respectively (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;729&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;724&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;229&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total stock-based compensation &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,267&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,776&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2018Q3YTD" id="Fact-06345B96E7A980BCE3B417BC8FB05023">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Quoted&amp;#160;Prices&amp;#160;In&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Observable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs (Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,774&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,774&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,774&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,774&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;975&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;975&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Quoted&amp;#160;Prices&amp;#160;In&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Observable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs (Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Restricted cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,245&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,245&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,907&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,907&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2018Q3YTD" id="Fact-B7F9B04708C31644EAB817BC8F8D7078">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes stock option activity of the Company for the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;nine months ended September 30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Shares &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Weighted Average Remaining Contractual Term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding at January&amp;#160;1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,240.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;483&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Canceled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding at September&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;434&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;34.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options exercisable at September&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;265.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2018Q3YTD" id="Fact-3149BE517CCB42B4902817BC8F8D2B63">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company uses the Black-Scholes option-pricing model and the following assumptions were used to determine the fair value of all its stock options granted during the nine months ended September 30, 2018:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Nine Months Ended September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;80.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected lives (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2018Q3YTD" id="Fact-3D77343352D0B7A61E4217BC8F7E47BA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Basis of Presentation and Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Basis of Presentation &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&amp;#8220;U.S. GAAP&amp;#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&amp;#160;GAAP as found in the ASC and Accounting Standards Updates (&amp;#8220;ASU&amp;#8221;) of the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Principles of Consolidation &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The condensed consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Unaudited Interim Results &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company's annual consolidated financial statements and the notes thereto included in its Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, which was filed with the Securities and Exchange Commission ("SEC") on April 13, 2018 (the "2017 Annual Report"). The accompanying condensed consolidated financial statements at&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;and for the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;three and nine months ended September 30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and 2017, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; have been derived from the audited financial statements as of that date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&amp;#8217;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&amp;#8217; equity.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Convertible Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that feature conversion options. The accounting standards require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company also records, when necessary, deemed dividends for the intrinsic value of the conversion options embedded in preferred stock based upon the difference between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements Pending Adoption&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In June 2018, the FASB issued ASU 2018-07, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Improvements to Nonemployee Share-Based Accounting&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The ASU supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees. As a&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (1) liability-classified nonemployee awards that have not been settled as of the adoption date and (2) equity-classified nonemployee awards for which a measurement date has not been established. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2019 and interim periods within those years. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In February 2016, the FASB issued ASU 2016-02&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;, Leases&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. In July 2018, the FASB issued ASU 2018-10, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, and No. 2018-11, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842) - Targeted Improvements&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The new standard establishes a right-of-use&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; or ROU&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the potential impact of the adoption of the new standard on the consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In August 2018, FASB issued ASU 2018-13, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. ASU 2018-13 modifies, adds and removes certain specific the disclosure requirements on fair value measurements in Topic 820&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; The amendments in ASU 2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date.  Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of the new standard on the consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements Adopted&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In November 2016, the FASB issued ASU No. 2016-18,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Restricted Cash&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. ASU No. 2016-18 requires that restricted cash be included&amp;#160;with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the statement of cash flows.&amp;#160;In accordance&amp;#160;with ASU No. 2016-18, the Company adopted this standard in the first quarter of 2018. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's condensed consolidated balance sheets to the total of the amount presented in the condensed consolidated statements of cash flows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,968&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Restricted cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,431&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total cash, cash equivalents, restricted cash, and restricted cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In connection with the Company's Senior Secured Debenture described in Notes 7 and 8, the Company was required to maintain a minimum of the lesser of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$18.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; or the outstanding principal amount of unencumbered cash in a restricted account. Any funds in the restricted account in excess of the outstanding principal balance were to be transferred to the Company's unrestricted account to fund its ongoing operations. As of December&amp;#160;31, 2017, the Company maintained &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$10.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of cash and cash equivalents in a restricted account. The Senior Secured Debenture was deemed to be no longer outstanding as of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. In addition, the Company maintained &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and December 31, 2017, respectively, on hand with the Company's financial institutions as collateral for its corporate credit cards.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In May 2017, the FASB issued ASU No. 2017-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Scope of Modification Accounting&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. ASU&amp;#160;No. 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting.&amp;#160;This guidance is to be applied prospectively to awards modified on or after the adoption date and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted. In accordance with ASU No. 2017-09, the Company adopted this standard prospectively in the first quarter of 2018. The adoption of ASU No. 2017-09 did not have a material impact on the Company's condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Reclassifications&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2018Q3YTD" id="Fact-3FFA8D95703532692B4317BC8F9644DE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Stockholders&amp;#8217; Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company has authorized up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,000,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;shares of preferred stock, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;par value per share, for issuance. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Series A Convertible Preferred &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On March&amp;#160;7, 2018, the Company entered into a securities purchase agreement with investors, pursuant to which the Company agreed to sell to the investors, in a private placement pursuant to Rule 4(a)(2) and Regulation S under the Securities Act, an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,700&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the Company&amp;#8217;s newly-created non-voting Series A Convertible Preferred, and warrants to acquire an aggregate &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,383,631&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock, par value &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share at an aggregate purchase price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$10.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The Series A Convertible Preferred was initially convertible into &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,844,835&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock based on an initial conversion price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$5.80&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;At the first closing of the Series A Convertible Preferred on March&amp;#160;9, 2018, the Company issued an aggregate &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,987&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of Series A Convertible Preferred and warrants to acquire &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;774,186&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock for aggregate gross proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$6.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The second closing of the remaining &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,713&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the Series A Convertible Preferred and warrants to acquire &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;609,445&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of its common stock, for aggregate gross proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, occurred on May 1, 2018 following receipt of stockholder approval. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In the event of a "qualified offering," as defined in the securities purchase agreement, holders of the Series A Convertible Preferred (the "Series A Holders"), had the right to exchange their shares of Series A Convertible Preferred for the same securities sold in a qualified offering on a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.00&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; for &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.00&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; basis based on the stated value of their shares of Series A Convertible Preferred under the most favored nation provision. On July 16, 2018, following consummation of the July 2018 Offering, which was deemed a qualified offering as described below and also in Note 2 above, the Series A Holders exchanged an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$7,871,186&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of stated valued and accrued but unpaid dividends on their Series A Convertible Preferred for an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,748,184&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock and warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,748,184&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock. Following such exchange there are no shares of Series A Convertible Preferred issued and outstanding. The warrants have an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share and a term of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years. The fair value of the common stock and warrants to purchase shares of common stock exceeded the carrying amount of the Series A Preferred by &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$8.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and that amount is recorded as a deemed dividend in the condensed consolidated statements of operations during the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;three and nine months ended&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; as it represents a transfer of value from the common stockholders to the preferred investors. Since the Company does not have accumulated earnings, the deemed dividend is taken from additional paid-in capital. This one-time, non-cash charge impacted net loss attributable to common stockholders and loss per share for the three and nine months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In addition, pursuant to the terms of the warrants, the exercise price of the warrants issued to the investors in March 2018 and May 2018 was adjusted to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share from the original exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$6.59&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. The Company recognized the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; increase to the fair value of the warrant liability as a result of the adjusted stock price as a deemed dividend in the condensed consolidated statements of operations during the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;three and nine months ended&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. This one-time, non-cash charge impacted net loss attributable to common stockholders and loss per share for the three and nine months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Series A Convertible Preferred generally had no voting rights. However, for so long as any shares of Series A Convertible Preferred were outstanding, the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Convertible Preferred was required to: (a)&amp;#160;alter or change adversely the powers, preferences or rights given to the Series A Convertible Preferred or alter or amend the Certificate of Designation, (b)&amp;#160;authorize or create any class of stock ranking as to dividends, redemption or distribution of assets upon a Liquidation (as defined in the Certificate of Designation) senior to, or otherwise &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;pari passu&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; with, the Series A Convertible Preferred, (c)&amp;#160;amend the Company's certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Convertible Preferred, (d)&amp;#160;increase the number of authorized shares of Series A Convertible Preferred, or (e)&amp;#160;enter into any agreement with respect to any of the foregoing. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary that is not a Fundamental Transaction (as defined in the Certificate of Designation), the holders of Series A Convertible Preferred were entitled to receive from the Company's assets the same amount they would have received on an as converted basis, disregarding any conversion limitations. Such amounts would have been paid on a&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;pari&amp;#160;passu basis with all holders of common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company evaluated the Series A Convertible Preferred in accordance with the provisions of ASC 815,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, including consideration of embedded derivatives requiring bifurcation. The issuance of the Series A Convertible Preferred could generate a beneficial conversion feature (&amp;#8220;BCF&amp;#8221;), which arises when a debt or equity security is issued with an embedded conversion option that is beneficial to the investor or in the money at inception because the conversion option has an effective conversion price that is less than the market price of the underlying stock at the commitment date. The Company recognized the BCF by allocating the intrinsic value of the conversion option, which is the number of shares of common stock available upon conversion multiplied by the difference between the effective conversion price per share and the fair value of common stock per share on the commitment date, to additional paid-in capital, resulting in a discount on the convertible preferred stock. As the Series A Convertible Preferred could have been converted immediately, the Company recognized a BCF of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; as a deemed dividend in the condensed consolidated statements of operations related to the first closing on March 9, 2018 and an additional BCF of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; as a deemed dividend related to the second closing on May 1, 2018.&amp;#160;These one-time, non-cash charges impacted net loss attributable to common stockholders and loss per share for the nine months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Common Stock&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company has authorized up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;350,000,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;shares of common stock, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;par value per share, for issuance. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On July 16, 2018, the Company closed the July 2018 Offering, issuing &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,845,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,675,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; pre-funded warrants exercisable for shares of common stock and accompanying common stock warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,520,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share and accompanying common stock warrant. The pre-funded warrants and accompanying common stock warrants were sold at a combined price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.0999&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per pre-funded warrant and common stock warrant.  Each accompanying common stock warrant sold with the shares of common stock and pre-funded warrants represents the right to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; share of the Company&amp;#8217;s common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. The common stock warrants are exercisable immediately and will expire on July 16, 2023, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years from the date of issuance. The pre-funded warrants are exercisable immediately, have an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share, and will expire on July 16, 2023, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years from the date of issuance.  The net proceeds to the Company from the July 2018 Offering, after deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants, were approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$21.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;During its evaluation of equity classification for the pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock issued in the July 2018 Offering, the Company considered the conditions as prescribed within ASC 815-40, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Contracts in an Entity&amp;#8217;s own Equity&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (&amp;#8220;ASC 815-40&amp;#8221;). The conditions within ASC 815-40 are not subject to a probability assessment. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do not fall under the liability criteria within ASC 480, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Distinguishing Liabilities from Equity,&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; as they are not puttable and do not represent an instrument that has a redeemable underlying security. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do meet the definition of a derivative instrument under ASC 815, but are eligible for the scope exception as they are indexed to the Company&amp;#8217;s own stock and would be classified in permanent equity if freestanding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shares of common stock for future issuance are reserved for as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;19,224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock options outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;434&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options reserved for future issuance under the Company&amp;#8217;s 2017 Equity Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;381&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shares reserved for future issuance under the Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total reserved for future issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20,167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy contextRef="FD2018Q3YTD" id="Fact-8A7BF41D9CF379D8BAC417BC8FB0889D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&amp;#8217;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&amp;#8217; equity.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2018Q3YTD" id="Fact-B9955143C7EE4C63D43517BC8FBBAAF9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company evaluated all events or transactions that occurred after &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the condensed consolidated financial statements, the Company did not have any material subsequent events.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>gale-20180930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.galenabiopharma.com/20180930" xmlns:gale="http://www.galenabiopharma.com/20180930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20180930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20180930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20180930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20180930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>2106100 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>2406402 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>2306301 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisition" roleURI="http://www.galenabiopharma.com/role/Acquisition">
        <link:definition>2104100 - Disclosure - Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionDetails" roleURI="http://www.galenabiopharma.com/role/AcquisitionDetails">
        <link:definition>2404402 - Disclosure - Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionTables" roleURI="http://www.galenabiopharma.com/role/AcquisitionTables">
        <link:definition>2304301 - Disclosure - Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPolicies" roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies">
        <link:definition>2103100 - Disclosure - Basis Of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails" roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails">
        <link:definition>2403403 - Disclosure - Basis Of Presentation and Significant Accounting Policies - Components of Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesPolicies" roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Basis Of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesTables" roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables">
        <link:definition>2303302 - Disclosure - Basis Of Presentation and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementOfStockholdersEquity" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquity">
        <link:definition>1003000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperations" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.galenabiopharma.com/role/Debt">
        <link:definition>2107100 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtConvertibleDebtDetails" roleURI="http://www.galenabiopharma.com/role/DebtConvertibleDebtDetails">
        <link:definition>2407404 - Disclosure - Debt (Convertible Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSeniorSecuredDebentureDetails" roleURI="http://www.galenabiopharma.com/role/DebtSeniorSecuredDebentureDetails">
        <link:definition>2407403 - Disclosure - Debt (Senior Secured Debenture) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSummaryOfDebtDetails" roleURI="http://www.galenabiopharma.com/role/DebtSummaryOfDebtDetails">
        <link:definition>2407402 - Disclosure - Debt (Summary of Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.galenabiopharma.com/role/DebtTables">
        <link:definition>2307301 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements">
        <link:definition>2105100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails">
        <link:definition>2405402 - Disclosure - Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails">
        <link:definition>2405403 - Disclosure - Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables">
        <link:definition>2305301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsCommitmentsAndContingencies" roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingencies">
        <link:definition>2108100 - Disclosure - Legal Proceedings, Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsCommitmentsAndContingenciesDetails" roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetails">
        <link:definition>2408401 - Disclosure - Legal Proceedings, Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Liquidity" roleURI="http://www.galenabiopharma.com/role/Liquidity">
        <link:definition>2102100 - Disclosure - Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiquidityDetails" roleURI="http://www.galenabiopharma.com/role/LiquidityDetails">
        <link:definition>2402401 - Disclosure - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndDescriptionOfBusiness" roleURI="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusiness">
        <link:definition>2101100 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndDescriptionOfBusinessNarrativeDetails" roleURI="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusinessNarrativeDetails">
        <link:definition>2401401 - Disclosure - Organization and Description of Business (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation">
        <link:definition>2111100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAllocatedStockBasedCompensationDetails" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails">
        <link:definition>2411403 - Disclosure - Stock-Based Compensation (Allocated Stock-based Compensation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails">
        <link:definition>2411404 - Disclosure - Stock-Based Compensation (Assumptions for Option Grants Issued) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2411402 - Disclosure - Stock-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2411405 - Disclosure - Stock-Based Compensation (Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables">
        <link:definition>2311301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.galenabiopharma.com/role/StockholdersEquity">
        <link:definition>2109100 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails" roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails">
        <link:definition>2409403 - Disclosure - Stockholders' Equity (Common Stock are Reserved for Future Issuance) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2409402 - Disclosure - Stockholders' Equity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables">
        <link:definition>2309301 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.galenabiopharma.com/role/SubsequentEvents">
        <link:definition>2112100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsToAcquireSharesOfCommonStock" roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStock">
        <link:definition>2110100 - Disclosure - Warrants to Acquire Shares of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails" roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails">
        <link:definition>2410405 - Disclosure - Warrants to Acquire Shares of Common Stock (Changes in Fair Value of Warrant Liability) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails" roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails">
        <link:definition>2410404 - Disclosure - Warrants to Acquire Shares of Common Stock (Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsToAcquireSharesOfCommonStockNarrativeDetails" roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockNarrativeDetails">
        <link:definition>2410403 - Disclosure - Warrants to Acquire Shares of Common Stock (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails" roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails">
        <link:definition>2410402 - Disclosure - Warrants to Acquire Shares of Common Stock (Schedule of Warrant Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsToAcquireSharesOfCommonStockTables" roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables">
        <link:definition>2310301 - Disclosure - Warrants to Acquire Shares of Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails" roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails">
        <link:definition>2410406 - Disclosure - Warrants to Acquire Shares of Common Stock (Warrants Classified as Equity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="gale_AmendmentAgreementMember" name="AmendmentAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_AptheraInc.Member" name="AptheraInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture" name="BalanceOfRestrictedCashOverSeniorSecuredDebenture" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" name="ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangeInFairValueOfContingentPurchaseConsideration" name="ChangeInFairValueOfContingentPurchaseConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangeInFairValueOfContingentPurchasePriceConsideration" name="ChangeInFairValueOfContingentPurchasePriceConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangeInFairValueOfWarrantLiabilities" name="ChangeInFairValueOfWarrantLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" name="ChangesInFairValueOfWarrantLiabilityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_ClassOfWarrantOrRightExercised" name="ClassOfWarrantOrRightExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightCanceledOrExpired" name="ClassofWarrantorRightCanceledOrExpired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ClassofWarrantorRightFairValueRollForward" name="ClassofWarrantorRightFairValueRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightGranted" name="ClassofWarrantorRightGranted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ClassofWarrantorRightOutstandingRollForward" name="ClassofWarrantorRightOutstandingRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock" name="ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightTerm" name="ClassofWarrantorRightTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClosingPriceOfCommonStock" name="ClosingPriceOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" name="CommonStockAreReservedForFutureIssuanceTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" name="CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_CommonStockConversionRatio" name="CommonStockConversionRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants" name="CommonStockIssuedDuringThePeriodForCancellationOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_CommonStockSharesAcquiredinExchangeforWarrants" name="CommonStockSharesAcquiredinExchangeforWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ConsiderationExchangedFairValue" name="ConsiderationExchangedFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" name="ContingentPurchasePriceConsiderationNetOfCurrentPortion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ContractResearchPayable" name="ContractResearchPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ConvertiblePreferredStockConversionPrice" name="ConvertiblePreferredStockConversionPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_ConvertiblePreferredStockDividends" name="ConvertiblePreferredStockDividends" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_ConvertiblePreferredStockIssuedShares" name="ConvertiblePreferredStockIssuedShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_ConvertiblePreferredStockNumberOfTranches" name="ConvertiblePreferredStockNumberOfTranches" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_ConvertiblePromissoryNotesMember" name="ConvertiblePromissoryNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_CorporateCreditCardsMember" name="CorporateCreditCardsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_DebtInstrumentCovenantLiquidityCovenant" name="DebtInstrumentCovenantLiquidityCovenant" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_DebtInstrumentRedemptionPrincipalAmountRedeemed" name="DebtInstrumentRedemptionPrincipalAmountRedeemed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash" name="DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares" name="DebtInstrumentRedemptionPrincipalAmountRedeemedShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock" name="DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_DepositOfRestrictedCashOverSeniorSecuredDebenture" name="DepositOfRestrictedCashOverSeniorSecuredDebenture" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_DividendModificationOfWarrants" name="DividendModificationOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_DividendOnConversionOfSeriesAConvertiblePreferredStock" name="DividendOnConversionOfSeriesAConvertiblePreferredStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation" name="DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_DocumentDocumentAndEntityInformationAbstract" name="DocumentDocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" name="EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" name="EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_EqcWarrantsMember" name="EqcWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" name="FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" name="FairValueOfWarrantLiabilityAssumptionsExpectedTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantsCanceled" name="FairValueOfWarrantsCanceled" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantsExercisePriceAdjustment" name="FairValueOfWarrantsExercisePriceAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" name="FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantsLiabilities" name="FairValueOfWarrantsLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_FairValueOfWarrantsPotentiallySettleableInCash" name="FairValueOfWarrantsPotentiallySettleableInCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_FairValueofWarrantsGranted" name="FairValueofWarrantsGranted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueofWarrantsGrantedperShare" name="FairValueofWarrantsGrantedperShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_February2017WarrantsMember" name="February2017WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_FirstTrancheMember" name="FirstTrancheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_GainLossOnExtinguishmentOfPayables" name="GainLossOnExtinguishmentOfPayables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_GalenaBiopharmaIncMember" name="GalenaBiopharmaIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_InProcessResearchDevelopment" name="InProcessResearchDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_IncentivePlan2016Member" name="IncentivePlan2016Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_IncreaseDecreaseInFairValueOfWarrantLiability" name="IncreaseDecreaseInFairValueOfWarrantLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_JBGLitigationMember" name="JBGLitigationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_JGBActionMember" name="JGBActionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_July2018OfferingMember" name="July2018OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_LiabilityClassifiedWarrantsAntidilutionProtection" name="LiabilityClassifiedWarrantsAntidilutionProtection" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_LitigationSettlementIssuanceofCommonStockValue" name="LitigationSettlementIssuanceofCommonStockValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_LongtermDebtIssuedInConnectionWithWarrantExchanges" name="LongtermDebtIssuedInConnectionWithWarrantExchanges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_LossContingencyNumberOfCounterclaims" name="LossContingencyNumberOfCounterclaims" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_LossOnSettlementOfLiabilityClassifiedWarrants" name="LossOnSettlementOfLiabilityClassifiedWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_LossOnSettlementOfWarrantsLiability" name="LossOnSettlementOfWarrantsLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" name="OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_OtherWarrantIssuesMember" name="OtherWarrantIssuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_PatelvsGalenabiopharmaIncMember" name="PatelvsGalenabiopharmaIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" name="PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PercentageOfFullyDilutedShareCapitalOwned" name="PercentageOfFullyDilutedShareCapitalOwned" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_PreMergerSecurityholdersMember" name="PreMergerSecurityholdersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PreferredStockIssuedDuringPeriodValueNewIssues" name="PreferredStockIssuedDuringPeriodValueNewIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_Prefunded2018OfferingMember" name="Prefunded2018OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_PrivatePlacementFirstClosingMember" name="PrivatePlacementFirstClosingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_PrivatePlacementSecondClosingMember" name="PrivatePlacementSecondClosingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_PrivateSELLASSecurityHoldersMember" name="PrivateSELLASSecurityHoldersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet" name="ProceedsfromIssuanceofLongtermDebtandWarrantsNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_RebatesAndReturnsOfFormerCommercialProducts" name="RebatesAndReturnsOfFormerCommercialProducts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock" name="ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ReimbursementOfLegalFees" name="ReimbursementOfLegalFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_RestrictedCashandCashEquivalentsFairValueDisclosure" name="RestrictedCashandCashEquivalentsFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_RestrictedStockSharesReservedforFutureIssuance" name="RestrictedStockSharesReservedforFutureIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" name="ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" name="ScheduleOfSummaryOfSignificantAccountingPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ScheduleOfWarrantActivityTableTextBlock" name="ScheduleOfWarrantActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" name="ScheduleOfWarrantValuationAssumptionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SecondTrancheMember" name="SecondTrancheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SeriesAConvertiblePreferredWarrantsMember" name="SeriesAConvertiblePreferredWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SeriesANonvotingConvertibleMember" name="SeriesANonvotingConvertibleMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_StockIssuedDuringPeriodSharesPrefundedWarrant" name="StockIssuedDuringPeriodSharesPrefundedWarrant" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_TwoThousandAndSeventeenEquityIncentivePlanMember" name="TwoThousandAndSeventeenEquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_WarrantExchangeAgreementsAmount" name="WarrantExchangeAgreementsAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_WarrantExchangeAgreementsIssuanceOfCommonStock" name="WarrantExchangeAgreementsIssuanceOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_WarrantStrikePrice" name="WarrantStrikePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_WarrantsFairValueAssumptionsExpectedVolatility" name="WarrantsFairValueAssumptionsExpectedVolatility" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" name="WarrantsFairValueAssumptionsRiskFreeInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_WarrantsIssuedShares" name="WarrantsIssuedShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>gale-20180930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="gale-20180930.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="gale-20180930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="gale-20180930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Acquisition" xlink:href="gale-20180930.xsd#Acquisition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionDetails" xlink:href="gale-20180930.xsd#AcquisitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionTables" xlink:href="gale-20180930.xsd#AcquisitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:href="gale-20180930.xsd#BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails" xlink:href="gale-20180930.xsd#BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:href="gale-20180930.xsd#BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:href="gale-20180930.xsd#BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:href="gale-20180930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="gale-20180930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:href="gale-20180930.xsd#CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="gale-20180930.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="gale-20180930.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Debt" xlink:href="gale-20180930.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtConvertibleDebtDetails" xlink:href="gale-20180930.xsd#DebtConvertibleDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtSeniorSecuredDebentureDetails" xlink:href="gale-20180930.xsd#DebtSeniorSecuredDebentureDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtSummaryOfDebtDetails" xlink:href="gale-20180930.xsd#DebtSummaryOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtTables" xlink:href="gale-20180930.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:href="gale-20180930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:href="gale-20180930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails" xlink:href="gale-20180930.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails" xlink:href="gale-20180930.xsd#FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:href="gale-20180930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingencies" xlink:href="gale-20180930.xsd#LegalProceedingsCommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetails" xlink:href="gale-20180930.xsd#LegalProceedingsCommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Liquidity" xlink:href="gale-20180930.xsd#Liquidity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LiquidityDetails" xlink:href="gale-20180930.xsd#LiquidityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="gale-20180930.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:href="gale-20180930.xsd#OrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:href="gale-20180930.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:href="gale-20180930.xsd#StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails" xlink:href="gale-20180930.xsd#StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails" xlink:href="gale-20180930.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="gale-20180930.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:href="gale-20180930.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:href="gale-20180930.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails" xlink:href="gale-20180930.xsd#StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails" xlink:href="gale-20180930.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:href="gale-20180930.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:href="gale-20180930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStock" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockNarrativeDetails" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStockNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_113b0150-367f-99b9-4773-3f3df4696704" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_113b0150-367f-99b9-4773-3f3df4696704" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ContractResearchPayable" xlink:label="loc_gale_ContractResearchPayable_02d01603-90ae-c905-6599-17bc9e28dcbf" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_gale_ContractResearchPayable_02d01603-90ae-c905-6599-17bc9e28dcbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0e2721e-44a1-957d-5aaa-294b580a15e3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0e2721e-44a1-957d-5aaa-294b580a15e3" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_RebatesAndReturnsOfFormerCommercialProducts" xlink:label="loc_gale_RebatesAndReturnsOfFormerCommercialProducts_cc52048c-36c4-6827-6376-17bc9e23a62f" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_gale_RebatesAndReturnsOfFormerCommercialProducts_cc52048c-36c4-6827-6376-17bc9e23a62f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_e11f4ed8-bba4-2471-6835-a5baa4d63b38" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_TaxesPayableCurrent_e11f4ed8-bba4-2471-6835-a5baa4d63b38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d9354686-0832-bbe3-9389-140489c487e8" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d9354686-0832-bbe3-9389-140489c487e8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/Acquisition" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0e2b0aef-f283-e3cd-a77b-e835b6efc171" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0e2b0aef-f283-e3cd-a77b-e835b6efc171" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0e2b0aef-f283-e3cd-a77b-e835b6efc171" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0e2b0aef-f283-e3cd-a77b-e835b6efc171" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_dbfa1e75-5ca7-c18e-328b-85edddaeec4f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_dbfa1e75-5ca7-c18e-328b-85edddaeec4f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableCurrent_5bf5de9d-0910-f3f9-d348-0687d2fc48d3" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_InsuranceSettlementsReceivableCurrent_5bf5de9d-0910-f3f9-d348-0687d2fc48d3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_InProcessResearchDevelopment" xlink:label="loc_gale_InProcessResearchDevelopment_e319bb5e-0ace-aac2-b19a-17bc9d22ab42" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_gale_InProcessResearchDevelopment_e319bb5e-0ace-aac2-b19a-17bc9d22ab42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_61ff83b4-33a0-68aa-a4ad-7dbd9b595dbf" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_61ff83b4-33a0-68aa-a4ad-7dbd9b595dbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_0d8925ae-714a-26e4-aa69-2d9eac65a5c6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_LongTermDebtCurrent_0d8925ae-714a-26e4-aa69-2d9eac65a5c6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaap_LitigationReserveCurrent_c53143dc-fefd-4b2a-77bb-40f522645337" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_LitigationReserveCurrent_c53143dc-fefd-4b2a-77bb-40f522645337" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d3ba3006-9df7-8186-2eb2-dc5094562cfe" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d3ba3006-9df7-8186-2eb2-dc5094562cfe" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_dab54599-28be-451a-76ee-17bc9d920e36" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_dab54599-28be-451a-76ee-17bc9d920e36" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_cf2b256c-b8de-9fbc-9661-17bc9d59ca79" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_cf2b256c-b8de-9fbc-9661-17bc9d59ca79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_273ee7a0-7a7a-98e9-4dc3-2da4f56d5e34" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_273ee7a0-7a7a-98e9-4dc3-2da4f56d5e34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ec8bc8e-bcd9-36ad-d8ae-2c2fa1dfd920" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ec8bc8e-bcd9-36ad-d8ae-2c2fa1dfd920" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends_13cc8818-e792-6246-5e41-c56e1150a319" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsOfDividends_13cc8818-e792-6246-5e41-c56e1150a319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_cfa1e746-5920-c3b5-33ed-a7dee018f26c" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_cfa1e746-5920-c3b5-33ed-a7dee018f26c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_98ad2198-806f-6053-5326-b79be5cbb9ef" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_98ad2198-806f-6053-5326-b79be5cbb9ef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11620bd8-431c-98f6-ac51-02db9613dc06" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11620bd8-431c-98f6-ac51-02db9613dc06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_74538844-e2fb-8444-e093-2ede9444fc66" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_PaidInKindInterest_74538844-e2fb-8444-e093-2ede9444fc66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_d346b6a0-4ddf-16a5-9e91-c8c6b50db7a6" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_d346b6a0-4ddf-16a5-9e91-c8c6b50db7a6" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_GainLossOnExtinguishmentOfPayables" xlink:label="loc_gale_GainLossOnExtinguishmentOfPayables_0C1C590F210A646E3D60087F66D41CC7" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_gale_GainLossOnExtinguishmentOfPayables_0C1C590F210A646E3D60087F66D41CC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_08057203-8e1b-1ed2-423f-88fae95e960a" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AdjustmentForAmortization_08057203-8e1b-1ed2-423f-88fae95e960a" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" xlink:label="loc_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_4b758f59-092a-4b1f-38aa-17bc9e00005e" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_4b758f59-092a-4b1f-38aa-17bc9e00005e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_db5982bd-3de4-fd63-1787-cc859b87dd73" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_db5982bd-3de4-fd63-1787-cc859b87dd73" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_7f6dfe21-84a6-f0fb-b64a-17bc9de049e4" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_7f6dfe21-84a6-f0fb-b64a-17bc9de049e4" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_afeaee34-507a-04b1-d222-17bc9db3c621" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_afeaee34-507a-04b1-d222-17bc9db3c621" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_LossOnSettlementOfLiabilityClassifiedWarrants" xlink:label="loc_gale_LossOnSettlementOfLiabilityClassifiedWarrants_049327f6-4f1a-4a0b-258d-17bc9d829e98" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_gale_LossOnSettlementOfLiabilityClassifiedWarrants_049327f6-4f1a-4a0b-258d-17bc9d829e98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_5c03a9d6-b8ac-bbf3-746c-c7ea8b29c405" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_5c03a9d6-b8ac-bbf3-746c-c7ea8b29c405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="locator" />
    <link:calculationArc order="14" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_76f69c20-4865-0552-96fd-a8f1a7ac2ab5" xlink:type="locator" />
    <link:calculationArc order="15" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_76f69c20-4865-0552-96fd-a8f1a7ac2ab5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="locator" />
    <link:calculationArc order="16" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="locator" />
    <link:calculationArc order="17" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_693c47dd-e6fa-9c85-6a65-7baa26f76b5e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_693c47dd-e6fa-9c85-6a65-7baa26f76b5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_da0488c8-4667-4c6e-d497-cb359798025e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_da0488c8-4667-4c6e-d497-cb359798025e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_2d563f7c-9c66-4ccb-995c-599c680a5434" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_da0488c8-4667-4c6e-d497-cb359798025e" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_2d563f7c-9c66-4ccb-995c-599c680a5434" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_d57563c0-6fc0-b615-1758-17bc9e4e60db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_da0488c8-4667-4c6e-d497-cb359798025e" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_d57563c0-6fc0-b615-1758-17bc9e4e60db" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_LossOnSettlementOfWarrantsLiability" xlink:label="loc_gale_LossOnSettlementOfWarrantsLiability_766cc8f9-d788-0e67-153c-17bc9d616c92" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_da0488c8-4667-4c6e-d497-cb359798025e" xlink:to="loc_gale_LossOnSettlementOfWarrantsLiability_766cc8f9-d788-0e67-153c-17bc9d616c92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11620bd8-431c-98f6-ac51-02db9613dc06" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_da0488c8-4667-4c6e-d497-cb359798025e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11620bd8-431c-98f6-ac51-02db9613dc06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_80036452-8f22-8b77-cf8f-49eda674198d" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_da0488c8-4667-4c6e-d497-cb359798025e" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_80036452-8f22-8b77-cf8f-49eda674198d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_63184a46-2bac-760c-5a30-fe8e316dca8f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_63184a46-2bac-760c-5a30-fe8e316dca8f" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_9D48823448558264AEDD08719566ACBF" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:to="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_9D48823448558264AEDD08719566ACBF" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_LiabilityClassifiedWarrantsAntidilutionProtection" xlink:label="loc_gale_LiabilityClassifiedWarrantsAntidilutionProtection_7C5E155244EBB81FF333139D3950F3A3" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:to="loc_gale_LiabilityClassifiedWarrantsAntidilutionProtection_7C5E155244EBB81FF333139D3950F3A3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/Debt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/DebtConvertibleDebtDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/DebtSeniorSecuredDebentureDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/DebtSummaryOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_2626dbdc-6898-b850-c1cf-ef9f01bbb308" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_0d8925ae-714a-26e4-aa69-2d9eac65a5c6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_2626dbdc-6898-b850-c1cf-ef9f01bbb308" xlink:to="loc_us-gaap_LongTermDebtCurrent_0d8925ae-714a-26e4-aa69-2d9eac65a5c6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_422d7c41-753d-7765-5880-50978d071d31" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_2626dbdc-6898-b850-c1cf-ef9f01bbb308" xlink:to="loc_us-gaap_ShortTermBorrowings_422d7c41-753d-7765-5880-50978d071d31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_2626dbdc-6898-b850-c1cf-ef9f01bbb308" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/DebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_4a556cad-a799-834d-b974-434a5dc27747" xlink:type="locator" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_dab54599-28be-451a-76ee-17bc9d920e36" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityFairValueDisclosure_4a556cad-a799-834d-b974-434a5dc27747" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_dab54599-28be-451a-76ee-17bc9d920e36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7eaebfe3-265e-b8d0-3c5e-69c4ef718fdc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityFairValueDisclosure_4a556cad-a799-834d-b974-434a5dc27747" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7eaebfe3-265e-b8d0-3c5e-69c4ef718fdc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4f2d2e40-e149-3246-b591-f2ca332c7df6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_67a1f3e7-c91e-d9a1-0253-362c8d727f2d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4f2d2e40-e149-3246-b591-f2ca332c7df6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_67a1f3e7-c91e-d9a1-0253-362c8d727f2d" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_RestrictedCashandCashEquivalentsFairValueDisclosure" xlink:label="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_9b7e18d2-a7d0-3db9-fed8-17bc9df74ff8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4f2d2e40-e149-3246-b591-f2ca332c7df6" xlink:to="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_9b7e18d2-a7d0-3db9-fed8-17bc9df74ff8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/Liquidity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/LiquidityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e9735e37-5710-672d-af6f-37eb830178c7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b4d15047-d47c-676e-7447-8be27ad2f8e1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e9735e37-5710-672d-af6f-37eb830178c7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b4d15047-d47c-676e-7447-8be27ad2f8e1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2a2243c4-9ac2-481f-6794-d746fea55dde" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e9735e37-5710-672d-af6f-37eb830178c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2a2243c4-9ac2-481f-6794-d746fea55dde" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:label="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_fca6e29c-36e8-0041-474c-17bc9e188ea1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e9735e37-5710-672d-af6f-37eb830178c7" xlink:to="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_fca6e29c-36e8-0041-474c-17bc9e188ea1" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:label="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_095183ea-49a5-8e05-9d99-17bc9e083754" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e9735e37-5710-672d-af6f-37eb830178c7" xlink:to="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_095183ea-49a5-8e05-9d99-17bc9e083754" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_RestrictedStockSharesReservedforFutureIssuance" xlink:label="loc_gale_RestrictedStockSharesReservedforFutureIssuance_b0fb1e12-9ec5-4083-ffa8-17bc9e475d36" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e9735e37-5710-672d-af6f-37eb830178c7" xlink:to="loc_gale_RestrictedStockSharesReservedforFutureIssuance_b0fb1e12-9ec5-4083-ffa8-17bc9e475d36" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStock" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>gale-20180930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="gale-20180930.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="gale-20180930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="gale-20180930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Acquisition" xlink:href="gale-20180930.xsd#Acquisition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionDetails" xlink:href="gale-20180930.xsd#AcquisitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionTables" xlink:href="gale-20180930.xsd#AcquisitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:href="gale-20180930.xsd#BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails" xlink:href="gale-20180930.xsd#BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:href="gale-20180930.xsd#BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:href="gale-20180930.xsd#BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:href="gale-20180930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="gale-20180930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:href="gale-20180930.xsd#CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="gale-20180930.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="gale-20180930.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Debt" xlink:href="gale-20180930.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtConvertibleDebtDetails" xlink:href="gale-20180930.xsd#DebtConvertibleDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtSeniorSecuredDebentureDetails" xlink:href="gale-20180930.xsd#DebtSeniorSecuredDebentureDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtSummaryOfDebtDetails" xlink:href="gale-20180930.xsd#DebtSummaryOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtTables" xlink:href="gale-20180930.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:href="gale-20180930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:href="gale-20180930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails" xlink:href="gale-20180930.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails" xlink:href="gale-20180930.xsd#FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:href="gale-20180930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingencies" xlink:href="gale-20180930.xsd#LegalProceedingsCommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetails" xlink:href="gale-20180930.xsd#LegalProceedingsCommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Liquidity" xlink:href="gale-20180930.xsd#Liquidity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LiquidityDetails" xlink:href="gale-20180930.xsd#LiquidityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="gale-20180930.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:href="gale-20180930.xsd#OrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:href="gale-20180930.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:href="gale-20180930.xsd#StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails" xlink:href="gale-20180930.xsd#StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails" xlink:href="gale-20180930.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="gale-20180930.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:href="gale-20180930.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:href="gale-20180930.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails" xlink:href="gale-20180930.xsd#StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails" xlink:href="gale-20180930.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:href="gale-20180930.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:href="gale-20180930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStock" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockNarrativeDetails" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStockNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_B5F57C47B1C7CC5E257C0ED5D7A8D531" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_B5F57C47B1C7CC5E257C0ED5D7A8D531" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_4931852F52BEA0DCB0650ED600DCEDC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_B5F57C47B1C7CC5E257C0ED5D7A8D531" xlink:to="loc_srt_LitigationCaseAxis_4931852F52BEA0DCB0650ED600DCEDC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_35584495654EC9B39DF30ED600DDD899_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_4931852F52BEA0DCB0650ED600DCEDC2" xlink:to="loc_srt_LitigationCaseTypeDomain_35584495654EC9B39DF30ED600DDD899_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_35584495654EC9B39DF30ED600DDD899" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_4931852F52BEA0DCB0650ED600DCEDC2" xlink:to="loc_srt_LitigationCaseTypeDomain_35584495654EC9B39DF30ED600DDD899" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_JBGLitigationMember" xlink:label="loc_gale_JBGLitigationMember_658D7BEAAC75694782330ED699F624DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_35584495654EC9B39DF30ED600DDD899" xlink:to="loc_gale_JBGLitigationMember_658D7BEAAC75694782330ED699F624DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_9057888168DA42D4C8C90EB15C6A5017" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_9057888168DA42D4C8C90EB15C6A5017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_27CB222A92316D9794AD0EB15C6B572C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_27CB222A92316D9794AD0EB15C6B572C" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ContractResearchPayable" xlink:label="loc_gale_ContractResearchPayable_33526AF70FB77FE3BDA90EB15C6BE4D0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:to="loc_gale_ContractResearchPayable_33526AF70FB77FE3BDA90EB15C6BE4D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_39431B83957064BF0EB60EB15C6B11EA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:to="loc_us-gaap_TaxesPayableCurrent_39431B83957064BF0EB60EB15C6B11EA" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_RebatesAndReturnsOfFormerCommercialProducts" xlink:label="loc_gale_RebatesAndReturnsOfFormerCommercialProducts_99F8FA7240879A51868E0EB15C6B0D6C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:to="loc_gale_RebatesAndReturnsOfFormerCommercialProducts_99F8FA7240879A51868E0EB15C6B0D6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2344F99894B8F68002A70EB15C6BA23A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2344F99894B8F68002A70EB15C6BA23A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_B03B1AE705AB78A8C46F0EB15C6CFD19" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_B03B1AE705AB78A8C46F0EB15C6CFD19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaap_LitigationReserveCurrent_E4A710B936B1F2873ECE0EC436FF45E0" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:to="loc_us-gaap_LitigationReserveCurrent_E4A710B936B1F2873ECE0EC436FF45E0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/Acquisition" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_EB1AA0182B3B8F100B08139A7271B5C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_EB1AA0182B3B8F100B08139A7271B5C6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonrecurringAdjustmentAxis" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis_B12E75E214B7B9DDCA81139A7272A3A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_EB1AA0182B3B8F100B08139A7271B5C6" xlink:to="loc_us-gaap_NonrecurringAdjustmentAxis_B12E75E214B7B9DDCA81139A7272A3A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_0FB44404F63E70E9A1C6139A7272D3D1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_B12E75E214B7B9DDCA81139A7272A3A0" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_0FB44404F63E70E9A1C6139A7272D3D1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_0FB44404F63E70E9A1C6139A7272D3D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_B12E75E214B7B9DDCA81139A7272A3A0" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_0FB44404F63E70E9A1C6139A7272D3D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquisitionRelatedCostsMember" xlink:label="loc_us-gaap_AcquisitionRelatedCostsMember_62B9144C2AF5DBFDF074139A72723221" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_0FB44404F63E70E9A1C6139A7272D3D1" xlink:to="loc_us-gaap_AcquisitionRelatedCostsMember_62B9144C2AF5DBFDF074139A72723221" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_EB6614E6435DB5E2A9D4139A72736210" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_EB6614E6435DB5E2A9D4139A72736210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_FA20D3E4474DDE6D1839139A72733C50" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_FA20D3E4474DDE6D1839139A72733C50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_CFDD4826AF6DAE0C1FCF139A7273AAA2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_CFDD4826AF6DAE0C1FCF139A7273AAA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_27EBFA3BDFBB60C6AFAD139A7273E71B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:to="loc_us-gaap_ProfitLoss_27EBFA3BDFBB60C6AFAD139A7273E71B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_AFDCE2F5311DF980671A139A7273AB06" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_AFDCE2F5311DF980671A139A7273AB06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_E8B062E9E8EE98348EB1139A7273CF7C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_E8B062E9E8EE98348EB1139A7273CF7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_3AAD9B86E3DF4F5AA508139A7274AAC3" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_3AAD9B86E3DF4F5AA508139A7274AAC3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_98CCB02F289B4A2E81451361E73D050C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_98CCB02F289B4A2E81451361E73D050C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_37E20E26ED27B82B4AA71361E73D2ABC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_98CCB02F289B4A2E81451361E73D050C" xlink:to="loc_us-gaap_DebtInstrumentAxis_37E20E26ED27B82B4AA71361E73D2ABC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_52890DE1DAE16F2E55211361E73D5079_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_37E20E26ED27B82B4AA71361E73D2ABC" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_52890DE1DAE16F2E55211361E73D5079_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_52890DE1DAE16F2E55211361E73D5079" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_37E20E26ED27B82B4AA71361E73D2ABC" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_52890DE1DAE16F2E55211361E73D5079" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_AmendmentAgreementMember" xlink:label="loc_gale_AmendmentAgreementMember_DB0BBD9CD2548FB0EB2C1361E73E66EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52890DE1DAE16F2E55211361E73D5079" xlink:to="loc_gale_AmendmentAgreementMember_DB0BBD9CD2548FB0EB2C1361E73E66EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_BAB3F54747F17D382A081361E73E6B9D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_98CCB02F289B4A2E81451361E73D050C" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_BAB3F54747F17D382A081361E73E6B9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_355EABFC3A15A34A67141361E73E2463_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_BAB3F54747F17D382A081361E73E6B9D" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_355EABFC3A15A34A67141361E73E2463_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_355EABFC3A15A34A67141361E73E2463" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_BAB3F54747F17D382A081361E73E6B9D" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_355EABFC3A15A34A67141361E73E2463" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_20009DB3B47C281DAC6A1361E73FCFE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_355EABFC3A15A34A67141361E73E2463" xlink:to="loc_us-gaap_SecuredDebtMember_20009DB3B47C281DAC6A1361E73FCFE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_45CEE4A65D2C8F55CEA31361E73FB765" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_98CCB02F289B4A2E81451361E73D050C" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_45CEE4A65D2C8F55CEA31361E73FB765" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DA9471803FC86D222BE21361E73F1C38_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_45CEE4A65D2C8F55CEA31361E73FB765" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DA9471803FC86D222BE21361E73F1C38_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DA9471803FC86D222BE21361E73F1C38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_45CEE4A65D2C8F55CEA31361E73FB765" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DA9471803FC86D222BE21361E73F1C38" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_CorporateCreditCardsMember" xlink:label="loc_gale_CorporateCreditCardsMember_E0C6D1B4B268239025C71361E74041C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DA9471803FC86D222BE21361E73F1C38" xlink:to="loc_gale_CorporateCreditCardsMember_E0C6D1B4B268239025C71361E74041C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2EA991C5D4B807F97F711361E740C771" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2EA991C5D4B807F97F711361E740C771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4C0103688B2023AD1EE31361E740F72E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4C0103688B2023AD1EE31361E740F72E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF677FFAF123F3AE957B1361E740738E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF677FFAF123F3AE957B1361E740738E" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DebtInstrumentCovenantLiquidityCovenant" xlink:label="loc_gale_DebtInstrumentCovenantLiquidityCovenant_B163E7168FC9D6B0F2041361E7418D98" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6" xlink:to="loc_gale_DebtInstrumentCovenantLiquidityCovenant_B163E7168FC9D6B0F2041361E7418D98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_D38695AD2C06356588FC1361E7417927" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6" xlink:to="loc_us-gaap_RestrictedCash_D38695AD2C06356588FC1361E7417927" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_B65F57E667658785906717BCD0914EC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:to="loc_us-gaap_StatementTable_B65F57E667658785906717BCD0914EC1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A26ACA03B4504DD5F25917BCD092ABD2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_B65F57E667658785906717BCD0914EC1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A26ACA03B4504DD5F25917BCD092ABD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A3DCB356775EBC075B5C17BCD092D959_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A26ACA03B4504DD5F25917BCD092ABD2" xlink:to="loc_us-gaap_ClassOfStockDomain_A3DCB356775EBC075B5C17BCD092D959_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A3DCB356775EBC075B5C17BCD092D959" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A26ACA03B4504DD5F25917BCD092ABD2" xlink:to="loc_us-gaap_ClassOfStockDomain_A3DCB356775EBC075B5C17BCD092D959" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_B0733B1FDCBE6A62E80D17BCD09217BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_A3DCB356775EBC075B5C17BCD092D959" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_B0733B1FDCBE6A62E80D17BCD09217BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_B3EA0A337AF4A20777FA17BCD093D48F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_B3EA0A337AF4A20777FA17BCD093D48F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_37A27F7BE9CEB818B7C317BCD093EFE4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_37A27F7BE9CEB818B7C317BCD093EFE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_D89E98F229079333DBD517BCD093B5E0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:to="loc_us-gaap_PreferredStockSharesIssued_D89E98F229079333DBD517BCD093B5E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_A7BA2F510F5FCFA2C84217BCD093CDDB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_A7BA2F510F5FCFA2C84217BCD093CDDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_153ECB4136E3C73C2E4D17BCD0930C84" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_153ECB4136E3C73C2E4D17BCD0930C84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_F05E8159CC7787B83FC117BCD094EF77" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_F05E8159CC7787B83FC117BCD094EF77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_881544FF30911EF7D37617BCD0946248" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:to="loc_us-gaap_CommonStockSharesIssued_881544FF30911EF7D37617BCD0946248" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_B4E9F877B6B93E7BF72F17BCD094027C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_B4E9F877B6B93E7BF72F17BCD094027C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3A4568217958F838862D139A72CE1C9B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_C14A8EC2ABD1ECDDA5FF139A72C966CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3A4568217958F838862D139A72CE1C9B" xlink:to="loc_us-gaap_StatementTable_C14A8EC2ABD1ECDDA5FF139A72C966CA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_35B2C34276F84FE81DFD139A72CAB4E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_C14A8EC2ABD1ECDDA5FF139A72C966CA" xlink:to="loc_us-gaap_StatementClassOfStockAxis_35B2C34276F84FE81DFD139A72CAB4E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2B52E4E35182FB6D1596139A72CA6AD8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_35B2C34276F84FE81DFD139A72CAB4E3" xlink:to="loc_us-gaap_ClassOfStockDomain_2B52E4E35182FB6D1596139A72CA6AD8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2B52E4E35182FB6D1596139A72CA6AD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_35B2C34276F84FE81DFD139A72CAB4E3" xlink:to="loc_us-gaap_ClassOfStockDomain_2B52E4E35182FB6D1596139A72CA6AD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_239F1233EFED7081378B139A72CB0CA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2B52E4E35182FB6D1596139A72CA6AD8" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_239F1233EFED7081378B139A72CB0CA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_4BAC23C0E553FDB00012139A72CB2ADF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2B52E4E35182FB6D1596139A72CA6AD8" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_4BAC23C0E553FDB00012139A72CB2ADF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_48DDDFBC0308A10ED728139A72CB0A83" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_C14A8EC2ABD1ECDDA5FF139A72C966CA" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_48DDDFBC0308A10ED728139A72CB0A83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_A0207ED82AF7ACD11FB2139A72CB2B9A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_48DDDFBC0308A10ED728139A72CB0A83" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_A0207ED82AF7ACD11FB2139A72CB2B9A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_A0207ED82AF7ACD11FB2139A72CB2B9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_48DDDFBC0308A10ED728139A72CB0A83" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_A0207ED82AF7ACD11FB2139A72CB2B9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_6DFBC3AE6F7ED899F352139A72CB6C4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_A0207ED82AF7ACD11FB2139A72CB2B9A" xlink:to="loc_us-gaap_SecuredDebtMember_6DFBC3AE6F7ED899F352139A72CB6C4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_DA9E4482690EB5802E09139A72CCA3DB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_C14A8EC2ABD1ECDDA5FF139A72C966CA" xlink:to="loc_srt_LitigationCaseAxis_DA9E4482690EB5802E09139A72CCA3DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_A04E5F12A7BF185CDC1C139A72CC57A8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_DA9E4482690EB5802E09139A72CCA3DB" xlink:to="loc_srt_LitigationCaseTypeDomain_A04E5F12A7BF185CDC1C139A72CC57A8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_A04E5F12A7BF185CDC1C139A72CC57A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_DA9E4482690EB5802E09139A72CCA3DB" xlink:to="loc_srt_LitigationCaseTypeDomain_A04E5F12A7BF185CDC1C139A72CC57A8" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PatelvsGalenabiopharmaIncMember" xlink:label="loc_gale_PatelvsGalenabiopharmaIncMember_C6713175261115B3EAD1139A72CCF396" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_A04E5F12A7BF185CDC1C139A72CC57A8" xlink:to="loc_gale_PatelvsGalenabiopharmaIncMember_C6713175261115B3EAD1139A72CCF396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_75079EED3E01D7D83ACA139A72CD0474" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_C14A8EC2ABD1ECDDA5FF139A72C966CA" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_75079EED3E01D7D83ACA139A72CD0474" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3CE17E7B35F9EA682178139A72CDF456_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_75079EED3E01D7D83ACA139A72CD0474" xlink:to="loc_us-gaap_EquityComponentDomain_3CE17E7B35F9EA682178139A72CDF456_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3CE17E7B35F9EA682178139A72CDF456" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_75079EED3E01D7D83ACA139A72CD0474" xlink:to="loc_us-gaap_EquityComponentDomain_3CE17E7B35F9EA682178139A72CDF456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_435BF2C8E1E36CFB0959139A72CD9F2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3CE17E7B35F9EA682178139A72CDF456" xlink:to="loc_us-gaap_PreferredStockMember_435BF2C8E1E36CFB0959139A72CD9F2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_C57B506FAA718B6F646B139A72CD2341" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3CE17E7B35F9EA682178139A72CDF456" xlink:to="loc_us-gaap_CommonStockMember_C57B506FAA718B6F646B139A72CD2341" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_22F9B599838556C72ED7139A72CD34C1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3CE17E7B35F9EA682178139A72CDF456" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_22F9B599838556C72ED7139A72CD34C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_A02C396EAEAE02BCE154139A72CEE70F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3CE17E7B35F9EA682178139A72CDF456" xlink:to="loc_us-gaap_RetainedEarningsMember_A02C396EAEAE02BCE154139A72CEE70F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3A4568217958F838862D139A72CE1C9B" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_98030877B39A9894DEF3139A72CE838D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_SharesOutstanding_98030877B39A9894DEF3139A72CE838D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D45E931BD3B83E9A81F0139A72CFF982" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D45E931BD3B83E9A81F0139A72CFF982" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C87707F3ABA94D7C5C3139A72CFC00A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C87707F3ABA94D7C5C3139A72CFC00A" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PreferredStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_gale_PreferredStockIssuedDuringPeriodValueNewIssues_F91DD5F1A114339E477E139A72CF8AAC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_gale_PreferredStockIssuedDuringPeriodValueNewIssues_F91DD5F1A114339E477E139A72CF8AAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ADE5FB63D188A7CB169139A72CFCE6A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ADE5FB63D188A7CB169139A72CFCE6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EADFD13E20030EEED1C4139A72CFCD24" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EADFD13E20030EEED1C4139A72CFCD24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_C4C137680B5CE58B9D46139A72CF9468" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_C4C137680B5CE58B9D46139A72CF9468" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStock" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_0D1084DBDA5CAA7045A4139A72D03B82" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_0D1084DBDA5CAA7045A4139A72D03B82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_D3F3761425B2B85CBC20139A72D08B85" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_D3F3761425B2B85CBC20139A72D08B85" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ConvertiblePreferredStockDividends" xlink:label="loc_gale_ConvertiblePreferredStockDividends_4BBC5DE6A124A5163906139A72D0CB7C" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_gale_ConvertiblePreferredStockDividends_4BBC5DE6A124A5163906139A72D0CB7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_956E58F63CDB7BBC247E139A72D01A5F" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_956E58F63CDB7BBC247E139A72D01A5F" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_48ECC7DA9378CAF38A37139A72D0AEF4" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_48ECC7DA9378CAF38A37139A72D0AEF4" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DividendModificationOfWarrants" xlink:label="loc_gale_DividendModificationOfWarrants_760E7614F9BAB4F470C9139A72D0A1CD" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_gale_DividendModificationOfWarrants_760E7614F9BAB4F470C9139A72D0A1CD" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_WarrantExchangeAgreementsIssuanceOfCommonStock" xlink:label="loc_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_90C45F1C4ED95CC54E44139A72D1D964" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_90C45F1C4ED95CC54E44139A72D1D964" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_WarrantExchangeAgreementsAmount" xlink:label="loc_gale_WarrantExchangeAgreementsAmount_E9BF47F89DF608DAB14D139A72D17D7A" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_gale_WarrantExchangeAgreementsAmount_E9BF47F89DF608DAB14D139A72D17D7A" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_StockIssuedDuringPeriodSharesPrefundedWarrant" xlink:label="loc_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_0DC29105016BAFE4DBFF139A72D1BEC1" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_0DC29105016BAFE4DBFF139A72D1BEC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_CD06970FF64135C93215139A72D1F8E0" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_CD06970FF64135C93215139A72D1F8E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0F44CE05480F07A42341139A72D1766E" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_NetIncomeLoss_0F44CE05480F07A42341139A72D1766E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/Debt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/DebtConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F5BB01A8FC69954A066008F4613D9D9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:to="loc_us-gaap_DebtInstrumentTable_F5BB01A8FC69954A066008F4613D9D9C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_548A605DADB227C4A7DA08F4613F148E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_F5BB01A8FC69954A066008F4613D9D9C" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_548A605DADB227C4A7DA08F4613F148E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_E1920DFA0DEB6EB219DC08F4613F21CB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_548A605DADB227C4A7DA08F4613F148E" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_E1920DFA0DEB6EB219DC08F4613F21CB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_E1920DFA0DEB6EB219DC08F4613F21CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_548A605DADB227C4A7DA08F4613F148E" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_E1920DFA0DEB6EB219DC08F4613F21CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_5913C03B51D910D4D87F08F4613FA457" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_E1920DFA0DEB6EB219DC08F4613F21CB" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_5913C03B51D910D4D87F08F4613FA457" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_ED3BB9BE9738BE9F1B5C08F4614096C2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_F5BB01A8FC69954A066008F4613D9D9C" xlink:to="loc_us-gaap_DebtInstrumentAxis_ED3BB9BE9738BE9F1B5C08F4614096C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_339371011F8C728AF72908F46140349E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ED3BB9BE9738BE9F1B5C08F4614096C2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_339371011F8C728AF72908F46140349E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_339371011F8C728AF72908F46140349E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ED3BB9BE9738BE9F1B5C08F4614096C2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_339371011F8C728AF72908F46140349E" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ConvertiblePromissoryNotesMember" xlink:label="loc_gale_ConvertiblePromissoryNotesMember_42BA5EB175501218BA5B08F461400539" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_339371011F8C728AF72908F46140349E" xlink:to="loc_gale_ConvertiblePromissoryNotesMember_42BA5EB175501218BA5B08F461400539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1E434134C8976BAF92C108F461466558" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1E434134C8976BAF92C108F461466558" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_CommonStockSharesAcquiredinExchangeforWarrants" xlink:label="loc_gale_CommonStockSharesAcquiredinExchangeforWarrants_5D38128C544736CF192A08F461476318" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:to="loc_gale_CommonStockSharesAcquiredinExchangeforWarrants_5D38128C544736CF192A08F461476318" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_65E7AA64D39F51C7242708F46147CFB9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_65E7AA64D39F51C7242708F46147CFB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_48D9266F1BEAB5AC7CF708F461473D25" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_48D9266F1BEAB5AC7CF708F461473D25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_FBD1AFF2922D41DE49AC08F46147DAF3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_FBD1AFF2922D41DE49AC08F46147DAF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_397369C059418B78509808F4614786BB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_397369C059418B78509808F4614786BB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/DebtSeniorSecuredDebentureDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_49F8A4E6DE4EA6D7362012EF8A3CF028" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_us-gaap_DebtInstrumentTable_49F8A4E6DE4EA6D7362012EF8A3CF028" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_735C8DC179945E5FF2CD12F152E939B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_49F8A4E6DE4EA6D7362012EF8A3CF028" xlink:to="loc_srt_LitigationCaseAxis_735C8DC179945E5FF2CD12F152E939B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_CF6E2D20951CFBDF0B8012F152F2E97C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_735C8DC179945E5FF2CD12F152E939B3" xlink:to="loc_srt_LitigationCaseTypeDomain_CF6E2D20951CFBDF0B8012F152F2E97C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_CF6E2D20951CFBDF0B8012F152F2E97C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_735C8DC179945E5FF2CD12F152E939B3" xlink:to="loc_srt_LitigationCaseTypeDomain_CF6E2D20951CFBDF0B8012F152F2E97C" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_JGBActionMember" xlink:label="loc_gale_JGBActionMember_D874BB8D33545D4E3CC312F18FEFB05D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_CF6E2D20951CFBDF0B8012F152F2E97C" xlink:to="loc_gale_JGBActionMember_D874BB8D33545D4E3CC312F18FEFB05D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6CAF6219C5B9BC25989C12EF8A3C03EB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_49F8A4E6DE4EA6D7362012EF8A3CF028" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6CAF6219C5B9BC25989C12EF8A3C03EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_48C9B0EA75DC3D535FB012EF8A3C382C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6CAF6219C5B9BC25989C12EF8A3C03EB" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_48C9B0EA75DC3D535FB012EF8A3C382C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_48C9B0EA75DC3D535FB012EF8A3C382C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6CAF6219C5B9BC25989C12EF8A3C03EB" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_48C9B0EA75DC3D535FB012EF8A3C382C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_BCDA7EDF18009C93F07312EF8A3C5B7E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_48C9B0EA75DC3D535FB012EF8A3C382C" xlink:to="loc_us-gaap_SubsequentEventMember_BCDA7EDF18009C93F07312EF8A3C5B7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9055B53BEBCBE81BC7A712EF8A3D7F87" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_49F8A4E6DE4EA6D7362012EF8A3CF028" xlink:to="loc_us-gaap_DebtInstrumentAxis_9055B53BEBCBE81BC7A712EF8A3D7F87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8E2AE503C564D0A942F712EF8A3D2CA9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9055B53BEBCBE81BC7A712EF8A3D7F87" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8E2AE503C564D0A942F712EF8A3D2CA9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8E2AE503C564D0A942F712EF8A3D2CA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9055B53BEBCBE81BC7A712EF8A3D7F87" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8E2AE503C564D0A942F712EF8A3D2CA9" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SecuritiesPurchaseAgreementMember" xlink:label="loc_gale_SecuritiesPurchaseAgreementMember_3E377431F1DD41F9534612EF8A3F9C5F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8E2AE503C564D0A942F712EF8A3D2CA9" xlink:to="loc_gale_SecuritiesPurchaseAgreementMember_3E377431F1DD41F9534612EF8A3F9C5F" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_AmendmentAgreementMember" xlink:label="loc_gale_AmendmentAgreementMember_B03AF8FE1C1B3D4E3D9912EF8A3F0A4D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8E2AE503C564D0A942F712EF8A3D2CA9" xlink:to="loc_gale_AmendmentAgreementMember_B03AF8FE1C1B3D4E3D9912EF8A3F0A4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E0D52AF3145A6A325F1E12EF8A3F1A38" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_49F8A4E6DE4EA6D7362012EF8A3CF028" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_E0D52AF3145A6A325F1E12EF8A3F1A38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7F65419524091DFBBD3D12EF8A3F00AC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E0D52AF3145A6A325F1E12EF8A3F1A38" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7F65419524091DFBBD3D12EF8A3F00AC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7F65419524091DFBBD3D12EF8A3F00AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E0D52AF3145A6A325F1E12EF8A3F1A38" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7F65419524091DFBBD3D12EF8A3F00AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_25D7FD805B5238CA275212EF8A406D67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7F65419524091DFBBD3D12EF8A3F00AC" xlink:to="loc_us-gaap_SecuredDebtMember_25D7FD805B5238CA275212EF8A406D67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3C73DD7141966E4D3DA112EF8A40E07C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3C73DD7141966E4D3DA112EF8A40E07C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6E87794C45607C0FCF3412EF8A4157A6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6E87794C45607C0FCF3412EF8A4157A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7A2C64241A3CE9DA5C6412EF8A41C143" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7A2C64241A3CE9DA5C6412EF8A41C143" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet" xlink:label="loc_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_36BC08B9049C02D31D9712EF8A419668" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_36BC08B9049C02D31D9712EF8A419668" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_3BA02BA514107036B23012EF8A41ED1B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_3BA02BA514107036B23012EF8A41ED1B" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DebtInstrumentCovenantLiquidityCovenant" xlink:label="loc_gale_DebtInstrumentCovenantLiquidityCovenant_8A368140E1E4AD2F12D812EF8A41AC67" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_gale_DebtInstrumentCovenantLiquidityCovenant_8A368140E1E4AD2F12D812EF8A41AC67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_EE6FEA4146016DD6F5EE12EF8A41F6ED" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_us-gaap_DebtInstrumentFairValue_EE6FEA4146016DD6F5EE12EF8A41F6ED" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DebtInstrumentRedemptionPrincipalAmountRedeemed" xlink:label="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_FE4EA050C6D935EC528812EF8A421703" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_FE4EA050C6D935EC528812EF8A421703" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares" xlink:label="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_53D23B85559F5EB568CC12EF8A421C30" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_53D23B85559F5EB568CC12EF8A421C30" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash" xlink:label="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_FA7A3E800609DB8EBDB212EF8A42F8F5" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_FA7A3E800609DB8EBDB212EF8A42F8F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DecreaseInRestrictedCash" xlink:label="loc_us-gaap_DecreaseInRestrictedCash_A3A77E071A7C06257BB712EF8A428736" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_us-gaap_DecreaseInRestrictedCash_A3A77E071A7C06257BB712EF8A428736" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_BE2390E92266700742D312EF8A4266D3" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_us-gaap_RestrictedCash_BE2390E92266700742D312EF8A4266D3" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture" xlink:label="loc_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_E690F8E980AD757A0EE012EF8A430A42" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_E690F8E980AD757A0EE012EF8A430A42" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DepositOfRestrictedCashOverSeniorSecuredDebenture" xlink:label="loc_gale_DepositOfRestrictedCashOverSeniorSecuredDebenture_DD3E24426FE3A4CADC4213347257A15C" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_gale_DepositOfRestrictedCashOverSeniorSecuredDebenture_DD3E24426FE3A4CADC4213347257A15C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_0D95B4F24487E9220BEB12EF8A43CB43" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_0D95B4F24487E9220BEB12EF8A43CB43" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ReimbursementOfLegalFees" xlink:label="loc_gale_ReimbursementOfLegalFees_3C59C9FCC4AEDED25D9A12EF8A4307F6" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_gale_ReimbursementOfLegalFees_3C59C9FCC4AEDED25D9A12EF8A4307F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_837D880C2F1D52D0679712EF8A433E32" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_837D880C2F1D52D0679712EF8A433E32" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/DebtSummaryOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_91DBDAE592901545025217BCCEEBCAB2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_E7B5B475BBD06EDA50A317BCCEE9883E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91DBDAE592901545025217BCCEEBCAB2" xlink:to="loc_us-gaap_DebtInstrumentTable_E7B5B475BBD06EDA50A317BCCEE9883E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_4619EA73C4E19132AE9117BCCEE9502F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_E7B5B475BBD06EDA50A317BCCEE9883E" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_4619EA73C4E19132AE9117BCCEE9502F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_65FFE5377AC8EE0A20D817BCCEE9A082_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_4619EA73C4E19132AE9117BCCEE9502F" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_65FFE5377AC8EE0A20D817BCCEE9A082_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_65FFE5377AC8EE0A20D817BCCEE9A082" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_4619EA73C4E19132AE9117BCCEE9502F" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_65FFE5377AC8EE0A20D817BCCEE9A082" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_BAD8DF96143E04C5EC9F17BCCEE99CB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_65FFE5377AC8EE0A20D817BCCEE9A082" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_BAD8DF96143E04C5EC9F17BCCEE99CB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_BA640D3CC0EB72BE4A4617BCCEEAD0C0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_E7B5B475BBD06EDA50A317BCCEE9883E" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_BA640D3CC0EB72BE4A4617BCCEEAD0C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_BA8A32EF1D7B778AD76517BCCEEACBBF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_BA640D3CC0EB72BE4A4617BCCEEAD0C0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_BA8A32EF1D7B778AD76517BCCEEACBBF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_BA8A32EF1D7B778AD76517BCCEEACBBF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_BA640D3CC0EB72BE4A4617BCCEEAD0C0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_BA8A32EF1D7B778AD76517BCCEEACBBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_892F785A24B63E60F2E017BCCEEA4C86" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_BA8A32EF1D7B778AD76517BCCEEACBBF" xlink:to="loc_us-gaap_SecuredDebtMember_892F785A24B63E60F2E017BCCEEA4C86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9050EBE0A3DE1702FAEA17BCCEEBA46C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_E7B5B475BBD06EDA50A317BCCEE9883E" xlink:to="loc_us-gaap_DebtInstrumentAxis_9050EBE0A3DE1702FAEA17BCCEEBA46C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9128C9DAED9A0DFC373717BCCEEB88F1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9050EBE0A3DE1702FAEA17BCCEEBA46C" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9128C9DAED9A0DFC373717BCCEEB88F1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9128C9DAED9A0DFC373717BCCEEB88F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9050EBE0A3DE1702FAEA17BCCEEBA46C" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9128C9DAED9A0DFC373717BCCEEB88F1" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SecuritiesPurchaseAgreementMember" xlink:label="loc_gale_SecuritiesPurchaseAgreementMember_01B54BBBEA88743317F217BCCEEBD6A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9128C9DAED9A0DFC373717BCCEEB88F1" xlink:to="loc_gale_SecuritiesPurchaseAgreementMember_01B54BBBEA88743317F217BCCEEBD6A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_0A7F0771432C2B13CD1517BCCEEC77EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91DBDAE592901545025217BCCEEBCAB2" xlink:to="loc_us-gaap_LongTermDebtCurrent_0A7F0771432C2B13CD1517BCCEEC77EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_8CF34BE9DD466479AA7B17BCCEEC06E4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91DBDAE592901545025217BCCEEBCAB2" xlink:to="loc_us-gaap_ShortTermBorrowings_8CF34BE9DD466479AA7B17BCCEEC06E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_29C6C9BBBFE3FD2626E817BCCEEC2DD5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91DBDAE592901545025217BCCEEBCAB2" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_29C6C9BBBFE3FD2626E817BCCEEC2DD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_3DE998C0512614AB183217BCCEED3DB9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91DBDAE592901545025217BCCEEBCAB2" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_3DE998C0512614AB183217BCCEED3DB9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/DebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25E4A8A3092039C9C1E517BCD0C9479F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C1831758892F19C45AB17BCD0C71C65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25E4A8A3092039C9C1E517BCD0C9479F" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C1831758892F19C45AB17BCD0C71C65" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2D9CE88FF3D1E5F8EEF617BCD0C7C4A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C1831758892F19C45AB17BCD0C71C65" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2D9CE88FF3D1E5F8EEF617BCD0C7C4A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_93FBFA3EEA1C3B37F2E717BCD0C7A6B4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2D9CE88FF3D1E5F8EEF617BCD0C7C4A9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_93FBFA3EEA1C3B37F2E717BCD0C7A6B4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_93FBFA3EEA1C3B37F2E717BCD0C7A6B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2D9CE88FF3D1E5F8EEF617BCD0C7C4A9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_93FBFA3EEA1C3B37F2E717BCD0C7A6B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6FDEEB9A239E59A618FB17BCD0C85E48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_93FBFA3EEA1C3B37F2E717BCD0C7A6B4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6FDEEB9A239E59A618FB17BCD0C85E48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_01BB2CF57CD37B1D7EF717BCD0C8A9E8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C1831758892F19C45AB17BCD0C71C65" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_01BB2CF57CD37B1D7EF717BCD0C8A9E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_682152669767E25E07FD17BCD0C8B7E3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_01BB2CF57CD37B1D7EF717BCD0C8A9E8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_682152669767E25E07FD17BCD0C8B7E3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_682152669767E25E07FD17BCD0C8B7E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_01BB2CF57CD37B1D7EF717BCD0C8A9E8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_682152669767E25E07FD17BCD0C8B7E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0F39224EDCB89D073A6417BCD0C8881F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_682152669767E25E07FD17BCD0C8B7E3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0F39224EDCB89D073A6417BCD0C8881F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_712C75803779265BFDC117BCD0C93C43" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_682152669767E25E07FD17BCD0C8B7E3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_712C75803779265BFDC117BCD0C93C43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7DD06866C5264018253F17BCD0C97DF4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_682152669767E25E07FD17BCD0C8B7E3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7DD06866C5264018253F17BCD0C97DF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_24A66C176252E9CE3BA617BCD0C9C454" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25E4A8A3092039C9C1E517BCD0C9479F" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_24A66C176252E9CE3BA617BCD0C9C454" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_A2C4D33FB3918ABB711017BCD0CA94B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_24A66C176252E9CE3BA617BCD0C9C454" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_A2C4D33FB3918ABB711017BCD0CA94B5" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_RestrictedCashandCashEquivalentsFairValueDisclosure" xlink:label="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_76BE728BCEB2EE009AE617BCD0CAA279" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_24A66C176252E9CE3BA617BCD0C9C454" xlink:to="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_76BE728BCEB2EE009AE617BCD0CAA279" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5EE015EA28F8EFBC842317BCD0CAA27C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_24A66C176252E9CE3BA617BCD0C9C454" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5EE015EA28F8EFBC842317BCD0CAA27C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0AC697E0768E89D9362517BCD0CAA966" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25E4A8A3092039C9C1E517BCD0C9479F" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0AC697E0768E89D9362517BCD0CAA966" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_B953F4769474DB491C0017BCD0CB6A66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0AC697E0768E89D9362517BCD0CAA966" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_B953F4769474DB491C0017BCD0CB6A66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_81D949FB3D1FF6C4C53317BCD0CB8A4C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0AC697E0768E89D9362517BCD0CAA966" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_81D949FB3D1FF6C4C53317BCD0CB8A4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_FBACED4D12D9ADFA912617BCD0CBC926" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0AC697E0768E89D9362517BCD0CAA966" xlink:to="loc_us-gaap_EquityFairValueDisclosure_FBACED4D12D9ADFA912617BCD0CBC926" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E816959CAF9376D1889517BCCEBFE10A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6023AA8D9298360F0FB817BCCEBC97BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E816959CAF9376D1889517BCCEBFE10A" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6023AA8D9298360F0FB817BCCEBC97BC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A4DD832D1E1B0FBD5C7317BCCEBD4EFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6023AA8D9298360F0FB817BCCEBC97BC" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A4DD832D1E1B0FBD5C7317BCCEBD4EFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0EC01474E6F93FF5667F17BCCEBDFE38_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A4DD832D1E1B0FBD5C7317BCCEBD4EFF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0EC01474E6F93FF5667F17BCCEBDFE38_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0EC01474E6F93FF5667F17BCCEBDFE38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A4DD832D1E1B0FBD5C7317BCCEBD4EFF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0EC01474E6F93FF5667F17BCCEBDFE38" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_AptheraInc.Member" xlink:label="loc_gale_AptheraInc.Member_9847B784F0C7AD357E3E17BCCEBDB54C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0EC01474E6F93FF5667F17BCCEBDFE38" xlink:to="loc_gale_AptheraInc.Member_9847B784F0C7AD357E3E17BCCEBDB54C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92B6F9BC1C56772E2DC317BCCEBEEFEF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6023AA8D9298360F0FB817BCCEBC97BC" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92B6F9BC1C56772E2DC317BCCEBEEFEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B7EE2D2293CFCD55C30017BCCEBE0A9D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92B6F9BC1C56772E2DC317BCCEBEEFEF" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B7EE2D2293CFCD55C30017BCCEBE0A9D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B7EE2D2293CFCD55C30017BCCEBE0A9D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92B6F9BC1C56772E2DC317BCCEBEEFEF" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B7EE2D2293CFCD55C30017BCCEBE0A9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3A34C1C0F3B30F8FE84417BCCEBE2090" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B7EE2D2293CFCD55C30017BCCEBE0A9D" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3A34C1C0F3B30F8FE84417BCCEBE2090" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40CA17889608A9450A5E17BCCEBFE21A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E816959CAF9376D1889517BCCEBFE10A" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40CA17889608A9450A5E17BCCEBFE21A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_D6D64BC92AEC9AC91AC917BCCEBF7C94" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40CA17889608A9450A5E17BCCEBFE21A" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_D6D64BC92AEC9AC91AC917BCCEBF7C94" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_0F59EAA00F914BBE08D217BCCEC035F6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40CA17889608A9450A5E17BCCEBFE21A" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_0F59EAA00F914BBE08D217BCCEC035F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_A2F50D785D9C34B7074217BCCEC06596" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E816959CAF9376D1889517BCCEBFE10A" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_A2F50D785D9C34B7074217BCCEC06596" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:to="loc_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_CE7862A629A30E4FBE171361E6BF72E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_CE7862A629A30E4FBE171361E6BF72E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_F797323218C9CDD0C2091361E6C0B78C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_CE7862A629A30E4FBE171361E6BF72E2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_F797323218C9CDD0C2091361E6C0B78C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_F797323218C9CDD0C2091361E6C0B78C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_CE7862A629A30E4FBE171361E6BF72E2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_F797323218C9CDD0C2091361E6C0B78C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_EE50E20024FF7F7916911361E6C0B5DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_F797323218C9CDD0C2091361E6C0B78C" xlink:to="loc_us-gaap_SubsequentEventMember_EE50E20024FF7F7916911361E6C0B5DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_700236F8655F9CA4D2081361E6C09F6C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_700236F8655F9CA4D2081361E6C09F6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_D89D3AA33AA788145F391361E6C0A45C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_700236F8655F9CA4D2081361E6C09F6C" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_D89D3AA33AA788145F391361E6C0A45C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_D89D3AA33AA788145F391361E6C0A45C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_700236F8655F9CA4D2081361E6C09F6C" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_D89D3AA33AA788145F391361E6C0A45C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_47BE0B3B229D30FE10F61361E6C18714" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_D89D3AA33AA788145F391361E6C0A45C" xlink:to="loc_us-gaap_SecuredDebtMember_47BE0B3B229D30FE10F61361E6C18714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F90A90E8556279899EEA1361E6C19A21" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E" xlink:to="loc_us-gaap_DebtInstrumentAxis_F90A90E8556279899EEA1361E6C19A21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1C94037B4CE57873C81D1361E6C176E0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_F90A90E8556279899EEA1361E6C19A21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1C94037B4CE57873C81D1361E6C176E0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1C94037B4CE57873C81D1361E6C176E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_F90A90E8556279899EEA1361E6C19A21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1C94037B4CE57873C81D1361E6C176E0" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_AmendmentAgreementMember" xlink:label="loc_gale_AmendmentAgreementMember_33992BF5809B365543841361E6C29436" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1C94037B4CE57873C81D1361E6C176E0" xlink:to="loc_gale_AmendmentAgreementMember_33992BF5809B365543841361E6C29436" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_58B32434B4B5AB6D1A511361E6C2CD55" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E" xlink:to="loc_us-gaap_LitigationStatusAxis_58B32434B4B5AB6D1A511361E6C2CD55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_118383FFC8E1361F19A31361E6C217BD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_58B32434B4B5AB6D1A511361E6C2CD55" xlink:to="loc_us-gaap_LitigationStatusDomain_118383FFC8E1361F19A31361E6C217BD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_118383FFC8E1361F19A31361E6C217BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_58B32434B4B5AB6D1A511361E6C2CD55" xlink:to="loc_us-gaap_LitigationStatusDomain_118383FFC8E1361F19A31361E6C217BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_FA7627A188111479DCEB1361E6C282A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_118383FFC8E1361F19A31361E6C217BD" xlink:to="loc_us-gaap_PendingLitigationMember_FA7627A188111479DCEB1361E6C282A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_8CD80ED4B3A86469BF901361E6C32270" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E" xlink:to="loc_srt_LitigationCaseAxis_8CD80ED4B3A86469BF901361E6C32270" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_F82440ECC338D98B5F7C1361E6C334AF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_8CD80ED4B3A86469BF901361E6C32270" xlink:to="loc_srt_LitigationCaseTypeDomain_F82440ECC338D98B5F7C1361E6C334AF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_F82440ECC338D98B5F7C1361E6C334AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_8CD80ED4B3A86469BF901361E6C32270" xlink:to="loc_srt_LitigationCaseTypeDomain_F82440ECC338D98B5F7C1361E6C334AF" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PatelvsGalenabiopharmaIncMember" xlink:label="loc_gale_PatelvsGalenabiopharmaIncMember_A0E3DABF4A1E3CD571691361E6C3B9CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_F82440ECC338D98B5F7C1361E6C334AF" xlink:to="loc_gale_PatelvsGalenabiopharmaIncMember_A0E3DABF4A1E3CD571691361E6C3B9CE" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_JGBActionMember" xlink:label="loc_gale_JGBActionMember_34DAB73FB0FAABD49CF71361E6C473C1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_F82440ECC338D98B5F7C1361E6C334AF" xlink:to="loc_gale_JGBActionMember_34DAB73FB0FAABD49CF71361E6C473C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_068E9151B4C7FE2AF9AD1361E6C43586" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:to="loc_us-gaap_LegalFees_068E9151B4C7FE2AF9AD1361E6C43586" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_76077A78BFDEE83C7CF91361E6C44FE9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_76077A78BFDEE83C7CF91361E6C44FE9" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_LitigationSettlementIssuanceofCommonStockValue" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockValue_D4A60CAE3612E8B5D8A61361E6C4B5C9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:to="loc_gale_LitigationSettlementIssuanceofCommonStockValue_D4A60CAE3612E8B5D8A61361E6C4B5C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_980BD6DF8DC366EBC9951361E6C58834" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_980BD6DF8DC366EBC9951361E6C58834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_AEF7A9754BF0C6DF8B7B1361E6C5537B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:to="loc_us-gaap_RestrictedCash_AEF7A9754BF0C6DF8B7B1361E6C5537B" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_LossContingencyNumberOfCounterclaims" xlink:label="loc_gale_LossContingencyNumberOfCounterclaims_D710FE9DE4FAD61BC1B21361E6C591BD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:to="loc_gale_LossContingencyNumberOfCounterclaims_D710FE9DE4FAD61BC1B21361E6C591BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_4751EE56CF628CC5BA301361E6C54A87" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_4751EE56CF628CC5BA301361E6C54A87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_A55703540141BDA325331361E6C5BCCF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_A55703540141BDA325331361E6C5BCCF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/Liquidity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/LiquidityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C616F4D712EB99B8B3DC0E609F78E95B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C616F4D712EB99B8B3DC0E609F78E95B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E029C8C87F48448BA5B10E609F78A767" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C616F4D712EB99B8B3DC0E609F78E95B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_E029C8C87F48448BA5B10E609F78A767" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28AA088C62F3F5D9CEE0E609F780F08_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E029C8C87F48448BA5B10E609F78A767" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28AA088C62F3F5D9CEE0E609F780F08_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28AA088C62F3F5D9CEE0E609F780F08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E029C8C87F48448BA5B10E609F78A767" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28AA088C62F3F5D9CEE0E609F780F08" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PurchaseAgreementMember" xlink:label="loc_gale_PurchaseAgreementMember_839B04D6092AA090EA7B0E609F78BA4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28AA088C62F3F5D9CEE0E609F780F08" xlink:to="loc_gale_PurchaseAgreementMember_839B04D6092AA090EA7B0E609F78BA4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2572F0E54CC429216DD80E609F790624" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C616F4D712EB99B8B3DC0E609F78E95B" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2572F0E54CC429216DD80E609F790624" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_F36B8726BF34D1B0CDB10E609F793DF2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2572F0E54CC429216DD80E609F790624" xlink:to="loc_us-gaap_EquityComponentDomain_F36B8726BF34D1B0CDB10E609F793DF2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_F36B8726BF34D1B0CDB10E609F793DF2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2572F0E54CC429216DD80E609F790624" xlink:to="loc_us-gaap_EquityComponentDomain_F36B8726BF34D1B0CDB10E609F793DF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_534DC9BE83B39963F2220E609F799AB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F36B8726BF34D1B0CDB10E609F793DF2" xlink:to="loc_us-gaap_CommonStockMember_534DC9BE83B39963F2220E609F799AB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_B03409AEF47C159A9B3B0E609F795A0B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F36B8726BF34D1B0CDB10E609F793DF2" xlink:to="loc_us-gaap_WarrantMember_B03409AEF47C159A9B3B0E609F795A0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_29F04B5BBE649D43F8E60E609F7AB40A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C616F4D712EB99B8B3DC0E609F78E95B" xlink:to="loc_us-gaap_StatementClassOfStockAxis_29F04B5BBE649D43F8E60E609F7AB40A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_341983AD26269D4786F30E609F7AE04A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_29F04B5BBE649D43F8E60E609F7AB40A" xlink:to="loc_us-gaap_ClassOfStockDomain_341983AD26269D4786F30E609F7AE04A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_341983AD26269D4786F30E609F7AE04A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_29F04B5BBE649D43F8E60E609F7AB40A" xlink:to="loc_us-gaap_ClassOfStockDomain_341983AD26269D4786F30E609F7AE04A" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SeriesANonvotingConvertibleMember" xlink:label="loc_gale_SeriesANonvotingConvertibleMember_C5B8E3D67ED0F69DAC860E609F7A9745" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_341983AD26269D4786F30E609F7AE04A" xlink:to="loc_gale_SeriesANonvotingConvertibleMember_C5B8E3D67ED0F69DAC860E609F7A9745" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gale_SeriesAConvertiblePreferredStockMember_2A4EB6B2FD817216D65B0E609F7AC46D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_341983AD26269D4786F30E609F7AE04A" xlink:to="loc_gale_SeriesAConvertiblePreferredStockMember_2A4EB6B2FD817216D65B0E609F7AC46D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_92BFEA225781E16101630E609F7B66A0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C616F4D712EB99B8B3DC0E609F78E95B" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_92BFEA225781E16101630E609F7B66A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DDD850BD40D958A973850E609F7BADD7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_92BFEA225781E16101630E609F7B66A0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DDD850BD40D958A973850E609F7BADD7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DDD850BD40D958A973850E609F7BADD7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_92BFEA225781E16101630E609F7B66A0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DDD850BD40D958A973850E609F7BADD7" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FirstTrancheMember" xlink:label="loc_gale_FirstTrancheMember_0409836AFAF27553C86E0E609F7BC8E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DDD850BD40D958A973850E609F7BADD7" xlink:to="loc_gale_FirstTrancheMember_0409836AFAF27553C86E0E609F7BC8E6" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SecondTrancheMember" xlink:label="loc_gale_SecondTrancheMember_41559B2296FE7AF1AC920E609F7B8D84" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DDD850BD40D958A973850E609F7BADD7" xlink:to="loc_gale_SecondTrancheMember_41559B2296FE7AF1AC920E609F7B8D84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D830421D335BCFFA63810E609F7C2485" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D830421D335BCFFA63810E609F7C2485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0BD8395EB8C54A4C47BC0E609F7CD0A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0BD8395EB8C54A4C47BC0E609F7CD0A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_DBC0EAD27CF26FEF7B920E609F7C409C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_DBC0EAD27CF26FEF7B920E609F7C409C" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded" xlink:label="loc_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_918A89838E4531FCFF850E609F7DAD70" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_918A89838E4531FCFF850E609F7DAD70" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_77EBB3538F0BFE911BD60E609F7D8E7F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_gale_ClassofWarrantorRightTerm_77EBB3538F0BFE911BD60E609F7D8E7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_64ECD83B51F6C73F54480E609F7D46F0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_64ECD83B51F6C73F54480E609F7D46F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_56F3E511D673ECABE8720E609F7DEB81" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_PreferredStockSharesIssued_56F3E511D673ECABE8720E609F7DEB81" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ConvertiblePreferredStockConversionPrice" xlink:label="loc_gale_ConvertiblePreferredStockConversionPrice_F316CC4C7051048D26D40E609F7D498B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_gale_ConvertiblePreferredStockConversionPrice_F316CC4C7051048D26D40E609F7D498B" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ConvertiblePreferredStockNumberOfTranches" xlink:label="loc_gale_ConvertiblePreferredStockNumberOfTranches_E3CEF015BDCE2A23575E0E609F7E037E" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_gale_ConvertiblePreferredStockNumberOfTranches_E3CEF015BDCE2A23575E0E609F7E037E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_8E3C9F73F0F63DBFFC460E609F7E26D7" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_8E3C9F73F0F63DBFFC460E609F7E26D7" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture" xlink:label="loc_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_D447B5267DF7C1EE48660E609F7ED65F" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_D447B5267DF7C1EE48660E609F7ED65F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0A45740CF20CE7F9DD8B0E609F7E85FF" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0A45740CF20CE7F9DD8B0E609F7E85FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_6B781849534F30FE57B90E609F7E8507" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_6B781849534F30FE57B90E609F7E8507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_2F76BA137431EA5FB5C50E6CD6B3C64D" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_2F76BA137431EA5FB5C50E6CD6B3C64D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableCurrent_B60D74B5F27700CDB41C0E609F7FCB74" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_InsuranceSettlementsReceivableCurrent_B60D74B5F27700CDB41C0E609F7FCB74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_F59E099FC7A43025D0090E609F7F71FA" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_F59E099FC7A43025D0090E609F7F71FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_BE621911B569BB35716F0E609F7F5E39" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_LongTermDebt_BE621911B569BB35716F0E609F7F5E39" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="gale-20180930.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2" xlink:type="locator" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_0C7E694436639CB6023217BCD08A927E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2" xlink:to="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_0C7E694436639CB6023217BCD08A927E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_A6373970673B5FD33A4217BCD08A43BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_0C7E694436639CB6023217BCD08A927E" xlink:to="loc_srt_CounterpartyNameAxis_A6373970673B5FD33A4217BCD08A43BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_425A10D557F0634194D217BCD08A2A84_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_A6373970673B5FD33A4217BCD08A43BD" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_425A10D557F0634194D217BCD08A2A84_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_425A10D557F0634194D217BCD08A2A84" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_A6373970673B5FD33A4217BCD08A43BD" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_425A10D557F0634194D217BCD08A2A84" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PrivateSELLASSecurityHoldersMember" xlink:label="loc_gale_PrivateSELLASSecurityHoldersMember_CA60342E7909BB1A64FB17BCD08BED9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_425A10D557F0634194D217BCD08A2A84" xlink:to="loc_gale_PrivateSELLASSecurityHoldersMember_CA60342E7909BB1A64FB17BCD08BED9E" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PreMergerSecurityholdersMember" xlink:label="loc_gale_PreMergerSecurityholdersMember_55C64761D705D55AE9F017BCD08BA32D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_425A10D557F0634194D217BCD08A2A84" xlink:to="loc_gale_PreMergerSecurityholdersMember_55C64761D705D55AE9F017BCD08BA32D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_957DCC5C129E3812A5DB17BCD08B6019" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_0C7E694436639CB6023217BCD08A927E" xlink:to="loc_dei_LegalEntityAxis_957DCC5C129E3812A5DB17BCD08B6019" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6E1C501431768871E75817BCD08BAEB6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_957DCC5C129E3812A5DB17BCD08B6019" xlink:to="loc_dei_EntityDomain_6E1C501431768871E75817BCD08BAEB6_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6E1C501431768871E75817BCD08BAEB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_957DCC5C129E3812A5DB17BCD08B6019" xlink:to="loc_dei_EntityDomain_6E1C501431768871E75817BCD08BAEB6" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_GalenaBiopharmaIncMember" xlink:label="loc_gale_GalenaBiopharmaIncMember_5F77A59704828A027D6517BCD08C8E97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6E1C501431768871E75817BCD08BAEB6" xlink:to="loc_gale_GalenaBiopharmaIncMember_5F77A59704828A027D6517BCD08C8E97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8ED9DF91BDFC31684E9917BCD08C4823" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8ED9DF91BDFC31684E9917BCD08C4823" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_42C146FB2F718FA61BA017BCD08C177C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_42C146FB2F718FA61BA017BCD08C177C" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_CommonStockConversionRatio" xlink:label="loc_gale_CommonStockConversionRatio_3F25FC70FB06356B681517BCD08DB155" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2" xlink:to="loc_gale_CommonStockConversionRatio_3F25FC70FB06356B681517BCD08DB155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_A7C40287D366FDEB983B17BCD08D623B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_A7C40287D366FDEB983B17BCD08D623B" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PercentageOfFullyDilutedShareCapitalOwned" xlink:label="loc_gale_PercentageOfFullyDilutedShareCapitalOwned_92A61BD54FF300EFA6C817BCD08D5938" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2" xlink:to="loc_gale_PercentageOfFullyDilutedShareCapitalOwned_92A61BD54FF300EFA6C817BCD08D5938" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3616409147FDEF8D74D817BCCDFCC99E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4C6F67C34422129E980C17BCCDFAA6A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3616409147FDEF8D74D817BCCDFCC99E" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4C6F67C34422129E980C17BCCDFAA6A6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_831C23A99BAFB0082B7117BCCDFA303A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4C6F67C34422129E980C17BCCDFAA6A6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_831C23A99BAFB0082B7117BCCDFA303A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_947E3918EC854EAF310317BCCDFADBB0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_831C23A99BAFB0082B7117BCCDFA303A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_947E3918EC854EAF310317BCCDFADBB0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_947E3918EC854EAF310317BCCDFADBB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_831C23A99BAFB0082B7117BCCDFA303A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_947E3918EC854EAF310317BCCDFADBB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7809AE87CBFA6151853F17BCCDFB2A4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_947E3918EC854EAF310317BCCDFADBB0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7809AE87CBFA6151853F17BCCDFB2A4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_17A4AC66D22469B37F0217BCCDFB8EAD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_947E3918EC854EAF310317BCCDFADBB0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_17A4AC66D22469B37F0217BCCDFB8EAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_E264E9F0CECC5162E40517BCCDFC1AFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3616409147FDEF8D74D817BCCDFCC99E" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_E264E9F0CECC5162E40517BCCDFC1AFA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E87CF859F383323E96012E3AEA0EE6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E87CF859F383323E96012E3AEA0EE6E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_6561132EFEBEE1169BD012E3AEA1ABDF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E87CF859F383323E96012E3AEA0EE6E" xlink:to="loc_us-gaap_PlanNameAxis_6561132EFEBEE1169BD012E3AEA1ABDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_58C9F90890884170C83712E3AEA14142_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6561132EFEBEE1169BD012E3AEA1ABDF" xlink:to="loc_us-gaap_PlanNameDomain_58C9F90890884170C83712E3AEA14142_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_58C9F90890884170C83712E3AEA14142" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6561132EFEBEE1169BD012E3AEA1ABDF" xlink:to="loc_us-gaap_PlanNameDomain_58C9F90890884170C83712E3AEA14142" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:label="loc_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_77463FD79FC66EBADD1112E3AEA1A010" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_58C9F90890884170C83712E3AEA14142" xlink:to="loc_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_77463FD79FC66EBADD1112E3AEA1A010" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_IncentivePlan2016Member" xlink:label="loc_gale_IncentivePlan2016Member_316476F923915F04559812E3AEA13756" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_58C9F90890884170C83712E3AEA14142" xlink:to="loc_gale_IncentivePlan2016Member_316476F923915F04559812E3AEA13756" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_DDB07405FCD21584B93F12E3AEA2EAD2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E87CF859F383323E96012E3AEA0EE6E" xlink:to="loc_srt_RangeAxis_DDB07405FCD21584B93F12E3AEA2EAD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_50B2D5D99EE74DD407DE12E3AEA27C97_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_DDB07405FCD21584B93F12E3AEA2EAD2" xlink:to="loc_srt_RangeMember_50B2D5D99EE74DD407DE12E3AEA27C97_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_50B2D5D99EE74DD407DE12E3AEA27C97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_DDB07405FCD21584B93F12E3AEA2EAD2" xlink:to="loc_srt_RangeMember_50B2D5D99EE74DD407DE12E3AEA27C97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_D826EB013277A600B39E12E3AEA29AAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_50B2D5D99EE74DD407DE12E3AEA27C97" xlink:to="loc_srt_MaximumMember_D826EB013277A600B39E12E3AEA29AAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_34FE95EB271CAE5C7A1012E3AEA213F4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_50B2D5D99EE74DD407DE12E3AEA27C97" xlink:to="loc_srt_MinimumMember_34FE95EB271CAE5C7A1012E3AEA213F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_3E2B6A4A2C8ECE604FFB12E3AEA3ECFF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E87CF859F383323E96012E3AEA0EE6E" xlink:to="loc_us-gaap_AwardTypeAxis_3E2B6A4A2C8ECE604FFB12E3AEA3ECFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45B67F9A1D44F7B0BF1512E3AEA39367_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3E2B6A4A2C8ECE604FFB12E3AEA3ECFF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45B67F9A1D44F7B0BF1512E3AEA39367_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45B67F9A1D44F7B0BF1512E3AEA39367" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3E2B6A4A2C8ECE604FFB12E3AEA3ECFF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45B67F9A1D44F7B0BF1512E3AEA39367" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_D4F07C68B12ABCF2219212E3AEA36101" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45B67F9A1D44F7B0BF1512E3AEA39367" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_D4F07C68B12ABCF2219212E3AEA36101" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_92C57DF1148FC830DF5612E3AEA40AFB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_92C57DF1148FC830DF5612E3AEA40AFB" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_0ABAC08D444AF1FC6E1612E3AEA404A5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_0ABAC08D444AF1FC6E1612E3AEA404A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_08E5B966554670B8DB8812E3AEA44AD5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_08E5B966554670B8DB8812E3AEA44AD5" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" xlink:label="loc_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_DE3E1FD40DDE3F1CFD5E12E3AEA44A96" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_DE3E1FD40DDE3F1CFD5E12E3AEA44A96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_37BE7172F0312660238F12E3AEA4AC23" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_37BE7172F0312660238F12E3AEA4AC23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_54BDF103597F2945580E12E3AEA5EDB5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_54BDF103597F2945580E12E3AEA5EDB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4F14173B3475B09E182E12E3AEA51FD9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4F14173B3475B09E182E12E3AEA51FD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C7AF554AB325E0B3B50412E3AEA52007" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C7AF554AB325E0B3B50412E3AEA52007" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6C9D2D4BDD367D57631112E3AEA58106" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6C9D2D4BDD367D57631112E3AEA58106" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FA2C89D1B33A97F1893012E3AEA56772" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FA2C89D1B33A97F1893012E3AEA56772" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_2A57742865C7CAD98C2B12E3AEA6AD74" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_2A57742865C7CAD98C2B12E3AEA6AD74" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_A654216CDB317A19C91C12E3AEA698CD" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_A654216CDB317A19C91C12E3AEA698CD" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClosingPriceOfCommonStock" xlink:label="loc_gale_ClosingPriceOfCommonStock_675F8663873C0424F12612E3AEA6409C" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_gale_ClosingPriceOfCommonStock_675F8663873C0424F12612E3AEA6409C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_EA895FB4FD2A5111669512E3AEA6CCCE" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_EA895FB4FD2A5111669512E3AEA6CCCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5199E8D540B46044FB7A12E3AEA6FDFE" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5199E8D540B46044FB7A12E3AEA6FDFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9FBF2FF61C97DBCC7C1912E3AEA6C227" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9FBF2FF61C97DBCC7C1912E3AEA6C227" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6B96AE662C609742A4241361E69A77AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6B96AE662C609742A4241361E69A77AB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_BE9F2DBC5355C28310111361E69A82D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6B96AE662C609742A4241361E69A77AB" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_BE9F2DBC5355C28310111361E69A82D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A43AC7C9898017507D511361E69BF1BF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_BE9F2DBC5355C28310111361E69A82D2" xlink:to="loc_us-gaap_EquityComponentDomain_A43AC7C9898017507D511361E69BF1BF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A43AC7C9898017507D511361E69BF1BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_BE9F2DBC5355C28310111361E69A82D2" xlink:to="loc_us-gaap_EquityComponentDomain_A43AC7C9898017507D511361E69BF1BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_17865C92A13DF9F336781361E69C80F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A43AC7C9898017507D511361E69BF1BF" xlink:to="loc_us-gaap_WarrantMember_17865C92A13DF9F336781361E69C80F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_FBD80AF7D968DD2C51661361E69C7FF2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A43AC7C9898017507D511361E69BF1BF" xlink:to="loc_us-gaap_CommonStockMember_FBD80AF7D968DD2C51661361E69C7FF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_C762EF3833CDBE2B04D01361E69DB18B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6B96AE662C609742A4241361E69A77AB" xlink:to="loc_us-gaap_StatementClassOfStockAxis_C762EF3833CDBE2B04D01361E69DB18B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D5C5DDEEF86799C947C51361E69DF413_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_C762EF3833CDBE2B04D01361E69DB18B" xlink:to="loc_us-gaap_ClassOfStockDomain_D5C5DDEEF86799C947C51361E69DF413_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D5C5DDEEF86799C947C51361E69DF413" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_C762EF3833CDBE2B04D01361E69DB18B" xlink:to="loc_us-gaap_ClassOfStockDomain_D5C5DDEEF86799C947C51361E69DF413" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SeriesANonvotingConvertibleMember" xlink:label="loc_gale_SeriesANonvotingConvertibleMember_3A4447A73155E56BA3611361E69D5478" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D5C5DDEEF86799C947C51361E69DF413" xlink:to="loc_gale_SeriesANonvotingConvertibleMember_3A4447A73155E56BA3611361E69D5478" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gale_SeriesAConvertiblePreferredStockMember_01A38DACBDA475C7D3731361E69E65D6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D5C5DDEEF86799C947C51361E69DF413" xlink:to="loc_gale_SeriesAConvertiblePreferredStockMember_01A38DACBDA475C7D3731361E69E65D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_FC443C96554B097B93A21361E69E40D3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6B96AE662C609742A4241361E69A77AB" xlink:to="loc_us-gaap_TypeOfArrangementAxis_FC443C96554B097B93A21361E69E40D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F5C1FFAA9EEB88988D681361E69E0823_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FC443C96554B097B93A21361E69E40D3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F5C1FFAA9EEB88988D681361E69E0823_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F5C1FFAA9EEB88988D681361E69E0823" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FC443C96554B097B93A21361E69E40D3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F5C1FFAA9EEB88988D681361E69E0823" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PurchaseAgreementMember" xlink:label="loc_gale_PurchaseAgreementMember_CF6708067102EF90CF2A1361E69E83A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F5C1FFAA9EEB88988D681361E69E0823" xlink:to="loc_gale_PurchaseAgreementMember_CF6708067102EF90CF2A1361E69E83A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_DCF97BEDC07BF1E1B6BB1361E69F61E9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6B96AE662C609742A4241361E69A77AB" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_DCF97BEDC07BF1E1B6BB1361E69F61E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F60415701AF32605DBF01361E69FE4C6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_DCF97BEDC07BF1E1B6BB1361E69F61E9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F60415701AF32605DBF01361E69FE4C6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F60415701AF32605DBF01361E69FE4C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_DCF97BEDC07BF1E1B6BB1361E69F61E9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F60415701AF32605DBF01361E69FE4C6" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PrivatePlacementFirstClosingMember" xlink:label="loc_gale_PrivatePlacementFirstClosingMember_740FF7B55FB027C7322B1361E69F33C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F60415701AF32605DBF01361E69FE4C6" xlink:to="loc_gale_PrivatePlacementFirstClosingMember_740FF7B55FB027C7322B1361E69F33C5" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PrivatePlacementSecondClosingMember" xlink:label="loc_gale_PrivatePlacementSecondClosingMember_8AD50159BDE3F269E5731361E69F6FA0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F60415701AF32605DBF01361E69FE4C6" xlink:to="loc_gale_PrivatePlacementSecondClosingMember_8AD50159BDE3F269E5731361E69F6FA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_BE6F32651729E72A04951361E6A073FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_BE6F32651729E72A04951361E6A073FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8BF70592BE9C32F049291361E6A0787F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8BF70592BE9C32F049291361E6A0787F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_FDCA5456218CA1899E8C1361E6A0CB78" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_PreferredStockSharesIssued_FDCA5456218CA1899E8C1361E6A0CB78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6226B6FED66875FF9B501361E6A02BDC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6226B6FED66875FF9B501361E6A02BDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_4D8D07DB71C2CD63EAEC1361E6A17D90" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_4D8D07DB71C2CD63EAEC1361E6A17D90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_89C62ABFF1FA52715EE61361E6A1DC94" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_89C62ABFF1FA52715EE61361E6A1DC94" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ConvertiblePreferredStockConversionPrice" xlink:label="loc_gale_ConvertiblePreferredStockConversionPrice_71432579BC4DC4E186651361E6A1ACDE" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_gale_ConvertiblePreferredStockConversionPrice_71432579BC4DC4E186651361E6A1ACDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" xlink:label="loc_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_1BE7A906783A7EE546441361E6A1D1AA" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_1BE7A906783A7EE546441361E6A1D1AA" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ConvertiblePreferredStockIssuedShares" xlink:label="loc_gale_ConvertiblePreferredStockIssuedShares_6D654C2800D1D560957F1361E6A2DA6B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_gale_ConvertiblePreferredStockIssuedShares_6D654C2800D1D560957F1361E6A2DA6B" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_WarrantsIssuedShares" xlink:label="loc_gale_WarrantsIssuedShares_F5D1F28BA29D3DF847FD1361E6A210C1" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_gale_WarrantsIssuedShares_F5D1F28BA29D3DF847FD1361E6A210C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_012146FBA49479F56D151361E6A28E2B" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_012146FBA49479F56D151361E6A28E2B" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:label="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_32BAE66F0AD52BADCF161361E6A23347" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_32BAE66F0AD52BADCF161361E6A23347" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_AE150EBAAEDCD2E0DD221361E6A2C092" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_gale_ClassofWarrantorRightTerm_AE150EBAAEDCD2E0DD221361E6A2C092" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_B3C1DC433441B47C747E1361E6A2BB2E" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_B3C1DC433441B47C747E1361E6A2BB2E" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock" xlink:label="loc_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_DB09CAEDDEC9341E0B461361E6A35EA2" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_DB09CAEDDEC9341E0B461361E6A35EA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_E3A2E7B1E38A9952B9411361E6A36DBF" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_E3A2E7B1E38A9952B9411361E6A36DBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0F41F3DE9839348F34301361E6A3DE82" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0F41F3DE9839348F34301361E6A3DE82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_A813BE1CBE519278D2CF1361E6A34258" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_A813BE1CBE519278D2CF1361E6A34258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_5A80C732833BC65A9AD51361E6A3FFB4" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_5A80C732833BC65A9AD51361E6A3FFB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0B29A967DA0C1DF6C01513A440CBF972" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0B29A967DA0C1DF6C01513A440CBF972" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded" xlink:label="loc_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_A65FC4A74777A29FEA511361E6A3A188" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_A65FC4A74777A29FEA511361E6A3A188" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_674F3A9567FB3BE2D19B1361E6A4499E" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_674F3A9567FB3BE2D19B1361E6A4499E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStock" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_920B11B4E884585A210712CD0FB74628" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_DF5B5240ABB3F4D8DED312CD0FB5EFD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_920B11B4E884585A210712CD0FB74628" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_DF5B5240ABB3F4D8DED312CD0FB5EFD8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_A81F5AD5DA2539C3455612CD0FB6A375" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_DF5B5240ABB3F4D8DED312CD0FB5EFD8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_A81F5AD5DA2539C3455612CD0FB6A375" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2D9D28AC7F4FC3ACBB4D12CD0FB6B003_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_A81F5AD5DA2539C3455612CD0FB6A375" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2D9D28AC7F4FC3ACBB4D12CD0FB6B003_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2D9D28AC7F4FC3ACBB4D12CD0FB6B003" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_A81F5AD5DA2539C3455612CD0FB6A375" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2D9D28AC7F4FC3ACBB4D12CD0FB6B003" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SeriesAConvertiblePreferredWarrantsMember" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_1871C5C1823AB4AB76DB12CD0FB62E6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2D9D28AC7F4FC3ACBB4D12CD0FB6B003" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_1871C5C1823AB4AB76DB12CD0FB62E6D" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_February2017WarrantsMember" xlink:label="loc_gale_February2017WarrantsMember_1F096F7F247A09093DC812CD0FB6C599" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2D9D28AC7F4FC3ACBB4D12CD0FB6B003" xlink:to="loc_gale_February2017WarrantsMember_1F096F7F247A09093DC812CD0FB6C599" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_OtherWarrantIssuesMember" xlink:label="loc_gale_OtherWarrantIssuesMember_2522FBC5789751633C0312CD0FB77970" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2D9D28AC7F4FC3ACBB4D12CD0FB6B003" xlink:to="loc_gale_OtherWarrantIssuesMember_2522FBC5789751633C0312CD0FB77970" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightFairValueRollForward" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_920B11B4E884585A210712CD0FB74628" xlink:to="loc_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_FD3D59622B99A08F6DA412CD0FB75F3A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_FD3D59622B99A08F6DA412CD0FB75F3A" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueofWarrantsGranted" xlink:label="loc_gale_FairValueofWarrantsGranted_768565698ACF3949FD4912CD0FB848A9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:to="loc_gale_FairValueofWarrantsGranted_768565698ACF3949FD4912CD0FB848A9" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantsCanceled" xlink:label="loc_gale_FairValueOfWarrantsCanceled_896BCFA8C3698C9C0D6C12CD0FB8B7CA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:to="loc_gale_FairValueOfWarrantsCanceled_896BCFA8C3698C9C0D6C12CD0FB8B7CA" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantsExercisePriceAdjustment" xlink:label="loc_gale_FairValueOfWarrantsExercisePriceAdjustment_3869F1D21A4B689AF0B412CD0FB81B01" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:to="loc_gale_FairValueOfWarrantsExercisePriceAdjustment_3869F1D21A4B689AF0B412CD0FB81B01" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities_E11F6B299C69D160723712CD0FB80D22" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:to="loc_gale_ChangeInFairValueOfWarrantLiabilities_E11F6B299C69D160723712CD0FB80D22" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_1C6C2378450EAA99B7E717BCD0807052" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_92126F2F2DFFD6FE33C717BCD07EBC3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1C6C2378450EAA99B7E717BCD0807052" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_92126F2F2DFFD6FE33C717BCD07EBC3C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_D25B398ED7B4CA42019817BCD07FE84F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_92126F2F2DFFD6FE33C717BCD07EBC3C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_D25B398ED7B4CA42019817BCD07FE84F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_EA9569E8EE8F1F569C0F17BCD07F3610_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_D25B398ED7B4CA42019817BCD07FE84F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_EA9569E8EE8F1F569C0F17BCD07F3610_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_EA9569E8EE8F1F569C0F17BCD07F3610" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_D25B398ED7B4CA42019817BCD07FE84F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_EA9569E8EE8F1F569C0F17BCD07F3610" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SeriesAConvertiblePreferredWarrantsMember" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_1349E5984C7E93A89E0217BCD0802626" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EA9569E8EE8F1F569C0F17BCD07F3610" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_1349E5984C7E93A89E0217BCD0802626" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_February2017WarrantsMember" xlink:label="loc_gale_February2017WarrantsMember_ADADE1101A5BB71FABD817BCD080D381" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EA9569E8EE8F1F569C0F17BCD07F3610" xlink:to="loc_gale_February2017WarrantsMember_ADADE1101A5BB71FABD817BCD080D381" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_OtherWarrantIssuesMember" xlink:label="loc_gale_OtherWarrantIssuesMember_2B6A5226A3CD56A958D917BCD080285D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EA9569E8EE8F1F569C0F17BCD07F3610" xlink:to="loc_gale_OtherWarrantIssuesMember_2B6A5226A3CD56A958D917BCD080285D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_295D4852F8BC7A99FE2F17BCD080B710" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1C6C2378450EAA99B7E717BCD0807052" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_295D4852F8BC7A99FE2F17BCD080B710" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_WarrantStrikePrice" xlink:label="loc_gale_WarrantStrikePrice_DF39C75AAAB317787D9117BCD081459D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1C6C2378450EAA99B7E717BCD0807052" xlink:to="loc_gale_WarrantStrikePrice_DF39C75AAAB317787D9117BCD081459D" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD6E503350CFFE80D44C17BCD0815EFF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1C6C2378450EAA99B7E717BCD0807052" xlink:to="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD6E503350CFFE80D44C17BCD0815EFF" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_7279359D68F2719DDDCC17BCD0812ACA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1C6C2378450EAA99B7E717BCD0807052" xlink:to="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_7279359D68F2719DDDCC17BCD0812ACA" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_7A1E02B37CFE28C04B0417BCD08151F2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1C6C2378450EAA99B7E717BCD0807052" xlink:to="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_7A1E02B37CFE28C04B0417BCD08151F2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_F1C0A56C6408844D4BED0E609EAB501D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_F1C0A56C6408844D4BED0E609EAB501D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_B9D56BD8F7872BE675E90E609EABC312" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_F1C0A56C6408844D4BED0E609EAB501D" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_B9D56BD8F7872BE675E90E609EABC312" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_C54A519B2EE4B6CF99F10E609EAB71EC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_B9D56BD8F7872BE675E90E609EABC312" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_C54A519B2EE4B6CF99F10E609EAB71EC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_C54A519B2EE4B6CF99F10E609EAB71EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_B9D56BD8F7872BE675E90E609EABC312" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_C54A519B2EE4B6CF99F10E609EAB71EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_DCAACDE3ADFC569E9A830E609EABD56D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C54A519B2EE4B6CF99F10E609EAB71EC" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_DCAACDE3ADFC569E9A830E609EABD56D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1E539B698F505024BDB90E609EAC29BE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C54A519B2EE4B6CF99F10E609EAB71EC" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1E539B698F505024BDB90E609EAC29BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_BC5448849703FFCD3ECB0E609EAC90C1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C54A519B2EE4B6CF99F10E609EAB71EC" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_BC5448849703FFCD3ECB0E609EAC90C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_70ADC301336033C927A50E609EACA5BD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_F1C0A56C6408844D4BED0E609EAB501D" xlink:to="loc_us-gaap_DebtInstrumentAxis_70ADC301336033C927A50E609EACA5BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_99184FDDB75086E269DE0E609EAC1CEB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_70ADC301336033C927A50E609EACA5BD" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_99184FDDB75086E269DE0E609EAC1CEB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_99184FDDB75086E269DE0E609EAC1CEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_70ADC301336033C927A50E609EACA5BD" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_99184FDDB75086E269DE0E609EAC1CEB" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ConvertiblePromissoryNotesMember" xlink:label="loc_gale_ConvertiblePromissoryNotesMember_ED79EAA365D762FB31750E609EACF3E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_99184FDDB75086E269DE0E609EAC1CEB" xlink:to="loc_gale_ConvertiblePromissoryNotesMember_ED79EAA365D762FB31750E609EACF3E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_7EEBA697239D48D246840E609EAD5CAC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_F1C0A56C6408844D4BED0E609EAB501D" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_7EEBA697239D48D246840E609EAD5CAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_DEA1BB90FD1B33DF318D0E609EADB215_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_7EEBA697239D48D246840E609EAD5CAC" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_DEA1BB90FD1B33DF318D0E609EADB215_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_DEA1BB90FD1B33DF318D0E609EADB215" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_7EEBA697239D48D246840E609EAD5CAC" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_DEA1BB90FD1B33DF318D0E609EADB215" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_270A4619AC70C1CF1A490E609EADB9E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_DEA1BB90FD1B33DF318D0E609EADB215" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_270A4619AC70C1CF1A490E609EADB9E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3185E66BAE240B7EC7FA0E609EAEB854" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_F1C0A56C6408844D4BED0E609EAB501D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3185E66BAE240B7EC7FA0E609EAEB854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8F43FD69E1199DC70E6E0E609EAEFC12_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3185E66BAE240B7EC7FA0E609EAEB854" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8F43FD69E1199DC70E6E0E609EAEFC12_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8F43FD69E1199DC70E6E0E609EAEFC12" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3185E66BAE240B7EC7FA0E609EAEB854" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8F43FD69E1199DC70E6E0E609EAEFC12" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_February2017WarrantsMember" xlink:label="loc_gale_February2017WarrantsMember_0F2282DE98254E12273B0E609EAEE216" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8F43FD69E1199DC70E6E0E609EAEFC12" xlink:to="loc_gale_February2017WarrantsMember_0F2282DE98254E12273B0E609EAEE216" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SeriesAConvertiblePreferredWarrantsMember" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_CA9BE389A363D1ABDA0A0E609EAE2900" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8F43FD69E1199DC70E6E0E609EAEFC12" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_CA9BE389A363D1ABDA0A0E609EAE2900" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants" xlink:label="loc_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_1E7AF1B47F7E466002380E609EAE81A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:to="loc_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_1E7AF1B47F7E466002380E609EAE81A0" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock" xlink:label="loc_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_E144AF39CE5D030773110E609EAF8DC2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:to="loc_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_E144AF39CE5D030773110E609EAF8DC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0CCDDFA29071D6F7C8880E609EAF08A6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0CCDDFA29071D6F7C8880E609EAF08A6" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_CommonStockSharesAcquiredinExchangeforWarrants" xlink:label="loc_gale_CommonStockSharesAcquiredinExchangeforWarrants_16AAC3F3AD431B945DF20E609EAF5EC4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:to="loc_gale_CommonStockSharesAcquiredinExchangeforWarrants_16AAC3F3AD431B945DF20E609EAF5EC4" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ConsiderationExchangedFairValue" xlink:label="loc_gale_ConsiderationExchangedFairValue_CE138648E97C9F5C51BA0E609EAF647D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:to="loc_gale_ConsiderationExchangedFairValue_CE138648E97C9F5C51BA0E609EAF647D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_E4B8A38F39A21A9925490E609EB006A4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_E4B8A38F39A21A9925490E609EB006A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_2A5422FD6C6CD01B2F3E0E609EB0B22E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_2A5422FD6C6CD01B2F3E0E609EB0B22E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_922F3CF601C25B70C6400E609EB0FE9D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_922F3CF601C25B70C6400E609EB0FE9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_66BB263E0046A8D8758E0E609EB0B14D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_66BB263E0046A8D8758E0E609EB0B14D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_E1D6248FEF12CCD936A7139A71CEEDC2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_38D0970973C97292146B139A71CCDFEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E1D6248FEF12CCD936A7139A71CEEDC2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_38D0970973C97292146B139A71CCDFEE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_762BC38DD6B41BA53179139A71CCBCFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38D0970973C97292146B139A71CCDFEE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_762BC38DD6B41BA53179139A71CCBCFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_F632F015D80FC1824D02139A71CDDF34_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_762BC38DD6B41BA53179139A71CCBCFD" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_F632F015D80FC1824D02139A71CDDF34_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_F632F015D80FC1824D02139A71CDDF34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_762BC38DD6B41BA53179139A71CCBCFD" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_F632F015D80FC1824D02139A71CDDF34" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_July2018OfferingMember" xlink:label="loc_gale_July2018OfferingMember_8A8A144B86A6A985B425139A71CD1B9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_F632F015D80FC1824D02139A71CDDF34" xlink:to="loc_gale_July2018OfferingMember_8A8A144B86A6A985B425139A71CD1B9F" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_Prefunded2018OfferingMember" xlink:label="loc_gale_Prefunded2018OfferingMember_DEB763EC55A73136D834139A71CD43EB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_F632F015D80FC1824D02139A71CDDF34" xlink:to="loc_gale_Prefunded2018OfferingMember_DEB763EC55A73136D834139A71CD43EB" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SeriesAConvertiblePreferredWarrantsMember" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_5E89BA30A55535C01342139A71CD67B5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_F632F015D80FC1824D02139A71CDDF34" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_5E89BA30A55535C01342139A71CD67B5" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_EqcWarrantsMember" xlink:label="loc_gale_EqcWarrantsMember_D00FDCF94A3B8FB2B750139A71CEBACB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_F632F015D80FC1824D02139A71CDDF34" xlink:to="loc_gale_EqcWarrantsMember_D00FDCF94A3B8FB2B750139A71CEBACB" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_February2017WarrantsMember" xlink:label="loc_gale_February2017WarrantsMember_35104F8C4C61BC5100D1139A71CE6C4B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_F632F015D80FC1824D02139A71CDDF34" xlink:to="loc_gale_February2017WarrantsMember_35104F8C4C61BC5100D1139A71CE6C4B" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_OtherWarrantIssuesMember" xlink:label="loc_gale_OtherWarrantIssuesMember_556DF530FAF39DB892D8139A71CE66B2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_F632F015D80FC1824D02139A71CDDF34" xlink:to="loc_gale_OtherWarrantIssuesMember_556DF530FAF39DB892D8139A71CE66B2" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightOutstandingRollForward" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E1D6248FEF12CCD936A7139A71CEEDC2" xlink:to="loc_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_938DDB6AF4096EFD4887139A71CF098E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_938DDB6AF4096EFD4887139A71CF098E" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_754A09CD66C3131621E9139A71CFFA3E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A" xlink:to="loc_gale_ClassofWarrantorRightGranted_754A09CD66C3131621E9139A71CFFA3E" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassOfWarrantOrRightExercised" xlink:label="loc_gale_ClassOfWarrantOrRightExercised_C94E7EAD3F37DEF5A0AA139A71CFCCCF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A" xlink:to="loc_gale_ClassOfWarrantOrRightExercised_C94E7EAD3F37DEF5A0AA139A71CFCCCF" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightCanceledOrExpired" xlink:label="loc_gale_ClassofWarrantorRightCanceledOrExpired_AC652A89F980D7EADC2E139A71CF37CA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A" xlink:to="loc_gale_ClassofWarrantorRightCanceledOrExpired_AC652A89F980D7EADC2E139A71CF37CA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE4B69CD80ABB61367CF12E41C9F62AE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_97502148762739C9496112E41C986977" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE4B69CD80ABB61367CF12E41C9F62AE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_97502148762739C9496112E41C986977" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_E0F38AF7F81C77AD7C6612E41C982AC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_97502148762739C9496112E41C986977" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_E0F38AF7F81C77AD7C6612E41C982AC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_DEC3A910E5D1F989D8F112E41C9E4987_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_E0F38AF7F81C77AD7C6612E41C982AC3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_DEC3A910E5D1F989D8F112E41C9E4987_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_DEC3A910E5D1F989D8F112E41C9E4987" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_E0F38AF7F81C77AD7C6612E41C982AC3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_DEC3A910E5D1F989D8F112E41C9E4987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_B9AB23BD9D3CEBC62CF412E41C9E7595" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_DEC3A910E5D1F989D8F112E41C9E4987" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_B9AB23BD9D3CEBC62CF412E41C9E7595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_DF1A755CEA6647B5040E12F8824025E0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_DEC3A910E5D1F989D8F112E41C9E4987" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_DF1A755CEA6647B5040E12F8824025E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_A0522C0D5065AC8EF76212E41C9EB042" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_DEC3A910E5D1F989D8F112E41C9E4987" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_A0522C0D5065AC8EF76212E41C9EB042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_9AB44297F40B619930C612E41C9F1592" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_DEC3A910E5D1F989D8F112E41C9E4987" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_9AB44297F40B619930C612E41C9F1592" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_85AAC91E1B61B71619E412E41C9FA330" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE4B69CD80ABB61367CF12E41C9F62AE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_85AAC91E1B61B71619E412E41C9FA330" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_AE0EAAA7178E23F4419712E41C9F5A0E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE4B69CD80ABB61367CF12E41C9F62AE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_AE0EAAA7178E23F4419712E41C9F5A0E" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_E49F305DF3C2E8682E8E12E41C9FA01D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE4B69CD80ABB61367CF12E41C9F62AE" xlink:to="loc_gale_ClassofWarrantorRightTerm_E49F305DF3C2E8682E8E12E41C9FA01D" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueofWarrantsGrantedperShare" xlink:label="loc_gale_FairValueofWarrantsGrantedperShare_E41AAE999C269956601C12E41CA0B7E1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE4B69CD80ABB61367CF12E41C9F62AE" xlink:to="loc_gale_FairValueofWarrantsGrantedperShare_E41AAE999C269956601C12E41CA0B7E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1F72F979CF4FE1D552FA12E41CA037A4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE4B69CD80ABB61367CF12E41C9F62AE" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1F72F979CF4FE1D552FA12E41CA037A4" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>gale-20180930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_E903B976C7AF6094C43B17BCD0C73A50_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_E903B976C7AF6094C43B17BCD0C73A50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_E903B976C7AF6094C43B17BCD0C73A50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_E903B976C7AF6094C43B17BCD0C73A50" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_E903B976C7AF6094C43B17BCD0C73A50" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C1831758892F19C45AB17BCD0C71C65_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C1831758892F19C45AB17BCD0C71C65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C1831758892F19C45AB17BCD0C71C65_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C1831758892F19C45AB17BCD0C71C65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C1831758892F19C45AB17BCD0C71C65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C1831758892F19C45AB17BCD0C71C65" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C1831758892F19C45AB17BCD0C71C65" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2D9CE88FF3D1E5F8EEF617BCD0C7C4A9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2D9CE88FF3D1E5F8EEF617BCD0C7C4A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2D9CE88FF3D1E5F8EEF617BCD0C7C4A9_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2D9CE88FF3D1E5F8EEF617BCD0C7C4A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2D9CE88FF3D1E5F8EEF617BCD0C7C4A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2D9CE88FF3D1E5F8EEF617BCD0C7C4A9" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2D9CE88FF3D1E5F8EEF617BCD0C7C4A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_93FBFA3EEA1C3B37F2E717BCD0C7A6B4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_93FBFA3EEA1C3B37F2E717BCD0C7A6B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_93FBFA3EEA1C3B37F2E717BCD0C7A6B4_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_93FBFA3EEA1C3B37F2E717BCD0C7A6B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_93FBFA3EEA1C3B37F2E717BCD0C7A6B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_93FBFA3EEA1C3B37F2E717BCD0C7A6B4" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_93FBFA3EEA1C3B37F2E717BCD0C7A6B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_6FDEEB9A239E59A618FB17BCD0C85E48_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_6FDEEB9A239E59A618FB17BCD0C85E48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_6FDEEB9A239E59A618FB17BCD0C85E48_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_6FDEEB9A239E59A618FB17BCD0C85E48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6FDEEB9A239E59A618FB17BCD0C85E48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_6FDEEB9A239E59A618FB17BCD0C85E48" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_6FDEEB9A239E59A618FB17BCD0C85E48" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_01BB2CF57CD37B1D7EF717BCD0C8A9E8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_01BB2CF57CD37B1D7EF717BCD0C8A9E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_01BB2CF57CD37B1D7EF717BCD0C8A9E8_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_01BB2CF57CD37B1D7EF717BCD0C8A9E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_01BB2CF57CD37B1D7EF717BCD0C8A9E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_01BB2CF57CD37B1D7EF717BCD0C8A9E8" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_01BB2CF57CD37B1D7EF717BCD0C8A9E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_682152669767E25E07FD17BCD0C8B7E3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_682152669767E25E07FD17BCD0C8B7E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_682152669767E25E07FD17BCD0C8B7E3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_682152669767E25E07FD17BCD0C8B7E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_682152669767E25E07FD17BCD0C8B7E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_682152669767E25E07FD17BCD0C8B7E3" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_682152669767E25E07FD17BCD0C8B7E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0F39224EDCB89D073A6417BCD0C8881F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_0F39224EDCB89D073A6417BCD0C8881F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices In Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0F39224EDCB89D073A6417BCD0C8881F_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_0F39224EDCB89D073A6417BCD0C8881F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0F39224EDCB89D073A6417BCD0C8881F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_0F39224EDCB89D073A6417BCD0C8881F" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_0F39224EDCB89D073A6417BCD0C8881F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_712C75803779265BFDC117BCD0C93C43_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_712C75803779265BFDC117BCD0C93C43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_712C75803779265BFDC117BCD0C93C43_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_712C75803779265BFDC117BCD0C93C43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_712C75803779265BFDC117BCD0C93C43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_712C75803779265BFDC117BCD0C93C43" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_712C75803779265BFDC117BCD0C93C43" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7DD06866C5264018253F17BCD0C97DF4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_7DD06866C5264018253F17BCD0C97DF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7DD06866C5264018253F17BCD0C97DF4_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_7DD06866C5264018253F17BCD0C97DF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7DD06866C5264018253F17BCD0C97DF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_7DD06866C5264018253F17BCD0C97DF4" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_7DD06866C5264018253F17BCD0C97DF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25E4A8A3092039C9C1E517BCD0C9479F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25E4A8A3092039C9C1E517BCD0C9479F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25E4A8A3092039C9C1E517BCD0C9479F_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25E4A8A3092039C9C1E517BCD0C9479F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25E4A8A3092039C9C1E517BCD0C9479F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25E4A8A3092039C9C1E517BCD0C9479F" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25E4A8A3092039C9C1E517BCD0C9479F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_24A66C176252E9CE3BA617BCD0C9C454_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_24A66C176252E9CE3BA617BCD0C9C454" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_24A66C176252E9CE3BA617BCD0C9C454_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_24A66C176252E9CE3BA617BCD0C9C454" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_24A66C176252E9CE3BA617BCD0C9C454" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_24A66C176252E9CE3BA617BCD0C9C454" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_24A66C176252E9CE3BA617BCD0C9C454" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_A2C4D33FB3918ABB711017BCD0CA94B5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_A2C4D33FB3918ABB711017BCD0CA94B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_A2C4D33FB3918ABB711017BCD0CA94B5_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_A2C4D33FB3918ABB711017BCD0CA94B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_A2C4D33FB3918ABB711017BCD0CA94B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_A2C4D33FB3918ABB711017BCD0CA94B5" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_A2C4D33FB3918ABB711017BCD0CA94B5" xlink:type="arc" />
    <link:label id="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_76BE728BCEB2EE009AE617BCD0CAA279_terseLabel_en-US" xlink:label="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_76BE728BCEB2EE009AE617BCD0CAA279" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash equivalents</link:label>
    <link:label id="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_76BE728BCEB2EE009AE617BCD0CAA279_label_en-US" xlink:label="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_76BE728BCEB2EE009AE617BCD0CAA279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_76BE728BCEB2EE009AE617BCD0CAA279_documentation_en-US" xlink:label="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_76BE728BCEB2EE009AE617BCD0CAA279" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_RestrictedCashandCashEquivalentsFairValueDisclosure" xlink:label="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_76BE728BCEB2EE009AE617BCD0CAA279" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_76BE728BCEB2EE009AE617BCD0CAA279" xlink:to="lab_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_76BE728BCEB2EE009AE617BCD0CAA279" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_5EE015EA28F8EFBC842317BCD0CAA27C_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_5EE015EA28F8EFBC842317BCD0CAA27C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets measured and recorded at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_5EE015EA28F8EFBC842317BCD0CAA27C_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_5EE015EA28F8EFBC842317BCD0CAA27C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5EE015EA28F8EFBC842317BCD0CAA27C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_5EE015EA28F8EFBC842317BCD0CAA27C" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_5EE015EA28F8EFBC842317BCD0CAA27C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_0AC697E0768E89D9362517BCD0CAA966_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_0AC697E0768E89D9362517BCD0CAA966" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_0AC697E0768E89D9362517BCD0CAA966_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_0AC697E0768E89D9362517BCD0CAA966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0AC697E0768E89D9362517BCD0CAA966" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0AC697E0768E89D9362517BCD0CAA966" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_0AC697E0768E89D9362517BCD0CAA966" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_B953F4769474DB491C0017BCD0CB6A66_verboseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_B953F4769474DB491C0017BCD0CB6A66" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants potentially settleable in cash</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_B953F4769474DB491C0017BCD0CB6A66_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_B953F4769474DB491C0017BCD0CB6A66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Potentially Settleable In Cash</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_B953F4769474DB491C0017BCD0CB6A66_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_B953F4769474DB491C0017BCD0CB6A66" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of warrants potentially settleable in cash.</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_B953F4769474DB491C0017BCD0CB6A66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_B953F4769474DB491C0017BCD0CB6A66" xlink:to="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_B953F4769474DB491C0017BCD0CB6A66" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_81D949FB3D1FF6C4C53317BCD0CB8A4C_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_81D949FB3D1FF6C4C53317BCD0CB8A4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_81D949FB3D1FF6C4C53317BCD0CB8A4C_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_81D949FB3D1FF6C4C53317BCD0CB8A4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Classified as Equity, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_81D949FB3D1FF6C4C53317BCD0CB8A4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_81D949FB3D1FF6C4C53317BCD0CB8A4C" xlink:to="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_81D949FB3D1FF6C4C53317BCD0CB8A4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityFairValueDisclosure_FBACED4D12D9ADFA912617BCD0CBC926_totalLabel_en-US" xlink:label="lab_us-gaap_EquityFairValueDisclosure_FBACED4D12D9ADFA912617BCD0CBC926" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities measured and recorded at fair value</link:label>
    <link:label id="lab_us-gaap_EquityFairValueDisclosure_FBACED4D12D9ADFA912617BCD0CBC926_label_en-US" xlink:label="lab_us-gaap_EquityFairValueDisclosure_FBACED4D12D9ADFA912617BCD0CBC926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_FBACED4D12D9ADFA912617BCD0CBC926" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFairValueDisclosure_FBACED4D12D9ADFA912617BCD0CBC926" xlink:to="lab_us-gaap_EquityFairValueDisclosure_FBACED4D12D9ADFA912617BCD0CBC926" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F57C150801B26E69EF5412E3AEA047B5_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F57C150801B26E69EF5412E3AEA047B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F57C150801B26E69EF5412E3AEA047B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F57C150801B26E69EF5412E3AEA047B5" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F57C150801B26E69EF5412E3AEA047B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E87CF859F383323E96012E3AEA0EE6E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E87CF859F383323E96012E3AEA0EE6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E87CF859F383323E96012E3AEA0EE6E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E87CF859F383323E96012E3AEA0EE6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E87CF859F383323E96012E3AEA0EE6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E87CF859F383323E96012E3AEA0EE6E" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E87CF859F383323E96012E3AEA0EE6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_6561132EFEBEE1169BD012E3AEA1ABDF_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_6561132EFEBEE1169BD012E3AEA1ABDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_6561132EFEBEE1169BD012E3AEA1ABDF_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_6561132EFEBEE1169BD012E3AEA1ABDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_6561132EFEBEE1169BD012E3AEA1ABDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_6561132EFEBEE1169BD012E3AEA1ABDF" xlink:to="lab_us-gaap_PlanNameAxis_6561132EFEBEE1169BD012E3AEA1ABDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_58C9F90890884170C83712E3AEA14142_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_58C9F90890884170C83712E3AEA14142" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_58C9F90890884170C83712E3AEA14142_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_58C9F90890884170C83712E3AEA14142" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_58C9F90890884170C83712E3AEA14142" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_58C9F90890884170C83712E3AEA14142" xlink:to="lab_us-gaap_PlanNameDomain_58C9F90890884170C83712E3AEA14142" xlink:type="arc" />
    <link:label id="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_77463FD79FC66EBADD1112E3AEA1A010_terseLabel_en-US" xlink:label="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_77463FD79FC66EBADD1112E3AEA1A010" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Equity Plan</link:label>
    <link:label id="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_77463FD79FC66EBADD1112E3AEA1A010_label_en-US" xlink:label="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_77463FD79FC66EBADD1112E3AEA1A010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Seventeen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_77463FD79FC66EBADD1112E3AEA1A010_documentation_en-US" xlink:label="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_77463FD79FC66EBADD1112E3AEA1A010" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand And Seventeen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:label="loc_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_77463FD79FC66EBADD1112E3AEA1A010" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_77463FD79FC66EBADD1112E3AEA1A010" xlink:to="lab_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_77463FD79FC66EBADD1112E3AEA1A010" xlink:type="arc" />
    <link:label id="lab_gale_IncentivePlan2016Member_316476F923915F04559812E3AEA13756_terseLabel_en-US" xlink:label="lab_gale_IncentivePlan2016Member_316476F923915F04559812E3AEA13756" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incentive Plan 2016</link:label>
    <link:label id="lab_gale_IncentivePlan2016Member_316476F923915F04559812E3AEA13756_label_en-US" xlink:label="lab_gale_IncentivePlan2016Member_316476F923915F04559812E3AEA13756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Plan 2016 [Member]</link:label>
    <link:label id="lab_gale_IncentivePlan2016Member_316476F923915F04559812E3AEA13756_documentation_en-US" xlink:label="lab_gale_IncentivePlan2016Member_316476F923915F04559812E3AEA13756" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incentive Plan 2016 [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_IncentivePlan2016Member" xlink:label="loc_gale_IncentivePlan2016Member_316476F923915F04559812E3AEA13756" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IncentivePlan2016Member_316476F923915F04559812E3AEA13756" xlink:to="lab_gale_IncentivePlan2016Member_316476F923915F04559812E3AEA13756" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_DDB07405FCD21584B93F12E3AEA2EAD2_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_DDB07405FCD21584B93F12E3AEA2EAD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_DDB07405FCD21584B93F12E3AEA2EAD2_label_en-US" xlink:label="lab_srt_RangeAxis_DDB07405FCD21584B93F12E3AEA2EAD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_DDB07405FCD21584B93F12E3AEA2EAD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_DDB07405FCD21584B93F12E3AEA2EAD2" xlink:to="lab_srt_RangeAxis_DDB07405FCD21584B93F12E3AEA2EAD2" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_50B2D5D99EE74DD407DE12E3AEA27C97_terseLabel_en-US" xlink:label="lab_srt_RangeMember_50B2D5D99EE74DD407DE12E3AEA27C97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_50B2D5D99EE74DD407DE12E3AEA27C97_label_en-US" xlink:label="lab_srt_RangeMember_50B2D5D99EE74DD407DE12E3AEA27C97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_50B2D5D99EE74DD407DE12E3AEA27C97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_50B2D5D99EE74DD407DE12E3AEA27C97" xlink:to="lab_srt_RangeMember_50B2D5D99EE74DD407DE12E3AEA27C97" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_D826EB013277A600B39E12E3AEA29AAD_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_D826EB013277A600B39E12E3AEA29AAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_D826EB013277A600B39E12E3AEA29AAD_label_en-US" xlink:label="lab_srt_MaximumMember_D826EB013277A600B39E12E3AEA29AAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_D826EB013277A600B39E12E3AEA29AAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_D826EB013277A600B39E12E3AEA29AAD" xlink:to="lab_srt_MaximumMember_D826EB013277A600B39E12E3AEA29AAD" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_34FE95EB271CAE5C7A1012E3AEA213F4_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_34FE95EB271CAE5C7A1012E3AEA213F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_34FE95EB271CAE5C7A1012E3AEA213F4_label_en-US" xlink:label="lab_srt_MinimumMember_34FE95EB271CAE5C7A1012E3AEA213F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_34FE95EB271CAE5C7A1012E3AEA213F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_34FE95EB271CAE5C7A1012E3AEA213F4" xlink:to="lab_srt_MinimumMember_34FE95EB271CAE5C7A1012E3AEA213F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_3E2B6A4A2C8ECE604FFB12E3AEA3ECFF_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_3E2B6A4A2C8ECE604FFB12E3AEA3ECFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_3E2B6A4A2C8ECE604FFB12E3AEA3ECFF_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_3E2B6A4A2C8ECE604FFB12E3AEA3ECFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_3E2B6A4A2C8ECE604FFB12E3AEA3ECFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_3E2B6A4A2C8ECE604FFB12E3AEA3ECFF" xlink:to="lab_us-gaap_AwardTypeAxis_3E2B6A4A2C8ECE604FFB12E3AEA3ECFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45B67F9A1D44F7B0BF1512E3AEA39367_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45B67F9A1D44F7B0BF1512E3AEA39367" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45B67F9A1D44F7B0BF1512E3AEA39367_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45B67F9A1D44F7B0BF1512E3AEA39367" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45B67F9A1D44F7B0BF1512E3AEA39367" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45B67F9A1D44F7B0BF1512E3AEA39367" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45B67F9A1D44F7B0BF1512E3AEA39367" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_D4F07C68B12ABCF2219212E3AEA36101_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_D4F07C68B12ABCF2219212E3AEA36101" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_D4F07C68B12ABCF2219212E3AEA36101_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_D4F07C68B12ABCF2219212E3AEA36101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_D4F07C68B12ABCF2219212E3AEA36101" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_D4F07C68B12ABCF2219212E3AEA36101" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_D4F07C68B12ABCF2219212E3AEA36101" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_92C57DF1148FC830DF5612E3AEA40AFB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_92C57DF1148FC830DF5612E3AEA40AFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_92C57DF1148FC830DF5612E3AEA40AFB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_92C57DF1148FC830DF5612E3AEA40AFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_92C57DF1148FC830DF5612E3AEA40AFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_92C57DF1148FC830DF5612E3AEA40AFB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_92C57DF1148FC830DF5612E3AEA40AFB" xlink:type="arc" />
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_0ABAC08D444AF1FC6E1612E3AEA404A5_terseLabel_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_0ABAC08D444AF1FC6E1612E3AEA404A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options assumed in merger (in shares)</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_0ABAC08D444AF1FC6E1612E3AEA404A5_label_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_0ABAC08D444AF1FC6E1612E3AEA404A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Merger</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_0ABAC08D444AF1FC6E1612E3AEA404A5_documentation_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_0ABAC08D444AF1FC6E1612E3AEA404A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Merger</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_0ABAC08D444AF1FC6E1612E3AEA404A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_0ABAC08D444AF1FC6E1612E3AEA404A5" xlink:to="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_0ABAC08D444AF1FC6E1612E3AEA404A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_08E5B966554670B8DB8812E3AEA44AD5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_08E5B966554670B8DB8812E3AEA44AD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options expire from date of grant</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_08E5B966554670B8DB8812E3AEA44AD5_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_08E5B966554670B8DB8812E3AEA44AD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_08E5B966554670B8DB8812E3AEA44AD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_08E5B966554670B8DB8812E3AEA44AD5" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_08E5B966554670B8DB8812E3AEA44AD5" xlink:type="arc" />
    <link:label id="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_DE3E1FD40DDE3F1CFD5E12E3AEA44A96_terseLabel_en-US" xlink:label="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_DE3E1FD40DDE3F1CFD5E12E3AEA44A96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage increase in number of shares available for future issuance under stock based awards</link:label>
    <link:label id="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_DE3E1FD40DDE3F1CFD5E12E3AEA44A96_label_en-US" xlink:label="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_DE3E1FD40DDE3F1CFD5E12E3AEA44A96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Increase In Number Of Shares Available For Future Issuance Under Stock Based Awards</link:label>
    <link:label id="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_DE3E1FD40DDE3F1CFD5E12E3AEA44A96_documentation_en-US" xlink:label="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_DE3E1FD40DDE3F1CFD5E12E3AEA44A96" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Increase In Number Of Shares Available For Future Issuance Under Stock Based Awards</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" xlink:label="loc_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_DE3E1FD40DDE3F1CFD5E12E3AEA44A96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_DE3E1FD40DDE3F1CFD5E12E3AEA44A96" xlink:to="lab_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_DE3E1FD40DDE3F1CFD5E12E3AEA44A96" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_37BE7172F0312660238F12E3AEA4AC23_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_37BE7172F0312660238F12E3AEA4AC23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_37BE7172F0312660238F12E3AEA4AC23_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_37BE7172F0312660238F12E3AEA4AC23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_37BE7172F0312660238F12E3AEA4AC23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_37BE7172F0312660238F12E3AEA4AC23" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_37BE7172F0312660238F12E3AEA4AC23" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_54BDF103597F2945580E12E3AEA5EDB5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_54BDF103597F2945580E12E3AEA5EDB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, grants in period, net of forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_54BDF103597F2945580E12E3AEA5EDB5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_54BDF103597F2945580E12E3AEA5EDB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_54BDF103597F2945580E12E3AEA5EDB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_54BDF103597F2945580E12E3AEA5EDB5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_54BDF103597F2945580E12E3AEA5EDB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4F14173B3475B09E182E12E3AEA51FD9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4F14173B3475B09E182E12E3AEA51FD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, granted (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4F14173B3475B09E182E12E3AEA51FD9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4F14173B3475B09E182E12E3AEA51FD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4F14173B3475B09E182E12E3AEA51FD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4F14173B3475B09E182E12E3AEA51FD9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4F14173B3475B09E182E12E3AEA51FD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C7AF554AB325E0B3B50412E3AEA52007_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C7AF554AB325E0B3B50412E3AEA52007" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Averages contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C7AF554AB325E0B3B50412E3AEA52007_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C7AF554AB325E0B3B50412E3AEA52007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C7AF554AB325E0B3B50412E3AEA52007" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C7AF554AB325E0B3B50412E3AEA52007" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C7AF554AB325E0B3B50412E3AEA52007" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6C9D2D4BDD367D57631112E3AEA58106_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6C9D2D4BDD367D57631112E3AEA58106" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average vesting term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6C9D2D4BDD367D57631112E3AEA58106_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6C9D2D4BDD367D57631112E3AEA58106" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6C9D2D4BDD367D57631112E3AEA58106" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6C9D2D4BDD367D57631112E3AEA58106" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6C9D2D4BDD367D57631112E3AEA58106" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FA2C89D1B33A97F1893012E3AEA56772_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FA2C89D1B33A97F1893012E3AEA56772" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FA2C89D1B33A97F1893012E3AEA56772_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FA2C89D1B33A97F1893012E3AEA56772" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FA2C89D1B33A97F1893012E3AEA56772" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FA2C89D1B33A97F1893012E3AEA56772" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FA2C89D1B33A97F1893012E3AEA56772" xlink:type="arc" />
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_2A57742865C7CAD98C2B12E3AEA6AD74_terseLabel_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_2A57742865C7CAD98C2B12E3AEA6AD74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_2A57742865C7CAD98C2B12E3AEA6AD74_label_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_2A57742865C7CAD98C2B12E3AEA6AD74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_2A57742865C7CAD98C2B12E3AEA6AD74_documentation_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_2A57742865C7CAD98C2B12E3AEA6AD74" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_2A57742865C7CAD98C2B12E3AEA6AD74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_2A57742865C7CAD98C2B12E3AEA6AD74" xlink:to="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_2A57742865C7CAD98C2B12E3AEA6AD74" xlink:type="arc" />
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_A654216CDB317A19C91C12E3AEA698CD_terseLabel_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_A654216CDB317A19C91C12E3AEA698CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses weighted average period</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_A654216CDB317A19C91C12E3AEA698CD_label_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_A654216CDB317A19C91C12E3AEA698CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_A654216CDB317A19C91C12E3AEA698CD_documentation_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_A654216CDB317A19C91C12E3AEA698CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_A654216CDB317A19C91C12E3AEA698CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_A654216CDB317A19C91C12E3AEA698CD" xlink:to="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_A654216CDB317A19C91C12E3AEA698CD" xlink:type="arc" />
    <link:label id="lab_gale_ClosingPriceOfCommonStock_675F8663873C0424F12612E3AEA6409C_terseLabel_en-US" xlink:label="lab_gale_ClosingPriceOfCommonStock_675F8663873C0424F12612E3AEA6409C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Closing price of the Company's common stock (in USD per share)</link:label>
    <link:label id="lab_gale_ClosingPriceOfCommonStock_675F8663873C0424F12612E3AEA6409C_label_en-US" xlink:label="lab_gale_ClosingPriceOfCommonStock_675F8663873C0424F12612E3AEA6409C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Closing Price Of Common Stock</link:label>
    <link:label id="lab_gale_ClosingPriceOfCommonStock_675F8663873C0424F12612E3AEA6409C_documentation_en-US" xlink:label="lab_gale_ClosingPriceOfCommonStock_675F8663873C0424F12612E3AEA6409C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Closing price of common stock.</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ClosingPriceOfCommonStock" xlink:label="loc_gale_ClosingPriceOfCommonStock_675F8663873C0424F12612E3AEA6409C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClosingPriceOfCommonStock_675F8663873C0424F12612E3AEA6409C" xlink:to="lab_gale_ClosingPriceOfCommonStock_675F8663873C0424F12612E3AEA6409C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_EA895FB4FD2A5111669512E3AEA6CCCE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_EA895FB4FD2A5111669512E3AEA6CCCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity instruments other than options, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_EA895FB4FD2A5111669512E3AEA6CCCE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_EA895FB4FD2A5111669512E3AEA6CCCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_EA895FB4FD2A5111669512E3AEA6CCCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_EA895FB4FD2A5111669512E3AEA6CCCE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_EA895FB4FD2A5111669512E3AEA6CCCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5199E8D540B46044FB7A12E3AEA6FDFE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5199E8D540B46044FB7A12E3AEA6FDFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity instruments other than options, outstanding, number (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5199E8D540B46044FB7A12E3AEA6FDFE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5199E8D540B46044FB7A12E3AEA6FDFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5199E8D540B46044FB7A12E3AEA6FDFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5199E8D540B46044FB7A12E3AEA6FDFE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5199E8D540B46044FB7A12E3AEA6FDFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9FBF2FF61C97DBCC7C1912E3AEA6C227_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9FBF2FF61C97DBCC7C1912E3AEA6C227" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity instruments other than options, outstanding, weighted average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9FBF2FF61C97DBCC7C1912E3AEA6C227_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9FBF2FF61C97DBCC7C1912E3AEA6C227" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9FBF2FF61C97DBCC7C1912E3AEA6C227" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9FBF2FF61C97DBCC7C1912E3AEA6C227" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9FBF2FF61C97DBCC7C1912E3AEA6C227" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_1B4BBE9D2B602AC0B41B0E343F485FC9_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_1B4BBE9D2B602AC0B41B0E343F485FC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1B4BBE9D2B602AC0B41B0E343F485FC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_1B4BBE9D2B602AC0B41B0E343F485FC9" xlink:to="lab_us-gaap_EquityAbstract_1B4BBE9D2B602AC0B41B0E343F485FC9" xlink:type="arc" />
    <link:label id="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_61DD4C5467DD03E161350E343F482F66_terseLabel_en-US" xlink:label="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_61DD4C5467DD03E161350E343F482F66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock are Reserved for Future Issuance</link:label>
    <link:label id="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_61DD4C5467DD03E161350E343F482F66_label_en-US" xlink:label="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_61DD4C5467DD03E161350E343F482F66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Are Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_61DD4C5467DD03E161350E343F482F66_documentation_en-US" xlink:label="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_61DD4C5467DD03E161350E343F482F66" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock are reserved for future issuance.</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:label="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_61DD4C5467DD03E161350E343F482F66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_61DD4C5467DD03E161350E343F482F66" xlink:to="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_61DD4C5467DD03E161350E343F482F66" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6023AA8D9298360F0FB817BCCEBC97BC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6023AA8D9298360F0FB817BCCEBC97BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6023AA8D9298360F0FB817BCCEBC97BC_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6023AA8D9298360F0FB817BCCEBC97BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6023AA8D9298360F0FB817BCCEBC97BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6023AA8D9298360F0FB817BCCEBC97BC" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6023AA8D9298360F0FB817BCCEBC97BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_A4DD832D1E1B0FBD5C7317BCCEBD4EFF_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_A4DD832D1E1B0FBD5C7317BCCEBD4EFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_A4DD832D1E1B0FBD5C7317BCCEBD4EFF_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_A4DD832D1E1B0FBD5C7317BCCEBD4EFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A4DD832D1E1B0FBD5C7317BCCEBD4EFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A4DD832D1E1B0FBD5C7317BCCEBD4EFF" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_A4DD832D1E1B0FBD5C7317BCCEBD4EFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_0EC01474E6F93FF5667F17BCCEBDFE38_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_0EC01474E6F93FF5667F17BCCEBDFE38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_0EC01474E6F93FF5667F17BCCEBDFE38_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_0EC01474E6F93FF5667F17BCCEBDFE38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0EC01474E6F93FF5667F17BCCEBDFE38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0EC01474E6F93FF5667F17BCCEBDFE38" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_0EC01474E6F93FF5667F17BCCEBDFE38" xlink:type="arc" />
    <link:label id="lab_gale_AptheraInc.Member_9847B784F0C7AD357E3E17BCCEBDB54C_terseLabel_en-US" xlink:label="lab_gale_AptheraInc.Member_9847B784F0C7AD357E3E17BCCEBDB54C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Apthera, Inc.</link:label>
    <link:label id="lab_gale_AptheraInc.Member_9847B784F0C7AD357E3E17BCCEBDB54C_label_en-US" xlink:label="lab_gale_AptheraInc.Member_9847B784F0C7AD357E3E17BCCEBDB54C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Apthera, Inc. [Member]</link:label>
    <link:label id="lab_gale_AptheraInc.Member_9847B784F0C7AD357E3E17BCCEBDB54C_documentation_en-US" xlink:label="lab_gale_AptheraInc.Member_9847B784F0C7AD357E3E17BCCEBDB54C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Apthera, Inc. [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_AptheraInc.Member" xlink:label="loc_gale_AptheraInc.Member_9847B784F0C7AD357E3E17BCCEBDB54C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AptheraInc.Member_9847B784F0C7AD357E3E17BCCEBDB54C" xlink:to="lab_gale_AptheraInc.Member_9847B784F0C7AD357E3E17BCCEBDB54C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E816959CAF9376D1889517BCCEBFE10A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E816959CAF9376D1889517BCCEBFE10A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E816959CAF9376D1889517BCCEBFE10A_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E816959CAF9376D1889517BCCEBFE10A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E816959CAF9376D1889517BCCEBFE10A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E816959CAF9376D1889517BCCEBFE10A" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E816959CAF9376D1889517BCCEBFE10A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40CA17889608A9450A5E17BCCEBFE21A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40CA17889608A9450A5E17BCCEBFE21A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40CA17889608A9450A5E17BCCEBFE21A_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40CA17889608A9450A5E17BCCEBFE21A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40CA17889608A9450A5E17BCCEBFE21A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40CA17889608A9450A5E17BCCEBFE21A" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40CA17889608A9450A5E17BCCEBFE21A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_D6D64BC92AEC9AC91AC917BCCEBF7C94_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_D6D64BC92AEC9AC91AC917BCCEBF7C94" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_D6D64BC92AEC9AC91AC917BCCEBF7C94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_D6D64BC92AEC9AC91AC917BCCEBF7C94" xlink:to="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_D6D64BC92AEC9AC91AC917BCCEBF7C94" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_0F59EAA00F914BBE08D217BCCEC035F6_terseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_0F59EAA00F914BBE08D217BCCEC035F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_0F59EAA00F914BBE08D217BCCEC035F6_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_0F59EAA00F914BBE08D217BCCEC035F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Contingent Purchase Price Consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_0F59EAA00F914BBE08D217BCCEC035F6_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_0F59EAA00F914BBE08D217BCCEC035F6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in the fair value of contingent purchase price consideration.</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_0F59EAA00F914BBE08D217BCCEC035F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_0F59EAA00F914BBE08D217BCCEC035F6" xlink:to="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_0F59EAA00F914BBE08D217BCCEC035F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_5281B14C052ACED9DE8817BCCEC03DFE_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_5281B14C052ACED9DE8817BCCEC03DFE" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_5281B14C052ACED9DE8817BCCEC03DFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_5281B14C052ACED9DE8817BCCEC03DFE" xlink:to="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_5281B14C052ACED9DE8817BCCEC03DFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_A2F50D785D9C34B7074217BCCEC06596_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_A2F50D785D9C34B7074217BCCEC06596" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration payable, maximum amount</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_A2F50D785D9C34B7074217BCCEC06596_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_A2F50D785D9C34B7074217BCCEC06596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_A2F50D785D9C34B7074217BCCEC06596" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_A2F50D785D9C34B7074217BCCEC06596" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_A2F50D785D9C34B7074217BCCEC06596" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_2DABCEE768D1764333B612CD0FB5E815_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_2DABCEE768D1764333B612CD0FB5E815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_2DABCEE768D1764333B612CD0FB5E815" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_2DABCEE768D1764333B612CD0FB5E815" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_2DABCEE768D1764333B612CD0FB5E815" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_DF5B5240ABB3F4D8DED312CD0FB5EFD8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_DF5B5240ABB3F4D8DED312CD0FB5EFD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_DF5B5240ABB3F4D8DED312CD0FB5EFD8_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_DF5B5240ABB3F4D8DED312CD0FB5EFD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_DF5B5240ABB3F4D8DED312CD0FB5EFD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_DF5B5240ABB3F4D8DED312CD0FB5EFD8" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_DF5B5240ABB3F4D8DED312CD0FB5EFD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_A81F5AD5DA2539C3455612CD0FB6A375_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_A81F5AD5DA2539C3455612CD0FB6A375" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_A81F5AD5DA2539C3455612CD0FB6A375_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_A81F5AD5DA2539C3455612CD0FB6A375" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_A81F5AD5DA2539C3455612CD0FB6A375" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_A81F5AD5DA2539C3455612CD0FB6A375" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_A81F5AD5DA2539C3455612CD0FB6A375" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_2D9D28AC7F4FC3ACBB4D12CD0FB6B003_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_2D9D28AC7F4FC3ACBB4D12CD0FB6B003" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_2D9D28AC7F4FC3ACBB4D12CD0FB6B003_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_2D9D28AC7F4FC3ACBB4D12CD0FB6B003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2D9D28AC7F4FC3ACBB4D12CD0FB6B003" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2D9D28AC7F4FC3ACBB4D12CD0FB6B003" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_2D9D28AC7F4FC3ACBB4D12CD0FB6B003" xlink:type="arc" />
    <link:label id="lab_gale_SeriesAConvertiblePreferredWarrantsMember_1871C5C1823AB4AB76DB12CD0FB62E6D_terseLabel_en-US" xlink:label="lab_gale_SeriesAConvertiblePreferredWarrantsMember_1871C5C1823AB4AB76DB12CD0FB62E6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred</link:label>
    <link:label id="lab_gale_SeriesAConvertiblePreferredWarrantsMember_1871C5C1823AB4AB76DB12CD0FB62E6D_label_en-US" xlink:label="lab_gale_SeriesAConvertiblePreferredWarrantsMember_1871C5C1823AB4AB76DB12CD0FB62E6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Warrants [Member]</link:label>
    <link:label id="lab_gale_SeriesAConvertiblePreferredWarrantsMember_1871C5C1823AB4AB76DB12CD0FB62E6D_documentation_en-US" xlink:label="lab_gale_SeriesAConvertiblePreferredWarrantsMember_1871C5C1823AB4AB76DB12CD0FB62E6D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Warrants [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_SeriesAConvertiblePreferredWarrantsMember" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_1871C5C1823AB4AB76DB12CD0FB62E6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SeriesAConvertiblePreferredWarrantsMember_1871C5C1823AB4AB76DB12CD0FB62E6D" xlink:to="lab_gale_SeriesAConvertiblePreferredWarrantsMember_1871C5C1823AB4AB76DB12CD0FB62E6D" xlink:type="arc" />
    <link:label id="lab_gale_February2017WarrantsMember_1F096F7F247A09093DC812CD0FB6C599_terseLabel_en-US" xlink:label="lab_gale_February2017WarrantsMember_1F096F7F247A09093DC812CD0FB6C599" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Galena February 2017</link:label>
    <link:label id="lab_gale_February2017WarrantsMember_1F096F7F247A09093DC812CD0FB6C599_label_en-US" xlink:label="lab_gale_February2017WarrantsMember_1F096F7F247A09093DC812CD0FB6C599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">February 2017 Warrants [Member]</link:label>
    <link:label id="lab_gale_February2017WarrantsMember_1F096F7F247A09093DC812CD0FB6C599_documentation_en-US" xlink:label="lab_gale_February2017WarrantsMember_1F096F7F247A09093DC812CD0FB6C599" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">February 2017 Warrants [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_February2017WarrantsMember" xlink:label="loc_gale_February2017WarrantsMember_1F096F7F247A09093DC812CD0FB6C599" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_February2017WarrantsMember_1F096F7F247A09093DC812CD0FB6C599" xlink:to="lab_gale_February2017WarrantsMember_1F096F7F247A09093DC812CD0FB6C599" xlink:type="arc" />
    <link:label id="lab_gale_OtherWarrantIssuesMember_2522FBC5789751633C0312CD0FB77970_terseLabel_en-US" xlink:label="lab_gale_OtherWarrantIssuesMember_2522FBC5789751633C0312CD0FB77970" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Galena Other</link:label>
    <link:label id="lab_gale_OtherWarrantIssuesMember_2522FBC5789751633C0312CD0FB77970_label_en-US" xlink:label="lab_gale_OtherWarrantIssuesMember_2522FBC5789751633C0312CD0FB77970" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Warrant Issues [Member]</link:label>
    <link:label id="lab_gale_OtherWarrantIssuesMember_2522FBC5789751633C0312CD0FB77970_documentation_en-US" xlink:label="lab_gale_OtherWarrantIssuesMember_2522FBC5789751633C0312CD0FB77970" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Warrant Issues [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_OtherWarrantIssuesMember" xlink:label="loc_gale_OtherWarrantIssuesMember_2522FBC5789751633C0312CD0FB77970" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OtherWarrantIssuesMember_2522FBC5789751633C0312CD0FB77970" xlink:to="lab_gale_OtherWarrantIssuesMember_2522FBC5789751633C0312CD0FB77970" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_920B11B4E884585A210712CD0FB74628_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_920B11B4E884585A210712CD0FB74628" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_920B11B4E884585A210712CD0FB74628_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_920B11B4E884585A210712CD0FB74628" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_920B11B4E884585A210712CD0FB74628" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_920B11B4E884585A210712CD0FB74628" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_920B11B4E884585A210712CD0FB74628" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightFairValueRollForward" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:to="lab_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_FD3D59622B99A08F6DA412CD0FB75F3A_periodStartLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_FD3D59622B99A08F6DA412CD0FB75F3A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Warrant liability, Beginning balance</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_FD3D59622B99A08F6DA412CD0FB75F3A_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_FD3D59622B99A08F6DA412CD0FB75F3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Liabilities</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_FD3D59622B99A08F6DA412CD0FB75F3A_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_FD3D59622B99A08F6DA412CD0FB75F3A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of warrant liabilities as of the balance sheet date.</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_FD3D59622B99A08F6DA412CD0FB75F3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsLiabilities_FD3D59622B99A08F6DA412CD0FB75F3A" xlink:to="lab_gale_FairValueOfWarrantsLiabilities_FD3D59622B99A08F6DA412CD0FB75F3A" xlink:type="arc" />
    <link:label id="lab_gale_FairValueofWarrantsGranted_768565698ACF3949FD4912CD0FB848A9_terseLabel_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted_768565698ACF3949FD4912CD0FB848A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants granted</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGranted_768565698ACF3949FD4912CD0FB848A9_label_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted_768565698ACF3949FD4912CD0FB848A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGranted_768565698ACF3949FD4912CD0FB848A9_documentation_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted_768565698ACF3949FD4912CD0FB848A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueofWarrantsGranted" xlink:label="loc_gale_FairValueofWarrantsGranted_768565698ACF3949FD4912CD0FB848A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueofWarrantsGranted_768565698ACF3949FD4912CD0FB848A9" xlink:to="lab_gale_FairValueofWarrantsGranted_768565698ACF3949FD4912CD0FB848A9" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsCanceled_896BCFA8C3698C9C0D6C12CD0FB8B7CA_negatedTerseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsCanceled_896BCFA8C3698C9C0D6C12CD0FB8B7CA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants canceled</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsCanceled_896BCFA8C3698C9C0D6C12CD0FB8B7CA_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsCanceled_896BCFA8C3698C9C0D6C12CD0FB8B7CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Canceled</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsCanceled_896BCFA8C3698C9C0D6C12CD0FB8B7CA_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsCanceled_896BCFA8C3698C9C0D6C12CD0FB8B7CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Canceled</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantsCanceled" xlink:label="loc_gale_FairValueOfWarrantsCanceled_896BCFA8C3698C9C0D6C12CD0FB8B7CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsCanceled_896BCFA8C3698C9C0D6C12CD0FB8B7CA" xlink:to="lab_gale_FairValueOfWarrantsCanceled_896BCFA8C3698C9C0D6C12CD0FB8B7CA" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsExercisePriceAdjustment_3869F1D21A4B689AF0B412CD0FB81B01_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsExercisePriceAdjustment_3869F1D21A4B689AF0B412CD0FB81B01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to exercise price of warrants</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsExercisePriceAdjustment_3869F1D21A4B689AF0B412CD0FB81B01_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsExercisePriceAdjustment_3869F1D21A4B689AF0B412CD0FB81B01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants, Exercise Price, Adjustment</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsExercisePriceAdjustment_3869F1D21A4B689AF0B412CD0FB81B01_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsExercisePriceAdjustment_3869F1D21A4B689AF0B412CD0FB81B01" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants, Exercise Price, Adjustment</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantsExercisePriceAdjustment" xlink:label="loc_gale_FairValueOfWarrantsExercisePriceAdjustment_3869F1D21A4B689AF0B412CD0FB81B01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsExercisePriceAdjustment_3869F1D21A4B689AF0B412CD0FB81B01" xlink:to="lab_gale_FairValueOfWarrantsExercisePriceAdjustment_3869F1D21A4B689AF0B412CD0FB81B01" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_E11F6B299C69D160723712CD0FB80D22_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities_E11F6B299C69D160723712CD0FB80D22" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrants</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_E11F6B299C69D160723712CD0FB80D22_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities_E11F6B299C69D160723712CD0FB80D22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Warrant Liabilities</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_E11F6B299C69D160723712CD0FB80D22_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities_E11F6B299C69D160723712CD0FB80D22" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Warrant Liabilities</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities_E11F6B299C69D160723712CD0FB80D22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfWarrantLiabilities_E11F6B299C69D160723712CD0FB80D22" xlink:to="lab_gale_ChangeInFairValueOfWarrantLiabilities_E11F6B299C69D160723712CD0FB80D22" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_7A56C8ACB70D7AEAA9F412CD0FB8E0F9_periodEndLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_7A56C8ACB70D7AEAA9F412CD0FB8E0F9" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Warrant liability, Ending balance</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_7A56C8ACB70D7AEAA9F412CD0FB8E0F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsLiabilities_7A56C8ACB70D7AEAA9F412CD0FB8E0F9" xlink:to="lab_gale_FairValueOfWarrantsLiabilities_7A56C8ACB70D7AEAA9F412CD0FB8E0F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CA6E5EA7EADC3BAC624617BCCF9F1927_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CA6E5EA7EADC3BAC624617BCCF9F1927" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CA6E5EA7EADC3BAC624617BCCF9F1927_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CA6E5EA7EADC3BAC624617BCCF9F1927" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CA6E5EA7EADC3BAC624617BCCF9F1927" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CA6E5EA7EADC3BAC624617BCCF9F1927" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CA6E5EA7EADC3BAC624617BCCF9F1927" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27C9D8BC25E1274995C617BCCFA098A6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27C9D8BC25E1274995C617BCCFA098A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27C9D8BC25E1274995C617BCCFA098A6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27C9D8BC25E1274995C617BCCFA098A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27C9D8BC25E1274995C617BCCFA098A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27C9D8BC25E1274995C617BCCFA098A6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27C9D8BC25E1274995C617BCCFA098A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_F51371E52014EF02528517BCCFA0C5E8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_F51371E52014EF02528517BCCFA0C5E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected lives (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_F51371E52014EF02528517BCCFA0C5E8_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_F51371E52014EF02528517BCCFA0C5E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_F51371E52014EF02528517BCCFA0C5E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_F51371E52014EF02528517BCCFA0C5E8" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_F51371E52014EF02528517BCCFA0C5E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_FA3817CB8F63B0CD443317BCD03F90FE_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_FA3817CB8F63B0CD443317BCD03F90FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_FA3817CB8F63B0CD443317BCD03F90FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_FA3817CB8F63B0CD443317BCD03F90FE" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_FA3817CB8F63B0CD443317BCD03F90FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0DE49F35E6C5ED29FD0717BCD03FB39C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0DE49F35E6C5ED29FD0717BCD03FB39C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0DE49F35E6C5ED29FD0717BCD03FB39C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0DE49F35E6C5ED29FD0717BCD03FB39C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0DE49F35E6C5ED29FD0717BCD03FB39C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0DE49F35E6C5ED29FD0717BCD03FB39C" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0DE49F35E6C5ED29FD0717BCD03FB39C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4C6F67C34422129E980C17BCCDFAA6A6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4C6F67C34422129E980C17BCCDFAA6A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4C6F67C34422129E980C17BCCDFAA6A6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4C6F67C34422129E980C17BCCDFAA6A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4C6F67C34422129E980C17BCCDFAA6A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4C6F67C34422129E980C17BCCDFAA6A6" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4C6F67C34422129E980C17BCCDFAA6A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_831C23A99BAFB0082B7117BCCDFA303A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_831C23A99BAFB0082B7117BCCDFA303A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_831C23A99BAFB0082B7117BCCDFA303A_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_831C23A99BAFB0082B7117BCCDFA303A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_831C23A99BAFB0082B7117BCCDFA303A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_831C23A99BAFB0082B7117BCCDFA303A" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_831C23A99BAFB0082B7117BCCDFA303A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_947E3918EC854EAF310317BCCDFADBB0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_947E3918EC854EAF310317BCCDFADBB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_947E3918EC854EAF310317BCCDFADBB0_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_947E3918EC854EAF310317BCCDFADBB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_947E3918EC854EAF310317BCCDFADBB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_947E3918EC854EAF310317BCCDFADBB0" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_947E3918EC854EAF310317BCCDFADBB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7809AE87CBFA6151853F17BCCDFB2A4B_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7809AE87CBFA6151853F17BCCDFB2A4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7809AE87CBFA6151853F17BCCDFB2A4B_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7809AE87CBFA6151853F17BCCDFB2A4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7809AE87CBFA6151853F17BCCDFB2A4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7809AE87CBFA6151853F17BCCDFB2A4B" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7809AE87CBFA6151853F17BCCDFB2A4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_17A4AC66D22469B37F0217BCCDFB8EAD_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_17A4AC66D22469B37F0217BCCDFB8EAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_17A4AC66D22469B37F0217BCCDFB8EAD_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_17A4AC66D22469B37F0217BCCDFB8EAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_17A4AC66D22469B37F0217BCCDFB8EAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_17A4AC66D22469B37F0217BCCDFB8EAD" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_17A4AC66D22469B37F0217BCCDFB8EAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3616409147FDEF8D74D817BCCDFCC99E_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3616409147FDEF8D74D817BCCDFCC99E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3616409147FDEF8D74D817BCCDFCC99E_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3616409147FDEF8D74D817BCCDFCC99E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3616409147FDEF8D74D817BCCDFCC99E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3616409147FDEF8D74D817BCCDFCC99E" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3616409147FDEF8D74D817BCCDFCC99E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_E264E9F0CECC5162E40517BCCDFC1AFA_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_E264E9F0CECC5162E40517BCCDFC1AFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated share based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_E264E9F0CECC5162E40517BCCDFC1AFA_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_E264E9F0CECC5162E40517BCCDFC1AFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_E264E9F0CECC5162E40517BCCDFC1AFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_E264E9F0CECC5162E40517BCCDFC1AFA" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_E264E9F0CECC5162E40517BCCDFC1AFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8A03C120D7E6F33791900E343F6E594C_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8A03C120D7E6F33791900E343F6E594C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8A03C120D7E6F33791900E343F6E594C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8A03C120D7E6F33791900E343F6E594C" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8A03C120D7E6F33791900E343F6E594C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D2027C745FC3797405AA0E343F74DD08_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D2027C745FC3797405AA0E343F74DD08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Proceedings, Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D2027C745FC3797405AA0E343F74DD08_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D2027C745FC3797405AA0E343F74DD08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D2027C745FC3797405AA0E343F74DD08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D2027C745FC3797405AA0E343F74DD08" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D2027C745FC3797405AA0E343F74DD08" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5A3B4198FEC5465A698A1361E7BA29D9_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_5A3B4198FEC5465A698A1361E7BA29D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_5A3B4198FEC5465A698A1361E7BA29D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_5A3B4198FEC5465A698A1361E7BA29D9" xlink:to="lab_us-gaap_IncomeStatementAbstract_5A3B4198FEC5465A698A1361E7BA29D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_66AD51D3FD0696B491731361E7BA931F_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_66AD51D3FD0696B491731361E7BA931F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_66AD51D3FD0696B491731361E7BA931F_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_66AD51D3FD0696B491731361E7BA931F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_66AD51D3FD0696B491731361E7BA931F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66AD51D3FD0696B491731361E7BA931F" xlink:to="lab_us-gaap_OperatingExpensesAbstract_66AD51D3FD0696B491731361E7BA931F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_956B8C8AE891FD1389281361E7BAE895_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_956B8C8AE891FD1389281361E7BAE895" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_956B8C8AE891FD1389281361E7BAE895_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_956B8C8AE891FD1389281361E7BAE895" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_956B8C8AE891FD1389281361E7BAE895" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_956B8C8AE891FD1389281361E7BAE895" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_956B8C8AE891FD1389281361E7BAE895" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_E3DFE4E1A16198F3984A1361E7BA39AC_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_E3DFE4E1A16198F3984A1361E7BA39AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_E3DFE4E1A16198F3984A1361E7BA39AC_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_E3DFE4E1A16198F3984A1361E7BA39AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_E3DFE4E1A16198F3984A1361E7BA39AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_E3DFE4E1A16198F3984A1361E7BA39AC" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_E3DFE4E1A16198F3984A1361E7BA39AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_9D135D91701F7685F0A21361E7BAF0DB_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_9D135D91701F7685F0A21361E7BAF0DB" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses and operating loss</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_9D135D91701F7685F0A21361E7BAF0DB_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_9D135D91701F7685F0A21361E7BAF0DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_9D135D91701F7685F0A21361E7BAF0DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_9D135D91701F7685F0A21361E7BAF0DB" xlink:to="lab_us-gaap_CostsAndExpenses_9D135D91701F7685F0A21361E7BAF0DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_3E25FB9FB6E8A8D72CA41361E7BB1B91_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_3E25FB9FB6E8A8D72CA41361E7BB1B91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-operating income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_3E25FB9FB6E8A8D72CA41361E7BB1B91_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_3E25FB9FB6E8A8D72CA41361E7BB1B91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3E25FB9FB6E8A8D72CA41361E7BB1B91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3E25FB9FB6E8A8D72CA41361E7BB1B91" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_3E25FB9FB6E8A8D72CA41361E7BB1B91" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_2AF726A0544D51B3C5691361E7BB529C_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_2AF726A0544D51B3C5691361E7BB529C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_2AF726A0544D51B3C5691361E7BB529C_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_2AF726A0544D51B3C5691361E7BB529C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_2AF726A0544D51B3C5691361E7BB529C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_2AF726A0544D51B3C5691361E7BB529C" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_2AF726A0544D51B3C5691361E7BB529C" xlink:type="arc" />
    <link:label id="lab_gale_LossOnSettlementOfWarrantsLiability_13C7B1019826D89A83701361E7BC433A_negatedTerseLabel_en-US" xlink:label="lab_gale_LossOnSettlementOfWarrantsLiability_13C7B1019826D89A83701361E7BC433A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on settlement of liability-classified warrants</link:label>
    <link:label id="lab_gale_LossOnSettlementOfWarrantsLiability_13C7B1019826D89A83701361E7BC433A_label_en-US" xlink:label="lab_gale_LossOnSettlementOfWarrantsLiability_13C7B1019826D89A83701361E7BC433A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss On Settlement Of Warrants Liability</link:label>
    <link:label id="lab_gale_LossOnSettlementOfWarrantsLiability_13C7B1019826D89A83701361E7BC433A_documentation_en-US" xlink:label="lab_gale_LossOnSettlementOfWarrantsLiability_13C7B1019826D89A83701361E7BC433A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss On Settlement Of Warrants Liability</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_LossOnSettlementOfWarrantsLiability" xlink:label="loc_gale_LossOnSettlementOfWarrantsLiability_13C7B1019826D89A83701361E7BC433A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LossOnSettlementOfWarrantsLiability_13C7B1019826D89A83701361E7BC433A" xlink:to="lab_gale_LossOnSettlementOfWarrantsLiability_13C7B1019826D89A83701361E7BC433A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_B4DBDB15315C239AC5B71361E7BC4AAF_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_B4DBDB15315C239AC5B71361E7BC4AAF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_B4DBDB15315C239AC5B71361E7BC4AAF_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_B4DBDB15315C239AC5B71361E7BC4AAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_B4DBDB15315C239AC5B71361E7BC4AAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_B4DBDB15315C239AC5B71361E7BC4AAF" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_B4DBDB15315C239AC5B71361E7BC4AAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_7FDAE6D8FD47A08184FE1361E7BCEEA2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet_7FDAE6D8FD47A08184FE1361E7BCEEA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_7FDAE6D8FD47A08184FE1361E7BCEEA2_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet_7FDAE6D8FD47A08184FE1361E7BCEEA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_7FDAE6D8FD47A08184FE1361E7BCEEA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet_7FDAE6D8FD47A08184FE1361E7BCEEA2" xlink:to="lab_us-gaap_InterestIncomeExpenseNet_7FDAE6D8FD47A08184FE1361E7BCEEA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_06791843B0AB1CBEF9001361E7BCAF4C_totalLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet_06791843B0AB1CBEF9001361E7BCAF4C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-operating income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_06791843B0AB1CBEF9001361E7BCAF4C_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet_06791843B0AB1CBEF9001361E7BCAF4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_06791843B0AB1CBEF9001361E7BCAF4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_06791843B0AB1CBEF9001361E7BCAF4C" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet_06791843B0AB1CBEF9001361E7BCAF4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_0C0BBBE1A9C7B54230B61361E7BCE19E_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_0C0BBBE1A9C7B54230B61361E7BCE19E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_0C0BBBE1A9C7B54230B61361E7BCE19E_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_0C0BBBE1A9C7B54230B61361E7BCE19E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0C0BBBE1A9C7B54230B61361E7BCE19E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0C0BBBE1A9C7B54230B61361E7BCE19E" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_0C0BBBE1A9C7B54230B61361E7BCE19E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_39496BD7FEBFB0F342961361E7BCACD0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_39496BD7FEBFB0F342961361E7BCACD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_39496BD7FEBFB0F342961361E7BCACD0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_39496BD7FEBFB0F342961361E7BCACD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_39496BD7FEBFB0F342961361E7BCACD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_39496BD7FEBFB0F342961361E7BCACD0" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_39496BD7FEBFB0F342961361E7BCACD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_F83D0828C329E4A810271361E7BD3DD4_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_F83D0828C329E4A810271361E7BD3DD4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_F83D0828C329E4A810271361E7BD3DD4_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_F83D0828C329E4A810271361E7BD3DD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F83D0828C329E4A810271361E7BD3DD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_F83D0828C329E4A810271361E7BD3DD4" xlink:to="lab_us-gaap_NetIncomeLoss_F83D0828C329E4A810271361E7BD3DD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_635F48ACE4C2DF7332F61361E7BD93AC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_635F48ACE4C2DF7332F61361E7BD93AC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend arising from beneficial conversion feature of convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_635F48ACE4C2DF7332F61361E7BD93AC_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_635F48ACE4C2DF7332F61361E7BD93AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_635F48ACE4C2DF7332F61361E7BD93AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_635F48ACE4C2DF7332F61361E7BD93AC" xlink:to="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_635F48ACE4C2DF7332F61361E7BD93AC" xlink:type="arc" />
    <link:label id="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_D3D645130E5CCF497ED81361E7BD17D9_negatedLabel_en-US" xlink:label="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_D3D645130E5CCF497ED81361E7BD17D9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision</link:label>
    <link:label id="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_D3D645130E5CCF497ED81361E7BD17D9_label_en-US" xlink:label="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_D3D645130E5CCF497ED81361E7BD17D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend On Conversion Of Series A Convertible Preferred Stock, Most Favored Nation</link:label>
    <link:label id="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_D3D645130E5CCF497ED81361E7BD17D9_documentation_en-US" xlink:label="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_D3D645130E5CCF497ED81361E7BD17D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dividend On Conversion Of Series A Convertible Preferred Stock, Most Favored Nation</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_D3D645130E5CCF497ED81361E7BD17D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_D3D645130E5CCF497ED81361E7BD17D9" xlink:to="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_D3D645130E5CCF497ED81361E7BD17D9" xlink:type="arc" />
    <link:label id="lab_gale_LiabilityClassifiedWarrantsAntidilutionProtection_3124004756B33B42D35B139D4E634D0E_negatedTerseLabel_en-US" xlink:label="lab_gale_LiabilityClassifiedWarrantsAntidilutionProtection_3124004756B33B42D35B139D4E634D0E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of anti-dilution protection on liability-classified warrants</link:label>
    <link:label id="lab_gale_LiabilityClassifiedWarrantsAntidilutionProtection_3124004756B33B42D35B139D4E634D0E_label_en-US" xlink:label="lab_gale_LiabilityClassifiedWarrantsAntidilutionProtection_3124004756B33B42D35B139D4E634D0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Classified Warrants, Anti-dilution Protection</link:label>
    <link:label id="lab_gale_LiabilityClassifiedWarrantsAntidilutionProtection_3124004756B33B42D35B139D4E634D0E_documentation_en-US" xlink:label="lab_gale_LiabilityClassifiedWarrantsAntidilutionProtection_3124004756B33B42D35B139D4E634D0E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Classified Warrants, Anti-dilution Protection</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_LiabilityClassifiedWarrantsAntidilutionProtection" xlink:label="loc_gale_LiabilityClassifiedWarrantsAntidilutionProtection_3124004756B33B42D35B139D4E634D0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LiabilityClassifiedWarrantsAntidilutionProtection_3124004756B33B42D35B139D4E634D0E" xlink:to="lab_gale_LiabilityClassifiedWarrantsAntidilutionProtection_3124004756B33B42D35B139D4E634D0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_69EAE66F799D548B26FA1361E7BD781D_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_69EAE66F799D548B26FA1361E7BD781D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_69EAE66F799D548B26FA1361E7BD781D_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_69EAE66F799D548B26FA1361E7BD781D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_69EAE66F799D548B26FA1361E7BD781D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_69EAE66F799D548B26FA1361E7BD781D" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_69EAE66F799D548B26FA1361E7BD781D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_44ABD1C037DC235267841361E7BDABC3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_44ABD1C037DC235267841361E7BDABC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Per share information:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_44ABD1C037DC235267841361E7BDABC3_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_44ABD1C037DC235267841361E7BDABC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_44ABD1C037DC235267841361E7BDABC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_44ABD1C037DC235267841361E7BDABC3" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_44ABD1C037DC235267841361E7BDABC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_B83274243FA47E467FD61361E7BEF0F6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_B83274243FA47E467FD61361E7BEF0F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_B83274243FA47E467FD61361E7BEF0F6_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_B83274243FA47E467FD61361E7BEF0F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_B83274243FA47E467FD61361E7BEF0F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_B83274243FA47E467FD61361E7BEF0F6" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_B83274243FA47E467FD61361E7BEF0F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FA23B078D16CE30856831361E7BE17DD_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FA23B078D16CE30856831361E7BE17DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FA23B078D16CE30856831361E7BE17DD_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FA23B078D16CE30856831361E7BE17DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FA23B078D16CE30856831361E7BE17DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FA23B078D16CE30856831361E7BE17DD" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FA23B078D16CE30856831361E7BE17DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B9FC3239C2881BEF2B30139A70FD4FB5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B9FC3239C2881BEF2B30139A70FD4FB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B9FC3239C2881BEF2B30139A70FD4FB5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B9FC3239C2881BEF2B30139A70FD4FB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B9FC3239C2881BEF2B30139A70FD4FB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B9FC3239C2881BEF2B30139A70FD4FB5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B9FC3239C2881BEF2B30139A70FD4FB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_035576739E68754AA3A7139A70FD8819_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_035576739E68754AA3A7139A70FD8819" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_035576739E68754AA3A7139A70FD8819_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_035576739E68754AA3A7139A70FD8819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_035576739E68754AA3A7139A70FD8819" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_035576739E68754AA3A7139A70FD8819" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_035576739E68754AA3A7139A70FD8819" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EC494A1BBBD9855EAB6A139A70FE8B68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EC494A1BBBD9855EAB6A139A70FE8B68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EC494A1BBBD9855EAB6A139A70FE8B68_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EC494A1BBBD9855EAB6A139A70FE8B68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EC494A1BBBD9855EAB6A139A70FE8B68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EC494A1BBBD9855EAB6A139A70FE8B68" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EC494A1BBBD9855EAB6A139A70FE8B68" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6BE006A42667F1A93762139A70FE4679_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6BE006A42667F1A93762139A70FE4679" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6BE006A42667F1A93762139A70FE4679_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6BE006A42667F1A93762139A70FE4679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6BE006A42667F1A93762139A70FE4679" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6BE006A42667F1A93762139A70FE4679" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6BE006A42667F1A93762139A70FE4679" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_402BC17EAEE2531CDBFB139A70FE57F2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_402BC17EAEE2531CDBFB139A70FE57F2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_402BC17EAEE2531CDBFB139A70FE57F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_402BC17EAEE2531CDBFB139A70FE57F2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_402BC17EAEE2531CDBFB139A70FE57F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C00AA001930F45806487139A70FEADB4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C00AA001930F45806487139A70FEADB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C00AA001930F45806487139A70FEADB4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C00AA001930F45806487139A70FEADB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C00AA001930F45806487139A70FEADB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C00AA001930F45806487139A70FEADB4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C00AA001930F45806487139A70FEADB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B47738992A501980042E139A70FEB91A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B47738992A501980042E139A70FEB91A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B47738992A501980042E139A70FEB91A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B47738992A501980042E139A70FEB91A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B47738992A501980042E139A70FEB91A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B47738992A501980042E139A70FEB91A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B47738992A501980042E139A70FEB91A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_34DB50B13F848B01F7D0139A70FE34B2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_34DB50B13F848B01F7D0139A70FE34B2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_34DB50B13F848B01F7D0139A70FE34B2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_34DB50B13F848B01F7D0139A70FE34B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_34DB50B13F848B01F7D0139A70FE34B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_34DB50B13F848B01F7D0139A70FE34B2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_34DB50B13F848B01F7D0139A70FE34B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_97BE682636C4A0FB612B139A70FF85C9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_97BE682636C4A0FB612B139A70FF85C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_97BE682636C4A0FB612B139A70FF85C9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_97BE682636C4A0FB612B139A70FF85C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_97BE682636C4A0FB612B139A70FF85C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_97BE682636C4A0FB612B139A70FF85C9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_97BE682636C4A0FB612B139A70FF85C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F2D5A34E244B0C684BB5139A70FFB28A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F2D5A34E244B0C684BB5139A70FFB28A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, canceled (use per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F2D5A34E244B0C684BB5139A70FFB28A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F2D5A34E244B0C684BB5139A70FFB28A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F2D5A34E244B0C684BB5139A70FFB28A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F2D5A34E244B0C684BB5139A70FFB28A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F2D5A34E244B0C684BB5139A70FFB28A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4734AD49F668381BE03E139A70FF9875_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4734AD49F668381BE03E139A70FF9875" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, ending balance (usd per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4734AD49F668381BE03E139A70FF9875" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4734AD49F668381BE03E139A70FF9875" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4734AD49F668381BE03E139A70FF9875" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1C0F0F9FF03E21A3916F139A7100B829_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1C0F0F9FF03E21A3916F139A7100B829" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, exercisable (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1C0F0F9FF03E21A3916F139A7100B829_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1C0F0F9FF03E21A3916F139A7100B829" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1C0F0F9FF03E21A3916F139A7100B829" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1C0F0F9FF03E21A3916F139A7100B829" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1C0F0F9FF03E21A3916F139A7100B829" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6A26CE9F5D39B5EA7993139A7100776B_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6A26CE9F5D39B5EA7993139A7100776B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term, options exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6A26CE9F5D39B5EA7993139A7100776B_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6A26CE9F5D39B5EA7993139A7100776B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6A26CE9F5D39B5EA7993139A7100776B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6A26CE9F5D39B5EA7993139A7100776B" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6A26CE9F5D39B5EA7993139A7100776B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_052E6323B9DB68351CA0139A71005E3F_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_052E6323B9DB68351CA0139A71005E3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term, outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_052E6323B9DB68351CA0139A71005E3F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_052E6323B9DB68351CA0139A71005E3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_052E6323B9DB68351CA0139A71005E3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_052E6323B9DB68351CA0139A71005E3F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_052E6323B9DB68351CA0139A71005E3F" xlink:type="arc" />
    <link:label id="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_1BCDD9407EE20E2EA9F6139A71008344_terseLabel_en-US" xlink:label="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_1BCDD9407EE20E2EA9F6139A71008344" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Roll Forward]</link:label>
    <link:label id="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_1BCDD9407EE20E2EA9F6139A71008344_label_en-US" xlink:label="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_1BCDD9407EE20E2EA9F6139A71008344" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Roll Forward]</link:label>
    <link:label id="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_1BCDD9407EE20E2EA9F6139A71008344_documentation_en-US" xlink:label="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_1BCDD9407EE20E2EA9F6139A71008344" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" xlink:label="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_1BCDD9407EE20E2EA9F6139A71008344" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_1BCDD9407EE20E2EA9F6139A71008344" xlink:to="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_1BCDD9407EE20E2EA9F6139A71008344" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4EA94B16F5BC179DD3F6139A71004B8E_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4EA94B16F5BC179DD3F6139A71004B8E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, aggregate intrinsic value, beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4EA94B16F5BC179DD3F6139A71004B8E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4EA94B16F5BC179DD3F6139A71004B8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4EA94B16F5BC179DD3F6139A71004B8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4EA94B16F5BC179DD3F6139A71004B8E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4EA94B16F5BC179DD3F6139A71004B8E" xlink:type="arc" />
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_AC70F2636B3692D14336139A710010A9_terseLabel_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_AC70F2636B3692D14336139A710010A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, aggregate intrinsic value, granted</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_AC70F2636B3692D14336139A710010A9_label_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_AC70F2636B3692D14336139A710010A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_AC70F2636B3692D14336139A710010A9_documentation_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_AC70F2636B3692D14336139A710010A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_AC70F2636B3692D14336139A710010A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_AC70F2636B3692D14336139A710010A9" xlink:to="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_AC70F2636B3692D14336139A710010A9" xlink:type="arc" />
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_F3CDD4E73DE017C60767139A7101DB9D_terseLabel_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_F3CDD4E73DE017C60767139A7101DB9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, aggregate intrinsic value, canceled</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_F3CDD4E73DE017C60767139A7101DB9D_label_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_F3CDD4E73DE017C60767139A7101DB9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_F3CDD4E73DE017C60767139A7101DB9D_documentation_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_F3CDD4E73DE017C60767139A7101DB9D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_F3CDD4E73DE017C60767139A7101DB9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_F3CDD4E73DE017C60767139A7101DB9D" xlink:to="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_F3CDD4E73DE017C60767139A7101DB9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_AC997103E90EB4B1F6FE139A7101C0C3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_AC997103E90EB4B1F6FE139A7101C0C3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, aggregate intrinsic value, ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_AC997103E90EB4B1F6FE139A7101C0C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_AC997103E90EB4B1F6FE139A7101C0C3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_AC997103E90EB4B1F6FE139A7101C0C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_21CA1899CD48A288337C139A71015492_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_21CA1899CD48A288337C139A71015492" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_21CA1899CD48A288337C139A71015492_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_21CA1899CD48A288337C139A71015492" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_21CA1899CD48A288337C139A71015492" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_21CA1899CD48A288337C139A71015492" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_21CA1899CD48A288337C139A71015492" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_684B4034FE17E9D2B7E017BCD042B4E4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_684B4034FE17E9D2B7E017BCD042B4E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_684B4034FE17E9D2B7E017BCD042B4E4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_684B4034FE17E9D2B7E017BCD042B4E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_684B4034FE17E9D2B7E017BCD042B4E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_684B4034FE17E9D2B7E017BCD042B4E4" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_684B4034FE17E9D2B7E017BCD042B4E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_107D03EC4EB23E435BF517BCD0423805_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_107D03EC4EB23E435BF517BCD0423805" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Level 3 Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_107D03EC4EB23E435BF517BCD0423805_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_107D03EC4EB23E435BF517BCD0423805" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_107D03EC4EB23E435BF517BCD0423805" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_107D03EC4EB23E435BF517BCD0423805" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_107D03EC4EB23E435BF517BCD0423805" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTextBlock_C8A33BFDBBF9373EE1EF17BCCE87BD21_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTextBlock_C8A33BFDBBF9373EE1EF17BCCE87BD21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Activity Table</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTextBlock_C8A33BFDBBF9373EE1EF17BCCE87BD21_label_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTextBlock_C8A33BFDBBF9373EE1EF17BCCE87BD21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Activity [Table Text Block]</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTextBlock_C8A33BFDBBF9373EE1EF17BCCE87BD21_documentation_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTextBlock_C8A33BFDBBF9373EE1EF17BCCE87BD21" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Activity</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ScheduleOfWarrantActivityTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantActivityTableTextBlock_C8A33BFDBBF9373EE1EF17BCCE87BD21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfWarrantActivityTableTextBlock_C8A33BFDBBF9373EE1EF17BCCE87BD21" xlink:to="lab_gale_ScheduleOfWarrantActivityTableTextBlock_C8A33BFDBBF9373EE1EF17BCCE87BD21" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_2B59BD58419FE41A139E17BCCE875164_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_2B59BD58419FE41A139E17BCCE875164" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_2B59BD58419FE41A139E17BCCE875164_label_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_2B59BD58419FE41A139E17BCCE875164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_2B59BD58419FE41A139E17BCCE875164_documentation_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_2B59BD58419FE41A139E17BCCE875164" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Valuation Assumptions</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_2B59BD58419FE41A139E17BCCE875164" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_2B59BD58419FE41A139E17BCCE875164" xlink:to="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_2B59BD58419FE41A139E17BCCE875164" xlink:type="arc" />
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_F07FFF49C72905B3A94D17BCCE87BF07_terseLabel_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_F07FFF49C72905B3A94D17BCCE87BF07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Fair Value of Warrant Liability</link:label>
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_F07FFF49C72905B3A94D17BCCE87BF07_label_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_F07FFF49C72905B3A94D17BCCE87BF07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes In Fair Value Of Warrant Liability [Table Text Block]</link:label>
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_F07FFF49C72905B3A94D17BCCE87BF07_documentation_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_F07FFF49C72905B3A94D17BCCE87BF07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Changes In Fair Value Of Warrant Liability</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:label="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_F07FFF49C72905B3A94D17BCCE87BF07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_F07FFF49C72905B3A94D17BCCE87BF07" xlink:to="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_F07FFF49C72905B3A94D17BCCE87BF07" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_0D4C7FCF662EE841733417BCCDD03A24_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0D4C7FCF662EE841733417BCCDD03A24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0D4C7FCF662EE841733417BCCDD03A24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0D4C7FCF662EE841733417BCCDD03A24" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0D4C7FCF662EE841733417BCCDD03A24" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_AB63E18870137FBE5BED17BCCDD1D7EC_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_AB63E18870137FBE5BED17BCCDD1D7EC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_AB63E18870137FBE5BED17BCCDD1D7EC_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_AB63E18870137FBE5BED17BCCDD1D7EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_AB63E18870137FBE5BED17BCCDD1D7EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_AB63E18870137FBE5BED17BCCDD1D7EC" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_AB63E18870137FBE5BED17BCCDD1D7EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_593E0431D00AB2DFFFC917BCCF9648EE_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_593E0431D00AB2DFFFC917BCCF9648EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_593E0431D00AB2DFFFC917BCCF9648EE_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_593E0431D00AB2DFFFC917BCCF9648EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_593E0431D00AB2DFFFC917BCCF9648EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_593E0431D00AB2DFFFC917BCCF9648EE" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_593E0431D00AB2DFFFC917BCCF9648EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_295D4852F8BC7A99FE2F17BCD080B710_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_295D4852F8BC7A99FE2F17BCD080B710" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_295D4852F8BC7A99FE2F17BCD080B710_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_295D4852F8BC7A99FE2F17BCD080B710" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_295D4852F8BC7A99FE2F17BCD080B710" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_295D4852F8BC7A99FE2F17BCD080B710" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_295D4852F8BC7A99FE2F17BCD080B710" xlink:type="arc" />
    <link:label id="lab_gale_WarrantStrikePrice_DF39C75AAAB317787D9117BCD081459D_terseLabel_en-US" xlink:label="lab_gale_WarrantStrikePrice_DF39C75AAAB317787D9117BCD081459D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strike price (in usd per share)</link:label>
    <link:label id="lab_gale_WarrantStrikePrice_DF39C75AAAB317787D9117BCD081459D_label_en-US" xlink:label="lab_gale_WarrantStrikePrice_DF39C75AAAB317787D9117BCD081459D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Strike Price</link:label>
    <link:label id="lab_gale_WarrantStrikePrice_DF39C75AAAB317787D9117BCD081459D_documentation_en-US" xlink:label="lab_gale_WarrantStrikePrice_DF39C75AAAB317787D9117BCD081459D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Strike Price</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_WarrantStrikePrice" xlink:label="loc_gale_WarrantStrikePrice_DF39C75AAAB317787D9117BCD081459D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantStrikePrice_DF39C75AAAB317787D9117BCD081459D" xlink:to="lab_gale_WarrantStrikePrice_DF39C75AAAB317787D9117BCD081459D" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD6E503350CFFE80D44C17BCD0815EFF_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD6E503350CFFE80D44C17BCD0815EFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD6E503350CFFE80D44C17BCD0815EFF_label_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD6E503350CFFE80D44C17BCD0815EFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrant Liability Assumptions Expected Term</link:label>
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD6E503350CFFE80D44C17BCD0815EFF_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD6E503350CFFE80D44C17BCD0815EFF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrant Liability Assumptions Expected Term</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD6E503350CFFE80D44C17BCD0815EFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD6E503350CFFE80D44C17BCD0815EFF" xlink:to="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD6E503350CFFE80D44C17BCD0815EFF" xlink:type="arc" />
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_7279359D68F2719DDDCC17BCD0812ACA_terseLabel_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_7279359D68F2719DDDCC17BCD0812ACA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility %</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_7279359D68F2719DDDCC17BCD0812ACA_label_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_7279359D68F2719DDDCC17BCD0812ACA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Expected Volatility</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_7279359D68F2719DDDCC17BCD0812ACA_documentation_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_7279359D68F2719DDDCC17BCD0812ACA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Expected Volatility</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_7279359D68F2719DDDCC17BCD0812ACA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_7279359D68F2719DDDCC17BCD0812ACA" xlink:to="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_7279359D68F2719DDDCC17BCD0812ACA" xlink:type="arc" />
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_7A1E02B37CFE28C04B0417BCD08151F2_terseLabel_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_7A1E02B37CFE28C04B0417BCD08151F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free rate %</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_7A1E02B37CFE28C04B0417BCD08151F2_label_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_7A1E02B37CFE28C04B0417BCD08151F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_7A1E02B37CFE28C04B0417BCD08151F2_documentation_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_7A1E02B37CFE28C04B0417BCD08151F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_7A1E02B37CFE28C04B0417BCD08151F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_7A1E02B37CFE28C04B0417BCD08151F2" xlink:to="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_7A1E02B37CFE28C04B0417BCD08151F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_98CCB02F289B4A2E81451361E73D050C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_98CCB02F289B4A2E81451361E73D050C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_98CCB02F289B4A2E81451361E73D050C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_98CCB02F289B4A2E81451361E73D050C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_98CCB02F289B4A2E81451361E73D050C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_98CCB02F289B4A2E81451361E73D050C" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_98CCB02F289B4A2E81451361E73D050C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_37E20E26ED27B82B4AA71361E73D2ABC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_37E20E26ED27B82B4AA71361E73D2ABC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_37E20E26ED27B82B4AA71361E73D2ABC_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_37E20E26ED27B82B4AA71361E73D2ABC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_37E20E26ED27B82B4AA71361E73D2ABC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_37E20E26ED27B82B4AA71361E73D2ABC" xlink:to="lab_us-gaap_DebtInstrumentAxis_37E20E26ED27B82B4AA71361E73D2ABC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_52890DE1DAE16F2E55211361E73D5079_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_52890DE1DAE16F2E55211361E73D5079" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_52890DE1DAE16F2E55211361E73D5079_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_52890DE1DAE16F2E55211361E73D5079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_52890DE1DAE16F2E55211361E73D5079" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52890DE1DAE16F2E55211361E73D5079" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_52890DE1DAE16F2E55211361E73D5079" xlink:type="arc" />
    <link:label id="lab_gale_AmendmentAgreementMember_DB0BBD9CD2548FB0EB2C1361E73E66EA_terseLabel_en-US" xlink:label="lab_gale_AmendmentAgreementMember_DB0BBD9CD2548FB0EB2C1361E73E66EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Agreement</link:label>
    <link:label id="lab_gale_AmendmentAgreementMember_DB0BBD9CD2548FB0EB2C1361E73E66EA_label_en-US" xlink:label="lab_gale_AmendmentAgreementMember_DB0BBD9CD2548FB0EB2C1361E73E66EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Agreement [Member]</link:label>
    <link:label id="lab_gale_AmendmentAgreementMember_DB0BBD9CD2548FB0EB2C1361E73E66EA_documentation_en-US" xlink:label="lab_gale_AmendmentAgreementMember_DB0BBD9CD2548FB0EB2C1361E73E66EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amendment Agreement [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_AmendmentAgreementMember" xlink:label="loc_gale_AmendmentAgreementMember_DB0BBD9CD2548FB0EB2C1361E73E66EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AmendmentAgreementMember_DB0BBD9CD2548FB0EB2C1361E73E66EA" xlink:to="lab_gale_AmendmentAgreementMember_DB0BBD9CD2548FB0EB2C1361E73E66EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_BAB3F54747F17D382A081361E73E6B9D_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_BAB3F54747F17D382A081361E73E6B9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_BAB3F54747F17D382A081361E73E6B9D_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_BAB3F54747F17D382A081361E73E6B9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_BAB3F54747F17D382A081361E73E6B9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_BAB3F54747F17D382A081361E73E6B9D" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_BAB3F54747F17D382A081361E73E6B9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_355EABFC3A15A34A67141361E73E2463_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_355EABFC3A15A34A67141361E73E2463" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_355EABFC3A15A34A67141361E73E2463_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_355EABFC3A15A34A67141361E73E2463" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_355EABFC3A15A34A67141361E73E2463" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_355EABFC3A15A34A67141361E73E2463" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_355EABFC3A15A34A67141361E73E2463" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuredDebtMember_20009DB3B47C281DAC6A1361E73FCFE1_verboseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_20009DB3B47C281DAC6A1361E73FCFE1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_20009DB3B47C281DAC6A1361E73FCFE1_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_20009DB3B47C281DAC6A1361E73FCFE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_20009DB3B47C281DAC6A1361E73FCFE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember_20009DB3B47C281DAC6A1361E73FCFE1" xlink:to="lab_us-gaap_SecuredDebtMember_20009DB3B47C281DAC6A1361E73FCFE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_45CEE4A65D2C8F55CEA31361E73FB765_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_45CEE4A65D2C8F55CEA31361E73FB765" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_45CEE4A65D2C8F55CEA31361E73FB765_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_45CEE4A65D2C8F55CEA31361E73FB765" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_45CEE4A65D2C8F55CEA31361E73FB765" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_45CEE4A65D2C8F55CEA31361E73FB765" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_45CEE4A65D2C8F55CEA31361E73FB765" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DA9471803FC86D222BE21361E73F1C38_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DA9471803FC86D222BE21361E73F1C38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DA9471803FC86D222BE21361E73F1C38_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DA9471803FC86D222BE21361E73F1C38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DA9471803FC86D222BE21361E73F1C38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DA9471803FC86D222BE21361E73F1C38" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DA9471803FC86D222BE21361E73F1C38" xlink:type="arc" />
    <link:label id="lab_gale_CorporateCreditCardsMember_E0C6D1B4B268239025C71361E74041C9_terseLabel_en-US" xlink:label="lab_gale_CorporateCreditCardsMember_E0C6D1B4B268239025C71361E74041C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Credit Cards</link:label>
    <link:label id="lab_gale_CorporateCreditCardsMember_E0C6D1B4B268239025C71361E74041C9_label_en-US" xlink:label="lab_gale_CorporateCreditCardsMember_E0C6D1B4B268239025C71361E74041C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Credit Cards [Member]</link:label>
    <link:label id="lab_gale_CorporateCreditCardsMember_E0C6D1B4B268239025C71361E74041C9_documentation_en-US" xlink:label="lab_gale_CorporateCreditCardsMember_E0C6D1B4B268239025C71361E74041C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Credit Cards [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_CorporateCreditCardsMember" xlink:label="loc_gale_CorporateCreditCardsMember_E0C6D1B4B268239025C71361E74041C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CorporateCreditCardsMember_E0C6D1B4B268239025C71361E74041C9" xlink:to="lab_gale_CorporateCreditCardsMember_E0C6D1B4B268239025C71361E74041C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2EA991C5D4B807F97F711361E740C771_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2EA991C5D4B807F97F711361E740C771" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2EA991C5D4B807F97F711361E740C771_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2EA991C5D4B807F97F711361E740C771" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2EA991C5D4B807F97F711361E740C771" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2EA991C5D4B807F97F711361E740C771" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2EA991C5D4B807F97F711361E740C771" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4C0103688B2023AD1EE31361E740F72E_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4C0103688B2023AD1EE31361E740F72E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4C0103688B2023AD1EE31361E740F72E_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4C0103688B2023AD1EE31361E740F72E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4C0103688B2023AD1EE31361E740F72E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4C0103688B2023AD1EE31361E740F72E" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4C0103688B2023AD1EE31361E740F72E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF677FFAF123F3AE957B1361E740738E_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF677FFAF123F3AE957B1361E740738E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents, restricted cash, and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF677FFAF123F3AE957B1361E740738E_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF677FFAF123F3AE957B1361E740738E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF677FFAF123F3AE957B1361E740738E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF677FFAF123F3AE957B1361E740738E" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF677FFAF123F3AE957B1361E740738E" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentCovenantLiquidityCovenant_B163E7168FC9D6B0F2041361E7418D98_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentCovenantLiquidityCovenant_B163E7168FC9D6B0F2041361E7418D98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum prepayment of principle if demanded</link:label>
    <link:label id="lab_gale_DebtInstrumentCovenantLiquidityCovenant_B163E7168FC9D6B0F2041361E7418D98_label_en-US" xlink:label="lab_gale_DebtInstrumentCovenantLiquidityCovenant_B163E7168FC9D6B0F2041361E7418D98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Covenant</link:label>
    <link:label id="lab_gale_DebtInstrumentCovenantLiquidityCovenant_B163E7168FC9D6B0F2041361E7418D98_documentation_en-US" xlink:label="lab_gale_DebtInstrumentCovenantLiquidityCovenant_B163E7168FC9D6B0F2041361E7418D98" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Covenant</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_DebtInstrumentCovenantLiquidityCovenant" xlink:label="loc_gale_DebtInstrumentCovenantLiquidityCovenant_B163E7168FC9D6B0F2041361E7418D98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentCovenantLiquidityCovenant_B163E7168FC9D6B0F2041361E7418D98" xlink:to="lab_gale_DebtInstrumentCovenantLiquidityCovenant_B163E7168FC9D6B0F2041361E7418D98" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCash_D38695AD2C06356588FC1361E7417927_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash_D38695AD2C06356588FC1361E7417927" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_D38695AD2C06356588FC1361E7417927_label_en-US" xlink:label="lab_us-gaap_RestrictedCash_D38695AD2C06356588FC1361E7417927" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_D38695AD2C06356588FC1361E7417927" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash_D38695AD2C06356588FC1361E7417927" xlink:to="lab_us-gaap_RestrictedCash_D38695AD2C06356588FC1361E7417927" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_664C296D93CFD461957C17BCCF16E1E3_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_664C296D93CFD461957C17BCCF16E1E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_664C296D93CFD461957C17BCCF16E1E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_664C296D93CFD461957C17BCCF16E1E3" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_664C296D93CFD461957C17BCCF16E1E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiquidationBasisOfAccountingTextBlock_EE771713BE5DBC51033717BCCF17E28D_terseLabel_en-US" xlink:label="lab_us-gaap_LiquidationBasisOfAccountingTextBlock_EE771713BE5DBC51033717BCCF17E28D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_us-gaap_LiquidationBasisOfAccountingTextBlock_EE771713BE5DBC51033717BCCF17E28D_label_en-US" xlink:label="lab_us-gaap_LiquidationBasisOfAccountingTextBlock_EE771713BE5DBC51033717BCCF17E28D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidation Basis of Accounting [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:label="loc_us-gaap_LiquidationBasisOfAccountingTextBlock_EE771713BE5DBC51033717BCCF17E28D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiquidationBasisOfAccountingTextBlock_EE771713BE5DBC51033717BCCF17E28D" xlink:to="lab_us-gaap_LiquidationBasisOfAccountingTextBlock_EE771713BE5DBC51033717BCCF17E28D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_3140C18D09046AC964DE08F4613D55D3_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_3140C18D09046AC964DE08F4613D55D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3140C18D09046AC964DE08F4613D55D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3140C18D09046AC964DE08F4613D55D3" xlink:to="lab_us-gaap_DebtDisclosureAbstract_3140C18D09046AC964DE08F4613D55D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_F5BB01A8FC69954A066008F4613D9D9C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_F5BB01A8FC69954A066008F4613D9D9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_F5BB01A8FC69954A066008F4613D9D9C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_F5BB01A8FC69954A066008F4613D9D9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F5BB01A8FC69954A066008F4613D9D9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_F5BB01A8FC69954A066008F4613D9D9C" xlink:to="lab_us-gaap_DebtInstrumentTable_F5BB01A8FC69954A066008F4613D9D9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_548A605DADB227C4A7DA08F4613F148E_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_548A605DADB227C4A7DA08F4613F148E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_548A605DADB227C4A7DA08F4613F148E_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_548A605DADB227C4A7DA08F4613F148E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_548A605DADB227C4A7DA08F4613F148E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_548A605DADB227C4A7DA08F4613F148E" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis_548A605DADB227C4A7DA08F4613F148E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_E1920DFA0DEB6EB219DC08F4613F21CB_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_E1920DFA0DEB6EB219DC08F4613F21CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_E1920DFA0DEB6EB219DC08F4613F21CB_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_E1920DFA0DEB6EB219DC08F4613F21CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_E1920DFA0DEB6EB219DC08F4613F21CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_E1920DFA0DEB6EB219DC08F4613F21CB" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain_E1920DFA0DEB6EB219DC08F4613F21CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_5913C03B51D910D4D87F08F4613FA457_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_5913C03B51D910D4D87F08F4613FA457" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_5913C03B51D910D4D87F08F4613FA457_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_5913C03B51D910D4D87F08F4613FA457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_5913C03B51D910D4D87F08F4613FA457" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember_5913C03B51D910D4D87F08F4613FA457" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember_5913C03B51D910D4D87F08F4613FA457" xlink:type="arc" />
    <link:label id="lab_gale_ConvertiblePromissoryNotesMember_42BA5EB175501218BA5B08F461400539_verboseLabel_en-US" xlink:label="lab_gale_ConvertiblePromissoryNotesMember_42BA5EB175501218BA5B08F461400539" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible Promissory Notes</link:label>
    <link:label id="lab_gale_ConvertiblePromissoryNotesMember_42BA5EB175501218BA5B08F461400539_label_en-US" xlink:label="lab_gale_ConvertiblePromissoryNotesMember_42BA5EB175501218BA5B08F461400539" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Promissory Notes [Member]</link:label>
    <link:label id="lab_gale_ConvertiblePromissoryNotesMember_42BA5EB175501218BA5B08F461400539_documentation_en-US" xlink:label="lab_gale_ConvertiblePromissoryNotesMember_42BA5EB175501218BA5B08F461400539" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Promissory Notes [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ConvertiblePromissoryNotesMember" xlink:label="loc_gale_ConvertiblePromissoryNotesMember_42BA5EB175501218BA5B08F461400539" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ConvertiblePromissoryNotesMember_42BA5EB175501218BA5B08F461400539" xlink:to="lab_gale_ConvertiblePromissoryNotesMember_42BA5EB175501218BA5B08F461400539" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:to="lab_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_1E434134C8976BAF92C108F461466558_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_1E434134C8976BAF92C108F461466558" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_1E434134C8976BAF92C108F461466558_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_1E434134C8976BAF92C108F461466558" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1E434134C8976BAF92C108F461466558" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_1E434134C8976BAF92C108F461466558" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_1E434134C8976BAF92C108F461466558" xlink:type="arc" />
    <link:label id="lab_gale_CommonStockSharesAcquiredinExchangeforWarrants_5D38128C544736CF192A08F461476318_terseLabel_en-US" xlink:label="lab_gale_CommonStockSharesAcquiredinExchangeforWarrants_5D38128C544736CF192A08F461476318" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock acquired in exchange for warrants (in shares)</link:label>
    <link:label id="lab_gale_CommonStockSharesAcquiredinExchangeforWarrants_5D38128C544736CF192A08F461476318_label_en-US" xlink:label="lab_gale_CommonStockSharesAcquiredinExchangeforWarrants_5D38128C544736CF192A08F461476318" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Acquired in Exchange for Warrants</link:label>
    <link:label id="lab_gale_CommonStockSharesAcquiredinExchangeforWarrants_5D38128C544736CF192A08F461476318_documentation_en-US" xlink:label="lab_gale_CommonStockSharesAcquiredinExchangeforWarrants_5D38128C544736CF192A08F461476318" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Acquired in Exchange for Warrants</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_CommonStockSharesAcquiredinExchangeforWarrants" xlink:label="loc_gale_CommonStockSharesAcquiredinExchangeforWarrants_5D38128C544736CF192A08F461476318" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockSharesAcquiredinExchangeforWarrants_5D38128C544736CF192A08F461476318" xlink:to="lab_gale_CommonStockSharesAcquiredinExchangeforWarrants_5D38128C544736CF192A08F461476318" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_65E7AA64D39F51C7242708F46147CFB9_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_65E7AA64D39F51C7242708F46147CFB9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_65E7AA64D39F51C7242708F46147CFB9_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_65E7AA64D39F51C7242708F46147CFB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_65E7AA64D39F51C7242708F46147CFB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_65E7AA64D39F51C7242708F46147CFB9" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_65E7AA64D39F51C7242708F46147CFB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_48D9266F1BEAB5AC7CF708F461473D25_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_48D9266F1BEAB5AC7CF708F461473D25" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, conversion price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_48D9266F1BEAB5AC7CF708F461473D25_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_48D9266F1BEAB5AC7CF708F461473D25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_48D9266F1BEAB5AC7CF708F461473D25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_48D9266F1BEAB5AC7CF708F461473D25" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_48D9266F1BEAB5AC7CF708F461473D25" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_FBD1AFF2922D41DE49AC08F46147DAF3_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_FBD1AFF2922D41DE49AC08F46147DAF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and rights outstanding</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_FBD1AFF2922D41DE49AC08F46147DAF3_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_FBD1AFF2922D41DE49AC08F46147DAF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_FBD1AFF2922D41DE49AC08F46147DAF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_FBD1AFF2922D41DE49AC08F46147DAF3" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_FBD1AFF2922D41DE49AC08F46147DAF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_397369C059418B78509808F4614786BB_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_397369C059418B78509808F4614786BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_397369C059418B78509808F4614786BB_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_397369C059418B78509808F4614786BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_397369C059418B78509808F4614786BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_397369C059418B78509808F4614786BB" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_397369C059418B78509808F4614786BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuredDebtMember_892F785A24B63E60F2E017BCCEEA4C86_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_892F785A24B63E60F2E017BCCEEA4C86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_892F785A24B63E60F2E017BCCEEA4C86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember_892F785A24B63E60F2E017BCCEEA4C86" xlink:to="lab_us-gaap_SecuredDebtMember_892F785A24B63E60F2E017BCCEEA4C86" xlink:type="arc" />
    <link:label id="lab_gale_SecuritiesPurchaseAgreementMember_01B54BBBEA88743317F217BCCEEBD6A7_terseLabel_en-US" xlink:label="lab_gale_SecuritiesPurchaseAgreementMember_01B54BBBEA88743317F217BCCEEBD6A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement</link:label>
    <link:label id="lab_gale_SecuritiesPurchaseAgreementMember_01B54BBBEA88743317F217BCCEEBD6A7_label_en-US" xlink:label="lab_gale_SecuritiesPurchaseAgreementMember_01B54BBBEA88743317F217BCCEEBD6A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
    <link:label id="lab_gale_SecuritiesPurchaseAgreementMember_01B54BBBEA88743317F217BCCEEBD6A7_documentation_en-US" xlink:label="lab_gale_SecuritiesPurchaseAgreementMember_01B54BBBEA88743317F217BCCEEBD6A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_SecuritiesPurchaseAgreementMember" xlink:label="loc_gale_SecuritiesPurchaseAgreementMember_01B54BBBEA88743317F217BCCEEBD6A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SecuritiesPurchaseAgreementMember_01B54BBBEA88743317F217BCCEEBD6A7" xlink:to="lab_gale_SecuritiesPurchaseAgreementMember_01B54BBBEA88743317F217BCCEEBD6A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_0A7F0771432C2B13CD1517BCCEEC77EF_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_0A7F0771432C2B13CD1517BCCEEC77EF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of Senior Secured Debenture</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_0A7F0771432C2B13CD1517BCCEEC77EF_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_0A7F0771432C2B13CD1517BCCEEC77EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_0A7F0771432C2B13CD1517BCCEEC77EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_0A7F0771432C2B13CD1517BCCEEC77EF" xlink:to="lab_us-gaap_LongTermDebtCurrent_0A7F0771432C2B13CD1517BCCEEC77EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermBorrowings_8CF34BE9DD466479AA7B17BCCEEC06E4_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings_8CF34BE9DD466479AA7B17BCCEEC06E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term convertible promissory notes</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_8CF34BE9DD466479AA7B17BCCEEC06E4_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings_8CF34BE9DD466479AA7B17BCCEEC06E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_8CF34BE9DD466479AA7B17BCCEEC06E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings_8CF34BE9DD466479AA7B17BCCEEC06E4" xlink:to="lab_us-gaap_ShortTermBorrowings_8CF34BE9DD466479AA7B17BCCEEC06E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_29C6C9BBBFE3FD2626E817BCCEEC2DD5_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_29C6C9BBBFE3FD2626E817BCCEEC2DD5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion of Senior Secured Debenture</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_29C6C9BBBFE3FD2626E817BCCEEC2DD5_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_29C6C9BBBFE3FD2626E817BCCEEC2DD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_29C6C9BBBFE3FD2626E817BCCEEC2DD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_29C6C9BBBFE3FD2626E817BCCEEC2DD5" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_29C6C9BBBFE3FD2626E817BCCEEC2DD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_3DE998C0512614AB183217BCCEED3DB9_totalLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_3DE998C0512614AB183217BCCEED3DB9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_3DE998C0512614AB183217BCCEED3DB9_label_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_3DE998C0512614AB183217BCCEED3DB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Long-term and Short-term, Combined Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_3DE998C0512614AB183217BCCEED3DB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_3DE998C0512614AB183217BCCEED3DB9" xlink:to="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_3DE998C0512614AB183217BCCEED3DB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_2A38F6635FB116C5D29F17BCCDBB7339_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_2A38F6635FB116C5D29F17BCCDBB7339" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_2A38F6635FB116C5D29F17BCCDBB7339_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_2A38F6635FB116C5D29F17BCCDBB7339" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_2A38F6635FB116C5D29F17BCCDBB7339" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_2A38F6635FB116C5D29F17BCCDBB7339" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_2A38F6635FB116C5D29F17BCCDBB7339" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_AC9E51FE0E9F3F2D221717BCD0B73A05_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_AC9E51FE0E9F3F2D221717BCD0B73A05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_AC9E51FE0E9F3F2D221717BCD0B73A05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_AC9E51FE0E9F3F2D221717BCD0B73A05" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_AC9E51FE0E9F3F2D221717BCD0B73A05" xlink:type="arc" />
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_5FBB5B32ED5BB5DE17BF17BCD0B70464_terseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_5FBB5B32ED5BB5DE17BF17BCD0B70464" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_5FBB5B32ED5BB5DE17BF17BCD0B70464_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_5FBB5B32ED5BB5DE17BF17BCD0B70464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_5FBB5B32ED5BB5DE17BF17BCD0B70464" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_5FBB5B32ED5BB5DE17BF17BCD0B70464" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_5FBB5B32ED5BB5DE17BF17BCD0B70464" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E" xlink:to="lab_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_CE7862A629A30E4FBE171361E6BF72E2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_CE7862A629A30E4FBE171361E6BF72E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_CE7862A629A30E4FBE171361E6BF72E2_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_CE7862A629A30E4FBE171361E6BF72E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_CE7862A629A30E4FBE171361E6BF72E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_CE7862A629A30E4FBE171361E6BF72E2" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_CE7862A629A30E4FBE171361E6BF72E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_F797323218C9CDD0C2091361E6C0B78C_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_F797323218C9CDD0C2091361E6C0B78C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_F797323218C9CDD0C2091361E6C0B78C_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_F797323218C9CDD0C2091361E6C0B78C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_F797323218C9CDD0C2091361E6C0B78C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_F797323218C9CDD0C2091361E6C0B78C" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_F797323218C9CDD0C2091361E6C0B78C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_EE50E20024FF7F7916911361E6C0B5DC_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_EE50E20024FF7F7916911361E6C0B5DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_EE50E20024FF7F7916911361E6C0B5DC_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_EE50E20024FF7F7916911361E6C0B5DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_EE50E20024FF7F7916911361E6C0B5DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_EE50E20024FF7F7916911361E6C0B5DC" xlink:to="lab_us-gaap_SubsequentEventMember_EE50E20024FF7F7916911361E6C0B5DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationStatusAxis_58B32434B4B5AB6D1A511361E6C2CD55_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis_58B32434B4B5AB6D1A511361E6C2CD55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_58B32434B4B5AB6D1A511361E6C2CD55_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis_58B32434B4B5AB6D1A511361E6C2CD55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_58B32434B4B5AB6D1A511361E6C2CD55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis_58B32434B4B5AB6D1A511361E6C2CD55" xlink:to="lab_us-gaap_LitigationStatusAxis_58B32434B4B5AB6D1A511361E6C2CD55" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationStatusDomain_118383FFC8E1361F19A31361E6C217BD_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain_118383FFC8E1361F19A31361E6C217BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_118383FFC8E1361F19A31361E6C217BD_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain_118383FFC8E1361F19A31361E6C217BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_118383FFC8E1361F19A31361E6C217BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain_118383FFC8E1361F19A31361E6C217BD" xlink:to="lab_us-gaap_LitigationStatusDomain_118383FFC8E1361F19A31361E6C217BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PendingLitigationMember_FA7627A188111479DCEB1361E6C282A3_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember_FA7627A188111479DCEB1361E6C282A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_FA7627A188111479DCEB1361E6C282A3_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember_FA7627A188111479DCEB1361E6C282A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_FA7627A188111479DCEB1361E6C282A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember_FA7627A188111479DCEB1361E6C282A3" xlink:to="lab_us-gaap_PendingLitigationMember_FA7627A188111479DCEB1361E6C282A3" xlink:type="arc" />
    <link:label id="lab_srt_LitigationCaseAxis_8CD80ED4B3A86469BF901361E6C32270_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis_8CD80ED4B3A86469BF901361E6C32270" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_8CD80ED4B3A86469BF901361E6C32270_label_en-US" xlink:label="lab_srt_LitigationCaseAxis_8CD80ED4B3A86469BF901361E6C32270" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_8CD80ED4B3A86469BF901361E6C32270" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis_8CD80ED4B3A86469BF901361E6C32270" xlink:to="lab_srt_LitigationCaseAxis_8CD80ED4B3A86469BF901361E6C32270" xlink:type="arc" />
    <link:label id="lab_srt_LitigationCaseTypeDomain_F82440ECC338D98B5F7C1361E6C334AF_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain_F82440ECC338D98B5F7C1361E6C334AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_F82440ECC338D98B5F7C1361E6C334AF_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain_F82440ECC338D98B5F7C1361E6C334AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_F82440ECC338D98B5F7C1361E6C334AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain_F82440ECC338D98B5F7C1361E6C334AF" xlink:to="lab_srt_LitigationCaseTypeDomain_F82440ECC338D98B5F7C1361E6C334AF" xlink:type="arc" />
    <link:label id="lab_gale_PatelvsGalenabiopharmaIncMember_A0E3DABF4A1E3CD571691361E6C3B9CE_terseLabel_en-US" xlink:label="lab_gale_PatelvsGalenabiopharmaIncMember_A0E3DABF4A1E3CD571691361E6C3B9CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patel vs Galena biopharma, Inc</link:label>
    <link:label id="lab_gale_PatelvsGalenabiopharmaIncMember_A0E3DABF4A1E3CD571691361E6C3B9CE_label_en-US" xlink:label="lab_gale_PatelvsGalenabiopharmaIncMember_A0E3DABF4A1E3CD571691361E6C3B9CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patel vs Galena biopharma, Inc [Member]</link:label>
    <link:label id="lab_gale_PatelvsGalenabiopharmaIncMember_A0E3DABF4A1E3CD571691361E6C3B9CE_documentation_en-US" xlink:label="lab_gale_PatelvsGalenabiopharmaIncMember_A0E3DABF4A1E3CD571691361E6C3B9CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patel vs Galena biopharma, Inc [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_PatelvsGalenabiopharmaIncMember" xlink:label="loc_gale_PatelvsGalenabiopharmaIncMember_A0E3DABF4A1E3CD571691361E6C3B9CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PatelvsGalenabiopharmaIncMember_A0E3DABF4A1E3CD571691361E6C3B9CE" xlink:to="lab_gale_PatelvsGalenabiopharmaIncMember_A0E3DABF4A1E3CD571691361E6C3B9CE" xlink:type="arc" />
    <link:label id="lab_gale_JGBActionMember_34DAB73FB0FAABD49CF71361E6C473C1_terseLabel_en-US" xlink:label="lab_gale_JGBActionMember_34DAB73FB0FAABD49CF71361E6C473C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">JGB (Cayman) Newton Ltd</link:label>
    <link:label id="lab_gale_JGBActionMember_34DAB73FB0FAABD49CF71361E6C473C1_label_en-US" xlink:label="lab_gale_JGBActionMember_34DAB73FB0FAABD49CF71361E6C473C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JGB Action [Member]</link:label>
    <link:label id="lab_gale_JGBActionMember_34DAB73FB0FAABD49CF71361E6C473C1_documentation_en-US" xlink:label="lab_gale_JGBActionMember_34DAB73FB0FAABD49CF71361E6C473C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">JGB Action</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_JGBActionMember" xlink:label="loc_gale_JGBActionMember_34DAB73FB0FAABD49CF71361E6C473C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_JGBActionMember_34DAB73FB0FAABD49CF71361E6C473C1" xlink:to="lab_gale_JGBActionMember_34DAB73FB0FAABD49CF71361E6C473C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:to="lab_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalFees_068E9151B4C7FE2AF9AD1361E6C43586_terseLabel_en-US" xlink:label="lab_us-gaap_LegalFees_068E9151B4C7FE2AF9AD1361E6C43586" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal fees</link:label>
    <link:label id="lab_us-gaap_LegalFees_068E9151B4C7FE2AF9AD1361E6C43586_label_en-US" xlink:label="lab_us-gaap_LegalFees_068E9151B4C7FE2AF9AD1361E6C43586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_068E9151B4C7FE2AF9AD1361E6C43586" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees_068E9151B4C7FE2AF9AD1361E6C43586" xlink:to="lab_us-gaap_LegalFees_068E9151B4C7FE2AF9AD1361E6C43586" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_76077A78BFDEE83C7CF91361E6C44FE9_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_76077A78BFDEE83C7CF91361E6C44FE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for legal settlement</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_76077A78BFDEE83C7CF91361E6C44FE9_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_76077A78BFDEE83C7CF91361E6C44FE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_76077A78BFDEE83C7CF91361E6C44FE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements_76077A78BFDEE83C7CF91361E6C44FE9" xlink:to="lab_us-gaap_PaymentsForLegalSettlements_76077A78BFDEE83C7CF91361E6C44FE9" xlink:type="arc" />
    <link:label id="lab_gale_LitigationSettlementIssuanceofCommonStockValue_D4A60CAE3612E8B5D8A61361E6C4B5C9_terseLabel_en-US" xlink:label="lab_gale_LitigationSettlementIssuanceofCommonStockValue_D4A60CAE3612E8B5D8A61361E6C4B5C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement with issuance of common stock</link:label>
    <link:label id="lab_gale_LitigationSettlementIssuanceofCommonStockValue_D4A60CAE3612E8B5D8A61361E6C4B5C9_label_en-US" xlink:label="lab_gale_LitigationSettlementIssuanceofCommonStockValue_D4A60CAE3612E8B5D8A61361E6C4B5C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Issuance of Common Stock, Value</link:label>
    <link:label id="lab_gale_LitigationSettlementIssuanceofCommonStockValue_D4A60CAE3612E8B5D8A61361E6C4B5C9_documentation_en-US" xlink:label="lab_gale_LitigationSettlementIssuanceofCommonStockValue_D4A60CAE3612E8B5D8A61361E6C4B5C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Issuance of Common Stock, Value</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_LitigationSettlementIssuanceofCommonStockValue" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockValue_D4A60CAE3612E8B5D8A61361E6C4B5C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LitigationSettlementIssuanceofCommonStockValue_D4A60CAE3612E8B5D8A61361E6C4B5C9" xlink:to="lab_gale_LitigationSettlementIssuanceofCommonStockValue_D4A60CAE3612E8B5D8A61361E6C4B5C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_980BD6DF8DC366EBC9951361E6C58834_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_980BD6DF8DC366EBC9951361E6C58834" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement insurance recovery</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_980BD6DF8DC366EBC9951361E6C58834_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_980BD6DF8DC366EBC9951361E6C58834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Insurance Settlement, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_980BD6DF8DC366EBC9951361E6C58834" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_980BD6DF8DC366EBC9951361E6C58834" xlink:to="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_980BD6DF8DC366EBC9951361E6C58834" xlink:type="arc" />
    <link:label id="lab_gale_LossContingencyNumberOfCounterclaims_D710FE9DE4FAD61BC1B21361E6C591BD_terseLabel_en-US" xlink:label="lab_gale_LossContingencyNumberOfCounterclaims_D710FE9DE4FAD61BC1B21361E6C591BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, number of counterclaims</link:label>
    <link:label id="lab_gale_LossContingencyNumberOfCounterclaims_D710FE9DE4FAD61BC1B21361E6C591BD_label_en-US" xlink:label="lab_gale_LossContingencyNumberOfCounterclaims_D710FE9DE4FAD61BC1B21361E6C591BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number Of Counterclaims</link:label>
    <link:label id="lab_gale_LossContingencyNumberOfCounterclaims_D710FE9DE4FAD61BC1B21361E6C591BD_documentation_en-US" xlink:label="lab_gale_LossContingencyNumberOfCounterclaims_D710FE9DE4FAD61BC1B21361E6C591BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number Of Counterclaims</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_LossContingencyNumberOfCounterclaims" xlink:label="loc_gale_LossContingencyNumberOfCounterclaims_D710FE9DE4FAD61BC1B21361E6C591BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LossContingencyNumberOfCounterclaims_D710FE9DE4FAD61BC1B21361E6C591BD" xlink:to="lab_gale_LossContingencyNumberOfCounterclaims_D710FE9DE4FAD61BC1B21361E6C591BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_4751EE56CF628CC5BA301361E6C54A87_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue_4751EE56CF628CC5BA301361E6C54A87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, damages awarded, value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_4751EE56CF628CC5BA301361E6C54A87_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue_4751EE56CF628CC5BA301361E6C54A87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_4751EE56CF628CC5BA301361E6C54A87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue_4751EE56CF628CC5BA301361E6C54A87" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue_4751EE56CF628CC5BA301361E6C54A87" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_A53314897FD9FAE6CF3D17BCD0B379CA_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_A53314897FD9FAE6CF3D17BCD0B379CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_A53314897FD9FAE6CF3D17BCD0B379CA_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_A53314897FD9FAE6CF3D17BCD0B379CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_A53314897FD9FAE6CF3D17BCD0B379CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_A53314897FD9FAE6CF3D17BCD0B379CA" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_A53314897FD9FAE6CF3D17BCD0B379CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_50DBDD014A7BF976FB2D17BCD09101AF_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_50DBDD014A7BF976FB2D17BCD09101AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_50DBDD014A7BF976FB2D17BCD09101AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_50DBDD014A7BF976FB2D17BCD09101AF" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_50DBDD014A7BF976FB2D17BCD09101AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_B65F57E667658785906717BCD0914EC1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_B65F57E667658785906717BCD0914EC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_B65F57E667658785906717BCD0914EC1_label_en-US" xlink:label="lab_us-gaap_StatementTable_B65F57E667658785906717BCD0914EC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_B65F57E667658785906717BCD0914EC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_B65F57E667658785906717BCD0914EC1" xlink:to="lab_us-gaap_StatementTable_B65F57E667658785906717BCD0914EC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_A26ACA03B4504DD5F25917BCD092ABD2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_A26ACA03B4504DD5F25917BCD092ABD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_A26ACA03B4504DD5F25917BCD092ABD2_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_A26ACA03B4504DD5F25917BCD092ABD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A26ACA03B4504DD5F25917BCD092ABD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A26ACA03B4504DD5F25917BCD092ABD2" xlink:to="lab_us-gaap_StatementClassOfStockAxis_A26ACA03B4504DD5F25917BCD092ABD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_A3DCB356775EBC075B5C17BCD092D959_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_A3DCB356775EBC075B5C17BCD092D959" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_A3DCB356775EBC075B5C17BCD092D959_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_A3DCB356775EBC075B5C17BCD092D959" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A3DCB356775EBC075B5C17BCD092D959" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_A3DCB356775EBC075B5C17BCD092D959" xlink:to="lab_us-gaap_ClassOfStockDomain_A3DCB356775EBC075B5C17BCD092D959" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_B0733B1FDCBE6A62E80D17BCD09217BD_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_B0733B1FDCBE6A62E80D17BCD09217BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_B0733B1FDCBE6A62E80D17BCD09217BD_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_B0733B1FDCBE6A62E80D17BCD09217BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_B0733B1FDCBE6A62E80D17BCD09217BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_B0733B1FDCBE6A62E80D17BCD09217BD" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_B0733B1FDCBE6A62E80D17BCD09217BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:to="lab_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_B3EA0A337AF4A20777FA17BCD093D48F_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_B3EA0A337AF4A20777FA17BCD093D48F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_B3EA0A337AF4A20777FA17BCD093D48F_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_B3EA0A337AF4A20777FA17BCD093D48F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_B3EA0A337AF4A20777FA17BCD093D48F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_B3EA0A337AF4A20777FA17BCD093D48F" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_B3EA0A337AF4A20777FA17BCD093D48F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_37A27F7BE9CEB818B7C317BCD093EFE4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_37A27F7BE9CEB818B7C317BCD093EFE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_37A27F7BE9CEB818B7C317BCD093EFE4_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_37A27F7BE9CEB818B7C317BCD093EFE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_37A27F7BE9CEB818B7C317BCD093EFE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_37A27F7BE9CEB818B7C317BCD093EFE4" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_37A27F7BE9CEB818B7C317BCD093EFE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_D89E98F229079333DBD517BCD093B5E0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_D89E98F229079333DBD517BCD093B5E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_D89E98F229079333DBD517BCD093B5E0_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_D89E98F229079333DBD517BCD093B5E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_D89E98F229079333DBD517BCD093B5E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_D89E98F229079333DBD517BCD093B5E0" xlink:to="lab_us-gaap_PreferredStockSharesIssued_D89E98F229079333DBD517BCD093B5E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_A7BA2F510F5FCFA2C84217BCD093CDDB_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_A7BA2F510F5FCFA2C84217BCD093CDDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_A7BA2F510F5FCFA2C84217BCD093CDDB_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_A7BA2F510F5FCFA2C84217BCD093CDDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_A7BA2F510F5FCFA2C84217BCD093CDDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_A7BA2F510F5FCFA2C84217BCD093CDDB" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_A7BA2F510F5FCFA2C84217BCD093CDDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_153ECB4136E3C73C2E4D17BCD0930C84_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_153ECB4136E3C73C2E4D17BCD0930C84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_153ECB4136E3C73C2E4D17BCD0930C84_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_153ECB4136E3C73C2E4D17BCD0930C84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_153ECB4136E3C73C2E4D17BCD0930C84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_153ECB4136E3C73C2E4D17BCD0930C84" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_153ECB4136E3C73C2E4D17BCD0930C84" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_F05E8159CC7787B83FC117BCD094EF77_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_F05E8159CC7787B83FC117BCD094EF77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_F05E8159CC7787B83FC117BCD094EF77_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_F05E8159CC7787B83FC117BCD094EF77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_F05E8159CC7787B83FC117BCD094EF77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_F05E8159CC7787B83FC117BCD094EF77" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_F05E8159CC7787B83FC117BCD094EF77" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_881544FF30911EF7D37617BCD0946248_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_881544FF30911EF7D37617BCD0946248" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_881544FF30911EF7D37617BCD0946248_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_881544FF30911EF7D37617BCD0946248" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_881544FF30911EF7D37617BCD0946248" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_881544FF30911EF7D37617BCD0946248" xlink:to="lab_us-gaap_CommonStockSharesIssued_881544FF30911EF7D37617BCD0946248" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_B4E9F877B6B93E7BF72F17BCD094027C_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_B4E9F877B6B93E7BF72F17BCD094027C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_B4E9F877B6B93E7BF72F17BCD094027C_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_B4E9F877B6B93E7BF72F17BCD094027C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_B4E9F877B6B93E7BF72F17BCD094027C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_B4E9F877B6B93E7BF72F17BCD094027C" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_B4E9F877B6B93E7BF72F17BCD094027C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9F9EDEE6B8CA01DA5B8E17BCD0363BDE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9F9EDEE6B8CA01DA5B8E17BCD0363BDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Allocated Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9F9EDEE6B8CA01DA5B8E17BCD0363BDE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9F9EDEE6B8CA01DA5B8E17BCD0363BDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9F9EDEE6B8CA01DA5B8E17BCD0363BDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9F9EDEE6B8CA01DA5B8E17BCD0363BDE" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9F9EDEE6B8CA01DA5B8E17BCD0363BDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_140399DCC8210E5E41AA17BCD036AC0D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_140399DCC8210E5E41AA17BCD036AC0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions for Option Grants Issued</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_140399DCC8210E5E41AA17BCD036AC0D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_140399DCC8210E5E41AA17BCD036AC0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_140399DCC8210E5E41AA17BCD036AC0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_140399DCC8210E5E41AA17BCD036AC0D" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_140399DCC8210E5E41AA17BCD036AC0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_239C32DDD2A4AD38821017BCD036D2BC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_239C32DDD2A4AD38821017BCD036D2BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_239C32DDD2A4AD38821017BCD036D2BC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_239C32DDD2A4AD38821017BCD036D2BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_239C32DDD2A4AD38821017BCD036D2BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_239C32DDD2A4AD38821017BCD036D2BC" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_239C32DDD2A4AD38821017BCD036D2BC" xlink:type="arc" />
    <link:label id="lab_gale_JGBActionMember_D874BB8D33545D4E3CC312F18FEFB05D_verboseLabel_en-US" xlink:label="lab_gale_JGBActionMember_D874BB8D33545D4E3CC312F18FEFB05D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">JGB Action</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_JGBActionMember" xlink:label="loc_gale_JGBActionMember_D874BB8D33545D4E3CC312F18FEFB05D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_JGBActionMember_D874BB8D33545D4E3CC312F18FEFB05D" xlink:to="lab_gale_JGBActionMember_D874BB8D33545D4E3CC312F18FEFB05D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3C73DD7141966E4D3DA112EF8A40E07C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3C73DD7141966E4D3DA112EF8A40E07C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed coupon rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3C73DD7141966E4D3DA112EF8A40E07C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3C73DD7141966E4D3DA112EF8A40E07C" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3C73DD7141966E4D3DA112EF8A40E07C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_6E87794C45607C0FCF3412EF8A4157A6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_6E87794C45607C0FCF3412EF8A4157A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal amount of debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6E87794C45607C0FCF3412EF8A4157A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_6E87794C45607C0FCF3412EF8A4157A6" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_6E87794C45607C0FCF3412EF8A4157A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7A2C64241A3CE9DA5C6412EF8A41C143_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7A2C64241A3CE9DA5C6412EF8A41C143" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7A2C64241A3CE9DA5C6412EF8A41C143_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7A2C64241A3CE9DA5C6412EF8A41C143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7A2C64241A3CE9DA5C6412EF8A41C143" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7A2C64241A3CE9DA5C6412EF8A41C143" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7A2C64241A3CE9DA5C6412EF8A41C143" xlink:type="arc" />
    <link:label id="lab_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_36BC08B9049C02D31D9712EF8A419668_terseLabel_en-US" xlink:label="lab_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_36BC08B9049C02D31D9712EF8A419668" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of debt and warrants</link:label>
    <link:label id="lab_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_36BC08B9049C02D31D9712EF8A419668_label_en-US" xlink:label="lab_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_36BC08B9049C02D31D9712EF8A419668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt and Warrants, Net</link:label>
    <link:label id="lab_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_36BC08B9049C02D31D9712EF8A419668_documentation_en-US" xlink:label="lab_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_36BC08B9049C02D31D9712EF8A419668" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt and Warrants, Net</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet" xlink:label="loc_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_36BC08B9049C02D31D9712EF8A419668" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_36BC08B9049C02D31D9712EF8A419668" xlink:to="lab_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_36BC08B9049C02D31D9712EF8A419668" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_3BA02BA514107036B23012EF8A41ED1B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_3BA02BA514107036B23012EF8A41ED1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final payment of interest</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_3BA02BA514107036B23012EF8A41ED1B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_3BA02BA514107036B23012EF8A41ED1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_3BA02BA514107036B23012EF8A41ED1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_3BA02BA514107036B23012EF8A41ED1B" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_3BA02BA514107036B23012EF8A41ED1B" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentCovenantLiquidityCovenant_8A368140E1E4AD2F12D812EF8A41AC67_verboseLabel_en-US" xlink:label="lab_gale_DebtInstrumentCovenantLiquidityCovenant_8A368140E1E4AD2F12D812EF8A41AC67" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, compensating cash balance</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_DebtInstrumentCovenantLiquidityCovenant" xlink:label="loc_gale_DebtInstrumentCovenantLiquidityCovenant_8A368140E1E4AD2F12D812EF8A41AC67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentCovenantLiquidityCovenant_8A368140E1E4AD2F12D812EF8A41AC67" xlink:to="lab_gale_DebtInstrumentCovenantLiquidityCovenant_8A368140E1E4AD2F12D812EF8A41AC67" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_EE6FEA4146016DD6F5EE12EF8A41F6ED_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_EE6FEA4146016DD6F5EE12EF8A41F6ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_EE6FEA4146016DD6F5EE12EF8A41F6ED_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_EE6FEA4146016DD6F5EE12EF8A41F6ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_EE6FEA4146016DD6F5EE12EF8A41F6ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_EE6FEA4146016DD6F5EE12EF8A41F6ED" xlink:to="lab_us-gaap_DebtInstrumentFairValue_EE6FEA4146016DD6F5EE12EF8A41F6ED" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_FE4EA050C6D935EC528812EF8A421703_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_FE4EA050C6D935EC528812EF8A421703" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal redeemed</link:label>
    <link:label id="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_FE4EA050C6D935EC528812EF8A421703_label_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_FE4EA050C6D935EC528812EF8A421703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Principal Amount Redeemed</link:label>
    <link:label id="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_FE4EA050C6D935EC528812EF8A421703_documentation_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_FE4EA050C6D935EC528812EF8A421703" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Principal Amount Redeemed</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_DebtInstrumentRedemptionPrincipalAmountRedeemed" xlink:label="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_FE4EA050C6D935EC528812EF8A421703" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_FE4EA050C6D935EC528812EF8A421703" xlink:to="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_FE4EA050C6D935EC528812EF8A421703" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_53D23B85559F5EB568CC12EF8A421C30_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_53D23B85559F5EB568CC12EF8A421C30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, redemption, principal amount redeemed, shares</link:label>
    <link:label id="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_53D23B85559F5EB568CC12EF8A421C30_label_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_53D23B85559F5EB568CC12EF8A421C30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Principal Amount Redeemed, Shares</link:label>
    <link:label id="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_53D23B85559F5EB568CC12EF8A421C30_documentation_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_53D23B85559F5EB568CC12EF8A421C30" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Principal Amount Redeemed, Shares</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares" xlink:label="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_53D23B85559F5EB568CC12EF8A421C30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_53D23B85559F5EB568CC12EF8A421C30" xlink:to="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_53D23B85559F5EB568CC12EF8A421C30" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_FA7A3E800609DB8EBDB212EF8A42F8F5_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_FA7A3E800609DB8EBDB212EF8A42F8F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt amount redeemed, settled in cash</link:label>
    <link:label id="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_FA7A3E800609DB8EBDB212EF8A42F8F5_label_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_FA7A3E800609DB8EBDB212EF8A42F8F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Principal Amount Redeemed, Settled In Cash</link:label>
    <link:label id="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_FA7A3E800609DB8EBDB212EF8A42F8F5_documentation_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_FA7A3E800609DB8EBDB212EF8A42F8F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Principal Amount Redeemed, Settled In Cash</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash" xlink:label="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_FA7A3E800609DB8EBDB212EF8A42F8F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_FA7A3E800609DB8EBDB212EF8A42F8F5" xlink:to="lab_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_FA7A3E800609DB8EBDB212EF8A42F8F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DecreaseInRestrictedCash_A3A77E071A7C06257BB712EF8A428736_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInRestrictedCash_A3A77E071A7C06257BB712EF8A428736" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in restricted cash</link:label>
    <link:label id="lab_us-gaap_DecreaseInRestrictedCash_A3A77E071A7C06257BB712EF8A428736_label_en-US" xlink:label="lab_us-gaap_DecreaseInRestrictedCash_A3A77E071A7C06257BB712EF8A428736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease in Restricted Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DecreaseInRestrictedCash" xlink:label="loc_us-gaap_DecreaseInRestrictedCash_A3A77E071A7C06257BB712EF8A428736" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInRestrictedCash_A3A77E071A7C06257BB712EF8A428736" xlink:to="lab_us-gaap_DecreaseInRestrictedCash_A3A77E071A7C06257BB712EF8A428736" xlink:type="arc" />
    <link:label id="lab_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_E690F8E980AD757A0EE012EF8A430A42_terseLabel_en-US" xlink:label="lab_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_E690F8E980AD757A0EE012EF8A430A42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance of restricted cash over senior secured debenture</link:label>
    <link:label id="lab_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_E690F8E980AD757A0EE012EF8A430A42_label_en-US" xlink:label="lab_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_E690F8E980AD757A0EE012EF8A430A42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Of Restricted Cash Over Senior Secured Debenture</link:label>
    <link:label id="lab_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_E690F8E980AD757A0EE012EF8A430A42_documentation_en-US" xlink:label="lab_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_E690F8E980AD757A0EE012EF8A430A42" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Balance Of Restricted Cash Over Senior Secured Debenture</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture" xlink:label="loc_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_E690F8E980AD757A0EE012EF8A430A42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_E690F8E980AD757A0EE012EF8A430A42" xlink:to="lab_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_E690F8E980AD757A0EE012EF8A430A42" xlink:type="arc" />
    <link:label id="lab_gale_DepositOfRestrictedCashOverSeniorSecuredDebenture_DD3E24426FE3A4CADC4213347257A15C_terseLabel_en-US" xlink:label="lab_gale_DepositOfRestrictedCashOverSeniorSecuredDebenture_DD3E24426FE3A4CADC4213347257A15C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposit of restricted cash over senior secured debenture</link:label>
    <link:label id="lab_gale_DepositOfRestrictedCashOverSeniorSecuredDebenture_DD3E24426FE3A4CADC4213347257A15C_label_en-US" xlink:label="lab_gale_DepositOfRestrictedCashOverSeniorSecuredDebenture_DD3E24426FE3A4CADC4213347257A15C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposit Of Restricted Cash Over Senior Secured Debenture</link:label>
    <link:label id="lab_gale_DepositOfRestrictedCashOverSeniorSecuredDebenture_DD3E24426FE3A4CADC4213347257A15C_documentation_en-US" xlink:label="lab_gale_DepositOfRestrictedCashOverSeniorSecuredDebenture_DD3E24426FE3A4CADC4213347257A15C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deposit Of Restricted Cash Over Senior Secured Debenture</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_DepositOfRestrictedCashOverSeniorSecuredDebenture" xlink:label="loc_gale_DepositOfRestrictedCashOverSeniorSecuredDebenture_DD3E24426FE3A4CADC4213347257A15C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DepositOfRestrictedCashOverSeniorSecuredDebenture_DD3E24426FE3A4CADC4213347257A15C" xlink:to="lab_gale_DepositOfRestrictedCashOverSeniorSecuredDebenture_DD3E24426FE3A4CADC4213347257A15C" xlink:type="arc" />
    <link:label id="lab_gale_ReimbursementOfLegalFees_3C59C9FCC4AEDED25D9A12EF8A4307F6_terseLabel_en-US" xlink:label="lab_gale_ReimbursementOfLegalFees_3C59C9FCC4AEDED25D9A12EF8A4307F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on reimbursement of legal fees</link:label>
    <link:label id="lab_gale_ReimbursementOfLegalFees_3C59C9FCC4AEDED25D9A12EF8A4307F6_label_en-US" xlink:label="lab_gale_ReimbursementOfLegalFees_3C59C9FCC4AEDED25D9A12EF8A4307F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Of Legal Fees</link:label>
    <link:label id="lab_gale_ReimbursementOfLegalFees_3C59C9FCC4AEDED25D9A12EF8A4307F6_documentation_en-US" xlink:label="lab_gale_ReimbursementOfLegalFees_3C59C9FCC4AEDED25D9A12EF8A4307F6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursement Of Legal Fees</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ReimbursementOfLegalFees" xlink:label="loc_gale_ReimbursementOfLegalFees_3C59C9FCC4AEDED25D9A12EF8A4307F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ReimbursementOfLegalFees_3C59C9FCC4AEDED25D9A12EF8A4307F6" xlink:to="lab_gale_ReimbursementOfLegalFees_3C59C9FCC4AEDED25D9A12EF8A4307F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C616F4D712EB99B8B3DC0E609F78E95B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C616F4D712EB99B8B3DC0E609F78E95B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C616F4D712EB99B8B3DC0E609F78E95B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C616F4D712EB99B8B3DC0E609F78E95B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C616F4D712EB99B8B3DC0E609F78E95B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C616F4D712EB99B8B3DC0E609F78E95B" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C616F4D712EB99B8B3DC0E609F78E95B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_E029C8C87F48448BA5B10E609F78A767_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_E029C8C87F48448BA5B10E609F78A767" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_E029C8C87F48448BA5B10E609F78A767_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_E029C8C87F48448BA5B10E609F78A767" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E029C8C87F48448BA5B10E609F78A767" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E029C8C87F48448BA5B10E609F78A767" xlink:to="lab_us-gaap_TypeOfArrangementAxis_E029C8C87F48448BA5B10E609F78A767" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28AA088C62F3F5D9CEE0E609F780F08_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28AA088C62F3F5D9CEE0E609F780F08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28AA088C62F3F5D9CEE0E609F780F08_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28AA088C62F3F5D9CEE0E609F780F08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28AA088C62F3F5D9CEE0E609F780F08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28AA088C62F3F5D9CEE0E609F780F08" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28AA088C62F3F5D9CEE0E609F780F08" xlink:type="arc" />
    <link:label id="lab_gale_PurchaseAgreementMember_839B04D6092AA090EA7B0E609F78BA4A_terseLabel_en-US" xlink:label="lab_gale_PurchaseAgreementMember_839B04D6092AA090EA7B0E609F78BA4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Agreement</link:label>
    <link:label id="lab_gale_PurchaseAgreementMember_839B04D6092AA090EA7B0E609F78BA4A_label_en-US" xlink:label="lab_gale_PurchaseAgreementMember_839B04D6092AA090EA7B0E609F78BA4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement [Member]</link:label>
    <link:label id="lab_gale_PurchaseAgreementMember_839B04D6092AA090EA7B0E609F78BA4A_documentation_en-US" xlink:label="lab_gale_PurchaseAgreementMember_839B04D6092AA090EA7B0E609F78BA4A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_PurchaseAgreementMember" xlink:label="loc_gale_PurchaseAgreementMember_839B04D6092AA090EA7B0E609F78BA4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PurchaseAgreementMember_839B04D6092AA090EA7B0E609F78BA4A" xlink:to="lab_gale_PurchaseAgreementMember_839B04D6092AA090EA7B0E609F78BA4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2572F0E54CC429216DD80E609F790624_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_2572F0E54CC429216DD80E609F790624" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2572F0E54CC429216DD80E609F790624_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_2572F0E54CC429216DD80E609F790624" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2572F0E54CC429216DD80E609F790624" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2572F0E54CC429216DD80E609F790624" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_2572F0E54CC429216DD80E609F790624" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_F36B8726BF34D1B0CDB10E609F793DF2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_F36B8726BF34D1B0CDB10E609F793DF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_F36B8726BF34D1B0CDB10E609F793DF2_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_F36B8726BF34D1B0CDB10E609F793DF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_F36B8726BF34D1B0CDB10E609F793DF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_F36B8726BF34D1B0CDB10E609F793DF2" xlink:to="lab_us-gaap_EquityComponentDomain_F36B8726BF34D1B0CDB10E609F793DF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_534DC9BE83B39963F2220E609F799AB1_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_534DC9BE83B39963F2220E609F799AB1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_534DC9BE83B39963F2220E609F799AB1_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_534DC9BE83B39963F2220E609F799AB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_534DC9BE83B39963F2220E609F799AB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_534DC9BE83B39963F2220E609F799AB1" xlink:to="lab_us-gaap_CommonStockMember_534DC9BE83B39963F2220E609F799AB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_B03409AEF47C159A9B3B0E609F795A0B_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_B03409AEF47C159A9B3B0E609F795A0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_B03409AEF47C159A9B3B0E609F795A0B_label_en-US" xlink:label="lab_us-gaap_WarrantMember_B03409AEF47C159A9B3B0E609F795A0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_B03409AEF47C159A9B3B0E609F795A0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_B03409AEF47C159A9B3B0E609F795A0B" xlink:to="lab_us-gaap_WarrantMember_B03409AEF47C159A9B3B0E609F795A0B" xlink:type="arc" />
    <link:label id="lab_gale_SeriesANonvotingConvertibleMember_C5B8E3D67ED0F69DAC860E609F7A9745_terseLabel_en-US" xlink:label="lab_gale_SeriesANonvotingConvertibleMember_C5B8E3D67ED0F69DAC860E609F7A9745" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Non-voting Convertible</link:label>
    <link:label id="lab_gale_SeriesANonvotingConvertibleMember_C5B8E3D67ED0F69DAC860E609F7A9745_label_en-US" xlink:label="lab_gale_SeriesANonvotingConvertibleMember_C5B8E3D67ED0F69DAC860E609F7A9745" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Non-voting Convertible [Member]</link:label>
    <link:label id="lab_gale_SeriesANonvotingConvertibleMember_C5B8E3D67ED0F69DAC860E609F7A9745_documentation_en-US" xlink:label="lab_gale_SeriesANonvotingConvertibleMember_C5B8E3D67ED0F69DAC860E609F7A9745" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A Non-voting Convertible [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_SeriesANonvotingConvertibleMember" xlink:label="loc_gale_SeriesANonvotingConvertibleMember_C5B8E3D67ED0F69DAC860E609F7A9745" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SeriesANonvotingConvertibleMember_C5B8E3D67ED0F69DAC860E609F7A9745" xlink:to="lab_gale_SeriesANonvotingConvertibleMember_C5B8E3D67ED0F69DAC860E609F7A9745" xlink:type="arc" />
    <link:label id="lab_gale_SeriesAConvertiblePreferredStockMember_2A4EB6B2FD817216D65B0E609F7AC46D_terseLabel_en-US" xlink:label="lab_gale_SeriesAConvertiblePreferredStockMember_2A4EB6B2FD817216D65B0E609F7AC46D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A- Convertible Preferred Stock</link:label>
    <link:label id="lab_gale_SeriesAConvertiblePreferredStockMember_2A4EB6B2FD817216D65B0E609F7AC46D_label_en-US" xlink:label="lab_gale_SeriesAConvertiblePreferredStockMember_2A4EB6B2FD817216D65B0E609F7AC46D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A- Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_gale_SeriesAConvertiblePreferredStockMember_2A4EB6B2FD817216D65B0E609F7AC46D_documentation_en-US" xlink:label="lab_gale_SeriesAConvertiblePreferredStockMember_2A4EB6B2FD817216D65B0E609F7AC46D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gale_SeriesAConvertiblePreferredStockMember_2A4EB6B2FD817216D65B0E609F7AC46D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SeriesAConvertiblePreferredStockMember_2A4EB6B2FD817216D65B0E609F7AC46D" xlink:to="lab_gale_SeriesAConvertiblePreferredStockMember_2A4EB6B2FD817216D65B0E609F7AC46D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_92BFEA225781E16101630E609F7B66A0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_92BFEA225781E16101630E609F7B66A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_92BFEA225781E16101630E609F7B66A0_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_92BFEA225781E16101630E609F7B66A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_92BFEA225781E16101630E609F7B66A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_92BFEA225781E16101630E609F7B66A0" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_92BFEA225781E16101630E609F7B66A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_DDD850BD40D958A973850E609F7BADD7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_DDD850BD40D958A973850E609F7BADD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_DDD850BD40D958A973850E609F7BADD7_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_DDD850BD40D958A973850E609F7BADD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DDD850BD40D958A973850E609F7BADD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DDD850BD40D958A973850E609F7BADD7" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_DDD850BD40D958A973850E609F7BADD7" xlink:type="arc" />
    <link:label id="lab_gale_FirstTrancheMember_0409836AFAF27553C86E0E609F7BC8E6_terseLabel_en-US" xlink:label="lab_gale_FirstTrancheMember_0409836AFAF27553C86E0E609F7BC8E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Tranche</link:label>
    <link:label id="lab_gale_FirstTrancheMember_0409836AFAF27553C86E0E609F7BC8E6_label_en-US" xlink:label="lab_gale_FirstTrancheMember_0409836AFAF27553C86E0E609F7BC8E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Tranche [Member]</link:label>
    <link:label id="lab_gale_FirstTrancheMember_0409836AFAF27553C86E0E609F7BC8E6_documentation_en-US" xlink:label="lab_gale_FirstTrancheMember_0409836AFAF27553C86E0E609F7BC8E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First Tranche [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_FirstTrancheMember" xlink:label="loc_gale_FirstTrancheMember_0409836AFAF27553C86E0E609F7BC8E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FirstTrancheMember_0409836AFAF27553C86E0E609F7BC8E6" xlink:to="lab_gale_FirstTrancheMember_0409836AFAF27553C86E0E609F7BC8E6" xlink:type="arc" />
    <link:label id="lab_gale_SecondTrancheMember_41559B2296FE7AF1AC920E609F7B8D84_terseLabel_en-US" xlink:label="lab_gale_SecondTrancheMember_41559B2296FE7AF1AC920E609F7B8D84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second Tranche</link:label>
    <link:label id="lab_gale_SecondTrancheMember_41559B2296FE7AF1AC920E609F7B8D84_label_en-US" xlink:label="lab_gale_SecondTrancheMember_41559B2296FE7AF1AC920E609F7B8D84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second Tranche [Member]</link:label>
    <link:label id="lab_gale_SecondTrancheMember_41559B2296FE7AF1AC920E609F7B8D84_documentation_en-US" xlink:label="lab_gale_SecondTrancheMember_41559B2296FE7AF1AC920E609F7B8D84" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Second Tranche [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_SecondTrancheMember" xlink:label="loc_gale_SecondTrancheMember_41559B2296FE7AF1AC920E609F7B8D84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SecondTrancheMember_41559B2296FE7AF1AC920E609F7B8D84" xlink:to="lab_gale_SecondTrancheMember_41559B2296FE7AF1AC920E609F7B8D84" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D830421D335BCFFA63810E609F7C2485_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D830421D335BCFFA63810E609F7C2485" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, number of shares issued in transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D830421D335BCFFA63810E609F7C2485_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D830421D335BCFFA63810E609F7C2485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D830421D335BCFFA63810E609F7C2485" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D830421D335BCFFA63810E609F7C2485" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D830421D335BCFFA63810E609F7C2485" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_DBC0EAD27CF26FEF7B920E609F7C409C_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_DBC0EAD27CF26FEF7B920E609F7C409C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_DBC0EAD27CF26FEF7B920E609F7C409C_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_DBC0EAD27CF26FEF7B920E609F7C409C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_DBC0EAD27CF26FEF7B920E609F7C409C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_DBC0EAD27CF26FEF7B920E609F7C409C" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_DBC0EAD27CF26FEF7B920E609F7C409C" xlink:type="arc" />
    <link:label id="lab_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_918A89838E4531FCFF850E609F7DAD70_verboseLabel_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_918A89838E4531FCFF850E609F7DAD70" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (usd per share)</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_918A89838E4531FCFF850E609F7DAD70_label_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_918A89838E4531FCFF850E609F7DAD70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights Prefunded</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_918A89838E4531FCFF850E609F7DAD70_documentation_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_918A89838E4531FCFF850E609F7DAD70" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights Prefunded</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded" xlink:label="loc_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_918A89838E4531FCFF850E609F7DAD70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_918A89838E4531FCFF850E609F7DAD70" xlink:to="lab_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_918A89838E4531FCFF850E609F7DAD70" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightTerm_77EBB3538F0BFE911BD60E609F7D8E7F_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm_77EBB3538F0BFE911BD60E609F7D8E7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant term</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightTerm_77EBB3538F0BFE911BD60E609F7D8E7F_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm_77EBB3538F0BFE911BD60E609F7D8E7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Term</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightTerm_77EBB3538F0BFE911BD60E609F7D8E7F_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm_77EBB3538F0BFE911BD60E609F7D8E7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Term</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_77EBB3538F0BFE911BD60E609F7D8E7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightTerm_77EBB3538F0BFE911BD60E609F7D8E7F" xlink:to="lab_gale_ClassofWarrantorRightTerm_77EBB3538F0BFE911BD60E609F7D8E7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_64ECD83B51F6C73F54480E609F7D46F0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_64ECD83B51F6C73F54480E609F7D46F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_64ECD83B51F6C73F54480E609F7D46F0_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_64ECD83B51F6C73F54480E609F7D46F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_64ECD83B51F6C73F54480E609F7D46F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_64ECD83B51F6C73F54480E609F7D46F0" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_64ECD83B51F6C73F54480E609F7D46F0" xlink:type="arc" />
    <link:label id="lab_gale_ConvertiblePreferredStockConversionPrice_F316CC4C7051048D26D40E609F7D498B_terseLabel_en-US" xlink:label="lab_gale_ConvertiblePreferredStockConversionPrice_F316CC4C7051048D26D40E609F7D498B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion price (USD per share)</link:label>
    <link:label id="lab_gale_ConvertiblePreferredStockConversionPrice_F316CC4C7051048D26D40E609F7D498B_label_en-US" xlink:label="lab_gale_ConvertiblePreferredStockConversionPrice_F316CC4C7051048D26D40E609F7D498B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Conversion Price</link:label>
    <link:label id="lab_gale_ConvertiblePreferredStockConversionPrice_F316CC4C7051048D26D40E609F7D498B_documentation_en-US" xlink:label="lab_gale_ConvertiblePreferredStockConversionPrice_F316CC4C7051048D26D40E609F7D498B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Conversion Price</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ConvertiblePreferredStockConversionPrice" xlink:label="loc_gale_ConvertiblePreferredStockConversionPrice_F316CC4C7051048D26D40E609F7D498B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ConvertiblePreferredStockConversionPrice_F316CC4C7051048D26D40E609F7D498B" xlink:to="lab_gale_ConvertiblePreferredStockConversionPrice_F316CC4C7051048D26D40E609F7D498B" xlink:type="arc" />
    <link:label id="lab_gale_ConvertiblePreferredStockNumberOfTranches_E3CEF015BDCE2A23575E0E609F7E037E_terseLabel_en-US" xlink:label="lab_gale_ConvertiblePreferredStockNumberOfTranches_E3CEF015BDCE2A23575E0E609F7E037E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_gale_ConvertiblePreferredStockNumberOfTranches_E3CEF015BDCE2A23575E0E609F7E037E_label_en-US" xlink:label="lab_gale_ConvertiblePreferredStockNumberOfTranches_E3CEF015BDCE2A23575E0E609F7E037E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Number Of Tranches</link:label>
    <link:label id="lab_gale_ConvertiblePreferredStockNumberOfTranches_E3CEF015BDCE2A23575E0E609F7E037E_documentation_en-US" xlink:label="lab_gale_ConvertiblePreferredStockNumberOfTranches_E3CEF015BDCE2A23575E0E609F7E037E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Number Of Tranches</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ConvertiblePreferredStockNumberOfTranches" xlink:label="loc_gale_ConvertiblePreferredStockNumberOfTranches_E3CEF015BDCE2A23575E0E609F7E037E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ConvertiblePreferredStockNumberOfTranches_E3CEF015BDCE2A23575E0E609F7E037E" xlink:to="lab_gale_ConvertiblePreferredStockNumberOfTranches_E3CEF015BDCE2A23575E0E609F7E037E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_8E3C9F73F0F63DBFFC460E609F7E26D7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_8E3C9F73F0F63DBFFC460E609F7E26D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_8E3C9F73F0F63DBFFC460E609F7E26D7_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_8E3C9F73F0F63DBFFC460E609F7E26D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_8E3C9F73F0F63DBFFC460E609F7E26D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_8E3C9F73F0F63DBFFC460E609F7E26D7" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_8E3C9F73F0F63DBFFC460E609F7E26D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0A45740CF20CE7F9DD8B0E609F7E85FF_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0A45740CF20CE7F9DD8B0E609F7E85FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0A45740CF20CE7F9DD8B0E609F7E85FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0A45740CF20CE7F9DD8B0E609F7E85FF" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0A45740CF20CE7F9DD8B0E609F7E85FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_6B781849534F30FE57B90E609F7E8507_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_6B781849534F30FE57B90E609F7E8507" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_6B781849534F30FE57B90E609F7E8507" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_6B781849534F30FE57B90E609F7E8507" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_6B781849534F30FE57B90E609F7E8507" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_2F76BA137431EA5FB5C50E6CD6B3C64D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_2F76BA137431EA5FB5C50E6CD6B3C64D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivable</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_2F76BA137431EA5FB5C50E6CD6B3C64D_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_2F76BA137431EA5FB5C50E6CD6B3C64D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_2F76BA137431EA5FB5C50E6CD6B3C64D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent_2F76BA137431EA5FB5C50E6CD6B3C64D" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent_2F76BA137431EA5FB5C50E6CD6B3C64D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InsuranceSettlementsReceivableCurrent_B60D74B5F27700CDB41C0E609F7FCB74_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceSettlementsReceivableCurrent_B60D74B5F27700CDB41C0E609F7FCB74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement insurance recovery</link:label>
    <link:label id="lab_us-gaap_InsuranceSettlementsReceivableCurrent_B60D74B5F27700CDB41C0E609F7FCB74_label_en-US" xlink:label="lab_us-gaap_InsuranceSettlementsReceivableCurrent_B60D74B5F27700CDB41C0E609F7FCB74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance Settlements Receivable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableCurrent_B60D74B5F27700CDB41C0E609F7FCB74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceSettlementsReceivableCurrent_B60D74B5F27700CDB41C0E609F7FCB74" xlink:to="lab_us-gaap_InsuranceSettlementsReceivableCurrent_B60D74B5F27700CDB41C0E609F7FCB74" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_F59E099FC7A43025D0090E609F7F71FA_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_F59E099FC7A43025D0090E609F7F71FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_F59E099FC7A43025D0090E609F7F71FA_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_F59E099FC7A43025D0090E609F7F71FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_F59E099FC7A43025D0090E609F7F71FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_F59E099FC7A43025D0090E609F7F71FA" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_F59E099FC7A43025D0090E609F7F71FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_BE621911B569BB35716F0E609F7F5E39_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_BE621911B569BB35716F0E609F7F5E39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_BE621911B569BB35716F0E609F7F5E39_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_BE621911B569BB35716F0E609F7F5E39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_BE621911B569BB35716F0E609F7F5E39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_BE621911B569BB35716F0E609F7F5E39" xlink:to="lab_us-gaap_LongTermDebt_BE621911B569BB35716F0E609F7F5E39" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_6CD760F734CC9AC2ABBD13B0C3A8451B_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_6CD760F734CC9AC2ABBD13B0C3A8451B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6CD760F734CC9AC2ABBD13B0C3A8451B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6CD760F734CC9AC2ABBD13B0C3A8451B" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_6CD760F734CC9AC2ABBD13B0C3A8451B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1716DAE29B858B50949A13B0C3A9FBAB_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1716DAE29B858B50949A13B0C3A9FBAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1716DAE29B858B50949A13B0C3A9FBAB_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1716DAE29B858B50949A13B0C3A9FBAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1716DAE29B858B50949A13B0C3A9FBAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1716DAE29B858B50949A13B0C3A9FBAB" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1716DAE29B858B50949A13B0C3A9FBAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_D6F4CB3034C72E709A2413B0C3A9E289_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_D6F4CB3034C72E709A2413B0C3A9E289" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_D6F4CB3034C72E709A2413B0C3A9E289_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_D6F4CB3034C72E709A2413B0C3A9E289" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_D6F4CB3034C72E709A2413B0C3A9E289" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_D6F4CB3034C72E709A2413B0C3A9E289" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_D6F4CB3034C72E709A2413B0C3A9E289" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_C88D2E1F5E60335541A013B0C3A9C699_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_C88D2E1F5E60335541A013B0C3A9C699" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on extinguishment of debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_C88D2E1F5E60335541A013B0C3A9C699" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_C88D2E1F5E60335541A013B0C3A9C699" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_C88D2E1F5E60335541A013B0C3A9C699" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaidInKindInterest_5162EAA4BB209006C59013B0C3AA0661_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_5162EAA4BB209006C59013B0C3AA0661" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_5162EAA4BB209006C59013B0C3AA0661_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_5162EAA4BB209006C59013B0C3AA0661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_5162EAA4BB209006C59013B0C3AA0661" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest_5162EAA4BB209006C59013B0C3AA0661" xlink:to="lab_us-gaap_PaidInKindInterest_5162EAA4BB209006C59013B0C3AA0661" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_4A55F655EFB6C8A7834213B0C3AA921B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_4A55F655EFB6C8A7834213B0C3AA921B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_4A55F655EFB6C8A7834213B0C3AA921B_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_4A55F655EFB6C8A7834213B0C3AA921B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_4A55F655EFB6C8A7834213B0C3AA921B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_4A55F655EFB6C8A7834213B0C3AA921B" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_4A55F655EFB6C8A7834213B0C3AA921B" xlink:type="arc" />
    <link:label id="lab_gale_GainLossOnExtinguishmentOfPayables_5B73FFD897CA3296A62713B0C3AA4DC7_negatedLabel_en-US" xlink:label="lab_gale_GainLossOnExtinguishmentOfPayables_5B73FFD897CA3296A62713B0C3AA4DC7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of payables</link:label>
    <link:label id="lab_gale_GainLossOnExtinguishmentOfPayables_5B73FFD897CA3296A62713B0C3AA4DC7_label_en-US" xlink:label="lab_gale_GainLossOnExtinguishmentOfPayables_5B73FFD897CA3296A62713B0C3AA4DC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Extinguishment Of Payables</link:label>
    <link:label id="lab_gale_GainLossOnExtinguishmentOfPayables_5B73FFD897CA3296A62713B0C3AA4DC7_documentation_en-US" xlink:label="lab_gale_GainLossOnExtinguishmentOfPayables_5B73FFD897CA3296A62713B0C3AA4DC7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Extinguishment Of Payables</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_GainLossOnExtinguishmentOfPayables" xlink:label="loc_gale_GainLossOnExtinguishmentOfPayables_5B73FFD897CA3296A62713B0C3AA4DC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_GainLossOnExtinguishmentOfPayables_5B73FFD897CA3296A62713B0C3AA4DC7" xlink:to="lab_gale_GainLossOnExtinguishmentOfPayables_5B73FFD897CA3296A62713B0C3AA4DC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_43942B211D88D570E93E13B0C3AA8FB8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_43942B211D88D570E93E13B0C3AA8FB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_43942B211D88D570E93E13B0C3AA8FB8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_43942B211D88D570E93E13B0C3AA8FB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_43942B211D88D570E93E13B0C3AA8FB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_43942B211D88D570E93E13B0C3AA8FB8" xlink:to="lab_us-gaap_ShareBasedCompensation_43942B211D88D570E93E13B0C3AA8FB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentForAmortization_147426B5CD944B5AB62313B0C3AB53BE_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization_147426B5CD944B5AB62313B0C3AB53BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of research and development expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_147426B5CD944B5AB62313B0C3AB53BE_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization_147426B5CD944B5AB62313B0C3AB53BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_147426B5CD944B5AB62313B0C3AB53BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization_147426B5CD944B5AB62313B0C3AB53BE" xlink:to="lab_us-gaap_AdjustmentForAmortization_147426B5CD944B5AB62313B0C3AB53BE" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_653F6AB530D7FAAAB52D13B0C3AB6C7E_terseLabel_en-US" xlink:label="lab_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_653F6AB530D7FAAAB52D13B0C3AB6C7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of common stock issued in exchange for services</link:label>
    <link:label id="lab_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_653F6AB530D7FAAAB52D13B0C3AB6C7E_label_en-US" xlink:label="lab_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_653F6AB530D7FAAAB52D13B0C3AB6C7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Parent Company Common Stock Issued In Exchange For Services</link:label>
    <link:label id="lab_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_653F6AB530D7FAAAB52D13B0C3AB6C7E_documentation_en-US" xlink:label="lab_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_653F6AB530D7FAAAB52D13B0C3AB6C7E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of common stock warrants issued in exchange for services.</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" xlink:label="loc_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_653F6AB530D7FAAAB52D13B0C3AB6C7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_653F6AB530D7FAAAB52D13B0C3AB6C7E" xlink:to="lab_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_653F6AB530D7FAAAB52D13B0C3AB6C7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_A5E74B16F2C5D856E64913B0C3AB6EB7_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_A5E74B16F2C5D856E64913B0C3AB6EB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of common stock issued in connection with litigation settlements</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_A5E74B16F2C5D856E64913B0C3AB6EB7_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_A5E74B16F2C5D856E64913B0C3AB6EB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_A5E74B16F2C5D856E64913B0C3AB6EB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_A5E74B16F2C5D856E64913B0C3AB6EB7" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_A5E74B16F2C5D856E64913B0C3AB6EB7" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1C751A8F43C5D9691EC113B0C3AB2409_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1C751A8F43C5D9691EC113B0C3AB2409" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrants</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1C751A8F43C5D9691EC113B0C3AB2409_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1C751A8F43C5D9691EC113B0C3AB2409" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1C751A8F43C5D9691EC113B0C3AB2409_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1C751A8F43C5D9691EC113B0C3AB2409" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrants issued in connection with various equity financings.</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1C751A8F43C5D9691EC113B0C3AB2409" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1C751A8F43C5D9691EC113B0C3AB2409" xlink:to="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1C751A8F43C5D9691EC113B0C3AB2409" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_A5D6C34E1D982EDF0A2713B0C3AB647D_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_A5D6C34E1D982EDF0A2713B0C3AB647D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_A5D6C34E1D982EDF0A2713B0C3AB647D_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_A5D6C34E1D982EDF0A2713B0C3AB647D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Contingent Purchase Consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_A5D6C34E1D982EDF0A2713B0C3AB647D_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_A5D6C34E1D982EDF0A2713B0C3AB647D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent purchase consideration.</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_A5D6C34E1D982EDF0A2713B0C3AB647D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_A5D6C34E1D982EDF0A2713B0C3AB647D" xlink:to="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_A5D6C34E1D982EDF0A2713B0C3AB647D" xlink:type="arc" />
    <link:label id="lab_gale_LossOnSettlementOfLiabilityClassifiedWarrants_F0A986BEF2EEAC72FAFE13B0C3ACE06B_terseLabel_en-US" xlink:label="lab_gale_LossOnSettlementOfLiabilityClassifiedWarrants_F0A986BEF2EEAC72FAFE13B0C3ACE06B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on settlement of liability-classified warrants</link:label>
    <link:label id="lab_gale_LossOnSettlementOfLiabilityClassifiedWarrants_F0A986BEF2EEAC72FAFE13B0C3ACE06B_label_en-US" xlink:label="lab_gale_LossOnSettlementOfLiabilityClassifiedWarrants_F0A986BEF2EEAC72FAFE13B0C3ACE06B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss On Settlement Of Liability Classified Warrants</link:label>
    <link:label id="lab_gale_LossOnSettlementOfLiabilityClassifiedWarrants_F0A986BEF2EEAC72FAFE13B0C3ACE06B_documentation_en-US" xlink:label="lab_gale_LossOnSettlementOfLiabilityClassifiedWarrants_F0A986BEF2EEAC72FAFE13B0C3ACE06B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss On Settlement Of Liability Classified Warrants</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_LossOnSettlementOfLiabilityClassifiedWarrants" xlink:label="loc_gale_LossOnSettlementOfLiabilityClassifiedWarrants_F0A986BEF2EEAC72FAFE13B0C3ACE06B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LossOnSettlementOfLiabilityClassifiedWarrants_F0A986BEF2EEAC72FAFE13B0C3ACE06B" xlink:to="lab_gale_LossOnSettlementOfLiabilityClassifiedWarrants_F0A986BEF2EEAC72FAFE13B0C3ACE06B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_658427AFFEC1A0334C8113B0C3AC2069_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_658427AFFEC1A0334C8113B0C3AC2069" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_658427AFFEC1A0334C8113B0C3AC2069_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_658427AFFEC1A0334C8113B0C3AC2069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_658427AFFEC1A0334C8113B0C3AC2069" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_658427AFFEC1A0334C8113B0C3AC2069" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_658427AFFEC1A0334C8113B0C3AC2069" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_971324B351DFFB79EFA713B0C3AC2E82_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables_971324B351DFFB79EFA713B0C3AC2E82" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_971324B351DFFB79EFA713B0C3AC2E82_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables_971324B351DFFB79EFA713B0C3AC2E82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_971324B351DFFB79EFA713B0C3AC2E82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables_971324B351DFFB79EFA713B0C3AC2E82" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables_971324B351DFFB79EFA713B0C3AC2E82" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6B55BD8E80423801EA0813B0C3AC91EF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6B55BD8E80423801EA0813B0C3AC91EF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6B55BD8E80423801EA0813B0C3AC91EF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6B55BD8E80423801EA0813B0C3AC91EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6B55BD8E80423801EA0813B0C3AC91EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6B55BD8E80423801EA0813B0C3AC91EF" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6B55BD8E80423801EA0813B0C3AC91EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_741539BEDCE276DCF8C813B0C3AC87AD_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_741539BEDCE276DCF8C813B0C3AC87AD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement insurance recovery</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_741539BEDCE276DCF8C813B0C3AC87AD_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_741539BEDCE276DCF8C813B0C3AC87AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Insurance Settlements Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_741539BEDCE276DCF8C813B0C3AC87AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_741539BEDCE276DCF8C813B0C3AC87AD" xlink:to="lab_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_741539BEDCE276DCF8C813B0C3AC87AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6DD6E4476836B7B77C7613B0C3AC9405_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6DD6E4476836B7B77C7613B0C3AC9405" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6DD6E4476836B7B77C7613B0C3AC9405_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6DD6E4476836B7B77C7613B0C3AC9405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6DD6E4476836B7B77C7613B0C3AC9405" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6DD6E4476836B7B77C7613B0C3AC9405" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6DD6E4476836B7B77C7613B0C3AC9405" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_CD6FE6CFD5A305A718B213B0C3AD8744_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_CD6FE6CFD5A305A718B213B0C3AD8744" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_CD6FE6CFD5A305A718B213B0C3AD8744_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_CD6FE6CFD5A305A718B213B0C3AD8744" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_CD6FE6CFD5A305A718B213B0C3AD8744" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_CD6FE6CFD5A305A718B213B0C3AD8744" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_CD6FE6CFD5A305A718B213B0C3AD8744" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_BEB3989D483652CE80D013B0C3AD0081_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_BEB3989D483652CE80D013B0C3AD0081" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_BEB3989D483652CE80D013B0C3AD0081_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_BEB3989D483652CE80D013B0C3AD0081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_BEB3989D483652CE80D013B0C3AD0081" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_BEB3989D483652CE80D013B0C3AD0081" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_BEB3989D483652CE80D013B0C3AD0081" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F7178A1586D3EC51129D13B0C3AD2C0C_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F7178A1586D3EC51129D13B0C3AD2C0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F7178A1586D3EC51129D13B0C3AD2C0C_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F7178A1586D3EC51129D13B0C3AD2C0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F7178A1586D3EC51129D13B0C3AD2C0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F7178A1586D3EC51129D13B0C3AD2C0C" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F7178A1586D3EC51129D13B0C3AD2C0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_8108907AB01CB4F0553613B0C3AD218B_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_8108907AB01CB4F0553613B0C3AD218B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of Series A convertible preferred stock and common stock warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_8108907AB01CB4F0553613B0C3AD218B_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_8108907AB01CB4F0553613B0C3AD218B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_8108907AB01CB4F0553613B0C3AD218B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_8108907AB01CB4F0553613B0C3AD218B" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_8108907AB01CB4F0553613B0C3AD218B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_395F6595F49BF2013BE213B0C3ADA3DE_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_395F6595F49BF2013BE213B0C3ADA3DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_395F6595F49BF2013BE213B0C3ADA3DE_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_395F6595F49BF2013BE213B0C3ADA3DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_395F6595F49BF2013BE213B0C3ADA3DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_395F6595F49BF2013BE213B0C3ADA3DE" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_395F6595F49BF2013BE213B0C3ADA3DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDividends_50DEBBBA25DCE0D8263E13B0C3AECA11_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends_50DEBBBA25DCE0D8263E13B0C3AECA11" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_50DEBBBA25DCE0D8263E13B0C3AECA11_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends_50DEBBBA25DCE0D8263E13B0C3AECA11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends_50DEBBBA25DCE0D8263E13B0C3AECA11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends_50DEBBBA25DCE0D8263E13B0C3AECA11" xlink:to="lab_us-gaap_PaymentsOfDividends_50DEBBBA25DCE0D8263E13B0C3AECA11" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_1A0F732853A8088D221013B0C3AEF3CF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_1A0F732853A8088D221013B0C3AEF3CF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_1A0F732853A8088D221013B0C3AEF3CF_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_1A0F732853A8088D221013B0C3AEF3CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_1A0F732853A8088D221013B0C3AEF3CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_1A0F732853A8088D221013B0C3AEF3CF" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_1A0F732853A8088D221013B0C3AEF3CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9E1D1FCD78BC52043E8413B0C3AE4C21_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9E1D1FCD78BC52043E8413B0C3AE4C21" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9E1D1FCD78BC52043E8413B0C3AE4C21_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9E1D1FCD78BC52043E8413B0C3AE4C21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9E1D1FCD78BC52043E8413B0C3AE4C21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9E1D1FCD78BC52043E8413B0C3AE4C21" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9E1D1FCD78BC52043E8413B0C3AE4C21" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_29E2B83D21802143956013B0C3AE6E81_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_29E2B83D21802143956013B0C3AE6E81" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_29E2B83D21802143956013B0C3AE6E81_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_29E2B83D21802143956013B0C3AE6E81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_29E2B83D21802143956013B0C3AE6E81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_29E2B83D21802143956013B0C3AE6E81" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_29E2B83D21802143956013B0C3AE6E81" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_511A07E21118005AE9BD13B0C3AE8F60_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_511A07E21118005AE9BD13B0C3AE8F60" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_511A07E21118005AE9BD13B0C3AE8F60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_511A07E21118005AE9BD13B0C3AE8F60" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_511A07E21118005AE9BD13B0C3AE8F60" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2554ECBBE2F4DEA7ADEF13B0C3AE7CAA_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2554ECBBE2F4DEA7ADEF13B0C3AE7CAA" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2554ECBBE2F4DEA7ADEF13B0C3AE7CAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2554ECBBE2F4DEA7ADEF13B0C3AE7CAA" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2554ECBBE2F4DEA7ADEF13B0C3AE7CAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_C999377BD247C1504ABA13B0C3AF6EC5_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_C999377BD247C1504ABA13B0C3AF6EC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_C999377BD247C1504ABA13B0C3AF6EC5_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_C999377BD247C1504ABA13B0C3AF6EC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_C999377BD247C1504ABA13B0C3AF6EC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_C999377BD247C1504ABA13B0C3AF6EC5" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_C999377BD247C1504ABA13B0C3AF6EC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_88566FECEB5A65651B5A13B0C3AF3A30_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived_88566FECEB5A65651B5A13B0C3AF3A30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received during the periods for interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_88566FECEB5A65651B5A13B0C3AF3A30_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived_88566FECEB5A65651B5A13B0C3AF3A30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_88566FECEB5A65651B5A13B0C3AF3A30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInterestReceived_88566FECEB5A65651B5A13B0C3AF3A30" xlink:to="lab_us-gaap_ProceedsFromInterestReceived_88566FECEB5A65651B5A13B0C3AF3A30" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_23C61AECA86CC8CB61B413B0C3AF1E32_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_23C61AECA86CC8CB61B413B0C3AF1E32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid during the periods for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_23C61AECA86CC8CB61B413B0C3AF1E32_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_23C61AECA86CC8CB61B413B0C3AF1E32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_23C61AECA86CC8CB61B413B0C3AF1E32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_23C61AECA86CC8CB61B413B0C3AF1E32" xlink:to="lab_us-gaap_InterestPaidNet_23C61AECA86CC8CB61B413B0C3AF1E32" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_A04A3CE123CD72B4117213B0C3AF17BD_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_A04A3CE123CD72B4117213B0C3AF17BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_A04A3CE123CD72B4117213B0C3AF17BD_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_A04A3CE123CD72B4117213B0C3AF17BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_A04A3CE123CD72B4117213B0C3AF17BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_A04A3CE123CD72B4117213B0C3AF17BD" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_A04A3CE123CD72B4117213B0C3AF17BD" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_278DDA521F81373AD83713B0C3AFA1BF_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_278DDA521F81373AD83713B0C3AFA1BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock recorded as issuance cost</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_278DDA521F81373AD83713B0C3AFA1BF_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_278DDA521F81373AD83713B0C3AFA1BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_278DDA521F81373AD83713B0C3AFA1BF_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_278DDA521F81373AD83713B0C3AFA1BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of warrants issued in connection with common stock recorded as a cost of equity.</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:label="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_278DDA521F81373AD83713B0C3AFA1BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_278DDA521F81373AD83713B0C3AFA1BF" xlink:to="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_278DDA521F81373AD83713B0C3AFA1BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_99D3FDEB704B817B8FB613B0C3B0FCB3_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_99D3FDEB704B817B8FB613B0C3B0FCB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of interest and principal on long-term debt through issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_99D3FDEB704B817B8FB613B0C3B0FCB3_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_99D3FDEB704B817B8FB613B0C3B0FCB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_99D3FDEB704B817B8FB613B0C3B0FCB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1_99D3FDEB704B817B8FB613B0C3B0FCB3" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1_99D3FDEB704B817B8FB613B0C3B0FCB3" xlink:type="arc" />
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_130D84AED5C367430BD913B0C3B0C94B_terseLabel_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_130D84AED5C367430BD913B0C3B0C94B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of warrant liabilities upon exchange for shares of common stock</link:label>
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_130D84AED5C367430BD913B0C3B0C94B_label_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_130D84AED5C367430BD913B0C3B0C94B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Of Warrant Liabilities Upon Exchange For Shares Of Common Stock</link:label>
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_130D84AED5C367430BD913B0C3B0C94B_documentation_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_130D84AED5C367430BD913B0C3B0C94B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification Of Warrant Liabilities Upon Exchange For Shares Of Common Stock</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock" xlink:label="loc_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_130D84AED5C367430BD913B0C3B0C94B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_130D84AED5C367430BD913B0C3B0C94B" xlink:to="lab_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_130D84AED5C367430BD913B0C3B0C94B" xlink:type="arc" />
    <link:label id="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_3EB1DFE69B87000D009B13B0C3B06B7F_terseLabel_en-US" xlink:label="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_3EB1DFE69B87000D009B13B0C3B06B7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of anti-dilution protection on liability-classified warrants</link:label>
    <link:label id="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_3EB1DFE69B87000D009B13B0C3B06B7F_label_en-US" xlink:label="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_3EB1DFE69B87000D009B13B0C3B06B7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Fair Value Of Warrant Liability</link:label>
    <link:label id="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_3EB1DFE69B87000D009B13B0C3B06B7F_documentation_en-US" xlink:label="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_3EB1DFE69B87000D009B13B0C3B06B7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Fair Value Of Warrant Liability</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:label="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_3EB1DFE69B87000D009B13B0C3B06B7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_3EB1DFE69B87000D009B13B0C3B06B7F" xlink:to="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_3EB1DFE69B87000D009B13B0C3B06B7F" xlink:type="arc" />
    <link:label id="lab_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_09A3D82CF2CE43A468D113B0C3B0178F_terseLabel_en-US" xlink:label="lab_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_09A3D82CF2CE43A468D113B0C3B0178F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issued in connection with warrant exchange agreements</link:label>
    <link:label id="lab_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_09A3D82CF2CE43A468D113B0C3B0178F_label_en-US" xlink:label="lab_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_09A3D82CF2CE43A468D113B0C3B0178F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt Issued In Connection With Warrant Exchanges</link:label>
    <link:label id="lab_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_09A3D82CF2CE43A468D113B0C3B0178F_documentation_en-US" xlink:label="lab_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_09A3D82CF2CE43A468D113B0C3B0178F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Debt Issued In Connection With Warrant Exchanges</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_LongtermDebtIssuedInConnectionWithWarrantExchanges" xlink:label="loc_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_09A3D82CF2CE43A468D113B0C3B0178F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_09A3D82CF2CE43A468D113B0C3B0178F" xlink:to="lab_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_09A3D82CF2CE43A468D113B0C3B0178F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_1AC74E994E09ADA9B79717BCCEC95884_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_1AC74E994E09ADA9B79717BCCEC95884" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_1AC74E994E09ADA9B79717BCCEC95884_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_1AC74E994E09ADA9B79717BCCEC95884" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_1AC74E994E09ADA9B79717BCCEC95884" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_1AC74E994E09ADA9B79717BCCEC95884" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock_1AC74E994E09ADA9B79717BCCEC95884" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_52E2E4432E2A02AB07F808F2AE20B4E5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_52E2E4432E2A02AB07F808F2AE20B4E5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_52E2E4432E2A02AB07F808F2AE20B4E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_52E2E4432E2A02AB07F808F2AE20B4E5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_52E2E4432E2A02AB07F808F2AE20B4E5" xlink:type="arc" />
    <link:label id="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_621C369CF6F871616B6A08F2AE21E094_terseLabel_en-US" xlink:label="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_621C369CF6F871616B6A08F2AE21E094" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options reserved for future issuance under the Company's 2017 Incentive Plan (in shares)</link:label>
    <link:label id="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_621C369CF6F871616B6A08F2AE21E094_label_en-US" xlink:label="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_621C369CF6F871616B6A08F2AE21E094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options Reserved For Future Issuance Under Companies Incentive Plan</link:label>
    <link:label id="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_621C369CF6F871616B6A08F2AE21E094_documentation_en-US" xlink:label="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_621C369CF6F871616B6A08F2AE21E094" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options reserved for future issuance under the Company's 2007 Incentive Plan.</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:label="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_621C369CF6F871616B6A08F2AE21E094" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_621C369CF6F871616B6A08F2AE21E094" xlink:to="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_621C369CF6F871616B6A08F2AE21E094" xlink:type="arc" />
    <link:label id="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_EA4F841CEAA3F48FF32608F2AE21ACB8_terseLabel_en-US" xlink:label="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_EA4F841CEAA3F48FF32608F2AE21ACB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserved for future issuance under the Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_EA4F841CEAA3F48FF32608F2AE21ACB8_label_en-US" xlink:label="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_EA4F841CEAA3F48FF32608F2AE21ACB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan</link:label>
    <link:label id="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_EA4F841CEAA3F48FF32608F2AE21ACB8_documentation_en-US" xlink:label="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_EA4F841CEAA3F48FF32608F2AE21ACB8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:label="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_EA4F841CEAA3F48FF32608F2AE21ACB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_EA4F841CEAA3F48FF32608F2AE21ACB8" xlink:to="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_EA4F841CEAA3F48FF32608F2AE21ACB8" xlink:type="arc" />
    <link:label id="lab_gale_RestrictedStockSharesReservedforFutureIssuance_144CDE3169541AEED58408F2AE216E92_terseLabel_en-US" xlink:label="lab_gale_RestrictedStockSharesReservedforFutureIssuance_144CDE3169541AEED58408F2AE216E92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units (in shares)</link:label>
    <link:label id="lab_gale_RestrictedStockSharesReservedforFutureIssuance_144CDE3169541AEED58408F2AE216E92_label_en-US" xlink:label="lab_gale_RestrictedStockSharesReservedforFutureIssuance_144CDE3169541AEED58408F2AE216E92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock, Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_gale_RestrictedStockSharesReservedforFutureIssuance_144CDE3169541AEED58408F2AE216E92_documentation_en-US" xlink:label="lab_gale_RestrictedStockSharesReservedforFutureIssuance_144CDE3169541AEED58408F2AE216E92" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock, Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_RestrictedStockSharesReservedforFutureIssuance" xlink:label="loc_gale_RestrictedStockSharesReservedforFutureIssuance_144CDE3169541AEED58408F2AE216E92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_RestrictedStockSharesReservedforFutureIssuance_144CDE3169541AEED58408F2AE216E92" xlink:to="lab_gale_RestrictedStockSharesReservedforFutureIssuance_144CDE3169541AEED58408F2AE216E92" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_BD44B07637E196479FC608F2AE215C5A_totalLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_BD44B07637E196479FC608F2AE215C5A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_BD44B07637E196479FC608F2AE215C5A_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_BD44B07637E196479FC608F2AE215C5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_BD44B07637E196479FC608F2AE215C5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_BD44B07637E196479FC608F2AE215C5A" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_BD44B07637E196479FC608F2AE215C5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_B9D56BD8F7872BE675E90E609EABC312_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_B9D56BD8F7872BE675E90E609EABC312" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_B9D56BD8F7872BE675E90E609EABC312_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_B9D56BD8F7872BE675E90E609EABC312" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_B9D56BD8F7872BE675E90E609EABC312" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_B9D56BD8F7872BE675E90E609EABC312" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_B9D56BD8F7872BE675E90E609EABC312" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_C54A519B2EE4B6CF99F10E609EAB71EC_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_C54A519B2EE4B6CF99F10E609EAB71EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_C54A519B2EE4B6CF99F10E609EAB71EC_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_C54A519B2EE4B6CF99F10E609EAB71EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_C54A519B2EE4B6CF99F10E609EAB71EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C54A519B2EE4B6CF99F10E609EAB71EC" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_C54A519B2EE4B6CF99F10E609EAB71EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_DCAACDE3ADFC569E9A830E609EABD56D_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_DCAACDE3ADFC569E9A830E609EABD56D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_DCAACDE3ADFC569E9A830E609EABD56D_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_DCAACDE3ADFC569E9A830E609EABD56D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_DCAACDE3ADFC569E9A830E609EABD56D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember_DCAACDE3ADFC569E9A830E609EABD56D" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember_DCAACDE3ADFC569E9A830E609EABD56D" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_1E539B698F505024BDB90E609EAC29BE_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_1E539B698F505024BDB90E609EAC29BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_1E539B698F505024BDB90E609EAC29BE_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_1E539B698F505024BDB90E609EAC29BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1E539B698F505024BDB90E609EAC29BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1E539B698F505024BDB90E609EAC29BE" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_1E539B698F505024BDB90E609EAC29BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_BC5448849703FFCD3ECB0E609EAC90C1_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember_BC5448849703FFCD3ECB0E609EAC90C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_BC5448849703FFCD3ECB0E609EAC90C1_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember_BC5448849703FFCD3ECB0E609EAC90C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_BC5448849703FFCD3ECB0E609EAC90C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember_BC5448849703FFCD3ECB0E609EAC90C1" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember_BC5448849703FFCD3ECB0E609EAC90C1" xlink:type="arc" />
    <link:label id="lab_gale_ConvertiblePromissoryNotesMember_ED79EAA365D762FB31750E609EACF3E2_terseLabel_en-US" xlink:label="lab_gale_ConvertiblePromissoryNotesMember_ED79EAA365D762FB31750E609EACF3E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Promissory Notes</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ConvertiblePromissoryNotesMember" xlink:label="loc_gale_ConvertiblePromissoryNotesMember_ED79EAA365D762FB31750E609EACF3E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ConvertiblePromissoryNotesMember_ED79EAA365D762FB31750E609EACF3E2" xlink:to="lab_gale_ConvertiblePromissoryNotesMember_ED79EAA365D762FB31750E609EACF3E2" xlink:type="arc" />
    <link:label id="lab_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_1E7AF1B47F7E466002380E609EAE81A0_terseLabel_en-US" xlink:label="lab_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_1E7AF1B47F7E466002380E609EAE81A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued for cancellation of warrants (in shares)</link:label>
    <link:label id="lab_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_1E7AF1B47F7E466002380E609EAE81A0_label_en-US" xlink:label="lab_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_1E7AF1B47F7E466002380E609EAE81A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Issued During The Period For Cancellation Of Warrants</link:label>
    <link:label id="lab_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_1E7AF1B47F7E466002380E609EAE81A0_documentation_en-US" xlink:label="lab_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_1E7AF1B47F7E466002380E609EAE81A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Issued During The Period For Cancellation Of Warrants</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants" xlink:label="loc_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_1E7AF1B47F7E466002380E609EAE81A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_1E7AF1B47F7E466002380E609EAE81A0" xlink:to="lab_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_1E7AF1B47F7E466002380E609EAE81A0" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_E144AF39CE5D030773110E609EAF8DC2_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_E144AF39CE5D030773110E609EAF8DC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Surrender and cancellation of warrants (in shares)</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_E144AF39CE5D030773110E609EAF8DC2_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_E144AF39CE5D030773110E609EAF8DC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Surrendered and Canceled to Purchase Common Stock</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_E144AF39CE5D030773110E609EAF8DC2_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_E144AF39CE5D030773110E609EAF8DC2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Surrendered and Canceled to Purchase Common Stock</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock" xlink:label="loc_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_E144AF39CE5D030773110E609EAF8DC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_E144AF39CE5D030773110E609EAF8DC2" xlink:to="lab_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_E144AF39CE5D030773110E609EAF8DC2" xlink:type="arc" />
    <link:label id="lab_gale_ConsiderationExchangedFairValue_CE138648E97C9F5C51BA0E609EAF647D_terseLabel_en-US" xlink:label="lab_gale_ConsiderationExchangedFairValue_CE138648E97C9F5C51BA0E609EAF647D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of consideration exchanged</link:label>
    <link:label id="lab_gale_ConsiderationExchangedFairValue_CE138648E97C9F5C51BA0E609EAF647D_label_en-US" xlink:label="lab_gale_ConsiderationExchangedFairValue_CE138648E97C9F5C51BA0E609EAF647D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration Exchanged, Fair Value</link:label>
    <link:label id="lab_gale_ConsiderationExchangedFairValue_CE138648E97C9F5C51BA0E609EAF647D_documentation_en-US" xlink:label="lab_gale_ConsiderationExchangedFairValue_CE138648E97C9F5C51BA0E609EAF647D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consideration Exchanged, Fair Value</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ConsiderationExchangedFairValue" xlink:label="loc_gale_ConsiderationExchangedFairValue_CE138648E97C9F5C51BA0E609EAF647D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ConsiderationExchangedFairValue_CE138648E97C9F5C51BA0E609EAF647D" xlink:to="lab_gale_ConsiderationExchangedFairValue_CE138648E97C9F5C51BA0E609EAF647D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_922F3CF601C25B70C6400E609EB0FE9D_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_922F3CF601C25B70C6400E609EB0FE9D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_922F3CF601C25B70C6400E609EB0FE9D_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_922F3CF601C25B70C6400E609EB0FE9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_922F3CF601C25B70C6400E609EB0FE9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_922F3CF601C25B70C6400E609EB0FE9D" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_922F3CF601C25B70C6400E609EB0FE9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_66BB263E0046A8D8758E0E609EB0B14D_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_66BB263E0046A8D8758E0E609EB0B14D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants and rights outstanding, measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_66BB263E0046A8D8758E0E609EB0B14D_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_66BB263E0046A8D8758E0E609EB0B14D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_66BB263E0046A8D8758E0E609EB0B14D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_66BB263E0046A8D8758E0E609EB0B14D" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_66BB263E0046A8D8758E0E609EB0B14D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6E58879CED0AD3F4597317BCCDDB0774_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6E58879CED0AD3F4597317BCCDDB0774" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6E58879CED0AD3F4597317BCCDDB0774_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6E58879CED0AD3F4597317BCCDDB0774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6E58879CED0AD3F4597317BCCDDB0774" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6E58879CED0AD3F4597317BCCDDB0774" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6E58879CED0AD3F4597317BCCDDB0774" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_DF1637511DA6A7CF99F90891C4D7807B_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_DF1637511DA6A7CF99F90891C4D7807B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_DF1637511DA6A7CF99F90891C4D7807B_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_DF1637511DA6A7CF99F90891C4D7807B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_DF1637511DA6A7CF99F90891C4D7807B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_DF1637511DA6A7CF99F90891C4D7807B" xlink:to="lab_us-gaap_AssetsAbstract_DF1637511DA6A7CF99F90891C4D7807B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_2FF7E513E3720D99DC000891C4D7FEE7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_2FF7E513E3720D99DC000891C4D7FEE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_2FF7E513E3720D99DC000891C4D7FEE7_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_2FF7E513E3720D99DC000891C4D7FEE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2FF7E513E3720D99DC000891C4D7FEE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2FF7E513E3720D99DC000891C4D7FEE7" xlink:to="lab_us-gaap_AssetsCurrentAbstract_2FF7E513E3720D99DC000891C4D7FEE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7D2866937AE5E309463D0891C4D9A14D_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7D2866937AE5E309463D0891C4D9A14D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7D2866937AE5E309463D0891C4D9A14D_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7D2866937AE5E309463D0891C4D9A14D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7D2866937AE5E309463D0891C4D9A14D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7D2866937AE5E309463D0891C4D9A14D" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7D2866937AE5E309463D0891C4D9A14D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_3C880301EA0B8CA7A4B30891C4D97FDA_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_3C880301EA0B8CA7A4B30891C4D97FDA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_3C880301EA0B8CA7A4B30891C4D97FDA_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_3C880301EA0B8CA7A4B30891C4D97FDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_3C880301EA0B8CA7A4B30891C4D97FDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_3C880301EA0B8CA7A4B30891C4D97FDA" xlink:to="lab_us-gaap_AssetsCurrent_3C880301EA0B8CA7A4B30891C4D97FDA" xlink:type="arc" />
    <link:label id="lab_gale_InProcessResearchDevelopment_0FF156F14BF2978B13830891C4D9D398_terseLabel_en-US" xlink:label="lab_gale_InProcessResearchDevelopment_0FF156F14BF2978B13830891C4D9D398" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_gale_InProcessResearchDevelopment_0FF156F14BF2978B13830891C4D9D398_label_en-US" xlink:label="lab_gale_InProcessResearchDevelopment_0FF156F14BF2978B13830891C4D9D398" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research Development</link:label>
    <link:label id="lab_gale_InProcessResearchDevelopment_0FF156F14BF2978B13830891C4D9D398_documentation_en-US" xlink:label="lab_gale_InProcessResearchDevelopment_0FF156F14BF2978B13830891C4D9D398" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-process research and development.</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_InProcessResearchDevelopment" xlink:label="loc_gale_InProcessResearchDevelopment_0FF156F14BF2978B13830891C4D9D398" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_InProcessResearchDevelopment_0FF156F14BF2978B13830891C4D9D398" xlink:to="lab_gale_InProcessResearchDevelopment_0FF156F14BF2978B13830891C4D9D398" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_1753E2495EE77008F9F00891C4D9274E_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_1753E2495EE77008F9F00891C4D9274E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_1753E2495EE77008F9F00891C4D9274E_label_en-US" xlink:label="lab_us-gaap_Goodwill_1753E2495EE77008F9F00891C4D9274E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1753E2495EE77008F9F00891C4D9274E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_1753E2495EE77008F9F00891C4D9274E" xlink:to="lab_us-gaap_Goodwill_1753E2495EE77008F9F00891C4D9274E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_AC5D9821F23665524E4A0891C4DA9F84_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent_AC5D9821F23665524E4A0891C4DA9F84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposits and other assets</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_AC5D9821F23665524E4A0891C4DA9F84_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent_AC5D9821F23665524E4A0891C4DA9F84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposits Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_AC5D9821F23665524E4A0891C4DA9F84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsNoncurrent_AC5D9821F23665524E4A0891C4DA9F84" xlink:to="lab_us-gaap_DepositsAssetsNoncurrent_AC5D9821F23665524E4A0891C4DA9F84" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_865ED972D670975D16ED0891C4DA9E9A_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_865ED972D670975D16ED0891C4DA9E9A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_865ED972D670975D16ED0891C4DA9E9A_label_en-US" xlink:label="lab_us-gaap_Assets_865ED972D670975D16ED0891C4DA9E9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_865ED972D670975D16ED0891C4DA9E9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_865ED972D670975D16ED0891C4DA9E9A" xlink:to="lab_us-gaap_Assets_865ED972D670975D16ED0891C4DA9E9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5A0DC4D81DE39E6D2C750891C4DAAEBB_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5A0DC4D81DE39E6D2C750891C4DAAEBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5A0DC4D81DE39E6D2C750891C4DAAEBB_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5A0DC4D81DE39E6D2C750891C4DAAEBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5A0DC4D81DE39E6D2C750891C4DAAEBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5A0DC4D81DE39E6D2C750891C4DAAEBB" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5A0DC4D81DE39E6D2C750891C4DAAEBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_AC015F12B0B0EC2053E60891C4DAE7A6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_AC015F12B0B0EC2053E60891C4DAE7A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_AC015F12B0B0EC2053E60891C4DAE7A6_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_AC015F12B0B0EC2053E60891C4DAE7A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_AC015F12B0B0EC2053E60891C4DAE7A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_AC015F12B0B0EC2053E60891C4DAE7A6" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_AC015F12B0B0EC2053E60891C4DAE7A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_C2713DB7F9BBFAEFD8500891C4DAF068_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_C2713DB7F9BBFAEFD8500891C4DAF068" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_C2713DB7F9BBFAEFD8500891C4DAF068" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_C2713DB7F9BBFAEFD8500891C4DAF068" xlink:to="lab_us-gaap_LongTermDebtCurrent_C2713DB7F9BBFAEFD8500891C4DAF068" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1C8F84A527C23167EAC60891C4DBD0F4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_1C8F84A527C23167EAC60891C4DBD0F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1C8F84A527C23167EAC60891C4DBD0F4_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_1C8F84A527C23167EAC60891C4DBD0F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_1C8F84A527C23167EAC60891C4DBD0F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_1C8F84A527C23167EAC60891C4DBD0F4" xlink:to="lab_us-gaap_AccountsPayableCurrent_1C8F84A527C23167EAC60891C4DBD0F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_29F6C9BC8C153E5092D10891C4DB7224_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_29F6C9BC8C153E5092D10891C4DB7224" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_29F6C9BC8C153E5092D10891C4DB7224_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_29F6C9BC8C153E5092D10891C4DB7224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_29F6C9BC8C153E5092D10891C4DB7224" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_29F6C9BC8C153E5092D10891C4DB7224" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_29F6C9BC8C153E5092D10891C4DB7224" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationReserveCurrent_376EC81B0FE160ED9B730891C4DBC82B_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent_376EC81B0FE160ED9B730891C4DBC82B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement payable</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_376EC81B0FE160ED9B730891C4DBC82B_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent_376EC81B0FE160ED9B730891C4DBC82B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaap_LitigationReserveCurrent_376EC81B0FE160ED9B730891C4DBC82B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent_376EC81B0FE160ED9B730891C4DBC82B" xlink:to="lab_us-gaap_LitigationReserveCurrent_376EC81B0FE160ED9B730891C4DBC82B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_D1F7AA0E255EC794E88C0891C4DB773E_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_D1F7AA0E255EC794E88C0891C4DB773E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_D1F7AA0E255EC794E88C0891C4DB773E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_D1F7AA0E255EC794E88C0891C4DB773E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_D1F7AA0E255EC794E88C0891C4DB773E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_D1F7AA0E255EC794E88C0891C4DB773E" xlink:to="lab_us-gaap_LiabilitiesCurrent_D1F7AA0E255EC794E88C0891C4DB773E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_BE1DC1A83874F75244C00891C4DBF590_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_BE1DC1A83874F75244C00891C4DBF590" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_BE1DC1A83874F75244C00891C4DBF590_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_BE1DC1A83874F75244C00891C4DBF590" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_BE1DC1A83874F75244C00891C4DBF590" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_BE1DC1A83874F75244C00891C4DBF590" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_BE1DC1A83874F75244C00891C4DBF590" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_0A3BF1DC5CF22B82DF400891C4DB0239_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_0A3BF1DC5CF22B82DF400891C4DB0239" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_0A3BF1DC5CF22B82DF400891C4DB0239" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_0A3BF1DC5CF22B82DF400891C4DB0239" xlink:to="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_0A3BF1DC5CF22B82DF400891C4DB0239" xlink:type="arc" />
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C4227BFBEF3F496EBF050891C4DC0044_terseLabel_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C4227BFBEF3F496EBF050891C4DC0044" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C4227BFBEF3F496EBF050891C4DC0044_label_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C4227BFBEF3F496EBF050891C4DC0044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Purchase Price Consideration Net Of Current Portion</link:label>
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C4227BFBEF3F496EBF050891C4DC0044_documentation_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C4227BFBEF3F496EBF050891C4DC0044" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent purchase price consideration, net of current portion.</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C4227BFBEF3F496EBF050891C4DC0044" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C4227BFBEF3F496EBF050891C4DC0044" xlink:to="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C4227BFBEF3F496EBF050891C4DC0044" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_C8299BF53B581D0008110891C4DCD60B_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_C8299BF53B581D0008110891C4DCD60B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_C8299BF53B581D0008110891C4DCD60B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_C8299BF53B581D0008110891C4DCD60B" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_C8299BF53B581D0008110891C4DCD60B" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_0E8595D7C3A5E611F5E50891C4DC5276_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_0E8595D7C3A5E611F5E50891C4DC5276" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_0E8595D7C3A5E611F5E50891C4DC5276_label_en-US" xlink:label="lab_us-gaap_Liabilities_0E8595D7C3A5E611F5E50891C4DC5276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_0E8595D7C3A5E611F5E50891C4DC5276" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_0E8595D7C3A5E611F5E50891C4DC5276" xlink:to="lab_us-gaap_Liabilities_0E8595D7C3A5E611F5E50891C4DC5276" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_765AB6DAE765791BA9CA0891C4DC8FC8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_765AB6DAE765791BA9CA0891C4DC8FC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_765AB6DAE765791BA9CA0891C4DC8FC8_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_765AB6DAE765791BA9CA0891C4DC8FC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_765AB6DAE765791BA9CA0891C4DC8FC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_765AB6DAE765791BA9CA0891C4DC8FC8" xlink:to="lab_us-gaap_CommitmentsAndContingencies_765AB6DAE765791BA9CA0891C4DC8FC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_5E2F886F65590272B8820891C4DCB963_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_5E2F886F65590272B8820891C4DCB963" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_5E2F886F65590272B8820891C4DCB963_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_5E2F886F65590272B8820891C4DCB963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5E2F886F65590272B8820891C4DCB963" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5E2F886F65590272B8820891C4DCB963" xlink:to="lab_us-gaap_StockholdersEquityAbstract_5E2F886F65590272B8820891C4DCB963" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_162BB44521DA5698169C0891C4DCE9BE_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_162BB44521DA5698169C0891C4DCE9BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; Series A convertible preferred stock, 17,500 shares designated; no shares issued and outstanding at September 30, 2018 and December 31, 2017</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_162BB44521DA5698169C0891C4DCE9BE_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_162BB44521DA5698169C0891C4DCE9BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_162BB44521DA5698169C0891C4DCE9BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_162BB44521DA5698169C0891C4DCE9BE" xlink:to="lab_us-gaap_PreferredStockValue_162BB44521DA5698169C0891C4DCE9BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_E7A99F5852417BDA6ED80891C4DD1DF1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_E7A99F5852417BDA6ED80891C4DD1DF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 350,000,000 shares authorized, 20,501,476 shares issued and outstanding at September 30, 2018; 5,766,891 shares issued and outstanding at December 31, 2017</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_E7A99F5852417BDA6ED80891C4DD1DF1_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_E7A99F5852417BDA6ED80891C4DD1DF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_E7A99F5852417BDA6ED80891C4DD1DF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_E7A99F5852417BDA6ED80891C4DD1DF1" xlink:to="lab_us-gaap_CommonStockValue_E7A99F5852417BDA6ED80891C4DD1DF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_ECD45D8DAA4041ACC6A40891C4DDB27A_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_ECD45D8DAA4041ACC6A40891C4DDB27A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_ECD45D8DAA4041ACC6A40891C4DDB27A_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_ECD45D8DAA4041ACC6A40891C4DDB27A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ECD45D8DAA4041ACC6A40891C4DDB27A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ECD45D8DAA4041ACC6A40891C4DDB27A" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_ECD45D8DAA4041ACC6A40891C4DDB27A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2FC23503DFDC82FFF1CD0891C4DD6A98_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2FC23503DFDC82FFF1CD0891C4DD6A98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2FC23503DFDC82FFF1CD0891C4DD6A98_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2FC23503DFDC82FFF1CD0891C4DD6A98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2FC23503DFDC82FFF1CD0891C4DD6A98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2FC23503DFDC82FFF1CD0891C4DD6A98" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2FC23503DFDC82FFF1CD0891C4DD6A98" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_8473B24667B2E68E67250891C4DDC8E6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_8473B24667B2E68E67250891C4DDC8E6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_8473B24667B2E68E67250891C4DDC8E6_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_8473B24667B2E68E67250891C4DDC8E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8473B24667B2E68E67250891C4DDC8E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_8473B24667B2E68E67250891C4DDC8E6" xlink:to="lab_us-gaap_StockholdersEquity_8473B24667B2E68E67250891C4DDC8E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_DD4C14028108006888C20891C4DDBBF2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_DD4C14028108006888C20891C4DDBBF2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_DD4C14028108006888C20891C4DDBBF2_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_DD4C14028108006888C20891C4DDBBF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_DD4C14028108006888C20891C4DDBBF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_DD4C14028108006888C20891C4DDBBF2" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_DD4C14028108006888C20891C4DDBBF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BF5FEAE695436D01D52A17BCD0B5B43A_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BF5FEAE695436D01D52A17BCD0B5B43A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BF5FEAE695436D01D52A17BCD0B5B43A_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BF5FEAE695436D01D52A17BCD0B5B43A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BF5FEAE695436D01D52A17BCD0B5B43A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BF5FEAE695436D01D52A17BCD0B5B43A" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BF5FEAE695436D01D52A17BCD0B5B43A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_EB1AA0182B3B8F100B08139A7271B5C6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_EB1AA0182B3B8F100B08139A7271B5C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_EB1AA0182B3B8F100B08139A7271B5C6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_EB1AA0182B3B8F100B08139A7271B5C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_EB1AA0182B3B8F100B08139A7271B5C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_EB1AA0182B3B8F100B08139A7271B5C6" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_EB1AA0182B3B8F100B08139A7271B5C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonrecurringAdjustmentAxis_B12E75E214B7B9DDCA81139A7272A3A0_terseLabel_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentAxis_B12E75E214B7B9DDCA81139A7272A3A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrecurring Adjustment [Axis]</link:label>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentAxis_B12E75E214B7B9DDCA81139A7272A3A0_label_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentAxis_B12E75E214B7B9DDCA81139A7272A3A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrecurring Adjustment [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonrecurringAdjustmentAxis" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis_B12E75E214B7B9DDCA81139A7272A3A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_B12E75E214B7B9DDCA81139A7272A3A0" xlink:to="lab_us-gaap_NonrecurringAdjustmentAxis_B12E75E214B7B9DDCA81139A7272A3A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonrecurringAdjustmentDomain_0FB44404F63E70E9A1C6139A7272D3D1_terseLabel_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentDomain_0FB44404F63E70E9A1C6139A7272D3D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrecurring Adjustment [Domain]</link:label>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentDomain_0FB44404F63E70E9A1C6139A7272D3D1_label_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentDomain_0FB44404F63E70E9A1C6139A7272D3D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrecurring Adjustment [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_0FB44404F63E70E9A1C6139A7272D3D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_0FB44404F63E70E9A1C6139A7272D3D1" xlink:to="lab_us-gaap_NonrecurringAdjustmentDomain_0FB44404F63E70E9A1C6139A7272D3D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcquisitionRelatedCostsMember_62B9144C2AF5DBFDF074139A72723221_terseLabel_en-US" xlink:label="lab_us-gaap_AcquisitionRelatedCostsMember_62B9144C2AF5DBFDF074139A72723221" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Historical Interest Expense</link:label>
    <link:label id="lab_us-gaap_AcquisitionRelatedCostsMember_62B9144C2AF5DBFDF074139A72723221_label_en-US" xlink:label="lab_us-gaap_AcquisitionRelatedCostsMember_62B9144C2AF5DBFDF074139A72723221" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition-related Costs [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquisitionRelatedCostsMember" xlink:label="loc_us-gaap_AcquisitionRelatedCostsMember_62B9144C2AF5DBFDF074139A72723221" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquisitionRelatedCostsMember_62B9144C2AF5DBFDF074139A72723221" xlink:to="lab_us-gaap_AcquisitionRelatedCostsMember_62B9144C2AF5DBFDF074139A72723221" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_EB6614E6435DB5E2A9D4139A72736210_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_EB6614E6435DB5E2A9D4139A72736210" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_EB6614E6435DB5E2A9D4139A72736210_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_EB6614E6435DB5E2A9D4139A72736210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_EB6614E6435DB5E2A9D4139A72736210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_EB6614E6435DB5E2A9D4139A72736210" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_EB6614E6435DB5E2A9D4139A72736210" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_FA20D3E4474DDE6D1839139A72733C50_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_FA20D3E4474DDE6D1839139A72733C50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic net loss per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_FA20D3E4474DDE6D1839139A72733C50_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_FA20D3E4474DDE6D1839139A72733C50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_FA20D3E4474DDE6D1839139A72733C50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_FA20D3E4474DDE6D1839139A72733C50" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_FA20D3E4474DDE6D1839139A72733C50" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_CFDD4826AF6DAE0C1FCF139A7273AAA2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_CFDD4826AF6DAE0C1FCF139A7273AAA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net loss per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_CFDD4826AF6DAE0C1FCF139A7273AAA2_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_CFDD4826AF6DAE0C1FCF139A7273AAA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_CFDD4826AF6DAE0C1FCF139A7273AAA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_CFDD4826AF6DAE0C1FCF139A7273AAA2" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_CFDD4826AF6DAE0C1FCF139A7273AAA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_27EBFA3BDFBB60C6AFAD139A7273E71B_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_27EBFA3BDFBB60C6AFAD139A7273E71B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pro forma adjustments to net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_27EBFA3BDFBB60C6AFAD139A7273E71B_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_27EBFA3BDFBB60C6AFAD139A7273E71B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_27EBFA3BDFBB60C6AFAD139A7273E71B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_27EBFA3BDFBB60C6AFAD139A7273E71B" xlink:to="lab_us-gaap_ProfitLoss_27EBFA3BDFBB60C6AFAD139A7273E71B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_AFDCE2F5311DF980671A139A7273AB06_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_AFDCE2F5311DF980671A139A7273AB06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible notes</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_AFDCE2F5311DF980671A139A7273AB06_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_AFDCE2F5311DF980671A139A7273AB06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_AFDCE2F5311DF980671A139A7273AB06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_AFDCE2F5311DF980671A139A7273AB06" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_AFDCE2F5311DF980671A139A7273AB06" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_E8B062E9E8EE98348EB1139A7273CF7C_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_E8B062E9E8EE98348EB1139A7273CF7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and intangible assets impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_E8B062E9E8EE98348EB1139A7273CF7C_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_E8B062E9E8EE98348EB1139A7273CF7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_E8B062E9E8EE98348EB1139A7273CF7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_E8B062E9E8EE98348EB1139A7273CF7C" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_E8B062E9E8EE98348EB1139A7273CF7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_3AAD9B86E3DF4F5AA508139A7274AAC3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_3AAD9B86E3DF4F5AA508139A7274AAC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition, transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_3AAD9B86E3DF4F5AA508139A7274AAC3_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_3AAD9B86E3DF4F5AA508139A7274AAC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_3AAD9B86E3DF4F5AA508139A7274AAC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_3AAD9B86E3DF4F5AA508139A7274AAC3" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_3AAD9B86E3DF4F5AA508139A7274AAC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_51817762E2E16364202E17BCCE9E81F1_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_51817762E2E16364202E17BCCE9E81F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_51817762E2E16364202E17BCCE9E81F1_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_51817762E2E16364202E17BCCE9E81F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_51817762E2E16364202E17BCCE9E81F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_51817762E2E16364202E17BCCE9E81F1" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_51817762E2E16364202E17BCCE9E81F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_DD920E236A1DBD03A08B139A72C9C9B5_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_DD920E236A1DBD03A08B139A72C9C9B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_DD920E236A1DBD03A08B139A72C9C9B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_DD920E236A1DBD03A08B139A72C9C9B5" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_DD920E236A1DBD03A08B139A72C9C9B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_239F1233EFED7081378B139A72CB0CA1_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_239F1233EFED7081378B139A72CB0CA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_239F1233EFED7081378B139A72CB0CA1_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_239F1233EFED7081378B139A72CB0CA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_239F1233EFED7081378B139A72CB0CA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember_239F1233EFED7081378B139A72CB0CA1" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember_239F1233EFED7081378B139A72CB0CA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_435BF2C8E1E36CFB0959139A72CD9F2D_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_435BF2C8E1E36CFB0959139A72CD9F2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_435BF2C8E1E36CFB0959139A72CD9F2D_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_435BF2C8E1E36CFB0959139A72CD9F2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_435BF2C8E1E36CFB0959139A72CD9F2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_435BF2C8E1E36CFB0959139A72CD9F2D" xlink:to="lab_us-gaap_PreferredStockMember_435BF2C8E1E36CFB0959139A72CD9F2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_C57B506FAA718B6F646B139A72CD2341_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_C57B506FAA718B6F646B139A72CD2341" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_C57B506FAA718B6F646B139A72CD2341" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_C57B506FAA718B6F646B139A72CD2341" xlink:to="lab_us-gaap_CommonStockMember_C57B506FAA718B6F646B139A72CD2341" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_22F9B599838556C72ED7139A72CD34C1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_22F9B599838556C72ED7139A72CD34C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_22F9B599838556C72ED7139A72CD34C1_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_22F9B599838556C72ED7139A72CD34C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_22F9B599838556C72ED7139A72CD34C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_22F9B599838556C72ED7139A72CD34C1" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_22F9B599838556C72ED7139A72CD34C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_A02C396EAEAE02BCE154139A72CEE70F_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_A02C396EAEAE02BCE154139A72CEE70F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_A02C396EAEAE02BCE154139A72CEE70F_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_A02C396EAEAE02BCE154139A72CEE70F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_A02C396EAEAE02BCE154139A72CEE70F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_A02C396EAEAE02BCE154139A72CEE70F" xlink:to="lab_us-gaap_RetainedEarningsMember_A02C396EAEAE02BCE154139A72CEE70F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_98030877B39A9894DEF3139A72CE838D_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_98030877B39A9894DEF3139A72CE838D" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_98030877B39A9894DEF3139A72CE838D_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_98030877B39A9894DEF3139A72CE838D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_98030877B39A9894DEF3139A72CE838D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_98030877B39A9894DEF3139A72CE838D" xlink:to="lab_us-gaap_SharesOutstanding_98030877B39A9894DEF3139A72CE838D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D45E931BD3B83E9A81F0139A72CFF982_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D45E931BD3B83E9A81F0139A72CFF982" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D45E931BD3B83E9A81F0139A72CFF982_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D45E931BD3B83E9A81F0139A72CFF982" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D45E931BD3B83E9A81F0139A72CFF982" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D45E931BD3B83E9A81F0139A72CFF982" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D45E931BD3B83E9A81F0139A72CFF982" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C87707F3ABA94D7C5C3139A72CFC00A_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C87707F3ABA94D7C5C3139A72CFC00A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C87707F3ABA94D7C5C3139A72CFC00A_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C87707F3ABA94D7C5C3139A72CFC00A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C87707F3ABA94D7C5C3139A72CFC00A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C87707F3ABA94D7C5C3139A72CFC00A" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C87707F3ABA94D7C5C3139A72CFC00A" xlink:type="arc" />
    <link:label id="lab_gale_PreferredStockIssuedDuringPeriodValueNewIssues_F91DD5F1A114339E477E139A72CF8AAC_terseLabel_en-US" xlink:label="lab_gale_PreferredStockIssuedDuringPeriodValueNewIssues_F91DD5F1A114339E477E139A72CF8AAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Series A convertible preferred stock, net of offering costs</link:label>
    <link:label id="lab_gale_PreferredStockIssuedDuringPeriodValueNewIssues_F91DD5F1A114339E477E139A72CF8AAC_label_en-US" xlink:label="lab_gale_PreferredStockIssuedDuringPeriodValueNewIssues_F91DD5F1A114339E477E139A72CF8AAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Issued During Period, Value, New Issues</link:label>
    <link:label id="lab_gale_PreferredStockIssuedDuringPeriodValueNewIssues_F91DD5F1A114339E477E139A72CF8AAC_documentation_en-US" xlink:label="lab_gale_PreferredStockIssuedDuringPeriodValueNewIssues_F91DD5F1A114339E477E139A72CF8AAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_PreferredStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_gale_PreferredStockIssuedDuringPeriodValueNewIssues_F91DD5F1A114339E477E139A72CF8AAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PreferredStockIssuedDuringPeriodValueNewIssues_F91DD5F1A114339E477E139A72CF8AAC" xlink:to="lab_gale_PreferredStockIssuedDuringPeriodValueNewIssues_F91DD5F1A114339E477E139A72CF8AAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ADE5FB63D188A7CB169139A72CFCE6A_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ADE5FB63D188A7CB169139A72CFCE6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock, amount</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ADE5FB63D188A7CB169139A72CFCE6A_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ADE5FB63D188A7CB169139A72CFCE6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ADE5FB63D188A7CB169139A72CFCE6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ADE5FB63D188A7CB169139A72CFCE6A" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ADE5FB63D188A7CB169139A72CFCE6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EADFD13E20030EEED1C4139A72CFCD24_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EADFD13E20030EEED1C4139A72CFCD24" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock offering</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EADFD13E20030EEED1C4139A72CFCD24_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EADFD13E20030EEED1C4139A72CFCD24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EADFD13E20030EEED1C4139A72CFCD24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EADFD13E20030EEED1C4139A72CFCD24" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EADFD13E20030EEED1C4139A72CFCD24" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_C4C137680B5CE58B9D46139A72CF9468_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_C4C137680B5CE58B9D46139A72CF9468" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beneficial conversion feature arising from Series A convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_C4C137680B5CE58B9D46139A72CF9468_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_C4C137680B5CE58B9D46139A72CF9468" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_C4C137680B5CE58B9D46139A72CF9468" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_C4C137680B5CE58B9D46139A72CF9468" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_C4C137680B5CE58B9D46139A72CF9468" xlink:type="arc" />
    <link:label id="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_0D1084DBDA5CAA7045A4139A72D03B82_terseLabel_en-US" xlink:label="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_0D1084DBDA5CAA7045A4139A72D03B82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend arising from beneficial conversion feature of Series A convertible preferred stock</link:label>
    <link:label id="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_0D1084DBDA5CAA7045A4139A72D03B82_label_en-US" xlink:label="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_0D1084DBDA5CAA7045A4139A72D03B82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend On Conversion Of Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_0D1084DBDA5CAA7045A4139A72D03B82_documentation_en-US" xlink:label="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_0D1084DBDA5CAA7045A4139A72D03B82" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dividend On Conversion Of Series A Convertible Preferred Stock</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStock" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_0D1084DBDA5CAA7045A4139A72D03B82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_0D1084DBDA5CAA7045A4139A72D03B82" xlink:to="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_0D1084DBDA5CAA7045A4139A72D03B82" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_D3F3761425B2B85CBC20139A72D08B85_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_D3F3761425B2B85CBC20139A72D08B85" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_D3F3761425B2B85CBC20139A72D08B85_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_D3F3761425B2B85CBC20139A72D08B85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_D3F3761425B2B85CBC20139A72D08B85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_D3F3761425B2B85CBC20139A72D08B85" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_D3F3761425B2B85CBC20139A72D08B85" xlink:type="arc" />
    <link:label id="lab_gale_ConvertiblePreferredStockDividends_4BBC5DE6A124A5163906139A72D0CB7C_negatedTerseLabel_en-US" xlink:label="lab_gale_ConvertiblePreferredStockDividends_4BBC5DE6A124A5163906139A72D0CB7C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock dividends</link:label>
    <link:label id="lab_gale_ConvertiblePreferredStockDividends_4BBC5DE6A124A5163906139A72D0CB7C_label_en-US" xlink:label="lab_gale_ConvertiblePreferredStockDividends_4BBC5DE6A124A5163906139A72D0CB7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock Dividends</link:label>
    <link:label id="lab_gale_ConvertiblePreferredStockDividends_4BBC5DE6A124A5163906139A72D0CB7C_documentation_en-US" xlink:label="lab_gale_ConvertiblePreferredStockDividends_4BBC5DE6A124A5163906139A72D0CB7C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock Dividends</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ConvertiblePreferredStockDividends" xlink:label="loc_gale_ConvertiblePreferredStockDividends_4BBC5DE6A124A5163906139A72D0CB7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ConvertiblePreferredStockDividends_4BBC5DE6A124A5163906139A72D0CB7C" xlink:to="lab_gale_ConvertiblePreferredStockDividends_4BBC5DE6A124A5163906139A72D0CB7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_956E58F63CDB7BBC247E139A72D01A5F_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_956E58F63CDB7BBC247E139A72D01A5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock as result of conversion</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_956E58F63CDB7BBC247E139A72D01A5F_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_956E58F63CDB7BBC247E139A72D01A5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_956E58F63CDB7BBC247E139A72D01A5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_956E58F63CDB7BBC247E139A72D01A5F" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_956E58F63CDB7BBC247E139A72D01A5F" xlink:type="arc" />
    <link:label id="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_48ECC7DA9378CAF38A37139A72D0AEF4_terseLabel_en-US" xlink:label="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_48ECC7DA9378CAF38A37139A72D0AEF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_48ECC7DA9378CAF38A37139A72D0AEF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_48ECC7DA9378CAF38A37139A72D0AEF4" xlink:to="lab_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_48ECC7DA9378CAF38A37139A72D0AEF4" xlink:type="arc" />
    <link:label id="lab_gale_DividendModificationOfWarrants_760E7614F9BAB4F470C9139A72D0A1CD_terseLabel_en-US" xlink:label="lab_gale_DividendModificationOfWarrants_760E7614F9BAB4F470C9139A72D0A1CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of anti-dilution protection on liability-classified warrants</link:label>
    <link:label id="lab_gale_DividendModificationOfWarrants_760E7614F9BAB4F470C9139A72D0A1CD_label_en-US" xlink:label="lab_gale_DividendModificationOfWarrants_760E7614F9BAB4F470C9139A72D0A1CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend, Modification Of Warrants</link:label>
    <link:label id="lab_gale_DividendModificationOfWarrants_760E7614F9BAB4F470C9139A72D0A1CD_documentation_en-US" xlink:label="lab_gale_DividendModificationOfWarrants_760E7614F9BAB4F470C9139A72D0A1CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dividend, Modification Of Warrants</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_DividendModificationOfWarrants" xlink:label="loc_gale_DividendModificationOfWarrants_760E7614F9BAB4F470C9139A72D0A1CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DividendModificationOfWarrants_760E7614F9BAB4F470C9139A72D0A1CD" xlink:to="lab_gale_DividendModificationOfWarrants_760E7614F9BAB4F470C9139A72D0A1CD" xlink:type="arc" />
    <link:label id="lab_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_90C45F1C4ED95CC54E44139A72D1D964_terseLabel_en-US" xlink:label="lab_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_90C45F1C4ED95CC54E44139A72D1D964" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with warrant exchange agreements (in shares)</link:label>
    <link:label id="lab_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_90C45F1C4ED95CC54E44139A72D1D964_label_en-US" xlink:label="lab_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_90C45F1C4ED95CC54E44139A72D1D964" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Exchange Agreements, Issuance Of Common Stock</link:label>
    <link:label id="lab_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_90C45F1C4ED95CC54E44139A72D1D964_documentation_en-US" xlink:label="lab_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_90C45F1C4ED95CC54E44139A72D1D964" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Exchange Agreements, Issuance Of Common Stock</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_WarrantExchangeAgreementsIssuanceOfCommonStock" xlink:label="loc_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_90C45F1C4ED95CC54E44139A72D1D964" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_90C45F1C4ED95CC54E44139A72D1D964" xlink:to="lab_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_90C45F1C4ED95CC54E44139A72D1D964" xlink:type="arc" />
    <link:label id="lab_gale_WarrantExchangeAgreementsAmount_E9BF47F89DF608DAB14D139A72D17D7A_terseLabel_en-US" xlink:label="lab_gale_WarrantExchangeAgreementsAmount_E9BF47F89DF608DAB14D139A72D17D7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with warrant exchange agreements</link:label>
    <link:label id="lab_gale_WarrantExchangeAgreementsAmount_E9BF47F89DF608DAB14D139A72D17D7A_label_en-US" xlink:label="lab_gale_WarrantExchangeAgreementsAmount_E9BF47F89DF608DAB14D139A72D17D7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Exchange Agreements, Amount</link:label>
    <link:label id="lab_gale_WarrantExchangeAgreementsAmount_E9BF47F89DF608DAB14D139A72D17D7A_documentation_en-US" xlink:label="lab_gale_WarrantExchangeAgreementsAmount_E9BF47F89DF608DAB14D139A72D17D7A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Exchange Agreements, Amount</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_WarrantExchangeAgreementsAmount" xlink:label="loc_gale_WarrantExchangeAgreementsAmount_E9BF47F89DF608DAB14D139A72D17D7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantExchangeAgreementsAmount_E9BF47F89DF608DAB14D139A72D17D7A" xlink:to="lab_gale_WarrantExchangeAgreementsAmount_E9BF47F89DF608DAB14D139A72D17D7A" xlink:type="arc" />
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_0DC29105016BAFE4DBFF139A72D1BEC1_terseLabel_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_0DC29105016BAFE4DBFF139A72D1BEC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of pre-funded warrants</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_0DC29105016BAFE4DBFF139A72D1BEC1_label_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_0DC29105016BAFE4DBFF139A72D1BEC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Pre-funded Warrant</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_0DC29105016BAFE4DBFF139A72D1BEC1_documentation_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_0DC29105016BAFE4DBFF139A72D1BEC1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Pre-funded Warrant</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_StockIssuedDuringPeriodSharesPrefundedWarrant" xlink:label="loc_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_0DC29105016BAFE4DBFF139A72D1BEC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_0DC29105016BAFE4DBFF139A72D1BEC1" xlink:to="lab_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_0DC29105016BAFE4DBFF139A72D1BEC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_CD06970FF64135C93215139A72D1F8E0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_CD06970FF64135C93215139A72D1F8E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_CD06970FF64135C93215139A72D1F8E0_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_CD06970FF64135C93215139A72D1F8E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_CD06970FF64135C93215139A72D1F8E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_CD06970FF64135C93215139A72D1F8E0" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_CD06970FF64135C93215139A72D1F8E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_0F44CE05480F07A42341139A72D1766E_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_0F44CE05480F07A42341139A72D1766E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0F44CE05480F07A42341139A72D1766E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_0F44CE05480F07A42341139A72D1766E" xlink:to="lab_us-gaap_NetIncomeLoss_0F44CE05480F07A42341139A72D1766E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_2109606E5C1C75E3DF21139A72D195EE_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_2109606E5C1C75E3DF21139A72D195EE" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_2109606E5C1C75E3DF21139A72D195EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_2109606E5C1C75E3DF21139A72D195EE" xlink:to="lab_us-gaap_SharesOutstanding_2109606E5C1C75E3DF21139A72D195EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4783E21BA89B2AE98E87139A72D172B4_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4783E21BA89B2AE98E87139A72D172B4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4783E21BA89B2AE98E87139A72D172B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4783E21BA89B2AE98E87139A72D172B4" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4783E21BA89B2AE98E87139A72D172B4" xlink:type="arc" />
    <link:label id="lab_gale_July2018OfferingMember_8A8A144B86A6A985B425139A71CD1B9F_terseLabel_en-US" xlink:label="lab_gale_July2018OfferingMember_8A8A144B86A6A985B425139A71CD1B9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">July 2018 Offering</link:label>
    <link:label id="lab_gale_July2018OfferingMember_8A8A144B86A6A985B425139A71CD1B9F_label_en-US" xlink:label="lab_gale_July2018OfferingMember_8A8A144B86A6A985B425139A71CD1B9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">July 2018 Offering [Member]</link:label>
    <link:label id="lab_gale_July2018OfferingMember_8A8A144B86A6A985B425139A71CD1B9F_documentation_en-US" xlink:label="lab_gale_July2018OfferingMember_8A8A144B86A6A985B425139A71CD1B9F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">July 2018 Offering [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_July2018OfferingMember" xlink:label="loc_gale_July2018OfferingMember_8A8A144B86A6A985B425139A71CD1B9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_July2018OfferingMember_8A8A144B86A6A985B425139A71CD1B9F" xlink:to="lab_gale_July2018OfferingMember_8A8A144B86A6A985B425139A71CD1B9F" xlink:type="arc" />
    <link:label id="lab_gale_Prefunded2018OfferingMember_DEB763EC55A73136D834139A71CD43EB_terseLabel_en-US" xlink:label="lab_gale_Prefunded2018OfferingMember_DEB763EC55A73136D834139A71CD43EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-funded 2018 Offering</link:label>
    <link:label id="lab_gale_Prefunded2018OfferingMember_DEB763EC55A73136D834139A71CD43EB_label_en-US" xlink:label="lab_gale_Prefunded2018OfferingMember_DEB763EC55A73136D834139A71CD43EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-funded 2018 Offering [Member]</link:label>
    <link:label id="lab_gale_Prefunded2018OfferingMember_DEB763EC55A73136D834139A71CD43EB_documentation_en-US" xlink:label="lab_gale_Prefunded2018OfferingMember_DEB763EC55A73136D834139A71CD43EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-funded 2018 Offering [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_Prefunded2018OfferingMember" xlink:label="loc_gale_Prefunded2018OfferingMember_DEB763EC55A73136D834139A71CD43EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_Prefunded2018OfferingMember_DEB763EC55A73136D834139A71CD43EB" xlink:to="lab_gale_Prefunded2018OfferingMember_DEB763EC55A73136D834139A71CD43EB" xlink:type="arc" />
    <link:label id="lab_gale_EqcWarrantsMember_D00FDCF94A3B8FB2B750139A71CEBACB_terseLabel_en-US" xlink:label="lab_gale_EqcWarrantsMember_D00FDCF94A3B8FB2B750139A71CEBACB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Equilibria</link:label>
    <link:label id="lab_gale_EqcWarrantsMember_D00FDCF94A3B8FB2B750139A71CEBACB_label_en-US" xlink:label="lab_gale_EqcWarrantsMember_D00FDCF94A3B8FB2B750139A71CEBACB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eqc Warrants [Member]</link:label>
    <link:label id="lab_gale_EqcWarrantsMember_D00FDCF94A3B8FB2B750139A71CEBACB_documentation_en-US" xlink:label="lab_gale_EqcWarrantsMember_D00FDCF94A3B8FB2B750139A71CEBACB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eqc Warrants [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_EqcWarrantsMember" xlink:label="loc_gale_EqcWarrantsMember_D00FDCF94A3B8FB2B750139A71CEBACB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EqcWarrantsMember_D00FDCF94A3B8FB2B750139A71CEBACB" xlink:to="lab_gale_EqcWarrantsMember_D00FDCF94A3B8FB2B750139A71CEBACB" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightOutstandingRollForward" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A" xlink:to="lab_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_938DDB6AF4096EFD4887139A71CF098E_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_938DDB6AF4096EFD4887139A71CF098E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding , Beginning balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_938DDB6AF4096EFD4887139A71CF098E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_938DDB6AF4096EFD4887139A71CF098E" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_938DDB6AF4096EFD4887139A71CF098E" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightGranted_754A09CD66C3131621E9139A71CFFA3E_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightGranted_754A09CD66C3131621E9139A71CFFA3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightGranted_754A09CD66C3131621E9139A71CFFA3E_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightGranted_754A09CD66C3131621E9139A71CFFA3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right Granted</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightGranted_754A09CD66C3131621E9139A71CFFA3E_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightGranted_754A09CD66C3131621E9139A71CFFA3E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right Granted</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_754A09CD66C3131621E9139A71CFFA3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightGranted_754A09CD66C3131621E9139A71CFFA3E" xlink:to="lab_gale_ClassofWarrantorRightGranted_754A09CD66C3131621E9139A71CFFA3E" xlink:type="arc" />
    <link:label id="lab_gale_ClassOfWarrantOrRightExercised_C94E7EAD3F37DEF5A0AA139A71CFCCCF_negatedTerseLabel_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightExercised_C94E7EAD3F37DEF5A0AA139A71CFCCCF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightExercised_C94E7EAD3F37DEF5A0AA139A71CFCCCF_label_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightExercised_C94E7EAD3F37DEF5A0AA139A71CFCCCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Exercised</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightExercised_C94E7EAD3F37DEF5A0AA139A71CFCCCF_documentation_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightExercised_C94E7EAD3F37DEF5A0AA139A71CFCCCF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Exercised</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassOfWarrantOrRightExercised" xlink:label="loc_gale_ClassOfWarrantOrRightExercised_C94E7EAD3F37DEF5A0AA139A71CFCCCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassOfWarrantOrRightExercised_C94E7EAD3F37DEF5A0AA139A71CFCCCF" xlink:to="lab_gale_ClassOfWarrantOrRightExercised_C94E7EAD3F37DEF5A0AA139A71CFCCCF" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightCanceledOrExpired_AC652A89F980D7EADC2E139A71CF37CA_negatedTerseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightCanceledOrExpired_AC652A89F980D7EADC2E139A71CF37CA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Canceled/Expired (in shares)</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightCanceledOrExpired_AC652A89F980D7EADC2E139A71CF37CA_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightCanceledOrExpired_AC652A89F980D7EADC2E139A71CF37CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Canceled Or Expired</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightCanceledOrExpired_AC652A89F980D7EADC2E139A71CF37CA_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightCanceledOrExpired_AC652A89F980D7EADC2E139A71CF37CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Canceled Or Expired</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightCanceledOrExpired" xlink:label="loc_gale_ClassofWarrantorRightCanceledOrExpired_AC652A89F980D7EADC2E139A71CF37CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightCanceledOrExpired_AC652A89F980D7EADC2E139A71CF37CA" xlink:to="lab_gale_ClassofWarrantorRightCanceledOrExpired_AC652A89F980D7EADC2E139A71CF37CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_518AFFB2F67D08E045A3139A71D016B3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_518AFFB2F67D08E045A3139A71D016B3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding , Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_518AFFB2F67D08E045A3139A71D016B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_518AFFB2F67D08E045A3139A71D016B3" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_518AFFB2F67D08E045A3139A71D016B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_CBD770FC7F3DEAB538DC17BCCEDA6138_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_CBD770FC7F3DEAB538DC17BCCEDA6138" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to Acquire Shares of Common Stock</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_CBD770FC7F3DEAB538DC17BCCEDA6138_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_CBD770FC7F3DEAB538DC17BCCEDA6138" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Indexed to Issuer's Equity, Description [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_CBD770FC7F3DEAB538DC17BCCEDA6138" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_CBD770FC7F3DEAB538DC17BCCEDA6138" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_CBD770FC7F3DEAB538DC17BCCEDA6138" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_DF1A755CEA6647B5040E12F8824025E0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_DF1A755CEA6647B5040E12F8824025E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_DF1A755CEA6647B5040E12F8824025E0_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_DF1A755CEA6647B5040E12F8824025E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_DF1A755CEA6647B5040E12F8824025E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_DF1A755CEA6647B5040E12F8824025E0" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_DF1A755CEA6647B5040E12F8824025E0" xlink:type="arc" />
    <link:label id="lab_gale_FairValueofWarrantsGrantedperShare_E41AAE999C269956601C12E41CA0B7E1_terseLabel_en-US" xlink:label="lab_gale_FairValueofWarrantsGrantedperShare_E41AAE999C269956601C12E41CA0B7E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants granted, per share</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGrantedperShare_E41AAE999C269956601C12E41CA0B7E1_label_en-US" xlink:label="lab_gale_FairValueofWarrantsGrantedperShare_E41AAE999C269956601C12E41CA0B7E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted, per Share</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGrantedperShare_E41AAE999C269956601C12E41CA0B7E1_documentation_en-US" xlink:label="lab_gale_FairValueofWarrantsGrantedperShare_E41AAE999C269956601C12E41CA0B7E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted, per Share</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueofWarrantsGrantedperShare" xlink:label="loc_gale_FairValueofWarrantsGrantedperShare_E41AAE999C269956601C12E41CA0B7E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueofWarrantsGrantedperShare_E41AAE999C269956601C12E41CA0B7E1" xlink:to="lab_gale_FairValueofWarrantsGrantedperShare_E41AAE999C269956601C12E41CA0B7E1" xlink:type="arc" />
    <link:label id="lab_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD_label_en-US" xlink:label="lab_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD_documentation_en-US" xlink:label="lab_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_DocumentDocumentAndEntityInformationAbstract" xlink:label="loc_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD" xlink:to="lab_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_1CD5927B794F43C6C8C50891C4E56354_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_1CD5927B794F43C6C8C50891C4E56354" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_1CD5927B794F43C6C8C50891C4E56354_label_en-US" xlink:label="lab_dei_EntityRegistrantName_1CD5927B794F43C6C8C50891C4E56354" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1CD5927B794F43C6C8C50891C4E56354" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_1CD5927B794F43C6C8C50891C4E56354" xlink:to="lab_dei_EntityRegistrantName_1CD5927B794F43C6C8C50891C4E56354" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_7685223A3109BC405F910891C4E5B333_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_7685223A3109BC405F910891C4E5B333" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_7685223A3109BC405F910891C4E5B333_label_en-US" xlink:label="lab_dei_TradingSymbol_7685223A3109BC405F910891C4E5B333" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_7685223A3109BC405F910891C4E5B333" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_7685223A3109BC405F910891C4E5B333" xlink:to="lab_dei_TradingSymbol_7685223A3109BC405F910891C4E5B333" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_C35745B9CE313C6F1AAC0891C4E5E98C_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_C35745B9CE313C6F1AAC0891C4E5E98C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_C35745B9CE313C6F1AAC0891C4E5E98C_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_C35745B9CE313C6F1AAC0891C4E5E98C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_C35745B9CE313C6F1AAC0891C4E5E98C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_C35745B9CE313C6F1AAC0891C4E5E98C" xlink:to="lab_dei_EntityCentralIndexKey_C35745B9CE313C6F1AAC0891C4E5E98C" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6BC412F5880E3D39DB050891C4E67CB9_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_6BC412F5880E3D39DB050891C4E67CB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6BC412F5880E3D39DB050891C4E67CB9_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_6BC412F5880E3D39DB050891C4E67CB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_6BC412F5880E3D39DB050891C4E67CB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_6BC412F5880E3D39DB050891C4E67CB9" xlink:to="lab_dei_CurrentFiscalYearEndDate_6BC412F5880E3D39DB050891C4E67CB9" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_609376423C93766DCBD00891C4E639AC_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_609376423C93766DCBD00891C4E639AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_609376423C93766DCBD00891C4E639AC_label_en-US" xlink:label="lab_dei_EntityFilerCategory_609376423C93766DCBD00891C4E639AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_609376423C93766DCBD00891C4E639AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_609376423C93766DCBD00891C4E639AC" xlink:to="lab_dei_EntityFilerCategory_609376423C93766DCBD00891C4E639AC" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_26295A9D871E1D4FD7990891C4E6D038_terseLabel_en-US" xlink:label="lab_dei_DocumentType_26295A9D871E1D4FD7990891C4E6D038" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_26295A9D871E1D4FD7990891C4E6D038_label_en-US" xlink:label="lab_dei_DocumentType_26295A9D871E1D4FD7990891C4E6D038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_26295A9D871E1D4FD7990891C4E6D038" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_26295A9D871E1D4FD7990891C4E6D038" xlink:to="lab_dei_DocumentType_26295A9D871E1D4FD7990891C4E6D038" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_D5C9C8909793D5D735510891C4E6BA24_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_D5C9C8909793D5D735510891C4E6BA24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_D5C9C8909793D5D735510891C4E6BA24_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_D5C9C8909793D5D735510891C4E6BA24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_D5C9C8909793D5D735510891C4E6BA24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_D5C9C8909793D5D735510891C4E6BA24" xlink:to="lab_dei_DocumentPeriodEndDate_D5C9C8909793D5D735510891C4E6BA24" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_5F734367FFC28538148E0891C4E66077_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_5F734367FFC28538148E0891C4E66077" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_5F734367FFC28538148E0891C4E66077_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_5F734367FFC28538148E0891C4E66077" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_5F734367FFC28538148E0891C4E66077" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_5F734367FFC28538148E0891C4E66077" xlink:to="lab_dei_DocumentFiscalYearFocus_5F734367FFC28538148E0891C4E66077" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_F97A02E1F4D80C1882050891C4E6951D_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_F97A02E1F4D80C1882050891C4E6951D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_F97A02E1F4D80C1882050891C4E6951D_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_F97A02E1F4D80C1882050891C4E6951D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_F97A02E1F4D80C1882050891C4E6951D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_F97A02E1F4D80C1882050891C4E6951D" xlink:to="lab_dei_DocumentFiscalPeriodFocus_F97A02E1F4D80C1882050891C4E6951D" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_F6BA6C22D3B17ABFB2310891C4E66A48_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_F6BA6C22D3B17ABFB2310891C4E66A48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_F6BA6C22D3B17ABFB2310891C4E66A48_label_en-US" xlink:label="lab_dei_AmendmentFlag_F6BA6C22D3B17ABFB2310891C4E66A48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_F6BA6C22D3B17ABFB2310891C4E66A48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_F6BA6C22D3B17ABFB2310891C4E66A48" xlink:to="lab_dei_AmendmentFlag_F6BA6C22D3B17ABFB2310891C4E66A48" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8000EC9915CF78DCEC8708B8823A5C0A_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_8000EC9915CF78DCEC8708B8823A5C0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8000EC9915CF78DCEC8708B8823A5C0A_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_8000EC9915CF78DCEC8708B8823A5C0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_8000EC9915CF78DCEC8708B8823A5C0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_8000EC9915CF78DCEC8708B8823A5C0A" xlink:to="lab_dei_EntityEmergingGrowthCompany_8000EC9915CF78DCEC8708B8823A5C0A" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_9CDE0B5CFE84C96710CB08B92116FEE7_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_9CDE0B5CFE84C96710CB08B92116FEE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_9CDE0B5CFE84C96710CB08B92116FEE7_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_9CDE0B5CFE84C96710CB08B92116FEE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_9CDE0B5CFE84C96710CB08B92116FEE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_9CDE0B5CFE84C96710CB08B92116FEE7" xlink:to="lab_dei_EntitySmallBusiness_9CDE0B5CFE84C96710CB08B92116FEE7" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1009CF5F72E9D9F1E5680891C4E782D2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_1009CF5F72E9D9F1E5680891C4E782D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1009CF5F72E9D9F1E5680891C4E782D2_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_1009CF5F72E9D9F1E5680891C4E782D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1009CF5F72E9D9F1E5680891C4E782D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_1009CF5F72E9D9F1E5680891C4E782D2" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_1009CF5F72E9D9F1E5680891C4E782D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_6B96AE662C609742A4241361E69A77AB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_6B96AE662C609742A4241361E69A77AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_6B96AE662C609742A4241361E69A77AB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_6B96AE662C609742A4241361E69A77AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6B96AE662C609742A4241361E69A77AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6B96AE662C609742A4241361E69A77AB" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_6B96AE662C609742A4241361E69A77AB" xlink:type="arc" />
    <link:label id="lab_gale_PrivatePlacementFirstClosingMember_740FF7B55FB027C7322B1361E69F33C5_terseLabel_en-US" xlink:label="lab_gale_PrivatePlacementFirstClosingMember_740FF7B55FB027C7322B1361E69F33C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement First Closing</link:label>
    <link:label id="lab_gale_PrivatePlacementFirstClosingMember_740FF7B55FB027C7322B1361E69F33C5_label_en-US" xlink:label="lab_gale_PrivatePlacementFirstClosingMember_740FF7B55FB027C7322B1361E69F33C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement First Closing [Member]</link:label>
    <link:label id="lab_gale_PrivatePlacementFirstClosingMember_740FF7B55FB027C7322B1361E69F33C5_documentation_en-US" xlink:label="lab_gale_PrivatePlacementFirstClosingMember_740FF7B55FB027C7322B1361E69F33C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Placement First Closing [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_PrivatePlacementFirstClosingMember" xlink:label="loc_gale_PrivatePlacementFirstClosingMember_740FF7B55FB027C7322B1361E69F33C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PrivatePlacementFirstClosingMember_740FF7B55FB027C7322B1361E69F33C5" xlink:to="lab_gale_PrivatePlacementFirstClosingMember_740FF7B55FB027C7322B1361E69F33C5" xlink:type="arc" />
    <link:label id="lab_gale_PrivatePlacementSecondClosingMember_8AD50159BDE3F269E5731361E69F6FA0_terseLabel_en-US" xlink:label="lab_gale_PrivatePlacementSecondClosingMember_8AD50159BDE3F269E5731361E69F6FA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement Second Closing</link:label>
    <link:label id="lab_gale_PrivatePlacementSecondClosingMember_8AD50159BDE3F269E5731361E69F6FA0_label_en-US" xlink:label="lab_gale_PrivatePlacementSecondClosingMember_8AD50159BDE3F269E5731361E69F6FA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement Second Closing [Member]</link:label>
    <link:label id="lab_gale_PrivatePlacementSecondClosingMember_8AD50159BDE3F269E5731361E69F6FA0_documentation_en-US" xlink:label="lab_gale_PrivatePlacementSecondClosingMember_8AD50159BDE3F269E5731361E69F6FA0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Placement Second Closing [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_PrivatePlacementSecondClosingMember" xlink:label="loc_gale_PrivatePlacementSecondClosingMember_8AD50159BDE3F269E5731361E69F6FA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PrivatePlacementSecondClosingMember_8AD50159BDE3F269E5731361E69F6FA0" xlink:to="lab_gale_PrivatePlacementSecondClosingMember_8AD50159BDE3F269E5731361E69F6FA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="lab_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_4D8D07DB71C2CD63EAEC1361E6A17D90_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_4D8D07DB71C2CD63EAEC1361E6A17D90" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of preferred stock, preference stock, and warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_4D8D07DB71C2CD63EAEC1361E6A17D90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_4D8D07DB71C2CD63EAEC1361E6A17D90" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_4D8D07DB71C2CD63EAEC1361E6A17D90" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_89C62ABFF1FA52715EE61361E6A1DC94_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_89C62ABFF1FA52715EE61361E6A1DC94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_89C62ABFF1FA52715EE61361E6A1DC94_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_89C62ABFF1FA52715EE61361E6A1DC94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_89C62ABFF1FA52715EE61361E6A1DC94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_89C62ABFF1FA52715EE61361E6A1DC94" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_89C62ABFF1FA52715EE61361E6A1DC94" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_1BE7A906783A7EE546441361E6A1D1AA_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_1BE7A906783A7EE546441361E6A1D1AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock converted to other securities</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_1BE7A906783A7EE546441361E6A1D1AA_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_1BE7A906783A7EE546441361E6A1D1AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock Converted to Other Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" xlink:label="loc_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_1BE7A906783A7EE546441361E6A1D1AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_1BE7A906783A7EE546441361E6A1D1AA" xlink:to="lab_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_1BE7A906783A7EE546441361E6A1D1AA" xlink:type="arc" />
    <link:label id="lab_gale_ConvertiblePreferredStockIssuedShares_6D654C2800D1D560957F1361E6A2DA6B_terseLabel_en-US" xlink:label="lab_gale_ConvertiblePreferredStockIssuedShares_6D654C2800D1D560957F1361E6A2DA6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock issued shares (in shares)</link:label>
    <link:label id="lab_gale_ConvertiblePreferredStockIssuedShares_6D654C2800D1D560957F1361E6A2DA6B_label_en-US" xlink:label="lab_gale_ConvertiblePreferredStockIssuedShares_6D654C2800D1D560957F1361E6A2DA6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock Issued Shares</link:label>
    <link:label id="lab_gale_ConvertiblePreferredStockIssuedShares_6D654C2800D1D560957F1361E6A2DA6B_documentation_en-US" xlink:label="lab_gale_ConvertiblePreferredStockIssuedShares_6D654C2800D1D560957F1361E6A2DA6B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock Issued Shares</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ConvertiblePreferredStockIssuedShares" xlink:label="loc_gale_ConvertiblePreferredStockIssuedShares_6D654C2800D1D560957F1361E6A2DA6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ConvertiblePreferredStockIssuedShares_6D654C2800D1D560957F1361E6A2DA6B" xlink:to="lab_gale_ConvertiblePreferredStockIssuedShares_6D654C2800D1D560957F1361E6A2DA6B" xlink:type="arc" />
    <link:label id="lab_gale_WarrantsIssuedShares_F5D1F28BA29D3DF847FD1361E6A210C1_terseLabel_en-US" xlink:label="lab_gale_WarrantsIssuedShares_F5D1F28BA29D3DF847FD1361E6A210C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued shares (in shares)</link:label>
    <link:label id="lab_gale_WarrantsIssuedShares_F5D1F28BA29D3DF847FD1361E6A210C1_label_en-US" xlink:label="lab_gale_WarrantsIssuedShares_F5D1F28BA29D3DF847FD1361E6A210C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued Shares</link:label>
    <link:label id="lab_gale_WarrantsIssuedShares_F5D1F28BA29D3DF847FD1361E6A210C1_documentation_en-US" xlink:label="lab_gale_WarrantsIssuedShares_F5D1F28BA29D3DF847FD1361E6A210C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Issued Shares</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_WarrantsIssuedShares" xlink:label="loc_gale_WarrantsIssuedShares_F5D1F28BA29D3DF847FD1361E6A210C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsIssuedShares_F5D1F28BA29D3DF847FD1361E6A210C1" xlink:to="lab_gale_WarrantsIssuedShares_F5D1F28BA29D3DF847FD1361E6A210C1" xlink:type="arc" />
    <link:label id="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_32BAE66F0AD52BADCF161361E6A23347_verboseLabel_en-US" xlink:label="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_32BAE66F0AD52BADCF161361E6A23347" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in fair value of warrant liability</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:label="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_32BAE66F0AD52BADCF161361E6A23347" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_32BAE66F0AD52BADCF161361E6A23347" xlink:to="lab_gale_IncreaseDecreaseInFairValueOfWarrantLiability_32BAE66F0AD52BADCF161361E6A23347" xlink:type="arc" />
    <link:label id="lab_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_DB09CAEDDEC9341E0B461361E6A35EA2_terseLabel_en-US" xlink:label="lab_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_DB09CAEDDEC9341E0B461361E6A35EA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend on beneficial conversion feature of convertible preferred stock</link:label>
    <link:label id="lab_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_DB09CAEDDEC9341E0B461361E6A35EA2_label_en-US" xlink:label="lab_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_DB09CAEDDEC9341E0B461361E6A35EA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deemed Dividend On Beneficial Conversion Feature Of Convertible Preferred Stock</link:label>
    <link:label id="lab_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_DB09CAEDDEC9341E0B461361E6A35EA2_documentation_en-US" xlink:label="lab_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_DB09CAEDDEC9341E0B461361E6A35EA2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deemed Dividend On Beneficial Conversion Feature Of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock" xlink:label="loc_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_DB09CAEDDEC9341E0B461361E6A35EA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_DB09CAEDDEC9341E0B461361E6A35EA2" xlink:to="lab_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_DB09CAEDDEC9341E0B461361E6A35EA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0B29A967DA0C1DF6C01513A440CBF972_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0B29A967DA0C1DF6C01513A440CBF972" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrant, shares to purchase</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0B29A967DA0C1DF6C01513A440CBF972_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0B29A967DA0C1DF6C01513A440CBF972" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0B29A967DA0C1DF6C01513A440CBF972" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0B29A967DA0C1DF6C01513A440CBF972" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0B29A967DA0C1DF6C01513A440CBF972" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_DBB8B7254E70E3080B4D17BCD04A7E78_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_DBB8B7254E70E3080B4D17BCD04A7E78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_DBB8B7254E70E3080B4D17BCD04A7E78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_DBB8B7254E70E3080B4D17BCD04A7E78" xlink:to="lab_us-gaap_SubsequentEventsAbstract_DBB8B7254E70E3080B4D17BCD04A7E78" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_05F6B5A16B663C47EEC417BCD04ADBB0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_05F6B5A16B663C47EEC417BCD04ADBB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_05F6B5A16B663C47EEC417BCD04ADBB0_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_05F6B5A16B663C47EEC417BCD04ADBB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_05F6B5A16B663C47EEC417BCD04ADBB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_05F6B5A16B663C47EEC417BCD04ADBB0" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_05F6B5A16B663C47EEC417BCD04ADBB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_02ED518B9B9DC502F3F917BCD06C3ED8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_02ED518B9B9DC502F3F917BCD06C3ED8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_02ED518B9B9DC502F3F917BCD06C3ED8_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_02ED518B9B9DC502F3F917BCD06C3ED8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_02ED518B9B9DC502F3F917BCD06C3ED8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_02ED518B9B9DC502F3F917BCD06C3ED8" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_02ED518B9B9DC502F3F917BCD06C3ED8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_B5F57C47B1C7CC5E257C0ED5D7A8D531_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_B5F57C47B1C7CC5E257C0ED5D7A8D531" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Table]</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_B5F57C47B1C7CC5E257C0ED5D7A8D531_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_B5F57C47B1C7CC5E257C0ED5D7A8D531" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_B5F57C47B1C7CC5E257C0ED5D7A8D531" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_B5F57C47B1C7CC5E257C0ED5D7A8D531" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_B5F57C47B1C7CC5E257C0ED5D7A8D531" xlink:type="arc" />
    <link:label id="lab_gale_JBGLitigationMember_658D7BEAAC75694782330ED699F624DC_terseLabel_en-US" xlink:label="lab_gale_JBGLitigationMember_658D7BEAAC75694782330ED699F624DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">JBG Litigation</link:label>
    <link:label id="lab_gale_JBGLitigationMember_658D7BEAAC75694782330ED699F624DC_label_en-US" xlink:label="lab_gale_JBGLitigationMember_658D7BEAAC75694782330ED699F624DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JBG Litigation [Member]</link:label>
    <link:label id="lab_gale_JBGLitigationMember_658D7BEAAC75694782330ED699F624DC_documentation_en-US" xlink:label="lab_gale_JBGLitigationMember_658D7BEAAC75694782330ED699F624DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">JBG Litigation [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_JBGLitigationMember" xlink:label="loc_gale_JBGLitigationMember_658D7BEAAC75694782330ED699F624DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_JBGLitigationMember_658D7BEAAC75694782330ED699F624DC" xlink:to="lab_gale_JBGLitigationMember_658D7BEAAC75694782330ED699F624DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Line Items]</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_9057888168DA42D4C8C90EB15C6A5017_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_9057888168DA42D4C8C90EB15C6A5017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_9057888168DA42D4C8C90EB15C6A5017_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_9057888168DA42D4C8C90EB15C6A5017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_9057888168DA42D4C8C90EB15C6A5017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_9057888168DA42D4C8C90EB15C6A5017" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_9057888168DA42D4C8C90EB15C6A5017" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_27CB222A92316D9794AD0EB15C6B572C_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_27CB222A92316D9794AD0EB15C6B572C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation and related benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_27CB222A92316D9794AD0EB15C6B572C_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_27CB222A92316D9794AD0EB15C6B572C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_27CB222A92316D9794AD0EB15C6B572C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_27CB222A92316D9794AD0EB15C6B572C" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_27CB222A92316D9794AD0EB15C6B572C" xlink:type="arc" />
    <link:label id="lab_gale_ContractResearchPayable_33526AF70FB77FE3BDA90EB15C6BE4D0_terseLabel_en-US" xlink:label="lab_gale_ContractResearchPayable_33526AF70FB77FE3BDA90EB15C6BE4D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trial costs</link:label>
    <link:label id="lab_gale_ContractResearchPayable_33526AF70FB77FE3BDA90EB15C6BE4D0_label_en-US" xlink:label="lab_gale_ContractResearchPayable_33526AF70FB77FE3BDA90EB15C6BE4D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Research Payable</link:label>
    <link:label id="lab_gale_ContractResearchPayable_33526AF70FB77FE3BDA90EB15C6BE4D0_documentation_en-US" xlink:label="lab_gale_ContractResearchPayable_33526AF70FB77FE3BDA90EB15C6BE4D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Research Payable</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ContractResearchPayable" xlink:label="loc_gale_ContractResearchPayable_33526AF70FB77FE3BDA90EB15C6BE4D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContractResearchPayable_33526AF70FB77FE3BDA90EB15C6BE4D0" xlink:to="lab_gale_ContractResearchPayable_33526AF70FB77FE3BDA90EB15C6BE4D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_39431B83957064BF0EB60EB15C6B11EA_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_39431B83957064BF0EB60EB15C6B11EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value-added tax</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_39431B83957064BF0EB60EB15C6B11EA_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_39431B83957064BF0EB60EB15C6B11EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_39431B83957064BF0EB60EB15C6B11EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_39431B83957064BF0EB60EB15C6B11EA" xlink:to="lab_us-gaap_TaxesPayableCurrent_39431B83957064BF0EB60EB15C6B11EA" xlink:type="arc" />
    <link:label id="lab_gale_RebatesAndReturnsOfFormerCommercialProducts_99F8FA7240879A51868E0EB15C6B0D6C_terseLabel_en-US" xlink:label="lab_gale_RebatesAndReturnsOfFormerCommercialProducts_99F8FA7240879A51868E0EB15C6B0D6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates and returns of former commercial products</link:label>
    <link:label id="lab_gale_RebatesAndReturnsOfFormerCommercialProducts_99F8FA7240879A51868E0EB15C6B0D6C_label_en-US" xlink:label="lab_gale_RebatesAndReturnsOfFormerCommercialProducts_99F8FA7240879A51868E0EB15C6B0D6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rebates And Returns Of Former Commercial Products</link:label>
    <link:label id="lab_gale_RebatesAndReturnsOfFormerCommercialProducts_99F8FA7240879A51868E0EB15C6B0D6C_documentation_en-US" xlink:label="lab_gale_RebatesAndReturnsOfFormerCommercialProducts_99F8FA7240879A51868E0EB15C6B0D6C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rebates and returns of former commercial products</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_RebatesAndReturnsOfFormerCommercialProducts" xlink:label="loc_gale_RebatesAndReturnsOfFormerCommercialProducts_99F8FA7240879A51868E0EB15C6B0D6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_RebatesAndReturnsOfFormerCommercialProducts_99F8FA7240879A51868E0EB15C6B0D6C" xlink:to="lab_gale_RebatesAndReturnsOfFormerCommercialProducts_99F8FA7240879A51868E0EB15C6B0D6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2344F99894B8F68002A70EB15C6BA23A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2344F99894B8F68002A70EB15C6BA23A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2344F99894B8F68002A70EB15C6BA23A_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2344F99894B8F68002A70EB15C6BA23A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2344F99894B8F68002A70EB15C6BA23A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2344F99894B8F68002A70EB15C6BA23A" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2344F99894B8F68002A70EB15C6BA23A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_B03B1AE705AB78A8C46F0EB15C6CFD19_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_B03B1AE705AB78A8C46F0EB15C6CFD19" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_B03B1AE705AB78A8C46F0EB15C6CFD19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_B03B1AE705AB78A8C46F0EB15C6CFD19" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_B03B1AE705AB78A8C46F0EB15C6CFD19" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationReserveCurrent_E4A710B936B1F2873ECE0EC436FF45E0_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent_E4A710B936B1F2873ECE0EC436FF45E0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Legal fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaap_LitigationReserveCurrent_E4A710B936B1F2873ECE0EC436FF45E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent_E4A710B936B1F2873ECE0EC436FF45E0" xlink:to="lab_us-gaap_LitigationReserveCurrent_E4A710B936B1F2873ECE0EC436FF45E0" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_0C7E694436639CB6023217BCD08A927E_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_0C7E694436639CB6023217BCD08A927E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_0C7E694436639CB6023217BCD08A927E_label_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_0C7E694436639CB6023217BCD08A927E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_0C7E694436639CB6023217BCD08A927E_documentation_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_0C7E694436639CB6023217BCD08A927E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_0C7E694436639CB6023217BCD08A927E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_0C7E694436639CB6023217BCD08A927E" xlink:to="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_0C7E694436639CB6023217BCD08A927E" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_A6373970673B5FD33A4217BCD08A43BD_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_A6373970673B5FD33A4217BCD08A43BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_A6373970673B5FD33A4217BCD08A43BD_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_A6373970673B5FD33A4217BCD08A43BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_A6373970673B5FD33A4217BCD08A43BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_A6373970673B5FD33A4217BCD08A43BD" xlink:to="lab_srt_CounterpartyNameAxis_A6373970673B5FD33A4217BCD08A43BD" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_425A10D557F0634194D217BCD08A2A84_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_425A10D557F0634194D217BCD08A2A84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_425A10D557F0634194D217BCD08A2A84_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_425A10D557F0634194D217BCD08A2A84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_425A10D557F0634194D217BCD08A2A84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_425A10D557F0634194D217BCD08A2A84" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_425A10D557F0634194D217BCD08A2A84" xlink:type="arc" />
    <link:label id="lab_gale_PrivateSELLASSecurityHoldersMember_CA60342E7909BB1A64FB17BCD08BED9E_terseLabel_en-US" xlink:label="lab_gale_PrivateSELLASSecurityHoldersMember_CA60342E7909BB1A64FB17BCD08BED9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private SELLAS Security Holders</link:label>
    <link:label id="lab_gale_PrivateSELLASSecurityHoldersMember_CA60342E7909BB1A64FB17BCD08BED9E_label_en-US" xlink:label="lab_gale_PrivateSELLASSecurityHoldersMember_CA60342E7909BB1A64FB17BCD08BED9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private SELLAS Security Holders [Member]</link:label>
    <link:label id="lab_gale_PrivateSELLASSecurityHoldersMember_CA60342E7909BB1A64FB17BCD08BED9E_documentation_en-US" xlink:label="lab_gale_PrivateSELLASSecurityHoldersMember_CA60342E7909BB1A64FB17BCD08BED9E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private SELLAS Security Holders [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_PrivateSELLASSecurityHoldersMember" xlink:label="loc_gale_PrivateSELLASSecurityHoldersMember_CA60342E7909BB1A64FB17BCD08BED9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PrivateSELLASSecurityHoldersMember_CA60342E7909BB1A64FB17BCD08BED9E" xlink:to="lab_gale_PrivateSELLASSecurityHoldersMember_CA60342E7909BB1A64FB17BCD08BED9E" xlink:type="arc" />
    <link:label id="lab_gale_PreMergerSecurityholdersMember_55C64761D705D55AE9F017BCD08BA32D_terseLabel_en-US" xlink:label="lab_gale_PreMergerSecurityholdersMember_55C64761D705D55AE9F017BCD08BA32D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Merger Securityholders</link:label>
    <link:label id="lab_gale_PreMergerSecurityholdersMember_55C64761D705D55AE9F017BCD08BA32D_label_en-US" xlink:label="lab_gale_PreMergerSecurityholdersMember_55C64761D705D55AE9F017BCD08BA32D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Merger Securityholders [Member]</link:label>
    <link:label id="lab_gale_PreMergerSecurityholdersMember_55C64761D705D55AE9F017BCD08BA32D_documentation_en-US" xlink:label="lab_gale_PreMergerSecurityholdersMember_55C64761D705D55AE9F017BCD08BA32D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Merger Securityholders [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_PreMergerSecurityholdersMember" xlink:label="loc_gale_PreMergerSecurityholdersMember_55C64761D705D55AE9F017BCD08BA32D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PreMergerSecurityholdersMember_55C64761D705D55AE9F017BCD08BA32D" xlink:to="lab_gale_PreMergerSecurityholdersMember_55C64761D705D55AE9F017BCD08BA32D" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_957DCC5C129E3812A5DB17BCD08B6019_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_957DCC5C129E3812A5DB17BCD08B6019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_957DCC5C129E3812A5DB17BCD08B6019_label_en-US" xlink:label="lab_dei_LegalEntityAxis_957DCC5C129E3812A5DB17BCD08B6019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_957DCC5C129E3812A5DB17BCD08B6019" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_957DCC5C129E3812A5DB17BCD08B6019" xlink:to="lab_dei_LegalEntityAxis_957DCC5C129E3812A5DB17BCD08B6019" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_6E1C501431768871E75817BCD08BAEB6_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_6E1C501431768871E75817BCD08BAEB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_6E1C501431768871E75817BCD08BAEB6_label_en-US" xlink:label="lab_dei_EntityDomain_6E1C501431768871E75817BCD08BAEB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6E1C501431768871E75817BCD08BAEB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_6E1C501431768871E75817BCD08BAEB6" xlink:to="lab_dei_EntityDomain_6E1C501431768871E75817BCD08BAEB6" xlink:type="arc" />
    <link:label id="lab_gale_GalenaBiopharmaIncMember_5F77A59704828A027D6517BCD08C8E97_terseLabel_en-US" xlink:label="lab_gale_GalenaBiopharmaIncMember_5F77A59704828A027D6517BCD08C8E97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Galena Biopharma, Inc</link:label>
    <link:label id="lab_gale_GalenaBiopharmaIncMember_5F77A59704828A027D6517BCD08C8E97_label_en-US" xlink:label="lab_gale_GalenaBiopharmaIncMember_5F77A59704828A027D6517BCD08C8E97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Galena Biopharma, Inc [Member]</link:label>
    <link:label id="lab_gale_GalenaBiopharmaIncMember_5F77A59704828A027D6517BCD08C8E97_documentation_en-US" xlink:label="lab_gale_GalenaBiopharmaIncMember_5F77A59704828A027D6517BCD08C8E97" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Galena Biopharma, Inc [Member]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_GalenaBiopharmaIncMember" xlink:label="loc_gale_GalenaBiopharmaIncMember_5F77A59704828A027D6517BCD08C8E97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_GalenaBiopharmaIncMember_5F77A59704828A027D6517BCD08C8E97" xlink:to="lab_gale_GalenaBiopharmaIncMember_5F77A59704828A027D6517BCD08C8E97" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2_label_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2_documentation_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2" xlink:to="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8ED9DF91BDFC31684E9917BCD08C4823_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8ED9DF91BDFC31684E9917BCD08C4823" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse stock split ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8ED9DF91BDFC31684E9917BCD08C4823_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8ED9DF91BDFC31684E9917BCD08C4823" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8ED9DF91BDFC31684E9917BCD08C4823" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8ED9DF91BDFC31684E9917BCD08C4823" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8ED9DF91BDFC31684E9917BCD08C4823" xlink:type="arc" />
    <link:label id="lab_gale_CommonStockConversionRatio_3F25FC70FB06356B681517BCD08DB155_terseLabel_en-US" xlink:label="lab_gale_CommonStockConversionRatio_3F25FC70FB06356B681517BCD08DB155" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock conversion ratio</link:label>
    <link:label id="lab_gale_CommonStockConversionRatio_3F25FC70FB06356B681517BCD08DB155_label_en-US" xlink:label="lab_gale_CommonStockConversionRatio_3F25FC70FB06356B681517BCD08DB155" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Conversion Ratio</link:label>
    <link:label id="lab_gale_CommonStockConversionRatio_3F25FC70FB06356B681517BCD08DB155_documentation_en-US" xlink:label="lab_gale_CommonStockConversionRatio_3F25FC70FB06356B681517BCD08DB155" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Conversion Ratio</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_CommonStockConversionRatio" xlink:label="loc_gale_CommonStockConversionRatio_3F25FC70FB06356B681517BCD08DB155" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockConversionRatio_3F25FC70FB06356B681517BCD08DB155" xlink:to="lab_gale_CommonStockConversionRatio_3F25FC70FB06356B681517BCD08DB155" xlink:type="arc" />
    <link:label id="lab_gale_PercentageOfFullyDilutedShareCapitalOwned_92A61BD54FF300EFA6C817BCD08D5938_terseLabel_en-US" xlink:label="lab_gale_PercentageOfFullyDilutedShareCapitalOwned_92A61BD54FF300EFA6C817BCD08D5938" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock ownership percentage</link:label>
    <link:label id="lab_gale_PercentageOfFullyDilutedShareCapitalOwned_92A61BD54FF300EFA6C817BCD08D5938_label_en-US" xlink:label="lab_gale_PercentageOfFullyDilutedShareCapitalOwned_92A61BD54FF300EFA6C817BCD08D5938" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Fully Diluted Share Capital Owned</link:label>
    <link:label id="lab_gale_PercentageOfFullyDilutedShareCapitalOwned_92A61BD54FF300EFA6C817BCD08D5938_documentation_en-US" xlink:label="lab_gale_PercentageOfFullyDilutedShareCapitalOwned_92A61BD54FF300EFA6C817BCD08D5938" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Fully Diluted Share Capital Owned</link:label>
    <link:loc xlink:href="gale-20180930.xsd#gale_PercentageOfFullyDilutedShareCapitalOwned" xlink:label="loc_gale_PercentageOfFullyDilutedShareCapitalOwned_92A61BD54FF300EFA6C817BCD08D5938" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PercentageOfFullyDilutedShareCapitalOwned_92A61BD54FF300EFA6C817BCD08D5938" xlink:to="lab_gale_PercentageOfFullyDilutedShareCapitalOwned_92A61BD54FF300EFA6C817BCD08D5938" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_45F365CAEB034586057617BCCDBFE0F8_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_45F365CAEB034586057617BCCDBFE0F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_45F365CAEB034586057617BCCDBFE0F8_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_45F365CAEB034586057617BCCDBFE0F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_45F365CAEB034586057617BCCDBFE0F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_45F365CAEB034586057617BCCDBFE0F8" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_45F365CAEB034586057617BCCDBFE0F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_D259EB6936729D09DEB317BCCDBFC423_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_D259EB6936729D09DEB317BCCDBFC423" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_D259EB6936729D09DEB317BCCDBFC423_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_D259EB6936729D09DEB317BCCDBFC423" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_D259EB6936729D09DEB317BCCDBFC423" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_D259EB6936729D09DEB317BCCDBFC423" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_D259EB6936729D09DEB317BCCDBFC423" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_7886254FF23379F6A7EA17BCCDC051C6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_7886254FF23379F6A7EA17BCCDC051C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_7886254FF23379F6A7EA17BCCDC051C6_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_7886254FF23379F6A7EA17BCCDC051C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_7886254FF23379F6A7EA17BCCDC051C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_7886254FF23379F6A7EA17BCCDC051C6" xlink:to="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_7886254FF23379F6A7EA17BCCDC051C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_4EE835FA5CE55B77E0D917BCCDC09D58_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_4EE835FA5CE55B77E0D917BCCDC09D58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_4EE835FA5CE55B77E0D917BCCDC09D58_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_4EE835FA5CE55B77E0D917BCCDC09D58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_4EE835FA5CE55B77E0D917BCCDC09D58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_4EE835FA5CE55B77E0D917BCCDC09D58" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_4EE835FA5CE55B77E0D917BCCDC09D58" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_58D58D2EB85216BC5A9817BCCDC18101_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_58D58D2EB85216BC5A9817BCCDC18101" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_58D58D2EB85216BC5A9817BCCDC18101_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_58D58D2EB85216BC5A9817BCCDC18101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_58D58D2EB85216BC5A9817BCCDC18101" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_58D58D2EB85216BC5A9817BCCDC18101" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_58D58D2EB85216BC5A9817BCCDC18101" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_32EED4F69BAB6A8464BE0E344023C623_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_32EED4F69BAB6A8464BE0E344023C623" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_32EED4F69BAB6A8464BE0E344023C623_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_32EED4F69BAB6A8464BE0E344023C623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_32EED4F69BAB6A8464BE0E344023C623" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_32EED4F69BAB6A8464BE0E344023C623" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_32EED4F69BAB6A8464BE0E344023C623" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>gale-20180930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="gale-20180930.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="gale-20180930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="gale-20180930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Acquisition" xlink:href="gale-20180930.xsd#Acquisition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionDetails" xlink:href="gale-20180930.xsd#AcquisitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/AcquisitionTables" xlink:href="gale-20180930.xsd#AcquisitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:href="gale-20180930.xsd#BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails" xlink:href="gale-20180930.xsd#BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:href="gale-20180930.xsd#BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:href="gale-20180930.xsd#BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:href="gale-20180930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="gale-20180930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:href="gale-20180930.xsd#CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="gale-20180930.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="gale-20180930.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Debt" xlink:href="gale-20180930.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtConvertibleDebtDetails" xlink:href="gale-20180930.xsd#DebtConvertibleDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtSeniorSecuredDebentureDetails" xlink:href="gale-20180930.xsd#DebtSeniorSecuredDebentureDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtSummaryOfDebtDetails" xlink:href="gale-20180930.xsd#DebtSummaryOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DebtTables" xlink:href="gale-20180930.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:href="gale-20180930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:href="gale-20180930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails" xlink:href="gale-20180930.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails" xlink:href="gale-20180930.xsd#FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:href="gale-20180930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingencies" xlink:href="gale-20180930.xsd#LegalProceedingsCommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetails" xlink:href="gale-20180930.xsd#LegalProceedingsCommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/Liquidity" xlink:href="gale-20180930.xsd#Liquidity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/LiquidityDetails" xlink:href="gale-20180930.xsd#LiquidityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="gale-20180930.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:href="gale-20180930.xsd#OrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:href="gale-20180930.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:href="gale-20180930.xsd#StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails" xlink:href="gale-20180930.xsd#StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails" xlink:href="gale-20180930.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="gale-20180930.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:href="gale-20180930.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:href="gale-20180930.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails" xlink:href="gale-20180930.xsd#StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails" xlink:href="gale-20180930.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:href="gale-20180930.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:href="gale-20180930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStock" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockNarrativeDetails" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStockNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails" xlink:href="gale-20180930.xsd#WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_252D0921F4C0FDB0F7CB17BCCDDB5771" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6E58879CED0AD3F4597317BCCDDB0774" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_252D0921F4C0FDB0F7CB17BCCDDB5771" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6E58879CED0AD3F4597317BCCDDB0774" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_65A33BE00A8847D0588C0EB15C6A7633" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_B5F57C47B1C7CC5E257C0ED5D7A8D531" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_65A33BE00A8847D0588C0EB15C6A7633" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_B5F57C47B1C7CC5E257C0ED5D7A8D531" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_4931852F52BEA0DCB0650ED600DCEDC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_B5F57C47B1C7CC5E257C0ED5D7A8D531" xlink:to="loc_srt_LitigationCaseAxis_4931852F52BEA0DCB0650ED600DCEDC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_35584495654EC9B39DF30ED600DDD899" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_4931852F52BEA0DCB0650ED600DCEDC2" xlink:to="loc_srt_LitigationCaseTypeDomain_35584495654EC9B39DF30ED600DDD899" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_JBGLitigationMember" xlink:label="loc_gale_JBGLitigationMember_658D7BEAAC75694782330ED699F624DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_35584495654EC9B39DF30ED600DDD899" xlink:to="loc_gale_JBGLitigationMember_658D7BEAAC75694782330ED699F624DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_B5F57C47B1C7CC5E257C0ED5D7A8D531" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_9057888168DA42D4C8C90EB15C6A5017" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_9057888168DA42D4C8C90EB15C6A5017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_27CB222A92316D9794AD0EB15C6B572C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_27CB222A92316D9794AD0EB15C6B572C" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ContractResearchPayable" xlink:label="loc_gale_ContractResearchPayable_33526AF70FB77FE3BDA90EB15C6BE4D0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:to="loc_gale_ContractResearchPayable_33526AF70FB77FE3BDA90EB15C6BE4D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_39431B83957064BF0EB60EB15C6B11EA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:to="loc_us-gaap_TaxesPayableCurrent_39431B83957064BF0EB60EB15C6B11EA" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_RebatesAndReturnsOfFormerCommercialProducts" xlink:label="loc_gale_RebatesAndReturnsOfFormerCommercialProducts_99F8FA7240879A51868E0EB15C6B0D6C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:to="loc_gale_RebatesAndReturnsOfFormerCommercialProducts_99F8FA7240879A51868E0EB15C6B0D6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2344F99894B8F68002A70EB15C6BA23A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2344F99894B8F68002A70EB15C6BA23A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_B03B1AE705AB78A8C46F0EB15C6CFD19" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_B03B1AE705AB78A8C46F0EB15C6CFD19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaap_LitigationReserveCurrent_E4A710B936B1F2873ECE0EC436FF45E0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_BDA0F8976359A77DB97E0ED5D7A982A5" xlink:to="loc_us-gaap_LitigationReserveCurrent_E4A710B936B1F2873ECE0EC436FF45E0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_FA3817CB8F63B0CD443317BCD03F90FE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0DE49F35E6C5ED29FD0717BCD03FB39C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_FA3817CB8F63B0CD443317BCD03F90FE" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0DE49F35E6C5ED29FD0717BCD03FB39C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/Acquisition" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_AC9E51FE0E9F3F2D221717BCD0B73A05" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_5FBB5B32ED5BB5DE17BF17BCD0B70464" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_AC9E51FE0E9F3F2D221717BCD0B73A05" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_5FBB5B32ED5BB5DE17BF17BCD0B70464" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_ED3095644DD160AC611E139A7271D9A6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_EB1AA0182B3B8F100B08139A7271B5C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_ED3095644DD160AC611E139A7271D9A6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_EB1AA0182B3B8F100B08139A7271B5C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonrecurringAdjustmentAxis" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis_B12E75E214B7B9DDCA81139A7272A3A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_EB1AA0182B3B8F100B08139A7271B5C6" xlink:to="loc_us-gaap_NonrecurringAdjustmentAxis_B12E75E214B7B9DDCA81139A7272A3A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_0FB44404F63E70E9A1C6139A7272D3D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_B12E75E214B7B9DDCA81139A7272A3A0" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_0FB44404F63E70E9A1C6139A7272D3D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquisitionRelatedCostsMember" xlink:label="loc_us-gaap_AcquisitionRelatedCostsMember_62B9144C2AF5DBFDF074139A72723221" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_0FB44404F63E70E9A1C6139A7272D3D1" xlink:to="loc_us-gaap_AcquisitionRelatedCostsMember_62B9144C2AF5DBFDF074139A72723221" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_EB1AA0182B3B8F100B08139A7271B5C6" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_EB6614E6435DB5E2A9D4139A72736210" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_EB6614E6435DB5E2A9D4139A72736210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_FA20D3E4474DDE6D1839139A72733C50" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_FA20D3E4474DDE6D1839139A72733C50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_CFDD4826AF6DAE0C1FCF139A7273AAA2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_CFDD4826AF6DAE0C1FCF139A7273AAA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_27EBFA3BDFBB60C6AFAD139A7273E71B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:to="loc_us-gaap_ProfitLoss_27EBFA3BDFBB60C6AFAD139A7273E71B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_AFDCE2F5311DF980671A139A7273AB06" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_AFDCE2F5311DF980671A139A7273AB06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_E8B062E9E8EE98348EB1139A7273CF7C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_E8B062E9E8EE98348EB1139A7273CF7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_3AAD9B86E3DF4F5AA508139A7274AAC3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_246BD24213EBB043A4B9139A72721D97" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_3AAD9B86E3DF4F5AA508139A7274AAC3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/AcquisitionTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_564E3C62BA153B7E6A8D0E344023B958" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_32EED4F69BAB6A8464BE0E344023C623" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_564E3C62BA153B7E6A8D0E344023B958" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_32EED4F69BAB6A8464BE0E344023C623" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0D4C7FCF662EE841733417BCCDD03A24" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_AB63E18870137FBE5BED17BCCDD1D7EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0D4C7FCF662EE841733417BCCDD03A24" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_AB63E18870137FBE5BED17BCCDD1D7EC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_82120394B0700F68763C1361E73C02BA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_98CCB02F289B4A2E81451361E73D050C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82120394B0700F68763C1361E73C02BA" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_98CCB02F289B4A2E81451361E73D050C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_37E20E26ED27B82B4AA71361E73D2ABC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_98CCB02F289B4A2E81451361E73D050C" xlink:to="loc_us-gaap_DebtInstrumentAxis_37E20E26ED27B82B4AA71361E73D2ABC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_52890DE1DAE16F2E55211361E73D5079" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_37E20E26ED27B82B4AA71361E73D2ABC" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_52890DE1DAE16F2E55211361E73D5079" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_AmendmentAgreementMember" xlink:label="loc_gale_AmendmentAgreementMember_DB0BBD9CD2548FB0EB2C1361E73E66EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52890DE1DAE16F2E55211361E73D5079" xlink:to="loc_gale_AmendmentAgreementMember_DB0BBD9CD2548FB0EB2C1361E73E66EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_BAB3F54747F17D382A081361E73E6B9D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_98CCB02F289B4A2E81451361E73D050C" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_BAB3F54747F17D382A081361E73E6B9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_355EABFC3A15A34A67141361E73E2463" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_BAB3F54747F17D382A081361E73E6B9D" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_355EABFC3A15A34A67141361E73E2463" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_20009DB3B47C281DAC6A1361E73FCFE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_355EABFC3A15A34A67141361E73E2463" xlink:to="loc_us-gaap_SecuredDebtMember_20009DB3B47C281DAC6A1361E73FCFE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_45CEE4A65D2C8F55CEA31361E73FB765" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_98CCB02F289B4A2E81451361E73D050C" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_45CEE4A65D2C8F55CEA31361E73FB765" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DA9471803FC86D222BE21361E73F1C38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_45CEE4A65D2C8F55CEA31361E73FB765" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DA9471803FC86D222BE21361E73F1C38" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_CorporateCreditCardsMember" xlink:label="loc_gale_CorporateCreditCardsMember_E0C6D1B4B268239025C71361E74041C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_DA9471803FC86D222BE21361E73F1C38" xlink:to="loc_gale_CorporateCreditCardsMember_E0C6D1B4B268239025C71361E74041C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_98CCB02F289B4A2E81451361E73D050C" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2EA991C5D4B807F97F711361E740C771" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2EA991C5D4B807F97F711361E740C771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4C0103688B2023AD1EE31361E740F72E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4C0103688B2023AD1EE31361E740F72E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF677FFAF123F3AE957B1361E740738E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF677FFAF123F3AE957B1361E740738E" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DebtInstrumentCovenantLiquidityCovenant" xlink:label="loc_gale_DebtInstrumentCovenantLiquidityCovenant_B163E7168FC9D6B0F2041361E7418D98" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6" xlink:to="loc_gale_DebtInstrumentCovenantLiquidityCovenant_B163E7168FC9D6B0F2041361E7418D98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_D38695AD2C06356588FC1361E7417927" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_99BF2C09F7F390AAD3791361E74041A6" xlink:to="loc_us-gaap_RestrictedCash_D38695AD2C06356588FC1361E7417927" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_EB5C386D2DF06216D8C117BCCDBFFF50" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_45F365CAEB034586057617BCCDBFE0F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EB5C386D2DF06216D8C117BCCDBFFF50" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_45F365CAEB034586057617BCCDBFE0F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_D259EB6936729D09DEB317BCCDBFC423" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EB5C386D2DF06216D8C117BCCDBFFF50" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_D259EB6936729D09DEB317BCCDBFC423" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_7886254FF23379F6A7EA17BCCDC051C6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EB5C386D2DF06216D8C117BCCDBFFF50" xlink:to="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_7886254FF23379F6A7EA17BCCDC051C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_4EE835FA5CE55B77E0D917BCCDC09D58" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EB5C386D2DF06216D8C117BCCDBFFF50" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_4EE835FA5CE55B77E0D917BCCDC09D58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_58D58D2EB85216BC5A9817BCCDC18101" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EB5C386D2DF06216D8C117BCCDBFFF50" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_58D58D2EB85216BC5A9817BCCDC18101" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_45147F61D839576F48AB17BCCDB5A6A7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_2A38F6635FB116C5D29F17BCCDBB7339" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_45147F61D839576F48AB17BCCDB5A6A7" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_2A38F6635FB116C5D29F17BCCDBB7339" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_A4B121B7F5D01E2E4EE50891C4D743AD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_DF1637511DA6A7CF99F90891C4D7807B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A4B121B7F5D01E2E4EE50891C4D743AD" xlink:to="loc_us-gaap_AssetsAbstract_DF1637511DA6A7CF99F90891C4D7807B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2FF7E513E3720D99DC000891C4D7FEE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_DF1637511DA6A7CF99F90891C4D7807B" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2FF7E513E3720D99DC000891C4D7FEE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B1DE572117A041C600F00891C4D8351B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2FF7E513E3720D99DC000891C4D7FEE7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B1DE572117A041C600F00891C4D8351B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_359288A36D605EA280070891C4D88539" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2FF7E513E3720D99DC000891C4D7FEE7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_359288A36D605EA280070891C4D88539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_1459D3A080A43E124A5808BBD451EE03" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2FF7E513E3720D99DC000891C4D7FEE7" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_1459D3A080A43E124A5808BBD451EE03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableCurrent_5F7F3FFCC9E57A57E4C30891C4D97E24" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2FF7E513E3720D99DC000891C4D7FEE7" xlink:to="loc_us-gaap_InsuranceSettlementsReceivableCurrent_5F7F3FFCC9E57A57E4C30891C4D97E24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7D2866937AE5E309463D0891C4D9A14D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2FF7E513E3720D99DC000891C4D7FEE7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7D2866937AE5E309463D0891C4D9A14D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_3C880301EA0B8CA7A4B30891C4D97FDA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2FF7E513E3720D99DC000891C4D7FEE7" xlink:to="loc_us-gaap_AssetsCurrent_3C880301EA0B8CA7A4B30891C4D97FDA" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_InProcessResearchDevelopment" xlink:label="loc_gale_InProcessResearchDevelopment_0FF156F14BF2978B13830891C4D9D398" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_DF1637511DA6A7CF99F90891C4D7807B" xlink:to="loc_gale_InProcessResearchDevelopment_0FF156F14BF2978B13830891C4D9D398" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1753E2495EE77008F9F00891C4D9274E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_DF1637511DA6A7CF99F90891C4D7807B" xlink:to="loc_us-gaap_Goodwill_1753E2495EE77008F9F00891C4D9274E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_AC5D9821F23665524E4A0891C4DA9F84" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_DF1637511DA6A7CF99F90891C4D7807B" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_AC5D9821F23665524E4A0891C4DA9F84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_865ED972D670975D16ED0891C4DA9E9A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_DF1637511DA6A7CF99F90891C4D7807B" xlink:to="loc_us-gaap_Assets_865ED972D670975D16ED0891C4DA9E9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5A0DC4D81DE39E6D2C750891C4DAAEBB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A4B121B7F5D01E2E4EE50891C4D743AD" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5A0DC4D81DE39E6D2C750891C4DAAEBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_AC015F12B0B0EC2053E60891C4DAE7A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5A0DC4D81DE39E6D2C750891C4DAAEBB" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_AC015F12B0B0EC2053E60891C4DAE7A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_C2713DB7F9BBFAEFD8500891C4DAF068" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_AC015F12B0B0EC2053E60891C4DAE7A6" xlink:to="loc_us-gaap_LongTermDebtCurrent_C2713DB7F9BBFAEFD8500891C4DAF068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_1C8F84A527C23167EAC60891C4DBD0F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_AC015F12B0B0EC2053E60891C4DAE7A6" xlink:to="loc_us-gaap_AccountsPayableCurrent_1C8F84A527C23167EAC60891C4DBD0F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_29F6C9BC8C153E5092D10891C4DB7224" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_AC015F12B0B0EC2053E60891C4DAE7A6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_29F6C9BC8C153E5092D10891C4DB7224" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaap_LitigationReserveCurrent_376EC81B0FE160ED9B730891C4DBC82B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_AC015F12B0B0EC2053E60891C4DAE7A6" xlink:to="loc_us-gaap_LitigationReserveCurrent_376EC81B0FE160ED9B730891C4DBC82B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_D1F7AA0E255EC794E88C0891C4DB773E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_AC015F12B0B0EC2053E60891C4DAE7A6" xlink:to="loc_us-gaap_LiabilitiesCurrent_D1F7AA0E255EC794E88C0891C4DB773E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_BE1DC1A83874F75244C00891C4DBF590" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5A0DC4D81DE39E6D2C750891C4DAAEBB" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_BE1DC1A83874F75244C00891C4DBF590" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_0A3BF1DC5CF22B82DF400891C4DB0239" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5A0DC4D81DE39E6D2C750891C4DAAEBB" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_0A3BF1DC5CF22B82DF400891C4DB0239" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C4227BFBEF3F496EBF050891C4DC0044" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5A0DC4D81DE39E6D2C750891C4DAAEBB" xlink:to="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C4227BFBEF3F496EBF050891C4DC0044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_C8299BF53B581D0008110891C4DCD60B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5A0DC4D81DE39E6D2C750891C4DAAEBB" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_C8299BF53B581D0008110891C4DCD60B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_0E8595D7C3A5E611F5E50891C4DC5276" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5A0DC4D81DE39E6D2C750891C4DAAEBB" xlink:to="loc_us-gaap_Liabilities_0E8595D7C3A5E611F5E50891C4DC5276" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_765AB6DAE765791BA9CA0891C4DC8FC8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5A0DC4D81DE39E6D2C750891C4DAAEBB" xlink:to="loc_us-gaap_CommitmentsAndContingencies_765AB6DAE765791BA9CA0891C4DC8FC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5E2F886F65590272B8820891C4DCB963" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5A0DC4D81DE39E6D2C750891C4DAAEBB" xlink:to="loc_us-gaap_StockholdersEquityAbstract_5E2F886F65590272B8820891C4DCB963" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_162BB44521DA5698169C0891C4DCE9BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5E2F886F65590272B8820891C4DCB963" xlink:to="loc_us-gaap_PreferredStockValue_162BB44521DA5698169C0891C4DCE9BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_E7A99F5852417BDA6ED80891C4DD1DF1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5E2F886F65590272B8820891C4DCB963" xlink:to="loc_us-gaap_CommonStockValue_E7A99F5852417BDA6ED80891C4DD1DF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ECD45D8DAA4041ACC6A40891C4DDB27A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5E2F886F65590272B8820891C4DCB963" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ECD45D8DAA4041ACC6A40891C4DDB27A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2FC23503DFDC82FFF1CD0891C4DD6A98" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5E2F886F65590272B8820891C4DCB963" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2FC23503DFDC82FFF1CD0891C4DD6A98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8473B24667B2E68E67250891C4DDC8E6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5E2F886F65590272B8820891C4DCB963" xlink:to="loc_us-gaap_StockholdersEquity_8473B24667B2E68E67250891C4DDC8E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_DD4C14028108006888C20891C4DDBBF2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5A0DC4D81DE39E6D2C750891C4DAAEBB" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_DD4C14028108006888C20891C4DDBBF2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_50DBDD014A7BF976FB2D17BCD09101AF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_B65F57E667658785906717BCD0914EC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_50DBDD014A7BF976FB2D17BCD09101AF" xlink:to="loc_us-gaap_StatementTable_B65F57E667658785906717BCD0914EC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A26ACA03B4504DD5F25917BCD092ABD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_B65F57E667658785906717BCD0914EC1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A26ACA03B4504DD5F25917BCD092ABD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A3DCB356775EBC075B5C17BCD092D959" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A26ACA03B4504DD5F25917BCD092ABD2" xlink:to="loc_us-gaap_ClassOfStockDomain_A3DCB356775EBC075B5C17BCD092D959" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_B0733B1FDCBE6A62E80D17BCD09217BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_A3DCB356775EBC075B5C17BCD092D959" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_B0733B1FDCBE6A62E80D17BCD09217BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_B65F57E667658785906717BCD0914EC1" xlink:to="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_B3EA0A337AF4A20777FA17BCD093D48F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_B3EA0A337AF4A20777FA17BCD093D48F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_37A27F7BE9CEB818B7C317BCD093EFE4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_37A27F7BE9CEB818B7C317BCD093EFE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_D89E98F229079333DBD517BCD093B5E0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:to="loc_us-gaap_PreferredStockSharesIssued_D89E98F229079333DBD517BCD093B5E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_A7BA2F510F5FCFA2C84217BCD093CDDB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_A7BA2F510F5FCFA2C84217BCD093CDDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_153ECB4136E3C73C2E4D17BCD0930C84" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_153ECB4136E3C73C2E4D17BCD0930C84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_F05E8159CC7787B83FC117BCD094EF77" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_F05E8159CC7787B83FC117BCD094EF77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_881544FF30911EF7D37617BCD0946248" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:to="loc_us-gaap_CommonStockSharesIssued_881544FF30911EF7D37617BCD0946248" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_B4E9F877B6B93E7BF72F17BCD094027C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7C2FDA957703CDBF8E3B17BCD0920029" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_B4E9F877B6B93E7BF72F17BCD094027C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_DD920E236A1DBD03A08B139A72C9C9B5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_C14A8EC2ABD1ECDDA5FF139A72C966CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_DD920E236A1DBD03A08B139A72C9C9B5" xlink:to="loc_us-gaap_StatementTable_C14A8EC2ABD1ECDDA5FF139A72C966CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_35B2C34276F84FE81DFD139A72CAB4E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_C14A8EC2ABD1ECDDA5FF139A72C966CA" xlink:to="loc_us-gaap_StatementClassOfStockAxis_35B2C34276F84FE81DFD139A72CAB4E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2B52E4E35182FB6D1596139A72CA6AD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_35B2C34276F84FE81DFD139A72CAB4E3" xlink:to="loc_us-gaap_ClassOfStockDomain_2B52E4E35182FB6D1596139A72CA6AD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_239F1233EFED7081378B139A72CB0CA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2B52E4E35182FB6D1596139A72CA6AD8" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_239F1233EFED7081378B139A72CB0CA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_4BAC23C0E553FDB00012139A72CB2ADF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2B52E4E35182FB6D1596139A72CA6AD8" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_4BAC23C0E553FDB00012139A72CB2ADF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_48DDDFBC0308A10ED728139A72CB0A83" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_C14A8EC2ABD1ECDDA5FF139A72C966CA" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_48DDDFBC0308A10ED728139A72CB0A83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_A0207ED82AF7ACD11FB2139A72CB2B9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_48DDDFBC0308A10ED728139A72CB0A83" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_A0207ED82AF7ACD11FB2139A72CB2B9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_6DFBC3AE6F7ED899F352139A72CB6C4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_A0207ED82AF7ACD11FB2139A72CB2B9A" xlink:to="loc_us-gaap_SecuredDebtMember_6DFBC3AE6F7ED899F352139A72CB6C4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_DA9E4482690EB5802E09139A72CCA3DB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_C14A8EC2ABD1ECDDA5FF139A72C966CA" xlink:to="loc_srt_LitigationCaseAxis_DA9E4482690EB5802E09139A72CCA3DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_A04E5F12A7BF185CDC1C139A72CC57A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_DA9E4482690EB5802E09139A72CCA3DB" xlink:to="loc_srt_LitigationCaseTypeDomain_A04E5F12A7BF185CDC1C139A72CC57A8" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PatelvsGalenabiopharmaIncMember" xlink:label="loc_gale_PatelvsGalenabiopharmaIncMember_C6713175261115B3EAD1139A72CCF396" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_A04E5F12A7BF185CDC1C139A72CC57A8" xlink:to="loc_gale_PatelvsGalenabiopharmaIncMember_C6713175261115B3EAD1139A72CCF396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_75079EED3E01D7D83ACA139A72CD0474" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_C14A8EC2ABD1ECDDA5FF139A72C966CA" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_75079EED3E01D7D83ACA139A72CD0474" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3CE17E7B35F9EA682178139A72CDF456" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_75079EED3E01D7D83ACA139A72CD0474" xlink:to="loc_us-gaap_EquityComponentDomain_3CE17E7B35F9EA682178139A72CDF456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_435BF2C8E1E36CFB0959139A72CD9F2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3CE17E7B35F9EA682178139A72CDF456" xlink:to="loc_us-gaap_PreferredStockMember_435BF2C8E1E36CFB0959139A72CD9F2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_C57B506FAA718B6F646B139A72CD2341" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3CE17E7B35F9EA682178139A72CDF456" xlink:to="loc_us-gaap_CommonStockMember_C57B506FAA718B6F646B139A72CD2341" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_22F9B599838556C72ED7139A72CD34C1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3CE17E7B35F9EA682178139A72CDF456" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_22F9B599838556C72ED7139A72CD34C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_A02C396EAEAE02BCE154139A72CEE70F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3CE17E7B35F9EA682178139A72CDF456" xlink:to="loc_us-gaap_RetainedEarningsMember_A02C396EAEAE02BCE154139A72CEE70F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3A4568217958F838862D139A72CE1C9B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_C14A8EC2ABD1ECDDA5FF139A72C966CA" xlink:to="loc_us-gaap_StatementLineItems_3A4568217958F838862D139A72CE1C9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3A4568217958F838862D139A72CE1C9B" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_98030877B39A9894DEF3139A72CE838D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_SharesOutstanding_98030877B39A9894DEF3139A72CE838D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D45E931BD3B83E9A81F0139A72CFF982" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D45E931BD3B83E9A81F0139A72CFF982" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C87707F3ABA94D7C5C3139A72CFC00A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0C87707F3ABA94D7C5C3139A72CFC00A" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PreferredStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_gale_PreferredStockIssuedDuringPeriodValueNewIssues_F91DD5F1A114339E477E139A72CF8AAC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_gale_PreferredStockIssuedDuringPeriodValueNewIssues_F91DD5F1A114339E477E139A72CF8AAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ADE5FB63D188A7CB169139A72CFCE6A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ADE5FB63D188A7CB169139A72CFCE6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EADFD13E20030EEED1C4139A72CFCD24" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_EADFD13E20030EEED1C4139A72CFCD24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_C4C137680B5CE58B9D46139A72CF9468" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_C4C137680B5CE58B9D46139A72CF9468" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStock" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_0D1084DBDA5CAA7045A4139A72D03B82" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock_0D1084DBDA5CAA7045A4139A72D03B82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_D3F3761425B2B85CBC20139A72D08B85" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_D3F3761425B2B85CBC20139A72D08B85" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ConvertiblePreferredStockDividends" xlink:label="loc_gale_ConvertiblePreferredStockDividends_4BBC5DE6A124A5163906139A72D0CB7C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_gale_ConvertiblePreferredStockDividends_4BBC5DE6A124A5163906139A72D0CB7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_956E58F63CDB7BBC247E139A72D01A5F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_956E58F63CDB7BBC247E139A72D01A5F" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_48ECC7DA9378CAF38A37139A72D0AEF4" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_48ECC7DA9378CAF38A37139A72D0AEF4" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DividendModificationOfWarrants" xlink:label="loc_gale_DividendModificationOfWarrants_760E7614F9BAB4F470C9139A72D0A1CD" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_gale_DividendModificationOfWarrants_760E7614F9BAB4F470C9139A72D0A1CD" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_WarrantExchangeAgreementsIssuanceOfCommonStock" xlink:label="loc_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_90C45F1C4ED95CC54E44139A72D1D964" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_gale_WarrantExchangeAgreementsIssuanceOfCommonStock_90C45F1C4ED95CC54E44139A72D1D964" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_WarrantExchangeAgreementsAmount" xlink:label="loc_gale_WarrantExchangeAgreementsAmount_E9BF47F89DF608DAB14D139A72D17D7A" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_gale_WarrantExchangeAgreementsAmount_E9BF47F89DF608DAB14D139A72D17D7A" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_StockIssuedDuringPeriodSharesPrefundedWarrant" xlink:label="loc_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_0DC29105016BAFE4DBFF139A72D1BEC1" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_gale_StockIssuedDuringPeriodSharesPrefundedWarrant_0DC29105016BAFE4DBFF139A72D1BEC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_CD06970FF64135C93215139A72D1F8E0" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_CD06970FF64135C93215139A72D1F8E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0F44CE05480F07A42341139A72D1766E" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_NetIncomeLoss_0F44CE05480F07A42341139A72D1766E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_2109606E5C1C75E3DF21139A72D195EE" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_SharesOutstanding_2109606E5C1C75E3DF21139A72D195EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4783E21BA89B2AE98E87139A72D172B4" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FC5B8A419E8CE84A969D139A72CE45FE" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4783E21BA89B2AE98E87139A72D172B4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6CD760F734CC9AC2ABBD13B0C3A8451B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1716DAE29B858B50949A13B0C3A9FBAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6CD760F734CC9AC2ABBD13B0C3A8451B" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1716DAE29B858B50949A13B0C3A9FBAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_D6F4CB3034C72E709A2413B0C3A9E289" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1716DAE29B858B50949A13B0C3A9FBAB" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_D6F4CB3034C72E709A2413B0C3A9E289" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1716DAE29B858B50949A13B0C3A9FBAB" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_C88D2E1F5E60335541A013B0C3A9C699" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_C88D2E1F5E60335541A013B0C3A9C699" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_5162EAA4BB209006C59013B0C3AA0661" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249" xlink:to="loc_us-gaap_PaidInKindInterest_5162EAA4BB209006C59013B0C3AA0661" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_4A55F655EFB6C8A7834213B0C3AA921B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_4A55F655EFB6C8A7834213B0C3AA921B" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_GainLossOnExtinguishmentOfPayables" xlink:label="loc_gale_GainLossOnExtinguishmentOfPayables_5B73FFD897CA3296A62713B0C3AA4DC7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249" xlink:to="loc_gale_GainLossOnExtinguishmentOfPayables_5B73FFD897CA3296A62713B0C3AA4DC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_43942B211D88D570E93E13B0C3AA8FB8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249" xlink:to="loc_us-gaap_ShareBasedCompensation_43942B211D88D570E93E13B0C3AA8FB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_147426B5CD944B5AB62313B0C3AB53BE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249" xlink:to="loc_us-gaap_AdjustmentForAmortization_147426B5CD944B5AB62313B0C3AB53BE" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" xlink:label="loc_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_653F6AB530D7FAAAB52D13B0C3AB6C7E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249" xlink:to="loc_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_653F6AB530D7FAAAB52D13B0C3AB6C7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_A5E74B16F2C5D856E64913B0C3AB6EB7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_A5E74B16F2C5D856E64913B0C3AB6EB7" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1C751A8F43C5D9691EC113B0C3AB2409" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249" xlink:to="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1C751A8F43C5D9691EC113B0C3AB2409" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_A5D6C34E1D982EDF0A2713B0C3AB647D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_A5D6C34E1D982EDF0A2713B0C3AB647D" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_LossOnSettlementOfLiabilityClassifiedWarrants" xlink:label="loc_gale_LossOnSettlementOfLiabilityClassifiedWarrants_F0A986BEF2EEAC72FAFE13B0C3ACE06B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249" xlink:to="loc_gale_LossOnSettlementOfLiabilityClassifiedWarrants_F0A986BEF2EEAC72FAFE13B0C3ACE06B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_658427AFFEC1A0334C8113B0C3AC2069" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_569EE8DCFA5674B326A313B0C3A94249" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_658427AFFEC1A0334C8113B0C3AC2069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_971324B351DFFB79EFA713B0C3AC2E82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_658427AFFEC1A0334C8113B0C3AC2069" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_971324B351DFFB79EFA713B0C3AC2E82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6B55BD8E80423801EA0813B0C3AC91EF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_658427AFFEC1A0334C8113B0C3AC2069" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6B55BD8E80423801EA0813B0C3AC91EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_741539BEDCE276DCF8C813B0C3AC87AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_658427AFFEC1A0334C8113B0C3AC2069" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_741539BEDCE276DCF8C813B0C3AC87AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6DD6E4476836B7B77C7613B0C3AC9405" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_658427AFFEC1A0334C8113B0C3AC2069" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6DD6E4476836B7B77C7613B0C3AC9405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_CD6FE6CFD5A305A718B213B0C3AD8744" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_658427AFFEC1A0334C8113B0C3AC2069" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_CD6FE6CFD5A305A718B213B0C3AD8744" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_BEB3989D483652CE80D013B0C3AD0081" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1716DAE29B858B50949A13B0C3A9FBAB" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_BEB3989D483652CE80D013B0C3AD0081" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F7178A1586D3EC51129D13B0C3AD2C0C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6CD760F734CC9AC2ABBD13B0C3A8451B" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F7178A1586D3EC51129D13B0C3AD2C0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_8108907AB01CB4F0553613B0C3AD218B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F7178A1586D3EC51129D13B0C3AD2C0C" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_8108907AB01CB4F0553613B0C3AD218B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_395F6595F49BF2013BE213B0C3ADA3DE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F7178A1586D3EC51129D13B0C3AD2C0C" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_395F6595F49BF2013BE213B0C3ADA3DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends_50DEBBBA25DCE0D8263E13B0C3AECA11" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F7178A1586D3EC51129D13B0C3AD2C0C" xlink:to="loc_us-gaap_PaymentsOfDividends_50DEBBBA25DCE0D8263E13B0C3AECA11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_1A0F732853A8088D221013B0C3AEF3CF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F7178A1586D3EC51129D13B0C3AD2C0C" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_1A0F732853A8088D221013B0C3AEF3CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9E1D1FCD78BC52043E8413B0C3AE4C21" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F7178A1586D3EC51129D13B0C3AD2C0C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9E1D1FCD78BC52043E8413B0C3AE4C21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_29E2B83D21802143956013B0C3AE6E81" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6CD760F734CC9AC2ABBD13B0C3A8451B" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_29E2B83D21802143956013B0C3AE6E81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_511A07E21118005AE9BD13B0C3AE8F60" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6CD760F734CC9AC2ABBD13B0C3A8451B" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_511A07E21118005AE9BD13B0C3AE8F60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2554ECBBE2F4DEA7ADEF13B0C3AE7CAA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6CD760F734CC9AC2ABBD13B0C3A8451B" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2554ECBBE2F4DEA7ADEF13B0C3AE7CAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_C999377BD247C1504ABA13B0C3AF6EC5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6CD760F734CC9AC2ABBD13B0C3A8451B" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_C999377BD247C1504ABA13B0C3AF6EC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_88566FECEB5A65651B5A13B0C3AF3A30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_C999377BD247C1504ABA13B0C3AF6EC5" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_88566FECEB5A65651B5A13B0C3AF3A30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_23C61AECA86CC8CB61B413B0C3AF1E32" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_C999377BD247C1504ABA13B0C3AF6EC5" xlink:to="loc_us-gaap_InterestPaidNet_23C61AECA86CC8CB61B413B0C3AF1E32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_A04A3CE123CD72B4117213B0C3AF17BD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6CD760F734CC9AC2ABBD13B0C3A8451B" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_A04A3CE123CD72B4117213B0C3AF17BD" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:label="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_278DDA521F81373AD83713B0C3AFA1BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_A04A3CE123CD72B4117213B0C3AF17BD" xlink:to="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_278DDA521F81373AD83713B0C3AFA1BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_99D3FDEB704B817B8FB613B0C3B0FCB3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_A04A3CE123CD72B4117213B0C3AF17BD" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_99D3FDEB704B817B8FB613B0C3B0FCB3" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock" xlink:label="loc_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_130D84AED5C367430BD913B0C3B0C94B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_A04A3CE123CD72B4117213B0C3AF17BD" xlink:to="loc_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock_130D84AED5C367430BD913B0C3B0C94B" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:label="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_3EB1DFE69B87000D009B13B0C3B06B7F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_A04A3CE123CD72B4117213B0C3AF17BD" xlink:to="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_3EB1DFE69B87000D009B13B0C3B06B7F" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_LongtermDebtIssuedInConnectionWithWarrantExchanges" xlink:label="loc_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_09A3D82CF2CE43A468D113B0C3B0178F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_A04A3CE123CD72B4117213B0C3AF17BD" xlink:to="loc_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges_09A3D82CF2CE43A468D113B0C3B0178F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_5A3B4198FEC5465A698A1361E7BA29D9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_66AD51D3FD0696B491731361E7BA931F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5A3B4198FEC5465A698A1361E7BA29D9" xlink:to="loc_us-gaap_OperatingExpensesAbstract_66AD51D3FD0696B491731361E7BA931F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_956B8C8AE891FD1389281361E7BAE895" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66AD51D3FD0696B491731361E7BA931F" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_956B8C8AE891FD1389281361E7BAE895" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_E3DFE4E1A16198F3984A1361E7BA39AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66AD51D3FD0696B491731361E7BA931F" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_E3DFE4E1A16198F3984A1361E7BA39AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_9D135D91701F7685F0A21361E7BAF0DB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66AD51D3FD0696B491731361E7BA931F" xlink:to="loc_us-gaap_CostsAndExpenses_9D135D91701F7685F0A21361E7BAF0DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3E25FB9FB6E8A8D72CA41361E7BB1B91" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5A3B4198FEC5465A698A1361E7BA29D9" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3E25FB9FB6E8A8D72CA41361E7BB1B91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_2AF726A0544D51B3C5691361E7BB529C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3E25FB9FB6E8A8D72CA41361E7BB1B91" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_2AF726A0544D51B3C5691361E7BB529C" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_C15F1AFFB91517EEDCAE1361E7BB65F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3E25FB9FB6E8A8D72CA41361E7BB1B91" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_C15F1AFFB91517EEDCAE1361E7BB65F4" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_LossOnSettlementOfWarrantsLiability" xlink:label="loc_gale_LossOnSettlementOfWarrantsLiability_13C7B1019826D89A83701361E7BC433A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3E25FB9FB6E8A8D72CA41361E7BB1B91" xlink:to="loc_gale_LossOnSettlementOfWarrantsLiability_13C7B1019826D89A83701361E7BC433A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_B4DBDB15315C239AC5B71361E7BC4AAF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3E25FB9FB6E8A8D72CA41361E7BB1B91" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_B4DBDB15315C239AC5B71361E7BC4AAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_7FDAE6D8FD47A08184FE1361E7BCEEA2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3E25FB9FB6E8A8D72CA41361E7BB1B91" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_7FDAE6D8FD47A08184FE1361E7BCEEA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_06791843B0AB1CBEF9001361E7BCAF4C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3E25FB9FB6E8A8D72CA41361E7BB1B91" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_06791843B0AB1CBEF9001361E7BCAF4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0C0BBBE1A9C7B54230B61361E7BCE19E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5A3B4198FEC5465A698A1361E7BA29D9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_0C0BBBE1A9C7B54230B61361E7BCE19E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_39496BD7FEBFB0F342961361E7BCACD0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5A3B4198FEC5465A698A1361E7BA29D9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_39496BD7FEBFB0F342961361E7BCACD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F83D0828C329E4A810271361E7BD3DD4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5A3B4198FEC5465A698A1361E7BA29D9" xlink:to="loc_us-gaap_NetIncomeLoss_F83D0828C329E4A810271361E7BD3DD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_635F48ACE4C2DF7332F61361E7BD93AC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5A3B4198FEC5465A698A1361E7BA29D9" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_635F48ACE4C2DF7332F61361E7BD93AC" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_D3D645130E5CCF497ED81361E7BD17D9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5A3B4198FEC5465A698A1361E7BA29D9" xlink:to="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_D3D645130E5CCF497ED81361E7BD17D9" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_LiabilityClassifiedWarrantsAntidilutionProtection" xlink:label="loc_gale_LiabilityClassifiedWarrantsAntidilutionProtection_3124004756B33B42D35B139D4E634D0E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5A3B4198FEC5465A698A1361E7BA29D9" xlink:to="loc_gale_LiabilityClassifiedWarrantsAntidilutionProtection_3124004756B33B42D35B139D4E634D0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_69EAE66F799D548B26FA1361E7BD781D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5A3B4198FEC5465A698A1361E7BA29D9" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_69EAE66F799D548B26FA1361E7BD781D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_44ABD1C037DC235267841361E7BDABC3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5A3B4198FEC5465A698A1361E7BA29D9" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_44ABD1C037DC235267841361E7BDABC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_B83274243FA47E467FD61361E7BEF0F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_44ABD1C037DC235267841361E7BDABC3" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_B83274243FA47E467FD61361E7BEF0F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FA23B078D16CE30856831361E7BE17DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_44ABD1C037DC235267841361E7BDABC3" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FA23B078D16CE30856831361E7BE17DD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/Debt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_42DBEE159CF3B4CFAB2B17BCD06C78F1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_02ED518B9B9DC502F3F917BCD06C3ED8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_42DBEE159CF3B4CFAB2B17BCD06C78F1" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_02ED518B9B9DC502F3F917BCD06C3ED8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/DebtConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3140C18D09046AC964DE08F4613D55D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F5BB01A8FC69954A066008F4613D9D9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3140C18D09046AC964DE08F4613D55D3" xlink:to="loc_us-gaap_DebtInstrumentTable_F5BB01A8FC69954A066008F4613D9D9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_548A605DADB227C4A7DA08F4613F148E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_F5BB01A8FC69954A066008F4613D9D9C" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_548A605DADB227C4A7DA08F4613F148E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_E1920DFA0DEB6EB219DC08F4613F21CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_548A605DADB227C4A7DA08F4613F148E" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_E1920DFA0DEB6EB219DC08F4613F21CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_5913C03B51D910D4D87F08F4613FA457" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_E1920DFA0DEB6EB219DC08F4613F21CB" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_5913C03B51D910D4D87F08F4613FA457" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_ED3BB9BE9738BE9F1B5C08F4614096C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_F5BB01A8FC69954A066008F4613D9D9C" xlink:to="loc_us-gaap_DebtInstrumentAxis_ED3BB9BE9738BE9F1B5C08F4614096C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_339371011F8C728AF72908F46140349E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ED3BB9BE9738BE9F1B5C08F4614096C2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_339371011F8C728AF72908F46140349E" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ConvertiblePromissoryNotesMember" xlink:label="loc_gale_ConvertiblePromissoryNotesMember_42BA5EB175501218BA5B08F461400539" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_339371011F8C728AF72908F46140349E" xlink:to="loc_gale_ConvertiblePromissoryNotesMember_42BA5EB175501218BA5B08F461400539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_F5BB01A8FC69954A066008F4613D9D9C" xlink:to="loc_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1E434134C8976BAF92C108F461466558" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1E434134C8976BAF92C108F461466558" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_CommonStockSharesAcquiredinExchangeforWarrants" xlink:label="loc_gale_CommonStockSharesAcquiredinExchangeforWarrants_5D38128C544736CF192A08F461476318" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:to="loc_gale_CommonStockSharesAcquiredinExchangeforWarrants_5D38128C544736CF192A08F461476318" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_65E7AA64D39F51C7242708F46147CFB9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_65E7AA64D39F51C7242708F46147CFB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_48D9266F1BEAB5AC7CF708F461473D25" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_48D9266F1BEAB5AC7CF708F461473D25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_FBD1AFF2922D41DE49AC08F46147DAF3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_FBD1AFF2922D41DE49AC08F46147DAF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_397369C059418B78509808F4614786BB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E2BC20B33D92D0ED59B508F46146BEC1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_397369C059418B78509808F4614786BB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/DebtSeniorSecuredDebentureDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_E0814E39571706719F8A12EF8A3BAD27" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_49F8A4E6DE4EA6D7362012EF8A3CF028" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_E0814E39571706719F8A12EF8A3BAD27" xlink:to="loc_us-gaap_DebtInstrumentTable_49F8A4E6DE4EA6D7362012EF8A3CF028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_735C8DC179945E5FF2CD12F152E939B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_49F8A4E6DE4EA6D7362012EF8A3CF028" xlink:to="loc_srt_LitigationCaseAxis_735C8DC179945E5FF2CD12F152E939B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_CF6E2D20951CFBDF0B8012F152F2E97C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_735C8DC179945E5FF2CD12F152E939B3" xlink:to="loc_srt_LitigationCaseTypeDomain_CF6E2D20951CFBDF0B8012F152F2E97C" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_JGBActionMember" xlink:label="loc_gale_JGBActionMember_D874BB8D33545D4E3CC312F18FEFB05D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_CF6E2D20951CFBDF0B8012F152F2E97C" xlink:to="loc_gale_JGBActionMember_D874BB8D33545D4E3CC312F18FEFB05D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6CAF6219C5B9BC25989C12EF8A3C03EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_49F8A4E6DE4EA6D7362012EF8A3CF028" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6CAF6219C5B9BC25989C12EF8A3C03EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_48C9B0EA75DC3D535FB012EF8A3C382C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6CAF6219C5B9BC25989C12EF8A3C03EB" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_48C9B0EA75DC3D535FB012EF8A3C382C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_BCDA7EDF18009C93F07312EF8A3C5B7E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_48C9B0EA75DC3D535FB012EF8A3C382C" xlink:to="loc_us-gaap_SubsequentEventMember_BCDA7EDF18009C93F07312EF8A3C5B7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9055B53BEBCBE81BC7A712EF8A3D7F87" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_49F8A4E6DE4EA6D7362012EF8A3CF028" xlink:to="loc_us-gaap_DebtInstrumentAxis_9055B53BEBCBE81BC7A712EF8A3D7F87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8E2AE503C564D0A942F712EF8A3D2CA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9055B53BEBCBE81BC7A712EF8A3D7F87" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8E2AE503C564D0A942F712EF8A3D2CA9" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SecuritiesPurchaseAgreementMember" xlink:label="loc_gale_SecuritiesPurchaseAgreementMember_3E377431F1DD41F9534612EF8A3F9C5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8E2AE503C564D0A942F712EF8A3D2CA9" xlink:to="loc_gale_SecuritiesPurchaseAgreementMember_3E377431F1DD41F9534612EF8A3F9C5F" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_AmendmentAgreementMember" xlink:label="loc_gale_AmendmentAgreementMember_B03AF8FE1C1B3D4E3D9912EF8A3F0A4D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8E2AE503C564D0A942F712EF8A3D2CA9" xlink:to="loc_gale_AmendmentAgreementMember_B03AF8FE1C1B3D4E3D9912EF8A3F0A4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E0D52AF3145A6A325F1E12EF8A3F1A38" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_49F8A4E6DE4EA6D7362012EF8A3CF028" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_E0D52AF3145A6A325F1E12EF8A3F1A38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7F65419524091DFBBD3D12EF8A3F00AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E0D52AF3145A6A325F1E12EF8A3F1A38" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7F65419524091DFBBD3D12EF8A3F00AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_25D7FD805B5238CA275212EF8A406D67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7F65419524091DFBBD3D12EF8A3F00AC" xlink:to="loc_us-gaap_SecuredDebtMember_25D7FD805B5238CA275212EF8A406D67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_49F8A4E6DE4EA6D7362012EF8A3CF028" xlink:to="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3C73DD7141966E4D3DA112EF8A40E07C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3C73DD7141966E4D3DA112EF8A40E07C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6E87794C45607C0FCF3412EF8A4157A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6E87794C45607C0FCF3412EF8A4157A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7A2C64241A3CE9DA5C6412EF8A41C143" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7A2C64241A3CE9DA5C6412EF8A41C143" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet" xlink:label="loc_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_36BC08B9049C02D31D9712EF8A419668" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_36BC08B9049C02D31D9712EF8A419668" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_3BA02BA514107036B23012EF8A41ED1B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_3BA02BA514107036B23012EF8A41ED1B" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DebtInstrumentCovenantLiquidityCovenant" xlink:label="loc_gale_DebtInstrumentCovenantLiquidityCovenant_8A368140E1E4AD2F12D812EF8A41AC67" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_gale_DebtInstrumentCovenantLiquidityCovenant_8A368140E1E4AD2F12D812EF8A41AC67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_EE6FEA4146016DD6F5EE12EF8A41F6ED" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_us-gaap_DebtInstrumentFairValue_EE6FEA4146016DD6F5EE12EF8A41F6ED" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DebtInstrumentRedemptionPrincipalAmountRedeemed" xlink:label="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_FE4EA050C6D935EC528812EF8A421703" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed_FE4EA050C6D935EC528812EF8A421703" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares" xlink:label="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_53D23B85559F5EB568CC12EF8A421C30" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares_53D23B85559F5EB568CC12EF8A421C30" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash" xlink:label="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_FA7A3E800609DB8EBDB212EF8A42F8F5" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash_FA7A3E800609DB8EBDB212EF8A42F8F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DecreaseInRestrictedCash" xlink:label="loc_us-gaap_DecreaseInRestrictedCash_A3A77E071A7C06257BB712EF8A428736" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_us-gaap_DecreaseInRestrictedCash_A3A77E071A7C06257BB712EF8A428736" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_BE2390E92266700742D312EF8A4266D3" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_us-gaap_RestrictedCash_BE2390E92266700742D312EF8A4266D3" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture" xlink:label="loc_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_E690F8E980AD757A0EE012EF8A430A42" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_E690F8E980AD757A0EE012EF8A430A42" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DepositOfRestrictedCashOverSeniorSecuredDebenture" xlink:label="loc_gale_DepositOfRestrictedCashOverSeniorSecuredDebenture_DD3E24426FE3A4CADC4213347257A15C" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_gale_DepositOfRestrictedCashOverSeniorSecuredDebenture_DD3E24426FE3A4CADC4213347257A15C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_0D95B4F24487E9220BEB12EF8A43CB43" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_0D95B4F24487E9220BEB12EF8A43CB43" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ReimbursementOfLegalFees" xlink:label="loc_gale_ReimbursementOfLegalFees_3C59C9FCC4AEDED25D9A12EF8A4307F6" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_gale_ReimbursementOfLegalFees_3C59C9FCC4AEDED25D9A12EF8A4307F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_837D880C2F1D52D0679712EF8A433E32" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80DF532FEE59A3FA6BA812EF8A403FA0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_837D880C2F1D52D0679712EF8A433E32" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/DebtSummaryOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_741A8D243E63B358808D17BCCEE894CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_E7B5B475BBD06EDA50A317BCCEE9883E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_741A8D243E63B358808D17BCCEE894CA" xlink:to="loc_us-gaap_DebtInstrumentTable_E7B5B475BBD06EDA50A317BCCEE9883E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_4619EA73C4E19132AE9117BCCEE9502F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E7B5B475BBD06EDA50A317BCCEE9883E" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_4619EA73C4E19132AE9117BCCEE9502F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_65FFE5377AC8EE0A20D817BCCEE9A082" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_4619EA73C4E19132AE9117BCCEE9502F" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_65FFE5377AC8EE0A20D817BCCEE9A082" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_BAD8DF96143E04C5EC9F17BCCEE99CB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_65FFE5377AC8EE0A20D817BCCEE9A082" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_BAD8DF96143E04C5EC9F17BCCEE99CB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_BA640D3CC0EB72BE4A4617BCCEEAD0C0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E7B5B475BBD06EDA50A317BCCEE9883E" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_BA640D3CC0EB72BE4A4617BCCEEAD0C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_BA8A32EF1D7B778AD76517BCCEEACBBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_BA640D3CC0EB72BE4A4617BCCEEAD0C0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_BA8A32EF1D7B778AD76517BCCEEACBBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_892F785A24B63E60F2E017BCCEEA4C86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_BA8A32EF1D7B778AD76517BCCEEACBBF" xlink:to="loc_us-gaap_SecuredDebtMember_892F785A24B63E60F2E017BCCEEA4C86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9050EBE0A3DE1702FAEA17BCCEEBA46C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E7B5B475BBD06EDA50A317BCCEE9883E" xlink:to="loc_us-gaap_DebtInstrumentAxis_9050EBE0A3DE1702FAEA17BCCEEBA46C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9128C9DAED9A0DFC373717BCCEEB88F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9050EBE0A3DE1702FAEA17BCCEEBA46C" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9128C9DAED9A0DFC373717BCCEEB88F1" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SecuritiesPurchaseAgreementMember" xlink:label="loc_gale_SecuritiesPurchaseAgreementMember_01B54BBBEA88743317F217BCCEEBD6A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9128C9DAED9A0DFC373717BCCEEB88F1" xlink:to="loc_gale_SecuritiesPurchaseAgreementMember_01B54BBBEA88743317F217BCCEEBD6A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_91DBDAE592901545025217BCCEEBCAB2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E7B5B475BBD06EDA50A317BCCEE9883E" xlink:to="loc_us-gaap_DebtInstrumentLineItems_91DBDAE592901545025217BCCEEBCAB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_0A7F0771432C2B13CD1517BCCEEC77EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91DBDAE592901545025217BCCEEBCAB2" xlink:to="loc_us-gaap_LongTermDebtCurrent_0A7F0771432C2B13CD1517BCCEEC77EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_8CF34BE9DD466479AA7B17BCCEEC06E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91DBDAE592901545025217BCCEEBCAB2" xlink:to="loc_us-gaap_ShortTermBorrowings_8CF34BE9DD466479AA7B17BCCEEC06E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_29C6C9BBBFE3FD2626E817BCCEEC2DD5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91DBDAE592901545025217BCCEEBCAB2" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_29C6C9BBBFE3FD2626E817BCCEEC2DD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_3DE998C0512614AB183217BCCEED3DB9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91DBDAE592901545025217BCCEEBCAB2" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_3DE998C0512614AB183217BCCEED3DB9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_BF14880AD2150C5A848217BCCEC82A95" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_1AC74E994E09ADA9B79717BCCEC95884" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_BF14880AD2150C5A848217BCCEC82A95" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_1AC74E994E09ADA9B79717BCCEC95884" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="gale-20180930.xsd#gale_DocumentDocumentAndEntityInformationAbstract" xlink:label="loc_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1CD5927B794F43C6C8C50891C4E56354" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD" xlink:to="loc_dei_EntityRegistrantName_1CD5927B794F43C6C8C50891C4E56354" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_7685223A3109BC405F910891C4E5B333" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD" xlink:to="loc_dei_TradingSymbol_7685223A3109BC405F910891C4E5B333" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_C35745B9CE313C6F1AAC0891C4E5E98C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD" xlink:to="loc_dei_EntityCentralIndexKey_C35745B9CE313C6F1AAC0891C4E5E98C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_6BC412F5880E3D39DB050891C4E67CB9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD" xlink:to="loc_dei_CurrentFiscalYearEndDate_6BC412F5880E3D39DB050891C4E67CB9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_609376423C93766DCBD00891C4E639AC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD" xlink:to="loc_dei_EntityFilerCategory_609376423C93766DCBD00891C4E639AC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_26295A9D871E1D4FD7990891C4E6D038" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD" xlink:to="loc_dei_DocumentType_26295A9D871E1D4FD7990891C4E6D038" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_D5C9C8909793D5D735510891C4E6BA24" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD" xlink:to="loc_dei_DocumentPeriodEndDate_D5C9C8909793D5D735510891C4E6BA24" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_5F734367FFC28538148E0891C4E66077" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD" xlink:to="loc_dei_DocumentFiscalYearFocus_5F734367FFC28538148E0891C4E66077" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_F97A02E1F4D80C1882050891C4E6951D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD" xlink:to="loc_dei_DocumentFiscalPeriodFocus_F97A02E1F4D80C1882050891C4E6951D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_F6BA6C22D3B17ABFB2310891C4E66A48" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD" xlink:to="loc_dei_AmendmentFlag_F6BA6C22D3B17ABFB2310891C4E66A48" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_8000EC9915CF78DCEC8708B8823A5C0A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD" xlink:to="loc_dei_EntityEmergingGrowthCompany_8000EC9915CF78DCEC8708B8823A5C0A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_9CDE0B5CFE84C96710CB08B92116FEE7" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD" xlink:to="loc_dei_EntitySmallBusiness_9CDE0B5CFE84C96710CB08B92116FEE7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1009CF5F72E9D9F1E5680891C4E782D2" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_B3090A807DCB45A60B210891C4E593FD" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1009CF5F72E9D9F1E5680891C4E782D2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_DE758EE5F5043568247417BCD0B3B9F9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_A53314897FD9FAE6CF3D17BCD0B379CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DE758EE5F5043568247417BCD0B3B9F9" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_A53314897FD9FAE6CF3D17BCD0B379CA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_E903B976C7AF6094C43B17BCD0C73A50" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C1831758892F19C45AB17BCD0C71C65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_E903B976C7AF6094C43B17BCD0C73A50" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C1831758892F19C45AB17BCD0C71C65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2D9CE88FF3D1E5F8EEF617BCD0C7C4A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C1831758892F19C45AB17BCD0C71C65" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2D9CE88FF3D1E5F8EEF617BCD0C7C4A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_93FBFA3EEA1C3B37F2E717BCD0C7A6B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2D9CE88FF3D1E5F8EEF617BCD0C7C4A9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_93FBFA3EEA1C3B37F2E717BCD0C7A6B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6FDEEB9A239E59A618FB17BCD0C85E48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_93FBFA3EEA1C3B37F2E717BCD0C7A6B4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6FDEEB9A239E59A618FB17BCD0C85E48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_01BB2CF57CD37B1D7EF717BCD0C8A9E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C1831758892F19C45AB17BCD0C71C65" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_01BB2CF57CD37B1D7EF717BCD0C8A9E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_682152669767E25E07FD17BCD0C8B7E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_01BB2CF57CD37B1D7EF717BCD0C8A9E8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_682152669767E25E07FD17BCD0C8B7E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0F39224EDCB89D073A6417BCD0C8881F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_682152669767E25E07FD17BCD0C8B7E3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0F39224EDCB89D073A6417BCD0C8881F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_712C75803779265BFDC117BCD0C93C43" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_682152669767E25E07FD17BCD0C8B7E3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_712C75803779265BFDC117BCD0C93C43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7DD06866C5264018253F17BCD0C97DF4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_682152669767E25E07FD17BCD0C8B7E3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7DD06866C5264018253F17BCD0C97DF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25E4A8A3092039C9C1E517BCD0C9479F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0C1831758892F19C45AB17BCD0C71C65" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25E4A8A3092039C9C1E517BCD0C9479F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_24A66C176252E9CE3BA617BCD0C9C454" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25E4A8A3092039C9C1E517BCD0C9479F" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_24A66C176252E9CE3BA617BCD0C9C454" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_A2C4D33FB3918ABB711017BCD0CA94B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_24A66C176252E9CE3BA617BCD0C9C454" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_A2C4D33FB3918ABB711017BCD0CA94B5" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_RestrictedCashandCashEquivalentsFairValueDisclosure" xlink:label="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_76BE728BCEB2EE009AE617BCD0CAA279" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_24A66C176252E9CE3BA617BCD0C9C454" xlink:to="loc_gale_RestrictedCashandCashEquivalentsFairValueDisclosure_76BE728BCEB2EE009AE617BCD0CAA279" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5EE015EA28F8EFBC842317BCD0CAA27C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_24A66C176252E9CE3BA617BCD0C9C454" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5EE015EA28F8EFBC842317BCD0CAA27C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0AC697E0768E89D9362517BCD0CAA966" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25E4A8A3092039C9C1E517BCD0C9479F" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0AC697E0768E89D9362517BCD0CAA966" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_B953F4769474DB491C0017BCD0CB6A66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0AC697E0768E89D9362517BCD0CAA966" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_B953F4769474DB491C0017BCD0CB6A66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_81D949FB3D1FF6C4C53317BCD0CB8A4C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0AC697E0768E89D9362517BCD0CAA966" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_81D949FB3D1FF6C4C53317BCD0CB8A4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_FBACED4D12D9ADFA912617BCD0CBC926" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0AC697E0768E89D9362517BCD0CAA966" xlink:to="loc_us-gaap_EquityFairValueDisclosure_FBACED4D12D9ADFA912617BCD0CBC926" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_72B85008E42390BC012417BCCEBC3D3A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6023AA8D9298360F0FB817BCCEBC97BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_72B85008E42390BC012417BCCEBC3D3A" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6023AA8D9298360F0FB817BCCEBC97BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A4DD832D1E1B0FBD5C7317BCCEBD4EFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6023AA8D9298360F0FB817BCCEBC97BC" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A4DD832D1E1B0FBD5C7317BCCEBD4EFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0EC01474E6F93FF5667F17BCCEBDFE38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A4DD832D1E1B0FBD5C7317BCCEBD4EFF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0EC01474E6F93FF5667F17BCCEBDFE38" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_AptheraInc.Member" xlink:label="loc_gale_AptheraInc.Member_9847B784F0C7AD357E3E17BCCEBDB54C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0EC01474E6F93FF5667F17BCCEBDFE38" xlink:to="loc_gale_AptheraInc.Member_9847B784F0C7AD357E3E17BCCEBDB54C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92B6F9BC1C56772E2DC317BCCEBEEFEF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6023AA8D9298360F0FB817BCCEBC97BC" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92B6F9BC1C56772E2DC317BCCEBEEFEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B7EE2D2293CFCD55C30017BCCEBE0A9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92B6F9BC1C56772E2DC317BCCEBEEFEF" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B7EE2D2293CFCD55C30017BCCEBE0A9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3A34C1C0F3B30F8FE84417BCCEBE2090" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B7EE2D2293CFCD55C30017BCCEBE0A9D" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3A34C1C0F3B30F8FE84417BCCEBE2090" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E816959CAF9376D1889517BCCEBFE10A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6023AA8D9298360F0FB817BCCEBC97BC" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E816959CAF9376D1889517BCCEBFE10A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40CA17889608A9450A5E17BCCEBFE21A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E816959CAF9376D1889517BCCEBFE10A" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40CA17889608A9450A5E17BCCEBFE21A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_D6D64BC92AEC9AC91AC917BCCEBF7C94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40CA17889608A9450A5E17BCCEBFE21A" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_D6D64BC92AEC9AC91AC917BCCEBF7C94" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_0F59EAA00F914BBE08D217BCCEC035F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40CA17889608A9450A5E17BCCEBFE21A" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_0F59EAA00F914BBE08D217BCCEC035F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_5281B14C052ACED9DE8817BCCEC03DFE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40CA17889608A9450A5E17BCCEBFE21A" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_5281B14C052ACED9DE8817BCCEC03DFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_A2F50D785D9C34B7074217BCCEC06596" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_E816959CAF9376D1889517BCCEBFE10A" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_A2F50D785D9C34B7074217BCCEC06596" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4602913F7CC7572635FE17BCD042C425" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_684B4034FE17E9D2B7E017BCD042B4E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4602913F7CC7572635FE17BCD042C425" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_684B4034FE17E9D2B7E017BCD042B4E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_107D03EC4EB23E435BF517BCD0423805" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4602913F7CC7572635FE17BCD042C425" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_107D03EC4EB23E435BF517BCD0423805" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8A03C120D7E6F33791900E343F6E594C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D2027C745FC3797405AA0E343F74DD08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8A03C120D7E6F33791900E343F6E594C" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D2027C745FC3797405AA0E343F74DD08" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E7B2070DD1CB9EAC3C141361E6BE2824" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E7B2070DD1CB9EAC3C141361E6BE2824" xlink:to="loc_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_CE7862A629A30E4FBE171361E6BF72E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_CE7862A629A30E4FBE171361E6BF72E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_F797323218C9CDD0C2091361E6C0B78C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_CE7862A629A30E4FBE171361E6BF72E2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_F797323218C9CDD0C2091361E6C0B78C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_EE50E20024FF7F7916911361E6C0B5DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_F797323218C9CDD0C2091361E6C0B78C" xlink:to="loc_us-gaap_SubsequentEventMember_EE50E20024FF7F7916911361E6C0B5DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_700236F8655F9CA4D2081361E6C09F6C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_700236F8655F9CA4D2081361E6C09F6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_D89D3AA33AA788145F391361E6C0A45C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_700236F8655F9CA4D2081361E6C09F6C" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_D89D3AA33AA788145F391361E6C0A45C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_47BE0B3B229D30FE10F61361E6C18714" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_D89D3AA33AA788145F391361E6C0A45C" xlink:to="loc_us-gaap_SecuredDebtMember_47BE0B3B229D30FE10F61361E6C18714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F90A90E8556279899EEA1361E6C19A21" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E" xlink:to="loc_us-gaap_DebtInstrumentAxis_F90A90E8556279899EEA1361E6C19A21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1C94037B4CE57873C81D1361E6C176E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_F90A90E8556279899EEA1361E6C19A21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1C94037B4CE57873C81D1361E6C176E0" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_AmendmentAgreementMember" xlink:label="loc_gale_AmendmentAgreementMember_33992BF5809B365543841361E6C29436" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1C94037B4CE57873C81D1361E6C176E0" xlink:to="loc_gale_AmendmentAgreementMember_33992BF5809B365543841361E6C29436" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_58B32434B4B5AB6D1A511361E6C2CD55" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E" xlink:to="loc_us-gaap_LitigationStatusAxis_58B32434B4B5AB6D1A511361E6C2CD55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_118383FFC8E1361F19A31361E6C217BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_58B32434B4B5AB6D1A511361E6C2CD55" xlink:to="loc_us-gaap_LitigationStatusDomain_118383FFC8E1361F19A31361E6C217BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_FA7627A188111479DCEB1361E6C282A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_118383FFC8E1361F19A31361E6C217BD" xlink:to="loc_us-gaap_PendingLitigationMember_FA7627A188111479DCEB1361E6C282A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_8CD80ED4B3A86469BF901361E6C32270" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E" xlink:to="loc_srt_LitigationCaseAxis_8CD80ED4B3A86469BF901361E6C32270" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_F82440ECC338D98B5F7C1361E6C334AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_8CD80ED4B3A86469BF901361E6C32270" xlink:to="loc_srt_LitigationCaseTypeDomain_F82440ECC338D98B5F7C1361E6C334AF" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PatelvsGalenabiopharmaIncMember" xlink:label="loc_gale_PatelvsGalenabiopharmaIncMember_A0E3DABF4A1E3CD571691361E6C3B9CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_F82440ECC338D98B5F7C1361E6C334AF" xlink:to="loc_gale_PatelvsGalenabiopharmaIncMember_A0E3DABF4A1E3CD571691361E6C3B9CE" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_JGBActionMember" xlink:label="loc_gale_JGBActionMember_34DAB73FB0FAABD49CF71361E6C473C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_F82440ECC338D98B5F7C1361E6C334AF" xlink:to="loc_gale_JGBActionMember_34DAB73FB0FAABD49CF71361E6C473C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_A9C7EE33A7C7E2ECB1A01361E6BE2B9E" xlink:to="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_068E9151B4C7FE2AF9AD1361E6C43586" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:to="loc_us-gaap_LegalFees_068E9151B4C7FE2AF9AD1361E6C43586" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_76077A78BFDEE83C7CF91361E6C44FE9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_76077A78BFDEE83C7CF91361E6C44FE9" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_LitigationSettlementIssuanceofCommonStockValue" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockValue_D4A60CAE3612E8B5D8A61361E6C4B5C9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:to="loc_gale_LitigationSettlementIssuanceofCommonStockValue_D4A60CAE3612E8B5D8A61361E6C4B5C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_980BD6DF8DC366EBC9951361E6C58834" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_980BD6DF8DC366EBC9951361E6C58834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_AEF7A9754BF0C6DF8B7B1361E6C5537B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:to="loc_us-gaap_RestrictedCash_AEF7A9754BF0C6DF8B7B1361E6C5537B" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_LossContingencyNumberOfCounterclaims" xlink:label="loc_gale_LossContingencyNumberOfCounterclaims_D710FE9DE4FAD61BC1B21361E6C591BD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:to="loc_gale_LossContingencyNumberOfCounterclaims_D710FE9DE4FAD61BC1B21361E6C591BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_4751EE56CF628CC5BA301361E6C54A87" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_4751EE56CF628CC5BA301361E6C54A87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_A55703540141BDA325331361E6C5BCCF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_B18709F77C31B17C4E241361E6C44D8B" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_A55703540141BDA325331361E6C5BCCF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/Liquidity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_664C296D93CFD461957C17BCCF16E1E3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:label="loc_us-gaap_LiquidationBasisOfAccountingTextBlock_EE771713BE5DBC51033717BCCF17E28D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_664C296D93CFD461957C17BCCF16E1E3" xlink:to="loc_us-gaap_LiquidationBasisOfAccountingTextBlock_EE771713BE5DBC51033717BCCF17E28D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/LiquidityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2C1E8F7FE03BDA4683870E609F772FB1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C616F4D712EB99B8B3DC0E609F78E95B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2C1E8F7FE03BDA4683870E609F772FB1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C616F4D712EB99B8B3DC0E609F78E95B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E029C8C87F48448BA5B10E609F78A767" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C616F4D712EB99B8B3DC0E609F78E95B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_E029C8C87F48448BA5B10E609F78A767" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28AA088C62F3F5D9CEE0E609F780F08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E029C8C87F48448BA5B10E609F78A767" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28AA088C62F3F5D9CEE0E609F780F08" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PurchaseAgreementMember" xlink:label="loc_gale_PurchaseAgreementMember_839B04D6092AA090EA7B0E609F78BA4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28AA088C62F3F5D9CEE0E609F780F08" xlink:to="loc_gale_PurchaseAgreementMember_839B04D6092AA090EA7B0E609F78BA4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2572F0E54CC429216DD80E609F790624" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C616F4D712EB99B8B3DC0E609F78E95B" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2572F0E54CC429216DD80E609F790624" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_F36B8726BF34D1B0CDB10E609F793DF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2572F0E54CC429216DD80E609F790624" xlink:to="loc_us-gaap_EquityComponentDomain_F36B8726BF34D1B0CDB10E609F793DF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_534DC9BE83B39963F2220E609F799AB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F36B8726BF34D1B0CDB10E609F793DF2" xlink:to="loc_us-gaap_CommonStockMember_534DC9BE83B39963F2220E609F799AB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_B03409AEF47C159A9B3B0E609F795A0B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F36B8726BF34D1B0CDB10E609F793DF2" xlink:to="loc_us-gaap_WarrantMember_B03409AEF47C159A9B3B0E609F795A0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_29F04B5BBE649D43F8E60E609F7AB40A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C616F4D712EB99B8B3DC0E609F78E95B" xlink:to="loc_us-gaap_StatementClassOfStockAxis_29F04B5BBE649D43F8E60E609F7AB40A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_341983AD26269D4786F30E609F7AE04A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_29F04B5BBE649D43F8E60E609F7AB40A" xlink:to="loc_us-gaap_ClassOfStockDomain_341983AD26269D4786F30E609F7AE04A" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SeriesANonvotingConvertibleMember" xlink:label="loc_gale_SeriesANonvotingConvertibleMember_C5B8E3D67ED0F69DAC860E609F7A9745" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_341983AD26269D4786F30E609F7AE04A" xlink:to="loc_gale_SeriesANonvotingConvertibleMember_C5B8E3D67ED0F69DAC860E609F7A9745" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gale_SeriesAConvertiblePreferredStockMember_2A4EB6B2FD817216D65B0E609F7AC46D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_341983AD26269D4786F30E609F7AE04A" xlink:to="loc_gale_SeriesAConvertiblePreferredStockMember_2A4EB6B2FD817216D65B0E609F7AC46D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_92BFEA225781E16101630E609F7B66A0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C616F4D712EB99B8B3DC0E609F78E95B" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_92BFEA225781E16101630E609F7B66A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DDD850BD40D958A973850E609F7BADD7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_92BFEA225781E16101630E609F7B66A0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DDD850BD40D958A973850E609F7BADD7" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FirstTrancheMember" xlink:label="loc_gale_FirstTrancheMember_0409836AFAF27553C86E0E609F7BC8E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DDD850BD40D958A973850E609F7BADD7" xlink:to="loc_gale_FirstTrancheMember_0409836AFAF27553C86E0E609F7BC8E6" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SecondTrancheMember" xlink:label="loc_gale_SecondTrancheMember_41559B2296FE7AF1AC920E609F7B8D84" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_DDD850BD40D958A973850E609F7BADD7" xlink:to="loc_gale_SecondTrancheMember_41559B2296FE7AF1AC920E609F7B8D84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C616F4D712EB99B8B3DC0E609F78E95B" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D830421D335BCFFA63810E609F7C2485" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D830421D335BCFFA63810E609F7C2485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0BD8395EB8C54A4C47BC0E609F7CD0A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0BD8395EB8C54A4C47BC0E609F7CD0A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_DBC0EAD27CF26FEF7B920E609F7C409C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_DBC0EAD27CF26FEF7B920E609F7C409C" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded" xlink:label="loc_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_918A89838E4531FCFF850E609F7DAD70" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_918A89838E4531FCFF850E609F7DAD70" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_77EBB3538F0BFE911BD60E609F7D8E7F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_gale_ClassofWarrantorRightTerm_77EBB3538F0BFE911BD60E609F7D8E7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_64ECD83B51F6C73F54480E609F7D46F0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_64ECD83B51F6C73F54480E609F7D46F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_56F3E511D673ECABE8720E609F7DEB81" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_PreferredStockSharesIssued_56F3E511D673ECABE8720E609F7DEB81" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ConvertiblePreferredStockConversionPrice" xlink:label="loc_gale_ConvertiblePreferredStockConversionPrice_F316CC4C7051048D26D40E609F7D498B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_gale_ConvertiblePreferredStockConversionPrice_F316CC4C7051048D26D40E609F7D498B" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ConvertiblePreferredStockNumberOfTranches" xlink:label="loc_gale_ConvertiblePreferredStockNumberOfTranches_E3CEF015BDCE2A23575E0E609F7E037E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_gale_ConvertiblePreferredStockNumberOfTranches_E3CEF015BDCE2A23575E0E609F7E037E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_8E3C9F73F0F63DBFFC460E609F7E26D7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_8E3C9F73F0F63DBFFC460E609F7E26D7" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture" xlink:label="loc_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_D447B5267DF7C1EE48660E609F7ED65F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture_D447B5267DF7C1EE48660E609F7ED65F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0A45740CF20CE7F9DD8B0E609F7E85FF" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0A45740CF20CE7F9DD8B0E609F7E85FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_6B781849534F30FE57B90E609F7E8507" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_6B781849534F30FE57B90E609F7E8507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_2F76BA137431EA5FB5C50E6CD6B3C64D" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_2F76BA137431EA5FB5C50E6CD6B3C64D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableCurrent_B60D74B5F27700CDB41C0E609F7FCB74" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_InsuranceSettlementsReceivableCurrent_B60D74B5F27700CDB41C0E609F7FCB74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_F59E099FC7A43025D0090E609F7F71FA" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_F59E099FC7A43025D0090E609F7F71FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_BE621911B569BB35716F0E609F7F5E39" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2B4B76573B29CBD3A8EC0E609F7CE5D6" xlink:to="loc_us-gaap_LongTermDebt_BE621911B569BB35716F0E609F7F5E39" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8580FB9527BCE178707C17BCCE9EC7C7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_51817762E2E16364202E17BCCE9E81F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8580FB9527BCE178707C17BCCE9EC7C7" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_51817762E2E16364202E17BCCE9E81F1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9002102582398CCAB16C17BCD08AFBDF" xlink:type="locator" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_0C7E694436639CB6023217BCD08A927E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9002102582398CCAB16C17BCD08AFBDF" xlink:to="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_0C7E694436639CB6023217BCD08A927E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_A6373970673B5FD33A4217BCD08A43BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_0C7E694436639CB6023217BCD08A927E" xlink:to="loc_srt_CounterpartyNameAxis_A6373970673B5FD33A4217BCD08A43BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_425A10D557F0634194D217BCD08A2A84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_A6373970673B5FD33A4217BCD08A43BD" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_425A10D557F0634194D217BCD08A2A84" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PrivateSELLASSecurityHoldersMember" xlink:label="loc_gale_PrivateSELLASSecurityHoldersMember_CA60342E7909BB1A64FB17BCD08BED9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_425A10D557F0634194D217BCD08A2A84" xlink:to="loc_gale_PrivateSELLASSecurityHoldersMember_CA60342E7909BB1A64FB17BCD08BED9E" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PreMergerSecurityholdersMember" xlink:label="loc_gale_PreMergerSecurityholdersMember_55C64761D705D55AE9F017BCD08BA32D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_425A10D557F0634194D217BCD08A2A84" xlink:to="loc_gale_PreMergerSecurityholdersMember_55C64761D705D55AE9F017BCD08BA32D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_957DCC5C129E3812A5DB17BCD08B6019" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_0C7E694436639CB6023217BCD08A927E" xlink:to="loc_dei_LegalEntityAxis_957DCC5C129E3812A5DB17BCD08B6019" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6E1C501431768871E75817BCD08BAEB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_957DCC5C129E3812A5DB17BCD08B6019" xlink:to="loc_dei_EntityDomain_6E1C501431768871E75817BCD08BAEB6" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_GalenaBiopharmaIncMember" xlink:label="loc_gale_GalenaBiopharmaIncMember_5F77A59704828A027D6517BCD08C8E97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6E1C501431768871E75817BCD08BAEB6" xlink:to="loc_gale_GalenaBiopharmaIncMember_5F77A59704828A027D6517BCD08C8E97" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_0C7E694436639CB6023217BCD08A927E" xlink:to="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8ED9DF91BDFC31684E9917BCD08C4823" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8ED9DF91BDFC31684E9917BCD08C4823" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_42C146FB2F718FA61BA017BCD08C177C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_42C146FB2F718FA61BA017BCD08C177C" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_CommonStockConversionRatio" xlink:label="loc_gale_CommonStockConversionRatio_3F25FC70FB06356B681517BCD08DB155" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2" xlink:to="loc_gale_CommonStockConversionRatio_3F25FC70FB06356B681517BCD08DB155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_A7C40287D366FDEB983B17BCD08D623B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_A7C40287D366FDEB983B17BCD08D623B" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PercentageOfFullyDilutedShareCapitalOwned" xlink:label="loc_gale_PercentageOfFullyDilutedShareCapitalOwned_92A61BD54FF300EFA6C817BCD08D5938" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_B7F54DE2D9EEB833663317BCD08C7FB2" xlink:to="loc_gale_PercentageOfFullyDilutedShareCapitalOwned_92A61BD54FF300EFA6C817BCD08D5938" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8805C527061565078B1617BCD0B54F04" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BF5FEAE695436D01D52A17BCD0B5B43A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8805C527061565078B1617BCD0B54F04" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BF5FEAE695436D01D52A17BCD0B5B43A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_782509E4E7664AE3BB9917BCCDF97126" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4C6F67C34422129E980C17BCCDFAA6A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_782509E4E7664AE3BB9917BCCDF97126" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4C6F67C34422129E980C17BCCDFAA6A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_831C23A99BAFB0082B7117BCCDFA303A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4C6F67C34422129E980C17BCCDFAA6A6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_831C23A99BAFB0082B7117BCCDFA303A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_947E3918EC854EAF310317BCCDFADBB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_831C23A99BAFB0082B7117BCCDFA303A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_947E3918EC854EAF310317BCCDFADBB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7809AE87CBFA6151853F17BCCDFB2A4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_947E3918EC854EAF310317BCCDFADBB0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7809AE87CBFA6151853F17BCCDFB2A4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_17A4AC66D22469B37F0217BCCDFB8EAD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_947E3918EC854EAF310317BCCDFADBB0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_17A4AC66D22469B37F0217BCCDFB8EAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3616409147FDEF8D74D817BCCDFCC99E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4C6F67C34422129E980C17BCCDFAA6A6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3616409147FDEF8D74D817BCCDFCC99E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_E264E9F0CECC5162E40517BCCDFC1AFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3616409147FDEF8D74D817BCCDFCC99E" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_E264E9F0CECC5162E40517BCCDFC1AFA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F0AD5DA7520796ECAE0117BCCF9F0DFF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CA6E5EA7EADC3BAC624617BCCF9F1927" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F0AD5DA7520796ECAE0117BCCF9F0DFF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CA6E5EA7EADC3BAC624617BCCF9F1927" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27C9D8BC25E1274995C617BCCFA098A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F0AD5DA7520796ECAE0117BCCF9F0DFF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27C9D8BC25E1274995C617BCCFA098A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_F51371E52014EF02528517BCCFA0C5E8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F0AD5DA7520796ECAE0117BCCF9F0DFF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_F51371E52014EF02528517BCCFA0C5E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_AB5F32CDB75D098F4D8117BCCFA1578D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F0AD5DA7520796ECAE0117BCCF9F0DFF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_AB5F32CDB75D098F4D8117BCCFA1578D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F57C150801B26E69EF5412E3AEA047B5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E87CF859F383323E96012E3AEA0EE6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F57C150801B26E69EF5412E3AEA047B5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E87CF859F383323E96012E3AEA0EE6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_6561132EFEBEE1169BD012E3AEA1ABDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E87CF859F383323E96012E3AEA0EE6E" xlink:to="loc_us-gaap_PlanNameAxis_6561132EFEBEE1169BD012E3AEA1ABDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_58C9F90890884170C83712E3AEA14142" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6561132EFEBEE1169BD012E3AEA1ABDF" xlink:to="loc_us-gaap_PlanNameDomain_58C9F90890884170C83712E3AEA14142" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:label="loc_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_77463FD79FC66EBADD1112E3AEA1A010" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_58C9F90890884170C83712E3AEA14142" xlink:to="loc_gale_TwoThousandAndSeventeenEquityIncentivePlanMember_77463FD79FC66EBADD1112E3AEA1A010" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_IncentivePlan2016Member" xlink:label="loc_gale_IncentivePlan2016Member_316476F923915F04559812E3AEA13756" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_58C9F90890884170C83712E3AEA14142" xlink:to="loc_gale_IncentivePlan2016Member_316476F923915F04559812E3AEA13756" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_DDB07405FCD21584B93F12E3AEA2EAD2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E87CF859F383323E96012E3AEA0EE6E" xlink:to="loc_srt_RangeAxis_DDB07405FCD21584B93F12E3AEA2EAD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_50B2D5D99EE74DD407DE12E3AEA27C97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_DDB07405FCD21584B93F12E3AEA2EAD2" xlink:to="loc_srt_RangeMember_50B2D5D99EE74DD407DE12E3AEA27C97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_D826EB013277A600B39E12E3AEA29AAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_50B2D5D99EE74DD407DE12E3AEA27C97" xlink:to="loc_srt_MaximumMember_D826EB013277A600B39E12E3AEA29AAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_34FE95EB271CAE5C7A1012E3AEA213F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_50B2D5D99EE74DD407DE12E3AEA27C97" xlink:to="loc_srt_MinimumMember_34FE95EB271CAE5C7A1012E3AEA213F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_3E2B6A4A2C8ECE604FFB12E3AEA3ECFF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E87CF859F383323E96012E3AEA0EE6E" xlink:to="loc_us-gaap_AwardTypeAxis_3E2B6A4A2C8ECE604FFB12E3AEA3ECFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45B67F9A1D44F7B0BF1512E3AEA39367" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3E2B6A4A2C8ECE604FFB12E3AEA3ECFF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45B67F9A1D44F7B0BF1512E3AEA39367" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_D4F07C68B12ABCF2219212E3AEA36101" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45B67F9A1D44F7B0BF1512E3AEA39367" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_D4F07C68B12ABCF2219212E3AEA36101" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1E87CF859F383323E96012E3AEA0EE6E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_92C57DF1148FC830DF5612E3AEA40AFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_92C57DF1148FC830DF5612E3AEA40AFB" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_0ABAC08D444AF1FC6E1612E3AEA404A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_0ABAC08D444AF1FC6E1612E3AEA404A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_08E5B966554670B8DB8812E3AEA44AD5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_08E5B966554670B8DB8812E3AEA44AD5" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" xlink:label="loc_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_DE3E1FD40DDE3F1CFD5E12E3AEA44A96" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_DE3E1FD40DDE3F1CFD5E12E3AEA44A96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_37BE7172F0312660238F12E3AEA4AC23" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_37BE7172F0312660238F12E3AEA4AC23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_54BDF103597F2945580E12E3AEA5EDB5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_54BDF103597F2945580E12E3AEA5EDB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4F14173B3475B09E182E12E3AEA51FD9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4F14173B3475B09E182E12E3AEA51FD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C7AF554AB325E0B3B50412E3AEA52007" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C7AF554AB325E0B3B50412E3AEA52007" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6C9D2D4BDD367D57631112E3AEA58106" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6C9D2D4BDD367D57631112E3AEA58106" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FA2C89D1B33A97F1893012E3AEA56772" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FA2C89D1B33A97F1893012E3AEA56772" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_2A57742865C7CAD98C2B12E3AEA6AD74" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_2A57742865C7CAD98C2B12E3AEA6AD74" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_A654216CDB317A19C91C12E3AEA698CD" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_A654216CDB317A19C91C12E3AEA698CD" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClosingPriceOfCommonStock" xlink:label="loc_gale_ClosingPriceOfCommonStock_675F8663873C0424F12612E3AEA6409C" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_gale_ClosingPriceOfCommonStock_675F8663873C0424F12612E3AEA6409C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_EA895FB4FD2A5111669512E3AEA6CCCE" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_EA895FB4FD2A5111669512E3AEA6CCCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5199E8D540B46044FB7A12E3AEA6FDFE" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5199E8D540B46044FB7A12E3AEA6FDFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9FBF2FF61C97DBCC7C1912E3AEA6C227" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_557174A8162B6C4C2A9612E3AEA300A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9FBF2FF61C97DBCC7C1912E3AEA6C227" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DFEBEA6F37FDABD8A4B5139A70FCD35C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B9FC3239C2881BEF2B30139A70FD4FB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DFEBEA6F37FDABD8A4B5139A70FCD35C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B9FC3239C2881BEF2B30139A70FD4FB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_035576739E68754AA3A7139A70FD8819" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B9FC3239C2881BEF2B30139A70FD4FB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_035576739E68754AA3A7139A70FD8819" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EC494A1BBBD9855EAB6A139A70FE8B68" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B9FC3239C2881BEF2B30139A70FD4FB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EC494A1BBBD9855EAB6A139A70FE8B68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6BE006A42667F1A93762139A70FE4679" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B9FC3239C2881BEF2B30139A70FD4FB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6BE006A42667F1A93762139A70FE4679" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_402BC17EAEE2531CDBFB139A70FE57F2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B9FC3239C2881BEF2B30139A70FD4FB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_402BC17EAEE2531CDBFB139A70FE57F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C00AA001930F45806487139A70FEADB4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DFEBEA6F37FDABD8A4B5139A70FCD35C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_C00AA001930F45806487139A70FEADB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B47738992A501980042E139A70FEB91A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DFEBEA6F37FDABD8A4B5139A70FCD35C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B47738992A501980042E139A70FEB91A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_34DB50B13F848B01F7D0139A70FE34B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B47738992A501980042E139A70FEB91A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_34DB50B13F848B01F7D0139A70FE34B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_97BE682636C4A0FB612B139A70FF85C9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B47738992A501980042E139A70FEB91A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_97BE682636C4A0FB612B139A70FF85C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F2D5A34E244B0C684BB5139A70FFB28A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B47738992A501980042E139A70FEB91A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F2D5A34E244B0C684BB5139A70FFB28A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4734AD49F668381BE03E139A70FF9875" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_B47738992A501980042E139A70FEB91A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4734AD49F668381BE03E139A70FF9875" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1C0F0F9FF03E21A3916F139A7100B829" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DFEBEA6F37FDABD8A4B5139A70FCD35C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1C0F0F9FF03E21A3916F139A7100B829" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6A26CE9F5D39B5EA7993139A7100776B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DFEBEA6F37FDABD8A4B5139A70FCD35C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6A26CE9F5D39B5EA7993139A7100776B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_052E6323B9DB68351CA0139A71005E3F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DFEBEA6F37FDABD8A4B5139A70FCD35C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_052E6323B9DB68351CA0139A71005E3F" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" xlink:label="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_1BCDD9407EE20E2EA9F6139A71008344" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DFEBEA6F37FDABD8A4B5139A70FCD35C" xlink:to="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_1BCDD9407EE20E2EA9F6139A71008344" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4EA94B16F5BC179DD3F6139A71004B8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_1BCDD9407EE20E2EA9F6139A71008344" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4EA94B16F5BC179DD3F6139A71004B8E" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_AC70F2636B3692D14336139A710010A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_1BCDD9407EE20E2EA9F6139A71008344" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_AC70F2636B3692D14336139A710010A9" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_F3CDD4E73DE017C60767139A7101DB9D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_1BCDD9407EE20E2EA9F6139A71008344" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_F3CDD4E73DE017C60767139A7101DB9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_AC997103E90EB4B1F6FE139A7101C0C3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_1BCDD9407EE20E2EA9F6139A71008344" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_AC997103E90EB4B1F6FE139A7101C0C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_21CA1899CD48A288337C139A71015492" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DFEBEA6F37FDABD8A4B5139A70FCD35C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_21CA1899CD48A288337C139A71015492" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_229B49B9F20C2EBE74BD17BCD036ADBB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9F9EDEE6B8CA01DA5B8E17BCD0363BDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_229B49B9F20C2EBE74BD17BCD036ADBB" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9F9EDEE6B8CA01DA5B8E17BCD0363BDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_140399DCC8210E5E41AA17BCD036AC0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_229B49B9F20C2EBE74BD17BCD036ADBB" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_140399DCC8210E5E41AA17BCD036AC0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_239C32DDD2A4AD38821017BCD036D2BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_229B49B9F20C2EBE74BD17BCD036ADBB" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_239C32DDD2A4AD38821017BCD036D2BC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1BC274D30D8E39F279D017BCCF960F69" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_593E0431D00AB2DFFFC917BCCF9648EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1BC274D30D8E39F279D017BCCF960F69" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_593E0431D00AB2DFFFC917BCCF9648EE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_C5BD382C80E52433D19308F2AE1F8272" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1642D5C5D7F169BE053208F2AE1F877E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C5BD382C80E52433D19308F2AE1F8272" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1642D5C5D7F169BE053208F2AE1F877E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_52E2E4432E2A02AB07F808F2AE20B4E5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C5BD382C80E52433D19308F2AE1F8272" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_52E2E4432E2A02AB07F808F2AE20B4E5" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:label="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_621C369CF6F871616B6A08F2AE21E094" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C5BD382C80E52433D19308F2AE1F8272" xlink:to="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_621C369CF6F871616B6A08F2AE21E094" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:label="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_EA4F841CEAA3F48FF32608F2AE21ACB8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C5BD382C80E52433D19308F2AE1F8272" xlink:to="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_EA4F841CEAA3F48FF32608F2AE21ACB8" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_RestrictedStockSharesReservedforFutureIssuance" xlink:label="loc_gale_RestrictedStockSharesReservedforFutureIssuance_144CDE3169541AEED58408F2AE216E92" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C5BD382C80E52433D19308F2AE1F8272" xlink:to="loc_gale_RestrictedStockSharesReservedforFutureIssuance_144CDE3169541AEED58408F2AE216E92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_BD44B07637E196479FC608F2AE215C5A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C5BD382C80E52433D19308F2AE1F8272" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_BD44B07637E196479FC608F2AE215C5A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_8C10BA2591D1057D6D701361E69AE298" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6B96AE662C609742A4241361E69A77AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8C10BA2591D1057D6D701361E69AE298" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6B96AE662C609742A4241361E69A77AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_BE9F2DBC5355C28310111361E69A82D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6B96AE662C609742A4241361E69A77AB" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_BE9F2DBC5355C28310111361E69A82D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A43AC7C9898017507D511361E69BF1BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_BE9F2DBC5355C28310111361E69A82D2" xlink:to="loc_us-gaap_EquityComponentDomain_A43AC7C9898017507D511361E69BF1BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_17865C92A13DF9F336781361E69C80F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A43AC7C9898017507D511361E69BF1BF" xlink:to="loc_us-gaap_WarrantMember_17865C92A13DF9F336781361E69C80F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_FBD80AF7D968DD2C51661361E69C7FF2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A43AC7C9898017507D511361E69BF1BF" xlink:to="loc_us-gaap_CommonStockMember_FBD80AF7D968DD2C51661361E69C7FF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_C762EF3833CDBE2B04D01361E69DB18B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6B96AE662C609742A4241361E69A77AB" xlink:to="loc_us-gaap_StatementClassOfStockAxis_C762EF3833CDBE2B04D01361E69DB18B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D5C5DDEEF86799C947C51361E69DF413" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_C762EF3833CDBE2B04D01361E69DB18B" xlink:to="loc_us-gaap_ClassOfStockDomain_D5C5DDEEF86799C947C51361E69DF413" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SeriesANonvotingConvertibleMember" xlink:label="loc_gale_SeriesANonvotingConvertibleMember_3A4447A73155E56BA3611361E69D5478" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D5C5DDEEF86799C947C51361E69DF413" xlink:to="loc_gale_SeriesANonvotingConvertibleMember_3A4447A73155E56BA3611361E69D5478" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SeriesAConvertiblePreferredStockMember" xlink:label="loc_gale_SeriesAConvertiblePreferredStockMember_01A38DACBDA475C7D3731361E69E65D6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D5C5DDEEF86799C947C51361E69DF413" xlink:to="loc_gale_SeriesAConvertiblePreferredStockMember_01A38DACBDA475C7D3731361E69E65D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_FC443C96554B097B93A21361E69E40D3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6B96AE662C609742A4241361E69A77AB" xlink:to="loc_us-gaap_TypeOfArrangementAxis_FC443C96554B097B93A21361E69E40D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F5C1FFAA9EEB88988D681361E69E0823" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FC443C96554B097B93A21361E69E40D3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F5C1FFAA9EEB88988D681361E69E0823" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PurchaseAgreementMember" xlink:label="loc_gale_PurchaseAgreementMember_CF6708067102EF90CF2A1361E69E83A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F5C1FFAA9EEB88988D681361E69E0823" xlink:to="loc_gale_PurchaseAgreementMember_CF6708067102EF90CF2A1361E69E83A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_DCF97BEDC07BF1E1B6BB1361E69F61E9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6B96AE662C609742A4241361E69A77AB" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_DCF97BEDC07BF1E1B6BB1361E69F61E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F60415701AF32605DBF01361E69FE4C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_DCF97BEDC07BF1E1B6BB1361E69F61E9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F60415701AF32605DBF01361E69FE4C6" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PrivatePlacementFirstClosingMember" xlink:label="loc_gale_PrivatePlacementFirstClosingMember_740FF7B55FB027C7322B1361E69F33C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F60415701AF32605DBF01361E69FE4C6" xlink:to="loc_gale_PrivatePlacementFirstClosingMember_740FF7B55FB027C7322B1361E69F33C5" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_PrivatePlacementSecondClosingMember" xlink:label="loc_gale_PrivatePlacementSecondClosingMember_8AD50159BDE3F269E5731361E69F6FA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F60415701AF32605DBF01361E69FE4C6" xlink:to="loc_gale_PrivatePlacementSecondClosingMember_8AD50159BDE3F269E5731361E69F6FA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6B96AE662C609742A4241361E69A77AB" xlink:to="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_BE6F32651729E72A04951361E6A073FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_BE6F32651729E72A04951361E6A073FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8BF70592BE9C32F049291361E6A0787F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8BF70592BE9C32F049291361E6A0787F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_FDCA5456218CA1899E8C1361E6A0CB78" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_PreferredStockSharesIssued_FDCA5456218CA1899E8C1361E6A0CB78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6226B6FED66875FF9B501361E6A02BDC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6226B6FED66875FF9B501361E6A02BDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_4D8D07DB71C2CD63EAEC1361E6A17D90" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_4D8D07DB71C2CD63EAEC1361E6A17D90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_89C62ABFF1FA52715EE61361E6A1DC94" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_89C62ABFF1FA52715EE61361E6A1DC94" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ConvertiblePreferredStockConversionPrice" xlink:label="loc_gale_ConvertiblePreferredStockConversionPrice_71432579BC4DC4E186651361E6A1ACDE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_gale_ConvertiblePreferredStockConversionPrice_71432579BC4DC4E186651361E6A1ACDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" xlink:label="loc_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_1BE7A906783A7EE546441361E6A1D1AA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_1BE7A906783A7EE546441361E6A1D1AA" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ConvertiblePreferredStockIssuedShares" xlink:label="loc_gale_ConvertiblePreferredStockIssuedShares_6D654C2800D1D560957F1361E6A2DA6B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_gale_ConvertiblePreferredStockIssuedShares_6D654C2800D1D560957F1361E6A2DA6B" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_WarrantsIssuedShares" xlink:label="loc_gale_WarrantsIssuedShares_F5D1F28BA29D3DF847FD1361E6A210C1" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_gale_WarrantsIssuedShares_F5D1F28BA29D3DF847FD1361E6A210C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_012146FBA49479F56D151361E6A28E2B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_012146FBA49479F56D151361E6A28E2B" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:label="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_32BAE66F0AD52BADCF161361E6A23347" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_gale_IncreaseDecreaseInFairValueOfWarrantLiability_32BAE66F0AD52BADCF161361E6A23347" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_AE150EBAAEDCD2E0DD221361E6A2C092" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_gale_ClassofWarrantorRightTerm_AE150EBAAEDCD2E0DD221361E6A2C092" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation" xlink:label="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_B3C1DC433441B47C747E1361E6A2BB2E" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation_B3C1DC433441B47C747E1361E6A2BB2E" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock" xlink:label="loc_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_DB09CAEDDEC9341E0B461361E6A35EA2" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock_DB09CAEDDEC9341E0B461361E6A35EA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_E3A2E7B1E38A9952B9411361E6A36DBF" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_E3A2E7B1E38A9952B9411361E6A36DBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0F41F3DE9839348F34301361E6A3DE82" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0F41F3DE9839348F34301361E6A3DE82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_A813BE1CBE519278D2CF1361E6A34258" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_A813BE1CBE519278D2CF1361E6A34258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_5A80C732833BC65A9AD51361E6A3FFB4" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_5A80C732833BC65A9AD51361E6A3FFB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0B29A967DA0C1DF6C01513A440CBF972" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0B29A967DA0C1DF6C01513A440CBF972" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded" xlink:label="loc_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_A65FC4A74777A29FEA511361E6A3A188" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded_A65FC4A74777A29FEA511361E6A3A188" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_674F3A9567FB3BE2D19B1361E6A4499E" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2DF53CCD8CC9E3E30A751361E6A03B5F" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_674F3A9567FB3BE2D19B1361E6A4499E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1B4BBE9D2B602AC0B41B0E343F485FC9" xlink:type="locator" />
    <link:loc xlink:href="gale-20180930.xsd#gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:label="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_61DD4C5467DD03E161350E343F482F66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1B4BBE9D2B602AC0B41B0E343F485FC9" xlink:to="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_61DD4C5467DD03E161350E343F482F66" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_DBB8B7254E70E3080B4D17BCD04A7E78" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_05F6B5A16B663C47EEC417BCD04ADBB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_DBB8B7254E70E3080B4D17BCD04A7E78" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_05F6B5A16B663C47EEC417BCD04ADBB0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStock" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_258EFE2FB7B3A8E28C0517BCCED9E65A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_CBD770FC7F3DEAB538DC17BCCEDA6138" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_258EFE2FB7B3A8E28C0517BCCED9E65A" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_CBD770FC7F3DEAB538DC17BCCEDA6138" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_2DABCEE768D1764333B612CD0FB5E815" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_DF5B5240ABB3F4D8DED312CD0FB5EFD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_2DABCEE768D1764333B612CD0FB5E815" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_DF5B5240ABB3F4D8DED312CD0FB5EFD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_A81F5AD5DA2539C3455612CD0FB6A375" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_DF5B5240ABB3F4D8DED312CD0FB5EFD8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_A81F5AD5DA2539C3455612CD0FB6A375" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2D9D28AC7F4FC3ACBB4D12CD0FB6B003" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_A81F5AD5DA2539C3455612CD0FB6A375" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2D9D28AC7F4FC3ACBB4D12CD0FB6B003" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SeriesAConvertiblePreferredWarrantsMember" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_1871C5C1823AB4AB76DB12CD0FB62E6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2D9D28AC7F4FC3ACBB4D12CD0FB6B003" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_1871C5C1823AB4AB76DB12CD0FB62E6D" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_February2017WarrantsMember" xlink:label="loc_gale_February2017WarrantsMember_1F096F7F247A09093DC812CD0FB6C599" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2D9D28AC7F4FC3ACBB4D12CD0FB6B003" xlink:to="loc_gale_February2017WarrantsMember_1F096F7F247A09093DC812CD0FB6C599" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_OtherWarrantIssuesMember" xlink:label="loc_gale_OtherWarrantIssuesMember_2522FBC5789751633C0312CD0FB77970" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2D9D28AC7F4FC3ACBB4D12CD0FB6B003" xlink:to="loc_gale_OtherWarrantIssuesMember_2522FBC5789751633C0312CD0FB77970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_920B11B4E884585A210712CD0FB74628" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_DF5B5240ABB3F4D8DED312CD0FB5EFD8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_920B11B4E884585A210712CD0FB74628" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightFairValueRollForward" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_920B11B4E884585A210712CD0FB74628" xlink:to="loc_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_FD3D59622B99A08F6DA412CD0FB75F3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_FD3D59622B99A08F6DA412CD0FB75F3A" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueofWarrantsGranted" xlink:label="loc_gale_FairValueofWarrantsGranted_768565698ACF3949FD4912CD0FB848A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:to="loc_gale_FairValueofWarrantsGranted_768565698ACF3949FD4912CD0FB848A9" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantsCanceled" xlink:label="loc_gale_FairValueOfWarrantsCanceled_896BCFA8C3698C9C0D6C12CD0FB8B7CA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:to="loc_gale_FairValueOfWarrantsCanceled_896BCFA8C3698C9C0D6C12CD0FB8B7CA" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantsExercisePriceAdjustment" xlink:label="loc_gale_FairValueOfWarrantsExercisePriceAdjustment_3869F1D21A4B689AF0B412CD0FB81B01" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:to="loc_gale_FairValueOfWarrantsExercisePriceAdjustment_3869F1D21A4B689AF0B412CD0FB81B01" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities_E11F6B299C69D160723712CD0FB80D22" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:to="loc_gale_ChangeInFairValueOfWarrantLiabilities_E11F6B299C69D160723712CD0FB80D22" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_7A56C8ACB70D7AEAA9F412CD0FB8E0F9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_48D00B964A90522581DF12CD0FB795E4" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_7A56C8ACB70D7AEAA9F412CD0FB8E0F9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_C9FA16819327AF57736217BCD07E4119" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_92126F2F2DFFD6FE33C717BCD07EBC3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_C9FA16819327AF57736217BCD07E4119" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_92126F2F2DFFD6FE33C717BCD07EBC3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_D25B398ED7B4CA42019817BCD07FE84F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_92126F2F2DFFD6FE33C717BCD07EBC3C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_D25B398ED7B4CA42019817BCD07FE84F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_EA9569E8EE8F1F569C0F17BCD07F3610" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_D25B398ED7B4CA42019817BCD07FE84F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_EA9569E8EE8F1F569C0F17BCD07F3610" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SeriesAConvertiblePreferredWarrantsMember" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_1349E5984C7E93A89E0217BCD0802626" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EA9569E8EE8F1F569C0F17BCD07F3610" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_1349E5984C7E93A89E0217BCD0802626" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_February2017WarrantsMember" xlink:label="loc_gale_February2017WarrantsMember_ADADE1101A5BB71FABD817BCD080D381" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EA9569E8EE8F1F569C0F17BCD07F3610" xlink:to="loc_gale_February2017WarrantsMember_ADADE1101A5BB71FABD817BCD080D381" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_OtherWarrantIssuesMember" xlink:label="loc_gale_OtherWarrantIssuesMember_2B6A5226A3CD56A958D917BCD080285D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EA9569E8EE8F1F569C0F17BCD07F3610" xlink:to="loc_gale_OtherWarrantIssuesMember_2B6A5226A3CD56A958D917BCD080285D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_1C6C2378450EAA99B7E717BCD0807052" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_92126F2F2DFFD6FE33C717BCD07EBC3C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_1C6C2378450EAA99B7E717BCD0807052" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_295D4852F8BC7A99FE2F17BCD080B710" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1C6C2378450EAA99B7E717BCD0807052" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_295D4852F8BC7A99FE2F17BCD080B710" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_WarrantStrikePrice" xlink:label="loc_gale_WarrantStrikePrice_DF39C75AAAB317787D9117BCD081459D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1C6C2378450EAA99B7E717BCD0807052" xlink:to="loc_gale_WarrantStrikePrice_DF39C75AAAB317787D9117BCD081459D" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD6E503350CFFE80D44C17BCD0815EFF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1C6C2378450EAA99B7E717BCD0807052" xlink:to="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_BD6E503350CFFE80D44C17BCD0815EFF" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_7279359D68F2719DDDCC17BCD0812ACA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1C6C2378450EAA99B7E717BCD0807052" xlink:to="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_7279359D68F2719DDDCC17BCD0812ACA" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_7A1E02B37CFE28C04B0417BCD08151F2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1C6C2378450EAA99B7E717BCD0807052" xlink:to="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_7A1E02B37CFE28C04B0417BCD08151F2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_CD5D557EF88AB2FF12270E609EAA1EED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_F1C0A56C6408844D4BED0E609EAB501D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_CD5D557EF88AB2FF12270E609EAA1EED" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_F1C0A56C6408844D4BED0E609EAB501D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_B9D56BD8F7872BE675E90E609EABC312" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_F1C0A56C6408844D4BED0E609EAB501D" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_B9D56BD8F7872BE675E90E609EABC312" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_C54A519B2EE4B6CF99F10E609EAB71EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_B9D56BD8F7872BE675E90E609EABC312" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_C54A519B2EE4B6CF99F10E609EAB71EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_DCAACDE3ADFC569E9A830E609EABD56D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C54A519B2EE4B6CF99F10E609EAB71EC" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_DCAACDE3ADFC569E9A830E609EABD56D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1E539B698F505024BDB90E609EAC29BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C54A519B2EE4B6CF99F10E609EAB71EC" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1E539B698F505024BDB90E609EAC29BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_BC5448849703FFCD3ECB0E609EAC90C1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C54A519B2EE4B6CF99F10E609EAB71EC" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_BC5448849703FFCD3ECB0E609EAC90C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_70ADC301336033C927A50E609EACA5BD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_F1C0A56C6408844D4BED0E609EAB501D" xlink:to="loc_us-gaap_DebtInstrumentAxis_70ADC301336033C927A50E609EACA5BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_99184FDDB75086E269DE0E609EAC1CEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_70ADC301336033C927A50E609EACA5BD" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_99184FDDB75086E269DE0E609EAC1CEB" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ConvertiblePromissoryNotesMember" xlink:label="loc_gale_ConvertiblePromissoryNotesMember_ED79EAA365D762FB31750E609EACF3E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_99184FDDB75086E269DE0E609EAC1CEB" xlink:to="loc_gale_ConvertiblePromissoryNotesMember_ED79EAA365D762FB31750E609EACF3E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_7EEBA697239D48D246840E609EAD5CAC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_F1C0A56C6408844D4BED0E609EAB501D" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_7EEBA697239D48D246840E609EAD5CAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_DEA1BB90FD1B33DF318D0E609EADB215" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_7EEBA697239D48D246840E609EAD5CAC" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_DEA1BB90FD1B33DF318D0E609EADB215" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_270A4619AC70C1CF1A490E609EADB9E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_DEA1BB90FD1B33DF318D0E609EADB215" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_270A4619AC70C1CF1A490E609EADB9E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3185E66BAE240B7EC7FA0E609EAEB854" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_F1C0A56C6408844D4BED0E609EAB501D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3185E66BAE240B7EC7FA0E609EAEB854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8F43FD69E1199DC70E6E0E609EAEFC12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3185E66BAE240B7EC7FA0E609EAEB854" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8F43FD69E1199DC70E6E0E609EAEFC12" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_February2017WarrantsMember" xlink:label="loc_gale_February2017WarrantsMember_0F2282DE98254E12273B0E609EAEE216" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8F43FD69E1199DC70E6E0E609EAEFC12" xlink:to="loc_gale_February2017WarrantsMember_0F2282DE98254E12273B0E609EAEE216" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SeriesAConvertiblePreferredWarrantsMember" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_CA9BE389A363D1ABDA0A0E609EAE2900" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8F43FD69E1199DC70E6E0E609EAEFC12" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_CA9BE389A363D1ABDA0A0E609EAE2900" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_F1C0A56C6408844D4BED0E609EAB501D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants" xlink:label="loc_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_1E7AF1B47F7E466002380E609EAE81A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:to="loc_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants_1E7AF1B47F7E466002380E609EAE81A0" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock" xlink:label="loc_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_E144AF39CE5D030773110E609EAF8DC2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:to="loc_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock_E144AF39CE5D030773110E609EAF8DC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0CCDDFA29071D6F7C8880E609EAF08A6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0CCDDFA29071D6F7C8880E609EAF08A6" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_CommonStockSharesAcquiredinExchangeforWarrants" xlink:label="loc_gale_CommonStockSharesAcquiredinExchangeforWarrants_16AAC3F3AD431B945DF20E609EAF5EC4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:to="loc_gale_CommonStockSharesAcquiredinExchangeforWarrants_16AAC3F3AD431B945DF20E609EAF5EC4" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ConsiderationExchangedFairValue" xlink:label="loc_gale_ConsiderationExchangedFairValue_CE138648E97C9F5C51BA0E609EAF647D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:to="loc_gale_ConsiderationExchangedFairValue_CE138648E97C9F5C51BA0E609EAF647D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_E4B8A38F39A21A9925490E609EB006A4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_E4B8A38F39A21A9925490E609EB006A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_2A5422FD6C6CD01B2F3E0E609EB0B22E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_2A5422FD6C6CD01B2F3E0E609EB0B22E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_922F3CF601C25B70C6400E609EB0FE9D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_922F3CF601C25B70C6400E609EB0FE9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_66BB263E0046A8D8758E0E609EB0B14D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E272786A4AD155E733610E609EAEC3C1" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_66BB263E0046A8D8758E0E609EB0B14D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_A9795CE73CF66E7A2B15139A71CC5C72" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_38D0970973C97292146B139A71CCDFEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_A9795CE73CF66E7A2B15139A71CC5C72" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_38D0970973C97292146B139A71CCDFEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_762BC38DD6B41BA53179139A71CCBCFD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38D0970973C97292146B139A71CCDFEE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_762BC38DD6B41BA53179139A71CCBCFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_F632F015D80FC1824D02139A71CDDF34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_762BC38DD6B41BA53179139A71CCBCFD" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_F632F015D80FC1824D02139A71CDDF34" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_July2018OfferingMember" xlink:label="loc_gale_July2018OfferingMember_8A8A144B86A6A985B425139A71CD1B9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_F632F015D80FC1824D02139A71CDDF34" xlink:to="loc_gale_July2018OfferingMember_8A8A144B86A6A985B425139A71CD1B9F" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_Prefunded2018OfferingMember" xlink:label="loc_gale_Prefunded2018OfferingMember_DEB763EC55A73136D834139A71CD43EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_F632F015D80FC1824D02139A71CDDF34" xlink:to="loc_gale_Prefunded2018OfferingMember_DEB763EC55A73136D834139A71CD43EB" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_SeriesAConvertiblePreferredWarrantsMember" xlink:label="loc_gale_SeriesAConvertiblePreferredWarrantsMember_5E89BA30A55535C01342139A71CD67B5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_F632F015D80FC1824D02139A71CDDF34" xlink:to="loc_gale_SeriesAConvertiblePreferredWarrantsMember_5E89BA30A55535C01342139A71CD67B5" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_EqcWarrantsMember" xlink:label="loc_gale_EqcWarrantsMember_D00FDCF94A3B8FB2B750139A71CEBACB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_F632F015D80FC1824D02139A71CDDF34" xlink:to="loc_gale_EqcWarrantsMember_D00FDCF94A3B8FB2B750139A71CEBACB" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_February2017WarrantsMember" xlink:label="loc_gale_February2017WarrantsMember_35104F8C4C61BC5100D1139A71CE6C4B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_F632F015D80FC1824D02139A71CDDF34" xlink:to="loc_gale_February2017WarrantsMember_35104F8C4C61BC5100D1139A71CE6C4B" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_OtherWarrantIssuesMember" xlink:label="loc_gale_OtherWarrantIssuesMember_556DF530FAF39DB892D8139A71CE66B2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_F632F015D80FC1824D02139A71CDDF34" xlink:to="loc_gale_OtherWarrantIssuesMember_556DF530FAF39DB892D8139A71CE66B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_E1D6248FEF12CCD936A7139A71CEEDC2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38D0970973C97292146B139A71CCDFEE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_E1D6248FEF12CCD936A7139A71CEEDC2" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightOutstandingRollForward" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_E1D6248FEF12CCD936A7139A71CEEDC2" xlink:to="loc_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_938DDB6AF4096EFD4887139A71CF098E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_938DDB6AF4096EFD4887139A71CF098E" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_754A09CD66C3131621E9139A71CFFA3E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A" xlink:to="loc_gale_ClassofWarrantorRightGranted_754A09CD66C3131621E9139A71CFFA3E" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassOfWarrantOrRightExercised" xlink:label="loc_gale_ClassOfWarrantOrRightExercised_C94E7EAD3F37DEF5A0AA139A71CFCCCF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A" xlink:to="loc_gale_ClassOfWarrantOrRightExercised_C94E7EAD3F37DEF5A0AA139A71CFCCCF" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightCanceledOrExpired" xlink:label="loc_gale_ClassofWarrantorRightCanceledOrExpired_AC652A89F980D7EADC2E139A71CF37CA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A" xlink:to="loc_gale_ClassofWarrantorRightCanceledOrExpired_AC652A89F980D7EADC2E139A71CF37CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_518AFFB2F67D08E045A3139A71D016B3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_7B87869F44B72CE4B780139A71CE3F4A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_518AFFB2F67D08E045A3139A71D016B3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_C9EE90C843DD0CCB047C17BCCE86E7A7" xlink:type="locator" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ScheduleOfWarrantActivityTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantActivityTableTextBlock_C8A33BFDBBF9373EE1EF17BCCE87BD21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_C9EE90C843DD0CCB047C17BCCE86E7A7" xlink:to="loc_gale_ScheduleOfWarrantActivityTableTextBlock_C8A33BFDBBF9373EE1EF17BCCE87BD21" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_2B59BD58419FE41A139E17BCCE875164" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_C9EE90C843DD0CCB047C17BCCE86E7A7" xlink:to="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_2B59BD58419FE41A139E17BCCE875164" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:label="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_F07FFF49C72905B3A94D17BCCE87BF07" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_C9EE90C843DD0CCB047C17BCCE86E7A7" xlink:to="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_F07FFF49C72905B3A94D17BCCE87BF07" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_83E07100D65E2941A3CB12E41C981E22" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_97502148762739C9496112E41C986977" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_83E07100D65E2941A3CB12E41C981E22" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_97502148762739C9496112E41C986977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_E0F38AF7F81C77AD7C6612E41C982AC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_97502148762739C9496112E41C986977" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_E0F38AF7F81C77AD7C6612E41C982AC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_DEC3A910E5D1F989D8F112E41C9E4987" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_E0F38AF7F81C77AD7C6612E41C982AC3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_DEC3A910E5D1F989D8F112E41C9E4987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_B9AB23BD9D3CEBC62CF412E41C9E7595" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_DEC3A910E5D1F989D8F112E41C9E4987" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_B9AB23BD9D3CEBC62CF412E41C9E7595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_DF1A755CEA6647B5040E12F8824025E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_DEC3A910E5D1F989D8F112E41C9E4987" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_DF1A755CEA6647B5040E12F8824025E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_A0522C0D5065AC8EF76212E41C9EB042" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_DEC3A910E5D1F989D8F112E41C9E4987" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_A0522C0D5065AC8EF76212E41C9EB042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_9AB44297F40B619930C612E41C9F1592" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_DEC3A910E5D1F989D8F112E41C9E4987" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_9AB44297F40B619930C612E41C9F1592" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE4B69CD80ABB61367CF12E41C9F62AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_97502148762739C9496112E41C986977" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE4B69CD80ABB61367CF12E41C9F62AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_85AAC91E1B61B71619E412E41C9FA330" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE4B69CD80ABB61367CF12E41C9F62AE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_85AAC91E1B61B71619E412E41C9FA330" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_AE0EAAA7178E23F4419712E41C9F5A0E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE4B69CD80ABB61367CF12E41C9F62AE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_AE0EAAA7178E23F4419712E41C9F5A0E" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_E49F305DF3C2E8682E8E12E41C9FA01D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE4B69CD80ABB61367CF12E41C9F62AE" xlink:to="loc_gale_ClassofWarrantorRightTerm_E49F305DF3C2E8682E8E12E41C9FA01D" xlink:type="arc" />
    <link:loc xlink:href="gale-20180930.xsd#gale_FairValueofWarrantsGrantedperShare" xlink:label="loc_gale_FairValueofWarrantsGrantedperShare_E41AAE999C269956601C12E41CA0B7E1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE4B69CD80ABB61367CF12E41C9F62AE" xlink:to="loc_gale_FairValueofWarrantsGrantedperShare_E41AAE999C269956601C12E41CA0B7E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1F72F979CF4FE1D552FA12E41CA037A4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FE4B69CD80ABB61367CF12E41C9F62AE" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1F72F979CF4FE1D552FA12E41CA037A4" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>sellas-logoa05.jpg
<TEXT>
begin 644 sellas-logoa05.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "L @D# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#ZP_X*Y_\
M!=?6/@%\2M3^%_P=_L]=>T5C;ZWXBN(5N5L;C^*WMHVRC2)T=Y P#;EVY!(_
M.#4O^"J_[1VJWTEQ+\9/'2R2G<PAU PQCZ(F%7Z  5XQ\2;K5K[XBZ_-K_F?
MV[-J5P^H^9]_[296,N???NS69IFGR:MJ5O:P^4)KJ58D,LJQ1AF( W.Y"J,G
MEF( ')(%?TQE'#&78+#1IJG&3MK)I-M]7=].RV/YDSCBC,<;B95'4E%7TBFT
MDNBLNO=[L]S_ .'HW[17_19OB#_X-Y/\:/\ AZ-^T5_T6;X@_P#@WD_QKKH_
M^")O[44L:LOPGU!E89!&K:>01_X$4[_AR3^U'_T2;4O_  :Z?_\ )%'UCA_^
M:C]\!_5^(?Y:WW3./_X>C?M%?]%F^(/_ (-Y/\:/^'HW[17_ $6;X@_^#>3_
M !KL/^')/[4?_1)M2_\ !KI__P D4?\ #DG]J/\ Z)-J7_@UT_\ ^2*/K'#_
M /-1^^ ?5^(?Y:WW3./_ .'HW[17_19OB#_X-Y/\:/\ AZ-^T5_T6;X@_P#@
MWD_QKL/^')/[4?\ T2;4O_!KI_\ \D4?\.2?VH_^B3:E_P"#73__ )(H^L</
M_P U'[X!]7XA_EK?=,]>_P""2'[?OQJ^,'_!1'X:^&_%'Q/\9:]H.J75VEW8
M7NHO+!<!;&X=0RDX.&53]0*_>2OP_P#^"5G_  2L^/W[/_[?OPZ\8>,/AU?:
M+X;T6YNGO;U]0LY5@5[.>-25CF9CEW4< ]:_<"OR+Q G@Y8^F\"XN/(K\EK7
MYI=M+VL?KWA]#&QP$UCE)2YW;GO>W+'OK;<*_/G_ (+4?\%>-3_8;;3? /P]
M2QD^(&M6GV^YO[F(3Q:';,S+&5C/RO,[*Q ?*JJY*MN7'Z#5_.'_ ,%PM=N-
M=_X*B_%-KB1F^RSV-K$">$1+"V  ].Y^I-8<!Y10Q^9<N)7-&$7*W1NZ2OY:
MW^1MQ[G%?+\MYL,^64Y*-^J5FW;STM\SC]:_X*I_M&:_J$EU/\9/'D<DK%BM
MMJ36T8SZ)'M4#V  JG_P\Z_:&_Z+1\1O_!Y/_P#%5Y;\)?A5KGQQ^)>B^$/#
M-FNH>(/$5TEE86S3)")I6X5=[D*N?5B!7U)_PX._:F_Z)W9_^%'IG_R17[5B
MHY+A&H8A4H/HGRK3YGXGA99UBTYX=U9I;N/.]?.QY;_P\Z_:&_Z+1\1O_!Y/
M_P#%4?\ #SK]H;_HM'Q&_P#!Y/\ _%5ZE_PX._:F_P"B=V?_ (4>F?\ R11_
MPX._:F_Z)W9_^%'IG_R17+]>X=_GH_? ZOJ/$7\E;[IGEO\ P\Z_:&_Z+1\1
MO_!Y/_\ %4?\/.OVAO\ HM'Q&_\ !Y/_ /%5ZE_PX._:F_Z)W9_^%'IG_P D
M4?\ #@[]J;_HG=G_ .%'IG_R11]>X=_GH_? /J/$7\E;[IGEO_#SK]H;_HM'
MQ&_\'D__ ,51_P /.OVAO^BT?$;_ ,'D_P#\57J7_#@[]J;_ *)W9_\ A1Z9
M_P#)%'_#@[]J;_HG=G_X4>F?_)%'U[AW^>C]\ ^H\1?R5ONF?T34445_-9_3
M!\F_\%M/BQXF^"?_  3Q\6>(O".NZIX;UVTO=.2&_P!/N&@N(E>[B5P'7D94
MD'U!K\.?^'G7[0W_ $6CXC?^#R?_ .*K]IO^#@3_ )1?^-/^PAI?_I=#7\\M
M?M_AS@L/6RN4JM.,GSO5I/I'N?AOB1CL11S2,:5245R+1-KK+L?T'?\ ! 7X
MW^,/C]^Q#J6N>-O$FL^*M8C\5WEHEYJ=TUQ,L*V]JRH&8D[078@?[1K[>K\]
M_P#@VH_Y1\:M_P!CG??^DUG7Z$5^7<44XPS;$0@K)2>BV/U/A:I*>4X><W=N
M*U>X4445X)[X4444 %%%% !7XR_\%^?VR_BQ\ ?VWM-T/P3\0_%WA71Y/"EG
M=O9Z9J4EO"TK7%TK.54@;B$4$_[(K]FJ_!K_ (.5_P#E(/I/_8F6/_I3>5]Q
MX>T:=7-N2K%27++1JZZ=SX;Q#KU*64.=*3B^:.J=GU['SMHG_!37]H2?6;-'
M^,WQ&97G16!UN?!!8?[5?TW5_(_X?_Y#UC_U\1_^A"OZX*][Q.PM&B\-[&"C
M?GO9)?R]CP?"_%5JRQ/MIN5N2UVW_-W"BBBORD_5PHHHH **** "BBB@ HHH
MH JZYK=GX:T6\U+4+F&SL-/@>YN;B9@L<$2*6=V)X"A022>@%?SK_P#!3C_@
MJ]XU_;B^*^JVFDZUJNA_#&QG:#2-&MYFMUO(E) N+H*1YDC_ 'MK96,$*!G<
MS?J%_P '"?[4[? 7]AV;PKI]UY&N?$^Z_L= K8=;% )+MA_LE?+A/M<5^ =?
ML7AOD--TI9E7C=MVA?HENUYWTOTL^Y^-^)6?U%5CEE"5DE>=NK>R?E;6W6Z[
M'8?!W]H'QQ^S[XHM]:\$^*M<\,ZE:N'66PNWB5\'.'0':ZGNK@J1P017]#?_
M  29_P""@4?_  4$_9DCUK45M;7QIX=F&F^(K: ;8S+MW1W"+_#'*O('9ED4
M9"@G^;2ON3_@W\_:C;X _MX:?X=O+GR="^)EN="G5FP@NP?,M'QW8R Q#_KX
M-?2<<9#2QN7SKPBO:4US)]6ENO/3;S/F^!L^JX+,(4)R?LJCY6NB;V?EKOY'
M]!%%%%?SR?T0%%%% !1163X^\=:3\,/ ^L>)->O(M.T70;.6_OKJ7[L$,2%W
M8_10>!R:J,7)\L=R9245S2V1A_'G]H'P=^S)\-;[Q=XZUZQ\/:#8##W%PQW2
MN<E8XT&6DD;!PB L<'C@U^2W[6?_  <R^*-=U2ZTWX-^%K'0=+5BB:SKT?VJ
M^G'9T@5O*B^CF7CT/ ^-O^"D7_!0GQ-_P4%^.MUKFH37-CX3TR1X/#NBE_W>
MGV^?OL!P9Y  SOSSA0=JJ!\[@9-?N'#?A_A:%)5LQCSU'KROX8^5NK[WT[+J
M?AG$GB%BJ]5T<MER4UIS+XI>=^B[6U[OH?27B[_@K[^TMXVO'GO/B_XJMV<G
MY;!HK!!]%@1 /RK!_P"'G7[0W_1:/B-_X/)__BJZ7X&?\$>OVB_V@M%AU31/
MAMJECI=PH>*[UF:'2UD4]&5)V61E/4,JD$=Z]%_XAZOVFO\ H6_#O_@_MO\
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M/_G^O_ 9?_(GI_ZBYY_SX?\ X%'_ .2/RAHK]7O^(6;7_P#HLFC_ /A.2?\
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MOB/_ -"%?UP5[_BKOAO^W_\ VP^?\*=L5_VY_P"WA1117Y&?KP4444 %%%%
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M=AX8\8:?'XAL+.(8CL#)))'- @[*)8F95'"K(JCI7]%=?B1_P=!?\G5?#O\
M[%0_^EDU??>'&*J0S;V47[LHNZ]%=?=_F?G_ (D86G4RGVLE[T)*S]79_?\
MHC\X_AUXYOOAC\0="\2:9(T.I>']0M]2M7!P4EAD61#GV917]6W_  L33?[T
MW_?%?R85_4A7TWB=0A-X:3W]_P#]M/F?"^O.*Q,5M[G_ +<>M3PK<P/&V[;(
MI4X8J<'T(Y'U%?/LO_!*#]G&>5G?X/\ @UW<EF9K4DL3U).ZL&3_ (+2_LOQ
M2,K?%K1]RG!Q87I'YB&FK_P6G_9?9@/^%M:/SQSI]Z/_ &C7YQA\OSFA?V%*
MK&^]HS5_N1^D8C,<EKV]O5I2MM>4';[V;W_#IO\ 9O\ ^B.^"_\ P$/^->X>
M!/ FC?#'P=IOA_P]IEGHVB:/ MM965I$(X;:->BJH_R3DGFOG?\ X?.?LP_]
M%<T/_P !+O\ ^,T?\/G/V8?^BN:'_P" EW_\9IU\#G5=<M:G5DO-3?YH,/CL
MEH/FH5*46^S@OR9]/45\P_\ #YS]F'_HKFA_^ EW_P#&:/\ A\Y^S#_T5S0_
M_ 2[_P#C-<O]AYC_ - \_P#P"7^1U?VYEO\ T$0_\#C_ )GT]17S#_P^<_9A
M_P"BN:'_ . EW_\ &:/^'SG[,/\ T5S0_P#P$N__ (S1_8>8_P#0//\ \ E_
MD']N9;_T$0_\#C_F?3U%>"_"+_@I_P# 7X\_$73/"7A'XCZ3K?B+6&=+.RAM
MKE7G*(TC %HPO"(QY(Z5[U7'B,+7P\N2O!Q>]FFG;YG9A\70Q$>>A-26UTTU
M?Y!7\V__  6H_P"4H'Q:_P"PA;?^D-O7])%?S;_\%J/^4H'Q:_["%M_Z0V]?
MH7A?_P C*K_@?_I43\\\4?\ D6TO^OB_])D<W_P2J_Y2-?!O_L9[7_T*OZ;*
M_E]_X)R^.]'^&/[=/PL\0>(-1M=(T72/$-O<WM[<OLAMHU/+L>P%?T _\/5_
MV<?^BR>!?_!@*[O$K!8BMC:4J-.4ER]$WU?8X?#/'8>A@JL:U2,7S]6ET7<^
M@:*^?O\ AZO^SC_T63P+_P"# 4?\/5_V<?\ HLG@7_P8"OS?^R<=_P ^9_\
M@+_R/TG^U\#_ ,_H?^!1_P SZ!HKY^_X>K_LX_\ 19/ O_@P%'_#U?\ 9Q_Z
M+)X%_P#!@*/[)QW_ #YG_P" O_(/[7P/_/Z'_@4?\SZ!HKY^_P"'J_[./_19
M/ O_ (,!1_P]7_9Q_P"BR>!?_!@*/[)QW_/F?_@+_P @_M? _P#/Z'_@4?\
M,^@:***\\] ^+?\ @X$_Y1?^-/\ L(:7_P"ET-?SRU_0U_P<"?\ *+_QI_V$
M-+_]+H:_GEK]X\,_^13+_&__ $F)^">)W_(VC_U[7_I4C]Y/^#:C_E'QJW_8
MYWW_ *36=?H17Y2?\$#_ -M[X1_L[?L3:EH/CCX@^&?"^LR^*KR\2SO[H12M
M"UO:JKX_NDHPS_LFOMK_ (>K_LX_]%D\"_\ @P%?FO%&6XR>;8B<*4FG)V:B
MVOR/TSA?,\'3RG#PG5BFHJZ<DG^9] T5\_?\/5_V<?\ HLG@7_P8"C_AZO\
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M:I[*S^9Q\$\&X/'8%XO'Q;YG:.K6BT;T:W=U\C\8/^(7#QM_T5?PM_X*I_\
MXJC_ (A</&W_ $5?PM_X*I__ (JOV?HKX[_B(&=_\_5_X#'_ "/L_P#B'N1_
M\^G_ .!2_P S\8/^(7#QM_T5?PM_X*I__BJ/^(7#QM_T5?PM_P""J?\ ^*K]
MGZ*/^(@9W_S]7_@,?\@_XA[D?_/I_P#@4O\ ,_&#_B%P\;?]%7\+?^"J?_XJ
MODC_ (*1_P#!,WQ/_P $WO%GAFQUO6;'Q'I_BJTEGM-0L[=X8Q+$X66$JQ)W
M*KQ-G/(D]J_I6KXK_P""]O[,K?M"?\$_]<U2SM_.UKX=SKXDMBJ_.8(P4NES
M_=$#O(1W,*U[/#_'F8U,PI4L;-.G)V>B6^B=TNCM\CQN(> <NIY?5JX*#52*
MNM6]M6K-]5?YG\^OACQ+?>#?$NGZQIEQ)9ZEI-S'>6D\9^:":-@Z./<, ?PK
M^IS]E'X]V/[4/[-W@OX@:?Y:P^*=*AO)(T.1;SXVS0_6.59$/NE?RJU^T'_!
MLE^U!_PD_P )?&7PEU"XW77A>Y&NZ2C-R;2X(2=%']V.8*Q][JOJ?$G*_;Y?
M'%Q6M)Z_X9:/\;?B?*^&N:>PS"6$D_=JK3_%'5?A?\#]3***\5_X* ?M<W'[
M#_[,FL?$2W\):AXQ_LN6*%K2VF6%+<2-L6:9R"5B#E5)56.77@#+#\/PV'J8
MBK&A25Y2:26VKVWT/W+$XBGAZ4J]5VC%-M[Z+?;4]DU#4;?2+":ZNIX;6UMD
M,LTTKA(XD R69CP !R2>E,T;6;/Q'I%KJ&GW5M?6%]"EQ;7-O*LL-Q$X#*Z.
MI(964@@@D$$&OYI/VTO^"HOQ?_;HOYH?%GB!K#PT7W0^'=)W6VFQX.5WIDM,
MPZ[I68@YQM'%?1W_  2?_P""Y=U^R#X7L_AW\3+/4?$'@&U;;IFH6F)+[0E8
MY,>QB/.@!.0,AD&0NX;4'W^*\-\?1P?MXR4JG6"[>3>[\K>C9^?X7Q*R^MC?
M82BXT^DWW\UT7G?U2/W6HKY[\"_\%7OV<?B%HT=]8_&+P3:QR*&\O4[\:;,O
ML8[C8X/X5M_\/'_V?_\ HM7PM_\ "FL__CE?$RRO&Q?+*C-/_"_\C[>.:X*2
MYHUH-?XE_F>TT5XM_P /'_V?_P#HM7PM_P#"FL__ (Y45W_P4I_9\LX&D?XU
M?#%E7J(_$5K(WY*Y/Z4O[-QG_/J7_@+_ ,A_VG@_^?L?_ E_F>W5\M_MX_\
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M.UU=>JFO'J_J7_:L_8I^&O[:O@Z+1?B)X9M=:CM"S65VK-!>Z>S=3%,A#KG
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MTMQI_BKXE:3;R,6%JE]:31Q>RE[<MC_>+'WK/_XA@_@Y_P!#Y\3/^_\ 8_\
MR/7[)'Q$R9J_-+_P%GXQ+PYSI.W+'_P)'X>T5^X7_$,'\'/^A\^)G_?^Q_\
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M8J2OPC,,;/%XJIBJF\VW]_3Y;'[UEV!A@\+3PM/:"2^[K\]PHHHKC.P****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[]LSQ]\$/V(K[XW?$KQ-XD\;77B#6DT/PIH<^IO9V\H0L9[AVC7<?]7,HR"
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M#*2I!/IU<E:C4HU'2JIJ2=FGNF=="O3K4U5I-2C)736S045\[^$/V\W\5?\
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=T]_)GK8O!TL33]E65U=/MK%IK;S2"BBBN4ZC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773155744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Nov. 09, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DocumentDocumentAndEntityInformationAbstract', window );"><strong>Document Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SELLAS Life Sciences Group, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SLS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001390478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,026,476<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DocumentDocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DocumentDocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773628304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,968<span></span>
</td>
<td class="nump">$ 2,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">10,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivable</a></td>
<td class="nump">6,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceSettlementsReceivableCurrent', window );">Litigation settlement insurance recovery</a></td>
<td class="nump">474<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">651<span></span>
</td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">17,807<span></span>
</td>
<td class="nump">13,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_InProcessResearchDevelopment', window );">In-process research and development</a></td>
<td class="nump">17,600<span></span>
</td>
<td class="nump">17,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,914<span></span>
</td>
<td class="nump">1,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">1,149<span></span>
</td>
<td class="nump">925<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">38,470<span></span>
</td>
<td class="nump">33,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">8,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,238<span></span>
</td>
<td class="nump">11,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">4,683<span></span>
</td>
<td class="nump">3,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Litigation settlement payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,997<span></span>
</td>
<td class="nump">24,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">1,722<span></span>
</td>
<td class="nump">1,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrant liability</a></td>
<td class="nump">975<span></span>
</td>
<td class="nump">1,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion', window );">Contingent consideration</a></td>
<td class="nump">5,319<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,611<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">20,013<span></span>
</td>
<td class="nump">31,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; Series A convertible preferred stock, 17,500 shares designated; no shares issued and outstanding at September 30, 2018 and December 31, 2017</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 350,000,000 shares authorized, 20,501,476 shares issued and outstanding at September 30, 2018; 5,766,891 shares issued and outstanding at December 31, 2017</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">86,987<span></span>
</td>
<td class="nump">56,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(68,532)<span></span>
</td>
<td class="num">(54,185)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">18,457<span></span>
</td>
<td class="nump">2,070<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 38,470<span></span>
</td>
<td class="nump">$ 33,526<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent purchase price consideration, net of current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsPotentiallySettleableInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants potentially settleable in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsPotentiallySettleableInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_InProcessResearchDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In-process research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_InProcessResearchDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceSettlementsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy.   For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceSettlementsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6396582&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773251760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">20,501,476<span></span>
</td>
<td class="nump">5,766,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">20,501,476<span></span>
</td>
<td class="nump">5,766,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773070704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,720<span></span>
</td>
<td class="nump">$ 1,068<span></span>
</td>
<td class="nump">$ 5,116<span></span>
</td>
<td class="nump">$ 5,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,341<span></span>
</td>
<td class="nump">3,222<span></span>
</td>
<td class="nump">10,130<span></span>
</td>
<td class="nump">9,350<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses and operating loss</a></td>
<td class="num">(3,061)<span></span>
</td>
<td class="num">(4,290)<span></span>
</td>
<td class="num">(15,246)<span></span>
</td>
<td class="num">(14,429)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">2,241<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,340<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(162)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,025)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LossOnSettlementOfWarrantsLiability', window );">Loss on settlement of liability-classified warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(727)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="nump">766<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">766<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="num">(292)<span></span>
</td>
<td class="num">(360)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Total non-operating income (expense), net</a></td>
<td class="nump">2,771<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="nump">1,062<span></span>
</td>
<td class="num">(360)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Loss before income taxes</a></td>
<td class="num">(290)<span></span>
</td>
<td class="num">(4,392)<span></span>
</td>
<td class="num">(14,184)<span></span>
</td>
<td class="num">(14,789)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(290)<span></span>
</td>
<td class="num">(4,455)<span></span>
</td>
<td class="num">(14,347)<span></span>
</td>
<td class="num">(14,969)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Deemed dividend arising from beneficial conversion feature of convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,436)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation', window );">Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision</a></td>
<td class="num">(8,654)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,654)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LiabilityClassifiedWarrantsAntidilutionProtection', window );">Impact of anti-dilution protection on liability-classified warrants</a></td>
<td class="num">(491)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(491)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (9,435)<span></span>
</td>
<td class="num">$ (4,455)<span></span>
</td>
<td class="num">$ (27,928)<span></span>
</td>
<td class="num">$ (14,969)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (2.27)<span></span>
</td>
<td class="num">$ (2.75)<span></span>
</td>
<td class="num">$ (4.56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding, basic and diluted (in shares)</a></td>
<td class="nump">17,635,671<span></span>
</td>
<td class="nump">1,962,822<span></span>
</td>
<td class="nump">10,161,153<span></span>
</td>
<td class="nump">3,284,351<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the fair value of contingent purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfContingentPurchasePriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend On Conversion Of Series A Convertible Preferred Stock, Most Favored Nation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LiabilityClassifiedWarrantsAntidilutionProtection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability Classified Warrants, Anti-dilution Protection</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LiabilityClassifiedWarrantsAntidilutionProtection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LossOnSettlementOfWarrantsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss On Settlement Of Warrants Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LossOnSettlementOfWarrantsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775317472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 9 months ended Sep. 30, 2018 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Patel vs Galena biopharma, Inc</div></th>
<th class="th">
<div>Patel vs Galena biopharma, Inc </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Patel vs Galena biopharma, Inc </div>
<div>Additional Paid-In Capital</div>
</th>
<th class="th"><div>Secured Debt</div></th>
<th class="th">
<div>Secured Debt </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Secured Debt </div>
<div>Additional Paid-In Capital</div>
</th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Preferred Stock</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Additional Paid-In Capital</div>
</th>
<th class="th"><div>Convertible Notes Payable</div></th>
<th class="th">
<div>Convertible Notes Payable </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Convertible Notes Payable </div>
<div>Additional Paid-In Capital</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,766,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 2,070<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 56,254<span></span>
</td>
<td class="num">$ (54,185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
<td class="nump">6,845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">715,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PreferredStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A convertible preferred stock, net of offering costs</a></td>
<td class="nump">9,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, amount</a></td>
<td class="nump">21,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">21,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 2,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock offering</a></td>
<td class="num">(5,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature arising from Series A convertible preferred stock</a></td>
<td class="num">(4,436)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,436)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock', window );">Deemed dividend arising from beneficial conversion feature of Series A convertible preferred stock</a></td>
<td class="nump">4,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,898<span></span>
</td>
<td class="nump">499,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,802)<span></span>
</td>
<td class="nump">3,748,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ConvertiblePreferredStockDividends', window );">Convertible preferred stock dividends</a></td>
<td class="num">(487)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(487)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock as result of conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,654)<span></span>
</td>
<td class="nump">$ 825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation', window );">Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision</a></td>
<td class="nump">8,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DividendModificationOfWarrants', window );">Impact of anti-dilution protection on liability-classified warrants</a></td>
<td class="num">(491)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(491)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantExchangeAgreementsIssuanceOfCommonStock', window );">Issuance of common stock in connection with warrant exchange agreements (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantExchangeAgreementsAmount', window );">Issuance of common stock in connection with warrant exchange agreements</a></td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodSharesPrefundedWarrant', window );">Issuance of common stock upon exercise of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,524,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,501,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2018</a></td>
<td class="nump">$ 18,457<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 86,987<span></span>
</td>
<td class="num">$ (68,532)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ConvertiblePreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock Dividends</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ConvertiblePreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DividendModificationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend, Modification Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DividendModificationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DividendOnConversionOfSeriesAConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend On Conversion Of Series A Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DividendOnConversionOfSeriesAConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend On Conversion Of Series A Convertible Preferred Stock, Most Favored Nation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PreferredStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock Issued During Period, Value, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PreferredStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedDuringPeriodSharesPrefundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Pre-funded Warrant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedDuringPeriodSharesPrefundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantExchangeAgreementsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Exchange Agreements, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantExchangeAgreementsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantExchangeAgreementsIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Exchange Agreements, Issuance Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantExchangeAgreementsIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=109238393&amp;loc=d3e34017-109320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109245112&amp;loc=d3e23524-113945<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773746384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net loss</a></td>
<td class="num">$ (14,347)<span></span>
</td>
<td class="num">$ (14,969)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="num">(766)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred taxes</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_GainLossOnExtinguishmentOfPayables', window );">Loss on extinguishment of payables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">3,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization of research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices', window );">Fair value of common stock issued in exchange for services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Fair value of common stock issued in connection with litigation settlements</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings', window );">Change in fair value of common stock warrants</a></td>
<td class="num">(5,340)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchaseConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">4,025<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LossOnSettlementOfLiabilityClassifiedWarrants', window );">Loss on settlement of liability-classified warrants</a></td>
<td class="nump">727<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivable</a></td>
<td class="num">(6,600)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(538)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable', window );">Litigation settlement insurance recovery</a></td>
<td class="num">(474)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(4,453)<span></span>
</td>
<td class="nump">377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(25,867)<span></span>
</td>
<td class="num">(9,247)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Net proceeds from issuance of Series A convertible preferred stock and common stock warrants</a></td>
<td class="nump">9,647<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">21,564<span></span>
</td>
<td class="nump">6,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(487)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments on long-term debt</a></td>
<td class="num">(7,525)<span></span>
</td>
<td class="num">(353)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">23,199<span></span>
</td>
<td class="nump">5,654<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents</a></td>
<td class="num">(2,668)<span></span>
</td>
<td class="num">(3,593)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period</a></td>
<td class="nump">12,750<span></span>
</td>
<td class="nump">5,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period</a></td>
<td class="nump">10,082<span></span>
</td>
<td class="nump">2,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Cash received during the periods for interest</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the periods for interest</a></td>
<td class="nump">321<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity', window );">Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock recorded as issuance cost</a></td>
<td class="nump">5,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Repayment of interest and principal on long-term debt through issuance of common stock</a></td>
<td class="nump">3,587<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock', window );">Reclassification of warrant liabilities upon exchange for shares of common stock</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_IncreaseDecreaseInFairValueOfWarrantLiability', window );">Impact of anti-dilution protection on liability-classified warrants</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges', window );">Debt issued in connection with warrant exchange agreements</a></td>
<td class="nump">$ 966<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of common stock warrants issued in connection with various equity financings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfContingentPurchaseConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of contingent purchase consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfContingentPurchaseConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock warrants issued in exchange for services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants issued in connection with common stock recorded as a cost of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_GainLossOnExtinguishmentOfPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Extinguishment Of Payables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_GainLossOnExtinguishmentOfPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_IncreaseDecreaseInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Fair Value Of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_IncreaseDecreaseInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LongtermDebtIssuedInConnectionWithWarrantExchanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt Issued In Connection With Warrant Exchanges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LongtermDebtIssuedInConnectionWithWarrantExchanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LossOnSettlementOfLiabilityClassifiedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss On Settlement Of Liability Classified Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LossOnSettlementOfLiabilityClassifiedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification Of Warrant Liabilities Upon Exchange For Shares Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in insurance settlements receivable, which are amounts due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. The expectation is that such reimbursement will be received within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3337-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764436544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"> Organization and Description of Business</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Overview</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">SELLAS Life Sciences Group, Inc. (the "Company," or &#8220;SELLAS&#8221;) is a late-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapeutics for a broad range of indications. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Merger of Galena Biopharma, Inc. and SELLAS Life Sciences Group Ltd.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As used in this quarterly report on Form 10-Q, the words the &#8220;Company,&#8221; and &#8220;SELLAS&#8221; refer to SELLAS Life Sciences Group, Inc. and its consolidated subsidiaries following completion of the business combination with Galena Biopharma, Inc., a Delaware corporation ("Galena"). This business combination is referred to as the Merger. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;29, 2017, Galena completed the Merger with SELLAS Life Sciences Group, Ltd., a privately held Bermuda exempted company ("Private SELLAS"), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of August&#160;7, 2017 and amended November&#160;5, 2017 (the "Merger Agreement"), among the Company, Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc., Galena Bermuda Merger Sub, Ltd., and Private SELLAS. As a result of the Merger, the Company&#8217;s business is now substantially comprised of the business of Private SELLAS, and although the Company is considered the legal acquiror of Private SELLAS, for accounting purposes, Private SELLAS is considered to have acquired the Company in the Merger. Consequently, the Merger was accounted for as a reverse acquisition and the Private SELLAS financial statements became the Company's financial statements. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Immediately prior to the Merger, Galena effected a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-for-</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">30</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> reverse stock split of its outstanding common stock, par value </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. Under the terms of the Merger Agreement, Galena issued shares of its common stock to Private SELLAS&#8217; securityholders at an exchange ratio of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">43.9972</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of its common stock in exchange for each common share of Private SELLAS outstanding immediately prior to the Merger. The Company also assumed all of the restricted stock units (&#8220;RSUs&#8221;) issued and outstanding under the Private SELLAS Stock Incentive Plan #1, and all of the issued and outstanding warrants of Private SELLAS. Accordingly, such RSUs will now be settled in, and such warrants now are exercisable for, shares of the Company&#8217;s common stock. Accordingly, immediately after the Merger, there were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,766,891</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the Company&#8217;s common stock outstanding, with the former Private SELLAS securityholders owning </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">67.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the Company&#8217;s fully diluted common stock, and the Company&#8217;s pre-Merger securityholders owning the remaining </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The number of shares and per share amounts of common stock in the accompanying condensed consolidated financial statements and notes to the condensed consolidated financial statements have been restated to give retroactive effect to the common stock conversion ratio and reverse stock split for all periods presented, including common stock options, RSUs, and common stock warrants. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Upon completion of the Merger, the Company&#8217;s name changed from &#8220;Galena Biopharma, Inc.&#8221; to &#8220;SELLAS Life Sciences Group, Inc.," the Company&#8217;s financial statements became those of Private SELLAS and the Company's common stock began trading on The Nasdaq Capital Market under a new ticker symbol &#8220;SLS&#8221; on January&#160;2, 2018.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759336032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidationBasisOfAccountingTextBlock', window );">Liquidity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has not generated any revenues, including from product sales, and has funded operations primarily from the proceeds of sales of its equity interests and convertible notes, as well as through the Merger. Substantial additional financing will be required by the Company to continue to fund its research and development activities. No assurance can be given that any such financing will be available when needed or that the Company&#8217;s research and development efforts will be successful. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On July 16, 2018, the Company closed an underwritten public offering (the "July 2018 Offering"), issuing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,845,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,675,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> pre-funded warrants exercisable for shares of common stock and accompanying common stock warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,520,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share and accompanying common stock warrant. The pre-funded warrants and accompanying common stock warrants were sold at a combined price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.0999</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per pre-funded warrant and common stock warrant. Each common stock warrant sold with the shares of common stock and pre-funded warrants represents the right to purchase one share of the Company&#8217;s common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. The common stock warrants are exercisable immediately and will expire on July 16, 2023, five years from the date of issuance. The pre-funded warrants are exercisable immediately, have an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share, and will expire on July 16, 2023, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years from the date of issuance. The net proceeds to the Company from the July 2018 Offering, after deducting the underwriting discounts and commissions and other estimated July 2018 Offering expenses, and excluding the exercise of any warrants, were approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to the proceeds from the July 2018 Offering, on March&#160;7, 2018, the Company entered into a definitive securities purchase agreement to issue shares of its Series A convertible preferred stock (&#8220;Series A Convertible Preferred&#8221;) and warrants to purchase shares of its common stock in a private placement transaction to a select group of institutional investors. The sale of the aggregate </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,700</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of Series A Convertible Preferred and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.5</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> year warrants to acquire an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,383,631</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.59</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share closed in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">two</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> tranches and resulted in aggregate gross proceeds to the Company of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company closed the first tranche for approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> gross proceeds on March&#160;9, 2018. The Company closed the second tranche of the remaining </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> gross proceeds on May 1, 2018, following the receipt of necessary stockholder approval. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third parties and other strategic alliances and business transactions. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company currently does not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with third parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently, consider various other strategic alternatives, including a merger or sale of the Company, or cease operations. If the Company engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development process. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has evaluated the guidance of Accounting Standards Codification ("ASC") 205-40, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Presentation of Financial Statements - Going Concern</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year from the date its financial statements are available to be issued. The Company has prepared its condensed consolidated financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its potential product candidates, which raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Various internal and external factors will affect whether and when the Company&#8217;s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company&#8217;s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company&#8217;s financial condition and future operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the Company had cash and cash equivalents of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, restricted cash balance of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, other receivable of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (received in November 2018), and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in litigation insurance recovery (received in October 2018). In addition, the Company had outstanding accounts payable and accrued expenses of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$11.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and indebtedness of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company expects its existing cash as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, including amounts received in October and November 2018, will enable the Company to fund its operating expenses and capital expenditure requirements through March 2019.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidationBasisOfAccountingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the liquidation basis of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=35686142<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiquidationBasisOfAccountingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764434656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis Of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Basis of Presentation and Significant Accounting Policies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Basis of Presentation </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the ASC and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Principles of Consolidation </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The condensed consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Unaudited Interim Results </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company's annual consolidated financial statements and the notes thereto included in its Annual Report on Form 10-K for the year ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which was filed with the Securities and Exchange Commission ("SEC") on April 13, 2018 (the "2017 Annual Report"). The accompanying condensed consolidated financial statements at&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;and for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and 2017, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> have been derived from the audited financial statements as of that date.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Preferred Stock</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&#8217; equity.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Convertible Instruments</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that feature conversion options. The accounting standards require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company also records, when necessary, deemed dividends for the intrinsic value of the conversion options embedded in preferred stock based upon the difference between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred stock.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements Pending Adoption</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Improvements to Nonemployee Share-Based Accounting</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The ASU supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees. As a</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (1) liability-classified nonemployee awards that have not been settled as of the adoption date and (2) equity-classified nonemployee awards for which a measurement date has not been established. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2019 and interim periods within those years. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">, Leases</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In July 2018, the FASB issued ASU 2018-10, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and No. 2018-11, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842) - Targeted Improvements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The new standard establishes a right-of-use</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> or ROU</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the potential impact of the adoption of the new standard on the consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In August 2018, FASB issued ASU 2018-13, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU 2018-13 modifies, adds and removes certain specific the disclosure requirements on fair value measurements in Topic 820</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> The amendments in ASU 2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date.  Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of the new standard on the consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements Adopted</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU No. 2016-18 requires that restricted cash be included&#160;with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the statement of cash flows.&#160;In accordance&#160;with ASU No. 2016-18, the Company adopted this standard in the first quarter of 2018. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's condensed consolidated balance sheets to the total of the amount presented in the condensed consolidated statements of cash flows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,968</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,431</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total cash, cash equivalents, restricted cash, and restricted cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,082</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In connection with the Company's Senior Secured Debenture described in Notes 7 and 8, the Company was required to maintain a minimum of the lesser of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$18.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> or the outstanding principal amount of unencumbered cash in a restricted account. Any funds in the restricted account in excess of the outstanding principal balance were to be transferred to the Company's unrestricted account to fund its ongoing operations. As of December&#160;31, 2017, the Company maintained </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of cash and cash equivalents in a restricted account. The Senior Secured Debenture was deemed to be no longer outstanding as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In addition, the Company maintained </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and December 31, 2017, respectively, on hand with the Company's financial institutions as collateral for its corporate credit cards.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Scope of Modification Accounting</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU&#160;No. 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting.&#160;This guidance is to be applied prospectively to awards modified on or after the adoption date and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted. In accordance with ASU No. 2017-09, the Company adopted this standard prospectively in the first quarter of 2018. The adoption of ASU No. 2017-09 did not have a material impact on the Company's condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Reclassifications&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759375632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Acquisition</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;29, 2017, the Company completed the Merger with Private SELLAS as discussed in Note 1. The Merger was accounted for as a reverse merger under the acquisition method of accounting whereby Private SELLAS was considered to have acquired the Company for financial reporting purposes because, immediately upon completion of the Merger, Private SELLAS stockholders held a majority of the voting interest of the combined company. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following summary pro forma condensed consolidated financial information reflects the Merger with Galena as if it had occurred on January 1, 2017 for purposes of the statements of operations. This summary pro forma information is not necessarily representative of what the Company&#8217;s results of operations would have been had the Merger in fact occurred on January 1, 2017, and is not intended to project the Company&#8217;s results of operations for any future period.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Three Months Ended September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Nine Months Ended September 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(9,066</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(21,690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.92</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pro forma combined net loss includes an adjustment to reduce historical interest expense of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;for the&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three and nine months ended September 30, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively,&#160;due to the conversion of the convertible notes of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company excluded a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> impairment charge incurred by the Company and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of transaction costs related to the Merger from the pro forma financial information for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three and nine months ended September 30, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775337136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,774</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,774</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,774</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,774</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,319</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,319</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,662</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,662</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,245</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,245</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,907</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,907</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,603</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,603</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company did not transfer any financial instruments into or out of Level 3 classification during the three and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.  See Note 10 for a reconciliation of the changes in the fair value of the warrant liability for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A reconciliation of the change in the fair value of the contingent consideration liability for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> is as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Measurements</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Using&#160;Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in the estimated fair value of the contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration, September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The fair value of the contingent consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The contingent consideration relates to Galena&#8217;s acquisition of Apthera, Inc. in 2011 and the future contingent payments of up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$32.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> based on the achievement of certain development and commercial milestones relating to the Company&#8217;s nelipepimut-S ("NeuVax</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM" </sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">or "NPS") product candidate. The contingent consideration is payable at the election of the Company in either cash or shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration unless it has first obtained approval of its stockholders in accordance with Rule 5635(a) of the Nasdaq Marketplace Rules. The significant unobservable assumptions include the probability of achieving each milestone, the date the Company expects to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. The change in the estimated fair value of the contingent consideration during the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> reflects an adjusted probability and timeline for the potential approval of NPS associated with the positive interim data in the triple-negative breast cancer cohort from the prospective, randomized, single-blinded, controlled Phase 2b investigator-sponsored clinical trial ("IST") of trastuzumab (Herceptin&#174;) +/- NPS in HER2 1+/2+ breast cancer patients in the adjuvant setting to prevent recurrences that was announced on April 2, 2018.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759284928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Accrued Expenses and Other Current Liabilities</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Professional fees*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">808</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">566</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Value-added tax</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">426</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Rebates and returns of former commercial products</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">276</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">191</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,683</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,201</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">*Includes approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of legal fees incurred related to the JGB litigation as described in Note 8 that was reimbursed to the Company in November 2018 by JGB.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759275184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Debt</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Debt</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Current portion of Senior Secured Debenture</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,377</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Short-term convertible promissory notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-current portion of Senior Secured Debenture</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,611</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,988</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Senior Secured Debenture</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On May 10, 2016, the Company's predecessor company, Galena, entered into a Securities Purchase Agreement (the &#8220;Securities Purchase Agreement&#8221;) with JGB (the "Purchaser") pursuant to which Galena sold to the JGB, at a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.375%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> original issue discount, a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$25.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> Senior Secured Debenture (the "Senior Secured Debenture") and warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,333</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the Company's common stock. Net proceeds to Galena from the sale of the Senior Secured Debenture and warrants, after payment of commissions and legal fees, were approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$23.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Senior Secured Debenture originally matured November&#160;10, 2018, with accrued interest at&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;per year, payable monthly. In addition, on the maturity date of the Senior Secured Debenture (or such earlier date that the principal amount of the Senior Secured Debenture is paid in full by acceleration or otherwise) a fixed amount, which would have been deemed interest under the Senior Secured Debenture, equal to&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> was due and payable to JGB on such date in, at the option of the Company, cash and, subject to the same conditions for the payment of interest, in shares of the Company&#8217;s common stock, or a combination of cash and the Company&#8217;s common stock. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s obligations under the Senior Secured Debenture were secured under a security agreement by a senior lien on all of the Company&#8217;s assets, including all of the Company&#8217;s interests in its consolidated subsidiaries. Private SELLAS was not a party to the security agreement. Under the terms of a subsidiary guarantee agreement, each subsidiary guaranteed the performance of the Company of the Securities Purchase Agreement, Senior Secured Debenture and related agreements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:1pt;padding-left:66px;"><font style="font-family:Helvetica,sans-serif;font-size:1pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:Helvetica,sans-serif;font-size:1pt;">&#160;</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company was required to maintain a minimum of the lesser of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$18.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> or the outstanding principal amount of unencumbered cash in a restricted account. Any funds in the restricted account in excess of the outstanding principal balance were transferred to the Company's unrestricted account to fund its ongoing operations. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the Company maintained </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of cash and cash equivalents in a restricted account. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the outstanding principal balance of the Senior Secured Debenture was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In addition to the outstanding principal balance, the Senior Secured Debenture had&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of additional interest that was included in the current portion of long-term debt as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. During the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, JGB redeemed </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of outstanding principal, which the Company satisfied with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">659,529</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of its common stock and redeemed </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of outstanding principal, which the Company satisfied with cash. As a result of the redemptions during 2018, the Company transferred </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of restricted cash into unrestricted cash and cash equivalents which was used to fund the Company&#8217;s ongoing operations. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">JGB commenced a lawsuit against the Company as described in Note 8 ("JGB Action"). On September 24, 2018, JGB unilaterally issued a directive to (i) the financial institution that maintained the restricted cash and cash equivalents and (ii) the manager of the account to liquidate all assets in the restricted account. As a result of such directive, approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in cash was removed from the restricted account, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in excess of the outstanding principal balance of the Senior Secured Debenture at the time of the removal. On October 16, 2018, JGB was required to deposit the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> excess that JGB removed from the restricted account into an escrow account, as ordered by the Court in the JGB Action, pending resolution of the dispute between the Company and JGB.  On October 23, 2018, the Court entered an order, granting, among other things, the Company's Motion for Judgment seeking dismissal of JGB's amended complaint and allowing four of the Company's counterclaims to proceed to trial. As a result of the October 23rd Court order, on November 5, 2018, the parties to the JGB Action entered into a settlement agreement. The settlement agreement provides, among other things, that JGB make a one-time payment to the Company of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, representing the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> excess cash removed from the amount in the restricted account from the outstanding principal balance of the Senior Secured Debenture and reimbursement of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of legal fees incurred by the Company. The Company recognized a gain on extinguishment of debt of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> that was previously accrued in long-term debt representing an additional interest payable at maturity as the amount is no longer required to be repaid by the Company. Accordingly, the Senior Secured Debenture is no longer outstanding and the related agreements have been terminated.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Short-term Convertible Promissory Notes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the Company entered into convertible promissory notes in the principal amount of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in exchange for the surrender and cancellation of warrants to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">412,667</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of its common stock pursuant to the February 2017 offering by Galena. The convertible promissory notes accrue interest at a rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per annum and the remaining outstanding principal balance and accrued interest is due and payable in November 2018. The outstanding principal balance and accrued interest is convertible into shares of the Company's common stock at a conversion price equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$7.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In April 2018, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of outstanding principal and accrued interest was converted into </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">118,644</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> principal balance and accrued interest remains outstanding.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759293632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings, Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Legal Proceedings, Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Legal Proceedings, Commitments and Contingencies</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Legal Proceedings </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">From time to time, the Company is subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its condensed consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, when the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of the date hereof, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect the Company&#8217;s consolidated results of operations, financial position or cash flows. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s predecessor company, Galena, was involved in multiple legal proceedings and administrative actions, including stockholder class actions, both state and federal, some of which are ongoing and to which the Company are now subject as a result of the Merger. The Company is also involved in litigation matters as follows: </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On February&#160;13, 2017, putative shareholder securities class action complaints were filed in federal court alleging, among other things, that the Company and certain of the Company's former officers and directors failed to disclose that Galena&#8217;s promotional practices for Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (fentanyl sublingual tablets) were allegedly improper and that Galena may be subject to civil and criminal liability, and that these alleged failures rendered Galena&#8217;s statements about its business misleading. The actions were consolidated, lead plaintiffs were named by the Court and a consolidated complaint was filed. The Company filed a motion to dismiss the consolidated complaint. On August 21, 2018, the Company's motion to dismiss the consolidated complaint was granted without prejudice to file an amended complaint. On September 20, 2018, the plaintiffs filed an amended complaint. On October 22, 2018, the Company filed a motion to dismiss the amended complaint. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In March 2017, a derivative complaint was filed in U.S. District Court for the District of New Jersey against the Company&#8217;s former directors and Galena, as a nominal defendant. In July 2017, a derivative complaint was filed in California state court against the Company&#8217;s former directors and Galena, as a nominal defendant. In January 2018, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&#8217;s former directors, officers and employees, and the Company as a nominal defendant. In June 2018, a derivative complaint was filed in U.S. District Court for the Northern District of California against the Company&#8217;s current and former directors, and the Company as a nominal defendant. The plaintiff in the June 2018 case voluntarily withdrew his complaint from the U.S District Court of the Northern District of California and on August 27, 2018 refiled the complaint in the Court of Chancery of the State of Delaware. These complaints purport to assert derivative claims for breach of fiduciary duty on the Company&#8217;s behalf against the Company&#8217;s former directors and, in certain of the complaints, the Company&#8217;s current directors, and the Company&#8217;s former officers and former employees, based on substantially similar facts as alleged in the putative shareholder securities class action complaints mentioned above. The March 2017, July 2017, and January 2018 lawsuits are currently stayed pending resolution of motions to dismiss in the referenced securities class action. On October 29, 2018, the defendants in the August 2018 lawsuit notified the plaintiff of its intent to file a motion to dismiss the lawsuit.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:Helvetica,sans-serif;font-size:1pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In April 2017, a putative stockholder class action, captioned Patel vs. Galena Biopharma Inc. et. al, was filed in Delaware state court seeking relief under Section&#160;225 of the Delaware General Corporation Law ("DGCL") and alleging breaches of fiduciary duties by Galena&#8217;s former board of directors and former interim chief executive officer regarding the proposals to amend Galena&#8217;s certificate of incorporation to increase the amount of authorized shares of common stock and effectuate a reverse stock split at the July 2016 and October 2016 stockholder meetings, respectively. On June&#160;2, 2017, an amended verified complaint was filed along with a motion to expedite the proceedings. On June&#160;20, 2017, the Court consolidated the claims into In re Galena Biopharma, Inc., C. A. No. 2017-0423-JTL. On July&#160;24, 2017, Galena entered into a binding settlement term sheet, involving</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">payment of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$50,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in cash and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1,250,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in unrestricted shares of common stock. The Court enforced the settlement term sheet on November&#160;30, 2017. On February&#160;22, 2018, the plaintiff filed his brief in support of the settlement as well as his request for attorneys&#8217; fees and an incentive award. On June 14, 2018, the Court entered an Order and Final Judgment approving the settlement and awarding attorneys&#8217; fees to the plaintiff. All obligations related to the Order and Final Judgment were satisfied in full by the Company in June 2018. In October 2018, the Company received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> from its insurance carrier for previous amounts paid by the Company in excess of its deductible. The amount is recorded as a litigation insurance recovery as of September 30, 2018 in the Company's condensed consolidated balance sheet.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On or about April 9, 2018, JGB filed a lawsuit in the U.S. District Court for the Southern District of New York (the "Court") captioned JGB (Cayman) Newton, Ltd. v. Sellas Life Sciences Group, Inc., et al., Case 1:18-cv-3095 (DLC) (the "JGB Action"). The complaint in the JGB Action asserted claims under state law and federal securities law against the Company, the Company's Chief Executive Officer, Angelos M. Stergiou, M.D., ScD h.c., and the Company's former Interim Chief Financial Officer, Aleksey N. Krylov. On or about May 2, 2018, JGB filed an amended complaint, adding as defendants Jane Wasman, Stephen Ghiglieri, David Scheinberg, M.D., Robert Van Nostrand and John Varian, each of whom is a member of the Company's Board of Directors. On May 18, 2018, the Company filed an answer to the amended complaint and filed </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">seven</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> counterclaims. On June 18, 2018, the Company filed a motion for judgment on the pleadings and a motion to dismiss the amended complaint. On July 6, 2018, JGB filed a motion for partial judgment on the pleadings and motion to dismiss all of the Company's counterclaims. On September 24, 2018, without any prior written notice, JGB unilaterally directed that all of the funds, approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in cash, be removed from the restricted account, an amount in excess of the outstanding principal balance of the Senior Secured Debenture.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On October 23, 2018, the Court entered an Opinion and Order, granting, in full, the Company's motion to dismiss JGB's amended complaint and allowing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">four</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the Company's counterclaims to proceed to trial. Following the October 23 Opinion and Order of the Court, the parties to the JGB Action entered into a settlement agreement on November 5, 2018. The settlement agreement provides, among other things, that JGB will make a one-time payment to the Company of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, inclusive of the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> excess amount removed from the restricted account. The entire settlement amount was recorded as an other receivable as of September 30, 2018 in the condensed consolidated balance sheet as of September 30, 2018 and the amount was received in November 2018. The Company offset approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of legal fees incurred during the three months ended September 30, 2018 previously recorded in general and administrative expense in the condensed consolidated statement of operations with proceeds from the settlement and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> legal fees incurred subsequent to September 30, 2018 recorded as an accrued liability in the condensed consolidated balance sheet. The Company recognized a gain on extinguishment of debt of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> that was previously accrued in long-term debt for an additional interest payable at maturity as the amount is no longer payable by the Company. The settlement agreement also provides for the termination of the Senior Secured Debenture and all ancillary agreements, including the security agreement covering the Company's assets as well as a release of all security interests in the collateral.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759375632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Stockholders&#8217; Equity</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Preferred Stock</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has authorized up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;shares of preferred stock, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;par value per share, for issuance. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Series A Convertible Preferred </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On March&#160;7, 2018, the Company entered into a securities purchase agreement with investors, pursuant to which the Company agreed to sell to the investors, in a private placement pursuant to Rule 4(a)(2) and Regulation S under the Securities Act, an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,700</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the Company&#8217;s newly-created non-voting Series A Convertible Preferred, and warrants to acquire an aggregate </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,383,631</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the Company&#8217;s common stock, par value </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share at an aggregate purchase price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Series A Convertible Preferred was initially convertible into </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,844,835</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock based on an initial conversion price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.80</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">At the first closing of the Series A Convertible Preferred on March&#160;9, 2018, the Company issued an aggregate </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,987</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of Series A Convertible Preferred and warrants to acquire </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">774,186</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock for aggregate gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The second closing of the remaining </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,713</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the Series A Convertible Preferred and warrants to acquire </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">609,445</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of its common stock, for aggregate gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, occurred on May 1, 2018 following receipt of stockholder approval. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In the event of a "qualified offering," as defined in the securities purchase agreement, holders of the Series A Convertible Preferred (the "Series A Holders"), had the right to exchange their shares of Series A Convertible Preferred for the same securities sold in a qualified offering on a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> for </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> basis based on the stated value of their shares of Series A Convertible Preferred under the most favored nation provision. On July 16, 2018, following consummation of the July 2018 Offering, which was deemed a qualified offering as described below and also in Note 2 above, the Series A Holders exchanged an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$7,871,186</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of stated valued and accrued but unpaid dividends on their Series A Convertible Preferred for an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,748,184</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the Company&#8217;s common stock and warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,748,184</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the Company&#8217;s common stock. Following such exchange there are no shares of Series A Convertible Preferred issued and outstanding. The warrants have an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share and a term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years. The fair value of the common stock and warrants to purchase shares of common stock exceeded the carrying amount of the Series A Preferred by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and that amount is recorded as a deemed dividend in the condensed consolidated statements of operations during the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three and nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> as it represents a transfer of value from the common stockholders to the preferred investors. Since the Company does not have accumulated earnings, the deemed dividend is taken from additional paid-in capital. This one-time, non-cash charge impacted net loss attributable to common stockholders and loss per share for the three and nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, pursuant to the terms of the warrants, the exercise price of the warrants issued to the investors in March 2018 and May 2018 was adjusted to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share from the original exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.59</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. The Company recognized the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> increase to the fair value of the warrant liability as a result of the adjusted stock price as a deemed dividend in the condensed consolidated statements of operations during the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three and nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. This one-time, non-cash charge impacted net loss attributable to common stockholders and loss per share for the three and nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Series A Convertible Preferred generally had no voting rights. However, for so long as any shares of Series A Convertible Preferred were outstanding, the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Convertible Preferred was required to: (a)&#160;alter or change adversely the powers, preferences or rights given to the Series A Convertible Preferred or alter or amend the Certificate of Designation, (b)&#160;authorize or create any class of stock ranking as to dividends, redemption or distribution of assets upon a Liquidation (as defined in the Certificate of Designation) senior to, or otherwise </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">pari passu</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> with, the Series A Convertible Preferred, (c)&#160;amend the Company's certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Convertible Preferred, (d)&#160;increase the number of authorized shares of Series A Convertible Preferred, or (e)&#160;enter into any agreement with respect to any of the foregoing. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary that is not a Fundamental Transaction (as defined in the Certificate of Designation), the holders of Series A Convertible Preferred were entitled to receive from the Company's assets the same amount they would have received on an as converted basis, disregarding any conversion limitations. Such amounts would have been paid on a</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">pari&#160;passu basis with all holders of common stock.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company evaluated the Series A Convertible Preferred in accordance with the provisions of ASC 815,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, including consideration of embedded derivatives requiring bifurcation. The issuance of the Series A Convertible Preferred could generate a beneficial conversion feature (&#8220;BCF&#8221;), which arises when a debt or equity security is issued with an embedded conversion option that is beneficial to the investor or in the money at inception because the conversion option has an effective conversion price that is less than the market price of the underlying stock at the commitment date. The Company recognized the BCF by allocating the intrinsic value of the conversion option, which is the number of shares of common stock available upon conversion multiplied by the difference between the effective conversion price per share and the fair value of common stock per share on the commitment date, to additional paid-in capital, resulting in a discount on the convertible preferred stock. As the Series A Convertible Preferred could have been converted immediately, the Company recognized a BCF of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> as a deemed dividend in the condensed consolidated statements of operations related to the first closing on March 9, 2018 and an additional BCF of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> as a deemed dividend related to the second closing on May 1, 2018.&#160;These one-time, non-cash charges impacted net loss attributable to common stockholders and loss per share for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Common Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company has authorized up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">350,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;shares of common stock, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;par value per share, for issuance. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On July 16, 2018, the Company closed the July 2018 Offering, issuing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,845,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,675,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> pre-funded warrants exercisable for shares of common stock and accompanying common stock warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,520,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share and accompanying common stock warrant. The pre-funded warrants and accompanying common stock warrants were sold at a combined price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.0999</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per pre-funded warrant and common stock warrant.  Each accompanying common stock warrant sold with the shares of common stock and pre-funded warrants represents the right to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">one</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> share of the Company&#8217;s common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. The common stock warrants are exercisable immediately and will expire on July 16, 2023, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years from the date of issuance. The pre-funded warrants are exercisable immediately, have an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share, and will expire on July 16, 2023, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years from the date of issuance.  The net proceeds to the Company from the July 2018 Offering, after deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants, were approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During its evaluation of equity classification for the pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock issued in the July 2018 Offering, the Company considered the conditions as prescribed within ASC 815-40, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Contracts in an Entity&#8217;s own Equity</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (&#8220;ASC 815-40&#8221;). The conditions within ASC 815-40 are not subject to a probability assessment. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do not fall under the liability criteria within ASC 480, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Distinguishing Liabilities from Equity,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> as they are not puttable and do not represent an instrument that has a redeemable underlying security. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do meet the definition of a derivative instrument under ASC 815, but are eligible for the scope exception as they are indexed to the Company&#8217;s own stock and would be classified in permanent equity if freestanding. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares of common stock for future issuance are reserved for as follows (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:84%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">September&#160;30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">434</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options reserved for future issuance under the Company&#8217;s 2017 Equity Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">381</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares reserved for future issuance under the Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted stock units</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total reserved for future issuance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,167</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764436544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock', window );">Warrants to Acquire Shares of Common Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Warrants to Acquire Shares of Common Stock</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following is a summary of the Company's warrants to acquire shares of common stock activity for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Canceled/Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expiration</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">July 2018 Offering</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">July 2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Pre-funded July 2018 Offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,675</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,525</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,150</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">July 2023</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Series A Convertible Preferred</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2017 Equilibria</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 2022</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">February 2022</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">74</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2022</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,327</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,525</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(541</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,224</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants to acquire shares of common stock consist of warrants that may be settled in cash, which are liability-classified warrants, and equity-classified warrants. During the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, a total of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">534,333</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the Galena February 2017 liability-classified warrants to purchase shares of common stock were canceled under various warrant exchange agreements. The Company issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">54,613</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of its common stock in exchange for the surrender and cancellation of warrants to acquire </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">121,667</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of its common stock and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in convertible promissory notes in exchange for the surrender and cancellation of warrants to acquire </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">412,667</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of its common stock, as described in Note 7. The fair value of the common stock and promissory notes exchanged totaled </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which exceeded the fair value of the warrant liability of the warrants canceled by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and is recorded as loss on settlement of liability-classified warrants in the condensed consolidated statement of operations for the nine months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In April 2018, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of outstanding principal and accrued interest was converted into </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">118,644</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Warrants Classified as Liabilities </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liability-classified warrants consist of warrants to acquire common stock issued in connection with previous equity financings for the Series A Convertible Preferred, Galena's February 2017 financing, and various other Galena equity financings that were assumed by the Company at the consummation of the Merger. These warrants may be settled in cash and were determined to not be indexed to the Company&#8217;s common stock. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Prior to the consummation of the July 2018 Offering, the initial exercise price of the warrants to acquire shares of common stock in connection with the Series A Convertible Preferred was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.59</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share of common stock, subject to standard adjustments for certain transactions affecting the Company&#8217;s securities (such as stock dividends, and stock splits). From the original issue date until the one-year anniversary of a qualified offering, the initial exercise price and number of warrants to acquire shares of common stock are subject to anti-dilution protection in the event of non-exempt equity issuances at a price per share lower than the then exercise price (the "Base Share Price"). Simultaneously with the consummation of each non-exempt equity issuance the exercise price shall be reduced to equal the Base Share Price. Such adjustment shall be made whenever such common stock or common stock equivalents are issued.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the condensed consolidated statement of operations as change in fair value of warrant liability. The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding (in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Strike price (per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk-free rate %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Series A Convertible Preferred</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">83.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.38</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">85.39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">888.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">85.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding (in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Strike price (per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk-free rate %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">79.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.19</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">74.05</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.09</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The expected volatility assumptions are based on the Company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">zero</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">zero</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, because the Company has </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">no</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> present intention to pay cash dividends.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The changes in fair value of the warrant liability for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants canceled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Adjustment to exercise price of warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Series A Convertible Preferred</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,039</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,558</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,305</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(524</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(778</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,039</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(524</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">975</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Warrants Classified as Equity</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company issued warrants to acquire </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">316,163</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the its common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$7.42</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share, maturing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> from issuance, to EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund on December&#160;29, 2017. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent reporting periods. The fair value of the warrants granted was&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;per share using the Black-Scholes pricing model with the fair value assumptions for the grant including a volatility of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">90.10%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, expected term of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years, risk free rate of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.20%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and a dividend rate of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock issued during the July 2018 offering are recorded in equity upon issuance as described in Note 9.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for freestanding option contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock. Includes disclosure on the strike price and the number of shares to which the contract is indexed, the settlement date or dates of the contract, and the issuer's accounting for the contract. If the terms of the contract provide settlement alternatives, those settlement alternatives are disclosed, including who controls the settlement alternatives, and the maximum number of shares that could be required to be issued, to net share settle the contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that could be required to be issued, the fact that a potentially infinite number of shares that may be required to be issued to settle the contract is disclosed. Disclosure also includes the contract's current fair value for each settlement alternative and how changes in the price of the issuer's equity instruments affect those settlement amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229355<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759285904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Share and per share amounts below have been retroactively adjusted to reflect the exchange ratio and reverse stock split as described in Note 1. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">2017 Equity Incentive Plan </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;29, 2017, the 2017 Equity Incentive Plan was approved, and currently allows for the issuance of up to a maximum of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">575,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, not including shares subject to awards assumed in connection with certain transactions, including the Merger.  Upon the consummation of the Merger, the Company assumed approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,171</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares subject to outstanding common stock options granted under the Company&#8217;s 2016 Incentive Plan that will remain exercisable through December 29, 2018 for former Company employees and directors. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The number of shares reserved for issuance under the 2017 Equity Incentive Plan will automatically increase on January 1&#160;of each year, for a period of not more than </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years, commencing on January 1&#160;of the year following the year in which the effective date occurs and ending on (and including) January&#160;1, 2027, in an amount equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the total number of shares of common stock outstanding on December 31&#160;of the preceding calendar year. Notwithstanding the foregoing, the board of directors may act prior to January 1&#160;of a given year to provide that there will be no January 1&#160;increase in the share reserve for such year or that the increase in the share reserve for such year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. The number of shares reserved for issuance under the 2017 Equity Incentive Plan was automatically increased to approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">805,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> on January 1, 2018. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, an aggregate of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">381,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock were reserved for future grants under the Company&#8217;s 2017 Equity Incentive Plan. There were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">no</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> common stock options granted under the 2017 Equity Incentive Plan for the year ended December&#160;31, 2017. </font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:Helvetica,sans-serif;font-size:1pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of operations for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">724</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">229</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,047</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total stock-based compensation </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,267</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,776</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Options to Purchase Shares of Common Stock </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company uses the Black-Scholes option-pricing model and the following assumptions were used to determine the fair value of all its stock options granted during the nine months ended September 30, 2018:</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.73</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">80.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The weighted-average grant date fair value of options granted during the nine months ended September 30, 2018 was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.73</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. There were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">no</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> stock options granted during the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s expected common stock price volatility assumption is based upon the Company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method, which averages the contractual term of the Company&#8217;s options of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> with the average vesting term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">four years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> for an average of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">six years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">zero</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, because the Company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company accounts for forfeitures as they occur.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, there was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of unrecognized compensation cost related to outstanding stock options that is expected to be recognized as a component of the Company&#8217;s operating expenses over a weighted-average period of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.46</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes stock option activity of the Company for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">:</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted Average Remaining Contractual Term (in years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at January&#160;1, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,240.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">483</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">434</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">34.17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9.26</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options exercisable at September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">265.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The aggregate intrinsic values of outstanding and exercisable stock options at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> were calculated based on the closing price of the Company&#8217;s common stock as reported on the Nasdaq Capital Market on </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.22</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the Company&#8217;s common stock and the exercise price of the underlying stock options.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">RSUs with Time-Based and Performance-Based Conditions </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company granted RSUs subject to both time-based and performance-based vesting conditions to certain of its employees and&#160;non-employees&#160;pursuant to the 2016 Incentive Plan. These RSUs vest based on both (i)&#160;continued service either over a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-year measurement period or at the end of the required service period and (ii)&#160;the achievement of a liquidity event. The initial vesting date for these RSUs was February&#160;27, 2018. The liquidity event, as defined in the relevant RSU grant agreements, will be satisfied upon the earlier of either: (a) change of control or (b) a qualified public offering. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and December 31, 2017, there were approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> RSUs outstanding with a weighted average grant date fair value of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$52.94</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company recognizes compensation expense related to these RSUs when the liquidity event is deemed probable. As such, no compensation expense was recorded to date as the liquidity event is outside the Company&#8217;s control and not deemed probable until it occurs.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775337136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company evaluated all events or transactions that occurred after </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the condensed consolidated financial statements, the Company did not have any material subsequent events.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774551680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis Of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Basis of Presentation </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the ASC and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Principles of Consolidation </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The condensed consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Preferred Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Preferred Stock</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&#8217; equity.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Convertible Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Convertible Instruments</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that feature conversion options. The accounting standards require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company also records, when necessary, deemed dividends for the intrinsic value of the conversion options embedded in preferred stock based upon the difference between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred stock.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements Pending Adoption</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Improvements to Nonemployee Share-Based Accounting</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The ASU supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees. As a</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (1) liability-classified nonemployee awards that have not been settled as of the adoption date and (2) equity-classified nonemployee awards for which a measurement date has not been established. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2019 and interim periods within those years. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">, Leases</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In July 2018, the FASB issued ASU 2018-10, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and No. 2018-11, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842) - Targeted Improvements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The new standard establishes a right-of-use</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> or ROU</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the potential impact of the adoption of the new standard on the consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In August 2018, FASB issued ASU 2018-13, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU 2018-13 modifies, adds and removes certain specific the disclosure requirements on fair value measurements in Topic 820</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> The amendments in ASU 2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date.  Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of the new standard on the consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements Adopted</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU No. 2016-18 requires that restricted cash be included&#160;with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the statement of cash flows.&#160;In accordance&#160;with ASU No. 2016-18, the Company adopted this standard in the first quarter of 2018. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's condensed consolidated balance sheets to the total of the amount presented in the condensed consolidated statements of cash flows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,968</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,431</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total cash, cash equivalents, restricted cash, and restricted cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,082</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In connection with the Company's Senior Secured Debenture described in Notes 7 and 8, the Company was required to maintain a minimum of the lesser of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$18.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> or the outstanding principal amount of unencumbered cash in a restricted account. Any funds in the restricted account in excess of the outstanding principal balance were to be transferred to the Company's unrestricted account to fund its ongoing operations. As of December&#160;31, 2017, the Company maintained </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of cash and cash equivalents in a restricted account. The Senior Secured Debenture was deemed to be no longer outstanding as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In addition, the Company maintained </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and December 31, 2017, respectively, on hand with the Company's financial institutions as collateral for its corporate credit cards.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Scope of Modification Accounting</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. ASU&#160;No. 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting.&#160;This guidance is to be applied prospectively to awards modified on or after the adoption date and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted. In accordance with ASU No. 2017-09, the Company adopted this standard prospectively in the first quarter of 2018. The adoption of ASU No. 2017-09 did not have a material impact on the Company's condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Reclassifications&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6403650&amp;loc=d3e20905-112640<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764505808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis Of Presentation and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's condensed consolidated balance sheets to the total of the amount presented in the condensed consolidated statements of cash flows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,968</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,431</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total cash, cash equivalents, restricted cash, and restricted cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,082</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6594771056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Summary of Pro Forma Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following summary pro forma condensed consolidated financial information reflects the Merger with Galena as if it had occurred on January 1, 2017 for purposes of the statements of operations. This summary pro forma information is not necessarily representative of what the Company&#8217;s results of operations would have been had the Merger in fact occurred on January 1, 2017, and is not intended to project the Company&#8217;s results of operations for any future period.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Three Months Ended September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Nine Months Ended September 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(9,066</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(21,690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1.61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.92</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761688176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,774</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,774</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,774</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,774</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,319</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,319</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,662</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,662</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,245</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,245</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,907</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,907</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,603</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,603</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Level 3 Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A reconciliation of the change in the fair value of the contingent consideration liability for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> is as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Measurements</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Using&#160;Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in the estimated fair value of the contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent consideration, September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759272928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Professional fees*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">808</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">566</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Value-added tax</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">426</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Rebates and returns of former commercial products</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">276</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">191</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,683</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,201</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">*Includes approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of legal fees incurred related to the JGB litigation as described in Note 8 that was reimbursed to the Company in November 2018 by JGB.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764506608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Debt</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Current portion of Senior Secured Debenture</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,377</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Short-term convertible promissory notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-current portion of Senior Secured Debenture</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,611</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,988</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6658742336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock', window );">Common Stock are Reserved for Future Issuance</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares of common stock for future issuance are reserved for as follows (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:84%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">September&#160;30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">434</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options reserved for future issuance under the Company&#8217;s 2017 Equity Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">381</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares reserved for future issuance under the Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Restricted stock units</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total reserved for future issuance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,167</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock are reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockAreReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774104912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfWarrantActivityTableTextBlock', window );">Schedule Of Warrant Activity Table</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following is a summary of the Company's warrants to acquire shares of common stock activity for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Canceled/Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Outstanding, September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expiration</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">July 2018 Offering</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">July 2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Pre-funded July 2018 Offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,675</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,525</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,150</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">July 2023</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Series A Convertible Preferred</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2017 Equilibria</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 2022</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">February 2022</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">74</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2022</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,327</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,525</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(541</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,224</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock', window );">Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding (in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Strike price (per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk-free rate %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Series A Convertible Preferred</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">83.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.38</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">85.39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">888.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">85.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrant Issuance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding (in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Strike price (per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk-free rate %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">79.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.19</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">74.05</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.09</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock', window );">Changes in Fair Value of Warrant Liability</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The changes in fair value of the warrant liability for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant Issuance</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants canceled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Adjustment to exercise price of warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Series A Convertible Preferred</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,039</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,558</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena February 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,305</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(524</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(778</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Galena Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,039</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(524</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">975</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes In Fair Value Of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrant Activity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrant Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764464064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Stock-based Compensation Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of operations for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2017</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">724</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">229</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,047</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total stock-based compensation </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,267</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,776</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions for Option Grants Issued</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company uses the Black-Scholes option-pricing model and the following assumptions were used to determine the fair value of all its stock options granted during the nine months ended September 30, 2018:</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Nine Months Ended September 30, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.73</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">80.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes stock option activity of the Company for the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">:</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted Average Remaining Contractual Term (in years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at January&#160;1, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,240.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">483</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">434</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">34.17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9.26</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options exercisable at September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">265.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774192528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Description of Business (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 28, 2017 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares) | shares</a></td>
<td class="nump">5,766,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,501,476<span></span>
</td>
<td class="nump">5,766,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=gale_GalenaBiopharmaIncMember', window );">Galena Biopharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=gale_PrivateSELLASSecurityHoldersMember', window );">Private SELLAS Security Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PercentageOfFullyDilutedShareCapitalOwned', window );">Common stock ownership percentage</a></td>
<td class="nump">67.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=gale_PrivateSELLASSecurityHoldersMember', window );">Private SELLAS Security Holders | Galena Biopharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockConversionRatio', window );">Common stock conversion ratio</a></td>
<td class="nump">43.9972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=gale_PreMergerSecurityholdersMember', window );">Pre-Merger Securityholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PercentageOfFullyDilutedShareCapitalOwned', window );">Common stock ownership percentage</a></td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PercentageOfFullyDilutedShareCapitalOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Fully Diluted Share Capital Owned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PercentageOfFullyDilutedShareCapitalOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gale_GalenaBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gale_GalenaBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gale_PrivateSELLASSecurityHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gale_PrivateSELLASSecurityHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gale_PreMergerSecurityholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gale_PreMergerSecurityholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775969552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liquidity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Jul. 16, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 01, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 09, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 07, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares) | shares</a></td>
<td class="nump">11,520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="nump">$ 21,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,968<span></span>
</td>
<td class="nump">$ 2,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">10,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceSettlementsReceivableCurrent', window );">Litigation settlement insurance recovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember', window );">Series A- Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember', window );">Series A- Convertible Preferred Stock | First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember', window );">Series A- Convertible Preferred Stock | Second Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction | shares</a></td>
<td class="nump">6,845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction | shares</a></td>
<td class="nump">4,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 2.0999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gale_PurchaseAgreementMember', window );">Purchase Agreement | Series A Non-voting Convertible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,383,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ConvertiblePreferredStockConversionPrice', window );">Conversion price (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gale_PurchaseAgreementMember', window );">Purchase Agreement | Series A- Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ConvertiblePreferredStockConversionPrice', window );">Conversion price (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 6.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ConvertiblePreferredStockNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights Prefunded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ConvertiblePreferredStockConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ConvertiblePreferredStockConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ConvertiblePreferredStockNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ConvertiblePreferredStockNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceSettlementsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy.   For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceSettlementsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gale_FirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gale_FirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gale_SecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gale_SecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gale_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gale_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=gale_SeriesANonvotingConvertibleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=gale_SeriesANonvotingConvertibleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775487872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis Of Presentation and Significant Accounting Policies - Components of Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 24, 2018</div></th>
<th class="th"><div>May 18, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>May 10, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, restricted cash, and restricted cash equivalents</a></td>
<td class="nump">10,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,750<span></span>
</td>
<td class="nump">$ 2,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=gale_CorporateCreditCardsMember', window );">Corporate Credit Cards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gale_AmendmentAgreementMember', window );">Amendment Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentCovenantLiquidityCovenant', window );">Maximum prepayment of principle if demanded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="nump">$ 10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentCovenantLiquidityCovenant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Liquidity Covenant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentCovenantLiquidityCovenant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=gale_CorporateCreditCardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=gale_CorporateCreditCardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gale_AmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gale_AmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762091328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,066)<span></span>
</td>
<td class="num">$ (21,690)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Basic net loss per share (usd per share)</a></td>
<td class="num">$ (1.61)<span></span>
</td>
<td class="nump">$ 4.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Diluted net loss per share (usd per share)</a></td>
<td class="num">$ (1.61)<span></span>
</td>
<td class="nump">$ 4.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible notes</a></td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill and intangible assets impairment loss</a></td>
<td class="nump">5,200<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Business acquisition, transaction costs</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonrecurringAdjustmentAxis=us-gaap_AcquisitionRelatedCostsMember', window );">Historical Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Pro forma adjustments to net loss</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=84229725&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonrecurringAdjustmentAxis=us-gaap_AcquisitionRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonrecurringAdjustmentAxis=us-gaap_AcquisitionRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774806000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">$ 975<span></span>
</td>
<td class="nump">$ 1,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent consideration</a></td>
<td class="nump">5,319<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">6,774<span></span>
</td>
<td class="nump">1,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_RestrictedCashandCashEquivalentsFairValueDisclosure', window );">Restricted cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,245<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">6,774<span></span>
</td>
<td class="nump">11,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">975<span></span>
</td>
<td class="nump">1,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent consideration</a></td>
<td class="nump">5,319<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">6,294<span></span>
</td>
<td class="nump">2,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices In Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">6,774<span></span>
</td>
<td class="nump">1,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_RestrictedCashandCashEquivalentsFairValueDisclosure', window );">Restricted cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,245<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">6,774<span></span>
</td>
<td class="nump">11,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_RestrictedCashandCashEquivalentsFairValueDisclosure', window );">Restricted cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_RestrictedCashandCashEquivalentsFairValueDisclosure', window );">Restricted cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">975<span></span>
</td>
<td class="nump">1,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent consideration</a></td>
<td class="nump">5,319<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">$ 6,294<span></span>
</td>
<td class="nump">$ 2,603<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsPotentiallySettleableInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants potentially settleable in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsPotentiallySettleableInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_RestrictedCashandCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash and Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_RestrictedCashandCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration in a business combination that is classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761734368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="num">$ (162)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (4,025)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Beginning Balance Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Ending Balance Liabilities</a></td>
<td class="nump">$ 5,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gale_AptheraInc.Member', window );">Apthera, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration payable, maximum amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the fair value of contingent purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfContingentPurchasePriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration in a business combination that is classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gale_AptheraInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gale_AptheraInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774191424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">$ 2,836<span></span>
</td>
<td class="nump">$ 1,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">808<span></span>
</td>
<td class="nump">566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContractResearchPayable', window );">Clinical trial costs</a></td>
<td class="nump">583<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Value-added tax</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_RebatesAndReturnsOfFormerCommercialProducts', window );">Rebates and returns of former commercial products</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">4,683<span></span>
</td>
<td class="nump">3,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Legal fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gale_JBGLitigationMember', window );">JBG Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Legal fees</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContractResearchPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Research Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContractResearchPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_RebatesAndReturnsOfFormerCommercialProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rebates and returns of former commercial products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_RebatesAndReturnsOfFormerCommercialProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6396582&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gale_JBGLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gale_JBGLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774584688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Summary of Debt) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of Senior Secured Debenture</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">$ 8,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of Senior Secured Debenture</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,611<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Total debt</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">10,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of Senior Secured Debenture</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of Senior Secured Debenture</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term convertible promissory notes</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gale_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gale_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776333248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Senior Secured Debenture) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 05, 2018</div></th>
<th class="th"><div>May 10, 2016</div></th>
<th class="th"><div>Nov. 14, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Oct. 16, 2018</div></th>
<th class="th"><div>Sep. 24, 2018</div></th>
<th class="th"><div>Jul. 16, 2018</div></th>
<th class="th"><div>May 18, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Outstanding principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed', window );">Principal redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares', window );">Debt instrument, redemption, principal amount redeemed, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">659,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">659,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash', window );">Debt amount redeemed, settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInRestrictedCash', window );">Decrease in restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 766,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">766,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed coupon rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture', window );">Balance of restricted cash over senior secured debenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gale_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed coupon rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet', window );">Proceeds from issuance of debt and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gale_AmendmentAgreementMember', window );">Amendment Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Final payment of interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentCovenantLiquidityCovenant', window );">Debt instrument, covenant, compensating cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DepositOfRestrictedCashOverSeniorSecuredDebenture', window );">Deposit of restricted cash over senior secured debenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gale_JGBActionMember', window );">JGB Action | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture', window );">Balance of restricted cash over senior secured debenture</a></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Loss contingency, damages awarded, value</a></td>
<td class="nump">6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ReimbursementOfLegalFees', window );">Gain on reimbursement of legal fees</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance Of Restricted Cash Over Senior Secured Debenture</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_BalanceOfRestrictedCashOverSeniorSecuredDebenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentCovenantLiquidityCovenant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Liquidity Covenant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentCovenantLiquidityCovenant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentRedemptionPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption, Principal Amount Redeemed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentRedemptionPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption, Principal Amount Redeemed, Settled In Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption, Principal Amount Redeemed, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentRedemptionPrincipalAmountRedeemedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DepositOfRestrictedCashOverSeniorSecuredDebenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deposit Of Restricted Cash Over Senior Secured Debenture</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DepositOfRestrictedCashOverSeniorSecuredDebenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Long-term Debt and Warrants, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ProceedsfromIssuanceofLongtermDebtandWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ReimbursementOfLegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement Of Legal Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ReimbursementOfLegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gale_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gale_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gale_AmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gale_AmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gale_JGBActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gale_JGBActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762986208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Convertible Debt) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockSharesAcquiredinExchangeforWarrants', window );">Common stock acquired in exchange for warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Convertible Promissory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockSharesAcquiredinExchangeforWarrants', window );">Common stock acquired in exchange for warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of units (in shares)</a></td>
<td class="nump">118,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockSharesAcquiredinExchangeforWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Acquired in Exchange for Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockSharesAcquiredinExchangeforWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gale_ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gale_ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773570560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings, Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 05, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 23, 2018 </div>
<div>counterclaim</div>
</th>
<th class="th">
<div>May 18, 2018 </div>
<div>USD ($) </div>
<div>counterclaim</div>
</th>
<th class="th">
<div>Jul. 24, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 14, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 24, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gale_JGBActionMember', window );">JGB (Cayman) Newton Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LossContingencyNumberOfCounterclaims', window );">Loss contingency, number of counterclaims | counterclaim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation | Patel vs Galena biopharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LitigationSettlementIssuanceofCommonStockValue', window );">Litigation settlement with issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Amendment Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Litigation settlement insurance recovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | JGB (Cayman) Newton Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LossContingencyNumberOfCounterclaims', window );">Loss contingency, number of counterclaims | counterclaim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Loss contingency, damages awarded, value</a></td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LitigationSettlementIssuanceofCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Issuance of Common Stock, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LitigationSettlementIssuanceofCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LossContingencyNumberOfCounterclaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Counterclaims</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LossContingencyNumberOfCounterclaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3337-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21B<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=SL94080549-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gale_JGBActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gale_JGBActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gale_PatelvsGalenabiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gale_PatelvsGalenabiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gale_AmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gale_AmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6777276400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 16, 2018</div></th>
<th class="th"><div>May 01, 2018</div></th>
<th class="th"><div>Mar. 09, 2018</div></th>
<th class="th"><div>Mar. 07, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="nump">11,520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from issuance of preferred stock, preference stock, and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,647,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion (in shares)</a></td>
<td class="nump">3,748,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities', window );">Convertible preferred stock converted to other securities</a></td>
<td class="nump">$ 7,871,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_IncreaseDecreaseInFairValueOfWarrantLiability', window );">Increase (decrease) in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation', window );">Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,654,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,654,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Common stock warrant, shares to purchase</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded', window );">Exercise price (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="nump">$ 21,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gale_PurchaseAgreementMember', window );">Purchase Agreement | Private Placement First Closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsIssuedShares', window );">Warrants issued shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">774,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gale_SeriesANonvotingConvertibleMember', window );">Series A Non-voting Convertible | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,383,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from issuance of preferred stock, preference stock, and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,844,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ConvertiblePreferredStockConversionPrice', window );">Conversion price (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember', window );">Series A- Convertible Preferred Stock | Private Placement First Closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock', window );">Deemed dividend on beneficial conversion feature of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember', window );">Series A- Convertible Preferred Stock | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ConvertiblePreferredStockConversionPrice', window );">Conversion price (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 6.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember', window );">Series A- Convertible Preferred Stock | Purchase Agreement | Private Placement First Closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from issuance of preferred stock, preference stock, and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ConvertiblePreferredStockIssuedShares', window );">Convertible preferred stock issued shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember', window );">Series A- Convertible Preferred Stock | Purchase Agreement | Private Placement Second Closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from issuance of preferred stock, preference stock, and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ConvertiblePreferredStockIssuedShares', window );">Convertible preferred stock issued shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsIssuedShares', window );">Warrants issued shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">609,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion (in shares)</a></td>
<td class="nump">3,748,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="nump">4,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="nump">$ 2.0999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="nump">6,845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights Prefunded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPrefunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ConvertiblePreferredStockConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ConvertiblePreferredStockConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ConvertiblePreferredStockIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock Issued Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ConvertiblePreferredStockIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Dividend On Beneficial Conversion Feature Of Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DeemedDividendOnBeneficialConversionFeatureOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend On Conversion Of Series A Convertible Preferred Stock, Most Favored Nation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DividendOnConversionOfSeriesAConvertiblePreferredStockMostFavoredNation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_IncreaseDecreaseInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Fair Value Of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_IncreaseDecreaseInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantsIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Issued Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantsIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of convertible preferred stock that was converted to other securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gale_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gale_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gale_PrivatePlacementFirstClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gale_PrivatePlacementFirstClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=gale_SeriesANonvotingConvertibleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=gale_SeriesANonvotingConvertibleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=gale_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gale_PrivatePlacementSecondClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gale_PrivatePlacementSecondClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774377232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Common Stock are Reserved for Future Issuance) (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">19,224<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">434<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan', window );">Options reserved for future issuance under the Company's 2017 Incentive Plan (in shares)</a></td>
<td class="nump">381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan', window );">Shares reserved for future issuance under the Employee Stock Purchase Plan (in shares)</a></td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_RestrictedStockSharesReservedforFutureIssuance', window );">Restricted stock units (in shares)</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserved for future issuance (in shares)</a></td>
<td class="nump">20,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options reserved for future issuance under the Company's 2007 Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_RestrictedStockSharesReservedforFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Stock, Shares Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_RestrictedStockSharesReservedforFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776044528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock (Schedule of Warrant Activity) (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2018 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance (in shares)</a></td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted (in shares)</a></td>
<td class="nump">21,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised (in shares)</a></td>
<td class="num">(2,525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="num">(541)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance (in shares)</a></td>
<td class="nump">19,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_July2018OfferingMember', window );">July 2018 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted (in shares)</a></td>
<td class="nump">15,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance (in shares)</a></td>
<td class="nump">15,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_Prefunded2018OfferingMember', window );">Pre-funded 2018 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted (in shares)</a></td>
<td class="nump">4,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised (in shares)</a></td>
<td class="num">(2,525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance (in shares)</a></td>
<td class="nump">2,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember', window );">Series A Convertible Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted (in shares)</a></td>
<td class="nump">1,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance (in shares)</a></td>
<td class="nump">1,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_EqcWarrantsMember', window );">2017 Equilibria</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance (in shares)</a></td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance (in shares)</a></td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember', window );">Galena February 2017</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance (in shares)</a></td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="num">(535)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance (in shares)</a></td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember', window );">Galena Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance (in shares)</a></td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance (in shares)</a></td>
<td class="nump">74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightCanceledOrExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Canceled Or Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightCanceledOrExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_July2018OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_July2018OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_Prefunded2018OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_Prefunded2018OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_EqcWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_EqcWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763345856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 16, 2018 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants', window );">Shares issued for cancellation of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock', window );">Surrender and cancellation of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockSharesAcquiredinExchangeforWarrants', window );">Common stock acquired in exchange for warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ConsiderationExchangedFairValue', window );">Fair value of consideration exchanged | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="nump">$ 6.59<span></span>
</td>
<td class="nump">$ 7.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember', window );">Series A Convertible Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gale_ConvertiblePromissoryNotesMember', window );">Convertible Promissory Notes | Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockSharesAcquiredinExchangeforWarrants', window );">Common stock acquired in exchange for warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding | $</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of units (in shares)</a></td>
<td class="nump">118,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Surrendered and Canceled to Purchase Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Issued During The Period For Cancellation Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockIssuedDuringThePeriodForCancellationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockSharesAcquiredinExchangeforWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Acquired in Exchange for Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockSharesAcquiredinExchangeforWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ConsiderationExchangedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration Exchanged, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ConsiderationExchangedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gale_ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gale_ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762989776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock (Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model) (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">19,224<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember', window );">Series A Convertible Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">1,384<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price (in usd per share)</a></td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">5 years 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">83.18%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">2.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember', window );">Galena February 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price (in usd per share)</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">3 years 4 months 17 days<span></span>
</td>
<td class="text">4 years 1 month 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">85.39%<span></span>
</td>
<td class="nump">79.29%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember', window );">Galena Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price (in usd per share)</a></td>
<td class="nump">$ 888.22<span></span>
</td>
<td class="nump">$ 28.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">2 years 8 months 5 days<span></span>
</td>
<td class="text">3 years 2 months 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">85.96%<span></span>
</td>
<td class="nump">74.05%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">2.32%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrant Liability Assumptions Expected Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantStrikePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Strike Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantStrikePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantsFairValueAssumptionsExpectedVolatility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Fair Value Assumptions Expected Volatility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantsFairValueAssumptionsExpectedVolatility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Fair Value Assumptions Risk Free Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantsFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774845552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock (Changes in Fair Value of Warrant Liability) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">$ 1,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair value of warrants granted</a></td>
<td class="nump">5,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsCanceled', window );">Fair value of warrants canceled</a></td>
<td class="num">(524)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercisePriceAdjustment', window );">Adjustment to exercise price of warrants</a></td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(5,340)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember', window );">Series A Convertible Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair value of warrants granted</a></td>
<td class="nump">5,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsCanceled', window );">Fair value of warrants canceled</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercisePriceAdjustment', window );">Adjustment to exercise price of warrants</a></td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(4,558)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember', window );">Galena February 2017</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">1,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair value of warrants granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsCanceled', window );">Fair value of warrants canceled</a></td>
<td class="num">(524)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercisePriceAdjustment', window );">Adjustment to exercise price of warrants</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(778)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember', window );">Galena Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair value of warrants granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsCanceled', window );">Fair value of warrants canceled</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercisePriceAdjustment', window );">Adjustment to exercise price of warrants</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Warrant Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Fair Value [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrants Canceled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsExercisePriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrants, Exercise Price, Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsExercisePriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueofWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueofWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeriesAConvertiblePreferredWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_February2017WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_OtherWarrantIssuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774845840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock (Warrants Classified as Equity) (Details)<br></strong></div></th>
<th class="th">
<div>Jul. 16, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>year </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th">
<div>May 31, 2018 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares) | shares</a></td>
<td class="nump">11,520,000<span></span>
</td>
<td class="nump">316,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="nump">$ 7.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGrantedperShare', window );">Fair value of warrants granted, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input | year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0220<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueofWarrantsGrantedperShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrants Granted, per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueofWarrantsGrantedperShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762729440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options, grants in period, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average exercise price, granted (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Averages contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition', window );">Operating expenses weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 5 months 16 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClosingPriceOfCommonStock', window );">Closing price of the Company's common stock (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Equity instruments other than options, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Equity instruments other than options, outstanding, number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Equity instruments other than options, outstanding, weighted average grant date fair value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.94<span></span>
</td>
<td class="nump">$ 52.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Average vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Average vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gale_TwoThousandAndSeventeenEquityIncentivePlanMember', window );">2017 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,000<span></span>
</td>
<td class="nump">381,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expire from date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards', window );">Percentage increase in number of shares available for future issuance under stock based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">805,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options, grants in period, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gale_TwoThousandAndSeventeenEquityIncentivePlanMember', window );">2017 Equity Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gale_IncentivePlan2016Member', window );">Incentive Plan 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger', window );">Options assumed in merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClosingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Closing price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClosingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share Based Compensation Unrecognized Compensation Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Increase In Number Of Shares Available For Future Issuance Under Stock Based Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Merger</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gale_TwoThousandAndSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gale_TwoThousandAndSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gale_IncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gale_IncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759508000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Allocated Stock-based Compensation) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 1,267<span></span>
</td>
<td class="nump">$ 284<span></span>
</td>
<td class="nump">$ 3,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">543<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 724<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
<td class="nump">$ 3,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773161312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Assumptions for Option Grants Issued) (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.73%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">80.83%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected lives (years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775033024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Stock Option Activity) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">434<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,240.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, canceled (use per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance (usd per share)</a></td>
<td class="nump">$ 1,240.55<span></span>
</td>
<td class="nump">$ 34.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, options exercisable (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">7 years 6 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, outstanding (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Stock options activity, aggregate intrinsic value, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue', window );">Stock options activity, aggregate intrinsic value, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue', window );">Stock options activity, aggregate intrinsic value, canceled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Stock options activity, aggregate intrinsic value, ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Stock options activity, aggregate intrinsic value, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>61
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M?_C=A)TW]F#_L?%54+;PZR[D%U!+ P04    " !3A6Y-F5R<(Q &  "<)P
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M?&RZXT*R?GI0!/.KIO@#4$L#!!0    ( %.%;DV=;#Z Z@,  )D2   8
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M^/LRZ/PZY]#Q]OI]])_'X/M@GHK6;^KRK\.NV]_/L_ELYY^+U[+[7)]_\9>
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M_S6B R]E=^5'J/4?;#$DU"X</_NSF<9L,ASV\P]BRS<N?@-02P,$%     @
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ML%120^>DZ8B%.J=WR>&X#_$QX*>$T:W.)%1R-N8I&%^JG.Z"(%!0^L @<+O
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MXSV>W31FDQ%L/_\@MGSC\A=02P,$%     @ 4X5N3>QF8<.U 0  T@,  !D
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M].%E4_\;1 ]!RNXFC% 7/MAB*&A\/-Z&LYW&;#(\]O,/8LLW+G\!4$L#!!0
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M)L==?\/J)X*UYO88G*^PBW]02P,$%     @ 5(5N32\+L)5M @  /P@  !D
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M((8$\?*U2"!!0A1$]A.]0N)1F;%@F;46%,1X%F$E*522@K7@F& %"59T+9C
M!!DDR(""R%J,C-29I*D%VE$02Q)'+2S$5@N!&/L%-*#)1"&/8L=,#E,S,%-B
MNYHMJ1N@&,O"U*$'VYN]P=\,&YPM<;@!Q;,6!R"WQQDV.:,N)QXSF%=,!E!N
MES&<&"P&:Y/:<F+ZN,<3&3D4Q9/083F&\X?1 !+,\>^ X>!@Z7+C,QP=;+7
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M!I-TB@1P%+NS#)U9A@^7;37L);EJ]U62D3/)R%%*;&V.46^]D@C85AZ KJR
MT'UPA XS-ZH!-\X>\/S: N?!,0?0X2*U_M,&U"TWDG>OO8^#SIE98+;7-Q[W
M,GHLA7+9B;:WZEQ?JE9\ <9+X(BOP/BUN3,O\LT5_@.Q?5YR;T.%/.GU>;RC
M5&#I/GR1.^8@OQK:"<$[H88#.6;-U=E,!*W,9T'0?IO,_@-02P,$%     @
M5(5N32PYJ%MH @  @P@  !D   !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
ME9;;CMHP$(9?)<H#;.PX)U! *E15*[42VJKMM0%#HDWBU#:P??O:3HC GE3J
M#3[DGYEO)F:<\L;%FZP84\%[VW1R%59*]<LHDH>*M52^\)YU^LF)BY8JO13G
M2/:"T:,U:ILH1BB+6EIWX;JT>SNQ+OE%-77'=B*0E[:EXL^&-?RV"G%XWWBM
MSY4R&]&Z[.F9?6?J1[\3>A5-7HYURSI9\RX0[+0*/^#E%A-C8!4_:W:3#_/
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MZC64[T5SPVP:@N_4[=EIK_#3OU!+ P04    " !4A6Y-Y=E^%34%  #\'
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MV?X?O;R75;YQ6FI7-NFO_>=ZVWY^.OU?8K2 = +R(""@5T Y ?4MH'H%P G
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M7?H8'4P94-$9V6$(KJB6J_V@8]3;]<3X>P:#^). 8DJ (DJ X'0PQ%;)\+0
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M25YC,AO3VIAE+K%(!D4R(,(SD<P1(2&IP#(YE,F!3#:3R1V9GRBC#,L44*8
M,OE,IG!E,O8\V05460"58J:R<%3$DHBQS!+*+(', B<0*<8D#:]!X2%-!%3A
M%'0_V]2C F%[%!10AE/0NS7-*/<M":92R(!*G()"YH/1%8C=>2$*%UZ?"F97
M('CGA2A<>O]OU3"^ O&[]*3 :(KB [6(N1,(/*<67?)\JXJQ$X@[IQ:7C@KG
MA>==19A.2@-*<0H*?"L2AI@0Q/-RI&"("4-,".)Y.9(+,8G,)X09)L P^U)@
M0(G#JY$P?83HFU<CN?3Y!HK)(T3>O!K)M4XA%QZS(<PG(>]TJM$U3]]T,,(4
MXIT$S-,_'4PQ 8I]+B\QG_(#[BDQ>#+$/:4+GA2Y1P>C)T/\4[KH>1Z>]/RC
M#?%.&>R=$J,ID7?.2T2ZWNE?,\RO!/RR[_%B.&7^@0K!V$F$G5,A+G99[OG_
M+3%X$H'G5$BP=TI,G43>Z52(ZYT>%<9@,C+.N9TQ,,Y,>GR3,;Z,\)V7(@-\
M??L\3"\#>MFSBV.,)G]DM^G9;@;M-UWN%KZ'A['CD!TG!]LF8S(Y9,/)KFWZ
M5#"\'++?9+#A]+RI&+/+(:;)+KO%W#*3N_.51G4'>[+41UM];NVQUEWK[?3J
MD>SYS'_AUZ.OW\ON4+5]]**-T8T]B]EK;=0PE/33,(BC*G>WFUKMS7A9#-?=
M]<CI>F/T:3I.2VYG>IM_ 5!+ P04    " !4A6Y-#G5-ISD#  "3#0  &0
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MJMIM?UOI.U(T]B86#M?!U3]02P,$%     @ 5(5N38R=]8IL P  >1   !D
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M&-L9> [4WKG"UGCZ[6M+5^Z>=+3Z,K_)X:5ELLV^Z/<"VOAS5M/MT?K")=R
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MD*\SSU?!(SJR+*S^,UI]E:EJC9*<AO*8/&@%R;7(#.0:$TU+$:28D]$ 9A;
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M>JC3I I6?# K:4B(>!7JB2?5S0D>58IS^/C^<X*\:YFOF/#-T4Y U&OR7 '
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M8)A]GSO^"_U&!0+BK7BF]J^K )_+SZJ\@ZI=8@$IX[;#[]0*D%5)5G93L";
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M/R )CF9S/X#LSQ:I7@BIFGVS!?;6+RG\B0V/Y.SN!9#5OU^OK"EE%*AJR$&
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MH9-JOLFV6ZR^C4*;MK.3'=Y.N$9T^'5NC$"1E45/NI8=#CYE9S:'[SQL=K/
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MJAO#I("VC96#A50708Z9$JEY^/!GC!Z-&CQ^+?CQ:\&/?XZ"'X'@8&+[HJ?
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MOZZ[QDR!?3CM: T'+$L/%($.H:<ENSX4P>>3@-[:-6;*Q _>C^?EM[ )HT"
M5AB[&MJ7))JR?X"H$M%4]V6!?+6,DB9:$.EO7WT?VNKMLA<]#)4FE7X_*W1Z
MR7O;0E]9J?3[#/S??@73O1 (>U2T?5)=9+F[S1+]Y<2O;$=#!AUAC=FO:,C?
MZZ\<EXVM<&A;M8:G\*7CU%2Y]P@NSF9&49UG[F52MMB%#AN7YTF+C^=<>IYT
M]_QW.R;MD![=!\3U&BIPDS3)='N%;N^>,S>"(_,-VFRQ?SRAI3;;R!.:RCMM
M&D]IT)"V:>W[IMG^_O\#4$L#!!0    ( %2%;DWW!%KO7 (   <-   -
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M8^S/=GA_K_3M6JE;]KVNI!E'.VOW%X.!*790<_.7VH/$*QNE:VXQJ;<#L]?
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M+GAM;%!+ 0(4 Q0    ( %.%;DUZK]8@[@   "L"   1              "
M 9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( %.%;DV97)PC$ 8
M )PG   3              "  ;8"  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ 4X5N3:ZF%IE\ @  X0@  !@              ( !]P@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( %.%;DV=;#Z Z@,
M )D2   8              "  :D+  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    " !3A6Y-KS$$;4D"   ;"   &               @ ')
M#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 4X5N3<"4
MB $\!   910  !@              ( !2!(  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( %.%;DV1-&3%G@0  #46   8
M  "  ;H6  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !3
MA6Y-)_^FRX\$  #S%@  &               @ &.&P  >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ 4X5N3136YGRT 0  T@,  !@
M         ( !4R   'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( %.%;DV';\2BL0$  -(#   8              "  3TB  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !3A6Y-GY@=M[@!  #2 P
M&               @ $D)   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ 4X5N33YF+*"S 0  T@,  !D              ( !$B8  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !3A6Y-:A/]KK0!
M  #2 P  &0              @ '\)P  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( %.%;DWL9F'#M0$  -(#   9              "
M ><I  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ 4X5N
M3:O,WUZS 0  T@,  !D              ( !TRL  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    " !3A6Y-/X45X+0!  #2 P  &0
M        @ &]+0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( %.%;DUM8Y0SM $  -(#   9              "  :@O  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ 4X5N30^H5C>U 0  T@,
M !D              ( !DS$  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    " !3A6Y-B!0E<[0!  #2 P  &0              @ %_,P
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( %.%;DV0(OS/
MM0$  -(#   9              "  6HU  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ 4X5N35_7#8CQ 0  904  !D
M ( !5C<  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !3
MA6Y-I".&!;@!  #2 P  &0              @ %^.0  >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( %.%;DVS@VEBM@$  -(#   9
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M970R-2YX;6Q02P$"% ,4    " !3A6Y-L1,53-0!  "<!   &0
M    @ $;10  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M %.%;DUXO5JGU0$  )P$   9              "  29'  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ 4X5N36O6;Q>& @  7 D  !D
M             ( !,DD  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    " !4A6Y-Y8BI91@$    %   &0              @ 'O2P  >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( %2%;DTP>PS"P0(
M ,X*   9              "  3Y0  !X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ 5(5N32\+L)5M @  /P@  !D              ( !
M-E,  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !4A6Y-
M(ZZ%XL\#  "&%   &0              @ ':50  >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( %2%;DUL4N,_@@(  *<(   9
M      "  >!9  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ 5(5N32PYJ%MH @  @P@  !D              ( !F5P  'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !4A6Y-AR'M8S("  "%!P
M&0              @ $X7P  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( %2%;DU0-/<['00  /P4   9              "  :%A  !X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ 5(5N3050 RA)
M @  :P<  !D              ( !]64  'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    " !4A6Y-UKECDU4#  #.#P  &0
M@ %U:   >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( %2%
M;DWEV7X5-04  /P<   9              "  0%L  !X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ 5(5N3=\DH0,! @  [P4  !D
M         ( !;7$  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
M    " !4A6Y--0XQ7;P#  #?$P  &0              @ &E<P  >&PO=V]R
M:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( %2%;DT.=4VG.0,  ),-
M   9              "  9AW  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL
M4$L! A0#%     @ 5(5N39_?)=D6 P  HPT  !D              ( !"'L
M 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " !4A6Y-P#+C
M(BT#  "F#@  &0              @ %5?@  >&PO=V]R:W-H965T<R]S:&5E
M=#0T+GAM;%!+ 0(4 Q0    ( %2%;DW9-O-,JP(  !H*   9
M  "  ;F!  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @
M5(5N38R=]8IL P  >1   !D              ( !FX0  'AL+W=O<FMS:&5E
M=',O<VAE970T-BYX;6Q02P$"% ,4    " !4A6Y-#F?,?G "   X"   &0
M            @ $^B   >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4
M Q0    ( %2%;DU)5I*\X0$   $%   9              "  >6*  !X;"]W
M;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ 5(5N34C@_C;9 @
MT@L  !D              ( !_8P  'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6Q02P$"% ,4    " !4A6Y-4\JVD$)F  !ALP$ %               @ $-
MD   >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " !4A6Y-]P1:[UP"
M   '#0  #0              @ &!]@  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( %2%;DU@HD?O-@0  -H@   /              "  0CY  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " !4A6Y-G.$P>-0!   ('@  &@
M    @ %K_0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" !4A6Y-8H^-M<0!  #_'0  $P              @ %W_P  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     .@ Z ,@/  !L 0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.10.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>154</ContextCount>
  <ElementCount>265</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/Liquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Basis Of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies</Role>
      <ShortName>Basis Of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/Acquisition</Role>
      <ShortName>Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Legal Proceedings, Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingencies</Role>
      <ShortName>Legal Proceedings, Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Warrants to Acquire Shares of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStock</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Basis Of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis Of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2303302 - Disclosure - Basis Of Presentation and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis Of Presentation and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AcquisitionTables</Role>
      <ShortName>Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/Acquisition</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/Debt</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Warrants to Acquire Shares of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStock</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Organization and Description of Business (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusinessNarrativeDetails</Role>
      <ShortName>Organization and Description of Business (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/OrganizationAndDescriptionOfBusiness</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LiquidityDetails</Role>
      <ShortName>Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/Liquidity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Basis Of Presentation and Significant Accounting Policies - Components of Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesComponentsOfCashDetails</Role>
      <ShortName>Basis Of Presentation and Significant Accounting Policies - Components of Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AcquisitionDetails</Role>
      <ShortName>Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/AcquisitionTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Debt (Summary of Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DebtSummaryOfDebtDetails</Role>
      <ShortName>Debt (Summary of Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/DebtTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Debt (Senior Secured Debenture) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DebtSeniorSecuredDebentureDetails</Role>
      <ShortName>Debt (Senior Secured Debenture) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/DebtTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Debt (Convertible Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DebtConvertibleDebtDetails</Role>
      <ShortName>Debt (Convertible Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/DebtTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2408401 - Disclosure - Legal Proceedings, Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetails</Role>
      <ShortName>Legal Proceedings, Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingencies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Stockholders' Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Stockholders' Equity (Common Stock are Reserved for Future Issuance) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity (Common Stock are Reserved for Future Issuance) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Warrants to Acquire Shares of Common Stock (Schedule of Warrant Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockScheduleOfWarrantActivityDetails</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock (Schedule of Warrant Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Warrants to Acquire Shares of Common Stock (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockNarrativeDetails</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Warrants to Acquire Shares of Common Stock (Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock (Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Warrants to Acquire Shares of Common Stock (Changes in Fair Value of Warrant Liability) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockChangesInFairValueOfWarrantLiabilityDetails</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock (Changes in Fair Value of Warrant Liability) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Warrants to Acquire Shares of Common Stock (Warrants Classified as Equity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockWarrantsClassifiedAsEquityDetails</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock (Warrants Classified as Equity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsToAcquireSharesOfCommonStockTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Stock-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Stock-Based Compensation (Allocated Stock-based Compensation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Allocated Stock-based Compensation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Stock-Based Compensation (Assumptions for Option Grants Issued) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetails</Role>
      <ShortName>Stock-Based Compensation (Assumptions for Option Grants Issued) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="gale-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Stock-Based Compensation (Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation (Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>gale-20180930.xml</File>
    <File>gale-20180930.xsd</File>
    <File>gale-20180930_cal.xml</File>
    <File>gale-20180930_def.xml</File>
    <File>gale-20180930_lab.xml</File>
    <File>gale-20180930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001390478-18-000035-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001390478-18-000035-xbrl.zip
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M6WP\\)#^CP1A7&DD)0UF_G&'A#3P\:M2:G1]J83$C_OWMXL'WN?B),)OTRU
M08%X$9DWUI.HI0&JEZ PHS1^^<M?Z1R*UJ\T@Y'@W!H(Y+@(7#$!1/$6!T?1
M' B- PGJ96Y.-8&Q^,HZ$'/XME\2(J472AF&@E&4.N9M+.B@'-?VY8I%U_JE
M=3"21MKBZY01"9RH98P4UL 3B5CQ=2  $R]_P>CJKZO?3:\N/Q=RE>3@5_"N
M7H\&V;?_S+YO\5W DB+C2' F8D6M%9X7W]54"[NJMEN_M ;&^/9V/,KU;2Y&
MI^_N9TGI#< !7(%IGL[*WHZ_ZI<O!EE_> M;#GY^&ZNDT=XR*Q$G.$1-&>-.
MEPM#/3,O7R0QD+^OU B$("*8%"L0=P"U"GX 2?PE^:J3\9^S:YAWUQMM0TML
M8045L&ODQL%".F$)4E8IQ*F*/JQ(E(Y/K4(3AS?9Q %G?1E/MEI19[EC$1M#
M=90<!)LI^-A&3M/-U;?CT56OW\]NDL+)!B_R+U2A6OGD*C0?LB^YSSZ:I8/O
M;22=#UX2)RWV,6!-K'"%F.71(D5>_O(QO'EC/KYX,_R<O?C8'V:C?C9] 02Y
MO_L_+\#<?U6%;/7SJZ!]!.:YL??3X2B;;B-SG)&1>J-(T$1A#B(825@N33 +
M+#)8KMGD?F6U5KY0?OSW22^QT,?OMY_&-UOM=*J4ILX0CPP(7\IIR<[$*IX(
M\N;C_*LKKT[?RVTFV[L!&R][]WEIVKK>]/K=5S!:LM%P#/_N@YH$U^<3;%+X
M4\.6HQ^SNUENZQ(VNUXX F_&HR]@CMW"U/H=S>5KR\96E2U[Q2LH>HH<8U8C
M8CQPH27&TLB]1DBCP"FN[-A<^V.!TO_^\M-^^!V4,DD8Y=CQV77Z(4]I>#.<
M#;_DCJ9+W9Z6Q7Q^M::??E[+L$G=J[)_W2>G\VLAJ%=)N3J^@9PJ6.80#=H#
MHTHE03?QG)S16A>=.18YW75*C'@]BKWAY+]Z-_?PCHH0+6^KY1<9!Z]';CP:
M93DQ_CZ<7?]7#W3B_72>]Q+!Y!SU@9,;MJ4L]D<%=UH5'T1(+[%5#K13- :[
MJ IIYJGR:AWW$NLCP/ZX=%'=='&@DN$?@60TDGE&#0V%%!$XVK!.%TY9A2<>
MG3H@/N%',)6*AFGPRQ1<CDF^IW9F"H=0D!YC2FR0.GA V)<J#F2XWXDI.D$[
M*%8;EI3!$V#S":PY8Z 9M,*%"0A:TW.WCA5,('S#FAX0N;RJS^9U^VL'AB2"
M$6!,E")0H2/'SA?K)@113C]HW>KP'06_KA6$?<>-$#&:")@Y\&9BL8)"6VI/
M'S_5O7X(?&1 CC"FL- ,4:MD@9^5&ML:AV)!=F301\*R:Q4!(^&=!F<0_!\P
MU"3HG0)+D#BQIG+VV8>/A^;"YEB\SWY?_/'?AS ;WOC]30J3KY@HBV?RVA33
M_ ':8*A4*4?!FF6<8:-YD,*  *,%?X".8C2N4^[HA"LTV9MA[U,J13;,=E>T
M&@N/$<TQT,0QRWP9F=".(;:SHJW#=!@,#E!3H8T&$A8S).]6.HS S)!2%SZ<
MX8$1M$X#*=5)DZ"USD@K8^/@4'+L)0<')F"$,"D( )X-JUE;[*31W[XO1.NF
ML$I) RXLCMI*BK3!N-SH%LN:1\(XWY\CFI )W[))?UB(@\7@M!B=+HK,-KF^
MJ48I%NWQ)@P[/4HD'%,*:VF!U0OYKSA'CJ\BMSPJ0*]2J*S$\2%0;X?[8&=9
M)HF,# 4;K-=:,"UT*9]UU,CRID@:7Q'1G? \$.S]^UJTX0OKQ1EH<HM4I(H2
M%EQI48/S2)HBAR>%Z1ZBFB+B%"CA$&2,*')ID2W5%=-&GSK*+>616SW! /J9
M$X-PY(1:QZ.*P,S@#FO+A9.GCN[.FHA9,*DY"TA(L$<9XUJX8GV-\B:>.L)=
M%<Y;<39&$E L$G1.T"@HL"YAD2F18&F"EW4>8NOA6A<'HYC2+A*K2!04_E/$
M? S2C!R*V<?E8^/Y8RZ%#V^RP;M)^'8WG.RA=UA(06X9H@;742.O&*=ER#MB
M01L !R]B;?TV@G4@+(XHG E1-B(JK V812L"T[*,6Y&(5!,=Z#H?GQH==I38
MT5L05!PQ;P1H)FPMFDOLX*BA#F]BXE-#?V<)[IA SG )GA1SD3(OL"Q/>C&8
MU T$$"?. OL(=4V()\#UU'L2%.P#'W@NU VR@L4F6_20-/@U_7D/40;.GN"<
M!H*"9,@S< H*ST>G_ G1I(LP:*H-*UB \R"8#V\_4ZW!XP>5RQQ6 80V%Z4Q
MZ3S:;#\_)99[B.>HM,*(XX D$]SQP&WI'CE-;=/:G@RZNTIAJI0%E(0UR&,O
M6? LE\+<..J9:T 5<R+4";'Q[J:S\4IY*CUQW@E"P,DO36=/+&\2O">#[#X2
MEO,@+,&P4QGSD@0<$<LE+!,B"M$D89F0F\R-Q\3Z ($J+F**68(;'!B)'/9U
M*<% S\0F:P-3Q0Y!@X]YSMX@ V![HT&IGF;CY5'<XL!U&RVT&J-*I^!<4X&9
M3)I3P.(6 4DK*&BF)KP(%D)VH;4#Q-VHIQ+F*SBM5,ZOQ&= WDAB0>!R"BZ[
M4%86R6?&I-/0E[^\Y__H@CA]: ]0U%_),A6CO$I0\&*.7HT%WP(+CM-11(47
MUW(^4I+'N\\F??Q+_L+*[BT(:+Y,LGRHY-JE:X>T=LX) T(I2"J)*Y.V9/1<
MN9P2XK>CT**Z7SRSWBG'F.&$!1"5$A<KHK &_MEU1<93H%D1[FQE^-<E&&W<
MCA2-T;J O"%"*LXC*HPNI<'15VT16?R*D 6P+: L@5W^YGIWPUGO9IXFF"Z3
M3+YF@SB>Q/N4'Y.4S3RC)MS>W8R_9UD^:7%"==,;;<1O+9>#640-<8@H,#^8
M!@>_0,]AHYO\>HRK<OJ D#>2(^?Y=-OB0SIQ:]W9?PRRX1]O,I@^3Y=;;H!?
MX5^CGAV.[P"PV][K4;_8/"FYRLWO -SU)K/OJV6)8+6^PNZ<)PCF:4KPUG\?
MWX"(:A#\JSRC+18$\^BU](Y2HCPJTNRDHG;%UR[3VAE]!08O::#J*@&::#3/
ME?'W22__?IV5R=&3N12]R4\JEQ'_W06^)]RSP(-CE@+X1,,N+7A$4F9L8PA%
M8%I'9C=(FW"=<Y?I_^L^^5G#4?C6ST]T/H\G^R.( V;86DRC<: -"%%*E!GQ
M3)$FBY1A4M%H.\%W8+062B E1[X>36>3^U4-L&+"C&^'(#@GW]^.9Z71NE1'
MU^-)+D0;4S KK\DGO^]][RTT48>U$)!SL ^D P$*\M)[5IR#2$IB"$>C;>68
MOGQPL#CUVRPD^8HURXP.V#JN%%):@S%7'L$&4%7U)$A238+< $H5Y(T)!V^S
M&6B0^8V,][!:M>2+XM)=J[PW/%AG71XS$(H(XGB91D,M=;739$PT6T%E'Q /
MCV*72H/]:R3X6H*#V$4HIELN!<=)0V(M YA3K ^+X@3 *.^!%MMDMU5RCC-D
MD/" @E< 'PG%*BG!G*\ELW"\BD # +L#V$5C92U#+L(_WF(E1:)V 2 )QM<S
M4Q3="<*:S[6F"_,U:03Y-(SK)=E(]0Q<^P">'_*8!JVYT=R&\J81X^O)U%5;
MLDJ[K6CS,&+.:8E_ZTWTCO1L_=Q!B;IFGV <I=5(1\<")9(15*9^,0Y\UT96
M_DH]%5G[U_(,"$M =4LNHO($!(SWVBM2&GX&&=M&6/&*ZX,3MFQ-M7L:'46<
M$QLH-LX*;@$-5Z;^!F54+66;*8DV;[@%/ < O<X+\Q3W="EK/(*_3E=,,3,8
M#)/2Z=V\[PU3DOS<\]H4CP+7SDMPICU"&$6/F!:+VU :\Z.386[]SZVX1Q8W
MZ=++<##L3;Y_A-FUMQ7.'CBA_6Q^O7,RG15N^Q'WEV3:"XFUH)@*PY71N+!4
M-,4<-YY-:R4W+4F5SL]I5< +'X\&QU\6ATRTH)!38$QR:Z1DA;]KA&"H*5C/
M9,7=/<BRO,T# ^\^_SXOJC ]A+'S%#HD"JE5C-X+$YQCC*0S:,VY9TAJ%ZJ6
MXJ*^!-E$RG7B+,BYZ@.[\==LE*=V@C0=Y/)T_D.-S\5?R6^][QAM=*87E_'7
M"'#H:XP$;!H7$>:14V:)M<&5-HT.EM4N F#%JS[GEG1X,-WD7ZFY_W(R5$,!
M*6<L8P8K0;W2SNAHL/:(4,G-<:GV(1MDMW>SN44SZ@_O>C?F-L47TP @O=V!
M?Q4=\,=I8$X(3V-,RIH;&[GG)MTOC[KF91'5CLU&Z/;%ZF,VF]WD5_5ZT^N=
M4211$T>00!%9L#(U^$1E>(A(H6HK)AZ X0JD>Z-;5Y1-WC):N9*<UW3@ AO,
MM/7.2O#NF2 "@XLOFO)B!=><Z#W17-4P/O^Q--/>C6PVRCX/^\/>S=($CUDO
MQ>CS2R_-$K?A[.:$+(.ZO=;*<!9'%A ES-@0,/8\EA4=M- !UQAN'LI;<MPA
MB'G\M4G:#.&S6QS)F+*!Z0@"W!I.4P9!&2 A#-5"=X0?=7'N .;9PV[TO^O/
MQH Q%I5*!X>]H0^.N6;@U5DJE>=48:/ H_.*":WAU]K%3[PF0G=$<DF>@LZ_
MC0=#H/(>ITRK$46PMYUEEJM(;2K 0[5!"BQOB2W30:ZC<<5T)>C9#<P#87X4
M[]QP JX@I8ARC=))%%8ZX2]5"%'HAIN?#\#_W6BY(V#_;MC^.Z]EP#82PL!S
M LU.@T<F%)$&0%'4;[$R1D4=E]V /!*.C[+V(A+)P!+ +"B, XZ>D?+N-O&H
M=OO^!.CUVW@ZB[VO8_C[V_TNY'MO"-5@R!H/_Q+@<0N*E,7*T!#!8F^[L'X@
M>!\%_ZY-8J1'DC*G.)"!6^4#F^/O'25$U(S[L\._X4+_BN5OL$R51,"O<?"X
MCA&#]V8)+'_ C-;PSZ.1#V3ZTZ#"2FQ:H)3KZT!*!D(-4 -,FL0%*A'"B1H5
M!&?G286NO> %X^#L!O#^!+*!.AIE3@6'./&B%J%_/E18<4VH\2#[L,28(1^E
M,B+M"*81-S&RFO5[OCOBL12KYS@B*@UU5KN4ILJY Z,*ZP#FE:W[$\?EJT7B
M6S;Y.NQGN9]N>U.PN 'G;#3-G_[;:)+UQU]&P_]9_=W!:[>SJE>$+/A3C'(2
M"/+*"<8<*2I(*.\CKRG9U<R5AP-\0-S_GJ4<SVQ@@.R]+T7N6/);\AG=&VZY
MQ1!'WH,_ ;ZE4E9KS\M4-N-EE"]_>4_^P7_#PA^,!)OA7A"I4I3@?6^2AR#S
MHHRU#+K7BSRBF#RT'+3=ZYNI& WS%,@!_J,+@N<UH.:WP8RKET2BU7NM#X/U
M:"AO4#06/&3G,"=8J\ $>"=EP5D;)6R3-J/K\-BN59WX;F#Z/*PW3<7BDR->
MRYENZLO\@*M(2S%IE%*>B50HT5%AJ"\O]TKNK*>P*]@_\&^8^CHYML3C"4G0
M?EEG:8N#=-1I*TC)F<=(*%Q<$M8<,Y?$ OT'^4V?"/Z'NXU6*1]F [($&^1P
M$ Z)( N7';0E8W,*L-^P/$L2;,,"P/HH.HN<($[KY) 6FD$*ZU,5:- ,ZC=^
MEOCO<)FI>GW)8 O^"5:"2&D"\$:9Q.Y=KBKY/]!O["@$F98W@'8O3BE,.OGC
MUD=BP*F4P2R2P9 C]=1)PAJ5VCH@#P'VB/=&M7=!<NQQ8-J:2*S1NC3P,-:U
MI)Y30G?G6Y3))^+"I\M 5D8A+6;E9169;EELH;V? L^'7R6T+E@/'*P852&F
MS!145M^0 6R9 R.^4BO*#/[[?CI+#MK.>Q%)BCRU,EB#A(.%LU9$(R1B1E.G
M:C4;5T+:V\-U0%2.N%.#\38(R@W78&U+I4#CS(DAB2>AME//@@X[;V'8NPXD
M%C(<[$QCI=0XY%3@/)V'GR<5'K[!65!(82VTADT-KA<#N3XG"Y+ 'K4PX!%V
M2G/%Y8J#DSS6R0 <V6GR:]]]GL=K=A8*'''EB9<8/$[ -SAB4=E2P5-:$^(<
M4=V)ZYZ =]&BM>#AIHL;H'%E )P<!>N1(@->IBE+H.FHZ]7G*>I&KJDJX1X
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M/Z;;>!2#P;VF,@:LP-RDDJ<RQ'/3GRL4:S$.+%<NQG4!LB>T78Z*M8+82%'
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MD W_R#N^!]@PL^]+0?1K.HGKV>'X#EYPFS+_-_;:L]HR+1D@#7]4.!"_"!3
MDK8><1P._3D;F_O9]7@R_)_UFU,;&3$@</&QL+#I(P=SV!O*RLN:D84F5Y_R
M>A9Y.SQ[@]W)=@9I!6:]!@<ME?)GS'E:IJ5B^/FX8#=5MMQ(:>5 W$;.,$-
M8X:1$:2\:>S42EV015!%"J%T,YM4(=D+V.YMS16X@1*9@,!=",)06QXL!)!0
M34T2".(HW1=]&+2[!"I7018(@ZH'U1 CQXKSL&AZJK#EH@GDS?3MT/_;@]U)
M:6 'Z2BVS%$PZ$'3F?(07#KPWYI,ERTH_5"XMSN H295(O7.!J$B.-P<F3('
MUQGBT)%(OL>5)2R%)9()GCP&X61$?E%!G@52K]G?)B?J]V$VPM5EVP3*K<7*
M><N=H(Z%B,O^U6#3KS?$3$N_/5R-U\=R*W?X>9@-S'1></?'NKJ#':)4("U
MNV')931E(B6VN-X:>H78^Q/T;!;FR;+*C0Z>*XUBZM*LP#>SJ#2(N=:ZJP['
M#[$P=%/I'0+"#01PT C^C65DL;R3Q@4SM>L08#:MN;\_$!6?H"9*I#'H5(F<
M*Y\.U3 U97,N&4R]3.M9+\]Q::G@PU$S93"-*'H,]M.B)!QQOI;M?R:T?"X7
MLY!!R@MOM9 Z96D;QDA9JDJ;>N>/'VUAGN[VK**<&1P]U\1S*A@MD^P5$\K4
M;. ?;6$VJ5CG240$@VN,F+2IIJXKC\@EB75;G=?*'OQ 5'Q\]DZ5?[ 6 EDI
M%/7&4%G*'7 Y9;U)V%DOSW%IJ:4"\2!X4)&Y8!%XS8N@1&I@]IBT++HYE>F.
MMZF'8G%4E W6[C!L<8$F8A2HL()K3BQ/EV9DX6@X'2+JO+ZZ"9@'0K[Q?HHS
MBJD80(*G\E;4Z5A>DE(-#$ZY6C\#V1G^AFZXB\=_'^>GMLOLQ(:&L%V!+V$\
M8<08DCI@ <<M^K :BH#O:FTJE,1Y%]8'0+@5@M58Y=_N\D(\!=G.-4<W4N6)
MIHHP)9U$6MFRW)862:DU'8\JQL!>V(+:[>0Z/+4W7D- .B JD2$H"JF<#ZSL
M2ZV9M;;Q.$,R!=B>)J8[=LDJ#J\W\8,"D:<,4XI@B[0$.1\+#\HHSTU3J/SP
M5)KFA]9EG?Z=:^()@P/A'G/.'4@.2ATN6^I%*^HU\1C1ZX<_JQ#L#%V7K);"
M>BJ"(X$8%0B.J39049H^"%9O:LP86=>@#P%O0]<89Z@P$3NO DH]5&EDA4 0
MUD1>+U:'Q'I$_('0=1(O!;*X@XTKP:AC)-A2,X!%QW M%HAYZLF\+7CI7LV2
M)Q>ZHG*A)]>*S99%5P7 0 BXN,Y&$4!%2RI@=V$2)"*I'&.]FRA7:\>1VT)V
M,&RZJO\I9X6R+O%P%, 6RK*BN8+CH#1JO1X.ALWR@8J(6;XHOP&WX>IJVP6M
M%9DUOAU.I^/)][?C69EMMI2VU^/)[/>V"UJ5U^23BX;>FZ2N ]Y%WA)K9! 2
M1Q!>9:=KH"]O+3<K7ZV3=2L2M=,5H,GFQ#]',C*P6)B55''IL'414UV$,4#H
MZM::=Z]::;@DQ\XD._'K@=19*R6CE(->I]$K7XIY*:*C]4*-G-/Z)MZ54H5#
MM_F MBINI(&M04G0F#D0YH(:1&&'4!81<[K>.@$CTB!O&L!HA_0U@ >6RBS=
MJ)_GV\">Z\- [\L&/_PT-P:0SP-94F%=IIDBR+NR.X_AW%:O'X_RFV5Y&A)O
MHV 7>0Y U!/?.H&J9$DB!/K<@\>D:2RS=3"*H868@LJ3HN>AJ"' 3=?<2\?3
MM6[G,5V>SD:#2#,U]&%),2^0,>S#=JB^I,FR8=5N8FU,9>"O@_RG@_/2BF@C
M&NQ9&\&.9<($Y1 MJW=9$;"JE0AL,J0V4N$ 9%MKPO;49/->4V92CA]73#E,
M92C%&>+1UXY,#T*V$G;P'7(9G?X\K\F<#=I,IJZ\(QL$ K"=8P;#IM'6NO)Z
M#OS?-Q0VTDK5T-@,U2'PZ,I34N#:!$53"J.4*2$[E GVJ=WR>FD+L%G%@Y$H
MZ]^L%LS9RIE<8:-H)'**@W:DS'%#*"\S&0FXNC6O#-?YJ!F256CG 9!YU?G?
M>]_>#'N?AC>YQGJ;[<@SQH*SZ#Q8;C1)#$U06=G2:.;KSCD6DJY!W G-@P#O
MO(/G'.8!+')O8P0;/;(RR4%8IAH:BDI"#@9XEOQ]^*^#'X=;5KM?"8DH!"YO
M<A:L!5/4&"Q*?Y=%59?2LAOR-7 >!OJ&> EH%B%E3#N4PZY,UPEL61.,\'K#
M&:8? /O=> J_S5O4O!V/^OLT;L2<([ A0)9X8A'2F$M4[DD?1(W6J730*L3-
M4.P':1=+<\NXU\#.PH)<-J"32F=3,,1E/=<$UXB[&=3&-C&IW^M^+5\HBC9*
M9EB@8'18I!DOXPR.A8Z6+^05D4O(-T#U4 0ZFKF XZ(BUIAR1XG%@@3*2Z*G
M\ORM"+!77#P. O7X:A6!J) GH"S!:/;4"L8C7=SQTGB]DEP% ?2*TT=#H&,%
M5%[*1 8#'C@UU+N4I5ST%2"<MH:J@(6J#M N"-S>W8R_9UG1%:0B^/=J#:NL
MP\&!'/38&A>L#N6^5=2S6#_ 7NN7LQ&<!\+>60Q34S!YG0 ="K(Q@"<ORM,Z
M''2]I3LHK@? _@/F@#,6&*@@)QE-CCW/$V;GIZ'&LEJ7RBIIM\E9^ &SMT64
ML-MT1)0S[273O+S&H#WC=98]'Y(^63H3%L%8T-Z>$1(01H8:56;K>;"P:[%;
M@5:]@$<B[)&3236X_53P=,T4:6V3I5M2@7!2<RF.3H5GDZ6;>KESPK4*WDLL
M%)*+VW*PAVO'>^=#TB<4@B%(9P+X7V L(:MD&>M1/++:S?XS(NG379M@8)BE
M"W+@@A-A"(<M7]BA2I"Z7A'KJ?Z/1-@C&RP66<>)=8Z80%/!9%2>>'I#UON4
M[DN%Q; 9_/?]-*\JL2PTNW-Z#D4!H52/*=#4N)HQ7V;C"N2XZ-H,G8 \#.*N
M*(K5F*1\,1H$00'X+M+2YPG8X!J5'P'B#5D\&'GD-;>:IPI]T5%L2HB-,4U=
M- E;3>,Y(N"=I&9.YC>'+?5:NW1YN#@1$=+"2 UP3AG:#_!?>\/1-+4!S:;O
M1N%;RKF\'TZOYQ-26+HA:96]'7_-=R1FL^L_II/9'V_ ??HRSV!.9X_+FDV_
M6M-//Z^?[]Y_FN9B8!:^PK_JIR"KXQM.0FS>Q%=BT->$&@[:A(:HHU=&:^#6
MVC'^>@1[(PT.1C!^$O2B.@H6K$%$ X5(J@B4RCAZT"04"%;;R8](KVU$ITQ9
MNC1U,>8!G%09\I(&$1OJ:'2BRYEZ!,B[]C7"F )K(J4Y"3(2%@PK(#<PTI5;
M?VS(-XA2C:CTZ1H^ S_6<TFU5W/(0;I*5:.Y7(L7/0+XG5<#?,"8@.<CK""4
M*JU$*,#WAJ-:N.MAX(_'@S^'-S>[1>0$>' V,F2!H$8& ^Y<*?-!*Y'Z!66-
M5XV8\K/;@=(58$OMDYQ&V*  OK0%R:K+(T$D93T M!,H9C1X/9KU1E]2^DX>
M]7]]>P?:ZK86!]PBI=0XB1C"Q"!FHA9,".^B(=1RY["MMV#FZTE1VT!U$"PZ
M&TEK8I24L,.(Q#%@)9C$)!BCB#/1U9*A'XS%LOEWG(QOYW>1[H&GW]T5]Y"F
MB[8J[\>3O*OR;#89?KJ?I3RKW\?IF 8F3<8W-_!(5Z))][F<\R@5STT=2W'P
M,FKJRB-%KU$M>'&%F5YK874<3)Z"5ALD6- D#]-CF_<9C4"NLOD.EXC4> 1H
M19E\$EK]WOM6Y)7;;)1]'NZNX0ES5'-%I+#(^$@Q+Z_7"6^=J-W$72NHW@+&
MOI!V*A;.DTJ7%&M!#9@A/)8.N/-:UG,1UHI"'Q+4#2J<I0OFS#O%,&=(8-AA
MHKP0@HBJ)7H<#\I.@AK+-8U"&\(5HT@8A<MZ:ZQ6+R\E=^RS]FLMI$R_G_)K
MRD32W7,CO )?S7&F+*Q[N@1=.IH:.U*_JD=E;6=V0_1 \#?0G"*%,"<2Y''$
M#'M"<2%; 'BC:^!?,<9K5'\@ I/[E9.XG9< C%+PDY'A4AHA),.IDTD1"4LU
M%VL^#=^,P!I,#\=A$^_'@%(%"'#$ @%-9P(MUL&",1#JR7!K/?X>CL3KT?1^
MDJI[?LQFLYM%%"X;?MUK7_# 3!#(DRBQB4J9(,M39A0PZRIUL2MLA\5KTP4L
M3Q5V2&AM! THY:&532B%%/5B0FRMM/)AD<OO\"X?WGWO* W2RQ#'A3+&86)]
M>3HI@0G%!LVP 9J'PKYA*3@XIDQ0QN$/*(+&4&21@ 169;W-M4 U#?P@#-Y/
M,C"Q!V626*%VP!+/7S-/:]IY16"S6\X\BT2#6Q# 4UUT&4 QF%J@X&J3.-X&
MRF/@N6'U(@F(@!LNN" ZF7S@ Q>:QX!9U5"30AT<T:Z-UY%;0UO=N> C(Q@I
M3+SQ(,F53,%F0\'!QUB[6O8>KW'D%B =!(?V:$042%.+,'@=5J5NLE24O1B]
M-Z[K^/.QP.].QTYI 19XBX)%IK&2RBVJ]N)Z?8ZZ@-X9A[DW-#<_"ZZK)0AO
MX_K@Z$"%&&^"TY%QE!BIB+U84R^$=C6_Z%4%O1F2O:'MM+I"E,H*1)S420<:
M7RIXH;1LL!RI6.?U0T*[P0/R1H&$ 0+;:%7*NY&B2&P2)IAZ<<NK&E<<&-A.
MH]PHQ\%C(P8\(&W @.)F 2SV-1:^(GI_1G@/(G.?]5?,LB MM\YR G],U14+
M^:T([PQHKWUZ)Z@VQ4ID*G!,A#!(2F*3'UG$+QV-GM>B@I3@1LHU@594OR\+
MEXP6'1CB>/(QFWP=]K/INXF[Z0UO=U?[8'EY N+)>U"'1-'4::!L"(L0ZRKR
MN1-@!\1HPU*@E*:EA!8)!6-8L+9D$.$$K>E"3-::<.R-5U[ /F:-57=.[0 S
MU?D1$E$BJ4F2U,J0#C"M)R85QJQG<:V;# MD-U.@(BAWP;P5=H:XTREJ$!@V
ML-&L!_L'8+<"=AZR-86U)>QM;O0FP\5I)D1@7@ @X*+!7BIC&<8&UU $"C.^
M>M;3XBQW0M1EB\"^U9:&&+PFD:5+!W'IH0"E&DI88[HC1.G.6-H>U^.;038I
M2H?M:/%AA97BT2CEP/1PE,4R@.)DU+6=2BE(V#8P&^%Y&.R=YIY-E2(<U0P'
M\",0>!$EB;FE=2E#51X:?SCL>]G6UAK8&QJ#@/?4(:8=*>^?!&==33T1X%#=
M!FV#+?K@_'JE0%9'9()PG. 4UD3EY08-UF;]3H_6<B?X2HE3-)?9BXI$>,N,
M4SIPI86A&)?M(@382:0>>:?K<J<%C/U [;PD):S34GI)&9%AWB^R9,^@ZJ68
MC@EDM\RWORZ'-MW:9H8Y%, A!.//4T*<2DU=#-@MSHGZR4==[F^#VGCTI2P#
ML9GF5?"X%(&G.U("9%IJL0[JJ?"CM(P-Q^GKT%6^W ;1?C=OP GQ07--6:I^
M1%!DA7'*O0&?M1:H7C\L:(!@'P!/HJ;$:KJ> 99*?KM!AG#M"9=E5!4VN*R=
M^AV%,IWW=UG4Q "S1]C+%C.O0ERJ2%IC^;5+W@<"[_06S@6$) X6U( !7>$<
M+:, &LQ9T14LVH$F^UZFC=YC38.BS!LCK'2RS+0%?D.V9AP0@7'KNC5?4-T!
MS!-</02^II6I'ZB6SH(1Q1>K!]9Q35(>D3Y=FT]JQ'CR,8*(%LP3&R,MCZ\E
MUEUG20<%\/06$&'-O1)4@-&KG0]""E?6T-"Q;J_M2)GIU)7%BOO??>^V]P5L
MY#][DT'1?^WT\UT1(20X R3QVJ.4RDA$-,B!$^ PM;5\MMH9T68B5$GV-INE
M^A?O)^.O0QBWW_\V3<4#XG#4&_7A%0GCK_N=<LO(4R?NB+S#@J6^ODZ710=#
M,/5\-\%70YC;PW8HC#8$B, GCH(8[ZS0GD4*OE!Y,U(Z%NK7^"AX&\=#J<B%
M>M BI1OA#FP7A[&S-NC(:1GST@9\^UKD5I.U3*WM@3L42ILN)#AOI/<(N0 F
MFB+@5)?G=%0*W'"3@BMQ()R6:6N['Z8$YT'S@[7-M \,5@7;LN *(%+;^"FQ
MA:]#O?S^;H!U9CX*"T(IB%1DF"(&8MLLG  <>)U%ZIF/^T*V*=$;TT@T8\"Q
MGJ9:]L2798-U(.N5#?)C!W0HN#HY,'*DM:)12!.I#];[TH<&'TILD__X,,AV
MK#3](9OU4N6FLL3#)M_'!L^C,8XB%,#&\:),A14B4%F+_.^-GOG:&][,\SDK
MW?&*6%=>?V+G7<:<L81@*T&,:>XX 4N[K*>"O=AUEVV&\-#(=4N^=&W,!.JY
M2BD95I7=>@1X?[J)[SIWZB-CMV&WRR 5$=Z!C$P1:BZE5^5%,^?J49(KS>CI
M+-VFU"##M2" 'SCMCC$9,"LCV@:OEJ@L1)G41!T,N_%H7.JVE2/8G?>7<M*!
M< A"6R603[Q8)C,$TQ#*NF)T[2BX%9;] >ZVZ9!Q6FL.YHY+J>J^['F= &Z4
MU5+IHT*\81\$YH%HJ9:5HL%3J[ M(CL"4U'/O*QKO</#VTEA#$J"$J,Y>#&@
M(+SU98$P9'G]A!LHC!7;'>)YTE0MB72OP*?7,:;V&M1JIBUH<";+]E!$FGJ)
M1*Q7PPS=L#P$ZLZCI8 Y AD"8A$%@RU;% TVX$3J>G1D+>BW(]3O&I=DGT0B
M9D)P2B9#SE#/P'8JS_.$Y(PW6!1KB43=\#P0\NXL",&<#13[@*D#QQ"5]8=X
M< T1\EI2T?$@WZ1.)>A0"[:]BV"4ZJ QQZ4E%('GZ\PB&WC\6)!WT=P3@I1R
M @>CO1.(*%%F&X%)2NM7_I!X$+=4TFN38[B//#$Q)<DGO\1$286S2I;MGB36
M]7/U=6 ;0=@7T"X10BV1GADM'4YEGY0-N.!GXX/V-<%7"S\=']R5V_3>ISI?
MWH$2-PAD!2(NA3! *RIIZXEG>X*;DJM>C_YSF%]9W._^(!<T<D[!RJ \2@:^
M:IGEZ93C=4@)7[7NZB#L"N"F704FJ/5$@U+VV(%Q3<KX _" J^=48,IV C O
MU9P2H?(<FDJN:BTF*^<-DPCK#,>^!\_VYNOT5_CS"%35^.ZZ-[GMP69>#UPO
MYB=G^'[5\WV?Y;WI.P^25P_R0P2;%O9$2)4'H]!E^6]'%&7UMI%HC4:M5&@B
MUKO/?I@"4*/!'H&]X'Q*V9%(!!:L,[1T*,#61:AF=35 6?G\SM#]_^R]>9/;
M1I(W_/?NIT!HU\]*SU)MW(<TXPB<7OFU)8TDS\3\]02:+'9C# (TCF[U?OHW
MLPH@P?MH@ V2-1%C-4D<55F9OSPJ*W-7PJABNX'GZ:8E@1&K2I[EUJV]9--:
MM534I>YWNX:8-9M8S2YA2#^+B>!YX^'AQHH&_H$'=@F,'?6F SQ1!^I4);"V
MM9T_9%RMSF=KU,"V#<VQ?;"Y03,9@:5Y==1 U31U6RO9EYG/#L,&S%]=<7TQ
MD'S3]US7=.2Z.(&)NW)]G,]6$Q,]4\LU;5'V;5%53,^J#37X-EB)<JJJLFC6
MMS.KSV'V*6,-'N@N4ET'=J<AM-A]0E8\F(4DJ;YMRF+@@0M;]P/#0.G2ZLRK
MT8HW,"=ITZ0V#:Z-Z6QM?&EJP%,F'M]R#<_1P!VO<X8U&^PEKU?3.:,NES8(
ML*\Z>F";-J@(196DV@%7P#D73T57U@#1+HO[-(O^=[GX\DYN!UM4],"6$G7;
M]PS,I-2J#%\C,,'T;TRC;L[(4L\VBN_R@)XS]*V<[5FRKNN.99NB8<J6Y1E6
M7<0!M/5"Z_>7&?H>##S/3Z \O/B272SHR:;G.F)@&QZF&,N*7C?-,W5/6R@C
M-&NT:FCM39]UW3P47AU5]A3)EDV5J3_0'74\PC3M==UA=PR8#>/8P6YE,5MQ
M-%LQ5=>39"PL"')BUSN+OF&M8[&N!GM&T"CZ:-$$>%C Q=8<OJO/*DAJCN^M
MXTO1V,67^U'N4UGD14A]I@,9TP(X,6PG %A1#!NS?>KS;&!)FPN!A3W7NC&6
M9PU[*XLZIF%:X &[@2NJCHCU >JM7%G3Q77$;F/8>S;=6PBSZPJ,#\BK^6!2
MF8;JUIE5NBB#"MK;[%W)$=IK:-N"2@!(JF>KBFT#'0W-=7V[WG3UP7_:E@ZW
M>VAX@GKMR>GC G6^H0:J90<VF-K8%\FKHZ*VKDKB2FQ148QEC;=K0,\>_S92
M6[)LR 8X<KXIVF@].=JLW8;KB2OY=;HF/6_\Z9"0$2W2M.8<\JYTGLK[^30L
M4H \_-!15ITO.SH63-75P/(#B9Y*!8T8*)+GH'NUZYC[X?/<3*6J71Z-.>[7
M3V4IE SFAZX9HJXKNN7[/DRILLM4!_!_JS!M'L?QX]T55U2M0 D"5[(TVY$\
M5\72 E6&&=A6JPV@]67O]8A!SPYB-C:_#T]@U$Q'U31$+A =1S&\.O')T@+/
M6:WL)8K+8+!C2,\<_P[*VX'GRZ8-5A8XUB(P/B8?5Q'=0/%7QB]+FJZV/8$E
M!XQ^(B@\2R=DU^ "6F/6@;:8NZF3_9JDW6@4A=G35[A[Y6F?L^@!7O<Y#H>L
M$'B4Y?#B-)\5^&[)M%O,_<6B@IKN@PA(HAD F]5[!-A82UL%[U5_ZSE+<"V+
M^97 \$:=KZ9KF(KLVAYFBX#+K(J.79L2HB6O'CICQSS/8S7EOKE(BS6C9=.0
M=,_%MI:RIZF>5O<NM&1IG<H1SX+T>UD'<N"#R6IBYCFXUAZP8+W1K%F.N,)T
M9S'GG0G?JJ3 K$4=E%K@X6SK6"%6J5VQV2U=W4=/MSGS10#J%SQ2W?8-+=K[
M-6W)%\_1BHJEN:;E2;)LRJ9H.'71/\WT[=5MN[T5U")]6J$H=L\6I9<A*=,P
M^]%4M<U L;S $CWXTPL,J[8R#<\TW./51!<T;9><F]TUWU "R?(\W[7=P%8"
MVZN2,L$[-Y<WB0X!\*U$&4?%MJ,;L\F#-LOJ=B_SGA4+[JD]_+.,\HB=&*>M
M^]PT+]9EUB\H+AN;2BNB9LDNR)>N>K(SM]CEU>.?J[.NYG# S/YYBIE9LJ<H
M7J";DF<ZAB%:=E#W00Q$QUW9Q%PN@+!^9E_(=)8(L/GX_1YJTW,M&7O9>(%B
M@@J1U*!NL^K*GN2L"*&R5%-VTT".&^PNC]I3),U47%_#VE&&[ZMURK(K.=IJ
M3PE#6VJYN]]H<X+!<.SPB6VCTBD]1G)D6KCC&Y:.G6TL654-VU)EKVZB*IFV
MM\8BT\VE(6\9SO/&O34$H*LZ=L"VG<"TT",SW+IDMF4YZLK9)TTTK).,>]?)
M*+#^5-MQ=4]T 41L0)2Z>AP S&IY K"3Q5.->WL17M\ IO9M,-M4FL0AUN%+
M'1%QA=Z2I!\][HV=Z/<]_F[#QQ']JOU#TPN>)  2B(LJ8<5H370<SYSG3%AK
M5E-<5@R;N]UOH<.'F1VE%?<+P=F7)HCF2K8ENK8N.:(,7HXJ.T9@:Y+C*+9N
M.NL+:+=$#^4KF19T>#(69&MY9J(&LNH&EHT:DI8TLOW EFQ7DP ZI95=G#9G
MUCP)3Y?[Y4_#&Q[\+S #3\2$:=FQ?!F#QI9&6Z7)*V:#M)S?NR\Y "_P'SPF
M^8 9I45N%RXX>$]@"!VQ&2>*EFO+(++@?WN:9LI.71P1])TEKHY;5!5IR\!W
M#J_MF37.AFY_V(97S/C$3;-IFH&9Z(( 1/CFT2Y;T<5:?#+V2;-T7[)-7ZD3
M^$P-B+>:*KUUS4]+NFU[<V!"J(&.I]$MR16E "E=GW(197E%MJ6E3D5]FM="
M14A)<1Q#!67M^*IM!Y)6'\S$@_7NBCVZ7+[JA>?UDJP.1IHNR9+OB< 8EBR)
MBFF#:>GY.MB7ZG+Z8,ND6SST;0^'Y:2D#IU'QM%PN1_*SDJ!JJ&(N@=>NR'9
M>N %;IT):;M@CZP>QM=4R5SV2W8-Z;D3V-I)S <'11-5'0$'_%08N5*?4S3U
M-:4P=%-3Y&=,H!$Z<M,DCT95:Z-Z=_-3@A&D/*1J=MV^^68KPG0D6[0#%T8G
MRYKN&4Z5_&_X[IKT>GE%;QXTM@V3^E@B[\.'1H+1AUUS.K!T06,O<F?>E.3I
MAHG]"51'45P/S,8Z3"QJQD*WGCJ5!Q/&-Y%EY^SZ2I5%0T7S=,LQ;$USL0BA
M!I2H2[B[LNOI%T24*EZ_BTT 8FW'-%39\%S5%/'L3.6"VAK:XFLHHNI&ZQ3Y
M#+"^+8N;'I&2],WS\!7%$BT'^!U+CMI8$L*N2\F9ZK+I/,^@EF^D]3-9&%%[
MHY:;YKZJ8]]F1?5$7P3#7_*5.K?%<;3E9J^G'7-;W*8NA#N,0)--WY!4%9C(
M<[ X=;5S91O+11J;\Q4MRSJ7&2]G5'J:@Y7#8=H!.+6.:=5IU;#VFM'JG EM
M__<S24!]8<=)>S2)D@AL)E!F#T<7N0"[Q5/P,*<NV9HLVX9>0X1N*)*YHEX5
M65ZT$_8;5TLSV1IODQ7PLWQ;T5U=UV35U>7ZX+TB2:L5S2QEZ43CZ6:R(^+I
M*L!7@0SJRS9%WPILQZJK8F#'^I7SCI*RU#[]I#/9VH9 450#(%KW=5LV/5N!
M2=2Q6]=;4RR:E6!_WE10<IPPQ\V<"?X:KBC=?=@I4#5=@J&[AABHMJ9:KF_7
MI=<LU5\QH15CJ0+%^G$<,](=1'9M50+U ARORCHZK8HY:R.H^*O'8^6EBB3'
M#K21W^(\S2^ISK/2*HT,9.?AU9RFX'Z[#Y-/4]KY%)-IP.\C(V9;;(_?T$>N
M1.'F?B,%T-]AKOF7K[_O,!9]W0ID4% B6,NBAG68:J+9OJV9_AK3:*D[P,F(
MTI.5:%JI;:Z$Y(.7:FK@PM@>J%(5=%"U$J;O: MH=V4K\0\2W=W#O_8#8-\=
M^1E-$@_,ER",LCW"G<]<I*8QZ^J!+X+J"4S=Q:+%NF+4U7AL[+ZZR=#1Y!M+
M/>E"[:19_]>P14%KKJ$?Z)[M*(JM@RH#715@J1\F9UC;>>/QWJM=P\;IIJ41
M?2&3,$I8"B@8(L.B#&-,/-A=Q/*H]9R']107''I'A =K8.MB3+KR*<$A%G7K
MU4^?E7^>8JF.($TK:S;C #O/RPD;"YJ 2+JZ&, 7X)1];*@E5R[P+<]W% M#
MC9YD:%K=UL11?5UM2D="=<%"OFGG$^J<>G]/8WA,#,N^+_V:SC_PGNLZ(K9:
M4337LAVM3EMU9$V6Q'74NS%%4^F8A(NSZHR(7Z+\CR C9':FYP@2!I;OZ9Z'
MX6Y-DS73L&JGS]$"W3+6DE"4C:Y(N&Y.K1"PCB+:HQ'-O OCK4?DJYSB?X7)
M/ 'V<QPF'\-)8PO_VV/Z[3XM<\ D["-%<#^>D*0&LB%\!&\1[]L51 X,+7 #
MS[4=T;$47Y?LF36J2NJZL[VFJ+5CCNZF3*L+<%AE@@YIKKJ>+X'3I8H:6"?@
MG 8SFMNR+:T+4RNFU"[-7X[2E=GND:%LT325+_A82F;\]%OX/9J4DZ74E Y7
MPY%$5=5]3]55V7$LR9*"*B)HNH9LKSLFKBWO&?1R-3[5NH%DPRC'$GE;7-W-
MZ8@J[0WKBZKIJIZ!)U/JDX@2'GE;MZ?2DKNZ:0(=46?)LJM^(31"O9-F\L)V
MNN.HDN@ZKN3[IJVHMFW7JDUT-Q<6DG7M1M$Z(=RVN;5)SB#-QB0J2MPO2V!F
M47KXJ>- LBU7,VP9)%*5=5.U]%DV@N&:ZS9[-:M5CELSBS:)1!V\+?19C=0N
MV>XBIEGYAHNE]RQ)U'31$C%+6[8TQ?!WU.-H=_2GI8O:]"W;U0E+M<%D*0#B
M L39%AZ8PO;"M5+ _:!+)?'J3LTB70Q/LVU3!VO$E71/5)4@J#8X3$M4K0NA
MR\_9,:U#=-/#=CR*+JJRJ&$IYMJEM@-E\0CX3%.:[:K*-=/HCDH'AOK64["I
M-R5/=<P 0$VQ'=/T1%_S:^9R+7FY+?E<;RHWK7B%QTVR3?HVPDS@AF91DD?#
M(S*854<"*BJ>8ON&8QB:YM45JVW/<>UM54$[F\$+D6F;94O3R20P5GW5LF5)
MLTVQCD HV /C@LBT9;=Q\W%TU;(DUP]45Z6-UR7=K0U_V7#==?4/);%5-%N9
MP(FIL[5'JRE;@2@;ENL[N@MFOJK5NPNNZ7GKJ*,J^^Q#]X\\A_E%2RS5Q'=;
M#D3+,F31]"71"QS7\NL"]:YKV,$F?)=D5;S16G2,]IQ<+^BYS<\4-=LP7%4.
M#"G0K$"QI9FC9*OBQG0L1;V1C+.FYM_IOAG8^'7@^UN*7S4<7OON+B-WH*B?
MHR%,4**.:ADTLURT;<<V9XZ\)ZUVJVA1N(^>X4%DS@]WA/?GWMT&GVMJGJYJ
M<J#J4J ;AFK4%1H=U7#]C96"M1OYD!W:EF?9*H6W6IO/(JZF&([B6+[J*9)O
MN+9LR%8=N N,Y8($G1%W_PFNT/5VM_C<KFSE?I]&[+C#&A?7:X:>VPPCS$UO
M8&.P'GU'TB0+3"?#<6H7)K!DW7[UTV=)7-ZR;F.>K1!OV]8B;FI+FWFPT=;%
M >/9ES4CD&79TE1=%FNV<PT_  KH_Y1_DV2O!2KL'' K9-D93MV4!""MX[Y?
MPJ0,LR<I+Q8;PTF6+<JJ#&:W8EN^Y\I87L,T?$NT7 _YI@VV.7XJ?:+D>LZ3
M-3,P%$NVI<!6=07PK^Z'[*#Z=H"&QC_UW]0V&*\?=#P\+47>@XZF:^BN;=FN
M9UC@X7B.9]=^L8I)I$!'ZY]*JW0\8B)MTG&WL?5<-MVUT=ED8T]R9-^P-,?T
M'4?3?5>7ZJ0GT75E"J#MD;Z]N9__BL #UJV(YLBJYVNNJ=.D*=50?+GV]6U%
M5&!%U#-=D>6-Y]^3$1B"F)3'!H-&3KY@I5&2->2U&G2+^(-'QT0[$%W1QP0U
M,&/KUN"FK1F.N)\-=?*9K1![9\7][L[+8HU^-] #6?=E'0OMV/5Y65U29'7=
M5H1FZ-C2:XFLFTK>=S+!PWI\&(ZD6Y+BVZ*B&QY,U:V;WNFV9ZS-7%KVSY\Q
MNTZ/.VNB(YDRV(2Z$3BBXOFF6_<#D+3%R'0]-<R0E51#?\D9'K9^KJ:;P):R
M:7F6)GHZ. MUH4  66_=)/=?OS0K4"B=-,O21SS.OX,_ZQO6E@!JE$+\F!8D
M!\P.9T5P-^<5B4;@@?\=>*9G&H'JJWI=@MQ2K-7>7PN36QG_P=-;6+X.IJ<9
MAJ%C(\G \3Q81M>8G7]UK,!:.86U<EIL^Q21@]B):Z_$BH;,RV6KS@:< SAC
M0?/9X&FEIM5&!>O2TG>W'=I*E.XDWS-TQPZ4P)1,TW/Q@)"NUCU+#-M<UU9'
MDDQ=;49LGD6ZOB["]I*N;2^#C+49;1\4IVH8V!HZ4"W1U.%?0]$"?QTV*88*
MB\;7H6TU(6FJ8AF*IP28+:YC,12LZ>(:ON)ZVMHN/F\-4Y3/>2%:8V/=%Q5#
M,3W15"71]W2S/L:FRY(FK<W=M"S=O%SB'<9[HN. D6E8+O*;K2NVH<V.V(O!
MVD1M,&?,%Z4>/4RUKOZS/<VB6!$;=0\WE8)<$/=T$N5YFCU1+;@L[^W8%4NI
M=Y*ORIJHJF!6F)H;^,JLEI/B!](ZN_YH%4B)M3>9/Y)'^M-F9FRCZ77K* !.
MD@I (#J^;HM@A7F:4I=7<,1 7I>J(,NF;NR+ C.RM$C(>IJ'E>;LCH:ZJ]F6
MJ5BV'1B&XOBR;]1,:?O>6F?3D#39,'I P_;5BJ9*KJEX-BA@1_. C3115!W-
M,G7/EAUE#3%6"T_UFQH'VBBJ+NJ8JQB ?.DJ>J^UGA55TU][I'^QK6-KY*"[
M82_N(&U.301;3G?M0'4#40I4T7;JC@F:9ZGR2OD=4]Z+;?:;]=F0[T!FG9^?
M^QQ&HP^@=Z91$<:[''A3-E1/\B77$14]<%W1JX-,GF9**QVKKF$I=G:Z6#@Z
MJ4J6)UHZ: 79=P+1%AT5/!/;UW3-UL25C@]O35U3KY*$)^%G2[$T;$JJ8Q=0
MW;+50$9'T?0D@_[1D^78J:DV8Z<DBD9@XF:4!@I'<CW=8FK75%1WM>#7:D_
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M02A2@50E%H4I+6+>X,FV6+%_5B1GU3-A518M7PWTMLVBG 4Y"^[OM^P1Y-]
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M629D;RQNR1K(+>Y)\83(ZU(;U+P7TFD1I4DG(G@YDJ8JK8G954O3-2JY3Y6
M+7AXRRX@4(1DX.@1 5QO&/33+./=>)_3,J:"_V<)#KOP(4'[)WH@PN<X3+BV
MW+_TB=E]OXFK%NX+EN$JF+.G"/N3:9P^$2(P#?NYS(;W8=ZNP%Z.7$H2KT7,
M=>MQO/.%Y$46#0LRJL*K91*UUX=]5^3C"I2FU%K!L*.)>=5"?<&R^RTMPGBK
M2NV&]7J\P=VQ,,OB0-(/Z8? -VF[WZ0]9J=UMD_[=7A/1F4\W]BUA^ :KNSK
M[K$SJSB:)CFNI#J*K06B+MF*RG9F3<57?/VD.[.JV>4&Y3<PT=GV*H@T@(T0
M"GDYF6"_D'3<],'_*Q<>ZPAUD0KA$#QP@*=\_<YN6)&>(AD^986%GCWR!(C6
M_E,%F$-QGPL$B#_J8-2'[*@\?S)M;9AWM+VTYU[=%>V'6]:-*6JB;LJR#O,S
MM?9VQR6CE>UQ67_F]K9\TNWQEF^W^.#YX*^-Z27E!"DI+Y!9T8]JTI6Q*GPX
MW-'C:2OK2?IIOGT[$#PRI :7H$B#0WO@]2P<T;M4>LZ &RK$HT23$><TSFD=
M<YK_G63#*.>\QGFM<UYST3R)R>A'__LTRCC+<98[K24WBYT)AR8A<PY\'GUZ
M[9QUK6 !ZT+,6MN7F'U,6#C!]E.K5/^EC&G#<E/X-![#13U-A3_#?<]35@^^
MBDW/,TI%.C.E<^62*FD#66_-Q.%"RH64"RE7IUQ2N:1R2>62RB652VI/)94;
MOEQ(KTM(6XN%+DNFV8)@FDM!.7GO8S!G?\JCU9CFYXR\'9<TK[B[\.;EG+;J
MP%Z[%E#GV'TM0J(.]/8J37+QX.)Q6>+Q6AYH<FORL<H#W1&&EY/FHM0K4>+F
M&!<2+B2[#I4/)*VUW@=</+AXO'A Y ("2OV,U'49:?H*/Y!<L 4W32A-\,CR
MYXR,2=9BVO855/PYY9[AM<!]C\3QO/3 %<B;-%!,7L.YEPS#)>VB)(UK-BYO
MIY2W_0^XG9"(YT"XWA#KW#CNVA&>VU(<VR]-TLXCK#4_I\R3I8X-8<VZ/,31
M;1:%+QE+[2>\*Y+>%E&N!<,Y5%^+</#-:BXD7$BXD' A>?F #H_;</ZY7I#E
M9CH7CAX(QWD$3F:E>F51ECN-F_0S*M5E0.7G,"9)* 3D-BNQNT>;E9"O()JN
MM=@KB,?2>R-\YX7\5R!G/"^!RQN7-RYO7-ZXO%VBO+W6E-;.H^XD%S^HRF6R
M5X3KITPJ>\<:N.KC8G8&8G8>T;Y&**KC:-^E!_4^%<"J+QE>[B>NF_PH]@G6
M_II0^G)D@R=_<"'A0L*%A L)%Y)G1K1:2W#A82LN1E<K1D9K9_6XBN&R\>)1
MCV[K1H7):0)'/8K*G1?O+38,5:;?A5%:8A6JNK_"M?>XL/2]#X9V1VO> 8/+
M.)?QSF1<E@:*W%[:*!=S+N9<S/LGYNT6F7\^N0\*G_0&&WA*$$>$BT$$397Z
M0VR.!QP/.!Z\)!Y(UD"6VZO%QAT!+N;7G:+8+\(U0LL_%B%(XMKKU_S]EQ_O
MPIB\^SJ\)Z,R)I_&_PBS+$P*>UA$#U'Q] T?]@UDS8G3X1\__?N__67]]7\/
MXS(LHC2Q\[R<3/&O?/%>H&>"0ON%C/_Z*O"P]>3?E']^\UX)T0B^"(?%6UTU
M?$-6/4_V?=%51$U6-<EP7#-P;-ORI%<_+2U"DZ#?H@G)A8_D4?B23L+-"]*X
M/8X2\O:>T/679/&']\N@0C]'":QO\4XU@4,ZP^=O]T08AU$F/  AB9".A0*^
M>63$S84H%TA>1).P(".AS(%MA5!P8A"'M[ 4:0PSGV;1$+^?I",2"X]1<4\?
M,4YCX%+\(4JF99&_$[;RU#;JS,?=:@;I46B[WS@WKOP"7HBPL,V5QL_-AR9I
M-@GC!4B1\)K9@ZG$"4,2Q]4U?WTEOJ*? 4"&]>?#>?8Q&A7W\"?,J=*;@$EQ
M.,W)N_J/%9:=#ZJYQ33',FUM&9O]=ZG8F&3]A]UHN1;8JSDIS[S_K&^7SWKT
MZLN^_KPYY[2CWR3+"W!PZAW\[<;\$!"89-TI6CM'Y3JOCZN( ]H&^PA+Z]2G
M/UKSG99MUTK/:4<8..=>U&U_FIX9'7M%NTO@1X7S(^='3D=.1TY'KJ\Y/_:5
MCIP?VPTG'Y"IO+ IM$J-%TT&[W8#N J""Q_RO R3(>F"7U^ O"_KJ7\JB[P(
M$QR@\#I*A.(^+>&64<Z/-KV >W-U[/>UR*(_"-U6(<+K*<F$_#[,"&>^%TGI
MZ)DZZ9KY_.]3,L2]/GC+1'C]1,*,P]Y+6(E7!WM_3^.PB.*H>!)^X S'&:YS
MAOL2Y7^\'6>$"%E8D/V9KH^G*4^0W=9JZL57^('D@BVX:4()AGD,GS,R)EE&
M1JUI\FO/O3Q)&UR>6<D3!$^KHOO/BGN+Z'^>C $O"]KD&ZFU"H?]9R>.;&>(
M;&=H\G7=2.A&;.]L&&?+'A#N#)G05&[V3[H[;1N"WNB;O8G96J2&BW,?"'>&
MXBS?6-V[N%R:6PB!]6D;_FS:2QY#M'X*:GN=1J[%\^*JKS>R<29!H/,%!^5&
MY!TK.#Z\.#ZT9G!T+3 W2FM.+.>CWNB9KF,?VHUBM4V6\R]9S_--N"0=''9H
MK^SA%0I2'W-H^AM9:+7'W14T-6VOGP1O:MH?F;M\5=<+;CNOU)5^ I!IFC?[
MM^?@(,1!J!L0ZA'A3FF:ZZ?;W^><=[56IJG=6*WU_VMWZ[F7]@+/%>%">0+P
M;V^?F<ODV65\;"AL(6/5U!>7S1-7"#FR"$@_:,7YZ@B^.DVE.,Y75\)7G%:<
M5EP/<KXZ%UIQOGJF,;]_=>ZK*Q;!JG=[9%@5[Y8&!Z5Y\[IVO*[=B_,PKVO7
M)V?LZMB/U[5[X>AOG]4)KVMWWIS'M2ZO:\<9KA<,=TEU[?J;D]O):=]K/\RO
MZ=V3LC?'\GE&73\UR^G2>GO#BN>5\WN&P":U>;ZY__S$H>T,H8W7JUM^B'HC
MG2Z9C+,EMXG7/<2P;N36SFSS"E=]Y$HNSM<CSO*-R*7YU-)\)MG+9WRJ_!AB
M]5- 35Z'BN]&O'C,J)=XR^O4R>:-RO&!X\.+XT-KAD;G=>JDU@N.<3YZ<3W3
M>0&?&Y&7U^HN>L$EZ5HDJ<UPPQ4*4B-P\&,1WL9D[?5K_O[+CW?@9;_[.KPG
MHS(FG\951OO?P[@,BRA-[#PO)U/\*_^&#_X&<W?B=/C'3__^;W\I\[=W83A]
M9P^':9D4^>?P":^!CUE)1K]&X2TFE$4DMY,1=>,;7WE1/HS3O,R(6V8928K9
MDX'Z"9+X"QG_]57@R:)D_DWYYS?OE1"-X(MP6+PU-,L.+,OR)5T)Q$ +/%V6
M#,<U U-3?5=Z]=/2DC7)_RV:D%SX2!Z%+^DDW"SCC=OC*"%OJX,QDBS^T,F2
M5[$Q450MH_KQD;WR-HU'U?D.1EH!\T23'*81)B,6(1$J,@H-&F]EGVW3HQP>
M)8" Q3M=FQY^$&AO%C_*J-]WZ*K9Y=#KM2#-M4CI6@RKM8CG:X%<G4=Y@>=S
MX!IAG,:@9U;/.+QK9]'T\UNTO=(.&T]9T'YX6JU) /S<?$V29I,P7M $$EXS
M>S"%36%(XKBZYJ^OQ%?T,VB"8?WY<#B9A-E=E+!!AF61UE\P[42_>8Q&Q3U<
M#82H@ML !7$XS<F[^H_WRSIG/NZU)^/,M8F>^X>:V9 ,Z8?=BG&M9JZF],S;
MY9=]_35-_DRV'GIGG_>LJ,4V(#5;T &S9WPETX*>,9U331'I85->[Y]SUW.Y
MJS[ W&"NDYQD[D^VQ,E\S,]9.B9Y#@Y>& MC0O+_^Y+RVXL:LN>59MS3@,[
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M'M*F/22$%1IE9Q;OS&'#$HIU +=VS?8(2WV%1ZW$,S ^]<\T^T-XC9>\HG>
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M'S$N0U4,9AW>",&L/B=U@6;$7R7P_/&P%)6;B5@Y=[4:)LQ28*7IO=UEA-3
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M3BJ97?-V5]54JF?6^4A+=*PN67*+4E+9O_X ("51OB1.(MFRS0_=%=NZD"
M B#PH!CVSF]=-;* 4%/P0<"<1B<GC:]E]AI^D8;Y1*9HX,WD\>#GD *Z>4!O
M]144%PQ$ZCSQ'ZE[19' E-]4O#;E5EMJ;@H9_:!'PV.K4 :M1K^Z(XVG8R[U
M=)6/R.O_&&1><2H2F8@\*1-P_6_H:>9AU<$Z!X=2G8'GJ8P9P^?@Z<KHI<#8
MG 0+S,U;,&WE>19<+<\O\GT7G>Y;>#M\&A<" :#)853X%KF5G*=[:+OY2W;#
ME7;#E_2&[,+6+^^D.EQG=!>'4-BUU#FH=X\*ATXPY.BQKEN=LM"\!1WX6)AB
ML* '!: -XD0%(V0D-8S2@P_F9U9!;NU78.HW[4'%9O[3Y*_(W>LU5G/PRMEB
M"OQ!Q]'13GPRNS/LV/U.%?; )KLVKF(KZ3=Z51G]TI96\100R_)?$S^$%8P=
M584SXT(!I8K$C^4$<IX"K2'$1LL%K8*J38!6LS&HT 2POJV&Q"B'@XZ<%84D
M.D'5,^U7FKZQM)*K>^A('41MHHC FG,W(XG:)"(^9["M5A($_$NWRJ5?2Q'P
M0%)30I9AIY9PQ!WN+2C9)> 8OF;1HYYXD!V?EAC3-E;E&\^20(DE/HM\RK#P
M0]QL&.BX*) 'U',.C\(5S8] T,K2#HU0,0K.O\L#)<D+\ISGGD5>F A+A&"J
M%<^E5 1=AF>D>:89G&E@7>#)MN^S21C)T=#V?B<+-]/8CQ?!,UA$-^;NG(CQ
M8.P.WP&RP>B(&7^=8+X<ILUH-J P_%@??I09 3'PHQMR><RI(CN/TG./Y>HC
M[!(E.Q6.#8$#Y3ICEM4$PP 4*,HO%LETZCF8H9"Q:XH%(E. 0LJ-X@L)@X#9
M1,BX4PKO^:"Y/A8SPAQ,5TCSKNB77/6I%]B8HD6!'#PEI+0C[K-'VQ(.>A*8
MVXP'A]SW*'$)@[USCM_ ^U*O9N/!(2C4NXC-!3T!G3GIRFEB@S*Z1E3HHC3S
M$)9#RW)1Y\7TS)@[LR#TPSLOS=& R<PI7$J"]H"1#Q1_.2\:&-Y7?#9RT8(3
M*V&H+LV*RC3$JLQF&JB@-ACH(SPWILP[S0U3JV'3FSG%;S,%M;)D/+AC"BJI
M2"9:*&0<VLB YV!OHZR<0M;=(@P*L\M2S>BD.*,=T"I OJ'T/ DG5G"VZ>J"
M/H.QR^N?N0[6 --PD5Y,@WQ*3_F7N .9T>BW^N@WS+S@F"Y(L49<N#O,. ID
MJ#K/-K)N8Y!U%H$^NPK='$KN_&Q\>W7V#@RPWD6W67(,6'[$>]][,9#*D>/_
M(L]*,D[/$JMPD+%BRPOK'R&.^RK$/+ *C%%4!!;5>TA=(S,]*0&#U ?^CV,R
MK]!R2K"0!#3W!/'Y4)&FB7YZV@@FG5EWH3R"H\&3,X-'0!15*,:M\2DY%J#(
M"4!'@EE:"+Q@PF60S"WZ"\@!BXB#(N:N"EDA$Z(/@:H&2UAD8NG:EV!RK32R
MI"ZFC>6)J=A 'X_.T$"KS!<R@3_B!<T%#^4J.$Y>S%(6LMXX)-WD"$4('II$
M,O*=VE6K4P7MG5 T">/[X"H)> I<Z^"N0"F&N.-2THZ>XYNF-J5WT!IH5F>:
MFSE%BY5S>98O=_ \B\F5.4$;-T\GQ,0E?!0NP\H&F">0BY2*$?-H_!LX;--!
MX79<U[#^K?9#RJI"@T8>-Z@/:?8R+3D#&QF&F#(_14=G/-@XA-4Y 7\Z:&E(
MKPP6R(V2.\D%L_"AD-\-#_4BV!HQ$5R%<E2FDJVLE:DB$)V8)C%NF$^?G%+"
MJN06'W9DL$_P<F_.U1F-(#]2K1;M_85:">]_E-<I^+JIP5\_P[).01J3[ QW
M;J4Y7;AQIL/#6>>)O6K'E-/#. 9FR>+1IB3WIOGDLHK"[&5,G1J5FC6B2A&>
MD7,WE$4"*G\>1RT3EN7/R^4A"'9W#^_0TIB7($AAMGF?'Y1WB\WEF9B2I/3C
M^GMU'4"J1]J ,B*6:TA8>D?Q YB;PL)$7BI[B1_-2=)>IS(6U02_=YK 7SR\
M0KN:"C6(9?$/S!&]Q\HT64:VB\!KA?%(&\4KCKR\(F7"_-12K"2IH57E9*23
M)WTKVJ^KF46_RN-PZUSYAG0&\ ET+I7U([>_LRLZ+X-UZ54X(P^Q3:E.A&KA
M@C0=6FTIC\4I?P83))LQN-9Y^&55-M$.0">&=F]'96!DE78R^RT"\SA+KZB(
M(UJMQJA" I+Q"BI\ F)*H<4#E$ZT1@]_>R@Z'ZDW0=4*/SQ!]I+<+XYALH6X
MF++=UDDJLF=!4=DJJTR%1HNU%%G]A#)9M>0GM<TN,#(@OP3!1^M6E6:HN*P*
M_M/)&;YO]-*RK:UJL/2B+5E+(L9Y_;D8!^X'3\A2//B85WV)EU1Q=497P]Y5
MY[)WW1E>]_JCP8?K@:SB&C=[XYO>T59Q::1\M:E[8$;YKJI-4BS"7$6TY:GR
M8*GT!/[U>1HCE"PNX_A?U('9[?6OOXZQ!I7R&Q,A4J,$NP5(59C>AK$&)X5]
MH(-Z09T$8'\7/(VI4\JD0B[(D1SF/)Z%KBS8SF*3#QAJFSPN#P7?DT;+Y4F'
M/+IQ5.E6(:,3W?/,\]5@+9((Q%9&)U@BN%W(,$ZC[T@:K3Y?SM->'D^AZ'W&
M,84>?/H_PDB5H..M]V$L#X%D'5M>PZW2[%5^OL'KWP%*2I9-()+Y'$_0P'U#
M1IFSYV.D7D 7*IP25>:]+#H2M02Y/S^9"1T5G\3\:A8D^%X%$TI,FC&DX@PM
M2 /?%",[%'Q>'KH^,D^>:*9GA!BDS$H1Y!$W1=*>+B%,_.5W6P]AXKM2VB:<
M!S0Q;?*@%C!X^-1<I?>BQH?20*GW5*P=_O%4Z&O]@$C)H)BKF"R!U902 EJ!
MY]VXG1X&+CYPRYT7R$&R) [3+R3:'7VCH-V;S?+ \D>E@.4/FOL%RS\HK/V:
MW6X:#:Q1&8?5Q='0IV[=%[;'(UQ#W*<VN5+;TGRC'G2_A805=$T;_0I$Z5XQ
MT@V3&B;]A+D=)?'HJW:?4\0P_J1R-,H2_AK1L'9:H72M68L> J:SQ-M)<SZR
MF_W^SNB3R].A-OG>NIF.T5>'H*]J@^I]6,KL &'DS]LMNS]:+7*NA:H[/#:L
MJ*E8#?L^EDPX/&B6Y6BNYR>QEJV<5R\;A[B^6TDMF:JT3>%P#=E6H[^*BO!&
M*AASU:@2HTI.395T&Z-V640PC8%,8Z#]I[Q\T9);5+)19G2JNA^M44$*NQ4A
MS!VW9AXB4A&0?Y:ZI!(UK7#ZA"9]NRIJ-MH59U-7,NA.=8/.R:W*$JND?TR'
M=TBFE8X?VYR0O/G]5)6BNE+XCW8^555MJ3J@8&JAEJ&W@@Q?-9?V&L-=02))
M/$BLJZN"<WN5BIL'4_ B60T+3BXUN%$Y8DM ^Q4)9J=*P51M33*P/UGP*]N8
MN2FSJAPYO>6!TLOKLPO3TN/C$^V79NJ_+O%>3]W_Q!_RY'[8$&7K%\JN_!+Z
MGO,H__^2I/WF8-!KM?KM9J_=OQI>MF^:_2O5>J7=[HWZ!YFT+S_BO05@AJ\<
MS^!UU(@B#:TO7)9?C=UP<4K9_/L":_UG G*;PZS>C&\O%0:$-;[]G7X!!MT-
M:L?'.=7U9W!)GX"V\X4?/H*.N<6 YL4EM2O,N:<*8T'" @C89WQO*JO'N5Y*
MD#5@N)#-$[,VD'>(Y"FU=)"/7&86WX6AFR*/1?>>D_:D0QJ+9(%5#6@\CV^O
MK%ZS=]%K*B %V,A<.0+AA N)N +7#%I#0K1-B^U]?]V0BB@\2YO(4O/+U0'*
M_04<T%EQ.C2P]%/#&L,WI;%^99PN<[YMV*'RBHD,QL8+,J(N]T?+^&_=BNL%
M;>F#)?:55EZFD7T)I(!0OV3G5+S4QNIO7R%=:11_=F4;NJ0J'!*?\O1I&.22
M(4Z(A/-($!89FZ<B<R-":)SW;).FAP*#P%)TYLQL20CP^9)YXE/*_P67V!++
M?I[JY AZ$;$CA:I:1%)/^)T7$*"D^F+J(988H=78,O4>6/B\]2Z#;7B\2*F%
M7J9&#?9 $$,$Z4#E YC^3R4$V*_-)["(#.Q8;2(2!P?I?=Y^IQI!/?-\'),"
M"-$723XI;6=%KP5'EDU\3\Q2V)R<KX1<4B?%UU$@@AFD'ZV*IU2$1A*A$4QB
MQ:=%6%:K1[;42!7QRH9]LEA!HJ81WDTH5-."HMT/ \K1ZA2F4XJ%F8/)H(7M
MQ"LT3!$RA()YPI(,!0:4E[>LK:VP-;LT-;1R" 3J6*G0:J6HN+D-5AX&A[$'
MMK(';O@DHBH;8++^1IN@?]%<C6U68!'8UJ\(CK>:W5>"0_PQR''HGS!^6CN"
M+"M@IBU;0M_"!>B-8;=='4%L57?=4--N[6;:<CK6>3;#=]:%]0W]>M0$.AVJ
M"HH$X#ME.BU7YE1OBD)Y$4XO8-/<^O5/A:GM*B(&D?7U\^^U'1ZU:9?;=6Z0
M6-@(FBNL,\1X@J]@$BG.$W5&]@D6,[,'TB;E*:(,+!%<FIH.OF0C"1N*$*B6
M'P9W5!T,UD^KK4(3#24^6=M"S0A F$/9*EON5H1HFH$**#-HV80C0RC;0EF,
MP&>X^:61;9S=7> II!*Z"FQ&!)S*JC+7<"'LLM+$0IOLQ;;!4+=+GS01],>"
M%?D"JQ"'F#6XQ!'*!9663 JY0.#&&2J#6J(,V(+%=H8!FS7TP G9ZTU&&"1:
MQ[$L<%;XRG)::=-L64\N[<M5B+)T"55;^T6$,39'04.XL@=P!H=8MN&TM,**
MF9^%53M$##+86,?)'7@&BAG7;ZME=X/:L+_<8+/S?U.S\]\T,S[=;]K-=U8>
M\K-N(C;G#V'T_>**FJ=GS1&T:[[JWAVR^_I75+%=:=1+914[/+EN:C_/8;,4
M&8>C *.NDJB!^0P*_BG&A_.&\)JK0]"9&9E*V5]6N?GM^\LW0@+D@9N-6:<2
M-6 KJ%)&2#(;_"[[>;>J>/FS?EK#6AXA1O45<WG8IE5"FX)LW,&:R864$*)2
M#Y*?+]$R2;IQIT+@1(D'J6->)D$XP>"-[#07+!)X62)2 &\)=/TK_FMU-BVY
MG4&J!AAA(**Y7#B1EZDRW1G6P!)A/Z:*_@E780Q7;P;O/RJ 6E\>T5"T))*Q
MX)3:5'\?).@C;E#JU.F)>BUG2T P'TK1@GP@_KA$%\WIO3JPPN[F4U0$N2)=
M[OR]!-XAH41S)D)E#:MZ32T(,B7O4=[E'-OMNC"0+.*B?X\OXOEMJ@?VG*!,
M8?;9[JOYOW((:=LY&?[[7;/2.PHBUF>/*QN.!C-?>"(,S-\PJR/;\P['YZ_3
M$0P=O7"W5G,YPDB+#G&V(=*BY+Q_ 6941;D'&YDDP_&\8F)6E3&C33#W#I6O
MN 0DRM/3#C>GA+3G-P*J$KPT>F"@8?Q4=64[-OKU:J>A(XW U;Z)0W)@%$H=
M;"$/F?^6*2KJ<99%,!OYL#Y21P[P:E%G+XUV>5F+&0M2\I;BK)E+@\VK_DQ8
MA(8&O#MO[+0Y1NMZKM:1),.'SM1V 7[[KR]"=C]$U^2(-$@1?TIB_6"PS'-E
MZ"IE>Q87DIKF8$^D4%#(O/:*V*R ^-II*[F"0.J")L'0<D/M67XJ!'$R)TL*
M76I*D.RM&H$;GE@$N=(.%LZEY9X(/$E]][Z,E3: 3F4 .@W+ 70Z*5"BFMUN
M$)G6R'SM"DYJ!N;R%KR680E;:/:,EX ?FW(GPWWE<M\JK&ZG93""*C&5KS9Y
MB/L4<X,E<?)8$B-[U"]MJZD_/U596'A :J]V.[11;4:UE4VWMMUIC8QJ*T.U
M'8C;NS.1_+H4B'RC89?-JOV,?_)F:(:]"F2KU2U+'(]%L.HG0[4S#4Y%.)IV
MMU,:[,^QR(>)+VQ[%$?G5F6=II5F-17B:1VPC[#QL\_?%%"KORFV!]/^.4*?
MF.T/VK0Y+ WZZ/74K0U+FL!'/:T;HSZ-^JRA^FS;@UYY ,-&?6YIX]8<D,XD
MS963=NN$0< EN)*L%BSDJ]WRP LC^,=)L"CM Y_ H+!F1E9!3/*.I<(:D"6_
ME,*)'46SPK@XM.98'8'%.,R:>X$W3^9I@AM5S$55=1 ?5MJ"70%*Z?W2%Y$7
M.-XBRYK%B24!#YP$3[E3/X<(H3D_"E<%*R8>J96S2//\5B_"7_@/1S4LW_S^
M-+GP 5Z+2S!1%8Q3'D4Y_DF^YEB"L_*N0F?IX"ZD0D2M=>:8!K'Y$+_(%2D7
M\$H0R5K5 ARF^91K<ZPW+BCFIVZ4)I02E_.Y7(X)@GBD!;OZFAY%VW-"&DAK
M<7;)%LU&ZQ!A+RO%ZCP&AB+29X6&N<(IH%QB:O^,J@97-SD=)5#$7IS(#KC4
M"]M'")8(B^Q <"6\2[0((T2]<4"&O1A40.2:Y/_=(N^"!OF-/6H;RX9*H<%%
M<[3C2J';%)?L-QW I$J(-BH=RB>I31WA&2()VB:QFYQB%;=$AD"$@C"0^ICT
M 5L/L85 4*DM5\30PD+21U6OF2)!9!/6"H&HO[8.!R4WN_4%LOA<B3V5%8)B
MX4:D*HO7XUD]B12Q137SEF7, X6=P(M%KUK%:Z'FR5HN=2*^W*+4J4B1EQ4^
M+;W.E#X=5<EJ 7=%;!GN.Z(JU9WPR%4&C8)F.]77IR60)$6$=Q=Q#30'40U#
M@AJF/V6]N+Q356XQ69H/TBKA<(H+"<]%*55*#(5RM8W1ZZ6M7FN\"D?\4C!A
M'8CX,RF^C\ 6/[C[+?R(MD DK@G;\$,.V? 2(.*;T<U-IWW3&S5[5^UV?]QN
M]KL*B'APV;SZ<)! Q"JHV6QV1P/UHP32>#\)?5>^XS\$IRD+$0D;.E* LV0>
MP!8Q!\:\C8&*I0AQOW=0BGY?-:T(GVF)9#Y'.$(5\<FWZP=MS9A:,Y&MF2/7
M3.":68CS=(^F6W5 Z A_7H&G5P!4/W2WM:Q*W/SAI;;OKM"F.+B*8%F?.1HU
MALU>LS^$S0#F-^R55_S;&I12_=ON'U0%:\FWC\S@S>!/C>E;G1U4C>^A%O75
MA^BE;H+*$K8^*L2QIQV:U^4*U[_0MU22?LX/M.S5L/T+"&R2U0T#OH8!_R'[
MDAA.,YQ6,:==_^"1XPG#:X;7*N>U*S1/?.[^?/UC@<E6AN4,R^W2DEMI;VA
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MWM9H D5#>=7B/3*T 8-E8;AO?]QGL"YV5T:#UB#A5RX9KOL4\_H''0ZK%OT
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MU#)^4T_)'#8;Y6%YG$!M7H4R>\2B>?UCP1WT#GWO'OR)\W(ATH]'&ON-=FE
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M;.384?\)+#V5A_8Z^7"/^;'2\FE%@K49T2GNA%L:Q+DG^QRP $>E]@UO"ES
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M.\-J2*2 XZMLJ),X'=_M^0'/80;^A'"Q5EB.M:*R:*255#.28T':HZA(1>B
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MT0;HHKF2/6)(\Q_*?[\G@AXX^_)A6N%]#-=C$!/F%<)<WD>8G7S6Y6@6-O;
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MIS)SSI;0N0R2FFPN\M4C%H=_/6=O^-6CULEF4AP[Q0\_&//7'8D=5"1PF@J
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MEK&."+1M"JH-38.O^WF?Q.D_U_,\G<V7I?/X.LO/1>]<-DM"+180"4,)X;%
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ML.+< 0X5-X ARK4N;U5(<%S?Y-5=E[+VM8M6L.F+^Y5Y_HP:[1"6P$F$&.,
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MM-9."<$)#ONAWQO&+5,C3#%OSHS+:@)=AE"?6GMILS#K/$]/9@X?>#H!BGO
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MC_WA2GNF%E;TZ2$<F(7-T1EBD]YE1'R^F>1I$7/HTMF[Y2-$*F[7YZ9)K,"
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M!6X^EX^N(/NK",PH%8A1RDE;>D,^OYNL8DNIZ>9@\_.\6.U27<ZH$&=')IP
M[[FFU&N N.$8H3T\&)OZE8^Z2ZILD3%9EV"UQO#/Z31;SFIQ_,#01"A+ :12
MQU)Y**A!=&^#\<RK^OWVNLM([(GES='JZQ!X:ER[H#C@Z8&)=BSB1R%'TG&D
M )'[>#Z.GW=F'\-VT&Y<8JOP#",,'R?Y5;[QR\PVH>X?TWQ#1V6A.#9!(K3G
M@$JDG308^4 \DGOJ!:\?8]2+=;MMX6@)IB%WC!BY?O%NL1V4>&L4)90A*(R"
M(J8NF9)*HQNXM#K+2NY^IZ@%3<_^Z5WLU%7^*:;([*ONIM-U'CB1%F:R6*0S
M?;][KM@]6"&(O^[,"4.(:>:=94QPZKW4%)1X(6WK9[AWEL_;KBCUBU]_&TXV
M3=-9X0-Z98K,U?6S/73SKS3\97MA6\Y*XDYN2DTF3H@5%G"K.33(6(:=<N77
M";F5]=7?SK)?V]ZX>H2OOVC+(W[GQQOS[]]BG9#XX&.SY,%XS(MG2X0T#"GM
M/?2*(@ZI<ZS$Q1I9OSQ19RF@+6]BG6-6OQC+L:4]+&53,N38I;KJ^(1#@A'E
M4AMB#7%0,%9B!Y6Q]3/K.RN=VXX,=(G2X#O([@^QA.$FW_CA0*ZS@QR?+8':
M<24!XP(K[APEC)#]UP!5_;MW9[5A>]I!6L.L_1UDNZUMM[B+MX_'@Q-F&24&
M"0 LM)0!2;G?48*L8O5COSLK3]K'WM$ HMK,+E6=*KP]]&SBJ84>":V0M-AZ
M0;BWY3HA, VZ%796/;-%7K8 R:!7XB>EH_=_W-^V3E4[KC5? B""A'FMB"1<
M>LHL+%%&PJ$&&>"OQ.C:!VRU=X.R0Y%-RTY%^R(B^U6]GT^^S!>/JE,\WR8N
MFB3!2,?(!P^4I>%':SPLU6*$,6E03F;DAM;.L:JO $3ZLO+UV58(8TFSHX?^
ML0&)<I "IY5RUECD@+4(E2LV0#;(WA^YY;157&ISLJRK?/7H(AJM;&?"U[-B
MY2=W6?CWA\FIHK(M39]H;,(5F 01)E 3;CCAKD1#:S3&(H<M2LDP*-:7J1AQ
M.'M8M$Z7 ?KI?+)X6+Y/)[%84"Q+>F3Y1T6JE=D3JX$TX>.RSDA,H(M5YG98
M8.I4@WUGY(;/X4 <(-?\@E" $Z,2AQ5R7$.'A9(RG*R2P)).9IN4DW@UYLRV
MP!E "&J$ %08G0!/H,?628&#\ N/"2[]3.&WHL$.,G+[9G<@#1$T^J31ZO:6
M_F[Y***J8OCHN6D2)2#6#AKM*)2("XM,::[!!-$&2:^OQ*#9(5H#R,WF(EYA
M)SDV)*%*@!@S*3#6AE$EPY6MI-![W:"!Q\A-G"TC,]* $3>9WCQ]MKV0D9=S
M)T CJ23C5H&@XWMF0#3_*$* T5XV:%&$1FYD'0K"9K:3"\U[4>U>;^NFGK"O
MU)TT=@'QAJAP'>1<(>EC]\SR@U-0U#^:T,A-KKUC-\!!%6YO1;CEY1L3P*=T
MFL[OTG#CNUC#.3]/PCCQ6$G*N-?A]$86REU"0/B*I*QOI4$CM]3V =>#Z/10
M=/M).>7>RENOOQ3I/]>Q .)=^BCHK;LWEI_U;YF:!E+S;9>EXF"+HF%786YB
MAG!QTOH_DFK73S?2]]7+7A\9F$@$-(2:."$(%32Z2#E$Q@*O.6&HTO'4(\7G
MRE\?'Y2$;4=31(#2&OL86N@LWE%*G;=]%D:J4OVZ,<.JZ'!UD)F,N0KV02K/
M)+L?'1,ORIZ&"Y)5B&)I,*&4[8 )&@CO,V/QHF3W-GA=17QJ@#3HC;)JK;Q#
MHX+>(BT2RG!/O,'*:$UL2:<&8.05=%K@7Q6):(35VY6-863B3"+[N$2B)0O
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M1QU4!&.EB?ZD !VK4[M4V>[]-=H/-$W<U(1N]B'3TTN]:+G9JNV T0O2.VD
MYZ'@TU)PNI=[^GBHYI/C:9T?]\7JC]^V^;[\\/&W;L(:"B^A<5HE+DRH" (?
M!9W-N"IO=1+#,$NN^\(??],\V7X@<6K*/!YGFIWCXX&_-3!0(P,_21K_.M&%
M=Q>YNB">=CB>API:\J5P,0HMU[GG%/3=X:ZC*$K\),2I'U>%. UI@%'< ?,\
MK'7GT AP'"N<REMOK[ST]L[T4KLQ@FFIU!TWCGJJ.U((IZF(7R5^2/UK+ZKS
MT/DQ'=:M;6US[3QC_/H@\UC[WF6)'_9?BEW^']EZ@0(:)4SX?I@*FD*/B:C#
M&7I8D%$2B#&Z,?))*=^G7A5W=Y4(E74A6'TOVSU6PG-3[$!>E@_+:D"#G_+J
MY_4?:%XH/4%0'2>24>(Y<EZY HU7A[?K2W!T[#O),^?BXB+M#!X#WWD6&NZ_
MK:1D*1)*;R$8@[R^E[]8XDI-[[+UV^TOV>ZVFGAYF&#JI2P,0RQ\06/N'R&&
M6.DZPDF .<Y,+2IY\XF$)4\+OJN!Z:>A:>)V.0/-/F0&R0>0R\F'M,FG_;VG
MDYHNWJU/\J3NQJLYQUCC=8\YQ]KL-9$I8J[VEHEEKE\H'B8-Z0S>:IG,]6(&
MCY3!C/;SZR@_GZ+D7^_SYDS>]]DN+]8++^4107$<16&<>"1E).W>\JD0,ZV;
MB\=#-5*=D$E<&9#C%*R7^_J,L%MY$KW!5'6<:&E,46<7J-&GID=O0./.!!-2
M&U%X;2(Z:J1G- $=U^^7)IX3,*\TX:P^6;[TN;S-WFY7NZR"\'9[,N%]7.8;
M>6B<*';B8?^PR]ZV+;O?ME7LZN6^.@?6F,L%XY#[@H4>J[X2/A4LXD>02/V%
M^?&A.4XF1X>J^6;CD9QX;@]]L6;>"9:=6W6#]*9V[-@G?9"NM9W41LR6M7<:
M,YD)@JXP7YUWO/5R4B_4G3-R_M&V0*^/+=!#J"N70.,3Z)P"M5?M[HEFAH._
M@U!K3%OG'7*SB>M$H5>;NUHG_-SL=;K(SF#^.J'SQ2R>KI%79?%ZG<L_66Z>
M]>AA0GCB)X'PH!_$L1? M'O[/<0T@*.NSP[ Z;@T.:[-+0\8#^7( >6$:[1#
M0CS2:NU(T9UPW?;HX7>_A'L^6"X7<RT,D1G-JJ=FPO8"K[7H.$]\;5ORY_HN
MS+==>R *"1.^!R.4B "%491Z77:.."/Z'=SQH(W3QKUJ>K:EG'7?U\"NP#;;
M2VFK9MHW62XKH'*"+&<83\>)S7TH1\]EAX'P\V$@O&\'PJ_-0!#'@?"=I+07
MP^0BBPT;#]]YXAKHO*U<92,&TZ2G?V;Y[9=]-95\S';5E+3^(5ONL\,%>XM0
M^*&?0 +#)"(>XGX:'+RH9IUHNOPU'+OC!-<!!,L&(<B^5I/_O,S _2Y?96WB
MDS.XWSXRF?N:!#=I?K,P(*9(@...A3EER,,@:UUO?@5(YWNWGW[/6?/5V(Z6
M5NV-LA\Q[UIDQVEBMAW%8;N"3F>UQQYO UZ^3%[R-G&\EWFC/G7P^F%?[I?;
M=;Z];9T\<>M#)E\^KWXL+_V6%UL^+#>?LMU=L* )%E$48@*#B'L$DLCK+KB,
MJE&D?VC(=^"3XTS?XBO!Z@@,5)^C>/C9]\;FH'U,\W-G_-1_];Q5VVXA:!87
M&P_KL]A+N1&J+1MK-D!-1U43' DYU@?/JH$#*Z!'"_AT:6B.N)MJ]+&@O1=K
MOJ-U1B7$]\2:TCZP&>,?9R-R"_\?62G!;^6NMTR>(_&ID-]J/9=KU(H.^HN8
M(A:PD# &XX1%20P/M\-$J>\I[4#[#MT:I_  CQ5\*?*V:HY9<NEZ^_2\1\=T
M38>&$"!O NLH ?NB_O:A.)&T?'?EQQ1CPL5N\.D&[IR+D'D39VL_^M2Q=[YN
M<6C+U.]N-=YV3K+\,5]GV_6'Y3Y;"'EB*V(^@1"C1/@I@MTYSE&<)%IW&D^/
MUG'A<!#R=0L*?,NSS?D-0W.-J>/%ADG".7JF/ZX3@)Z?5\=LW[D*I*_?R5J"
M:NA<K!Y8'S8SRK/SX,/6"H&C2"F]YL7O[C?%MRS[F.T>\U7VL@^_;7?9JKC=
MRC9$__NT*/?E(L!1DH1!&D<TH9BAE ;=6>4Q9HG248EC87&<T?K@Y-%61R%<
M5? TWLX9(RR7T]8<(Z*7E#KPH$7_Y$2()UGJ2=B>_*3V869QTWB-:F;Q,WMO
MRGT<U5Z1&D[FN7>B1@S3#%Z"&M/;8IJ'8=0$?#*I;C887-]\:/ZB%@D<1V'@
MQY01Z"?81Q3YM,-=.:%T<=]\T#K?$Y[)E^NWM_)PCPI[5H(_3W?1W5\^#&*N
M81XEY8\<X8F*@N=]YL91^2)OS]7O;HB,6EV,/%0FKC^&#IFQRI37H^*ND+$X
M(GZ(4L<F'W:+(>N14BJ7Z*8HJ]1<[W>XOJ'UZ='UIHA%G$0BC6.8)I!Z81 *
M/^B.48M##U'E&L?<A./"I 76[-R7KR3MOV2US"RWW_Y+^?0H;?FJFLF._J$D
M*U08X_"K5Q9TU#:[VRH];F U6^'&84XC\8[#H%FV?#9(^\/R;P-SVUG'SR6D
MX4S-((M8<**P.GI&6G5M[N)[NRWWNWH@EM>5X.T^?5ENVP7GWEXWQ97E<L%Q
MBB)!0L&JR;SO^W&,NIO08DHI'V6%=A+/7*_F-C<GYD>G0"&]JK+4<@N*;CVO
MVR6F,X/^/OEVO2X\^T$T^AIR.P1[E(#KXQ \["7K\:*U7>Q[>>_;Q<!PL4(]
MZ0#^SE>SI^7.ULKW#$; ]%7,K\7VL=XYUQPWLXA\A'C*HM C8>R%H2#5W+G%
M+YB8286BBWH>U4?1E_[V?-7Q3W6Q/R2F+C5<CH:YEA$'G[N3T'Z4\N DF).D
M?M,!]:.G=6->1DO9PR(WHW3\^COZ2! 1"!'[%"6,4)I0'QTJC2#0?XM][@[-
M,(D_6YJO#[1I[N*XD7N*'^L]Q:;]\.\J//,I \8=:M]!A?!#'9%C<1Q,6US8
M&Z;_V]0=%BD;OR2Q'6_5:J5!B#^7=:=BX9.0$(Y80&(OP+0JC'SB<1A"$::1
MH*K'EVE^JL--58T<_MY!&?EZ^*<\7% 40\+F\6R;@B^L#!J=+1K'%46\RSZT
M=WH_NTC@DWPA]%/V=4\V]=JCSUA(Y?U%C'E07H$'HPY((&+UVX'<F'>]M:.W
MW0#(W64?^E>AG]P!HK,?P4TL5'9Y3!X&S1T@_0C@?@1>NH7E]QHWD,!!C?R\
MY(T6%)T-)),'QW!S27^+DWQ,=OW'Y.1"K,&;34Q(.KL1Q2GC<]BDXM;!8K31
MJU?9'2K'=_GR<[[)]WE6_I(MRPK'^GK[(5L][';Y]K:J6?/RMVWQ66*5N-YN
M[Q_V<J_D=E7]5?T4U'@7\@H!C%.& I3"V!.>(*F?5)4H)U5)2I2V,4X&SG&6
M/$Z4KT#/)=#Y!"IM.'@%:K>N0-\Q4'L&GKK6BKFB@D\7>+5)P:QCKI>2)PJW
MDSF*[;!<F.5,-@+F,4^:SOUB)D^B7@8C#V6^S<H2KZJ985EOW,=?\W*!0\92
M&#"?5S-"05A$$]A:8R$70B<1F=IPG$\Z6*"'"_PND6DF V,.U31]#/KTI-F$
M.2>Z>H::"_(XE,QYJ-Q@+PJ[0VRXYL@O=UG&"KFO:^%QZOEA$O)8("A$%,>)
MZ.P*#M.AZJ-G;0(=N@(=1O![@]*")FER;*Y.[N@=KE,ZS(ZF64\(TU0O,[+G
MJV.&_B@HVA"FE'K?^%XN/2W?;E=_^R6KM[^@-$Q(DH;"HPEF,$KD3;FM$1*%
MZJ\EZG^T8]5J 5W)VZS/]]JL<*30;W9+CY[J/&$&_-[@T>D0&U"DT?UU2Y59
M9U>3,K4.[C-'SW5GS1F90>=U /C"RJB8K&/ZKA+XM_M,[OE/_1A%B.)*R9.8
M^6F*HA:JX+Z')^J:J@/\3CNGTD%0>SA=^U1C%(S>0G4S .;11E6)_=Q[J8?X
MC--/U1\.\ZC2IZ7 75_5-!X3Y#JZW*P>-O67'XK-1A0[N?5M$7H4^TF%-O92
MC,+(PQ$_X [\J1*?(=KO,@M>@9ZWX'?I+V@=GBXIF@Z7T3/D""-E#NG2:)#,
M/7N^'+MQ4NG <?/#Y=6A?+A+LE8BI9IQY=O@%:YLNZ^^*O-U?91GA6&S+,O\
M)L_6N&QVP!X<9'FYVA32L06+61P2B@+,*<(4^?)_+:2$HG#1'%KR<;_<[=52
MJE,X.AIXBER]@Y[=YMMM(W6;>N]C;T2,JUQ#R+P@2J/$:!YZ,XZKQ03/@,[^
M]"_RA9*WVX,Y>0A6!_%]]1A\6;87*C[!N_!$A#C&GB>0+S?->RD+&BC4@Y'0
MV*'N"(#K/>HU;'GO>^^]ROJ MPZ[_/*(5V='M*N0*"P<S"$:>A5J&XBWV_ZE
M.?69A8= =+C; PWIW.*BLU=]!O$QW*U^>&#D09UG'YK[+E;-D8E/GJ'!>]C-
MR#N[B]UQ+&:PFN+<Q6+$L3UB[1P%J4_\D'I1@"EGB/$T/4"21]0T%2C?KD>H
MG%\#HU\Y=[B5'W[>W(K^?XKF >'Y 8IF95=M%LUZ_.INVJ/%W>=\VQX$_B+*
MWCO;97,I^<WUPWY5W&5E#?5_Y+=?%C@0D<>2-&*(PI D7A(>-"R.D-9EW"-#
M<UUHGRFHP?WR6W/'\=WR:W[W< >6=\7#5O%>L:G"J+>)<(81--QQV//DJE^:
M/W&F?^9(>05J?V1YV'ETU76BI5?3[%*T$Q&%+8TCAWX>R64JY\]LEIPD!JH)
MZ)]+:7M?XNWZ@SS'H_RUV/?2WN%,@X!A0CE/XI3Y21Q""$GL!Y1Y@D0\]2-%
M2;)ESIW6= C!4EZ+6V,$$B0XHISL4 Y%]B[H@FW^Y_' 6_>J<#MJ-:>0LCZ]
MOFE!7.]J",W;:TQ$) I"#Q,"1<A2QAD\&!1,ZXV. 69<UVX2F<S@+;9J0#5/
MIME;QD/X5%.YD:C4[' :L^AF#GV6HTLSY.'$SD.Q;#AR.KNUQ<T@76I><$M]
M$6$6,1Q$4%8K4=3I8(QA$@V6)24KTZF2P=NN \@<H$G6>;0F21.\]GJ6(5U!
MTF)UQGJDYX>*'!DP,TB-VI?2 H98D&*:B%!0B"DA(>LLDHJMP7JD:&<Z13)Z
MVW40I0-4R0&;UG1IDI=;+["DJTV:W,Y8G70]4=$G(W:4-LA\S'9Y5F(J3TW=
M[?.J*GM?#9!LM\O6W>RR?4/,3Q.?1M1/ XA)B$D2,](9#WBL?J^X/9..=:L!
M"C#H004'K!I;*RR2K+#)91I^]93L,K6=OI4F[]-:)%MCY\HTI)OM5;%&OMJ^
M%&5JSNU$L<_M#/:>.'"J<#H>-9**R#[O'I:[;]582$ZM"0_%(A%!F& /50.%
MT;2S1B.$E+/( !N.T\;/%;SM$G0 @42HH5]#R%/(#B/QII<.GG U2/V'L*<A
M]R.Q:*;OIFRJR?EYU\_IMP6R9B#8-KPH[ XA#4FNKTEHS<A#<[/.5A %@2 T
M2E*41'X,(?6Z'FR2H,13%F1C"^/(<0U/0TC,"5,0X5&XTI/@YDZ;KK'0@#(1
M8'/>-.1W%/[,Q->,1S7I/>?V.>$=3-,,9'>X#X7-@6.A^?ON<! !"CSB^R3D
M:1I&:80#WTLZHV$<#%\F5S<U70OXG>FQ,D/)'= )=L.KM6:P"J7C-83?*9R[
M8HGE&;>%#9Q1Z0R;<J3V]J2T6'06B\;B81/ZDQ>\4^9Y!,4A1EZEI%'J,]$9
M1Q$/U=^7M&9R*D6[ZK^I9W)"B&WJ%>K1:5BWI'>S(USGA<=)B#=\Q=%F !1?
M:52EYUP%;)_?&93$#IPJG(Y)G=;Q\>W(KBG2>YUN(1AD$8J#@""$O53$#(>=
MQ4A K'YJAPUK.L^<\:$<W=.V:8%]NP+'<SH^-Z\<ZC1(!Q*LTF(>CU7--O.3
M5^@/C5&5]S7M$ZG3;1Z/4,..\Y/WW?\\&;%RL7%99P[Y;GP[9$'Y)<N:N[N'
MOOA^F9ZS76D[I,X@']CRI+ _Y$R4_Y!ZROK.WFR]2.(TBJ,8I9@*B$(D6(A:
M:VF88HU%0W,;CJ<3+SY!97/!O=9>DR$TZFB[6P:-=;WHZ?K/HY)GHN=N21R@
MY?ID:DKU,\]?E6ESKN8DT0.\>%&>A[)B6I13F<,WE;D4Q80*G%)8F:2(>BRF
MG3F24+S89K=5CE]_TI5H UM*#P=J'HYGL(9*]:I%.:R$5.?5K!"WRZ7-*IR.
MS-^P^ML)CX,%6XM/X^*Z^V2-REJ;KCEI]A W7JFI#7DQ56W^-=NM\O:8*;S^
M7P_E7HZW!4QC)'P6^#@D<8JP\$A7SJ<^\7S] GNX3<<%]Q$)V!<@:T&VY[+U
M='V8'!D3;J;N8W!M0^RO0(>T.;3P"AS!3D3XL'0P!O$VLX-1 (P3QAEV-/+'
M4'[GF4X&>_5*=K'#FNE!NRV*?MN(^[Z(28 0C1'S8R\)8+=&G7HL"'0G"W:L
MCC-M.'>DKD&BL42VRL+P> 1;/1ZW6S0Q:^U;XG?8P;>.>1YTS.T@OHU/LWW.
MR-EE7ZMTSB!Y6';HE7-I!W-E8ZDWP5%,4TQ)XK$$<XR1."0I[@FD>LBL#5OZ
M"[W:9\B^L,S;'BO[VAKOA(MDJKS-X FRY8G&(ID>.ZI[BC]^6>XRLBRS-2WN
M[K-M>7I4'_EV_)7WRV_R6UANUSB@Q67Y<'<O_ZK\D)=_B%U6/?[5%#HK]Q^J
MXF9!<<PCCA..&84$TS@(X_I$/U%5C2A(=+8E3X_6<1]!8@(W\H+QO$4%=A4L
MO:W,T[.DN!MZ>J#N:LD:^)O/$CGH>]<_MQ5\_@;ZO]>Z"&H?G^R#Z_EY!>I!
M(ET%G:_@PZ5!XF1SMO/8O9!$YC=NYK%%?$9\%'-]PB=,B_SK?;:JIOG_*.1=
M9K(:JY$'"44L)32(N!\D(4(1;9%C#Z58ZQCS.>!UG!J/:";,AJ:AG" ?CA#%
MV63$SE=P=/9[3XDOAV^LI#AP\/R :7$H(RX3HY5H::7&SZ\C_ZR#_%.VN_,7
M(O)AXO.H>KY"+KP@"M*H TPCKO4&ZX0P'2?"@]AM\L>L!#]]RY:[\J\&27&B
M(&KDPOG';WXI4/HX0=YS$JK7TMVTXV-&66YB(EY*;G.(C6I.>]]<CU3B[1JO
M5KN'Y:8\7'<@,$S]A))4Q)!XE(4AA-(B\Z! GN"*>C;$A#M!ZE#5]X!TN":[
M^>,"1Q>4P :S\WB4K7A2V!]WF@7BZDNV?MADUS>UP6S=6\6H3^K_E'W=D\KO
M/Q8>XR$2,.)Q]>RR  GF)1T  A'5*OCLF75<P'5(Y7Z-%FN=OK=E^R VI_[0
MA]TN,]EUX"(0BD7;-#'0+,)>H+^'L[TH!$BHH,8ZL@JJDWBI/+(?B7EHI O'
M3LL75]SI*RB_N]\4W[+L8[9[S%?9F:[!I@Y*]=7US8=L5=QN\_^HZJIZYP M
MRGT#>A'26,0)A6$8!'Z .$H]6I=.3& <:_:;)T$XHBYW;H'6+W!NZG8%CL[)
M/SRZ!QK_0.V@V25.$PT$7;&?ZQ@PSPNCA]]Q)K$8(:6D,\6(F%M^FH2#LZEL
MNHBH9KVW6WD7Z,?]<E_W"-ZU2.K;=%+HTP!BA @6Q//2@"1^9Q%Z$.ODKB%V
MON,,="4;BQ^R^V(GIQ3;S.@"KT$Q4DLK8X5'+SDTJ, !%NAP37*)UP6.+LBS
M#6;G(;)6/"GLCSLK@M=>SX/"A$/DIYRF4<BQ@+X'.YN,$*6CM.U8<KV>95WH
MGJB<T:5@ T,S2.D<1,6:UDUR,=A%GO3U3I/?62N>KB]JFF?$D*KJ?<C*K/K=
M+WB[9MECMBGNI>FV_]F>GYVD'L(\32@1./8C/XV@:"V3 (=$1_MLV'.]Z[N%
M6#=_UT>0>IIEA5@UY1J;4SW]>D)G#U_79-<^0-^.C"F0=D',;%(^#TFSZE'A
M;H!J]FZS3?73VY^S;;9;;N2JV_HNW^9RQ6V?/V;=.D]W-TN"0TSCF 5!&","
M$^$%'8:48Z5K$-U8=BQY+<KZ$5T^P:G9(;5+MV+G<S*F-3N:#<XKT&?[*=;C
MPN,THJA%Y:76HY.0S$,H'?EVVBITR*"J>-II4KX[W&( 8S\./>2'B6!<I"P)
M6=JBI!0AKB.O8V/[SF;= ZY>&3WJ:BH_YX!KYH'AVTZ?_)ET;,)[82P'YD)6
MF6H(S"/O3.9],8\'42]WM0"R]<OXVORYX$$<<B0\RBF-_#C@H1=UQGTLM%:R
M+)ETG&D.*$$I88)&7U9]0<D:I'IIPQ;A:ME@ J[U1/Y(\UFYYZ_0[$2MU8B[
M(,*6F9^'MMIVJG Z6C7O*2SN[O+Z;#BYZY@6VWTUK\BVJSPK65ZN-D7YL,L.
MFY!3[$'J!QY+>"P@3)"//(_#$(J81RA4W7IJUZB[Q[2'LYZ./T$*CE GVX2O
M1>2%Q]9-0.;Q]#KR[?2*/H<,6GV6C_MA6> %"4W"2- *05+)"<8-B*K(8I[>
M':1V33NN<MYEM\L->+\K5EDF#]HJZSG3^4==\W92RV&PJ*EN(N!*5"?;U:_'
MY5!=U0_*=R2L!LZ9**LIAX;;?PY"'F%(0A^E@M,HC",L+]_PJSDK3P@.$'OM
M8IVA'S_BOI*I2IPSU*AO)=$F<QY/UV O+F\?,61%]7FYOL_D4L3VMEN*.-B+
M8\PBGT'!O!C%)$1^ CM["/I"I^HPM^*XP#@ Z[HEY;_IU1 #^%-3G'&HT].<
M(VO'A<Z)5.<L/1=T9SBE\U >"WX4M@>;Q6UK"Q3%)*4IYBGR!?-ABH*TLUE]
M+[*V8>U52]__5K77R523H_%XU).DU[:GS6A7FNE^-&5VYZ%.EGS1V8.FR9#=
MW6<+#IG@(?>Q'\LR#:(T/!1H$&&]<Q?LF/RA]IN]3K":A$W K>;. O4=9G/<
M5S9X0YDR]?,0.MM.&6TAT^1,O5-=UMV<KAY<H$I5(U95?YXOY#6FPL-!9T9X
MC!RN!RKVRXUJ2UK3AM*3=W(9T &.\E-8_PDHGDT0ZZ?Q^.U-46JWG74Y56TL
MN^#1L'5<MDWC#LS8?>&G5%SL_!JR-@_Q,8?_K'L[B =50?FUV!Z>G:;3U1H\
MS#0A#R)!D" Q3W'*DH#BL+5+?(*4+KJT9\UQ!54!?'/4DKSIY?[42LU?-7M1
M%KA54YIQ:=63GCXVT#;'?VKA_76R-M6KC%U0*'MLST.R+/I3N!J7>J)V/&'S
M<('C\;JA18!%$L38B\*013Z!-(I19S,*$.U*)C5)&V;+H'32$[17KE \WIVE
M)VT#&5:3M1&H'7I!;^]*Y.)X5>RX6G:1I@LZ9H?>>6B8)5\*%P-0XWZ_=]7D
MY7K[,=OO-]E3:]WI?-\6/J0)\;UJ4AG$+$4XA55%V)BE(818]T)8&S9-9H &
MNX\JI*#8@O* 53YT!P5[L]HLRS*_R;.UR0VQ5KB_+&SC\FVD;37'UUMPQ->_
M _MPA*ABNK!'K,;%L&,3;'8M[&"BU>ZP5"#CA11AG<<9W&9IU9W"T7C3JW-_
M7N;;4IK/*@#\JRRS'_+R2P."99_W"Q(RPH@?03^B@6P[1B0YV,58+!ZSW>="
M=?H^W)[.<]6'IKX$4D$$]<LV?70R3ZPK?'I%K@5ZU0K=<7G52P@UH3])<'\%
M]=LUI[RR2[PZ*7A?I>M"T6N/ZGD4OA;]*5P-2MT=H\W%AT\:!K]F^T4B&.:5
M>@H6)MA+_304O#/'.0[TSHHS-.*X_WBXZ[1M.5Z!;::I6N;\J8G5*-3I:=2!
MM=/^XA7X]0)]CK;=ODS/!4T:S.@\I&BX&\]VWEKA17GKK;R0XOK%?J4TZL4)
MJBQ!XF'B4\(%\@XE'!8A7>S5EU@'FM(2(=.5UNW%I1 #81K*KYH\C4BMGD@U
M]YU<GUT+F4"K+G-U0;$LD3P/W;+ES.G>79L<#5[.77C4(X1P'Z-J)AJ% ?1(
M?-!,7YX2I"Y?YE8<*U?=5/F<W12[K%.L_?*K[GN( T@<N%YKE3^+Z[0S69PU
M6915IG0>8F3!#]5%6$UF]-[X^[3\VIHAV3:[R?<+B$(4$Y8(3@3Q! P#=+"&
M*3,XZEO?AO/96R<Y9H>]&%.G.G-SSYKNQ*TFK()T.+;VIQ;5R)ISAIN+L[9A
M;,Y#;P9[\>+;DD-942YWLG9R*!/_0J20>6F04A@@'N+4]X*N'\4@8Z%6B:/U
MR8[+F@J,P;Y637(42Q=GO&B6*]FQV],TI_%^O\L_/^SK>PWW!7B_W%UZ9<M-
MY=)GYU*U8L3B/!3#$/MI53*  >4+CZO(9KM=MOZX+U9_L/PQ7V?;=7GR0O?;
MN_OZA4H8B3#%E(<T8"*!,!"=0#$$,=785N'$_CA;+%A685J#=8L5+'=Y*2<$
M<AA4$RNIY:M\N0'56'FL/EV>MW:3+??RU)'BIOWN/I=/X'WG/"BE]WK293=R
M:LHV?K3,+K,^\%KC! >@5YT>'H^>:,".?+VU!HT7%-))-.8AH&Y<.[T1VQU_
M2CO9.HO76WJ0BNN;C]DNSTI,CSKQ%.<O1;D7R\>B^O>OS4Z?2O[C,/*AQR-*
M18@2SKHW2)F?,*2V67=42 9*;5&D]U\RD)?EP[(:BXTFW]W)/7.U6%1E4>,O
MP)?$^DNQJ9Z!$CQLJ_^ .WD0\DU# =@VAVS>[XK'7!*HL0]LM"%Q6>_G-Q:,
M\D#G@=Q#=O1![B$[1+CG!SA)&U= ^@):9T#CS1QCJ;'O;XXQ-=L;.&9LU;81
M6N+VW%;#L4,W@^V(H[M<3/BHZ&R![_9,TL-N[FX[)=[N\W6^>9"FW^^*?;:J
M04 _"#TO3**80$C"@,&(^!"QD,<P9![7WA!O'<$X<[>FF),YOX*:O^EPRES=
M I4;^*QME[<?)X6\/5%LS+;2=UC!$>QA@_<5P$^"=$0\;0QT]ME/&@O#7?>6
M8Z*X"5^7J7-YTAWE,\B(#ITK1AFV ]8N\.,RW\C.]:>"UA.VC[UY&%F6^6H1
M(XYY'(L$(1:%*0EBT1THPI+49\:K&Q9LC[3^ 98G/?[^Y+8%/&"-Q$80#%91
M1N9_\#I+!U<&H $,^HBO0(UYPH67UPE579JQ&)IY]!Z=>7=I><<ZB\HW[2UW
M6WE*_?MLUUT1DJ\.9P^$(:YF*=2#":,!C((X2;NS!Q@F%&K=FS?(DN-M*16H
M]E:B?'M3[.[JDDGS+).!5*K)XG@LZHE@ATO>!=A</-2*W&3GEUQDZH*ZV6%X
M'EIFR9?3>]@L,C1,I[9K)FO1;+T@*0R2, BAP&'"PS@1K%N?X<(3\7"E4K?E
M6*L.I=Y]]:AUY5VM70JUWY6\=JUZ*NMC>QM_P$_Y%JR+S6:Y:SZS_K#SF\O<
MQ&>(_+D)C2T!K(_W;?#-00$/9&EKH#[-<U9! V^4=-"4)54E_&>6WWZI/AX_
M9KOE;?;K@[R'^?JF1G#]L"_WU7BK4)V"$3B Q$M2YL>40R^-XK0[#9W["=.Z
M8=X1!,>ZV:%^LVQ@/]'.$A1'X.=$LOE-365T%2\UP9Q!J/1TM ,,6L2@@2Q[
M]A^;0%WW S6QQ)K1>T%Y'<=K'H+LVLEBU&= \V3VEV\M/E[ 3;X=?Z6]?+N^
M>_OZ7OYBV0/\H:K91+&3/UP0)"@,(*)!FOI5>@D(]'R(<.()%@JB=?'$1! =
MR[^%R\];_Z[Z$@1^ESZ"UDG-&^^G&@QJN>,[& =ZN67B(>#F@'LG0;J0H28>
M%?/(8%.3<'K@_AQB,D$&;%+YPH-1E,0)1#Q.DRC$&.*DPUDA1Q,E/T5TCO->
MB^MD?I/=YELY>:UF.IMZ'ZSQ_&:"<(Z>OAQ$<A:9ZZJ=77VW*:N!/TZVTAP$
M/URBTO7?78XRBL18Z>GG>I_,V^W[;)<7ZY]W\N4]3D,48I\0PE :11R3&+=(
M>4IBK>O0I\#G.$75D(;TV":)V3A9R'6XILM#C6?RW/W&-_F=2V]PSS(7O1 >
MA]EHR&#X,?+1( 8L9Z3AT1@K)U43NILLE^\@'^ N8L(]+\9A$,>)\#&"21QT
M2,,X009O<T\!<YP7!ZB<(VVF3%%&(1PG13D+V^0IJN?9,4]]7PGJA> X3%!#
MAL*/D: &,6 Y00V/QG0]O= +"/43CCD/(NA31@3I<$:)"!;WM3]\JW@)U?@(
M=23NJ3/#>GM9LRBAT]B;I7)-V^91C>Z/H5H#_'?>YM&+Q%B*Q;]FNU5>RJV6
M+4[J>1A[GH^@)\(H]>(P[=I1'#,2CMGDT4?GN,73 S1=#6T0LW$J:+?AFJY^
M[OGU?2XU/ N,PQQD/@A^C!PTP'_+.6AH)":HFD_VN+4>9.]W^2J32_HWW9)^
MF"0P12C D;QJR_/"@'>.$.3CB9;*;<'_/O>078%GNUX[!D!-P5PVF5D;9:.O
MX$\QP&:RQ/_JV)KH!;WQHSO.!-+V4/LQLKM+@MQ-0=W$<F;UP0*&C$1>-:D6
M:9@2SQ<)Z_;Y<1B2KM?V<;_<[6=5&KR*7+\'=W12_Y65[L6BK!/8>PGRQ=UV
M#^7:^%W+N9 [KRQN=2Q\'ZG[A\S7TR=IY9'TOU5F5F=EFG2L&35K.;C4VB5R
MT0.4$!ZG00QC&F)/D-@/NDZW2"-J=Q_[B+A'>K'W;/Z][?87.LVZ8PX$2YEW
MIF/ ?O8MS3<E?E\YV%Y$A^3A"<;5=Y*+IV!&-Q]/%KW1<O(+&V,NNB$"%F$8
M\B ,B4?C-"0DZMP@06JW:SXV^*FS\^JPM_)!?G.J]&Q]3(R4HZ<<#A,FZA>W
M9OYHV5HSMBY3MJMA]H/D;6?TV$[>;N,XM\YVF, 0LQ").$ZA?(?=@UU?7J T
MB2;<13H(]PA[2U_-VZ?[3!4GU_^G-SG*R/A.='5L5B;J3>I%;8(]K!?1^]03
MGD!"5*@#'T/DQZ)&[WL>28-1S]>PA7GJ64_6WQ [Y6J@M4$P^E;9T>(_DPVT
MW]?<QDX<Q]EO:V4D_1@9USHK[O;F6HR:5L;]_#KZS]KH/V1WRUSN$:'%MMZ-
M][#<?,IV=_XBQD%,.1(1@XA$'"<(P<Z3)(F)=O:=&?ZQ,_&N0RKO=^V@@NJ3
M[ZY T;Y0]R0[YUOP+5ONC-Y6F1G7.DEZ9M!_A(1]\![TW ?2_PF2][CQ?2V1
MSW2TS2BISY6AEQ+\7+&.FNS/-P?.>1(LO"C@,0P@08S$*8Q\BKW.DXA#,6:R
M=X%_5LF^=X3O5$G>R1@9)\E//3SFND?W1TGR!O%UF.1=CK8?(\D[9<ARDG<?
M3:6;U%]UX[.R&_CV=E<?+_:V@IUORWSUC^7F(>L?I^T3RA@*O83SP.,!QTC$
MG0,I#)4.B)@A[._UG=N#Z^#@.ZB=-WK;=H:!4;DM?EZ(O\/T_^./(HW[[N>%
M7&<T/7%RQJ-*M824X:@+0P]!KRX+QP_0"]7@C$?)M$7@G(DI9O^$3[;Y["GT
M15@A#(D?BTB>6(88@T>\(4GYI"]2:V(=Y=7I^IKSPZI+5>WGC_G^VQ58'O0O
M/^C?HX3]PLO4D[T\K1O\<39(C!/QF51?AMEQ'EL@SD9JG&V&AJ-C1LV2:7EP
MMY5P4&34&Q\#P)X>?5_]BU5J?2:E+S!-/"'? B,P1@'S0P@/'O@>5MI .$?<
MKEL?^MFQ?=59=[8Y'TJ5FQ;S@>PX;P)R.6^2-F^VO_<D;W9ILWNO^6WWIE3S
M#2#=-IALSG\4Z38MY@-]I*[%#$>51@MCM'!=[&',;]#,I8DQ0V:>=3%FB'&\
M HY_O<]WV;ISX02P@)2QD">0<<]/:.PE<=("]AE!;+1Z;1C,^95GW;ON(V;6
M@9$>H1P;+\A355^MA[U$.5VE-7 \C%A8C3<NIJZCS,?'.#73Q4BX*I'LA/\'
MJ(@L$6&S +(9F^F7;3!%J,(&.?(X"8DO8L$[O-2C<,)3 C21CG N@$'5\_2D
M@/_3I'<?_Q^]2:_,PVA->KW(C*5Y_\A*N;5RNZX$.UO)NT\+^:W>.Q;GYJR!
M3[&?(D19F.(@32%,:.=/%*)@S'?^W7DQOQEB[\W#<1>V'0Z5<1:^YS%*IEL8
M;_P'E3J!C@&P+^IOG[R7.+@U.X_4;!QPAZG;_2#\,5+["#Q93OUC15:Y-%A]
MR=8/F^SZ1BSS76T)EV6V+RN([_+EYWR3[_.L_"5;E@_55.UZ^R%;/>PJ7+>5
MAWGY22+^E'W=DRJL?RSDP6ZA!\.J:$DX8@%)Y-2-4.:% 0FYWN65HR)SG,+E
M:R@5,BFX[ZM?^;(\W)M4_:3,J\>L'D=7H','+/> E_O\3EXU#R0#[7[P2M4/
MCH+:4\T$/V[ %9/V;&.MF8A;/T!QTXM9E2IK9^JDVG/G&.SG006_UTX!Z16H
MW1K[7BV;(;F4*B<)_4S2WS2^GZ:T"2.@FJ8.R!0 _;8M/I?9[E'B>KN]?]A7
M/Z[B4?U5K;%'J+Z7L&JJ34-. LA#&!$1=5!AZD4ZV6H2@(Z3UE-84M/>98]5
M<&!?Q/2RSS1Q5$M"LP^A7B[JYQ_%I',%^GZ!VC%P,@JFSDLNHG0A/4TZ*.:1
MI::EH)C10ZJSL^:05/^YE)/#/6[;=B?IDJ880B(8(0+!!'+N<R%-4YXFA 6^
M^AX92P9=]S*["OGZ!K1 08<4?%+O5]HE665[R@3\&DX^7J)60[8=\JRS[6,"
MO@TW<%S@?>B."S42SNZ=L,SA''9!V':I<#CFAN0+F>2:WF)9/MPUS<,3& &)
M$&%1&OI(\-#'/D2\@Q'YL<9)( Z,.\XC_8[8X;$K05[VNF:_E75ENUFN_GA3
MN5A9*MMUCKKW)G_X2['.-D.4T$:83++/R!$:GHD.@$$/L>6T9",80U+4R$&Q
MEZY>#([MW/4Z.\IYS"+1<\QI-MV[F-^L\ZB4Z^@7N5A6OMT>)G,'0-VL[C3C
M"B\10H2()@'R(@(Q"MDAXU8_5$YU#FR[7CIJ$,OKR5Y,>H?FSOEB<YP0**2Q
MB=G7RV(=\6^?$'_] O'#TIB+6&ADL8EC8I;$U&,S,(OILW,NB3GD>08YS*5W
MQ3BC56]%"J]6Q4.]J/^^V%23B:S$G\OZJ,F%QT*:""KB.."\2IP)A&%MD#$/
MXD!U47R !7>B> 0%.E3@]P[7R$L!YPFZT-"WP.H\VO(V'"FLCSC-W4?Y[3:_
MR5=UJ^74]O$)QB2&W$_3Q/-A(@B/"&>M<9\EG"X>L]WG0GECD1VC.L]8'Y_R
MH];L ZD*O??5+W49LMY#TO, O/! :FX(LA0#Q9T^XY.OV;NXS&U5ZDVV(T>)
MNDM;;>QR/P\9M.W4Z>88%YPIRZ/<^/^EV%04EOQ?#U5I\VNQSUA>KC:%7/$\
MVH\0Y%X(?>9YF 2LJG<HJNT+%(<IYUH;+ZU9'>.]B!;H?P$-5$WMLT>PHOQ-
MPJVF KY *Y PP1'GE#*H2N$E);0>AIF(H7V_3O70$7.JDD@WR[(\3/FN=Q_D
ML?^]]^D6 8I8F$:!2 E-,$*"!Z+9RY%Z)/$]'24<;,RQ !Z6O4[OH"GE*PBZ
ME] ,IU9- T=E5;/E)Z'U>ZO%#M3PGAP8.J[>O4;7!9FSQO0\U,V>.X6C$:FQ
M"-(:^[C?Y7^TEXTR 1%-(HPQ@7Z2I E#?FO%#R.-\Y(,/MMYJ2:A-+=6UPIE
M<E>U,6\**Q..*=.3H4Y]6M8NW\MLAR*-!0/'5)DM"&A1IM;Z?^[GN=;^ $9F
MT+H?@KZP,RXT=/-"W[^WB'UXNS+;W2T(BWGD01AY5 B>>BP,:8<BXD+I-D17
MMAWK[O$5[@H,^$GG;D)G;"NH\<1$ZZGU:XO#_?U.AWA<O,AOG#AH2/[$\3!+
M":_LEC"(BUK>T"?K7%YQ2/L,\HY+[XIQ!J]^O5_VW[$\M?V/8E,-<0ELD00)
M@E6&C%,1)#YBC-$#@@!3K#L7L&77<;XZ(@'_MW[%:XU<]0G#%+P:32;*_D:9
M%Z7OB'9"YO7G(5-$8- <Q4HDM*8PBA2],KVQ3?0,4I KSUZ8%KEA;W#J^9"7
M?XA=)@^;R:JAN_^PW&>+!/O<"PA,J.!!2KV0>.$A_?E"Z=0V-Y8=IQ^)Z<U-
M!0KLY+E6ME*0&<D#DY!S?NVF(0D72+R@ PPDXDDC8"D9.8^$FW2D&Y'A*>DE
MHDR2TB#"9YZ6AOFFFI@L,*A_ AE=EE_P=BW_(Y>6'RN0%;QZ-^\"I902+Q!!
MBDB( R[[ASZ,?7D\M%=-T\Q.%AMBT?6*2>\H*8FOWOA7?]%#VKYXH/BV@67&
M%7>\C$ZVYFX7*SP[/H+K G67=KE8I7X>:\"6?3I[%)8]QE1UD&6?]V^WY7Y7
MIW+\-2\7,*DO+(XY"Q*2!I4QG'2& DRT1,_@XQTKG$0$CI# [Q*4II29D*:F
M6X[YTA,I3:J<J-%S0BY(SP#VYJ$S0QPHK(VD(0KRZ_(N8\7=,M\NHDJI/,9]
MAKD?BX!'4>!WYB(O4;HX=;"1<=7D"DAHX/<&W"!5T2'21%L<<3A(853I&T%I
MCO0HZXT!HW-4'1,W+FJ/,2]*;49<F5C7$G=;S1SE%[]D=Y^SW8(1CQ"&* NB
M,!7$XR2@K2T>QUQ]+<O8@F/M.> "!V :?2MSWA0ZA*-0IB<U+[ %?F]0Z;PV
M;TZ;1EMO%/K,VG=&-*KUZ,YY?:X7-YBE&?3<AOM0V!PW>I7?NV)[*W=X2;G_
M5/UE76023*"(PB1,A)\PF ;82P^F%*]?'63 L>I*3&_J?6T2U160N(PFD6;L
MJ95ZSHG3TUX3SIS4>"_Q<J&^&T3C/&J[82X4%H?5,&UI"T@811P302'V(PQ#
M'"=^V!D+PA@.41=%$Y/HB]&$TI1#,XUQ0)\-E9ED+ODR-QI*HTGF/+5&UXE7
MU,:($^7U0'F&=[:6MMJ:J6+ 0XQ $B8T2*LI*XUQ:T=0P7W-XS^T/U_G03$Z
MZ:.%5#\MFDMY^F0I+MLY94ESB:Y'C_84Q])2W"D=EY;=C*F;AW@,P'^ZG#:0
M"57)^)"5^UTN-]*]O&SW\G?KFBF,*.>5=$4LH*F(JG]AV $B2:QU!XQ#&*[W
MO1V07UH#-YA:N8R,FI#-)"AZBF<C'DYTT)S-"X(Y0HCFH:QC.%J,/OS'T.JN
M>X91F/BI5R6+-&9!$! >=)!\"E/W:JT(Q+%>7Q %H_FIVZ"X%&H'\="3Z@&A
MF)%"OUK4CA*=[UFE=5VUHM-&_*J=T5[L[@OY$@2M"OA\3Y>[=6>->S1F/@E)
M$*<!1%X0T7;S2NB%/E7:33+4AFM][9"!!AJHL>F<Z3V /H55W9&8TU3"%TDS
M6=H=PI[.R>?CL&AXPKDAFXK'FI]U_=P:KP6R9K#*:\.+PNX0TCS_[L4\\"[?
M9F_WV5VY0(B(@'I()**RB3&#"3I:Q;'6\7<#;4U7!$N,H :I60@/IE>MUAV3
M66OEK JI;D[ N\S6A:K5%L_S*$RM>7-Z_)U5EH8I&98:NON6;V_K5](6 <<(
M^31B(4F]1*!$)'YGFR:)YMJ/'9O.UX,.#^%*?I$=D=H0,VV&ATB:2VHM"=L5
M6-;%58VR>0UV#O)VPIRVR)DR/V>I,_9)2?"&,6:K_WF*(J2>[\$X34G@!1 S
MGW/8H1!)P/4$T+9UYU+86PE9V5%%ZP&PT]YTR;S]Q:<K0!]VNTO[W"=I;JJ+
MIJMPS$,^G7FGV;4<QJ).)7EB^!FPI]_H_>:"BCA)A,#"#Z" F*,H(1VF!*9\
ML2_VRXUZ?>D.B=9\^@!:^;G_)/^D%M>K9Q)[!79/A?BJEH63;PXK51V&4+V$
MG4?T]$O;JQ<D^B4A/_T>5XB8LZK7F.Q7JF'W09R'S(_DZPO5\U@,*ZU5/7W)
MD1:/V;8^Y+.RNL[WW[IO+(@?0Y[X<2HH8C'Q1."U^U5#/V5(:?> 58..&Z2_
M++_F=P]WX'Z7W2^_U2^(%3?R#/[M*K_?9""_ >OLKE*%;*VQ.&.-;85UKBF(
MUM/>9^]-=YBNP 'FX7M3L*RQ'C8%VV:+8W985ULJ4V3EW+J9;5)GL(AFW:7"
MX2 <TIU9,)C&*,(LH%X,HSA**VN=D00%2M?.&W[T>#M^9>4^I(7R.DLF'1*K
M! UJ@$S9XE#N8"C3-8_*U13\Q?Z#)@>JFG"]NUUN\_^H,Q0MMF6QR=?U/ZHZ
MMW\U[_6-R"MI6N7+S<?J._5;W\<+E.,XI &*&8)4L##VJ[J7-M?A^3'WN>J[
M?N. <?=L]?'+M-WSH)Z?/KGKN*I6#UZ HQN373ANA?P+C_2XP9V'$HSL<S'E
MXZ3YXG5=\]3FZZO KV^.-Q ?K]GD/$G\Q(>$1XS0R/<@3%K;"0]2O5,>K%AT
M7+D<2D'-5[#ML*FFTN,3J:?"/7S@<,U\[[;SZ6[W56+N@H3:97X>$FG9I].7
MNQTPIG-BX?'NX(.>0C_T:#6+\Y 7QIBB.&3<2T6EK)!%$5.ME0P_W7&SJ'^)
M]D1US,O$7'BJ!C(YC\=HJ!,O'*TWF!.SHSV;8XA%1(CGXVJ.$R,4A=B+8Z^S
MA!@:<#JPVN<[SO/]@[F?'BC2Z_P9GH!N1*>ZZ+AD4D]Q+)$XPC&?KQUF/H37
M^>B/L0<7S_4T84/Y.)8OQ6[_Z?2HJ2A,<>Q%##,2! D-<<)P:TOXH=PTH7$=
M@Y$%U^HC05DY7<Z00#6U<<^=IMZ8T.;FQ):7F+F@+\.8G(?"#/3A]/06"XP8
MJTQ[Q!3W4> Q@3W&2<Q)X"-&.VN!3\D@G5&T,8W2&+W';TRCH=HX8-"*WDSR
MYOT9=G0T1Y//F:J.KA>OZ8X1*\J;1XOM8[;;YU4%]6NQS\KWRV^RFFI?XHR0
M#ZD'2>0SY'LL9&DB.ILXC+06@(=9<JQ"/7"@1@=:>)K[.(>QJ29#XQ&I)T9G
M.9SHT+J+/%W:0FF%WWF(DR5?3K= 6F1(\3B.@\'WE8]Y61:[;[7IUF88$!QQ
MXB=1Y/F!GU;_(HW-T/,BB-1>$[)C2^<),WL_LO>@'2$VSYS6,1-#2;VL5^.S
M::Y7IS2:'=LQE$^MPSM&Y-7T"(\A_*H>Y'&9AG/;$JW1-X/]B/9\*5P,L"&=
M_G>'E_!Y0&C@$0@9"IC'681(U%J+":>^>;=?W8;C&O39+7?O3(_Q,";1I,?O
MAC^#E45=ZD;HZK]3.*1C*)OS*#0'>W&QPV_*BIGJB.4JPW=R#\#"YR$,?1C2
M%"4QP0(%U._,Q5&4ZKU^;FS&>4E9/T!Y[XV"FPH<6-;HAFB/#I4FXN.(PT'J
M<P4D*H ODS>"^AS)498? S[GJ#\F;EP4(&->%*>W=W?%]N.^6/WQ\<NR&FEX
M]:^'7!ZIMN5?5U^JL9;=%+ONPOI%Q&#J!RF-PC"!,14^"MHUB#")H:_^(I]E
MN\Y[=!(M*"5<L&R15J(%LA8KJ,""/UNTX*?J)V7MU5^U)G%V0Z$T19XL"KH3
MYCH -=(KT& %N!<(W@]$!WA"\K7FTY,%P71V;348JM-M'9;.3[Z=<#V+J;@;
MSPKW(W5(P?QV6\EY5NX_+/=9_7[ ^GU6C=IJ2-]FBSCB"<9QR" 2D4^3( R2
M#@ 51+$UZ\#P^$5UWL(%\LC4JRJ32<3@_@!Y2*4]+ 8FM?=HY ^LQCN<X$/-
M>@,5O'^=]1%*]$L<*A?M5@(QQS+>CF,7"WN+W)EI9Z_/VGQ95E7 ^UV^ROQ%
MF#(4Q+'P"<<DPK0R>K /61 -D<XA=L=7SM41;?</B5>>YE%-M66I_]M')I6T
M*?D5*WX'$3$1TK%",5!':3\&1Z"@1CJEB%[@3UE#;<1@CA)JQ:^+"FJ/.54!
M[6I;>=!2?OME7UX_[*M::EM5P+<+09B/A0A0$+#09SQ$F'8F&19:%_,.,N2X
M&])A:PZBJ]&!X@A/3P"',:JF>:.1J2=S3WAL@(%K!1Z=Z-HECBY(F15JYZ%>
M=EPI' P]S1W=<G[^MBP?LC5[V%5VJK(R+];-C/VHD]<WOVWS:I8.434Y1]2+
M4.BG)$DC#Z4=B#0F>AN][9H>9>=EV9YW\2 AZ;=N7;&NIFP3$JZG=350T" %
M#5308.TZB$\*NRH>->*1]Y%KL7E!%1V%91XZZ<JYT\WH+CDTOQ(]18&H/AT'
M(8DACST1<*]^'9]S'-)4ZYH?_4]WK(A*UZ'/\)IO5=IF\@"9XW_UFF\])I26
MB&LC^3[/RO?5L/FR+#-\N\OJ@WA:HYY/HI"0:J:5IDD(H9^(H#5*6(R5WM6P
M9&J,!Z0&"#J$X !18[G1 J<*R[OCTJE9$%QBTF0/M 5*-19MQZ76;)UV(,5J
MZ[*O$G%N*=8>@S-8?;7H3.%DE&D>@%;($XB:]P#;ZT86'DZ$ER1^" ,:$!]2
MYD>M)9HD7.BM")A8<-[[;X& ^V+7G8+X,=OFQ0[T"J/J%ZHO-8] ,^%3;0;H
MFD@]57]ZTLGAKAKPRW+?#N21#S5[SLZ%PG((E_,H+0=Y<'H\V6 VM,\@(,5N
M5_Q9S?7*14H%# E'C(5Q'"8(XX1TEKR8AT;G#VA\ONM"\OCZ?&^!$=P?7U;:
MJK]3-XA'Q4:38PHUB\>GAP],=-K D8I+D]4!Q,U#4P9Y<.Z$ 6,V3$J87RM'
M6P$+$(TIJ@HFP:%@01S$/.V,!8QI[FLP-.*\D*FPO%F-4<SH,*M?SSBB=%A)
MP[^N-@]R^696Q<V1*L7ZQH#;><C14"<N5#G&G.CLOY(&Y7#"VW6MAO)K6MQ]
MSK?9NGW/ S*.4$J]R ]B/\3$3V$WJ6.0$:1S,9XEDUKED.D->.M+N=PIH6K:
M- &7>EK5*-11L>3&@F.M)%?8&J"3O2'V.GNO;)NR2/\\Y,RV4R]LF++.F?*\
MKCT#]?KFY4M*Z],SCR==!QBF(HYA)(COQS1B 1(U"$9( B'2FO+9->UZ-M@[
M+/;LS;^:<T'+W"M.$Z>C77,&J<)X>SHOF.Q,?CTZ+\U"W<1E'A+JRKG3N:M+
M#E4EE3R4E6R79:/?]7K0\3843!&/?,$]C@04 0LJ#9<FF5=9Q)[J%&R0#7>/
M; <+]'%-=I+_)9(N/(A6N)W'8V?'E<+!V--[I'[)=K=5RJ[?92SSQN)VS?+R
MOFC_>;QLH#P^W]5S32(" \ZBZ@O&*R"B ^.%L5:#VA$$QU5+#ZY>;>**<35Y
MFP'9>L+7 KX"?<AUP=('W;O>I)SP&B$S=B\HIN-PS4-+73M9C/H(Z';JI=S7
MMQYEVU6>-874 B.:< XA3JK_!IP2'WOUE9(QX0%!6A<=&)IPK)\2%7@"R^Q.
M%5,"51ORSKG3;<AKT^:H_?X2,1?;[X.8G(=2#77B6?O= B?*_:B'SV7VKX=J
MLL8?Y>4MW<T*E"=I'. X0!AZ/!2$RPO7:FLB"7B@U7@RM.&ZPW2 !6I< VY5
M,251L8,T G^:K2(3ZMRT@U[FYE+?9R";\]"<P5Z<=G*LL#) ==I[%42"$AC
MP$\IHHQY-/!08X]6%56J=8^<N95IE,?LEA5S*HW5QP&+5O1GFIM6SO&CIT&:
MG,Y6A73]>%V'C)@Q5*)V"SGGD<<K0H)0B*0R[,?(/]B*V! 54K0PL@(-TAQ5
MTHSTQ@%? [5FFOM37J1%76(T:9REO.CZ<%E:C!A1;N#D^_RV;M7+8ZP>RN:V
MNI3 ((0A"4F$2<Q\''6F LJB2*M]8V+ =?/F@ DTH(PF4V;4*39N7+.FV;;1
M)<S1+??/2;G4LAG"X3QT99@+SZZL'\R'J:JTE9'OIS"%0M"42QO"K^9JG3$_
M(6R(KBB:&%]9C"9+I@2:J8L#[@;KRR13I)>)T= 832;GJ3*Z3KRB,T:<J"K-
M^ZP^CNEHLZV6!$[B(,%^FOJ^'R:(44XZ:VF M<YS,[7A6&M:6."(2T]CC*E3
M$YDQ6--3F>>$331%.D/-!9T92N8\A&:P%X7=(:8F->5NW],T*E_DEY532EGJ
M<182B-,XC!$1J%WFHC ($D]%80P_>KPB1D+2FAR9DG594T;@R;A@4:%(144J
M'WL*4OWK5#U>)N$%T1C(UK1:,11\867$F"I#OPV<!F'H<4HA3!E*2202VIF"
M(19F^J!A8&R5T)KH#*-.5RT<L390,VQ,<0Q4X^+"CQ7NYJ8@)BZ<U1%C/I0.
M;'N_W&>;Q_)G^5K"\G->W']9[NZ6;[>KMK3!'H<,$Q%BGT/*HD2V@5N3!%&E
MG756#+F>W$AXX+$$#4!P0"@OYEAI'"TVF-#+6C,ZEYI3GHLTFAS5-IA/C8/:
MQN35[)BVH?RJG=/V"@\OR+A5^F9P1ILU5PH'PTM#WO^?GPE>]6:J,*P,)% 0
M3V!,6(BH:'<MT3"!:O=3&WVP8_FNX("?Z/+;W7+[5_!K]N>^*GK>[=<:.J/-
ME().NR1)3Y<E/PT4$PW6YD9#<UUR9*:Q1ZX&RNB):^=DTY2!&<BD,?3"P@@8
M^.;(N\-EW<1/$P^))*'0)WY"0QZ$G<&0I5JW&@PPXWK^_,*K$.\4[I^WSJ;B
MFN$X1&I.J0TY'.>=D@-#EQ80A],ZC]Z^#4=>>[_$E!ME3<HJ 1195BZ\..7(
MCWP2TD3P  N$6??Y,-*[*4#]4UTKC@0";C+=HRDU:%'4$B>,:$I'38:X1(8;
ME>A\OR0*VOS,1 /T<9\^\H:>*V\7J*8D\KP/4>QJ4Q^S_7Y3G\E=+I+82Q*<
MI$0PSE,H;YU#!TT17.L(HR%VG'?6&FCU!=^;^BDH#^@T=Q ,85--*L8B4K>M
MUN.P49(>L)$W$YQGZ-*& @N\SD-TK'ARNK' &CM*7:'>CJF#(7E[TK(BH+CI
MW=S^C^7F(5NP$,<>Q;PR&O"41"S%<8> 1%1)J%S8'6_!\2A8X,]\_P7D+6AY
M(MBJA@U*B5NCIV([!@KMJ GI-UZY/"*] F][K#=H00WW"M2 )R1?H]\U81#,
MVF&6@Z'6.M-CZ5QGS1'7,VB\N?*L<#]2-0OH7;'*LG4I*O_?;LN'G;1^Q'-]
MG^V6<L(N.XB/];G:"Y1ZA,5,I(S"..:$(A2U0*(TA5J';3DP/TG6RCOL8)>M
MBL=L]TVS\G80!L6"?-H(:-;I+5@@'U=P@/M$. ^(P1'RR!6\-J67"GMW\9E)
MO>_0P=-I@&LNU68'3]J@WWY]D*LRUY7@/VPK/5IMEOE=N6")[U63#\9#@5GL
M$^J3H+.+?+57J^Q9&V/I9'4$>06V-<RF_.\!U2E!K;"L4O6/3?"@)96*VP8A
MN)9UY93<ZA3U8W-L6,H/YEJQ>E>@XVS-;I/*.53J5OTI7 VZ(8OIW]CR;GF;
ME?C/947ENID.A$GD<Q[%5,1!2FE$,.QVOD<A3I7N^;5H;O0,L6Y @F6#\@H\
MJO<H;-)LLMKNG.&A*:+%!W!'KE;/P<7R^TN4*2_##^)['E6R38<N+LM;X$I5
MY42^K0KP?+FI:O']KLZWO;-NCT?=X@A"/TQ1(A@2N+(I(&N/NH4)HEA'ZFS9
M=*QW8IGOFH<._)(M);3+*U%N^573N"FHU1.Z T+0@]@[JWO"H[H5R;L@>;;I
MGX?N6?>J<#MH-0^!JR883>OAY@#D?7OL]^&FA<ACA#'/#W%"!$IB08+6-/(]
M_]6WYZS:<O=L'N#)2?_Q0>T03G:WB IM%YY*JZS/XY&TZ]+I66GV^=)^&)MC
MKTD<B2CA<9S$49JD$?+BI#,2<K57.0P_VG%Q<7S4C(ZXU^5)4Y[L4V0J1).<
M9/^4!Q5ET2-L9AJB"?Z<6IAPH*T+=+,LR^N;>DVV/GT !S&FV(,DC+R0L4@$
M$6KM!9@PO;/JC:TX5HL:3WUCM41D=DR].8.:XN&4/#T=T>/-K9:<TJ(B*\94
MSDQAS/TX)S8#F5'5G;Z9]H "#!DE,(J3).*$>DE$(MH98BC2VM)L\/$C*XW1
M28LFK*F)C&/"AJG+),<K/F?D@K ,H&\>BC+$@<+:4-*L7;)=GI7X?17T;+?+
MUK7%]CU0XB40$E]4=GF,XX"G7C>+TCZ]=8@=U[.=&AK X "N>68T2Y@A1"H6
M,2-QJ#D=.D/?5*?1GR?I4E%C@=IYB) 53TX+&VOL:$^IWAW> $UH(!A&49)X
MD#(B4EZ9;0UY7J!WX;S^QX_7<GEG^DZX"6F:TR<W?!GW7U2H<CMQ>J?PRO<
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M@J-8SC<-N')80?J=<JUT6\7I[>$L34)"4@9A%$8LY)!2Z ?"3P47Q(N8V@*
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MU-3VN\U'3VR'?!2/E_;2IPG. G;=)W(TG[SARPZI>6<S;TQ^3XOG5101"+W
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M$1D_CDB;-#R0'"XO5"TB'9(F3^R8L<,HIQH'CY;KN\?NBO5,7.L8/XQR;F
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M@@1Z29Q@G\EOX"*V:,==;E=LLW7[JLJK]4Y, S6:E5+"'J%P%_TB4H7#5$W
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MD(P::C%H6 D[C/6+U*Q'::TYS-+*>J *LS(]A(N)XN1<RPGB"<T'@%:-T#I
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M]3_^6_<=]I^'=9G^C__V_P-02P,$%     @ 5(5N3>3F,6#$>   L/H% !4
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MWF)*HT=SSZH%R/L<_LGOKO8X0;SM2H/I87>E#%AB>'!P6; &G""08TS66;D
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M7[["N3\SW*[RF=5 :RN-190(KX'3J)YV'6-):24&SX!3U%:V#VIOMV/+V5V
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MF[0)?7'TZQ;XOHBX?"SR8S[.0[>CL_LA7S1\6GEKI0P2*BU60 !%L(.(*"J
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M5P.9QDX!A3%7GB@$..=>K:7'EHA&!O[%GD:=SH6]IU M@7T>JBU[6JG'Q=>
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MIKGFW'"V&8D$I*2L2THQ<:W38QK^9^7<_#'H<>VT[4\@UJ1Z9BSSCAEOJ<*
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M* WJ/JVX*'G,>1A^?#?[%KH<=QQFDRV[#[:HQM.R>ISG#5;+U*8S%;#&QL&
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M)DGQ>P.<8%)4O)<M)R-Z^G6LYR?<Y7U15>7\^W*6V[GD-*H7'':MJ L^.J4
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MT;#F&0N1AQ0YB672PR<#I<7)>BQ;!+(_.NP->-A7/#.>.601D,%I"P:1!UJ
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M3 0PRZ[LHEBJ8M^\(Y<&Y^5%Z0M@/<7(.T=E $<QK40M7_@U)?WRX".!VO2
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M@,&<A(XHBSQ$ML8**I.TI7!T$/\EK7P=@GPN.W[]2NP19ORZ1N8<\R[(0AB
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MYWE\F2!:$??%8KFTQBO!M2$Q+LZXR.[ITU&7YHYJ)Q,*8 -1L(4<\QAS"24
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MT,!AYT2K&*@A05H<J#):)VU ,UR-4_B\="99IO*+<Z3H#N41V-3"4:=&ZXB
M8: ^:$73+%) &:VN4M._JJQE+,N0?LGLZ@CM,2(JJDOX1S=)[Q:/O'=KQE:<
M>TTT"E,;L+.!8TVD\L15QCK*",^*<K]Z,WJ/2(_ N:TAI<9R=JQ)Y$:A,BY
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M)?ZL%&9WV%YFW%9"B@<AK F$(2N#DV#V8PQ6\9R,3!/*;M#CMM45M)<;JJ6
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M;&4M,C Q.# Y,S N>'-D4$L! A0#%     @ 5(5N308KHI*I&0  2P8! !4
M             ( !]B\! &=A;&4M,C Q.# Y,S!?8V%L+GAM;%!+ 0(4 Q0
M   ( %2%;DT^*%:C 5,  "<!!  5              "  =)) 0!G86QE+3(P
M,3@P.3,P7V1E9BYX;6Q02P$"% ,4    " !4A6Y-G#TP3[ZV  !-G@D %0
M            @ $&G0$ 9V%L92TR,#$X,#DS,%]L86(N>&UL4$L! A0#%
M  @ 5(5N3>3F,6#$>   L/H% !4              ( !]U," &=A;&4M,C Q
C.# Y,S!?<')E+GAM;%!+!08     !@ & (H!  #NS (    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
